Systemic O +
chemotherapy O +
induces O +
microsatellite O +
instability O +
in O +
the O +
peripheral O +
blood O +
mononuclear O +
cells O +
of O +
breast O +
cancer O +
patients O +
Abstract O +
Introduction O +
Systemic O +
chemotherapy O +
is O +
an O +
important O +
part O +
of O +
treatment O +
for O +
breast O +
cancer O -
. O +

We O +
conducted O +
the O +
present O +
study O +
to O +
evaluate O +
whether O +
systemic O +
chemotherapy O +
could O +
produce O +
microsatellite O +
instability O +
( O -
MSI O -
) O +
in O +
the O +
peripheral O +
blood O +
mononuclear O +
cell O +
fraction O +
of O +
breast O +
cancer O +
patients O -
. O +

Methods O +
We O +
studied O +
119 O +
sequential O +
blood O +
samples O +
from O +
30 O +
previously O +
untreated O +
breast O +
cancer O +
patients O +
before O -
, O +
during O +
and O +
after O +
chemotherapy O -
. O +

For O +
comparison O -
, O +
we O +
also O +
evaluated O +
20 O +
women O +
who O +
had O +
no O +
relevant O +
medical O +
history O +
( O -
control O +
group O -
) O -
. O +

Results O +
In O +
27 O +
out O +
of O +
30 O +
patients O +
we O +
observed O +
MSI O +
in O +
at O +
least O +
one O +
sample O -
, O +
and O +
six O +
patients O +
had O +
loss O +
of O +
heterozygosity O -
. O +

We O +
found O +
a O +
significant O +
correlation O +
between O +
the O +
number O +
of O +
MSI O +
events O +
per O +
sample O +
and O +
chemotherapy O +
with O +
alkylating O +
agents O +
( O -
P O +
< O +
0.0001 O -
) O -
. O +

We O +
also O +
observed O +
an O +
inverse O +
correlation O +
between O +
the O +
percentage O +
of O +
cells O +
positive O +
for O +
hMSH2 B-Gene +
and O +
the O +
number O +
of O +
MSI O +
events O +
per O +
sample O +
( O -
P O +
= O +
0.00019 O -
) O +
and O +
use O +
of O +
alkylating O +
agents O +
( O -
P O +
= O +
0.019 O -
) O -
. O +

Conclusion O +
We O +
conclude O +
that O +
systemic O +
chemotherapy O +
may O +
induce O +
MSI O +
and O +
loss O +
of O +
heterozygosity O +
in O +
peripheral O +
blood O +
mononuclear O +
cells O +
from O +
breast O +
cancer O +
patients O +
receiving O +
alkylating O +
agents O -
, O +
possibly O +
mediated O +
by O +
a O +
chemotherapy O -
- O -
induced O +
decrease O +
in O +
the O +
expression O +
of O +
hMSH2 B-Gene -
. O +

These O +
effects O +
may O +
be O +
related O +
to O +
the O +
generation O +
of O +
secondary O +
leukaemia O +
in O +
some O +
patients O -
, O +
and O +
may O +
also O +
intensify O +
the O +
genetic O +
instability O +
of O +
tumours O +
and O +
increase O +
resistance O +
to O +
treatment O -
. O +

Introduction O +
Systemic O +
chemotherapy O +
is O +
an O +
important O +
part O +
of O +
treatment O +
for O +
breast O +
cancer O +
in O +
both O +
the O +
adjuvant O +
and O +
palliative O +
settings O -
. O +

Despite O +
the O +
consistent O +
improvement O +
in O +
overall O +
survival O +
afforded O +
by O +
systemic O +
adjuvant O +
chemotherapy O -
, O +
about O +
1 O -
% O +
of O +
patients O +
develop O +
secondary O +
leukaemia O +
and/or O +
myelodysplasia O -
, O +
probably O +
as O +
a O +
consequence O +
of O +
the O +
genotoxic O +
effects O +
of O +
this O +
type O +
of O +
treatment O +
[ O -
1 O -
] O -
. O +

Deficiencies O +
in O +
the O +
DNA O +
mismatch O +
repair O +
system O +
leading O +
to O +
microsatellite O +
instability O +
( O -
MSI O -
) O +
may O +
produce O +
a O +
syndrome O +
of O +
familial O +
predisposition O +
to O +
colon O -
, O +
endometrial O +
and O +
upper O +
gastrointestinal O +
cancers O -
, O +
known O +
as O +
hereditary O +
nonpolyposis O +
colon O +
cancer O +
[ O -
2 O -
] O -
. O +

The O +
DNA O +
mismatch O +
repair O +
system O +
depends O +
on O +
the O +
coordinated O +
interplay O +
of O +
several O +
proteins O +
encoded O +
by O +
various O +
genes O -
, O +
including O +
hMLH1 B-Gene -
, O +
hMSH2 B-Gene -
, O +
hPMS1 B-Gene +
and O +
hPMS2 B-Gene +
[ O -
2 O -
] O -
. O +

Several O +
groups O +
have O +
reported O +
a O +
significant O +
association O +
between O +
MSI O +
and O +
treatment O -
- O -
related O +
secondary O +
acute O +
myeloid O +
leukaemia O +
( O -
AML O -
) O +
and O +
myelodysplasia O +
[ O -
3 O -
- O -
5 O -
] O -
. O +

In O +
some O +
studies O +
MSI O +
in O +
treatment O -
- O -
related O +
secondary O +
AML O -
/ O -
myelodysplasia O +
cases O +
was O +
accompanied O +
by O +
hMLH1 B-Gene +
hypermethylation O +
[ O -
3 O -
] O +
and O +
MSH2 B-Gene +
polymorphisms O +
[ O -
6 O -
] O -
. O +

In O +
order O +
to O +
evaluate O +
whether O +
systemic O +
chemotherapy O +
could O +
produce O +
MSI O +
in O +
normal O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O -
PBMCs O -
) O -
, O +
we O +
analyzed O +
PBMCs O +
from O +
breast O +
cancer O +
patients O +
collected O +
before O -
, O +
during O +
and O +
after O +
systemic O +
chemotherapy O -
. O +

Methods O +
Collection O +
and O +
preparation O +
of O +
samples O +
This O +
protocol O +
was O +
approved O +
by O +
our O +
institutional O +
review O +
board O -
. O +

We O +
obtained O +
blood O +
samples O +
from O +
33 O +
patients O +
with O +
histologically O +
confirmed O +
breast O +
cancer O +
after O +
informed O +
consent O +
had O +
been O +
obtained O -
. O +

We O +
had O +
only O +
the O +
initial O +
sample O +
in O +
three O +
patients O -
, O +
and O +
so O +
we O +
could O +
not O +
include O +
them O +
in O +
the O +
study O -
. O +

We O +
therefore O +
studied O +
119 O +
sequential O +
blood O +
samples O +
from O +
30 O +
previously O +
untreated O +
breast O +
cancer O +
patients O -
, O +
collected O +
at O +
3-month O +
intervals O +
before O -
, O +
during O +
and O +
after O +
receiving O +
systemic O +
treatment O +
( O -
13 O +
adjuvant O -
, O +
12 O +
neoadjuvant O +
and O +
5 O +
palliative O -
) O -
. O +

Three O +
patients O +
initially O +
received O +
hormones O +
( O -
two O +
adjuvant O +
and O +
one O +
palliative O -
) O -
. O +

Chemotherapy O +
combinations O +
containing O +
cyclophosphamide O +
were O +
classified O +
as O +
alkylating O +
regimens O +
( O -
FAC O +
[ O -
5-fluorouracil O -
, O +
doxorubicin O +
and O +
cyclophosphamide O -
] O -
, O +
AC O +
[ O -
doxorubicin O +
and O +
cyclophosphamide O -
] O -
, O +
CMF O +
[ O -
cyclophosphamide O -
, O +
methotrexate O -
, O +
and O +
5-fluorouracil O -
] O -
) O -
. O +

We O +
also O +
studied O +
PBMCs O +
from O +
20 O +
normal O +
control O +
women O -
, O +
who O +
had O +
no O +
relevant O +
previous O +
medical O +
history O -
, O +
by O +
immunocytochemistry O -
. O +

Afterward O -
, O +
we O +
collected O +
peripheral O +
blood O +
from O +
these O +
20 O +
normal O +
control O +
women O +
on O +
two O +
occasions O +
with O +
a O +
3-month O +
interval O +
to O +
evaluate O +
MSI O +
using O +
the O +
TP53Alu O +
and O +
PCR15.1 O +
markers O +
( O -
described O +
below O -
) O -
. O +

Each O +
sample O +
consisted O +
of O +
20 O +
ml O +
venous O +
blood O -
, O +
from O +
which O +
we O +
separated O +
the O +
PBMCs O +
by O +
Ficoll O +
gradient O +
( O -
Ficoll O +
Hypaque O -
; O +
Organon O +
Teknica O -
® O -
, O +
Durham O -
, O +
NC O -
, O +
USA O -
) O -
, O +
yielding O +
a O +
final O +
concentration O +
of O +
1.0 O +
× O +
106 O +
cells O -
/ O -
ml O -
; O +
we O +
sent O +
part O +
of O +
the O +
sample O +
for O +
cytospin O +
for O +
immunocytochemical O +
studies O +
and O +
part O +
for O +
DNA O +
extraction O -
. O +

DNA O +
was O +
extracted O +
from O +
mononuclear O +
fraction O +
by O +
the O +
use O +
of O +
Trizol O +
( O -
Invitrogen O -
, O +
Carlsbad O -
, O +
CA O -
, O +
USA O -
) O -
, O +
in O +
accordance O +
with O +
the O +
manufacturer O -
's O +
instructions O -
. O +

For O +
immunocytochemistry O +
analysis O -
, O +
assay O +
slides O +
were O +
prepared O +
( O -
described O +
in O +
detail O +
elsewhere O +
[ O -
7 O -
] O -
) O -
. O +

Microsatellite O +
analysis O +
The O +
sequences O +
of O +
all O +
primers O +
used O +
for O +
six O +
microsatellite O +
loci O +
( O -
BAT-26 O -
, O +
BAT-40 O -
, O +
MFD-28 O -
, O +
MFD-41 O -
, O +
TP53 B-Gene -
, O +
PCR15.1 O -
, O +
TP53ALU O -
) O +
and O +
the O +
PCR O +
protocols O +
used O +
to O +
study O +
each O +
of O +
these O +
markers O +
were O +
described O +
previously O +
[ O -
8 O -
] O -
. O +

Briefly O -
, O +
PCR O +
products O +
were O +
denatured O +
and O +
subjected O +
to O +
electrophoresis O +
in O +
Gene O +
Gel O +
Clean O +
15 O -
/ O -
24 O +
( O -
Amershan O +
Pharmacia O +
Biotech O +
AB O -
, O +
Uppsala O -
, O +
Sweden O -
) O +
for O +
90 O +
min O +
at O +
600 O +
V O +
and O +
8 O -
° O -
C O -
, O +
and O +
then O +
silver O +
stained O +
using O +
a O +
Hoefer O +
Automed O +
Gel O +
Stainer O +
( O -
Amershan O +
Pharmacia O +
Biotech O +
AB O -
) O -
. O +

MSI O +
was O +
defined O +
by O +
the O +
appearance O +
of O +
novel O +
bands O +
and O +
loss O +
of O +
heterozygosity O +
( O -
LOH O -
) O +
whenever O +
disappearance O +
of O +
previously O +
visualized O +
bands O +
occurred O -
, O +
as O +
described O +
previously O +
[ O -
8 O -
] O -
. O +

Three O +
independent O +
observers O +
analyzed O +
the O +
results O +
of O +
each O +
gel O +
for O +
LOH O +
and O +
MSI O -
. O +

Immunocytochemistry O +
For O +
immunostaining O +
for O +
proliferating O +
nuclear O +
antigen O +
( O -
PCNA B-Gene -
) O -
, O +
hMLH1 B-Gene -
, O +
hPMS1 B-Gene -
, O +
hPMS2 B-Gene -
, O +
hMSH2 B-Gene +
and O +
TP-53 B-Gene +
proteins O -
, O +
we O +
used O +
an O +
avidin O -
– O -
biotin O -
– O -
peroxidase O +
complex O +
and O +
3,3'-diaminobenzidine O +
as O +
chromogen O -
. O +

All O +
antibodies O +
were O +
supplied O +
by O +
Santa O +
Cruz O +
Biotechnology O +
( O -
Santa O +
Cruz O -
, O +
CA O -
, O +
USA O -
) O -
, O +
and O +
for O +
each O +
clone O +
we O +
employed O +
the O +
following O +
dilutions O -
: O +
PC-10 O +
( O -
anti O -
- O -
PCNA B-Gene -
) O -
, O +
1:1000 O -
; O +
C-20 O +
( O -
anti O -
- O -
hMLH1 B-Gene -
) O -
, O +
1:25 O -
; O +
K-20 O +
( O -
anti O -
- O -
hPMS1 B-Gene -
) O -
, O +
1:25 O -
; O +
C-20 O +
( O -
anti O -
- O -
hPMS2 B-Gene -
) O -
, O +
1:200 O -
; O +
N-20 O +
( O -
anti O -
- O -
hMSH2 B-Gene -
) O -
, O +
1:200 O -
; O +
and O +
Pab1801 O +
( O -
anti O -
- O -
P53 B-Gene -
) O -
, O +
1:400 O -
. O +

Endogenous O +
peroxidase O +
activity O +
was O +
blocked O +
by O +
incubation O +
with O +
H2O2 O +
and O +
washed O +
in O +
tap O +
water O -
. O +

The O +
cytospin O +
slides O +
were O +
then O +
treated O +
with O +
7 O -
% O +
skimmed O +
milk O +
for O +
60 O +
min O +
to O +
block O +
nonspecific O +
protein O +
binding O -
. O +

Each O +
antibody O +
was O +
applied O +
separately O -
, O +
and O +
cytospins O +
were O +
incubated O +
for O +
18 O +
hours O +
at O +
3 O -
° O -
C O -
. O +

After O +
3 O +
washes O +
in O +
phosphate O -
- O -
buffered O +
saline O -
, O +
antigen O -
- O -
bound O +
primary O +
antibody O +
was O +
detected O +
using O +
a O +
standard O +
streptavidin O -
– O -
biotin O +
complex O +
( O -
Strep O +
AB O +
Complex O -
; O +
Dako O -
, O +
Carpinteria O -
, O +
CA O -
, O +
USA O -
) O -
. O +

After O +
brief O +
washing O -
, O +
slides O +
were O +
incubated O +
with O +
diaminobenzidine O +
and O +
H2O2 O +
for O +
10 O +
min O +
and O +
then O +
counterstained O +
with O +
haematoxylin O -
, O +
dehydrated O +
in O +
graded O +
alcohols O +
and O +
cleared O +
in O +
xylene O -
. O +

Two O +
independent O +
observers O +
scored O +
300 O +
cells O -
/ O -
slide O +
as O +
positive O +
or O +
negative O +
according O +
to O +
the O +
presence O +
of O +
nuclear O +
staining O +
for O +
each O +
of O +
the O +
aforementioned O +
antibodies O -
. O +

Then O -
, O +
the O +
results O +
from O +
these O +
two O +
observers O +
were O +
averaged O +
to O +
obtain O +
a O +
percentage O +
of O +
positive O +
cells O +
per O +
sample O -
. O +

Results O +
We O +
studied O +
30 O +
patients O +
with O +
median O +
age O +
52 O +
years O +
( O -
range O +
25–80 O +
years O -
) O -
. O +

Twelve O +
patients O +
had O +
stage O +
II O -
, O +
13 O +
had O +
stage O +
III O +
and O +
five O +
had O +
stage O +
IV O +
breast O +
cancer O -
. O +

We O +
evaluated O +
samples O +
from O +
20 O +
normal O +
control O +
women O +
by O +
immunocytochemistry O +
for O +
PCNA B-Gene -
, O +
hMLH1 B-Gene -
, O +
hPMS2 B-Gene -
, O +
hMSH2 B-Gene +
and O +
TP-53 B-Gene +
( O -
Table O +
1 O -
) O -
; O +
the O +
raw O +
data O +
for O +
each O +
of O +
the O +
included O +
patients O +
appear O +
in O +
Additional O +
file O +
1 O -
. O +

We O +
observed O +
MSI O +
in O +
40 O +
out O +
of O +
the O +
119 O +
samples O +
collected O -
, O +
and O +
MSI O +
was O +
observed O +
in O +
27 O +
out O +
of O +
30 O +
patients O +
in O +
at O +
least O +
one O +
sample O -
. O +

We O +
observed O +
LOH O +
at O +
the O +
PCR15.1 O +
locus O +
in O +
six O +
patients O -
. O +

Whereas O +
MSI O +
was O +
usually O +
transient O -
, O +
disappearing O +
in O +
the O +
next O +
collected O +
sample O -
, O +
LOH O +
was O +
persistent O +
in O +
all O +
subsequent O +
samples O +
in O +
five O +
of O +
the O +
six O +
observed O +
cases O +
( O -
Fig. O +
1 O -
) O -
. O +

In O +
order O +
to O +
ensure O +
that O +
our O +
findings O +
in O +
the O +
patients O +
studied O +
were O +
not O +
due O +
to O +
chance O -
, O +
we O +
studied O +
20 O +
normal O +
blood O +
donors O +
( O -
women O +
who O +
had O +
no O +
relevant O +
medical O +
history O -
; O +
see O +
Additional O +
file O +
2 O -
) O -
. O +

In O +
those O +
women O +
blood O +
samples O +
were O +
collected O +
twice O -
, O +
with O +
a O +
3-month O +
interval O +
between O +
samples O -
. O +

We O +
studied O +
both O +
samples O +
from O +
each O +
of O +
these O +
normal O +
women O +
for O +
MSI O +
using O +
TP53ALU O +
and O +
PCR15.1 O +
markers O -
. O +

In O +
only O +
one O +
normal O +
woman O +
was O +
any O +
MSI O +
identified O +
( O -
one O +
additional O +
band O +
was O +
detected O +
in O +
the O +
PCR15 O -
- O -
1 O +
marker O +
after O +
3 O +
months O -
) O -
. O +

None O +
of O +
them O +
had O +
LOH O +
( O -
data O +
not O +
shown O -
) O -
. O +

Therefore O -
, O +
in O +
only O +
one O +
blood O +
sample O +
out O +
of O +
40 O +
drawn O +
from O +
these O +
20 O +
normal O +
women O +
was O +
there O +
any O +
evidence O +
of O +
MSI O -
, O +
as O +
compared O +
with O +
28 O +
out O +
of O +
119 O +
samples O +
from O +
the O +
breast O +
cancer O +
patients O +
studied O +
using O +
the O +
same O +
markers O +
( O -
P O +
= O +
0.018 O -
) O -
. O +

We O +
observed O +
a O +
significant O +
correlation O +
between O +
the O +
number O +
of O +
MSI O +
events O +
per O +
sample O +
and O +
the O +
use O +
of O +
chemotherapy O +
( O -
P O +
= O +
0.005 O -
) O -
, O +
especially O +
chemotherapy O +
containing O +
alkylating O +
agents O +
( O -
P O +
< O +
0.0001 O -
; O +
Fig. O +
2 O -
) O -
. O +

We O +
also O +
observed O +
an O +
inverse O +
correlation O +
between O +
the O +
number O +
of O +
MSI O +
events O +
per O +
sample O +
and O +
the O +
percentage O +
of O +
cells O +
positive O +
for O +
MSH2 B-Gene +
by O +
immunocytochemistry O +
( O -
P O +
= O +
0.00019 O -
) O +
and O +
especially O +
for O +
the O +
MFD41 O +
marker O +
( O -
P O +
= O +
0.000638 O -
) O -
. O +

The O +
percentage O +
of O +
cells O +
positive O +
for O +
MSH2 B-Gene +
by O +
immunocytochemistry O +
was O +
inversely O +
correlated O +
with O +
the O +
use O +
of O +
chemotherapy O +
regimens O +
containing O +
alkylating O +
agents O +
( O -
P O +
= O +
0.019 O -
) O -
. O +

We O +
found O +
no O +
significant O +
correlations O +
between O +
the O +
number O +
of O +
MSI O +
events O +
or O +
the O +
presence O +
of O +
LOH O +
and O +
the O +
frequency O +
of O +
cells O +
positive O +
for O +
TP53 B-Gene -
, O +
hMLH1 B-Gene -
, O +
hPMS1 B-Gene +
and O +
hPMS2 B-Gene -
. O +

In O +
the O +
present O +
study O -
, O +
the O +
percentage O +
of O +
cells O +
positive O +
for O +
PCNA B-Gene -
, O +
as O +
determined O +
by O +
immunocytochemistry O -
, O +
was O +
directly O +
correlated O +
with O +
use O +
of O +
radiation O +
therapy O +
( O -
P O +
= O +
0.046 O -
) O +
and O +
with O +
the O +
percentage O +
of O +
MSH2-positive B-Gene +
cells O +
( O -
P O +
= O +
0.000096 O -
) O -
, O +
and O +
inversely O +
correlated O +
with O +
the O +
presence O +
of O +
LOH O +
( O -
P O +
= O +
0.043 O -
) O -
, O +
but O +
it O +
was O +
not O +
correlated O +
with O +
the O +
number O +
of O +
MSI O +
events O +
per O +
sample O -
. O +

Discussion O +
Systemic O +
chemotherapy O +
administered O +
to O +
breast O +
cancer O +
patients O +
induces O +
secondary O +
leukaemia O +
and O +
myelodysplasia O +
in O +
about O +
1 O -
% O +
[ O -
1 O -
] O -
. O +

In O +
our O +
study O -
, O +
in O +
90 O -
% O +
of O +
patients O +
MSI O +
was O +
noted O +
in O +
at O +
least O +
one O +
of O +
the O +
samples O -
. O +

This O +
finding O +
does O +
not O +
appear O +
due O +
to O +
chance O +
because O +
only O +
one O +
of O +
the O +
sequential O +
blood O +
samples O +
drawn O +
from O +
20 O +
normal O +
donor O +
women O +
exhibited O +
MSI O -
. O +

Furthermore O -
, O +
we O +
observed O +
a O +
significant O +
and O +
direct O +
correlation O +
between O +
the O +
number O +
of O +
MSI O +
events O +
per O +
sample O +
and O +
the O +
use O +
of O +
chemotherapy O -
, O +
especially O +
with O +
regimens O +
containing O +
alkylating O +
agents O -
. O +

We O +
believe O +
that O +
our O +
data O +
reflect O +
the O +
genotoxic O +
effects O +
of O +
chemotherapy O +
on O +
normal O +
cells O +
because O +
in O +
only O +
one O +
normal O +
control O +
woman O +
out O +
of O +
20 O +
was O +
there O +
evidence O +
of O +
MSI O +
( O -
after O +
3 O +
months O -
) O +
and O +
with O +
only O +
one O +
of O +
the O +
two O +
surveyed O +
MSI O +
markers O -
. O +

Furthermore O -
, O +
no O +
LOH O +
was O +
observed O +
within O +
this O +
cohort O +
of O +
normal O +
women O -
. O +

Therefore O -
, O +
because O +
MSI O +
and O +
LOH O +
occurred O +
at O +
significantly O +
greater O +
frequency O +
among O +
patients O +
with O +
breast O +
cancer O -
, O +
it O +
is O +
unlikely O +
that O +
our O +
findings O +
could O +
be O +
due O +
to O +
normal O +
variations O +
in O +
MSI O +
occurrence O +
or O +
to O +
technical O +
artifacts O -
. O +

We O +
also O +
noted O +
a O +
significant O -
, O +
inverse O +
correlation O +
between O +
the O +
number O +
of O +
MSI O +
events O +
per O +
sample O +
and O +
the O +
expression O +
of O +
hMSH2 B-Gene +
by O +
immunocytochemistry O -
. O +

Because O +
we O +
noted O +
fluctuation O +
in O +
hMSH2 B-Gene +
levels O +
throughout O +
the O +
treatment O +
of O +
several O +
patients O -
, O +
it O +
is O +
possible O +
that O +
hMSH2 B-Gene +
downregulation O +
occurs O +
at O +
the O +
post O -
- O -
transcriptional O +
level O +
and O +
could O +
be O +
related O +
to O +
the O +
use O +
of O +
chemotherapy O +
based O +
on O +
alkylating O +
agents O -
. O +

Interestingly O -
, O +
Watanabe O +
and O +
coworkers O +
[ O -
9 O -
] O +
described O +
induction O +
of O +
MSI O +
in O +
ovarian O +
tumours O +
from O +
patients O +
studied O +
before O +
and O +
after O +
they O +
received O +
cisplatin O -
- O -
based O +
chemotherapy O -
, O +
but O +
in O +
their O +
study O +
the O +
cisplatin O -
- O -
induced O +
MSI O +
correlated O +
with O +
a O +
significant O +
decrease O +
in O +
hMLH1 B-Gene +
expression O -
. O +

We O +
believe O +
that O +
the O +
transient O +
decrease O +
in O +
hMSH2 B-Gene +
expression O +
that O +
we O +
noted O +
might O +
have O +
predisposed O +
to O +
an O +
increased O +
number O +
of O +
MSI O +
events O -
. O +

In O +
fact O -
, O +
Zhu O +
and O +
coworkers O +
[ O -
10 O -
] O +
also O +
described O +
abnormal O +
hMSH-2 B-Gene +
expression O +
in O +
about O +
one O -
- O -
third O +
of O +
cases O +
of O +
AML O -
, O +
mainly O +
in O +
those O +
with O +
treatment O -
- O -
related O +
secondary O +
AML O +
and O +
in O +
patients O +
who O +
were O +
elderly O -
. O +

PCNA B-Gene +
is O +
a O +
36 O +
kDa O +
nuclear O +
protein O +
that O +
functions O +
as O +
a O +
cofactor O +
for O +
δ O -
- O -
DNA O +
polymerase O -
, O +
which O +
is O +
regulated O +
in O +
a O +
cell O +
cycle O +
dependent O +
manner O -
. O +

PCNA B-Gene +
expression O +
also O +
increases O +
when O +
cells O +
are O +
actively O +
engaged O +
in O +
DNA O +
repair O +
[ O -
11 O -
] O -
. O +

The O +
correlation O +
of O +
PCNA B-Gene +
with O +
LOH O +
but O +
not O +
with O +
the O +
number O +
of O +
MSI O +
events O +
found O +
in O +
the O +
present O +
study O +
may O +
indicate O +
that O +
PCNA B-Gene +
may O +
have O +
greater O +
expression O +
in O +
situations O +
of O +
more O +
intense O +
DNA O +
damage O +
that O +
tend O +
to O +
be O +
long O -
- O -
lasting O -
. O +

Interestingly O -
, O +
our O +
group O +
previously O +
showed O +
that O +
PCNA B-Gene +
over O -
- O -
expression O +
was O +
associated O +
with O +
resistance O +
to O +
chemotherapy O +
AML O +
and O +
chronic O +
lymphocytic O +
leukaemia O +
[ O -
12,13 O -
] O -
. O +

Conclusion O +
We O +
conclude O +
that O +
systemic O +
chemotherapy O +
may O +
induce O +
MSI O +
and O +
LOH O +
in O +
PBMCs O +
from O +
breast O +
cancer O +
patients O +
receiving O +
chemotherapy O +
regimens O -
, O +
especially O +
chemotherapy O +
regimens O +
containing O +
alkylating O +
agents O -
. O +

Furthermore O -
, O +
it O +
is O +
possible O +
that O +
these O +
alterations O +
are O +
associated O +
with O +
a O +
chemotherapy O -
- O -
induced O +
decrease O +
in O +
the O +
expression O +
of O +
hMSH2 B-Gene -
. O +

These O +
effects O +
may O +
be O +
related O +
to O +
the O +
generation O +
of O +
secondary O +
leukaemia O +
in O +
some O +
patients O -
, O +
and O +
may O +
also O +
intensify O +
the O +
genetic O +
instability O +
of O +
tumours O +
and O +
increase O +
resistance O +
to O +
treatment O -
. O +

INTRODUCTION O +
Microsatellites O +
are O +
repetitive O +
DNA O +
sequences O +
comprising O +
short O +
reiterated O +
motifs O +
dispersed O +
throughout O +
the O +
eukaryotic O +
genome O +
( O -
1 O -
) O -
. O +

Microsatellite O +
lengths O +
are O +
highly O +
polymorphic O +
in O +
human O +
populations O -
, O +
but O +
appear O +
stable O +
during O +
the O +
life O +
span O +
of O +
the O +
individual O -
. O +

Somatic O +
instability O +
of O +
microsatellite O +
sequences O +
has O +
initially O +
been O +
reported O +
in O +
human O +
colorectal O +
cancer O +
( O -
2,3 O -
) O -
, O +
and O +
particularly O +
in O +
the O +
familial O +
cancer O -
- O -
prone O +
syndrome O -
, O +
hereditary O +
non O -
- O -
polyposis O +
colorectal O +
cancer O +
( O -
HNPCC O -
) O +
( O -
4,5 O -
) O -
. O +

In O +
1993 O -
, O +
mutations O +
in O +
one O +
of O +
the O +
genes O +
encoding O +
proteins O +
essential O +
for O +
DNA O +
mismatch O +
repair O +
( O -
MMR B-Gene -
) O +
were O +
found O +
in O +
HNPCC O +
individuals O +
( O -
6,7 O -
) O -
. O +

MMR B-Gene +
is O +
an O +
important O +
editing O +
system O -
. O +

It O +
counteracts O +
the O +
base O +
mismatches O +
and O +
strand O +
misalignments O +
that O +
occur O +
during O +
DNA O +
replication O +
and O +
recombination O +
( O -
8) O -
. O +

Repetitive O +
sequences O +
such O +
as O +
those O +
comprising O +
microsatellites O +
are O +
particularly O +
prone O +
to O +
polymerase O +
slippage O +
and O -
, O +
consequently O -
, O +
strand O +
misalignment O -
. O +

If O +
these O +
errors O +
remain O +
uncorrected O -
, O +
the O +
mutations O +
are O +
fixed O +
during O +
subsequent O +
replication O +
as O +
addition O +
or O +
deletion O +
of O +
one O +
( O -
or O +
more O -
) O +
repeat O +
units O -
. O +

The O +
phenomenon O +
of O +
unstable O +
microsatellites O -
, O +
i.e. O +
microsatellite O +
instability O +
( O -
MSI O -
) O -
, O +
in O +
which O +
tumour O +
cells O +
accumulate O +
this O +
type O +
of O +
repeat O +
length O +
alterations O +
in O +
microsatellites O -
, O +
is O +
considered O +
to O +
reflect O +
MMR B-Gene +
deficiency O -
. O +

The O +
MSI+ O +
phenotype O +
is O +
frequently O +
associated O +
with O +
various O +
human O +
malignancies O +
( O -
9 O -
) O -
. O +

As O +
defective O +
MMR B-Gene +
is O +
regarded O +
as O +
a O +
risk O +
factor O +
for O +
familial O +
predisposition O +
or O +
second O +
malignancies O -
, O +
analyses O +
of O +
microsatellite O +
instability O +
have O +
been O +
prevalent O -
, O +
particularly O +
in O +
the O +
field O +
of O +
oncology O -
. O +

However O -
, O +
the O +
reported O +
frequency O +
for O +
MSI+ O +
tumours O +
in O +
each O +
malignancy O +
differs O +
widely O +
in O +
the O +
literature O +
( O -
9 O -
) O -
. O +

Although O +
analysis O +
of O +
MSI O +
is O +
now O +
commonplace O -
, O +
a O +
designation O +
of O +
MSI+ O +
may O +
sometimes O +
be O +
a O +
difficult O +
decision O -
. O +

The O +
1997 O +
National O +
Cancer O +
Institute O +
( O -
NCI O -
) O +
workshop O -
, O +
' O -
Microsatellite O +
Instability O +
and O +
RER O +
Phenotypes O +
in O +
Cancer O +
Detection O +
and O +
Familial O +
Predisposition O -
' O -
, O +
suggested O +
that O +
the O +
variety O +
of O +
microsatellites O +
used O +
was O +
a O +
major O +
cause O +
of O +
discrepancies O +
among O +
data O +
from O +
various O +
laboratories O -
, O +
and O +
recommended O +
a O +
panel O +
of O +
five O +
microsatellites O +
as O +
' O -
working O +
reference O +
panel O -
' O +
( O -
10 O -
) O -
. O +

We O +
believe O +
that O -
, O +
in O +
addition O +
to O +
selection O +
of O +
targets O +
for O +
analysis O -
, O +
methodological O +
problems O +
also O +
account O +
for O +
some O +
of O +
the O +
variability O +
in O +
results O -
. O +

Changes O +
in O +
microsatellite O +
lengths O +
are O +
sometimes O +
minor O -
— O -
as O +
small O +
as O +
loss O +
or O +
gain O +
of O +
a O +
single O +
repeat O +
unit O -
. O +

In O +
addition O -
, O +
cells O +
carrying O +
changes O +
in O +
microsatellite O +
sequences O +
are O +
not O +
always O +
major O +
in O +
a O +
given O +
sample O -
. O +

However O -
, O +
in O +
an O +
assay O +
system O +
using O +
the O +
conventional O +
sequencing O +
gel O +
electrophoresis O +
and O +
autoradiography O -
, O +
it O +
appears O +
difficult O +
to O +
resolve O +
microsatellite O +
PCR O +
products O +
precisely O +
and O +
quantitatively O -
. O +

PCR O +
itself O +
has O +
an O +
intrinsic O +
variability O -
. O +

The O +
most O +
widely O +
used O +
thermostable O +
DNA O +
polymerase O +
( O -
Taq O -
) O +
has O +
a O +
terminal O +
deoxynucleotidyl O +
transferase O +
( O -
TDT O -
) O +
activity O -
, O +
which O +
adds O +
one O +
additional O +
base O +
to O +
PCR O +
products O +
in O +
a O +
sequence O -
- O -
dependent O +
manner O -
. O +

TDT O +
activity O +
of O +
Taq O +
polymerase O +
is O +
variably O +
expressed O -
, O +
depending O +
on O +
the O +
conditions O +
used O -
. O +

This O +
property O -
, O +
in O +
addition O +
to O +
intrinsic O +
strand O +
misalignment O +
during O +
amplification O +
of O +
microsatellite O +
repeats O -
, O +
increases O +
the O +
complexity O +
of O +
PCR O +
products O -
. O +

In O +
the O +
conventional O +
microsatellite O +
analysis O -
, O +
intrinsic O +
caution O +
and O +
the O +
desire O +
to O +
avoid O +
scoring O +
false O -
- O -
positives O +
may O +
have O +
led O +
to O +
an O +
underestimate O +
of O +
the O +
frequency O +
of O +
minor O -
, O +
more O +
subtle O +
microsatellite O +
changes O -
, O +
such O +
as O +
alterations O +
of O +
limited O +
numbers O +
of O +
repeat O +
units O -
. O +

We O +
have O +
applied O +
our O +
fluorescent O +
technique O +
for O +
microsatellite O +
instability O +
analysis O +
( O -
11 O -
) O +
to O +
address O +
these O +
problems O -
. O +

Here O -
, O +
we O +
report O +
that O +
relatively O +
subtle O +
alterations O +
in O +
microsatellites O +
are O +
indeed O +
generally O +
associated O +
with O +
MMR B-Gene +
deficiency O -
. O +

In O +
contrast O -
, O +
most O +
HNPCC O +
tumours O +
display O +
much O +
more O +
extensive O +
microsatellite O +
changes O -
. O +

Our O +
findings O +
suggest O +
that O +
there O +
are O +
previously O +
unrecognized O +
aspects O +
of O +
microsatellite O +
instability O +
in O +
human O +
cancer O -
. O +

MATERIALS O +
AND O +
METHODS O +
Cells O +
and O +
tissue O +
specimens O +
Msh2− B-Gene -
/ O -
− O +
mouse O +
embryonic O +
fibroblast O +
( O -
MEF O -
) O +
cell O +
line O -
, O +
RH95021 O +
( O -
12 O -
) O +
and O +
Mlh1− B-Gene -
/ O -
− O +
MEF O +
cell O +
line O -
, O +
MC2 O -
, O +
were O +
kindly O +
provided O +
by O +
Dr O +
Hein O +
te O +
Riele O -
, O +
Amsterdam O +
Cancer O +
Center O +
and O +
Dr O +
Michael O +
Liskay O -
, O +
University O +
of O +
Oregon O -
, O +
respectively O -
. O +

Cells O +
were O +
cultured O +
in O +
DMEM O +
supplemented O +
with O +
10 O -
% O +
fetal O +
calf O +
serum O -
, O +
penicillin O +
( O -
100 O +
U O -
/ O -
ml O -
) O +
and O +
streptomycin O +
( O -
100 O +
μg O -
/ O -
ml O -
) O -
. O +

Samples O +
of O +
cancer O +
tissues O +
and O +
the O +
corresponding O +
normal O +
mucosa O +
were O +
obtained O +
from O +
79 O +
patients O +
with O +
colorectal O +
carcinoma O +
who O +
underwent O +
surgery O +
in O +
the O +
Department O +
of O +
Surgery O +
and O +
Science O -
, O +
Kyushu O +
University O +
Hospital O +
from O +
1996 O +
to O +
1999 O -
. O +

Written O +
informed O +
consent O +
for O +
studies O +
using O +
the O +
tissues O +
was O +
obtained O +
from O +
each O +
patient O -
. O +

Ethical O +
approval O +
was O +
obtained O +
from O +
the O +
IRB O +
of O +
Kyushu O +
University O -
. O +

Specimens O -
, O +
taken O +
immediately O +
after O +
resection O -
, O +
were O +
placed O +
in O +
liquid O +
nitrogen O -
. O +

High O +
molecular O +
weight O +
DNA O +
was O +
extracted O +
and O +
subjected O +
to O +
microsatellite O +
analyses O -
. O +

Microsatellite O +
instability O +
Microsatellite O +
analysis O +
using O +
fluorescence O -
- O -
labelled O +
primers O +
and O +
an O +
automated O +
DNA O +
sequencer O +
has O +
been O +
described O +
in O +
detail O +
( O -
11 O -
) O -
. O +

Briefly O -
, O +
five O +
human O +
dinucleotide O +
microsatellites O -
, O +
D2S123 O -
, O +
D5S107 O -
, O +
D10S197 O -
, O +
D11S904 O +
and O +
D13S175 O -
, O +
in O +
genomic O +
DNA O +
from O +
tissue O +
specimens O +
were O +
amplified O +
by O +
PCR O -
. O +

5′ O +
primers O +
were O +
labelled O +
with O +
the O +
fluorescent O +
compound O -
, O +
ROX O +
( O -
6-carboxy O -
- O -
x O -
- O -
rhodamine O -
) O +
or O +
HEX O +
( O -
6-carboxy-2′,4′,7′,4,7,-hexachloro O -
- O -
fluorescein O -
) O -
. O +

PCR O +
reactions O +
were O +
done O +
using O +
TaKaRa O +
Taq O +
( O -
TaKaRa O +
Co. O +
Ltd. O -
, O +
Tokyo O -
, O +
Japan O -
) O -
. O +

T4 O +
DNA O +
polymerase O +
was O +
added O +
to O +
the O +
PCR O +
products O -
, O +
followed O +
by O +
incubation O +
at O +
37 O -
° O -
C O +
for O +
10 O +
min O -
. O +

To O +
compare O +
electrophoretic O +
profiles O +
between O +
two O +
samples O -
, O +
1.2 O +
μl O +
of O +
ROX O -
- O -
labelled O +
product O +
and O +
0.3 O +
μl O +
of O +
HEX O -
- O -
labelled O +
product O +
were O +
mixed O -
. O +

Samples O +
were O +
denatured O +
and O +
loaded O +
onto O +
the O +
ABI O +
373A O +
sequencer O +
( O -
Applied O +
Biosystems O -
, O +
Foster O +
City O -
, O +
CA O -
, O +
USA O -
) O -
. O +

The O +
data O +
were O +
processed O +
using O +
the O +
GeneScan O +
software O +
( O -
Applied O +
Biosystems O -
) O -
. O +

For O +
mice O -
, O +
three O +
dinucleotide O +
microsatellites O -
, O +
D1Mit62 O -
, O +
D6Mit59 O +
and O +
D7Mit91 O -
, O +
were O +
analysed O -
. O +

DNA O +
sequencing O +
All O +
the O +
exons O +
and O +
exon O -
– O -
intron O +
junctions O +
of O +
hMSH2 B-Gene +
and O +
hMLH1 B-Gene +
were O +
amplified O +
by O +
PCR O +
using O +
Taq O +
polymerase O +
with O +
3′ O +
exonuclease O +
activity O -
, O +
TaKaRa O +
Ex O +
Taq O +
( O -
TaKaRa O +
Co. O +
Ltd. O -
, O +
Tokyo O -
, O +
Japan O -
) O -
. O +

Primer O +
sequences O +
are O +
the O +
same O +
as O +
reported O +
by O +
Kolodner O +
et O +
al. O +
( O -
13,14 O -
) O -
, O +
except O +
that O +
the O +
additional O +
sequence O +
complementary O +
for O +
M13 O +
universal O +
primer O +
was O +
deleted O -
, O +
and O +
that O +
one O -
- O -
step O +
PCR O +
was O +
mainly O +
employed O -
. O +

PCR O +
products O +
were O +
used O +
as O +
a O +
template O +
for O +
cycle O +
sequencing O +
reactions O +
using O +
BigDye O +
terminator O +
cycle O +
sequencing O +
kit O +
( O -
Applied O +
Biosystems O -
, O +
Foster O +
City O -
, O +
CA O -
, O +
USA O -
) O -
. O +

Mutations O +
found O +
in O +
one O +
PCR O +
product O +
were O +
verified O +
by O +
reverse O +
sequencing O +
and O +
finally O +
confirmed O +
in O +
two O +
independently O +
amplified O +
PCR O +
products O -
. O +

Sequencing O +
analyses O +
of O +
p53 B-Gene +
gene O +
( O -
exon O +
5–9 O -
) O +
were O +
performed O +
using O +
p53 B-Gene +
primers O +
( O -
Nippon O +
Gene O -
, O +
Tokyo O -
, O +
Japan O -
) O -
. O +

Immunohistochemistry O +
Tissue O +
specimens O +
were O +
fixed O +
in O +
buffered O +
10 O -
% O +
paraformaldehyde O +
and O +
embedded O +
in O +
paraffin O -
. O +

Prior O +
to O +
the O +
assay O -
, O +
the O +
specimens O +
were O +
sectioned O +
at O +
4 O +
μm O +
and O +
deparaffinized O +
using O +
xylene O -
. O +

Immunohistochemistry O +
was O +
performed O +
using O +
the O +
streptavidin O -
– O -
biotin O -
– O -
peroxidase O +
complex O +
method O +
( O -
Histofine O +
SAB O +
kit O -
, O +
Nichirei O -
, O +
Tokyo O -
, O +
Japan O -
) O +
using O +
an O +
automated O +
stainer O +
( O -
VENTANA O +
Discovery O +
System O -
, O +
Ventana O +
Medical O +
Systems O +
Inc. O -
, O +
Tucson O -
, O +
AZ O -
, O +
USA O -
) O -
. O +

At O +
least O -
, O +
two O +
independent O +
antibodies O +
were O +
used O +
to O +
confirm O +
the O +
status O +
of O +
negative O +
staining O -
. O +

Sections O +
prepared O +
from O +
Msh2- B-Gene +
and O +
Mlh1-knockout B-Gene +
mice O +
were O +
also O +
used O +
as O +
negative O +
controls O -
. O +

Antibodies O +
used O +
were O +
as O +
follows O -
: O +
anti O -
- O -
MSH2 B-Gene -
; O +
NA27 O +
and O +
NA26 O +
( O -
Oncogene O +
Research O +
Products O -
, O +
Cambridge O -
, O +
MA O -
, O +
USA O -
) O -
, O +
anti O -
- O -
MLH1 B-Gene -
; O +
PM-13291A O +
( O -
PharMingen O -
, O +
Hamburg O -
, O +
Germany O -
) O -
, O +
NA28 O +
( O -
Oncogene O +
Research O +
Products O -
) O +
and O +
sc-581 O +
( O -
Santa O +
Cruz O +
Biotechnology O +
Inc. O -
, O +
Santa O +
Cruz O -
, O +
CA O -
, O +
USA O -
) O -
. O +

RESULTS O +
Two O +
modes O +
of O +
dinucleotide O +
microsatellite O +
instability O +
in O +
human O +
cancer O +
We O +
have O +
established O +
a O +
sensitive O +
fluorescent O +
technique O +
for O +
microsatellite O +
analysis O +
( O -
11 O -
) O -
. O +

Application O +
of O +
this O +
technique O +
to O +
human O +
cancers O +
revealed O +
a O +
number O +
of O +
previously O +
unrecognized O +
aspects O +
of O +
MSI O -
. O +

In O +
particular O -
, O +
we O +
observed O +
two O +
distinct O +
patterns O +
of O +
alterations O +
at O +
dinucleotide O +
microsatellites O +
in O +
human O +
malignancies O +
( O -
15–17 O -
) O -
. O +

Examples O +
are O +
shown O +
in O +
Figure O +
1 O -
. O +

In O +
some O +
cases O -
, O +
length O +
changes O +
are O +
relatively O +
small O +
and O +
affect O +
≤6 O +
bp O +
( O -
Type O +
A O -
, O +
Figure O +
1A O -
– O -
D O -
) O -
. O +

In O +
the O +
other O -
, O +
more O +
dramatic O +
changes O +
involving O +
≥8 O +
bp O +
are O +
observed O +
( O -
Type O +
B O -
) O +
( O -
Figure O +
1E O -
– O -
H O -
) O -
. O +

Because O +
Type O +
B O +
alterations O +
involve O +
large O +
differences O +
in O +
microsatellite O +
length O -
, O +
it O +
can O +
sometimes O +
appear O +
as O +
if O +
a O +
' O -
third O -
' O +
allele O +
is O +
present O +
in O +
addition O +
to O +
the O +
parental O +
alleles O +
( O -
Figure O +
1E O -
– O -
H O -
) O -
. O +

Throughout O +
the O +
analyses O +
using O +
this O +
technique O -
, O +
results O +
were O +
highly O +
reproducible O +
in O +
several O +
independent O +
experiments O -
. O +

Neither O +
additional O +
peaks O +
nor O +
changes O +
in O +
the O +
ratio O +
between O +
peaks O +
were O +
noted O -
. O +

Microsatellite O +
instability O +
observed O +
in O +
mismatch B-Gene +
repair I-Gene +
gene I-Gene -
- O -
knockout O +
mice O +
To O +
analyse O +
MSI O +
in O +
a O +
defined O +
genetic O +
background O -
, O +
we O +
used O +
the O +
Msh2− B-Gene -
/ O -
− O +
MEF O +
cell O +
line O +
RH95021 O +
( O -
12 O -
) O -
. O +

Alterations O +
in O +
the O +
lengths O +
of O +
three O +
dinucleotide O +
microsatellites O +
were O +
analysed O +
in O +
RH95021 O +
subclones O -
. O +

The O +
majority O +
of O +
subclones O +
( O -
14 O -
/ O -
21 O -
) O +
exhibited O +
the O +
same O +
configuration O +
at O +
the O +
D6Mit59 O +
locus O +
( O -
exemplified O +
by O +
clone O +
a O -
, O +
Figure O +
2A O -
) O -
. O +

In O +
clones O +
that O +
deviated O +
from O +
this O +
predominant O +
pattern O +
( O -
Figure O +
2A O -
, O +
clones O +
b O -
– O -
d O -
) O -
, O +
the O +
microsatellite O +
length O +
was O +
altered O +
by O +
≤4 O +
bp O -
. O +

In O +
other O +
words O -
, O +
the O +
microsatellite O +
changes O +
were O +
invariably O +
Type O +
A. O +
A O +
similar O +
pattern O +
of O +
small O -
- O -
scale O +
microsatellite O +
changes O +
was O +
observed O +
at O +
two O +
other O +
dinucleotide O +
microsatellites O -
, O +
D1Mit62 O +
and O +
D7Mit91 O +
( O -
data O +
not O +
shown O -
) O -
. O +

To O +
investigate O +
whether O +
Type O +
B O +
variations O +
might O +
simply O +
reflect O +
the O +
accumulation O +
of O +
numerous O +
smaller O +
alterations O +
over O +
many O +
generations O -
, O +
RH95021 O +
cells O +
were O +
continuously O +
cultured O -
, O +
and O +
sampled O +
periodically O +
at O +
different O +
passages O -
. O +

As O +
shown O +
in O +
Figure O +
2B O -
, O +
even O +
after O +
undergoing O +
81 O +
population O +
doublings O +
( O -
281 O +
corresponds O +
to O +
1024 O -
) O -
, O +
there O +
was O +
no O +
detectable O +
appearance O +
of O +
shorter O +
or O +
longer O +
D6Mit59 O +
alleles O -
. O +

Similar O +
patterns O +
were O +
observed O +
at O +
the O +
two O +
other O +
microsatellite O +
loci O +
( O -
data O +
not O +
shown O -
) O -
. O +

Thus O -
, O +
there O +
was O +
no O +
evidence O +
of O +
the O +
accumulation O +
of O +
changes O +
consistent O +
with O +
Type O +
B O +
instability O +
at O +
any O +
of O +
the O +
three O +
microsatellites O +
in O +
these O +
MMR B-Gene -
- O -
defective O +
MEFs O -
. O +

Similar O +
data O +
were O +
obtained O +
using O +
a O +
second O +
MMR B-Gene -
- O -
deficient O +
MEF O +
cell O +
line O -
, O +
MC2 O -
, O +
which O +
derived O +
from O +
an O +
Mlh1− B-Gene -
/ O -
− O +
mouse O +
( O -
data O +
not O +
shown O -
) O -
. O +

We O +
also O +
examined O +
microsatellite O +
instability O +
in O +
lymphomas O +
and O +
adenocarcinomas O +
that O +
arose O +
in O +
various O +
organs O +
of O +
Msh2− B-Gene -
/ O -
−mice O -
. O +

Among O +
16 O +
tumours O +
that O +
were O +
analysed O +
at O +
the O +
three O +
microsatellite O +
loci O -
, O +
each O +
contained O +
alterations O +
at O +
one O +
or O +
more O +
locus O -
. O +

In O +
all O +
cases O -
, O +
changes O +
were O +
limited O +
to O +
≤6 O +
bp O +
( O -
examples O +
are O +
shown O +
in O +
Figure O +
2C O -
) O +
and O +
no O +
Type O +
B O +
alteration O +
was O +
observed O -
. O +

Intriguingly O -
, O +
an O +
examination O +
of O +
published O +
microsatellite O +
changes O +
in O +
cells O +
of O +
MMR B-Gene +
gene O -
- O -
knockout O +
mice O +
clearly O +
indicates O +
that O +
most O +
changes O +
are O +
of O +
Type O +
A O +
( O -
12,18,19 O -
) O -
. O +

Type O +
B O +
MSI O +
may O +
involve O +
molecular O +
abnormalities O +
in O +
addition O +
to O +
defective O +
MMR B-Gene -
. O +

We O +
suggest O +
that O +
whereas O +
Type O +
A O +
MSI O +
probably O +
reflects O +
the O +
uncorrected O +
DNA O +
polymerase O +
slippage O +
events O +
that O +
accumulate O +
in O +
MMR B-Gene -
- O -
defective O +
cells O -
, O +
inappropriate O +
processing O +
of O +
damage O +
by O +
recombinational O +
DNA O +
repair O +
may O +
contribute O +
to O +
Type O +
B O +
MSI O -
. O +

This O +
hypothesis O +
may O +
be O +
supported O +
partly O +
by O +
our O +
observation O +
that O +
there O +
was O +
no O +
evidence O +
of O +
the O +
emergence O +
of O +
Type O +
B O +
instability O +
in O +
MMR B-Gene +
gene O -
- O -
knockout O +
animals O -
. O +

It O +
is O +
known O +
that O +
microsatellite O +
alterations O +
occur O +
via O +
several O +
independent O +
mechanisms O -
, O +
including O +
recombination O +
( O -
44–46 O -
) O -
, O +
and O +
MMR B-Gene +
counteracts O +
incorrect O +
strand O +
alignment O +
during O +
homologous O +
recombination O +
( O -
47 O -
) O -
. O +

The O +
drastic O +
microsatellite O +
changes O +
in O +
Type O +
B O +
MSI O +
may O +
be O +
more O +
consistent O +
with O +
dynamic O +
events O -
, O +
such O +
as O +
recombination O -
, O +
than O +
with O +
replication O +
slippage O -
. O +

In O +
this O +
context O -
, O +
defective O +
MMR B-Gene +
might O +
be O +
a O +
promoting O -
, O +
and O +
consequently O +
highly O +
coincidental O -
, O +
but O +
insufficient O +
factor O +
for O +
Type O +
B O +
changes O -
. O +

Connection O +
between O +
MSI O +
and O +
the O +
recombinational O +
repair O +
pathway O +
in O +
tumours O -
, O +
particularly O +
in O +
HNPCC O -
, O +
may O +
warrant O +
attention O -
. O +

Type O +
A O +
MSI O +
is O +
also O +
strongly O +
associated O +
with O +
p53 B-Gene +
mutation O +
in O +
human O +
colorectal O +
tumours O -
. O +

This O +
observation O +
may O +
be O +
compatible O +
with O +
several O +
recent O +
reports O +
( O -
36,48,49 O -
) O +
that O +
have O +
shown O +
a O +
connection O +
between O +
p53 B-Gene +
mutation O +
and O +
the O +
MSI O -
- O -
L O +
phenotype O -
, O +
since O +
in O +
colorectal O +
cancer O +
Type O +
A O +
MSI O +
tends O +
to O +
be O +
observed O +
in O +
a O +
limited O +
number O +
of O +
markers O +
and O -
, O +
consequently O -
, O +
categorized O +
as O +
MSI O -
- O -
L. O +
This O +
finding O +
may O +
also O +
provide O +
an O +
insight O +
to O +
the O +
mechanism O +
of O +
genetic O +
instability O +
in O +
tumours O -
. O +

Genetic O +
instability O +
in O +
tumours O +
has O +
been O +
regarded O +
as O +
deriving O +
from O +
two O +
mutually O +
exclusive O +
pathways O -
, O +
chromosomal O +
instability O +
( O -
CIN O -
) O -
—frequently O +
associated O +
with O +
mutations O +
in O +
various O +
oncogenes O +
or O +
tumour O +
suppressor O +
genes O +
such O +
as O +
p53—and B-Gene +
' O -
microsatellite O +
mutator O +
phenotype O +
( O -
MMP O -
) O -
' O +
( O -
29,30 O -
) O -
, O +
in O +
which O +
p53 B-Gene +
mutations O +
are O +
rare O +
and O -
, O +
instead O -
, O +
mutations O +
are O +
found O +
in O +
mononucleotide O +
repeats O +
within O +
genes O +
of O +
a O +
different O +
variety O -
. O +

Several O +
recent O +
reports O +
suggest O +
that O +
there O +
might O +
be O +
an O +
oversimplification O +
in O +
this O +
distinction O +
( O -
50–53 O -
) O -
. O +

From O +
our O +
observations O -
, O +
dinucleotide O +
MSI O +
in O +
tumours O +
can O +
be O +
divided O +
into O +
two O +
modes O -
, O +
Type O +
A O +
and O +
Type O +
B O -
, O +
and O +
Type O +
A O +
instability O +
is O +
the O +
direct O +
consequence O +
of O +
defective O +
MMR B-Gene -
. O +

A O +
close O +
association O +
of O +
Type O +
A O +
MSI O +
with O +
p53 B-Gene +
mutation O +
may O +
suggest O +
a O +
hitherto O +
unrecognized O +
causal O +
relationship O +
between O +
p53 B-Gene +
mutation O +
and O +
defective O +
MMR B-Gene -
. O +

p53 B-Gene +
mutations O +
may O +
derive O +
from O +
a O +
state O +
with O +
an O +
elevated O +
mutation O +
rate O -
, O +
i.e. O +
MMR B-Gene -
- O -
deficient O +
phenotype O -
, O +
as O +
initially O +
suspected O -
. O +

Thus O -
, O +
our O +
observations O +
suggest O +
added O +
complexities O +
to O +
the O +
relationship O +
between O +
MMR B-Gene +
defects O +
and O +
MSI O -
, O +
and O +
also O +
shed O +
light O +
on O +
previously O +
unrecognized O +
fundamental O +
processes O +
in O +
the O +
molecular O +
mechanisms O +
of O +
genetic O +
instability O +
underlying O +
tumour O +
development O -
. O +

Numbers O +
of O +
mutations O +
to O +
different O +
types O +
of O +
colorectal O +
cancer O +
Abstract O +
Background O +
The O +
numbers O +
of O +
oncogenic O +
mutations O +
required O +
for O +
transformation O +
are O +
uncertain O +
but O +
may O +
be O +
inferred O +
from O +
how O +
cancer O +
frequencies O +
increase O +
with O +
aging O -
. O +

Cancers O +
requiring O +
more O +
mutations O +
will O +
tend O +
to O +
appear O +
later O +
in O +
life O -
. O +

This O +
type O +
of O +
approach O +
may O +
be O +
confounded O +
by O +
biologic O +
heterogeneity O +
because O +
different O +
cancer O +
subtypes O +
may O +
require O +
different O +
numbers O +
of O +
mutations O -
. O +

For O +
example O -
, O +
a O +
sporadic O +
cancer O +
should O +
require O +
at O +
least O +
one O +
more O +
somatic O +
mutation O +
relative O +
to O +
its O +
hereditary O +
counterpart O -
. O +

Methods O +
To O +
better O +
estimate O +
numbers O +
of O +
mutations O +
before O +
transformation O -
, O +
1,022 O +
colorectal O +
cancers O +
were O +
classified O +
with O +
respect O +
to O +
microsatellite O +
instability O +
( O -
MSI O -
) O +
and O +
germline O +
DNA O +
mismatch O +
repair O +
mutations O +
characteristic O +
of O +
hereditary O +
nonpolyposis O +
colorectal O +
cancer O +
( O -
HNPCC O -
) O -
. O +

MSI- O +
cancers O +
were O +
also O +
classified O +
with O +
respect O +
to O +
clinical O +
stage O -
. O +

Ages O +
at O +
cancer O +
and O +
a O +
Bayesian O +
algorithm O +
were O +
used O +
to O +
estimate O +
the O +
numbers O +
of O +
oncogenic O +
mutations O +
required O +
for O +
transformation O +
for O +
each O +
cancer O +
subtype O -
. O +

Results O +
Ages O +
at O +
MSI+ O +
cancers O +
were O +
consistent O +
with O +
five O +
or O +
six O +
oncogenic O +
mutations O +
for O +
hereditary O +
( O -
HNPCC O -
) O +
cancers O -
, O +
and O +
seven O +
or O +
eight O +
mutations O +
for O +
its O +
sporadic O +
counterpart O -
. O +

Ages O +
at O +
cancer O +
were O +
consistent O +
with O +
seven O +
mutations O +
for O +
sporadic O +
MSI- O +
cancers O -
, O +
and O +
were O +
similar O +
( O -
six O +
to O +
eight O +
mutations O -
) O +
regardless O +
of O +
clinical O +
cancer O +
stage O -
. O +

Conclusion O +
Different O +
biologic O +
subtypes O +
of O +
colorectal O +
cancer O +
appear O +
to O +
require O +
different O +
numbers O +
of O +
oncogenic O +
mutations O +
before O +
transformation O -
. O +

Sporadic O +
MSI+ O +
cancers O +
may O +
require O +
more O +
than O +
a O +
single O +
additional O +
somatic O +
alteration O +
compared O +
to O +
hereditary O +
MSI+ O +
cancers O +
because O +
the O +
epigenetic O +
inactivation O +
of O +
MLH1 B-Gene +
commonly O +
observed O +
in O +
sporadic O +
MSI+ O +
cancers O +
may O +
be O +
a O +
multistep O +
process O -
. O +

Interestingly O -
, O +
estimated O +
numbers O +
of O +
MSI- O +
cancer O +
mutations O +
were O +
similar O +
( O -
six O +
to O +
eight O +
mutations O -
) O +
regardless O +
of O +
clinical O +
cancer O +
stage O -
, O +
suggesting O +
a O +
propensity O +
to O +
spread O +
or O +
metastasize O +
does O +
not O +
require O +
additional O +
mutations O +
after O +
transformation O -
. O +

Estimates O +
of O +
oncogenic O +
mutation O +
numbers O +
may O +
help O +
explain O +
some O +
of O +
the O +
biology O +
underlying O +
different O +
cancer O +
subtypes O -
. O +

Methods O +
Specimens O +
MSI O +
status O +
was O +
determined O +
for O +
1,022 O +
colorectal O +
cancers O +
sampled O +
from O +
nine O +
large O +
regional O +
hospitals O +
in O +
southeastern O +
Finland O +
as O +
part O +
of O +
a O +
study O +
to O +
characterize O +
genetic O +
alterations O +
in O +
a O +
well O -
- O -
defined O +
population O +
[ O -
9 O -
] O -
. O +

The O +
cancers O +
represent O +
approximately O +
60 O -
% O +
of O +
all O +
colorectal O +
cancers O +
removed O +
from O +
this O +
population O +
in O +
1994 O +
to O +
1998 O +
[ O -
9 O -
] O -
. O +

Germline O +
mutations O +
in O +
MLH1 B-Gene +
or O +
MSH2 B-Gene +
were O +
detected O +
by O +
allelic O +
specific O +
PCR O +
assays O +
( O -
for O +
the O +
two O +
common O +
Finnish O +
MLH1 B-Gene +
germline O +
mutations O -
) O +
or O +
by O +
direct O +
genomic O +
sequencing O +
of O +
coding O +
exons O +
[ O -
9 O -
] O -
. O +

The O +
data O +
can O +
be O +
downloaded O +
from O +
the O +
following O +
website O -
: O +
. O +

Approval O +
for O +
this O +
research O +
was O +
obtained O +
from O +
the O +
appropriate O +
ethics O +
committees O -
, O +
which O +
are O +
in O +
compliance O +
with O +
the O +
Helsinki O +
Declaration O -
. O +

A O +
second O +
data O +
set O +
( O -
SEER O +
11 O +
Regs O +
Public O -
- O -
Use O -
, O +
Nov O +
2001 O +
Sub O +
( O -
1992–1999 O -
) O -
) O +
was O +
obtained O +
from O +
the O +
Surveillance O -
, O +
Epidemiology O -
, O +
and O +
End O +
Results O +
( O -
SEER O -
) O +
Program O -
, O +
a O +
population O -
- O -
based O +
registry O +
in O +
the O +
United O +
States O +
of O +
America O +
that O +
records O +
all O +
cancers O +
regardless O +
of O +
clinical O +
treatment O +
[ O -
10 O -
] O -
. O +

A O +
total O +
of O +
108,275 O +
records O +
were O +
analyzed O +
for O +
ages O +
at O +
cancer O +
selected O +
by O +
site O +
( O -
colon O +
and O +
rectum O -
) O -
, O +
race O +
( O -
white O -
) O -
, O +
histology O +
( O -
adenocarcinoma O -
, O +
ICD-0 O -
- O -
2 O +
codes O +
8000–8500 O -
) O -
, O +
and O +
stage O +
( O -
localized O -
, O +
regional O -
, O +
or O +
distant O -
) O -
. O +

These O +
cancers O +
were O +
not O +
characterized O +
with O +
respect O +
to O +
HNPCC O +
or O +
MSI O -
. O +

Quantitative O +
analysis O +
Numbers O +
of O +
oncogenic O +
alterations O +
( O -
genetic O +
mutations O +
or O +
epigenetic O +
alterations O -
) O +
required O +
for O +
transformation O +
were O +
estimated O +
from O +
ages O +
at O +
cancer O +
using O +
a O +
Bayesian O +
approach O +
as O +
previously O +
described O +
[ O -
11 O -
] O -
. O +

This O +
method O +
requires O +
the O +
use O +
of O +
a O +
life O +
table O +
from O +
census O +
data O -
: O +
for O +
the O +
Finnish O +
data O +
set O +
we O +
used O +
a O +
Finnish O +
life O +
table O +
from O +
the O +
World O +
Health O +
Organization O +
website O +
, O +
for O +
the O +
SEER O +
dataset O +
we O +
used O +
a O +
United O +
States O +
life O +
table O +
as O +
described O +
previously O +
[ O -
11 O -
] O -
. O +

The O +
model O +
assumes O +
the O +
first O +
visible O +
clonal O +
expansion O +
occurs O +
at O +
the O +
time O +
of O +
transformation O +
and O +
ignores O +
the O +
interval O +
after O +
transformation O -
. O +

The O +
analysis O +
ignores O +
temporal O +
trends O -
, O +
which O +
may O +
influence O +
our O +
mutation O +
estimates O -
. O +

For O +
the O +
SEER O +
dataset O -
, O +
we O +
also O +
fit O +
our O +
model O +
for O +
cancer O +
progression O +
[ O -
11 O -
] O +
with O +
the O +
inferential O +
method O +
described O +
in O +
reference O +
12 O -
. O +

This O +
method O +
does O +
not O +
require O +
a O +
life O +
table O -
, O +
but O +
unlike O +
our O +
method O +
it O +
does O +
require O +
information O +
on O +
all O +
the O +
cancer O +
cases O +
for O +
the O +
population O +
at O +
risk O -
. O +

Therefore O +
this O +
method O +
is O +
appropriate O +
for O +
analysing O +
the O +
SEER O +
dataset O +
but O +
not O +
the O +
Finnish O +
dataset O -
. O +

Our O +
method O +
[ O -
11 O -
] O +
is O +
appropriate O +
for O +
analysing O +
both O +
datasets O -
. O +

For O +
the O +
SEER O +
dataset O -
, O +
the O +
two O +
methods O +
inferred O +
the O +
same O +
number O +
of O +
mutations O +
required O +
for O +
cancer O -
. O +

Results O +
The O +
presence O +
or O +
absence O +
of O +
MSI O +
was O +
determined O +
for O +
1,022 O +
colorectal O +
cancers O +
obtained O +
from O +
nine O +
large O +
regional O +
hospitals O +
in O +
southeastern O +
Finland O +
[ O -
9 O -
] O -
. O +

There O +
were O +
895 O +
( O -
87.6 O -
% O -
) O +
MSI- O +
cancers O +
and O +
127 O +
( O -
12.4 O -
% O -
) O +
MSI+ O +
cancers O -
. O +

The O +
MSI+ O +
cancers O +
were O +
further O +
classified O +
as O +
sporadic O +
( O -
N O +
= O +
98 O +
or O +
9.6 O -
% O +
of O +
all O +
cancers O -
) O +
or O +
HNPCC O +
( O -
N O +
= O +
29 O +
or O +
2.9 O -
% O +
of O +
all O +
cancers O -
) O +
based O +
on O +
germline O +
MLH1 B-Gene +
or O +
MSH2 B-Gene +
mutations O +
( O -
Table O +
1 O -
) O -
. O +

Ages O +
at O +
cancer O +
can O +
be O +
used O +
to O +
estimate O +
likely O +
numbers O +
of O +
oncogenic O +
mutations O +
required O +
before O +
transformation O +
[ O -
3 O -
- O -
6,11 O -
] O -
. O +

Average O +
ages O +
for O +
sporadic O +
MSI+ O -
, O +
MSI- O -
, O +
and O +
HNPCC O +
cancers O +
were O +
respectively O +
71.5 O -
, O +
67.5 O -
, O +
and O +
50.3 O +
years O +
( O -
Figure O +
1A O -
) O -
. O +

For O +
HNPCC O +
cancers O -
, O +
estimated O +
numbers O +
of O +
oncogenic O +
mutations O +
were O +
between O +
four O +
and O +
seven O +
( O -
95 O -
% O +
credibility O +
interval O -
) O -
, O +
with O +
the O +
most O +
likely O +
value O +
of O +
five O +
mutations O +
( O -
Table O +
1 O -
) O -
. O +

For O +
MSI+ O +
sporadic O +
cancers O -
, O +
estimated O +
numbers O +
of O +
mutations O +
were O +
between O +
six O +
and O +
nine O +
( O -
95 O -
% O +
credibility O +
interval O -
) O +
with O +
more O +
likely O +
values O +
of O +
seven O +
or O +
eight O +
mutations O -
. O +

The O +
most O +
likely O +
number O +
of O +
mutations O +
was O +
seven O +
for O +
sporadic O +
MSI- O +
cancers O -
. O +

Duke O -
's O +
stage O +
and O +
age O +
at O +
clinical O +
presentation O +
( O -
Figure O +
1B O -
) O +
were O +
documented O +
for O +
884 O +
of O +
the O +
895 O +
MSI- O +
sporadic O +
cancers O +
( O -
Table O +
1 O -
) O -
. O +

Average O +
ages O +
were O +
68.6 O +
years O +
for O +
stage O +
A O -
, O +
69.0 O +
years O +
for O +
stage O +
B O -
, O +
65.2 O +
years O +
for O +
stage O +
C O -
, O +
and O +
65.4 O +
years O +
for O +
stage O +
D. O +

The O +
most O +
likely O +
numbers O +
of O +
oncogenic O +
mutations O +
were O +
seven O +
for O +
stage O +
A O +
cancers O -
, O +
eight O +
for O +
stage O +
B O +
cancers O -
, O +
and O +
six O +
for O +
stage O +
C O +
or O +
D O +
cancers O +
( O -
Table O +
1 O -
) O -
. O +

Mutation O +
number O +
estimates O +
with O +
respect O +
to O +
clinical O +
stage O +
may O +
be O +
biased O +
with O +
the O +
Finnish O +
data O +
because O +
it O +
includes O +
only O +
specimens O +
with O +
tissue O +
available O +
for O +
molecular O +
analysis O -
. O +

Advanced O +
cancers O +
may O +
not O +
be O +
removed O -
. O +

Therefore O -
, O +
a O +
similar O +
analysis O +
was O +
performed O +
on O +
a O +
population O -
- O -
based O +
cancer O +
registry O +
[ O -
10 O -
] O +
from O +
the O +
United O +
States O +
of O +
America O +
( O -
SEER O +
11 O +
Regs O +
Public O -
- O -
Use O -
, O +
Nov O +
2001 O +
Sub O +
( O -
1992–1999 O -
) O -
) O -
, O +
which O +
records O +
ages O +
and O +
stages O +
at O +
diagnosis O +
regardless O +
of O +
treatment O +
( O -
Table O +
2 O -
) O -
. O +

The O +
average O +
age O +
at O +
diagnosis O +
was O +
70.5 O +
years O -
, O +
consistent O +
with O +
an O +
estimate O +
of O +
six O +
mutations O +
to O +
colorectal O +
cancer O +
for O +
the O +
108,275 O +
white O +
males O +
and O +
females O +
with O +
stage O +
data O -
. O +

Like O +
the O +
Finnish O +
cancers O -
, O +
ages O +
were O +
similar O +
for O +
SEER O +
patients O +
of O +
different O +
clinical O +
stages O -
, O +
with O +
an O +
estimate O +
of O +
six O +
mutations O +
for O +
cancers O +
with O +
localized O -
, O +
regional O +
or O +
distant O +
clinical O +
stages O +
( O -
Table O +
2 O +
and O +
Figure O +
1C O -
) O -
. O +

Colorectal O +
cancers O +
also O +
differ O +
by O +
their O +
extent O +
of O +
spread O -
. O +

Progression O +
to O +
metastasis O +
may O +
involve O +
a O +
long O +
sequence O +
of O +
potentially O +
rate O +
limiting O +
steps O +
[ O -
21 O -
] O -
. O +

If O +
invasion O +
or O +
metastasis O +
depends O +
on O +
mutations O +
that O +
arise O +
after O +
transformation O -
, O +
advanced O +
cancers O +
should O +
require O +
more O +
oncogenic O +
mutations O +
and O +
more O +
time O +
for O +
progression O +
( O -
Figure O +
2 O -
) O -
. O +

However O -
, O +
ages O +
at O +
diagnosis O +
and O +
estimated O +
mutation O +
numbers O +
did O +
not O +
markedly O +
differ O +
between O +
cancers O +
of O +
different O +
clinical O +
stages O -
. O +

Equivalent O +
numbers O +
of O +
mutations O +
regardless O +
of O +
clinical O +
stage O +
are O +
consistent O +
with O +
recent O +
speculation O +
that O +
an O +
invasive O +
potential O +
is O +
acquired O +
early O +
in O +
progression O +
[ O -
22 O -
] O -
, O +
albeit O +
only O +
rare O +
cells O +
actually O +
form O +
visible O +
metastases O -
. O +

Primary O +
breast O +
cancer O +
expression O +
patterns O +
correlate O +
with O +
clinical O +
outcomes O +
or O +
metastases O +
[ O -
22 O -
- O -
25 O -
] O -
, O +
suggesting O +
that O +
a O +
propensity O +
to O +
spread O +
is O +
already O +
present O +
at O +
the O +
time O +
of O +
transformation O -
. O +

Alternatively O -
, O +
all O +
cancers O +
may O +
have O +
the O +
same O +
abilities O +
to O +
invade O +
and O +
metastasize O -
, O +
with O +
clinical O +
stage O +
dependent O +
on O +
random O +
events O +
that O +
occur O +
rapidly O +
after O +
transformation O -
. O +

A O +
short O +
interval O +
between O +
transformation O +
and O +
detection O +
may O +
help O +
limit O +
spread O +
because O +
clinical O +
surveillance O +
tends O +
to O +
detect O +
localized O +
colorectal O +
cancers O +
[ O -
26 O -
- O -
28 O -
] O -
. O +

Multistage O +
models O +
are O +
mechanistically O +
different O +
from O +
tumor O +
progression O +
models O +
and O +
more O +
consistent O +
with O +
a O +
hypothesis O +
that O +
mutations O +
acquired O +
early O +
during O +
progression O +
help O +
determine O +
extent O +
of O +
invasion O +
( O -
Figure O +
3 O -
) O -
. O +

Mutations O +
sequentially O +
accumulate O +
before O +
transformation O +
in O +
both O +
models O -
, O +
but O +
the O +
adenoma O -
- O -
cancer O +
sequence O +
suggests O +
most O +
cancer O +
mutations O +
start O +
to O +
accumulate O +
after O +
the O +
age O +
of O +
50 O +
years O +
in O +
adenomas O +
[ O -
7 O -
] O -
. O +

Such O +
tumor O +
progression O +
imposes O +
purpose O +
to O +
early O +
mutations O +
because O +
each O +
additional O +
mutation O +
confers O +
incremental O +
changes O +
to O +
a O +
non O -
- O -
invasive O +
adenoma O +
phenotype O -
. O +

Therefore O -
, O +
tumor O +
progression O +
models O +
would O +
likely O +
differ O +
between O +
MSI+ O +
and O +
MSI- O +
cancers O +
because O +
their O +
biology O +
and O +
types O +
of O +
mutations O +
are O +
quite O +
different O +
[ O -
7,8 O -
] O -
. O +

In O +
contrast O -
, O +
mutations O +
accumulate O +
throughout O +
life O +
in O +
multistage O +
models O -
. O +

Genetically O +
engineered O +
mice O +
and O +
familial O +
cancer O +
syndromes O +
reveal O +
that O +
many O +
oncogenic O +
mutations O +
are O +
also O +
compatible O +
with O +
normal O +
phenotypes O +
[ O -
11 O -
] O -
, O +
allowing O +
for O +
the O +
possibility O +
that O +
many O +
" O -
cancer O -
" O +
mutations O +
may O +
first O +
accumulate O +
in O +
normal O -
- O -
appearing O +
colon O +
very O +
early O +
in O +
life O -
. O +

Such O +
pretumor O +
progression O +
[ O -
11 O -
] O +
more O +
readily O +
allows O +
for O +
an O +
invasive O +
or O +
metastatic O +
cancer O +
phenotype O +
at O +
transformation O +
because O +
genetic O +
progression O +
is O +
uncoupled O +
from O +
tumor O +
progression O +
( O -
Figure O +
2 O -
) O -
. O +

Rather O +
than O +
incremental O +
stepwise O +
changes O +
in O +
phenotype O +
after O +
each O +
new O +
mutation O -
, O +
a O +
tumor O +
phenotype O +
may O +
only O +
emerge O +
after O +
several O +
initially O +
occult O +
mutations O +
accumulate O +
in O +
a O +
single O +
normal O +
appearing O +
cell O -
. O +

In O +
this O +
way O +
our O +
multistage O +
model O +
can O +
apply O +
to O +
both O +
MSI+ O +
and O +
MSI- O +
cancers O +
despite O +
their O +
marked O +
differences O +
in O +
types O +
of O +
mutations O +
because O +
early O +
critical O +
mutations O +
( O -
whatever O +
they O +
are O -
) O +
do O +
not O +
visibly O +
change O +
phenotype O +
but O +
instead O +
accumulate O +
in O +
normal O +
appearing O +
colon O -
. O +

Early O +
or O +
advanced O +
sporadic O +
MSI- O +
colorectal O +
cancers O +
appeared O +
to O +
require O +
similar O +
numbers O +
of O +
mutations O -
, O +
consistent O +
with O +
the O +
phenotype O +
at O +
cancer O +
diagnosis O +
contingent O +
on O +
mutations O +
acquired O +
much O +
earlier O +
in O +
life O +
and O +
present O +
at O +
the O +
time O +
of O +
transformation O -
. O +

However O -
, O +
ascertainment O +
bias O +
may O +
also O +
be O +
responsible O +
for O +
the O +
similar O +
frequency O -
- O -
age O +
distributions O +
of O +
colorectal O +
cancers O +
of O +
different O +
clinical O +
stages O -
. O +

Progression O +
to O +
cancer O +
has O +
been O +
modeled O +
by O +
a O +
number O +
of O +
investigators O +
with O +
different O +
approaches O +
and O +
assumptions O +
[ O -
3 O -
- O -
6,11 O -
- O -
14,29,30 O -
] O -
. O +

In O +
our O +
previously O +
reported O +
approach O +
there O +
is O +
no O +
growth O +
until O +
after O +
the O +
last O +
required O +
mutation O +
has O +
been O +
acquired O +
[ O -
11 O -
] O -
. O +

In O +
this O +
paper O +
we O +
apply O +
this O +
model O +
to O +
cancer O +
subtypes O +
instead O +
of O +
considering O +
colorectal O +
cancers O +
as O +
a O +
single O +
uniform O +
disease O -
. O +

Modeling O +
is O +
potentially O +
more O +
informative O +
and O +
specific O +
when O +
applied O +
to O +
distinct O +
cancer O +
subtypes O +
because O +
their O +
progression O +
pathways O +
can O +
differ O -
. O +

The O +
ability O +
to O +
apply O +
a O +
simple O +
multistage O +
model O +
to O +
different O +
colorectal O +
cancer O +
subtypes O +
that O +
have O +
marked O +
differences O +
in O +
final O +
types O +
of O +
mutations O +
and O +
clinical O +
outcomes O +
suggests O +
its O +
basic O +
underlying O +
premise O +
( O -
most O +
critical O +
alterations O +
first O +
accumulate O +
in O +
normal O +
colon O -
) O +
may O +
be O +
correct O -
. O +

Mutations O +
in O +
, O +
and O +
genes O +
and O +
expression O +
of O +
hMLH1 B-Gene +
in O +
sporadic O +
colorectal O +
carcinomas O +
from O +
the O +
Netherlands O +
Cohort O +
Study O +
Abstract O +

Background O +
The O +
early O +
to O +
intermediate O +
stages O +
of O +
the O +
majority O +
of O +
colorectal O +
tumours O +
are O +
thought O +
to O +
be O +
driven O +
by O +
aberrations O +
in O +
the O +
Wnt B-Gene +
( O -
APC B-Gene -
, O +
CTNNB1 B-Gene -
) O +
and O +
Ras B-Gene +
( O -
K B-Gene -
- I-Gene -
ras I-Gene -
) O +
pathways O -
. O +

A O +
smaller O +
proportion O +
of O +
cancers O +
shows O +
mismatch O +
repair O +
deficiency O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
analyse O +
the O +
co O -
- O -
occurrence O +
of O +
these O +
genetic O +
alterations O +
in O +
relation O +
to O +
tumour O +
and O +
patient O +
characteristics O -
. O +

Methods O +
In O +
a O +
group O +
of O +
656 O +
unselected O +
sporadic O +
colorectal O +
cancer O +
patients O -
, O +
aberrations O +
in O +
the O +
APC B-Gene -
, O +
K B-Gene -
- I-Gene -
ras I-Gene -
, O +
CTNNB1 B-Gene +
genes O -
, O +
and O +
expression O +
of O +
hMLH1 B-Gene +
were O +
investigated O -
. O +

Additionally O -
, O +
tumours O +
were O +
divided O +
in O +
groups O +
based O +
on O +
molecular O +
features O +
and O +
compared O +
with O +
respect O +
to O +
patient O -
's O +
age O +
at O +
diagnosis O -
, O +
sex O -
, O +
family O +
history O +
of O +
colorectal O +
cancer O -
, O +
tumour O +
sub O -
- O -
localisation O -
, O +
Dukes O -
' O +
stage O +
and O +
differentiation O -
. O +

Results O +
Mutations O +
at O +
the O +
phosphorylation O +
sites O +
( O -
codons O +
31 O -
, O +
33 O -
, O +
37 O -
, O +
and O +
45 O -
) O +
in O +
the O +
CTNNB1 B-Gene +
gene O +
were O +
observed O +
in O +
tumours O +
from O +
only O +
5 O -
/ O -
464 O +
patients O -
. O +

Tumours O +
with O +
truncating O +
APC B-Gene +
mutations O +
and O +
activating O +
K B-Gene -
- I-Gene -
ras I-Gene +
mutations O +
in O +
codons O +
12 O +
and O +
13 O +
occurred O +
at O +
similar O +
frequencies O +
( O -
37 O -
% O +
( O -
245 O -
/ O -
656 O -
) O +
and O +
36 O -
% O +
( O -
235 O -
/ O -
656 O -
) O -
, O +
respectively O -
) O -
. O +

Seventeen O +
percent O +
of O +
tumours O +
harboured O +
both O +
an O +
APC B-Gene +
and O +
a O +
K B-Gene -
- I-Gene -
ras I-Gene +
mutation O +
( O -
109 O -
/ O -
656 O -
) O -
. O +

Nine O +
percent O +
of O +
all O +
tumours O +
( O -
58 O -
/ O -
656 O -
) O +
lacked O +
hMLH1 B-Gene +
expression O -
. O +

Patients O +
harbouring O +
a O +
tumour O +
with O +
absent O +
hMLH1 B-Gene +
expression O +
were O +
older O -
, O +
more O +
often O +
women O -
, O +
more O +
often O +
had O +
proximal O +
colon O +
tumours O +
that O +
showed O +
poorer O +
differentiation O +
when O +
compared O +
to O +
patients O +
harbouring O +
tumours O +
with O +
an O +
APC B-Gene +
and/or O +
K B-Gene -
- I-Gene -
ras I-Gene +
mutation O -
. O +

Conclusion O +
CTNNB1 B-Gene +
mutations O +
seem O +
to O +
be O +
of O +
minor O +
importance O +
in O +
sporadic O +
colorectal O +
cancer O -
. O +

The O +
main O +
differences O +
in O +
tumour O +
and O +
patient O +
characteristics O +
are O +
found O +
between O +
groups O +
of O +
patients O +
based O +
on O +
mismatch O +
repair O +
deficiency O -
. O +

Considering O +
the O +
aforementioned O +
issues O -
, O +
there O +
is O +
a O +
need O +
for O +
studies O +
addressing O +
the O +
heterogeneity O +
of O +
affected O +
genes O +
involved O +
in O +
early O +
to O +
intermediate O +
colorectal O +
cancer O +
development O +
in O +
large O +
groups O +
of O +
patients O -
. O +

We O +
have O +
previously O +
studied O +
the O +
occurrence O +
of O +
APC B-Gene +
and O +
K B-Gene -
- I-Gene -
ras I-Gene +
mutations O +
separately O +
[ O -
27,28 O -
] O -
. O +

In O +
the O +
current O +
study O -
, O +
in O +
addition O +
to O +
investigating O +
mutations O +
in O +
the O +
APC B-Gene -
, O +
CTNNB1 B-Gene +
and O +
K B-Gene -
- I-Gene -
ras I-Gene +
genes O +
as O +
well O +
as O +
mismatch O +
repair O +
deficiency O +
by O +
means O +
of O +
hMLH1 B-Gene +
expression O -
, O +
and O +
combinations O +
of O +
these O +
aberrations O -
, O +
their O +
relation O +
with O +
various O +
tumour O +
and O +
patient O +
characteristics O +
were O +
studied O +
in O +
a O +
large O -
, O +
unselected O +
group O +
of O +
incident O +
colorectal O +
cancer O +
patients O -
. O +

K B-Gene -
- I-Gene -
ras I-Gene +
mutation O +
analysis O +
Mutation O +
analysis O +
of O +
the O +
exon O +
1 O +
fragment O +
of O +
the O +
K B-Gene -
- I-Gene -
ras I-Gene +
oncogene O -
, O +
spanning O +
codons O +
8–29 O -
, O +
was O +
performed O +
on O +
archival O +
colorectal O +
adenocarcinoma O +
specimens O +
of O +
737 O +
patients O -
, O +
using O +
nested O +
PCR O -
, O +
followed O +
by O +
direct O +
sequencing O +
of O +
purified O +
fragments O +
[ O -
27 O -
] O -
. O +

The O +
detection O +
limit O +
was O +
5 O -
% O +
mutated O +
DNA O +
and O +
duplicate O +
experiments O +
revealed O +
a O +
good O +
reproducibility O +
( O -
88 O -
% O -
) O +
[ O -
27 O -
] O -
. O +

APC B-Gene +
mutation O +
analysis O +
The O +
majority O +
of O +
somatic O +
mutations O +
in O +
the O +
APC B-Gene +
gene O +
are O +
found O +
within O +
the O +
mutation O +
cluster O +
region O +
( O -
codons O +
1286–1520 O -
) O -
. O +

Mutation O +
analysis O +
of O +
the O +
mutation O +
cluster O +
region O +
was O +
performed O +
on O +
adenocarcinoma O +
DNA O +
using O +
nested O +
PCR O +
for O +
amplification O +
of O +
the O +
mutation O +
cluster O +
region O +
as O +
four O +
overlapping O +
DNA O +
fragments O +
followed O +
by O +
direct O +
sequencing O +
of O +
purified O +
fragments O -
, O +
as O +
previously O +
described O +
[ O -
28 O -
] O -
. O +

An O +
alternative O +
nested O +
PCR O +
strategy O +
was O +
performed O +
when O +
nested O +
PCR O +
failed O +
for O +
any O +
of O +
the O +
fragments O -
, O +
using O +
different O +
primers O -
. O +

The O +
detection O +
limit O +
was O +
5 O -
% O +
mutated O +
DNA O +
and O +
duplicate O +
experiments O +
revealed O +
good O +
reproducibility O +
( O -
85% O -
) O -
[ O -
28 O -
] O -
. O +

From O +
72 O +
of O +
the O +
737 O +
patients O +
with O +
sufficient O +
DNA O +
yield O -
, O +
one O +
or O +
more O +
fragments O +
of O +
the O +
mutation O +
cluster O +
region O +
could O +
not O +
be O +
amplified O +
and O +
these O +
patients O +
were O +
not O +
included O +
in O +
this O +
study O -
. O +

CTNNB1 B-Gene +
mutation O +
analysis O +
All O +
464 O +
samples O +
without O +
a O +
truncating O +
APC B-Gene +
mutation O +
( O -
n O +
= O +
411 O -
) O +
and O +
all O +
samples O +
with O +
absent O +
hMLH1 B-Gene +
expression O +
( O -
n O +
= O +
58 O -
) O +
were O +
analysed O +
for O +
mutations O +
in O +
the O +
phosphorylation O +
sites O +
at O +
codons O +
33 O -
, O +
37 O -
, O +
41 O +
and O +
45 O +
in O +
exon O +
3 O +
of O +
the O +
CTNNB1 B-Gene +
gene O -
. O +

This O +
selection O +
was O +
made O -
, O +
since O +
most O +
mutations O +
are O +
expected O +
in O +
these O +
samples O -
. O +

Tumours O +
lacking O +
truncating O +
APC B-Gene +
mutations O +
may O +
harbour O +
CTNNB1 B-Gene +
mutations O +
[ O -
7 O -
] O -
, O +
and O +
microsatellite O +
instable O +
tumours O +
are O +
also O +
expected O +
to O +
more O +
frequently O +
have O +
mutations O +
in O +
CTNNB1 B-Gene +
[ O -
26 O -
] O -
. O +

Amplification O +
of O +
exon O +
3 O +
of O +
the O +
CTNNB1 B-Gene +
gene O +
entailed O +
a O +
semi O -
- O -
nested O +
PCR O +
strategy O -
, O +
which O +
covered O +
codons O +
33 O -
, O +
37 O -
, O +
41 O +
and O +
45 O -
. O +

Flank O +
PCR O +
was O +
performed O +
to O +
generate O +
a O +
308 O +
bp O +
fragment O +
( O -
primers O -
, O +
forward O -
: O +
5'-CCAATCTACTAATGCTAATACTG-3 O -
' O -
, O +
reverse O -
: O +
5'-GCATTCTGACTTTCAGTAAGGC-3 O -
' O -
) O +
that O +
was O +
used O +
in O +
a O +
1:100 O +
dilution O +
for O +
amplification O +
of O +
the O +
final O +
PCR O +
product O +
( O -
primers O -
, O +
forward O -
: O +
5'-CCAATCTACTAATGCTAATACTG-3 O -
' O -
, O +
reverse O -
: O +
5'-CTTCCTCAGGATTGCCTTTACC-3 O -
' O -
) O -
. O +

In O +
each O +
PCR O -
, O +
one O +
round O +
of O +
35 O +
cycles O +
was O +
performed O -
. O +

The O +
semi O -
- O -
nested O +
PCR O +
products O +
from O +
samples O +
without O +
a O +
truncating O +
APC B-Gene +
mutation O +
were O +
screened O +
for O +
mutations O +
using O +
denaturing O +
high O -
- O -
pressure O +
liquid O +
chromatography O +
( O -
dHPLC O -
) O +
on O +
a O +
WAVE O +
3500 O +
HT O +
system O +
( O -
Transgenomic O +
Inc. O -
, O +
UK O -
) O -
. O +

WAVE O +
analysis O +
was O +
optimised O +
and O +
validated O +
using O +
specific O +
mutations O +
in O +
cell O +
line O +
DNA O -
, O +
i.e. O +
HCT116 O +
( O -
codon O +
45 O -
: O +
3 O +
bp O +
deletion O -
) O +
and O +
SW48 O +
( O -
codon O +
33 O -
: O +
C→A O -
) O +
as O +
well O +
as O +
DNA O +
derived O +
from O +
desmoid O +
tumours O +
from O +
patients O +
( O -
codon O +
41 O -
: O +
A→G O +
and O +
codon O +
45 O -
: O +
C→T O -
) O +
as O +
positive O +
controls O -
. O +

All O +
of O +
these O +
mutations O +
were O +
repeatedly O +
confirmed O +
by O +
sequencing O -
. O +

WAVE O +
analysis O +
was O +
carried O +
out O +
at O +
two O +
different O +
temperatures O +
( O -
57.7 O +
en O +
60 O -
° O -
C O -
) O -
. O +

Samples O +
showing O +
an O +
aberrant O +
elution O +
profile O +
were O +
re O -
- O -
amplified O +
and O +
re O -
- O -
screened O -
. O +

When O +
an O +
aberrant O +
elution O +
profile O +
was O +
confirmed O -
, O +
direct O +
sequencing O +
was O +
performed O -
. O +

All O +
samples O +
without O +
hMLH1 B-Gene +
expression O +
were O +
analysed O +
by O +
direct O +
sequencing O +
without O +
screening O -
. O +

The O +
sequence O +
profile O +
was O +
analysed O +
on O +
an O +
ALFexpress O +
II O +
DNA O +
analysis O +
system O +
using O +
ALFwin O +
software O +
( O -
Amersham O +
Biosciences O -
, O +
Roosendaal O -
, O +
the O +
Netherlands O -
) O -
. O +

hMLH1 B-Gene +
expression O +
Formalin O -
- O -
fixed O -
, O +
paraffin O -
- O -
embedded O +
tissue O +
sections O +
cut O +
at O +
4 O +
μm O -
, O +
which O +
included O +
tumour O +
tissue O +
with O +
normal O +
adjacent O +
mucosa O -
, O +
were O +
used O +
for O +
immunohistochemistry O -
. O +

Endogenous O +
peroxidase O +
activity O +
was O +
blocked O +
by O +
3 O -
% O +
H2O2 O -
. O +

Slides O +
were O +
submitted O +
to O +
microwave O +
antigen O +
retrieval O +
in O +
1 O +
mM O +
EDTA O +
buffer O +
( O -
pH O +
8.0 O -
) O +
and O +
incubated O +
with O +
10 O -
% O +
normal O +
horse O +
serum O +
for O +
ten O +
min O +
at O +
room O +
temperature O -
. O +

Then O -
, O +
sections O +
were O +
incubated O +
overnight O +
at O +
4 O -
° O -
C O +
with O +
mouse O +
monoclonal O +
antibodies O +
against O +
hMLH1 B-Gene +
protein O +
( O -
clone O +
G168 O -
- O -
15 O -
, O +
PharMingen O -
, O +
San O +
Diego O -
, O +
CA O -
) O +
at O +
a O +
1:100 O +
dilution O -
. O +

Antibody O +
binding O +
was O +
detected O +
by O +
incubating O +
the O +
sections O +
at O +
room O +
temperature O +
with O +
the O +
peroxidase O -
- O -
labelled O +
DAKO O +
Envision O +
System O +
( O -
DAKO O -
, O +
Carpinteris O -
, O +
CA O -
) O -
, O +
using O +
DAB O +
as O +
a O +
chromogen O -
. O +

Sections O +
were O +
counterstained O +
with O +
diluted O +
haematoxylin O -
. O +

Lesions O +
were O +
considered O +
to O +
lack O +
hMLH1 B-Gene +
protein O +
expression O +
when O +
unequivocal O +
absence O +
of O +
nuclear O +
staining O +
of O +
the O +
tumour O +
epithelial O +
cells O +
was O +
observed O -
. O +

Nuclear O +
staining O +
of O +
normal O +
epithelial O +
and O +
stromal O +
cells O +
or O +
lymphocytes O +
served O +
as O +
an O +
internal O +
positive O +
control O -
. O +

Staining O +
was O +
scored O +
independently O +
by O +
at O +
least O +
two O +
observers O +
and O +
in O +
case O +
of O +
discordant O +
results O +
discussed O +
with O +
a O +
pathologist O +
until O +
consensus O +
was O +
reached O -
. O +

hMLH1 B-Gene +
expression O +
could O +
be O +
determined O +
in O +
724 O +
of O +
737 O +
patients O -
. O +

BAT-26 O +
Analysis O +
of O +
the O +
BAT-26 O +
mononucleotide O +
repeat O +
was O +
performed O +
in O +
a O +
random O +
sample O +
of O +
tumour O +
specimens O +
from O +
114 O +
patients O -
, O +
and O +
a O +
series O +
of O +
48 O +
of O +
58 O +
tumours O +
that O +
lacked O +
hMLH1 B-Gene +
expression O -
, O +
to O +
assess O +
the O +
concordance O +
between O +
the O +
microsatellite O +
instability O +
marker O +
BAT-26 O +
and O +
hMLH1 B-Gene +
expression O -
. O +

The O +
primer O +
sequences O +
and O +
PCR O +
conditions O +
for O +
the O +
BAT-26 O +
mononucleotide O +
repeat O +
were O +
used O +
as O +
described O +
previously O +
[ O -
31 O -
] O -
. O +

Statistical O +
analysis O +
In O +
the O +
statistical O +
analysis O -
, O +
data O +
from O +
656 O +
patients O +
for O +
whom O +
information O +
on O +
APC B-Gene +
and O +
K B-Gene -
- I-Gene -
ras I-Gene +
mutation O +
status O +
as O +
well O +
as O +
hMLH1 B-Gene +
expression O +
was O +
complete O +
were O +
included O -
. O +

The O +
χ2 O +
test O +
and O +
Cramérs O +
V O +
test O +
were O +
used O +
to O +
estimate O +
the O +
association O +
of O +
the O +
co O -
- O -
occurrence O +
of O +
K B-Gene -
- I-Gene -
ras I-Gene +
and O +
APC B-Gene +
gene O +
mutations O -
. O +

Characteristics O +
of O +
patients O +
( O -
age O +
at O +
diagnosis O -
, O +
sex O -
, O +
family O +
history O +
of O +
colorectal O +
cancer O -
) O +
and O +
tumours O +
( O -
tumour O +
sub O -
- O -
localisation O -
, O +
Dukes O -
' O +
stage O +
and O +
tumour O +
differentiation O -
) O +
were O +
compared O +
between O +
patients O +
with O +
and O +
without O +
an O +
activating O +
K B-Gene -
- I-Gene -
ras I-Gene +
or O +
a O +
truncating O +
APC B-Gene +
mutation O +
as O +
well O +
as O +
patients O +
harbouring O +
tumours O +
with O +
and O +
without O +
hMLH1 B-Gene +
expression O -
, O +
using O +
Students O +
T O -
- O -
test O +
( O -
age O +
at O +
diagnosis O -
) O +
and O +
χ2 O +
tests O +
( O -
sex O -
, O +
family O +
history O +
of O +
colorectal O +
cancer O -
, O +
tumour O +
sub O -
- O -
localisation O -
, O +
Dukes O -
' O +
stage O +
and O +
differentiation O -
) O -
. O +

Additionally O -
, O +
patient O +
and O +
tumour O +
characteristics O +
of O +
tumours O +
with O +
an O +
activating O +
K B-Gene -
- I-Gene -
ras I-Gene +
and/or O +
a O +
truncating O +
APC B-Gene +
mutation O +
were O +
compared O +
to O +
tumours O +
lacking O +
hMLH1 B-Gene +
expression O -
. O +

All O +
P O -
- O -
values O +
are O +
reported O +
for O +
a O +
two O -
- O -
sided O +
test O -
; O +
P O -
- O -
values O +
of O +
less O +
than O +
0.05 O +
were O +
considered O +
to O +
be O +
statistically O +
significant O -
. O +

Results O +
Tumours O +
from O +
464 O +
of O +
656 O +
patients O -
, O +
which O +
did O +
not O +
harbour O +
a O +
truncating O +
APC B-Gene +
mutation O +
or O +
lacked O +
hMLH1 B-Gene +
expression O -
, O +
were O +
analysed O +
for O +
mutations O +
in O +
exon O +
3 O +
of O +
the O +
CTNNB1 B-Gene +
gene O -
. O +

Table O +
1 O +
describes O +
the O +
tumour O +
and O +
patient O +
characteristics O +
of O +
seven O +
colorectal O +
tumours O +
that O +
harboured O +
a O +
mutation O +
in O +
CTNNB1 B-Gene +
exon O +
3 O -
. O +

In O +
five O +
colorectal O +
cancers O -
, O +
a O +
CTNNB1 B-Gene +
mutation O +
that O +
would O +
lead O +
to O +
loss O +
of O +
one O +
of O +
the O +
Ser O -
/ O -
Thr O +
phosphorylation O +
sites O +
and O +
subsequent O +
stabilisation O +
of O +
the O +
protein O -
, O +
occurred O +
at O +
codons O +
37 O +
and O +
45 O -
, O +
all O +
were O +
C→T O +
transitions O -
, O +
leading O +
to O +
Ser→Phe O +
amino O +
acid O +
changes O +
and O +
occurred O +
in O +
the O +
proximal O +
colon O -
. O +

All O +
bar O +
one O +
also O +
had O +
an O +
activating O +
mutation O +
in O +
the O +
K B-Gene -
- I-Gene -
ras I-Gene +
gene O -
. O +

Three O +
of O +
these O +
five O +
tumours O +
showed O +
hMLH1 B-Gene +
deficiency O -
. O +

Two O +
colorectal O +
cancer O +
patients O +
harboured O +
a O +
mutation O +
in O +
the O +
CTNNB1 B-Gene +
gene O -
, O +
that O +
did O +
not O +
occur O +
at O +
the O +
Ser O -
/ O -
Thr O +
phosphorylation O +
sites O -
, O +
but O +
would O +
result O +
in O +
an O +
amino O +
acid O +
alteration O +
at O +
codons O +
22 O +
and O +
29 O -
, O +
the O +
effects O +
of O +
which O +
are O +
unknown O -
. O +

Because O +
of O +
the O +
very O +
low O +
frequency O +
of O +
tumours O +
harbouring O +
a O +
CTNNB1 B-Gene +
mutation O -
, O +
these O +
mutations O +
were O +
not O +
included O +
in O +
further O +
analyses O -
. O +

In O +
addition O -
, O +
mutation O +
analysis O +
of O +
remaining O +
samples O +
was O +
abandoned O -
, O +
since O +
this O +
was O +
deemed O +
irrelevant O +
as O +
these O +
harboured O +
truncating O +
APC B-Gene +
mutations O +
and O +
are O +
considered O +
to O +
be O +
unlikely O +
to O +
also O +
have O +
CTNNB1 B-Gene +
mutations O +
[ O -
7 O -
] O -
. O +

Of O +
656 O +
tumours O +
for O +
which O +
the O +
other O +
molecular O +
alterations O -
, O +
i.e. O +
mutations O +
in O +
the O +
APC B-Gene +
and O +
K B-Gene -
- I-Gene -
ras I-Gene +
genes O +
and O +
hMLH1 B-Gene +
expression O -
, O +
were O +
all O +
successfully O +
and O +
completely O +
analysed O -
, O +
103 O +
colorectal O +
tumours O +
did O +
not O +
harbour O +
a O +
truncating O +
or O +
missense O +
APC B-Gene +
mutation O -
, O +
an O +
activating O +
K B-Gene -
- I-Gene -
ras I-Gene +
mutation O +
or O +
showed O +
lack O +
of O +
hMLH1 B-Gene +
expression O -
, O +
as O +
depicted O +
in O +
figure O +
1 O -
. O +

Truncating O +
as O +
well O +
as O +
missense O +
APC B-Gene +
mutations O +
and O +
activating O +
K B-Gene -
- I-Gene -
ras I-Gene +
mutations O +
were O +
relatively O +
common O -
. O +

Truncating O +
APC B-Gene +
mutations O +
alone O +
and O +
activating O +
K B-Gene -
- I-Gene -
ras I-Gene +
mutations O +
in O +
codons O +
12 O +
and O +
13 O +
only O -
, O +
occurred O +
at O +
similar O +
frequencies O +
( O -
20 O -
% O +
( O -
130 O -
/ O -
656 O -
) O +
and O +
18 O -
% O +
( O -
121 O -
/ O -
656 O -
) O -
, O +
respectively O -
) O -
. O +

A O +
combination O +
of O +
a O +
truncating O +
mutation O +
in O +
APC B-Gene +
and O +
an O +
activating O +
mutation O +
in O +
K B-Gene -
- I-Gene -
ras I-Gene +
occurred O +
less O +
often O +
than O +
the O +
sole O +
occurrences O +
of O +
mutations O +
in O +
both O +
genes O -
. O +

However O -
, O +
as O +
shown O +
in O +
table O +
2 O -
, O +
the O +
simultaneous O +
occurrence O +
of O +
mutations O +
in O +
both O +
genes O +
occurred O +
more O +
frequently O +
than O +
expected O +
on O +
the O +
basis O +
of O +
chance O +
alone O -
. O +

A O +
χ2 O +
test O +
for O +
the O +
occurrence O +
of O +
a O +
truncating O +
APC B-Gene +
mutation O +
and O +
an O +
activating O +
K B-Gene -
- I-Gene -
ras I-Gene +
mutation O +
revealed O +
that O +
the O +
occurrence O +
of O +
these O +
mutations O +
was O +
not O +
independent O +
( O -
χ2 O +
= O +
8.7 O -
, O +
P O +
< O +
0.001 O -
) O -
, O +
but O +
the O +
correlation O +
was O +
weak O +
( O -
Cramérs O +
V O +
= O +
0.138 O -
) O -
. O +

Finally O -
, O +
although O +
11 O +
tumours O +
that O +
harboured O +
a O +
mutation O +
in O +
the O +
APC B-Gene +
or O +
K B-Gene -
- I-Gene -
ras I-Gene +
gene O +
also O +
lacked O +
hMLH1 B-Gene +
expression O -
, O +
hMLH1 B-Gene +
deficiency O +
occurred O +
more O +
frequently O +
in O +
tumours O +
that O +
did O +
not O +
harbour O +
these O +
mutations O +
( O -
χ2 O +
= O +
36.6 O -
, O +
P O +
< O +
0.001 O -
) O -
. O +

With O +
respect O +
to O +
the O +
localisation O +
in O +
the O +
colorectal O +
tract O -
, O +
tumours O +
of O +
the O +
rectosigmoid O +
and O +
rectum O +
more O +
frequently O +
harboured O +
truncating O +
APC B-Gene +
mutations O +
when O +
compared O +
to O +
colon O +
tumours O +
( O -
P O +
= O +
0.001 O -
) O -
, O +
as O +
shown O +
in O +
table O +
3 O -
. O +

Rectosigmoid O +
and O +
rectal O +
tumours O +
have O +
a O +
relatively O +
higher O +
frequency O +
of O +
K B-Gene -
- I-Gene -
ras I-Gene +
mutations O +
in O +
codons O +
12 O +
and O +
13 O +
when O +
compared O +
to O +
colon O +
tumours O +
( O -
P O +
= O +
0.05 O -
) O +
( O -
Table O +
3 O -
) O -
. O +

Nine O +
per O +
cent O +
of O +
tumours O +
showed O +
hMLH1 B-Gene +
deficiency O -
, O +
as O +
determined O +
by O +
immunohistochemistry O +
( O -
Figure O +
2 O -
) O -
. O +

Tumours O +
lacking O +
hMLH1 B-Gene +
expression O +
occur O +
almost O +
exclusively O +
in O +
the O +
proximal O +
colon O +
( O -
P O +
< O +
0.001 O -
) O +
and O +
relatively O +
more O +
frequently O +
show O +
poor O +
differentiation O +
or O +
are O +
undifferentiated O +
( O -
P O +
< O +
0.001 O -
) O +
when O +
compared O +
to O +
tumours O +
with O +
hMLH1 B-Gene +
expression O +
( O -
Table O +
3 O -
) O -
. O +

Next O -
, O +
we O +
compared O +
the O +
patient O +
and O +
tumour O +
characteristics O +
of O +
tumours O +
harbouring O +
a O +
truncating O +
APC B-Gene +
and/or O +
an O +
activating O +
K B-Gene -
- I-Gene -
ras I-Gene +
mutation O +
to O +
those O +
of O +
tumours O +
without O +
hMLH1 B-Gene +
expression O -
, O +
and O +
these O +
results O +
are O +
presented O +
in O +
table O +
4 O -
. O +

Patients O +
harbouring O +
hMLH1 B-Gene +
deficient O +
tumours O +
were O +
slightly O +
older O +
when O +
diagnosed O +
with O +
colorectal O +
cancer O +
( O -
69.3 O +
yr O +
( O -
68.0–70.5 O -
) O +
versus O +
67.8 O +
( O -
67.4–68.3 O -
) O -
, O +
P O +
= O +
0.03 O -
) O -
, O +
were O +
relatively O +
less O +
frequently O +
men O +
( O -
40 O -
% O +
versus O +
58 O -
% O -
, O +
P O +
= O +
0.02 O -
) O -
. O +

Tumours O +
without O +
hMLH1 B-Gene +
expression O +
occurred O +
relatively O +
more O +
frequently O +
in O +
the O +
proximal O +
colon O +
( O -
P O +
< O +
0.001 O -
) O +
and O +
relatively O +
more O +
frequently O +
showed O +
poor O +
differentiation O +
or O +
are O +
undifferentiated O +
( O -
P O +
< O +
0.001 O -
) O -
. O +

When O +
comparing O +
tumours O +
with O +
a O +
missense O +
( O -
but O +
not O +
a O +
truncating O -
) O +
mutation O +
in O +
APC B-Gene +
to O +
tumours O +
with O +
a O +
truncating O +
mutation O +
in O +
APC B-Gene -
, O +
missense O +
mutations O +
occurred O +
relatively O +
more O +
frequently O +
in O +
the O +
colon O +
( O -
P O +
= O +
0.002 O -
) O -
, O +
less O +
often O +
also O +
harboured O +
an O +
activating O +
K B-Gene -
- I-Gene -
ras I-Gene +
mutation O +
( O -
P O +
= O +
0.004 O -
) O -
, O +
and O +
more O +
often O +
also O +
lacked O +
hMLH1 B-Gene +
expression O +
( O -
P O +
< O +
0.001 O -
) O -
. O +

No O +
differences O +
were O +
observed O +
with O +
regard O +
to O +
age O +
at O +
diagnosis O -
, O +
gender O -
, O +
Dukes O -
' O +
stage O +
or O +
tumour O +
differentiation O +
( O -
data O +
not O +
shown O -
) O -
. O +

Finally O -
, O +
to O +
assess O +
agreement O +
between O +
hMLH1 B-Gene +
expression O +
and O +
microsatellite O +
instability O -
, O +
both O +
hMLH1 B-Gene +
expression O +
and O +
BAT-26 O +
were O +
analysed O +
in O +
162 O +
tumours O -
. O +

All O +
tumours O +
that O +
had O +
normal O +
BAT-26 O -
, O +
also O +
showed O +
hMLH1 B-Gene +
expression O -
. O +

Fourteen O +
tumours O +
with O +
unstable O +
BAT-26 O +
also O +
lacked O +
hMLH1 B-Gene +
expression O -
, O +
and O +
two O +
tumours O +
with O +
unstable O +
BAT-26 O +
were O +
found O +
to O +
express O +
hMLH1 B-Gene -
, O +
which O +
demonstrates O +
a O +
high O +
agreement O +
between O +
these O +
molecular O +
features O +
of O +
mismatch O +
repair O +
deficiency O -
. O +

The O +
model O +
describing O +
the O +
accumulation O +
of O +
genetic O +
alterations O +
of O +
the O +
APC B-Gene -
, O +
K B-Gene -
- I-Gene -
ras I-Gene -
, O +
TP53 B-Gene +
and O +
SMAD4 B-Gene +
genes O +
that O +
drive O +
the O +
development O +
of O +
a O +
carcinoma O -
, O +
has O +
become O +
generally O +
accepted O +
as O +
a O +
paradigm O +
for O +
the O +
genetic O +
basis O +
of O +
colorectal O +
carcinogenesis O +
[ O -
3,32 O -
] O -
. O +

The O +
relatively O +
low O +
frequency O +
of O +
simultaneous O +
occurrence O +
of O +
mutations O +
in O +
both O +
APC B-Gene +
and O +
K B-Gene -
- I-Gene -
ras I-Gene +
observed O +
in O +
this O +
study O +
seems O +
to O +
argue O +
against O +
this O +
synergy O -
. O +

This O +
contention O +
is O +
in O +
accordance O +
with O +
observations O +
from O +
another O +
cohort O +
study O -
, O +
in O +
which O +
APC B-Gene -
, O +
K B-Gene -
- I-Gene -
ras I-Gene +
and O +
TP53 B-Gene +
gene O +
mutations O +
were O +
studied O +
in O +
109 O +
tumours O +
and O +
these O +
mutations O +
were O +
found O +
to O +
rarely O +
occur O +
together O +
in O +
the O +
same O +
tumour O +
[ O -
9 O -
] O -
. O +

However O -
, O +
the O +
simultaneous O +
occurrence O +
of O +
APC B-Gene +
and O +
K B-Gene -
- I-Gene -
ras I-Gene +
mutations O +
observed O +
in O +
our O +
study O +
occurs O +
more O +
frequently O +
than O +
expected O +
based O +
on O +
chance O +
alone O +
and O +
therefore O +
mutations O +
in O +
the O +
APC B-Gene +
and O +
K B-Gene -
- I-Gene -
ras I-Gene +
genes O +
do O +
not O +
seem O +
to O +
occur O +
independently O -
. O +

When O +
data O +
on O +
APC B-Gene +
and O +
K B-Gene -
- I-Gene -
ras I-Gene +
mutations O +
are O +
derived O +
from O +
the O +
study O +
by O +
Smith O +
et O +
al. O +
[ O -
9 O -
] O -
, O +
similar O +
results O -
, O +
although O +
not O +
statistically O +
significant O -
, O +
could O +
be O +
obtained O -
. O +

The O +
K B-Gene -
- I-Gene -
ras I-Gene +
mutation O +
frequency O +
of O +
37 O -
% O +
is O +
in O +
accordance O +
with O +
reported O +
frequencies O +
of O +
30 O +
to O +
60 O -
% O +
[ O -
33 O -
- O -
43 O -
] O -
. O +

The O +
frequency O +
of O +
37 O -
% O +
of O +
truncating O +
mutations O +
in O +
the O +
mutation O +
cluster O +
region O +
of O +
APC B-Gene +
in O +
this O +
study O -
, O +
however O -
, O +
seems O +
low O +
in O +
comparison O +
to O +
the O +
general O +
assumption O +
that O +
most O +
colorectal O +
tumours O +
harbour O +
a O +
mutation O +
in O +
the O +
APC B-Gene +
gene O -
. O +

When O +
only O +
reports O +
from O +
studies O +
on O +
sporadic O +
rather O +
than O +
familial O +
colorectal O +
cancer O +
or O +
colorectal O +
cancer O +
cell O +
lines O +
are O +
considered O -
, O +
the O +
mutation O +
frequencies O +
are O +
lower O +
and O +
vary O +
between O +
30 O +
and O +
70 O -
% O +
[ O -
17,44 O -
- O -
49 O -
] O -
, O +
and O +
a O +
population O -
- O -
based O +
case O -
- O -
control O +
study O +
in O +
the O +
Netherlands O +
reported O +
a O +
32 O -
% O +
mutation O +
frequency O +
[ O -
50 O -
] O -
. O +

The O +
method O +
for O +
mutation O +
analysis O +
of O +
the O +
APC B-Gene +
mutation O +
cluster O +
region O +
and O +
exon O +
1 O +
of O +
K B-Gene -
- I-Gene -
ras I-Gene +
is O +
based O +
on O +
nested O +
amplification O +
and O +
direct O +
sequencing O +
of O +
purified O +
PCR O +
fragments O -
, O +
a O +
highly O +
sensitive O +
method O -
. O +

Since O +
no O +
screening O +
step O +
was O +
performed O +
prior O +
to O +
the O +
sequencing O +
of O +
the O +
gene O +
fragments O -
, O +
it O +
is O +
unlikely O +
that O +
mutations O +
would O +
have O +
escaped O +
detection O -
. O +

The O +
reproducibility O +
of O +
the O +
applied O +
assays O +
was O +
good O -
, O +
with O +
a O +
reproducibility O +
of O +
85 O -
% O +
and O +
88 O -
% O +
for O +
APC B-Gene +
and O +
K B-Gene -
- I-Gene -
ras I-Gene -
, O +
respectively O -
. O +

Arguably O -
, O +
this O +
indicates O +
the O +
extent O +
of O +
heterogeneity O +
present O +
in O +
the O +
tumour O +
samples O -
. O +

In O +
103 O +
sporadic O +
colorectal O +
cancers O +
no O +
alterations O +
were O +
found O +
in O +
the O +
K B-Gene -
- I-Gene -
ras I-Gene -
, O +
APC B-Gene +
or O +
hMLH1 B-Gene +
genes O -
. O +

It O +
is O +
plausible O +
that O +
these O +
tumours O +
have O +
harboured O +
mutations O +
in O +
other O +
components O +
of O +
the O +
Wnt O +
signalling O +
pathway O -
, O +
e.g. O +
mutations O +
in O +
the O +
Axin B-Gene +
genes O -
, O +
which O +
are O +
essential O +
for O +
the O +
degradation O +
of O +
β O -
- O -
catenin O -
, O +
and O +
were O +
observed O +
in O +
11 O -
% O +
of O +
patient O +
samples O +
[ O -
51 O -
] O -
. O +

In O +
addition O -
, O +
an O +
epi O -
- O -
genetic O +
change O -
, O +
i.e. O +
promotor O +
hypermethylation O +
of O +
the O +
APC B-Gene +
gene O +
that O +
leads O +
to O +
impaired O +
APC B-Gene +
function O +
has O +
been O +
observed O +
in O +
18 O -
% O +
of O +
sporadic O +
colorectal O +
adenomas O +
and O +
carcinomas O +
[ O -
52 O -
] O -
. O +

Of O +
the O +
microsatellite O +
instable O +
tumours O -
, O +
approximately O +
90 O -
% O +
show O +
absence O +
of O +
hMLH1 B-Gene +
expression O +
[ O -
24 O -
] O -
. O +

In O +
most O +
sporadic O +
colorectal O +
cancers O -
, O +
the O +
promoter O +
region O +
of O +
hMLH1 B-Gene +
is O +
hypermethylated O -
, O +
resulting O +
in O +
absence O +
of O +
the O +
protein O +
[ O -
53 O -
- O -
55 O -
] O -
. O +

BAT-26 O +
was O +
previously O +
shown O +
to O +
identify O +
microsatellite O +
instability O +
in O +
sporadic O +
colorectal O +
cancer O +
[ O -
56 O -
] O +
and O +
results O +
from O +
our O +
study O +
showed O +
a O +
good O +
agreement O +
between O +
unstable O +
BAT-26 O +
and O +
absent O +
hMLH1 B-Gene +
expression O -
. O +

Several O +
studies O +
have O +
shown O +
that O +
microsatellite O +
instability O +
and O +
mutations O +
in O +
APC B-Gene +
and O +
K B-Gene -
- I-Gene -
ras I-Gene +
occur O +
almost O +
mutually O +
exclusively O +
[ O -
18,19,21,57 O -
] O -
, O +
suggesting O +
that O +
these O +
characteristics O +
represent O +
separate O +
pathways O -
. O +

However O -
, O +
others O +
have O +
observed O +
aberrations O +
in O +
both O +
pathways O -
, O +
but O +
these O +
studies O +
have O +
been O +
performed O +
in O +
relatively O +
small O +
groups O +
of O +
HNPCC O +
and O +
sporadic O +
colorectal O +
cancer O +
patients O +
[ O -
14,20,58 O -
] O +
and O +
this O +
may O +
have O +
given O +
rise O +
to O +
a O +
relative O +
overrepresentation O +
of O +
mutation O +
detection O +
in O +
both O +
pathways O -
. O +

Although O +
in O +
our O +
study O +
the O +
simultaneous O +
occurrence O +
of O +
hMLH1 B-Gene +
deficiency O +
as O +
well O +
as O +
an O +
APC B-Gene +
or O +
K B-Gene -
- I-Gene -
ras I-Gene +
mutation O +
was O +
observed O +
in O +
a O +
small O +
number O +
of O +
tumours O -
, O +
the O +
mutually O +
exclusive O +
occurrence O +
of O +
hMLH1 B-Gene +
deficiency O +
and O +
mutations O +
in O +
APC B-Gene +
and/or O +
K B-Gene -
- I-Gene -
ras I-Gene +
seemed O +
to O +
predominate O -
. O +

Moreover O -
, O +
after O +
exclusion O +
of O +
tumours O +
displaying O +
this O +
overlap O -
, O +
a O +
striking O +
difference O +
between O +
occurrences O +
of O +
APC B-Gene +
and/or O +
K B-Gene -
- I-Gene -
ras I-Gene +
mutations O +
versus O +
absence O +
of O +
hMLH1 B-Gene +
expression O +
was O +
observed O -
. O +

The O +
differences O +
were O +
most O +
pronounced O +
with O +
regard O +
to O +
tumour O +
sub O -
- O -
localisation O +
and O +
differentiation O -
. O +

hMLH1 B-Gene +
deficient O +
tumours O +
occur O +
almost O +
exclusively O +
in O +
the O +
proximal O +
colon O +
and O +
are O +
relatively O +
more O +
frequently O +
poorly O +
differentiated O -
, O +
which O +
is O +
in O +
accordance O +
with O +
reports O +
from O +
other O +
studies O +
[ O -
22 O -
- O -
25 O -
] O -
. O +

mutations O +
are O +
associated O +
with O +
distinctive O +
clinical O -
, O +
pathological O +
and O +
molecular O +
features O +
of O +
colorectal O +
cancer O +
independently O +
of O +
microsatellite O +
instability O +
status O +
Abstract O +
Background O +
BRAF B-Gene +
is O +
a O +
member O +
of O +
RAF O +
family O +
of O +
serine O -
/ O -
threonine O +
kinases O +
and O +
mediates O +
cellular O +
responses O +
to O +
growth O +
signals O +
through O +
the O +
RAS O -
- O -
RAF O -
- O -
MAP O +
kinase O +
pathway O -
. O +

Activating O +
mutations O +
in O +
BRAF B-Gene +
have O +
recently O +
been O +
found O +
in O +
about O +
10 O -
% O +
of O +
colorectal O +
cancers O -
, O +
with O +
the O +
vast O +
majority O +
being O +
a O +
V600E O +
hotspot O +
mutation O -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
evaluate O +
the O +
clinical O -
, O +
pathological O +
and O +
molecular O +
phenotype O +
of O +
colorectal O +
tumors O +
with O +
BRAF B-Gene +
mutations O -
. O +

Results O +
Mutations O +
in O +
BRAF B-Gene +
were O +
identified O +
in O +
8 O -
% O +
( O -
23 O -
/ O -
275 O -
) O +
of O +
colorectal O +
cancers O -
. O +

They O +
were O +
5–10-fold O +
more O +
frequent O +
in O +
tumors O +
with O +
infiltrating O +
lymphocytes O -
, O +
location O +
in O +
the O +
proximal O +
colon O -
, O +
poor O +
histological O +
grade O +
and O +
mucinous O +
appearance O +
( O -
P O +
< O +
0.002 O +
for O +
each O -
) O -
. O +

Tumors O +
with O +
BRAF B-Gene +
mutation O +
were O +
also O +
10-fold O +
more O +
likely O +
to O +
show O +
microsatellite O +
instability O +
and O +
frequent O +
DNA O +
methylation O +
( O -
P O +
< O +
0.0001 O -
) O +
compared O +
to O +
tumors O +
without O +
this O +
mutation O -
. O +

The O +
characteristic O +
morphological O +
features O +
of O +
tumors O +
with O +
BRAF B-Gene +
mutation O +
( O -
infiltrating O +
lymphocytes O -
, O +
poor O +
grade O -
, O +
mucinous O -
) O +
remained O +
after O +
stratification O +
according O +
to O +
microsatellite O +
instability O +
and O +
methylator O +
phenotypes O -
. O +

Mutations O +
in O +
BRAF B-Gene +
were O +
mutually O +
exclusive O +
with O +
mutations O +
in O +
KRAS B-Gene +
but O +
showed O +
no O +
clear O +
association O +
with O +
the O +
presence O +
of O +
TP53 B-Gene +
mutation O -
. O +

Conclusion O +
BRAF B-Gene +
mutation O +
identifies O +
a O +
colorectal O +
cancer O +
subgroup O +
with O +
distinctive O +
phenotypic O +
properties O +
independent O +
of O +
microsatellite O +
instability O +
status O +
and O +
thus O +
could O +
be O +
a O +
valuable O +
marker O +
for O +
studies O +
into O +
the O +
clinical O +
properties O +
of O +
these O +
tumors O -
. O +

Clinicopathological O +
and O +
molecular O +
features O +
of O +
BRAF B-Gene +
mutant O +
colorectal O +
cancers O +
stratified O +
according O +
to O +
microsatellite O +
instability O +
status O -
. O +

aTumor O -
- O -
infiltrating O +
lymphocytes O +
Clinicopathological O +
and O +
molecular O +
features O +
of O +
BRAF B-Gene +
mutant O +
colorectal O +
cancers O +
stratified O +
according O +
to O +
methylator O +
phenotype O +
status O -
. O +

Discussion O +
The O +
BRAF B-Gene +
V600E O +
mutation O +
has O +
already O +
been O +
proposed O +
as O +
a O +
convenient O +
marker O +
to O +
discriminate O +
between O +
MSI+ O +
tumors O +
that O +
are O +
sporadic O +
or O +
HNPCC O +
in O +
origin O +
[ O -
5,8 O -
- O -
10 O -
] O -
. O +

This O +
is O +
a O +
very O +
important O +
issue O +
for O +
population O -
- O -
based O +
screening O +
programs O +
that O +
aim O +
to O +
identify O +
CRC O +
associated O +
with O +
the O +
HNPCC O +
syndrome O -
. O +

Compared O +
to O +
the O +
analysis O +
of O +
MLH1 B-Gene +
promoter O +
methylation O -
, O +
mutation O +
at O +
the O +
BRAF B-Gene +
V600E O +
hotspot O +
is O +
relatively O +
simple O +
to O +
detect O +
using O +
DNA O +
sequencing O -
, O +
RFLP O +
or O +
the O +
SSCP O +
method O +
used O +
in O +
the O +
present O +
work O +
( O -
Figure O +
1 O -
) O -
. O +

Similar O +
to O +
other O +
studies O +
[ O -
4,5,10,16,17 O -
] O +
we O +
observed O +
BRAF B-Gene +
mutation O +
frequencies O +
of O +
4 O -
% O +
in O +
MSI- O +
tumors O +
and O +
39 O -
% O +
in O +
MSI+ O +
tumors O +
( O -
Table O +
1 O -
) O -
. O +

The O +
highest O +
frequencies O +
were O +
seen O +
in O +
tumors O +
showing O +
methylation O +
of O +
the O +
MLH1 B-Gene +
promoter O +
proximal O +
region O +
( O -
46 O -
% O -
) O +
and O +
in O +
tumors O +
with O +
infiltrating O +
lymphocytes O +
( O -
48 O -
% O -
) O -
. O +

BRAF B-Gene +
mutation O +
frequencies O +
of O +
up O +
to O +
70–80 O -
% O +
have O +
been O +
reported O +
in O +
sporadic O +
MSI+ O -
, O +
CIMP+ O +
and O +
MLH1-methylated B-Gene +
CRC O +
and O +
polyps O +
[ O -
7,8,15,16 O -
] O -
. O +

For O +
reasons O +
that O +
are O +
still O +
unclear O -
, O +
BRAF B-Gene +
mutations O +
are O +
approximately O +
5–10-fold O +
more O +
frequent O +
in O +
tumors O +
that O +
have O +
characteristic O +
features O +
of O +
sporadic O +
MSI+ O +
( O -
ie O -
. O +

MLH1 B-Gene +
methylated O -
) O +
and O +
CIMP+ O +
phenotypes O -
. O +

These O +
include O +
proximal O +
colon O +
location O -
, O +
poor O +
differentiation O -
, O +
mucinous O +
histology O +
and O +
infiltrating O +
lymphocytes O +
[ O -
13,19,20 O -
] O -
. O +

Interestingly O +
however O -
, O +
in O +
the O +
present O +
study O +
BRAF B-Gene +
mutations O +
never O +
occurred O +
in O +
association O +
with O +
KRAS B-Gene +
mutation O -
, O +
were O +
present O +
in O +
only O +
3 O -
% O +
of O +
CIMP- O +
tumors O +
and O +
showed O +
no O +
association O +
with O +
TP53 B-Gene +
mutation O +
( O -
Table O +
2 O -
) O -
. O +

The O +
observation O +
that O +
BRAF B-Gene +
mutations O +
occur O +
only O +
very O +
rarely O +
in O +
HNPCC O -
- O -
related O +
MSI+ O +
CRC O +
demonstrates O +
that O +
defective O +
DNA O +
mismatch O +
repair O +
is O +
not O +
involved O +
in O +
causing O +
this O +
genetic O +
alteration O -
. O +

In O +
order O +
to O +
determine O +
whether O +
the O +
characteristic O +
clinicopathological O +
features O +
of O +
tumors O +
with O +
BRAF B-Gene +
mutation O +
were O +
due O +
to O +
their O +
close O +
association O +
with O +
MSI+ O +
and O +
CIMP+ O -
, O +
we O +
stratified O +
tumours O +
according O +
to O +
these O +
phenotypes O -
. O +

Despite O +
having O +
only O +
9 O +
MSI- O -
/ O -
BRAF B-Gene +
mutant O +
and O +
5 O +
CIMP- O -
/ O -
BRAF B-Gene +
mutant O +
tumors O -
, O +
the O +
results O +
showed O +
that O +
associations O +
between O +
BRAF B-Gene +
mutation O +
and O +
the O +
morphological O +
properties O +
of O +
tumor O -
- O -
infiltrating O +
infiltrating O +
lymphocytes O -
, O +
poor O +
histological O +
grade O +
and O +
mucinous O +
phenotype O +
were O +
retained O +
( O -
Tables O +
3 O +
and O +
4 O -
) O -
. O +

The O +
frequencies O +
of O +
BRAF B-Gene +
mutation O +
observed O +
in O +
MSI- O +
( O -
4 O -
% O -
) O +
and O +
MSI+ O +
( O -
39 O -
% O -
) O +
tumors O +
in O +
the O +
present O +
study O +
compare O +
favourably O +
( O -
5 O -
% O +
and O +
52 O -
% O -
, O +
respectively O -
) O +
to O +
those O +
reported O +
recently O +
in O +
another O +
large O -
, O +
population O -
- O -
based O +
study O +
[ O -
17 O -
] O -
. O +

Although O +
BRAF B-Gene +
mutations O +
are O +
much O +
more O +
frequent O +
in O +
MSI+ O +
tumors O -
, O +
the O +
comparative O +
rarity O +
of O +
this O +
phenotype O +
means O +
that O +
a O +
considerable O +
proportion O +
occur O +
in O +
MSI- O +
tumors O -
. O +

In O +
the O +
present O +
study O -
, O +
43 O -
% O +
of O +
all O +
BRAF B-Gene +
mutations O +
occurred O +
in O +
MSI- O +
tumors O +
compared O +
to O +
48 O -
% O +
in O +
the O +
study O +
by O +
Samowitz O +
et O +
al O +
[ O -
17 O -
] O -
. O +

BRAF B-Gene +
mutations O +
were O +
reported O +
to O +
show O +
prognostic O +
significance O +
in O +
MSI- O +
but O +
not O +
in O +
MSI+ O +
CRC O +
[ O -
17 O -
] O -
. O +

The O +
lack O +
of O +
follow O -
- O -
up O +
information O +
on O +
CRC O +
patients O +
in O +
the O +
current O +
study O +
and O +
the O +
small O +
number O +
of O +
BRAF B-Gene +
mutations O +
( O -
n O +
= O +
21 O -
) O +
meant O +
that O +
we O +
were O +
unable O +
to O +
evaluate O +
the O +
prognostic O +
significance O +
of O +
BRAF B-Gene +
mutation O +
according O +
to O +
MSI O +
status O -
. O +

Conclusion O +
Findings O +
from O +
the O +
present O +
study O +
and O +
from O +
previous O +
work O +
indicate O +
that O +
BRAF B-Gene +
mutation O +
is O +
likely O +
to O +
be O +
a O +
convenient O +
marker O +
for O +
the O +
identification O +
of O +
a O +
subset O +
of O +
CRCs O +
with O +
distinctive O +
clinical O -
, O +
pathological O +
and O +
molecular O +
features O +
and O +
which O +
may O +
originate O +
in O +
hyperplastic O +
polyps O +
and O +
serrated O +
adenomas O +
[ O -
7,14,15 O -
] O -
. O +

In O +
view O +
of O +
the O +
strong O +
associations O +
between O +
BRAF B-Gene +
mutation O +
and O +
specific O +
pathological O +
( O -
site O -
, O +
grade O -
, O +
mucinous O -
, O +
infiltrating O +
lymphocytes O -
) O +
and O +
molecular O +
( O -
methylated O +
MSI+ O -
, O +
CIMP+ O -
, O +
wildtype O +
KRAS B-Gene -
) O +
features O -
, O +
it O +
will O +
be O +
interesting O +
in O +
future O +
studies O +
to O +
determine O +
the O +
predictive O +
significance O +
of O +
this O +
marker O +
for O +
response O +
to O +
adjuvant O +
therapies O +
in O +
CRC O -
. O +

Methods O +
The O +
275 O +
colorectal O +
tumors O +
investigated O +
in O +
this O +
study O +
were O +
obtained O +
from O +
the O +
Colorectal O +
Unit O +
of O +
the O +
Royal O +
Adelaide O +
Hospital O -
. O +

These O +
were O +
snap O +
frozen O +
in O +
liquid O +
nitrogen O +
within O +
20–40 O +
min O +
after O +
resection O +
and O +
stored O +
at O +
-70 O -
° O -
C O +
prior O +
to O +
extraction O +
of O +
DNA O -
. O +

Clinical O +
data O +
available O +
for O +
this O +
series O +
included O +
patient O +
age O -
, O +
sex O +
and O +
family O +
history O +
of O +
CRC O -
. O +

Only O +
one O +
case O +
was O +
confirmed O +
as O +
HNPCC O -
- O -
related O -
. O +

Pathological O +
data O +
included O +
nodal O +
involvement O -
, O +
tumor O +
site O -
, O +
histological O +
grade O -
, O +
mucinous O +
appearance O +
and O +
the O +
presence O +
of O +
infiltrating O +
lymphocytes O -
. O +

Evaluation O +
of O +
MSI+ O +
[ O -
21 O -
] O -
, O +
CIMP+ O +
[ O -
18 O -
] O -
, O +
KRAS B-Gene +
mutation O +
[ O -
22 O -
] O +
and O +
TP53 B-Gene +
mutation O +
[ O -
23 O -
] O +
were O +
performed O +
as O +
described O +
previously O +
by O +
our O +
group O -
. O +

Mutations O +
in O +
exon O +
15 O +
of O +
BRAF B-Gene +
including O +
the O +
V600E O +
hotspot O +
were O +
detected O +
using O +
the O +
PCR O +
primer O +
sequences O +
reported O +
earlier O +
[ O -
1 O -
] O -
, O +
the O +
F O -
- O -
SSCP O +
method O +
[ O -
22,23 O -
] O +
and O +
confirmed O +
by O +
direct O +
sequencing O -
. O +

Statistical O +
analyses O +
were O +
performed O +
using O +
SPSS O +
Version O +
12.0 O +
( O -
Chicago O -
, O +
Illinois O -
, O +
USA O -
) O -
. O +

Associations O +
between O +
BRAF B-Gene +
mutation O +
and O +
clinical O -
, O +
pathological O +
or O +
molecular O +
features O +
were O +
evaluated O +
using O +
Fisher O -
's O +
exact O +
or O +
Pearson O -
's O +
chi O -
- O -
squared O +
tests O +
as O +
appropriate O -
. O +

Multivariate O +
analysis O +
was O +
performed O +
using O +
binary O +
logistic O +
regression O +
with O +
BRAF B-Gene +
mutation O +
as O +
the O +
dependent O +
variable O -
. O +

Microsatellite O +
instability O +
analysis O +
in O +
hereditary O +
non O -
- O -
polyposis O +
colon O +
cancer O +
using O +
the O +
Bethesda O +
consensus O +
panel O +
of O +
microsatellite O +
markers O +
in O +
the O +
absence O +
of O +
proband O +
normal O +
tissue O +
Abstract O +
Background O +
Hereditary O +
non O -
- O -
polyposis O +
colon O +
cancer O +
( O -
HNPCC O -
) O +
is O +
an O +
autosomal O +
dominant O +
syndrome O +
predisposing O +
to O +
the O +
early O +
development O +
of O +
various O +
cancers O +
including O +
those O +
of O +
colon O -
, O +
rectum O -
, O +
endometrium O -
, O +
ovarium O -
, O +
small O +
bowel O -
, O +
stomach O +
and O +
urinary O +
tract O -
. O +

HNPCC O +
is O +
caused O +
by O +
germline O +
mutations O +
in O +
the O +
DNA O +
mismatch O +
repair O +
genes O -
, O +
mostly O +
hMSH2 B-Gene +
or O +
hMLH1 B-Gene -
. O +

In O +
this O +
study O -
, O +
we O +
report O +
the O +
analysis O +
for O +
genetic O +
counseling O +
of O +
three O +
first O -
- O -
degree O +
relatives O +
( O -
the O +
mother O +
and O +
two O +
sisters O -
) O +
of O +
a O +
male O +
who O +
died O +
of O +
colorectal O +
adenocarcinoma O +
at O +
the O +
age O +
of O +
23 O -
. O +

The O +
family O +
fulfilled O +
strict O +
Amsterdam O -
- O -
I O +
criteria O +
( O -
AC O -
- O -
I O -
) O +
with O +
the O +
presence O +
of O +
extracolonic O +
tumors O +
in O +
the O +
extended O +
pedigree O -
. O +

We O +
overcame O +
the O +
difficulty O +
of O +
having O +
a O +
proband O +
post O -
- O -
mortem O +
non O -
- O -
tumor O +
tissue O +
sample O +
for O +
MSI O +
testing O +
by O +
studying O +
the O +
alleles O +
carried O +
by O +
his O +
progenitors O -
. O +

Methods O +
Tumor O +
MSI O +
testing O +
is O +
described O +
as O +
initial O +
screening O +
in O +
both O +
primary O +
and O +
metastasis O +
tumor O +
tissue O +
blocks O -
, O +
using O +
the O +
reference O +
panel O +
of O +
5 O +
microsatellite O +
markers O +
standardized O +
by O +
the O +
National O +
Cancer O +
Institute O +
( O -
NCI O -
) O +
for O +
the O +
screening O +
of O +
HNPCC O +
( O -
BAT-25 O -
, O +
BAT-26 O -
, O +
D2S123 O -
, O +
D5S346 O +
and O +
D17S250 O -
) O -
. O +

Subsequent O +
mutation O +
analysis O +
of O +
the O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
genes O +
was O +
performed O -
. O +

Results O +
Three O +
of O +
five O +
microsatellite O +
markers O +
( O -
BAT-25 O -
, O +
BAT-26 O +
and O +
D5S346 O -
) O +
presented O +
different O +
alleles O +
in O +
the O +
proband O -
's O +
tumor O +
as O +
compared O +
to O +
those O +
inherited O +
from O +
his O +
parents O -
. O +

The O +
tumor O +
was O +
classified O +
as O +
high O +
frequency O +
microsatellite O +
instability O +
( O -
MSI O -
- O -
H O -
) O -
. O +

We O +
identified O +
in O +
the O +
HNPCC O +
family O +
a O +
novel O +
germline O +
missense O +
( O -
c.1864C O -
> O -
A O -
) O +
mutation O +
in O +
exon O +
12 O +
of O +
hMSH2 B-Gene +
gene O -
, O +
leading O +
to O +
a O +
proline O +
622 O +
to O +
threonine O +
( O -
p. O +

Pro622Thr O -
) O +
amino O +
acid O +
substitution O -
. O +

Conclusion O +
This O +
approach O +
allowed O +
us O +
to O +
establish O +
the O +
tumor O +
MSI O +
status O +
using O +
the O +
NCI O +
recommended O +
panel O +
in O +
the O +
absence O +
of O +
proband O -
's O +
non O -
- O -
tumor O +
tissue O +
and O +
before O +
sequencing O +
the O +
obligate O +
carrier O -
. O +

According O +
to O +
the O +
Human O +
Gene O +
Mutation O +
Database O +
( O -
HGMD O -
) O +
and O +
the O +
International O +
Society O +
for O +
Gastrointestinal O +
Hereditary O +
Tumors O +
( O -
InSiGHT O -
) O +
Database O +
this O +
is O +
the O +
first O +
report O +
of O +
this O +
mutation O -
. O +

Methods O +
Patients O +
Three O +
first O -
- O -
degree O +
relatives O +
( O -
mother O +
and O +
two O +
sisters O -
) O +
of O +
a O +
male O +
who O +
died O +
of O +
poorly O +
differentiated O +
colorectal O +
adenocarcinoma O +
at O +
age O +
23 O +
contacted O +
us O +
for O +
genetic O +
counseling O -
. O +

A O +
detailed O +
family O +
and O +
medical O +
history O +
was O +
obtained O +
through O +
interview O +
with O +
the O +
proband O +
relatives O +
and O +
their O +
consent O +
for O +
release O +
of O +
medical O +
records O +
and O +
use O +
of O +
the O +
pathological O +
tissue O +
blocks O +
still O +
available O -
. O +

The O +
early O +
onset O +
of O +
the O +
colon O +
cancer O +
in O +
the O +
proband O +
and O +
the O +
study O +
of O +
the O +
family O -
's O +
pedigree O +
( O -
fig. O +
1 O -
) O -
, O +
that O +
fulfill O +
the O +
strict O +
Amsterdam-1 O +
criteria O -
, O +
prompted O +
genetic O +
analysis O +
with O +
suspicion O +
of O +
HNPCC O -
. O +

They O +
were O +
informed O +
about O +
the O +
risks O -
, O +
benefits O +
and O +
limitations O +
of O +
the O +
study O +
protocol O -
. O +

Pedigree O +
showing O +
HNPCC O +
family O -
. O +

An O +
arrow O +
indicates O +
the O +
male O +
index O +
patient O +
( O -
III:3 O -
) O +
diagnosed O +
with O +
colorectal O +
adenocarcinoma O +
at O +
the O +
age O +
of O +
23 O +
years O -
. O +

Family O +
members O +
suffering O +
from O +
a O +
malignancy O +
are O +
indicated O +
by O +
a O +
shaded O +
circle O +
or O +
square O -
. O +

The O +
age O -
, O +
type O +
of O +
malignancy O -
, O +
as O +
well O +
as O +
the O +
generation O +
( O -
roman O +
figures O -
) O -
, O +
are O +
described O +
below O +
the O +
indicated O +
patient O -
. O +

The O +
family O +
fulfill O +
the O +
Amsterdam O -
- O -
I O +
criteria O +
with O +
presence O +
of O +
extracolonic O +
tumors O +
in O +
the O +
extended O +
pedigree O -
, O +
having O +
more O +
than O +
three O +
carcinomas O +
of O +
colon O +
( O -
C O -
) O +
or O +
ovary O +
( O -
O O -
) O +
in O +
the O +
affected O +
members O -
. O +

The O +
syndrome O +
is O +
present O +
in O +
all O +
three O +
generations O +
( O -
I O -
- O -
III O -
) O +
and O +
three O +
family O +
members O +
are O +
younger O +
than O +
50 O +
years O +
( O -
III:3 O -
, O +
II:1 O +
and O +
I:3 O -
) O -
. O +

At O +
the O +
moment O +
of O +
the O +
study O +
the O +
proband O -
's O +
mother O +
( O -
II-5 O -
) O +
was O +
an O +
unaffected O +
carrier O -
, O +
but O +
two O +
years O +
later O +
she O +
developed O +
an O +
endometrial O +
( O -
E O -
) O +
adenocarcinoma O -
. O +

Study O +
protocol O +
As O +
screening O +
method O +
for O +
HNPCC O +
we O +
searched O +
for O +
MSI O +
in O +
the O +
proband O -
's O +
primary O +
tumor O +
and O +
metastasis O +
tissue O +
blocks O -
. O +

The O +
absence O +
of O +
proband O -
's O +
non O -
- O -
tumor O +
DNA O +
for O +
MSI O +
testing O +
was O +
overcome O +
studying O +
the O +
alleles O +
carried O +
by O +
his O +
progenitors O -
. O +

Once O +
the O +
MSI O +
was O +
established O -
, O +
a O +
second O +
blood O +
sample O +
was O +
obtained O +
from O +
the O +
proband O -
's O +
mother O +
( O -
obligate O +
carrier O +
but O +
at O +
the O +
moment O +
of O +
the O +
study O +
still O +
unaffected O -
) O +
to O +
full O +
mutation O +
analysis O +
of O +
the O +
hMSH2 B-Gene +
and O +
hMLH1 B-Gene +
genes O +
by O +
direct O +
sequencing O -
. O +

After O +
identifying O +
the O +
family O +
mutation O -
, O +
we O +
searched O +
it O +
in O +
both O +
proband O -
's O +
sisters O -
. O +

DNA O +
preparation O +
for O +
genetic O +
testing O +
Peripheral O +
blood O +
was O +
collected O +
from O +
the O +
three O +
consulting O +
family O +
members O +
and O +
the O +
proband O -
's O +
father O -
. O +

Genomic O +
DNA O +
isolation O +
from O +
their O +
lymphocytes O +
was O +
performed O +
using O +
a O +
standard O +
phenol O -
- O -
chloroform O +
extraction O -
. O +

DNA O +
from O +
the O +
proband O +
was O +
obtained O +
from O +
the O +
formalin O -
- O -
fixed O -
, O +
paraffin O +
embedded O +
tissue O +
blocks O +
and O +
isolated O +
by O +
microdissection O +
of O +
tumor O -
, O +
deparaffinization O -
, O +
proteinase O +
K O +
treatment O -
, O +
and O +
ethanol O +
precipitation O +
[ O -
7 O -
] O -
. O +

Determination O +
of O +
MSI O +
The O +
reference O +
panel O +
of O +
5 O +
microsatellite O +
markers O +
standardized O +
by O +
the O +
National O +
Cancer O +
Institute O +
for O +
the O +
screening O +
of O +
HNPCC O +
( O -
BAT-25 O -
, O +
BAT-26 O -
, O +
D2S123 O -
, O +
D5S346 O +
and O +
D17S250 O -
) O +
were O +
PCR O +
amplified O +
using O +
the O +
corresponding O +
specific O +
primers O +
for O +
each O +
one O +
[ O -
8 O -
] O -
. O +

All O +
the O +
PCR O +
products O +
were O +
electrophoresed O +
through O +
a O +
denaturing O +
6 O -
% O +
polyacrylamide O +
gels O +
and O +
visualized O +
by O +
silver O +
staining O +
( O -
fig. O +
2 O -
) O -
. O +

Results O +
and O +
discussion O +
Our O +
work O +
shows O +
that O +
the O +
absence O +
of O +
proband O -
's O +
non O -
- O -
tumor O +
DNA O +
for O +
MSI O +
testing O +
can O +
be O +
overcome O +
by O +
studying O +
the O +
alleles O +
carried O +
by O +
his O +
progenitors O +
avoiding O +
the O +
need O +
for O +
initial O +
sequencing O +
of O +
the O +
obligate O +
carrier O -
. O +

Although O +
BAT-26 O +
has O +
been O +
reported O +
to O +
be O +
sufficient O +
for O +
MSI O -
- O -
H O +
detection O +
even O +
without O +
normal O +
tissue O +
matching O +
[ O -
9 O -
] O -
, O +
careful O +
interpretation O +
is O +
needed O +
if O +
MSI O -
- O -
H O +
detection O +
is O +
based O +
solely O +
on O +
this O +
marker O -
, O +
since O +
polymorphism O +
at O +
the O +
BAT-26 O +
locus O +
has O +
been O +
detected O +
[ O -
10 O -
] O -
. O +

A O +
more O +
sensitive O +
approach O +
has O +
been O +
reported O +
using O +
a O +
quasimonomorphic O +
mononucleotide O +
markers O +
panel O +
( O -
that O +
includes O +
BAT-25 O +
and O +
BAT-26 O -
) O +
without O +
the O +
need O +
to O +
match O +
normal O +
DNA O -
[ O -
11 O -
] O -
. O +

In O +
the O +
present O +
case O -
, O +
we O +
overcame O +
the O +
difficulty O +
of O +
having O +
a O +
proband O +
post O -
- O -
mortem O +
non O -
- O -
tumor O +
tissue O +
sample O +
for O +
MSI O +
testing O +
by O +
studying O +
the O +
alleles O +
carried O +
by O +
his O +
progenitors O -
. O +

Microsatellites O +
are O +
inherited O +
according O +
to O +
Mendelian O +
rules O +
like O +
any O +
other O +
genetic O +
markers O -
. O +

Each O +
progenitor O +
pass O +
one O +
of O +
its O +
two O +
alleles O +
to O +
its O +
offspring O +
and O +
by O +
definition O -
, O +
the O +
alleles O +
present O +
in O +
the O +
proband O -
's O +
tumor O +
tissue O +
but O +
absent O +
in O +
his O +
progenitors O +
are O +
the O +
result O +
of O +
somatic O +
mutation O -
. O +

Three O +
out O +
of O +
five O +
microsatellite O +
markers O +
( O -
BAT-25 O -
, O +
BAT-26 O +
and O +
D5S346 O -
) O +
presented O +
alleles O +
in O +
the O +
proband O -
's O +
primary O +
tumor O +
( O -
T O -
' O -
) O +
and O +
its O +
metastasis O +
( O -
T O -
" O -
) O +
different O +
from O +
those O +
inherited O +
from O +
his O +
parents O -
. O +

This O +
observation O +
suggested O +
a O +
dysfunction O +
of O +
the O +
mismatch O +
repair O +
system O +
and O +
the O +
tumor O +
was O +
classified O +
as O +
high O +
frequency O +
MSI O +
( O -
MSI O -
- O -
H O -
) O +
according O +
to O +
the O +
NCI O +
workshop O +
[ O -
12 O -
] O -
. O +

Direct O +
sequencing O +
of O +
the O +
hMSH2 B-Gene +
and O +
hMLH1 B-Gene +
genes O +
was O +
indicated O -
, O +
detecting O +
a O +
novel O +
germline O +
mutation O -
, O +
a O +
c.1864C O -
> O -
A O +
transversion O +
in O +
exon O +
12 O +
of O +
hMSH2 B-Gene +
gene O +
at O +
the O +
heterozygous O +
state O +
( O -
fig. O +
3 O -
) O +
leading O +
to O +
a O +
proline O +
622 O +
to O +
threonine O +
( O -
p. O +

Pro622Thr O -
) O +
amino O +
acid O +
substitution O -
. O +

This O +
is O +
the O +
second O +
report O +
involving O +
the O +
622 O +
codon O +
in O +
HNPCC O +
[ O -
13 O -
] O -
. O +

DNA O +
sequence O +
analysis O +
of O +
hMSH2 B-Gene +
exon O +
12 O -
. O +

Genomic O +
DNA O +
was O +
isolated O +
from O +
leucocytes O +
and O +
PCR O +
amplified O +
with O +
the O +
help O +
of O +
hMSH2 B-Gene +
exon O +
12 O +
flanking O +
primers O -
. O +

In O +
the O +
image O +
the O +
result O +
of O +
the O +
sequencing O +
using O +
the O +
PCR O +
forward O +
primer O -
. O +

Panel O +
A O -
: O +
proband O -
's O +
mother O +
( O -
obligate O +
carrier O -
) O -
, O +
positive O +
for O +
the O +
mutation O -
. O +

Panel O +
B O -
: O +
negative O +
control O +
for O +
the O +
mutation O -
. O +

Evolutionary O +
conservation O -
, O +
examined O +
by O +
alignment O +
of O +
sequences O +
of O +
homologous O +
proteins O +
for O +
several O +
species O +
( O -
fig. O +
4 O -
) O -
, O +
suggests O +
a O +
functional O +
relevance O +
for O +
the O +
amino O +
acid O +
involved O -
. O +

This O +
is O +
also O +
supported O +
by O +
the O +
mutator O +
phenotype O +
described O +
for O +
Pro640Leu O +
mutant O +
yeast O +
[ O -
14 O -
] O -
, O +
homologous O +
to O +
Pro622Leu O +
hMSH2 B-Gene +
substitution O +
in O +
humans O +
( O -
fig. O +
4 O -
) O -
. O +

Protein O +
sequence O +
alignment O +
for O +
hMSH2 B-Gene +
and O +
homologues O -
. O +

Human O -
, O +
Mouse O -
, O +
Rat O -
, O +
Chicken O +
and O +
Saccharomyces O +
cerevisiae O +
( O -
the O +
site O +
of O +
mutation O +
is O +
highlighted O -
) O +
protein O +
sequence O +
alignment O -
. O +

Evolutionary O +
conservation O +
may O +
indicate O +
the O +
functional O +
relevance O +
of O +
the O +
aminoacid O +
involved O +
for O +
the O +
structure O +
or O +
functioning O +
of O +
the O +
protein O -
. O +

* O -
UniProtKB O -
/ O -
Swiss O -
- O -
Prot O +

Conclusion O +
We O +
overcame O +
the O +
absence O +
of O +
proband O -
's O +
non O -
- O -
tumor O +
DNA O +
for O +
MSI O +
testing O +
by O +
studying O +
the O +
alleles O +
carried O +
by O +
his O +
progenitors O -
, O +
the O +
natural O +
approach O +
for O +
the O +
research O +
team O +
due O +
its O +
paternity O +
testing O +
background O -
. O +

This O +
strategy O +
allowed O +
us O +
to O +
perform O +
the O +
screening O +
for O +
HNPCC O +
using O +
the O +
recommended O +
NCI O +
microsatellite O +
panel O +
before O +
sequencing O +
the O +
obligate O +
carrier O -
. O +

We O +
consider O +
highly O +
probable O +
the O +
disease O -
- O -
causing O +
nature O +
of O +
the O +
germline O +
mutation O +
in O +
the O +
hMSH2 B-Gene +
gene O +
found O +
in O +
the O +
family O -
. O +

To O +
establish O +
it O +
undoubtedly O -
, O +
both O +
immunohistochemical O +
data O +
of O +
the O +
investigated O +
tumor O +
and O +
screening O +
of O +
at O +
least O +
100 O +
chromosomes O +
in O +
healthy O +
controls O +
should O +
be O +
performed O -
. O +

This O +
is O +
the O +
second O +
report O +
of O +
an O +
HNPCC O +
related O +
mutation O +
in O +
Argentina O -
, O +
involving O +
the O +
hMSH2 B-Gene +
gene O +
[ O -
15 O -
] O -
. O +

According O +
to O +
the O +
Human O +
Gene O +
Mutation O +
Database O +
( O -
HGMD O -
) O +
[ O -
16 O -
] O +
and O +
the O +
International O +
Society O +
for O +
Gastrointestinal O +
Hereditary O +
Tumors O +
( O -
InSiGHT O -
) O +
[ O -
17 O -
] O +
Database O +
we O +
are O +
the O +
first O +
to O +
report O +
the O +
mutation O -
. O +

Background O +
Ovarian O +
cancer O +
is O +
the O +
leading O +
cause O +
of O +
death O +
from O +
gynecological O +
cancer O +
in O +
the O +
Western O +
world O +
[ O -
1 O -
] O -
. O +

The O +
treatment O +
of O +
ovarian O +
adenocarcinoma O +
has O +
improved O +
over O +
the O +
last O +
20 O +
years O +
owing O +
to O +
the O +
combined O +
treatment O +
of O +
cytoreductive O +
surgery O +
and O +
chemotherapy O +
[ O -
2 O -
] O -
. O +

Although O +
the O +
response O +
of O +
the O +
primary O +
tumor O +
to O +
taxane O +
and O +
platinum O -
- O -
based O +
chemotherapy O +
is O +
high O -
, O +
about O +
20 O -
% O +
of O +
patients O +
never O +
achieve O +
a O +
clinical O +
response O +
and O +
the O +
majority O +
of O +
the O +
patients O +
will O +
relapse O +
and O +
eventually O +
die O +
of O +
drug O -
- O -
resistant O +
disease O +
[ O -
3 O -
] O -
. O +

If O +
it O +
would O +
be O +
possible O +
to O +
predict O +
primary O +
platinum O +
resistance O -
, O +
patients O +
might O +
be O +
spared O +
an O +
ineffective O +
but O +
toxic O +
platinum O -
- O -
containing O +
therapy O +
and O +
might O +
benefit O +
from O +
an O +
early O +
therapy O +
with O +
different O +
drugs O -
. O +

Recently O -
, O +
several O +
molecular O +
profiling O +
studies O -
, O +
including O +
our O +
study O -
, O +
have O +
revealed O +
gene O +
sets O +
that O +
can O +
predict O +
response O +
to O +
platinum O -
- O -
based O +
chemotherapy O +
in O +
ovarian O +
cancer O +
[ O -
4 O -
- O -
6 O -
] O -
. O +

We O +
discovered O +
a O +
nine O -
- O -
gene O +
set O +
which O +
predicts O +
response O +
with O +
a O +
sensitivity O +
of O +
89 O -
% O +
and O +
a O +
specificity O +
of O +
59 O -
% O +
[ O -
5 O -
] O -
. O +

One O +
of O +
these O +
nine O +
genes O +
was O +
proliferating B-Gene +
cell I-Gene +
nuclear I-Gene +
antigen I-Gene +
( O -
PCNA B-Gene -
) O -
. O +

PCNA B-Gene +
is O +
a O +
DNA O +
sliding O +
clamp O +
that O +
interacts O +
with O +
several O +
proteins O +
involved O +
in O +
cell O +
cycle O +
control O -
, O +
DNA O +
methylation O -
, O +
DNA O +
replication O +
and O +
DNA O +
repair O +
including O +
mismatch O +
repair O +
[ O -
7 O -
] O -
. O +

In O +
this O +
study O -
, O +
we O +
have O +
focused O +
on O +
DNA O +
mismatch O +
repair O +
and O +
its O +
role O +
in O +
platinum O -
- O -
based O +
chemotherapy O +
resistance O +
in O +
ovarian O +
cancer O -
. O +

DNA O +
mismatch O +
repair O +
( O -
MMR B-Gene -
) O +
is O +
divided O +
into O +
three O +
steps O -
: O +
initiation O -
, O +
excision O +
and O +
resynthesis O +
( O -
Figure O +
1 O -
) O -
. O +

Several O +
proteins O +
are O +
involved O +
in O +
the O +
initiation O +
of O +
MMR B-Gene +
including O +
the O +
three O +
MutS O -
- O -
homologs O -
, O +
MSH2 B-Gene -
, O +
MSH3 B-Gene +
and O +
MSH6 B-Gene -
. O +

The O +
MutS O +
homologs O +
form O +
a O +
heterodimer O +
that O +
recognizes O +
DNA O +
damage O -
; O +
the O +
MSH2 B-Gene +
and O +
MSH6 B-Gene +
dimer O +
( O -
the O +
hMutSα O +
complex O -
) O +
recognizes O +
base O -
- O -
base O +
mismatches O +
and O +
single O +
base O +
loops O +
whereas O +
the O +
MSH2 B-Gene +
and O +
MSH3 B-Gene +
dimer O +
( O -
hMutSβ O +
complex O -
) O +
recognizes O +
insertion O -
/ O -
deletion O +
loops O +
of O +
more O +
then O +
one O +
base O -
. O +

After O +
the O +
recognition O +
of O +
the O +
DNA O +
damage O +
the O +
binding O +
of O +
a O +
heterodimer O +
of O +
the O +
MutS O -
- O -
homologs O +
MLH1 B-Gene +
and O +
PMS2 B-Gene +
( O -
the O +
hMutLα O +
complex O -
) O +
leads O +
to O +
the O +
further O +
initiation O +
of O +
MMR B-Gene -
. O +

Other O +
known O +
and O +
still O +
unknown O +
proteins O +
involved O +
in O +
the O +
last O +
two O +
steps O +
of O +
MMR B-Gene -
, O +
the O +
excision O +
of O +
the O +
damaged O +
strand O +
and O +
the O +
resynthesis O -
, O +
are O +
recruited O +
subsequently O -
. O +

Proteins O +
known O +
to O +
be O +
involved O +
are O +
exonuclease O +
ExoI B-Gene -
, O +
proliferating O +
cell O +
nuclear O +
antigen O +
( O -
PCNA B-Gene -
) O -
, O +
DNA O +
polymerase O +
δ O +
and O +
perhaps O +
ε O +
and O +
in O +
addition O +
based O +
on O +
its O +
association O +
with O +
DNA O +
polymerase O +
δ O +
and O +
PCNA B-Gene -
, O +
DNA O +
ligase O +
I O +
[ O -
8,9 O -
] O -
. O +

Inactivation O +
of O +
MMR B-Gene +
leads O +
to O +
the O +
occurrence O +
of O +
unrepaired O +
deletions O +
in O +
mono- O +
and O +
dinucleotide O +
repeats O +
resulting O +
in O +
variable O +
lengths O +
of O +
these O +
repeats O -
. O +

This O +
is O +
called O +
microsatellite O +
instability O +
( O -
MSI O -
) O +
and O +
MSI O +
is O +
therefore O +
used O +
as O +
a O +
marker O +
for O +
MMR B-Gene +
deficiency O -
. O +

MSI O +
can O +
be O +
caused O +
by O +
genetic O +
or O +
epigenetic O +
inactivation O +
of O +
several O +
genes O +
involved O +
in O +
MMR B-Gene -
. O +

Mouse O +
knockout O +
models O +
have O +
demonstrated O +
that O +
MSH2- B-Gene -
/ O -
- O -
, O +
MSH3- B-Gene -
/ O -
- O -
, O +
MLH1- B-Gene -
/ O -
- O +
and O +
PMS2- B-Gene -
/ O -
- O +
leads O +
to O +
a O +
high O +
frequency O +
of O +
MSI O +
while O +
MSH6- B-Gene -
/ O -
- O +
and O +
PMS1- B-Gene -
/ O -
- O +
cause O +
a O +
low O +
frequency O +
( O -
reviewed O +
by O +
Wei O +
et O +
al. O +
[ O -
10 O -
] O -
) O -
. O +

However O -
, O +
in O +
hereditary O +
nonpolyposis O +
colon O +
cancer O +
( O -
HNPCC O -
) O +
families O +
( O -
which O +
are O +
known O +
to O +
have O +
a O +
high O +
frequency O +
of O +
MSI O -
) O +
germline O +
mutations O +
in O +
MSH2 B-Gene +
and O +
MLH1 B-Gene +
are O +
responsible O +
for O +
the O +
MSI O -
, O +
while O +
MSH6 B-Gene +
and O +
PMS2 B-Gene +
are O +
less O +
frequently O +
involved O +
[ O -
9 O -
] O -
. O +

The O +
lesser O +
role O +
for O +
MSH6 B-Gene -
, O +
PMS2 B-Gene -
, O +
PMS1 B-Gene +
and O +
especially O +
MSH3 B-Gene +
inactivation O +
in O +
MSI O +
seen O +
in O +
HNPCC O +
patients O +
could O +
be O +
due O +
to O +
functional O +
redundancy O +
of O +
these O +
genes O -
. O +

Methods O +
Cell O +
culture O +
All O +
cell O +
lines O +
were O +
cultured O +
in O +
medium O +
supplemented O +
with O +
100 O +
U O -
/ O -
ml O +
penicillin O -
, O +
100 O +
μg O -
/ O -
ml O +
streptomycin O +
and O +
50 O +
μg O -
/ O -
ml O +
gentamycin O +
at O +
37 O -
° O -
C O +
in O +
humidified O +
air O +
with O +
5 O -
% O +
CO2 O +
( O -
except O +
for O +
SW48 O +
which O +
was O +
cultured O +
with O +
10 O -
% O +
CO2 O -
) O -
. O +

The O +
human O +
ovarian O +
cancer O +
cell O +
lines O +
SKOV6 O -
, O +
HOC7 O -
, O +
SKOV3 O -
, O +
2774 O -
, O +
KB3.1 O +
and O +
CAOV3 O +
were O +
cultured O +
in O +
DMEM O -
/ O -
HAMF12 O +
medium O +
with O +
10 O -
% O +
fetal O +
calf O +
serum O -
, O +
A2780 O +
in O +
RPMI O +
1640 O +
medium O +
with O +
10 O -
% O +
fetal O +
calf O +
serum O +
and O +
OVCAR3 O +
in O +
RPMI O +
1640 O +
with O +
20 O -
% O +
fetal O +
calf O +
serum O +
and O +
0.01 O +
mg O -
/ O -
ml O +
insulin O -
. O +

The O +
human O +
colon O +
cancer O +
cell O +
lines O +
SW480 O +
and O +
SW48 O -
, O +
included O +
as O +
controls O -
, O +
were O +
cultured O +
in O +
RPMI O +
1640 O +
with O +
5 O -
% O +
fetal O +
calf O +
serum O +
and O +
DMEM O -
/ O -
HAMF12 O +
with O +
10 O -
% O +
fetal O +
calf O +
serum O +
respectively O -
. O +

The O +
ovarian O +
cancer O +
cell O +
line O +
A2780 O +
has O +
been O +
cultured O +
separately O +
in O +
two O +
different O +
research O +
laboratories O +
at O +
our O +
department O -
. O +

The O +
isolated O +
DNA O +
and O +
RNA O +
from O +
each O +
culture O +
were O +
used O +
for O +
further O +
analysis O -
. O +

The O +
MTT O +
colorimetric O +
assay O -
, O +
which O +
measures O +
the O +
number O +
of O +
viable O +
cells O +
capable O +
of O +
reducing O +
the O +
tetrazolium O +
compound O +
( O -
Sigma O -
- O -
Aldrich O -
, O +
Zwijndrecht O -
, O +
The O +
Netherlands O -
) O +
to O +
a O +
blue O +
formazan O +
product O -
, O +
was O +
used O +
to O +
quantitate O +
the O +
chemosensitivity O +
of O +
the O +
ovarian O +
cancer O +
cell O +
lines O +
to O +
cisplatin O -
. O +

The O +
assay O +
was O +
performed O +
as O +
described O +
previously O +
by O +
us O +
[ O -
38 O -
] O -
. O +

Patients O +
The O +
study O +
design O +
was O +
approved O +
by O +
the O +
medical O +
ethical O +
committee O +
of O +
the O +
Erasmus O +
MC O +
Rotterdam O -
, O +
the O +
Netherlands O +
( O -
MEC O +
02.949 O -
) O -
. O +

Tissue O +
of O +
75 O +
ovarian O +
cancer O +
patients O +
and O +
four O +
normal O +
stromal O +
ovarian O +
tissues O +
collected O +
at O +
the O +
Erasmus O +
MC O +
in O +
Rotterdam O +
were O +
included O +
in O +
this O +
study O -
. O +

The O +
patient O +
and O +
tumor O +
characteristics O +
are O +
listed O +
in O +
Table O +
1 O -
. O +

Forty O -
- O -
six O +
patients O +
received O +
platinum O -
- O -
based O +
chemotherapy O +
of O +
whom O +
34 O +
responded O +
to O +
treatment O +
defined O +
as O +
complete O +
response O -
, O +
partial O +
response O -
, O +
stable O +
disease O +
or O +
no O +
relapse O +
within O +
6 O +
months O +
after O +
chemotherapy O -
, O +
whereas O +
eleven O +
patients O +
had O +
progressive O +
disease O +
or O +
a O +
relapse O +
within O +
6 O +
months O +
after O +
chemotherapy O -
. O +

In O +
one O +
patient O +
the O +
response O +
was O +
not O +
known O -
. O +

The O +
response O +
rate O +
of O +
74 O -
% O +
( O -
34 O -
/ O -
46 O -
) O +
is O +
comparable O +
with O +
the O +
response O +
rate O +
of O +
80 O -
% O +
seen O +
in O +
the O +
clinic O -
. O +

A O +
more O +
detailed O +
description O +
of O +
the O +
response O +
definitions O +
has O +
been O +
previously O +
described O +
by O +
us O +
[ O -
5 O -
] O -
. O +

The O +
median O +
age O +
at O +
the O +
time O +
of O +
surgery O +
was O +
52 O +
years O +
( O -
range O +
27–83 O -
) O -
. O +

DNA O +
isolation O -
: O +
microsatellite O +
analysis O +
and O +
methylation O +
specific O +
PCR O +
Microsatellite O +
analysis O +
and O +
methylation O +
specific O +
PCR O +
( O -
MSP O -
) O +
were O +
performed O +
on O +
DNA O +
from O +
eight O +
ovarian O +
cancer O +
cell O +
lines O -
, O +
75 O +
ovarian O +
cancer O +
specimens O +
( O -
part O +
of O +
a O +
collection O +
of O +
ovarian O +
tumor O +
specimens O +
described O +
by O +
us O +
previously O +
[ O -
39 O -
] O -
) O +
and O +
the O +
four O +
normal O +
stromal O +
ovarian O +
specimens O +
( O -
see O +
study O +
design O +
in O +
Figure O +
2 O -
) O -
. O +

Microsatellite O +
analysis O +
was O +
standard O +
performed O +
in O +
our O +
laboratory O +
as O +
described O +
by O +
Westenend O +
et O +
al O +
[ O -
40 O -
] O +
using O +
the O +
two O +
mononucleotide O +
markers O -
, O +
BAT25 O +
and O +
BAT26 O -
. O +

In O +
addition O -
, O +
the O +
75 O +
ovarian O +
carcinomas O +
were O +
also O +
analysed O +
with O +
the O +
mononucleotide O +
marker O +
BAT40 O +
( O -
n O +
= O +
42 O -
) O +
or O +
with O +
the O +
dinucleotide O +
marker O +
D2S123 O +
( O -
n O +
= O +
40 O -
) O -
. O +

So O +
all O +
ovarian O +
carcinomas O +
were O +
analysed O +
with O +
three O +
or O +
four O +
MSI O +
markers O -
. O +

A O +
PCR O +
containing O +
α-32PdATP O -
, O +
was O +
performed O +
on O +
100 O +
ng O +
DNA O -
. O +

PCR O +
products O +
were O +
separated O +
on O +
a O +
denaturing O +
6 O -
% O +
polyacrylamide O +
gel O -
. O +

After O +
electrophoresis O -
, O +
gels O +
were O +
dried O +
on O +
blotting O +
paper O +
on O +
a O +
vacuum O +
gel O +
dryer O +
and O +
exposed O +
to O +
x O -
- O -
ray O +
film O -
. O +

The O +
films O +
were O +
evaluated O +
by O +
visual O +
inspection O -
. O +

The O +
methylation O +
specific O +
PCR O +
( O -
MSP O -
) O +
was O +
used O +
to O +
determine O +
the O +
promoter O +
methylation O +
of O +
MLH1 B-Gene +
after O +
the O +
DNAs O +
were O +
modified O +
with O +
sodium O +
bisulfite O +
using O +
the O +
Ez O +
DNA O +
methylation O +
kit O +
( O -
Zymo O +
research O -
) O -
. O +

We O +
designed O +
and O +
optimized O +
primers O +
that O +
are O +
specific O +
for O +
methylated O +
and O +
unmethylated O +
CpG O +
islands O +
within O +
the O +
MLH1 B-Gene +
promoter O +
( O -
methylated O -
: O +
Forward O +
5'-CGAATTAATAGGAAGAGCGGATAGC-3 O -
' O -
, O +
Reverse O +
5'-ACCTCAATACCTCGTACTCACG-3 O -
' O -
; O +
unmethylated O -
: O +
Forward O +
5'-TGAATTAATAGGAAGAGTGGATAGT-3 O -
' O -
, O +
Reverse O +
5'-CCTCAATACCTCATACTCACA-3 O -
' O -
) O -
. O +

Both O +
primers O +
are O +
located O +
within O +
a O +
region O +
important O +
for O +
a O +
maximal O +
transcription O +
of O +
MLH1 B-Gene +
( O -
including O +
the O +
binding O +
site O +
for O +
the O +
transcription O +
factor O +
CBF O -
) O +
[ O -
41,42 O -
] O -
, O +
since O +
methylation O +
at O +
this O +
region O +
is O +
most O +
likely O +
to O +
inhibit O +
transcription O +
of O +
the O +
gene O -
. O +

The O +
PCR O +
mixture O +
contained O +
1 O -
× O +
PCR O +
buffer O +
( O -
as O +
described O +
by O +
Herman O +
et O +
al O +
[ O -
43 O -
] O -
) O -
, O +
dNTPs O +
( O -
each O +
at O +
5 O +
mM O -
) O -
, O +
primers O +
( O -
1 O +
pmol O -
/ O -
μl O +
each O +
per O +
reaction O -
) O -
, O +
Taq O +
polymerase O +
( O -
0.05 O +
U O -
/ O -
μl O -
) O +
and O +
100 O +
ng O +
modified O +
DNA O +
in O +
a O +
volume O +
of O +
25 O +
μl O -
. O +

Amplification O +
was O +
carried O +
out O +
for O +
35 O +
cycles O +
( O -
30 O +
sec O +
95 O -
° O -
C O -
, O +
30 O +
sec O +
58 O -
° O -
C O +
for O +
methylated O +
and O +
55 O -
° O -
C O +
for O +
unmethylated O +
and O +
30 O +
sec O +
72 O -
° O -
C O -
) O +
followed O +
by O +
a O +
final O +
4 O +
minutes O +
extension O +
at O +
72 O -
° O -
C O -
. O +

Controls O +
without O +
DNA O +
were O +
performed O +
and O +
in O +
addition O -
, O +
the O +
colon O +
cancer O +
cell O +
lines O +
SW48 O +
with O +
a O +
methylated O +
MLH1 B-Gene +
promoter O +
and O +
SW480 O +
with O +
an O +
unmethylated O +
MLH1 B-Gene +
promoter O -
, O +
were O +
used O +
as O +
positive O +
and O +
negative O +
control O +
respectively O -
. O +

Quantitative O +
RT O -
- O -
PCR O +
Quantitative O +
RT O -
- O -
PCR O +
analysis O +
was O +
used O +
to O +
measure O +
the O +
mRNA O +
expression O +
levels O +
of O +
MLH1 B-Gene -
, O +
MSH2 B-Gene -
, O +
MSH3 B-Gene -
, O +
MSH6 B-Gene +
and O +
PMS2 B-Gene +
in O +
the O +
eight O +
ovarian O +
cancer O +
cell O +
lines O +
and O +
50 O +
of O +
the O +
75 O +
ovarian O +
cancer O +
specimens O +
of O +
which O +
RNA O +
was O +
available O -
. O +

Thirty O -
- O -
six O +
of O +
these O +
50 O +
patients O +
received O +
platinum O -
- O -
based O +
chemotherapy O +
( O -
7 O +
non O -
- O -
responders O -
, O +
28 O +
responders O +
and O +
one O +
patients O +
with O +
unknown O +
response O -
) O -
. O +

The O +
following O +
20 O -
× O +
assay O -
- O -
on O -
- O -
demand O +
primers O +
and O +
FAM O -
- O -
TAMRA O +
labeled O +
probe O -
- O -
mix O +
from O +
Applied O +
Biosystems O +
were O +
used O -
; O +
for O +
MLH1 B-Gene +
( O -
Hs00179866_m1 O -
) O -
, O +
MSH2 B-Gene +
( O -
Hs00179887_m1 O -
) O -
, O +
MSH3 B-Gene +
( O -
Hs00267239_m1 O -
) O -
, O +
MSH6 B-Gene +
( O -
Hs00264721_m1 O -
) O +
and O +
PMS2 B-Gene +
( O -
Hs00241053_m1 O -
) O -
. O +

Results O +
Microsatellite O +
analysis O +
Two O +
sublines O +
of O +
the O +
ovarian O +
cancer O +
cell O +
line O +
A2780 O +
that O +
have O +
been O +
cultured O +
by O +
two O +
research O +
groups O +
in O +
our O +
department O +
and O +
the O +
cell O +
lines O +
SKOV3 O +
and O +
2774 O +
showed O +
a O +
microsatellite O +
instable O +
( O -
MSI O -
) O +
pattern O +
for O +
both O +
mononucleotide O +
markers O +
BAT25 O +
and O +
BAT26 O -
. O +

All O +
other O +
cell O +
lines O +
showed O +
no O +
aberrations O -
. O +

In O +
addition O -
, O +
the O +
75 O +
ovarian O +
carcinoma O +
tissues O +
and O +
the O +
four O +
normal O +
stromal O +
controls O +
showed O +
no O +
aberrations O +
for O +
BAT25 O -
, O +
BAT26 O +
and O +
BAT40 O +
or O +
D2S123 O -
, O +
indicating O +
that O +
these O +
are O +
microsatellite O +
stable O +
( O -
MSS O -
) O -
. O +

MLH1 B-Gene +
promoter O +
methylation O +
One O +
of O +
the O +
two O +
A2780 O +
sublines O +
showed O +
complete O +
methylation O +
of O +
the O +
MLH1 B-Gene +
promoter O +
while O +
the O +
other O +
showed O +
a O +
low O +
level O +
of O +
methylation O -
. O +

The O +
results O +
for O +
HOC7 O +
and O +
2774 O +
were O +
not O +
informative O +
and O +
the O +
other O +
five O +
cell O +
lines O +
showed O +
no O +
methylation O -
. O +

A O +
low O +
level O +
of O +
MLH1 B-Gene +
promoter O +
methylation O +
was O +
also O +
seen O +
in O +
six O +
ovarian O +
carcinoma O +
specimens O +
and O +
in O +
addition O -
, O +
one O +
ovarian O +
carcinoma O +
specimen O +
showed O +
abundant O +
methylation O -
. O +

Five O +
ovarian O +
carcinomas O +
were O +
not O +
informative O +
while O +
the O +
other O +
63 O +
ovarian O +
carcinomas O +
showed O +
no O +
methylation O -
. O +

Quantitative O +
RT O -
- O -
PCR O -
: O +
expression O +
of O +
MLH1 B-Gene -
, O +
MSH2 B-Gene -
, O +
MSH3 B-Gene -
, O +
MSH6 B-Gene +
and O +
PMS2 B-Gene +
The O +
mRNA O +
expression O +
data O +
for O +
the O +
cell O +
lines O +
is O +
shown O +
in O +
Figure O +
3A O -
. O +

One O +
of O +
the O +
two O +
separately O +
cultured O +
MSI O +
positive O +
A2780 O +
cell O +
lines O +
showed O +
complete O +
methylation O +
of O +
the O +
MLH1 B-Gene +
promoter O +
and O +
had O +
no O +
mRNA O +
expression O +
of O +
MLH1 B-Gene -
. O +

The O +
other O +
A2780 O +
showed O +
a O +
low O +
level O +
of O +
methylation O +
but O +
had O +
the O +
highest O +
MLH1 B-Gene +
expression O +
levels O +
compared O +
to O +
the O +
other O +
cell O +
lines O -
. O +

Of O +
the O +
other O +
two O +
MSI O +
positive O +
cell O +
lines O -
, O +
SKOV3 O +
also O +
showed O +
no O +
MLH1 B-Gene +
expression O +
while O +
2774 O +
did O +
express O +
MLH1 B-Gene +
mRNA O -
. O +

RNA O +
was O +
available O +
for O +
50 O +
of O +
the O +
75 O +
ovarian O +
carcinomas O +
and O +
the O +
mRNA O +
expression O +
data O +
for O +
these O +
carcinomas O +
is O +
shown O +
in O +
Figure O +
3B O -
. O +

Interestingly O -
, O +
the O +
ovarian O +
carcinoma O +
with O +
an O +
abundant O +
MLH1 B-Gene +
promoter O +
methylation O +
had O +
a O +
low O +
MLH1 B-Gene +
mRNA O +
expression O +
compared O +
to O +
the O +
other O +
carcinomas O -
. O +

Thirty O -
- O -
six O +
of O +
the O +
50 O +
patients O +
received O +
platinum O -
- O -
based O +
chemotherapy O +
( O -
7 O +
non O -
- O -
responders O -
, O +
28 O +
responders O +
and O +
one O +
patient O +
with O +
unknown O +
response O -
) O -
. O +

There O +
was O +
no O +
significant O +
association O +
between O +
the O +
response O +
to O +
platinum O -
- O -
based O +
chemotherapy O +
and O +
the O +
expression O +
of O +
each O +
of O +
these O +
genes O +
separately O +
( O -
Mann O -
- O -
Whitney O +
test O -
, O +
p O +
> O +
0.6 O -
) O -
. O +

Since O +
inactivation O +
of O +
only O +
one O +
of O +
these O +
genes O +
might O +
be O +
sufficient O +
to O +
cause O +
MMR B-Gene +
deficiency O -
, O +
we O +
used O +
the O +
expression O +
of O +
all O +
of O +
the O +
five O +
genes O +
to O +
mark O +
MMR B-Gene +
as O +
active O +
or O +
inactive O -
. O +

If O +
at O +
least O +
one O +
of O +
the O +
five O +
genes O +
had O +
an O +
expression O +
in O +
the O +
lowest O +
quartile O +
we O +
marked O +
MMR B-Gene +
as O +
inactive O -
. O +

If O +
none O +
of O +
the O +
genes O +
had O +
an O +
expression O +
in O +
the O +
lowest O +
quartile O +
MMR B-Gene +
was O +
marked O +
as O +
active O +
( O -
Figure O +
3B O -
) O -
. O +

Next O +
the O +
Mann O -
- O -
Whitney O +
test O +
demonstrated O +
that O +
there O +
was O +
no O +
significant O +
relation O +
between O +
the O +
deducted O +
MMR B-Gene +
status O +
and O +
response O +
to O +
platinum O -
- O -
based O +
chemotherapy O +
( O -
p O +
= O +
0.665 O -
) O -
. O +

Discussion O +
In O +
this O +
study O +
we O +
aimed O +
to O +
address O +
two O +
questions O -
; O +
1 O -
) O +
what O +
is O +
the O +
frequency O +
of O +
MMR B-Gene +
inactivation O +
in O +
ovarian O +
cancer O -
, O +
and O +
2 O -
) O +
is O +
it O +
associated O +
with O +
platinum O -
- O -
based O +
chemotherapy O +
response O -
. O +

First O +
we O +
analyzed O +
eight O +
ovarian O +
cancer O +
cell O +
lines O -
, O +
i.e. O +
SKOV6 O -
, O +
HOC7 O -
, O +
SKOV3 O -
, O +
2774 O -
, O +
OVCAR3 O -
, O +
KB3.1 O -
, O +
CAOV3 O +
and O +
A2780 O -
. O +

Microsatellite O +
instability O +
( O -
MSI O -
) O -
, O +
which O +
is O +
a O +
marker O +
for O +
MMR B-Gene +
inactivation O -
, O +
was O +
detected O +
in O +
three O +
out O +
of O +
eight O +
cell O +
lines O +
i.e. O +
SKOV3 O -
, O +
2774 O +
and O +
A2780 O -
. O +

This O +
results O +
in O +
a O +
frequency O +
of O +
MMR B-Gene +
inactivation O +
in O +
ovarian O +
cancer O +
cell O +
lines O +
of O +
38 O -
% O -
. O +

The O +
MSI O +
in O +
SKOV3 O +
can O +
be O +
explained O +
by O +
the O +
loss O +
of O +
MLH1 B-Gene +
mRNA O +
expression O +
which O -
, O +
however O -
, O +
was O +
not O +
caused O +
by O +
promoter O +
methylation O -
. O +

This O +
is O +
in O +
agreement O +
with O +
the O +
loss O +
of O +
MLH1 B-Gene +
protein O +
expression O +
seen O +
in O +
SKOV3 O +
described O +
in O +
a O +
study O +
of O +
the O +
60 O +
NCI O +
cancer O +
cell O +
lines O +
[ O -
44 O -
] O -
. O +

In O +
concordance O +
with O +
our O +
findings O -
, O +
2774 O +
was O +
also O +
described O +
to O +
be O +
MSI O +
[ O -
45 O -
] O -
. O +

One O +
of O +
the O +
MSI O +
positive O +
A2780 O +
sublines O +
showed O +
a O +
strong O +
methylation O +
of O +
the O +
MLH1 B-Gene +
promoter O +
without O +
MLH1 B-Gene +
mRNA O +
expression O -
, O +
while O +
the O +
other O +
subline O +
showed O +
a O +
low O +
level O +
of O +
methylation O +
and O +
relative O +
high O +
mRNA O +
expression O -
. O +

Strathdee O +
et O +
al. O +
described O +
that O +
one O +
MLH1 B-Gene +
allele O +
was O +
methylated O +
in O +
A2780 O +
[ O -
12 O -
] O +
which O +
is O +
comparable O +
with O +
the O +
methylation O +
status O +
we O +
saw O +
in O +
A2780 O -
, O +
moreover O +
one O +
of O +
our O +
A2780 O +
sublines O +
showed O +
complete O +
methylation O -
. O +

On O +
the O +
other O +
hand O -
, O +
another O +
study O +
did O +
not O +
detect O +
MSI O +
in O +
A2780 O +
[ O -
11 O -
] O -
. O +

Interestingly O -
, O +
Aquilina O +
and O +
colleagues O +
suggested O +
there O +
is O +
a O +
subpopulation O +
of O +
A2780 O +
cells O -
, O +
estimated O +
to O +
be O +
around O +
one O +
per O +
106 O +
cells O +
[ O -
46 O -
] O -
, O +
which O +
are O +
MLH1 B-Gene +
deficient O +
and O +
heterozygous O +
for O +
the O +
p53phe172 O +
mutation O +
[ O -
46,47 O -
] O -
. O +

Since O +
these O +
cells O +
have O +
a O +
growth O +
advantage O -
, O +
prolonged O +
culturing O +
of O +
the O +
A2780 O +
cell O +
line O +
can O +
result O +
in O +
selection O +
of O +
this O +
subpopulation O -
. O +

Thus O +
over O +
time O -
, O +
separately O +
cultured O +
A2780 O +
can O +
have O +
varying O +
percentages O +
of O +
cells O +
belonging O +
to O +
this O +
subpopulation O +
which O +
may O +
explain O +
the O +
discrepancies O +
in O +
MMR B-Gene +
status O +
seen O +
in O +
the O +
A2780 O +
cell O +
lines O +
analyzed O +
by O +
us O -
. O +

Next O +
we O +
studied O +
the O +
association O +
between O +
MMR B-Gene +
inactivation O +
and O +
cisplatin O +
resistance O +
in O +
these O +
cell O +
lines O -
. O +

MMR O +
inactivation O +
seen O +
in O +
SKOV3 O +
and O +
2774 O +
might O +
result O +
in O +
the O +
relative O +
resistance O +
to O +
cisplatin O +
compared O +
to O +
the O +
other O +
cell O +
lines O -
. O +

On O +
the O +
other O +
hand O -
, O +
A2780 O +
which O +
has O +
clearly O +
an O +
inactive O +
MMR O -
, O +
was O +
most O +
sensitive O +
to O +
cisplatin O -
. O +

Overall O -
, O +
there O +
seems O +
to O +
be O +
no O +
association O +
between O +
the O +
response O +
to O +
cisplatin O +
and O +
MMR B-Gene +
status O +
in O +
these O +
eight O +
cell O +
lines O -
. O +

This O +
is O +
similar O +
to O +
a O +
study O +
in O +
the O +
60 O +
NCI O +
cell O +
lines O +
which O +
also O +
showed O +
no O +
association O +
between O +
response O +
to O +
cisplatin O +
and O +
MMR B-Gene +
status O +
based O +
on O +
the O +
MLH1 B-Gene +
and/or O +
MSH2 B-Gene +
protein O +
expression O +
[ O -
44 O -
] O -
. O +

Furthermore O -
, O +
we O +
analyzed O +
MMR B-Gene +
status O +
in O +
75 O +
ovarian O +
carcinomas O +
to O +
determine O +
the O +
frequency O +
of O +
MMR B-Gene +
inactivation O +
in O +
ovarian O +
cancer O +
in O +
vivo O -
. O +

Seven O +
of O +
the O +
75 O +
ovarian O +
carcinomas O +
showed O +
MLH1 B-Gene +
promoter O +
methylation O -
. O +

We O +
confirmed O +
whether O +
the O +
observed O +
MLH1 B-Gene +
promoter O +
methylation O +
results O +
in O +
the O +
inactivation O +
of O +
the O +
gene O +
by O +
determining O +
the O +
MLH1 B-Gene +
mRNA O +
expression O +
with O +
quantitative O +
RT O -
- O -
PCR O -
. O +

The O +
six O +
tumors O +
with O +
low O +
level O +
MLH1 B-Gene +
promoter O +
methylation O +
appeared O +
to O +
express O +
MLH1 B-Gene +
at O +
mRNA O +
levels O +
similar O +
to O +
that O +
of O +
the O +
unmethylated O +
tumors O -
. O +

Thus O +
a O +
low O +
level O +
of O +
methylation O +
does O +
not O +
result O +
in O +
an O +
altered O +
expression O +
of O +
the O +
MLH1 B-Gene +
gene O -
. O +

In O +
contrast O -
, O +
the O +
abundant O +
methylation O +
seen O +
in O +
the O +
remaining O +
carcinoma O +
was O +
associated O +
with O +
the O +
lowest O +
MLH1 B-Gene +
mRNA O +
expression O +
level O +
of O +
all O +
50 O +
ovarian O +
carcinomas O +
tested O -
. O +

However O -
, O +
none O +
of O +
the O +
ovarian O +
carcinomas O +
showed O +
MSI O +
for O +
BAT25 O -
, O +
BAT26 O +
and O +
for O +
BAT40 O +
or O +
D2S123 O +
which O +
suggests O +
a O +
frequency O +
of O +
MMR B-Gene +
inactivation O +
of O +
0 O -
% O -
. O +

The O +
low O +
MLH1 B-Gene +
mRNA O +
expression O +
seen O +
in O +
the O +
abundant O +
methylated O +
carcinoma O +
might O +
be O +
sufficient O +
enough O +
for O +
a O +
functional O +
MMR B-Gene +
which O +
results O +
in O +
the O +
observed O +
absence O +
of O +
MSI O -
. O +

Since O +
ovarian O +
cancer O +
is O +
a O +
heterogeneous O +
disease O +
characterized O +
by O +
various O +
histological O +
types O +
which O +
may O +
have O +
different O +
MSI O +
frequencies O -
, O +
the O +
number O +
of O +
specimens O +
analyzed O +
is O +
very O +
important O +
in O +
characterizing O +
a O +
feature O +
that O +
may O +
be O +
uncommon O +
such O +
as O +
MSI O -
. O +

We O +
therefore O -
, O +
made O +
a O +
summary O +
of O +
20 O +
studies O +
totaling O +
1315 O +
ovarian O +
carcinomas O -
, O +
to O +
compare O +
the O +
findings O +
of O +
these O +
studies O +
with O +
our O +
results O +
( O -
Table O +
2 O -
) O -
. O +

The O +
MSI O +
frequencies O +
determined O +
in O +
these O +
studies O +
ranged O +
from O +
0 O -
% O +
to O +
39 O -
% O -
. O +

Overall O -
, O +
MSI O +
was O +
detected O +
in O +
165 O +
of O +
the O +
1315 O +
ovarian O +
carcinomas O +
tested O -
, O +
suggesting O +
an O +
overall O +
incidence O +
of O +
13 O -
% O +
[ O -
18 O -
- O -
37 O -
] O -
. O +

Multiple O +
differences O +
between O +
these O +
studies O +
could O +
have O +
caused O +
the O +
wide O +
range O +
in O +
the O +
MSI O +
frequency O +
( O -
0–39 O -
% O -
) O -
. O +

One O +
of O +
these O +
is O +
the O +
number O +
and O +
variety O +
of O +
microsatellite O +
markers O +
analyzed O +
to O +
determine O +
the O +
MSI O -
. O +

The O +
NCI O +
recommended O +
five O +
markers O +
comprising O +
the O +
National O +
Cancer O +
Institute O +
Consensus O +
Panel O +
( O -
NCI O -
- O -
CP O -
) O +
for O +
the O +
detection O +
of O +
MSI O -
, O +
i.e. O +
markers O +
for O +
the O +
mononucleotide O +
repeats O +
BAT25 O +
and O +
BAT26 O +
and O +
the O +
dinucleotide O +
repeats O +
D2S123 O -
, O +
D5S346 O +
and O +
D17S250 O +
[ O -
48 O -
] O -
. O +

Table O +
2 O +
shows O +
per O +
study O +
the O +
number O +
of O +
MS O +
markers O +
used O +
and O +
specifies O +
how O +
many O +
of O +
these O +
are O +
part O +
of O +
the O +
NCI O -
- O -
CP O -
. O +

Interestingly O -
, O +
the O +
studies O +
that O +
used O +
all O +
NCI O -
- O -
CP O +
markers O +
to O +
determine O +
the O +
MS O +
status O +
also O +
showed O +
a O +
wide O +
range O +
in O +
MSI O +
frequency O +
( O -
8–39 O -
% O -
) O +
which O +
is O +
similar O +
to O +
the O +
overall O +
range O +
( O -
0–39 O -
% O -
) O -
. O +

Therefore O -
, O +
the O +
various O +
MS O +
markers O +
used O +
can O -
not O +
be O +
the O +
sole O +
cause O +
for O +
the O +
wide O +
range O -
. O +

Moreover O -
, O +
Gras O +
et O +
al. O +
suggest O +
that O +
the O +
reliability O +
of O +
the O +
mononucleotide O +
markers O +
BAT25 O +
and O +
BAT26 O +
is O +
so O +
high O +
that O +
most O +
MSI O +
can O +
be O +
predicted O +
by O +
evaluating O +
these O +
two O +
markers O +
exclusively O +
[ O -
27 O -
] O -
, O +
confirming O +
the O +
less O +
stringent O +
role O +
for O +
the O +
various O +
markers O +
used O +
for O +
the O +
analysis O -
. O +

Conclusion O +

No O +
MMR B-Gene +
inactivation O +
was O +
detected O +
in O +
75 O +
ovarian O +
carcinoma O +
specimens O +
and O +
no O +
association O +
was O +
seen O +
between O +
MMR B-Gene +
inactivation O +
and O +
resistance O +
in O +
the O +
ovarian O +
cancer O +
cell O +
lines O +
as O +
well O +
as O +
the O +
ovarian O +
carcinomas O -
. O +

We O +
hypothesize O +
that O +
MMR B-Gene +
inactivation O +
is O +
not O +
clearly O +
associated O +
with O +
intrinsic O +
resistance O +
in O +
ovarian O +
cancer O -
. O +

However O -
, O +
it O +
might O +
play O +
a O +
role O +
in O +
acquired O +
resistance O +
due O +
to O +
selection O +
of O +
MMR B-Gene +
deficient O +
cells O +
during O +
platinum O -
- O -
based O +
chemotherapy O -
, O +
but O +
this O +
needs O +
further O +
investigation O -
. O +

A O +
genome O -
- O -
wide O +
map O +
of O +
aberrantly O +
expressed O +
chromosomal O +
islands O +
in O +
colorectal O +
cancer O +
Abstract O +
Background O +
Cancer O +
development O +
is O +
accompanied O +
by O +
genetic O +
phenomena O +
like O +
deletion O +
and O +
amplification O +
of O +
chromosome O +
parts O +
or O +
alterations O +
of O +
chromatin O +
structure O -
. O +

It O +
is O +
expected O +
that O +
these O +
mechanisms O +
have O +
a O +
strong O +
effect O +
on O +
regional O +
gene O +
expression O -
. O +

Results O +
We O +
investigated O +
genome O -
- O -
wide O +
gene O +
expression O +
in O +
colorectal O +
carcinoma O +
( O -
CRC O -
) O +
and O +
normal O +
epithelial O +
tissues O +
from O +
25 O +
patients O +
using O +
oligonucleotide O +
arrays O -
. O +

This O +
allowed O +
us O +
to O +
identify O +
81 O +
distinct O +
chromosomal O +
islands O +
with O +
aberrant O +
gene O +
expression O -
. O +

Of O +
these O -
, O +
38 O +
islands O +
show O +
a O +
gain O +
in O +
expression O +
and O +
43 O +
a O +
loss O +
of O +
expression O -
. O +

In O +
total O -
, O +
7.892 O +
genes O +
( O -
25.3 O -
% O +
of O +
all O +
human O +
genes O -
) O +
are O +
located O +
in O +
aberrantly O +
expressed O +
islands O -
. O +

Many O +
chromosomal O +
regions O +
that O +
are O +
linked O +
to O +
hereditary O +
colorectal O +
cancer O +
show O +
deregulated O +
expression O -
. O +

Also O -
, O +
many O +
known O +
tumor O +
genes O +
localize O +
to O +
chromosomal O +
islands O +
of O +
misregulated O +
expression O +
in O +
CRC O -
. O +

Conclusion O +
An O +
extensive O +
comparison O +
with O +
published O +
CGH O +
data O +
suggests O +
that O +
chromosomal O +
regions O +
known O +
for O +
frequent O +
deletions O +
in O +
colon O +
cancer O +
tend O +
to O +
show O +
reduced O +
expression O -
. O +

In O +
contrast O -
, O +
regions O +
that O +
are O +
often O +
amplified O +
in O +
colorectal O +
tumors O +
exhibit O +
heterogeneous O +
expression O +
patterns O -
: O +
even O +
show O +
a O +
decrease O +
of O +
mRNA O +
expression O -
. O +

Because O +
for O +
several O +
islands O +
of O +
deregulated O +
expression O +
chromosomal O +
aberrations O +
have O +
never O +
been O +
observed O -
, O +
we O +
speculate O +
that O +
additional O +
mechanisms O +
( O -
like O +
abnormal O +
states O +
of O +
regional O +
chromatin O -
) O +
also O +
have O +
a O +
substantial O +
impact O +
on O +
the O +
formation O +
of O +
co O -
- O -
expression O +
islands O +
in O +
colorectal O +
carcinoma O -
. O +

Background O +
DNA O +
microarrays O +
have O +
become O +
a O +
standard O +
tool O +
for O +
the O +
analysis O +
of O +
mRNA O +
expression O +
levels O +
in O +
colorectal O +
cancer O +
cells O -
. O +

Most O +
studies O +
focus O +
on O +
the O +
identification O +
of O +
differentially O +
expressed O +
genes O +
in O +
tissues O +
at O +
different O +
tumor O +
stages O +
or O +
on O +
the O +
identification O +
of O +
new O +
tumor O +
subclasses O +
and O +
their O +
diagnostic O +
gene O +
expression O +
signatures O +
[ O -
1 O -
- O -
6 O -
] O -
. O +

In O +
contrast O -
, O +
much O +
less O +
is O +
known O +
about O +
the O +
influence O +
of O +
chromosomal O +
neighborhood O +
on O +
gene O +
expression O +
in O +
tumors O -
. O +

In O +
tumors O +
different O +
genetic O +
mechanisms O +
are O +
known O +
to O +
affect O +
gene O +
expression O +
in O +
wider O +
chromosomal O +
regions O -
. O +

Chromosomal O +
aberrations O -
, O +
like O +
homozygous O +
and O +
heterozygous O +
deletions O +
or O +
amplifications O -
, O +
alter O +
the O +
DNA O +
copy O +
number O +
of O +
large O +
genomic O +
regions O +
or O +
even O +
whole O +
chromosome O +
arms O -
, O +
leading O +
to O +
inactivation O +
of O +
tumor O +
suppressor O +
genes O +
[ O -
7,8 O -
] O +
or O +
to O +
activation O +
of O +
oncogenes O -
. O +

Another O +
genetic O +
phenomenon O +
that O +
is O +
assumed O +
to O +
have O +
drastic O +
effects O +
on O +
gene O +
expression O +
in O +
cancer O +
cells O +
is O +
the O +
aberrant O +
alteration O +
of O +
chromatin O +
structure O -
. O +

Methylation O +
of O +
genomic O +
DNA O -
, O +
histone O +
acetylation O -
, O +
and O +
histone O +
methylation O +
are O +
assumed O +
to O +
have O +
a O +
large O +
impact O +
on O +
the O +
accessibility O +
of O +
DNA O +
for O +
transcription O +
initiation O +
[ O -
9 O -
] O -
. O +

Such O +
epigenetic O +
mechanisms O +
can O +
affect O +
large O +
genomic O +
regions O +
by O +
possibly O +
either O +
silencing O +
or O +
activating O +
large O +
arrays O +
of O +
genes O -
. O +

However O -
, O +
the O +
regulatory O +
mechanisms O +
governing O +
chromatin O +
assembly O +
and O +
disassembly O +
are O +
only O +
beginning O +
to O +
emerge O -
. O +

So O +
far O -
, O +
due O +
to O +
methodological O +
limitations O +
it O +
has O +
not O +
been O +
possible O +
to O +
study O +
the O +
role O +
of O +
such O +
phenomena O +
for O +
gene O +
expression O +
in O +
cancer O +
cells O +
on O +
a O +
genome O -
- O -
wide O +
scale O -
. O +

Nevertheless O -
, O +
evidence O +
from O +
single O -
- O -
gene O +
focused O +
studies O +
suggests O +
that O +
chromatin O +
regulation O +
does O +
play O +
an O +
important O +
role O +
in O +
tumorigenesis O +
[ O -
10,11 O -
] O -
. O +

Regardless O +
of O +
which O +
mechanism O +
leads O +
to O +
coordinated O +
expression O +
in O +
chromosomal O +
domains O -
, O +
solely O +
the O +
knowledge O +
about O +
such O +
domains O +
is O +
of O +
considerable O +
importance O -
. O +

Such O +
knowledge O +
could O +
guide O +
further O +
studies O +
that O +
aim O +
to O +
differentiate O +
between O +
those O +
differentially O +
expressed O +
genes O +
that O +
cause O +
tumorigenesis O +
and O +
are O +
the O +
primary O +
targets O +
of O +
regional O +
genomic O +
aberrations O +
and O +
those O +
that O +
are O +
rather O +
the O +
outcome O +
than O +
the O +
cause O +
of O +
tumor O +
development O -
. O +

The O +
rationale O +
for O +
the O +
existence O +
of O +
such O +
piggy O -
- O -
back O +
genes O +
is O +
the O +
following O -
. O +

The O +
silencing O +
of O +
genes O +
at O +
close O +
distance O +
to O +
a O +
known O +
tumor O +
suppressor O +
gene O +
( O -
TSGs O -
) O +
would O +
in O +
many O +
cases O +
just O +
be O +
a O +
side O +
effect O +
of O +
TSG O +
silencing O -
. O +

A O +
similar O +
reasoning O +
applies O +
to O +
oncogenes O +
that O +
can O +
be O +
activated O +
by O +
increased O +
expression O -
: O +
genes O +
that O +
are O +
co O -
- O -
amplified O +
could O +
also O +
be O +
expressed O +
at O +
higher O +
levels O +
although O +
they O +
do O +
not O +
contribute O +
to O +
tumorigenesis O -
. O +

Typical O +
searches O +
for O +
differentially O +
expressed O +
genes O +
by O +
microarrays O +
usually O +
ignore O +
such O +
piggy O -
- O -
back O +
effects O -
. O +

This O +
may O +
lead O +
to O +
the O +
identification O +
of O +
large O +
numbers O +
of O +
differentially O +
expressed O +
genes O +
( O -
DEGs O -
) O -
, O +
of O +
which O +
only O +
a O +
smaller O +
fraction O +
is O +
causative O +
for O +
tumor O +
development O -
. O +

Though O +
some O +
experimental O +
data O +
recently O +
became O +
available O +
linking O +
microarray O +
expression O +
with O +
DNA O +
copy O +
number O +
analyses O +
in O +
some O +
solid O +
tumors O +
[ O -
12 O -
- O -
16 O -
] O +
the O +
knowledge O +
about O +
the O +
existence O +
of O +
genomic O +
islands O +
of O +
coordinated O +
expression O +
in O +
colorectal O +
carcinoma O +
( O -
CRC O -
) O +
is O +
still O +
limited O -
. O +

During O +
the O +
preparation O +
of O +
this O +
manuscript O +
a O +
first O +
assessment O +
of O +
chromosomal O +
expression O +
patterns O +
in O +
CRC O +
in O +
conjunction O +
with O +
genome O -
- O -
wide O +
DNA O +
copy O +
number O +
analyses O +
became O +
available O +
[ O -
17 O -
] O -
. O +

Tsafrir O +
et O +
al. O +
described O +
a O +
correlation O +
of O +
gene O +
copy O +
number O +
and O +
expression O +
for O +
both O -
, O +
deleted O +
and O +
amplified O +
genes O -
. O +

They O +
claimed O +
that O +
the O +
described O +
alterations O +
become O +
more O +
frequent O +
as O +
the O +
tumors O +
progress O +
from O +
benign O +
to O +
metastatic O +
forms O -
, O +
highlighting O +
the O +
need O +
for O +
a O +
more O +
precise O +
characterization O +
of O +
regions O +
of O +
coordinate O +
expression O +
and O +
gene O +
copy O +
number O +
change O -
. O +

In O +
addition O +
to O +
this O +
most O +
recent O +
work O -
, O +
a O +
substantial O +
body O +
of O +
literature O +
on O +
chromosomal O +
aberrations O +
in O +
CRC O +
has O +
accumulated O +
[ O -
7,15,18 O -
- O -
25 O -
] O +
that O +
could O +
help O +
to O +
interpret O +
findings O +
on O +
islands O +
of O +
coordinated O +
chromosomal O +
expression O -
. O +

The O +
need O +
for O +
a O +
more O +
precise O +
definition O +
of O +
chromosomal O +
regions O +
of O +
altered O +
gene O +
expression O +
prompted O +
us O +
to O +
find O +
a O +
new O +
approach O +
to O +
investigate O +
chromosomal O +
co O -
- O -
expression O +
domains O +
in O +
CRC O -
. O +

The O +
focus O +
of O +
our O +
study O +
was O +
the O +
identification O +
of O +
up- O +
or O +
down O -
- O -
regulated O +
gene O +
expression O +
in O +
primary O +
colon O +
carcinoma O +
cells O +
compared O +
to O +
normal O +
colon O +
epithelia O +
of O +
the O +
same O +
patient O -
. O +

By O +
using O +
laser O +
capture O +
microdissection O +
( O -
LCM O -
) O +
we O +
aimed O +
to O +
investigate O +
transcript O +
abundance O +
in O +
relatively O +
pure O +
cell O +
populations O -
, O +
trying O +
to O +
minimize O +
the O +
influence O +
of O +
contaminating O +
stroma O +
tissue O +
or O +
infiltrating O +
peripheral O +
blood O +
cells O +
on O +
expression O +
measurements O -
. O +

The O +
use O +
of O +
Affymetrix O +
DNA O +
microarray O +
technology O +
allowed O +
us O +
to O +
simultaneously O +
assess O +
mRNA O +
levels O +
of O +
all O +
known O +
human O +
genes O +
using O +
only O +
small O +
amounts O +
of O +
cells O +
obtained O +
by O +
LCM O -
. O +

Finally O -
, O +
we O +
developed O +
a O +
new O +
bioinformatic O +
approach O +
to O +
identify O +
regions O +
of O +
chromosomal O +
deregulation O +
which O +
enabled O +
the O +
most O +
precise O +
survey O +
of O +
chromosomal O +
expression O +
domains O +
in O +
colon O +
cancer O +
available O +
today O -
. O +

In O +
particular O -
, O +
we O +
were O +
interested O +
in O +
the O +
question O +
whether O +
our O +
data O +
correlated O +
with O +
the O +
data O +
of O +
Tsafrir O +
et O +
al. O +
who O +
performed O +
genome O +
scale O +
arrayCGH O +
and O +
chip O -
- O -
based O +
expression O +
analyses O +
on O +
a O +
different O +
set O +
of O +
colorectal O +
cancer O +
patients O +
[ O -
17 O -
] O -
. O +

In O +
contrast O +
to O +
Tsafrir O +
et O +
al. O +
we O +
put O +
more O +
emphasis O +
on O +
the O +
identification O +
of O +
precise O +
boundaries O +
of O +
expression O +
domains O +
and O +
therefore O +
we O +
consider O +
our O +
work O +
as O +
complementary O +
to O +
their O +
pioneering O +
study O -
. O +

Results O +
Evaluation O +
of O +
data O +
set O +
quality O +
by O +
tissue O -
- O -
wise O +
hierarchical O +
clustering O +
Prior O +
to O +
the O +
analysis O +
of O +
chromosomal O +
expression O +
domains O -
, O +
we O +
aimed O +
to O +
check O +
whether O +
the O +
quality O +
of O +
our O +
complete O +
array O +
expression O +
data O +
set O +
( O -
> O +
44 O +
k O +
genes O -
) O +
allows O +
to O +
extract O +
discrepancies O +
between O +
tumor O +
samples O +
and O +
normal O +
epithelial O +
tissues O -
. O +

Purely O +
unsupervised O +
hierarchical O +
clustering O +
of O +
tissue O +
samples O +
based O +
on O +
gene O +
expression O +
vectors O +
can O +
provide O +
such O +
information O -
. O +

The O +
use O +
of O +
the O +
full O +
set O +
of O +
44 O +
k O +
genes O +
for O +
clustering O +
is O +
not O +
desirable O -
, O +
because O +
of O +
high O +
signal O -
- O -
noise O +
ratios O +
and O +
computational O +
considerations O -
. O +

Therefore O -
, O +
we O +
pre O -
- O -
selected O +
potentially O +
informative O +
genes O +
for O +
hierarchical O +
clustering O -
. O +

We O +
selected O +
only O +
genes O +
which O +
had O +
reliable O +
information O +
about O +
genomic O +
localization O +
and O +
for O +
which O +
probe O +
sets O +
exceeded O +
a O +
minimum O +
expression O +
threshold O +
in O +
at O +
least O +
20 O -
% O +
of O +
the O +
experiments O -
. O +

To O +
enrich O +
informative O +
genes O +
for O +
tissue O +
distinction O -
, O +
we O +
required O +
a O +
minimum O +
standard O +
deviation O +
across O +
all O +
50 O +
samples O -
. O +

The O +
pre O -
- O -
selection O +
resulted O +
in O +
514 O +
probe O +
sets O -
. O +

Note O +
that O +
we O +
avoided O +
to O +
pre O -
- O -
select O +
genes O +
based O +
on O +
differential O +
expression O +
between O +
tumor O +
and O +
normal O +
tissue O -
. O +

We O +
applied O +
three O +
rounds O +
of O +
normalization O +
to O +
genes O +
and O +
arrays O -
. O +

Finally O -
, O +
we O +
applied O +
standard O +
centroid O +
hierarchical O +
clustering O +
( O -
Pearson O +
correlation O -
) O +
to O +
this O +
dataset O -
. O +

Two O +
large O +
clusters O +
were O +
revealed O +
( O -
Figure O +
1 O -
) O -
. O +

18 O +
out O +
of O +
25 O +
normal O +
tissues O +
formed O +
one O +
single O +
cluster O -
. O +

The O +
remaining O +
8 O +
normal O +
tissues O +
mainly O +
clustered O +
together O +
with O +
matching O +
tumor O +
samples O +
from O +
same O +
patients O -
. O +

This O +
suggests O +
that O +
coalescence O +
between O +
tumor O +
and O +
normal O +
samples O +
from O +
the O +
same O +
patients O +
could O +
be O +
due O +
to O +
patient O -
- O -
specific O +
gene O +
expression O +
characteristics O -
. O +

As O +
the O +
majority O +
of O +
normal O +
samples O +
could O +
be O +
clearly O +
separated O +
from O +
tumors O -
, O +
we O +
concluded O +
that O +
our O +
data O +
set O +
is O +
well O +
suited O +
to O +
explore O +
differences O +
in O +
gene O +
expression O +
between O +
normal O +
and O +
tumor O +
cells O +
of O +
colorectal O +
origin O -
. O +

Hierarchical O +
clustering O +
of O +
samples O +
from O +
colorectal O +
tumors O +
and O +
normal O +
colon O +
epithelia O -
. O +

On O +
the O +
right O -
, O +
you O +
find O +
the O +
chromosomal O +
localization O +
of O +
the O +
genes O +
and O +
the O +
official O +
HUGO O +
symbol O +
or O +
prospective O +
Affymetrix O +
cluster O +
ID O -
. O +

On O +
the O +
top O -
, O +
the O +
binary O +
tree O +
of O +
tissue O +
samples O +
based O +
on O +
gene O +
expression O +
is O +
given O -
. O +

The O +
tissue O +
denominators O +
either O +
contain O +
TR O +
for O +
tumor O +
or O +
E O +
for O +
epithelium O +
and O +
a O +
code O +
reflecting O +
the O +
identity O +
of O +
each O +
patient O -
. O +

In O +
the O +
center O -
, O +
the O +
expression O +
values O +
after O +
normalization O +
have O +
been O +
color O -
- O -
coded O -
: O +
light O +
blue O +
means O +
high O +
expression O -
, O +
black O +
means O +
low O +
( O -
or O +
no O -
) O +
expression O -
. O +

Note O +
that O +
only O +
a O +
representative O +
fraction O +
of O +
the O +
514 O +
genes O +
is O +
visualized O +
here O +
( O -
white O +
bars O +
replace O +
some O +
portions O +
of O +
original O +
heat O +
map O -
) O -
. O +

The O +
right O +
cluster O +
contains O +
only O +
samples O +
from O +
normal O +
colon O +
epithelia O -
, O +
the O +
left O +
cluster O +
is O +
composed O +
primarily O +
of O +
tumors O +
along O +
with O +
some O +
interspersed O +
normal O +
epithelial O +
samples O -
. O +

Note O +
that O +
misplaced O +
normal O +
tissue O +
( O -
E O -
) O +
samples O +
often O +
cluster O +
along O +
with O +
matching O +
tumor O +
( O -
TR O -
) O +
samples O +
from O +
the O +
same O +
patient O -
. O +

Global O +
search O +
for O +
chromosomal O +
islands O +
with O +
up- O +
or O +
down O -
- O -
regulation O +
Chromosome O -
- O -
scale O +
analysis O +
of O +
gene O +
expression O +
( O -
see O +
Figures O +
2 O -
, O +
3 O -
, O +
4 O -
, O +
5 O -
) O +
already O +
suggested O +
that O +
there O +
are O +
many O +
regions O +
of O +
misregulated O +
expression O +
in O +
our O +
CRC O +
samples O -
. O +

The O +
detailed O +
analysis O +
of O +
expression O +
along O +
the O +
chromosome O +
in O +
windows O +
of O +
sizes O +
5 O -
, O +
11 O -
, O +
21 O -
, O +
31 O -
, O +
41 O -
, O +
51 O +
genes O +
resulted O +
in O +
the O +
identification O +
of O +
251 O +
partially O +
overlapping O +
intervals O +
of O +
up- O +
or O +
down O -
- O -
regulation O +
( O -
see O +
Additional O +
file O +
1 O -
) O -
. O +

These O +
intervals O +
were O +
condensed O +
in O +
81 O +
non O -
- O -
overlapping O +
regions O +
of O +
expression O +
imbalance O -
: O +
43 O +
regions O +
with O +
loss O +
of O +
expression O +
and O +
38 O +
regions O +
with O +
gain O +
of O +
expression O +
( O -
see O +
Table O +
1 O -
) O -
. O +

We O +
determined O +
the O +
fraction O +
of O +
affected O +
genes O +
on O +
each O +
chromosome O +
( O -
see O +
Table O +
2 O -
) O -
. O +

In O +
total O -
, O +
25.3 O -
% O +
of O +
all O +
genes O +
under O +
consideration O +
show O +
expression O +
imbalance O -
. O +

Slightly O +
more O +
genes O +
lie O +
in O +
chromosomal O +
regions O +
that O +
show O +
loss O +
of O +
expression O +
( O -
13.3 O -
% O -
) O +
than O +
gain O +
( O -
12 O -
% O -
) O +
of O +
expression O -
. O +

The O +
fractions O +
of O +
genes O +
with O +
gain O +
or O +
loss O +
of O +
expression O +
vary O +
strikingly O +
from O +
chromosome O +
to O +
chromosome O -
. O +

Chromosomes O +
9 O -
, O +
10 O -
, O +
15 O -
, O +
18 O -
, O +
and O +
22 O +
showed O +
only O +
regional O +
expression O +
loss O -
, O +
whereas O +
8 O -
, O +
13 O -
, O +
20 O -
, O +
and O +
X O +
showed O +
only O +
regional O +
increase O +
in O +
expression O -
. O +

There O +
were O +
too O +
few O +
informative O +
genes O +
on O +
chromosome O +
Y O +
to O +
carry O +
out O +
a O +
full O +
analysis O +
using O +
all O +
window O +
sizes O -
, O +
but O +
small O +
window O +
sizes O +
did O +
not O +
reveal O +
significant O +
deregulation O -
. O +

Whole O -
- O -
chromosome O +
plots O +
of O +
running O +
average O +
of O +
fractions O +
of O +
samples O +
showing O +
up- O -
/ O -
down O -
- O -
regulation O +
in O +
tumor O +
versus O +
normal O +
samples O +
( O -
Chromosomes O +
1 O -
, O +
2 O -
, O +
3 O -
, O +
4 O -
) O -
. O +

For O +
each O +
chromosome O +
you O +
see O +
a O +
separate O +
figure O -
. O +

Gray O +
dots O +
denote O +
the O +
number O +
of O +
patients O +
with O +
up- O +
or O +
down O -
- O -
regulation O +
for O +
a O +
single O +
gene O -
. O +

Orange O -
/ O -
green O +
lines O +
represent O +
a O +
running O +
average O +
of O +
these O +
values O -
. O +

The O +
plots O +
are O +
made O +
to O +
be O +
easily O +
comparable O +
with O +
whole O -
- O -
genome O +
CGH O +
plots O +
( O -
like O +
e.g. O +
those O +
in O +
Knösel O +
et O +
al. O +
[ O -
21 O -
] O -
) O +

Further O +
details O +
of O +
plot O +
construction O +
are O +
described O +
in O +
the O +
methods O +
section O -
. O +

Whole O -
- O -
chromosome O +
plots O +
of O +
running O +
average O +
of O +
fractions O +
of O +
samples O +
showing O +
up- O -
/ O -
down O -
- O -
regulation O +
in O +
tumor O +
versus O +
normal O +
samples O +
( O -
Chromosomes O +
5 O -
, O +
6 O -
, O +
7 O -
, O +
8 O -
, O +
9 O -
, O +
10 O -
) O -
. O +

For O +
each O +
chromosome O +
you O +
see O +
a O +
separate O +
figure O -
. O +

Gray O +
dots O +
denote O +
the O +
number O +
of O +
patients O +
with O +
up- O +
or O +
down O -
- O -
regulation O +
for O +
a O +
single O +
gene O -
. O +

Orange O -
/ O -
green O +
lines O +
represent O +
a O +
running O +
average O +
of O +
these O +
values O -
. O +

The O +
plots O +
are O +
made O +
to O +
be O +
easily O +
comparable O +
with O +
whole O -
- O -
genome O +
CGH O +
plots O +
( O -
like O +
e.g. O +
those O +
in O +
Knösel O +
et O +
al. O +
[ O -
21 O -
] O -
) O +

Further O +
details O +
of O +
plot O +
construction O +
are O +
described O +
in O +
the O +
methods O +
section O -
. O +

Whole O -
- O -
chromosome O +
plots O +
of O +
running O +
average O +
of O +
fractions O +
of O +
samples O +
showing O +
up- O -
/ O -
down O -
- O -
regulation O +
in O +
tumor O +
versus O +
normal O +
samples O +
( O -
Chromosomes O +
11 O -
, O +
12 O -
, O +
13 O -
, O +
14 O -
, O +
15 O -
, O +
16 O -
) O -
. O +

For O +
each O +
chromosome O +
you O +
see O +
a O +
separate O +
figure O -
. O +

Gray O +
dots O +
denote O +
the O +
number O +
of O +
patients O +
with O +
up- O +
or O +
down O -
- O -
regulation O +
for O +
a O +
single O +
gene O -
. O +

Orange O -
/ O -
green O +
lines O +
represent O +
a O +
running O +
average O +
of O +
these O +
values O -
. O +

The O +
plots O +
are O +
made O +
to O +
be O +
easily O +
comparable O +
with O +
whole O -
- O -
genome O +
CGH O +
plots O +
( O -
like O +
e.g. O +
those O +
in O +
Knösel O +
et O +
al. O +
[ O -
21 O -
] O -
) O +

Further O +
details O +
of O +
plot O +
construction O +
are O +
described O +
in O +
the O +
methods O +
section O -
. O +

Up O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
20q11.22-q11.23 O +
( O -
T O -
/ O -
N O +
relative O +
expression O +
heat O +
map O -
) O -
. O +

Heat O +
map O +
of O +
fold O +
change O +
of O +
tumor O -
- O -
versus O -
- O -
normal O +
expression O -
. O +

Genes O +
are O +
given O +
in O +
chromosomal O +
order O +
on O +
the O +
horizontal O +
axis O -
. O +

Patient O +
codes O +
are O +
given O +
on O +
the O +
vertical O +
axis O -
. O +

The O +
legend O +
depicts O +
which O +
colors O +
code O +
for O +
which O +
expression O +
changes O +
on O +
a O +
loge O +
scale O +
( O -
green O -
: O +
down O +
in O +
tumor O -
; O +
red O -
: O +
up O +
in O +
tumor O -
) O -
. O +

View O +
in O +
conjunction O +
with O +
Figures O +
13 O +
and O +
14 O -
. O +

Up O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
20q11.22-q11.23 O +
( O -
patient O +
counts O +
with O +
coordinate O +
up O -
- O -
regulation O -
) O -
. O +

Grayscale O +
plot O +
of O +
cross O -
- O -
comparison O +
of O +
up O -
- O -
regulation O +
patterns O +
across O +
patients O +
for O +
gene O +
pairs O +
in O +
a O +
particular O +
region O -
. O +

Both O -
, O +
horizontal O +
and O +
vertical O +
axes O +
comprise O +
the O +
same O +
genes O +
in O +
chromosomal O +
order O -
. O +

In O +
each O +
square O +
total O +
counts O +
of O +
patients O +
with O +
consistent O +
up O -
- O -
regulation O +
in O +
two O +
genes O +
are O +
coded O +
by O +
different O +
shades O +
of O +
gray O -
. O +

Dark O +
squared O +
regions O +
along O +
the O +
diagonal O +
indicate O +
coordinated O +
regulation O +
in O +
patient O +
subgroups O -
. O +

Note O -
, O +
that O +
many O +
more O +
patients O +
show O +
up O -
- O -
regulation O +
as O +
indicated O +
by O +
dark O +
spots O +
in O +
this O +
plot O +
than O +
down O -
- O -
regulation O +
as O +
indicated O +
by O +
dark O +
spots O +
in O +
Figure O +
14 O -
. O +

The O +
known O +
most O +
frequently O +
up O -
- O -
regulated O +
genes O +
in O +
this O +
region O +
are O +
EIF2S2 B-Gene -
, O +
AHCY B-Gene -
, O +
ITCH B-Gene -
, O +
DNCL2A B-Gene -
, O +
ITG4BP B-Gene -
, O +
C20orf24 B-Gene -
, O +
NDRGL3 B-Gene -
, O +
RPN2 B-Gene +
and O +
CTNNBL1 B-Gene -
. O +

Also O +
note O +
the O +
gene O +
C20orf110 O +
alias O +
TP53INP2 B-Gene +
which O +
is O +
down O -
- O -
regulated O +
in O +
the O +
majority O +
of O +
tumors O -
. O +

Up O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
20q11.22-q11.23 O +
( O -
patient O +
counts O +
with O +
coordinate O +
down O -
- O -
regulation O -
) O -
. O +

Grayscale O +
plot O +
of O +
cross O -
- O -
comparison O +
of O +
down O -
- O -
regulation O +
patterns O +
across O +
patients O +
for O +
gene O +
pairs O +
in O +
a O +
particular O +
region O -
. O +

Both O -
, O +
horizontal O +
and O +
vertical O +
axes O +
comprise O +
the O +
same O +
genes O +
in O +
chromosomal O +
order O -
. O +

In O +
each O +
square O +
total O +
counts O +
of O +
patients O +
with O +
consistent O +
down O -
- O -
regulation O +
in O +
two O +
genes O +
are O +
coded O +
by O +
different O +
shades O +
of O +
gray O -
. O +

Dark O +
squared O +
regions O +
along O +
the O +
diagonal O +
indicate O +
coordinated O +
regulation O +
in O +
patient O +
subgroups O -
. O +

View O +
in O +
conjunction O +
with O +
Figures O +
12 O +
and O +
13 O -
. O +

12q14.2 O -
- O -
12q22 O +
We O +
observed O +
increased O +
expression O +
of O +
genes O +
in O +
chromosomal O +
region O +
12q14.2 O -
- O -
12q22 O +
( O -
see O +
Figures O +
15 O -
, O +
16 O -
, O +
17 O -
) O -
. O +

The O +
MDM2 B-Gene +
gene O +
at O +
12q15 O +
is O +
a O +
possible O +
target O +
of O +
this O +
misregulation O -
. O +

However O -
, O +
within O +
this O +
large O +
region O +
there O +
is O +
a O +
smaller O +
region O +
at O +
12q21.1-q21.2 O +
spanning O +
eight O +
genes O +
that O +
exhibit O +
exceptionally O +
high O +
expression O +
in O +
our O +
tumor O +
samples O -
. O +

Among O +
these O +
is O +
LGR5 B-Gene +
alias O +
GPR49 B-Gene -
, O +
a O +
G O -
- O -
protein O +
coupled O +
receptor O +
that O +
has O +
large O +
leucine O -
- O -
rich O +
repeats O +
in O +
its O +
N O -
- O -
terminus O -
. O +

We O +
could O +
confirm O +
the O +
up O -
- O -
regulation O +
of O +
GPR49 B-Gene +
in O +
CRC O +
by O +
quantitative O +
PCR O +
and O +
in O -
- O -
situ O +
hybridization O +
( O -
data O +
not O +
shown O -
) O -
. O +

This O +
finding O +
and O +
the O +
exceptional O +
suitability O +
of O +
G O -
- O -
protein O -
- O -
coupled O +
receptors O +
as O +
drug O +
targets O +
make O +
the O +
LGR5 B-Gene -
/ O -
GPR49 B-Gene +
protein O +
a O +
potential O +
target O +
for O +
future O +
therapeutical O +
approaches O -
. O +

We O +
do O +
not O +
know O +
of O +
any O +
other O +
reports O +
that O +
link O +
this O +
region O +
to O +
CRC O -
. O +

Up O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
12q21.1-q21.2 O +
( O -
T O -
/ O -
N O +
relative O +
expression O +
heat O +
map O -
) O -
. O +

Heat O +
map O +
of O +
fold O +
change O +
of O +
tumor O -
- O -
versus O -
- O -
normal O +
expression O -
. O +

Genes O +
are O +
given O +
in O +
chromosomal O +
order O +
on O +
the O +
horizontal O +
axis O -
. O +

Patient O +
codes O +
are O +
given O +
on O +
the O +
vertical O +
axis O -
. O +

The O +
legend O +
depicts O +
which O +
colors O +
code O +
for O +
which O +
expression O +
changes O +
on O +
a O +
loge O +
scale O +
( O -
green O -
: O +
down O +
in O +
tumor O -
; O +
red O -
: O +
up O +
in O +
tumor O -
) O -
. O +

View O +
in O +
conjunction O +
with O +
Figures O +
16 O +
and O +
17 O -
. O +

Up O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
12q21.1-q21.2 O +
( O -
patient O +
counts O +
with O +
coordinate O +
up O -
- O -
regulation O -
) O -
. O +

Grayscale O +
cross O -
- O -
comparison O +
plots O +
of O +
up O -
- O -
regulation O +
patterns O +
across O +
patients O +
( O -
analogous O +
to O +
Figures O +
7 O -
, O +
10 O +
and O +
13 O -
) O -
. O +

View O +
this O +
plot O +
in O +
conjunction O +
with O +
Figures O +
15 O +
and O +
17 O -
. O +

Note O -
, O +
that O +
many O +
more O +
patients O +
show O +
up O -
- O -
regulation O +
as O +
indicated O +
by O +
dark O +
spots O +
in O +
this O +
plot O +
than O +
down O -
- O -
regulation O +
as O +
indicated O +
by O +
dark O +
spots O +
in O +
Figure O +
17 O -
. O +

Over O -
- O -
expressed O +
genes O +
in O +
this O +
region O +
comprise O +
leucine O -
- O -
rich O +
G O -
- O -
protein O +
coupled O +
receptor O +
5 O +
( O -
GPR49 O -
) O -
, O +
HIV-1 O +
rev O +
binding O +
protein O +
2 O +
( O -
HRB2 O -
) O -
, O +
pleckstrin O -
- O -
homology O -
- O -
like O +
domain O +
family O +
A O +
member O +
1 O +
( O -
PHLDA1 O -
) O -
, O +
nucleosome O +
assembly O +
protein O +
1-like O +
1 O +
( O -
NAP1L1 O -
) O -
, O +
oxysterol O +
binding O +
protein O -
- O -
like O +
8 O +
( O -
OSBPL8 O -
) O -
, O +
cystein- O +
and O +
glycine O -
- O -
rich O +
protein O +
2 O +
( O -
CSRP2 O -
) O -
, O +
E2F O +
transcription O +
factor O +
7 O +
( O -
LOC144455 O -
) O -
. O +

Up O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
12q21.1-q21.2 O +
( O -
patient O +
counts O +
with O +
coordinate O +
down O -
- O -
regulation O -
) O -
. O +

Grayscale O +
cross O -
- O -
comparison O +
plots O +
of O +
down O -
- O -
regulation O +
patterns O +
across O +
patients O +
( O -
analogous O +
to O +
Figures O +
8 O -
, O +
11 O -
, O +
14 O -
) O -
. O +

View O +
this O +
plot O +
in O +
conjunction O +
with O +
Figures O +
15 O +
and O +
16 O -
. O +

17q21.33 O -
- O -
17q23.2 O +
The O +
chromosomal O +
interval O +
17q21.33 O -
- O -
17q23.2 O +
harbors O +
numerous O +
up O -
- O -
regulated O +
genes O +
( O -
see O +
Figures O +
18 O -
, O +
19 O -
, O +
20 O -
) O -
. O +

Chromosomal O +
gains O +
of O +
this O +
region O +
in O +
CRC O +
have O +
been O +
described O +
by O +
two O +
independent O +
studies O +
[ O -
21,25 O -
] O -
. O +

Up O +
to O +
18 O +
of O +
25 O +
patients O +
show O +
up O -
- O -
regulation O +
of O +
expression O +
in O +
this O +
region O -
. O +

The O +
known O +
tumor O +
gene O +
NME1 B-Gene +
( O -
non O -
- O -
metastatic O +
1 O -
; O +
encoding O +
the O +
NM23A B-Gene +
protein O -
, O +
a O +
nucleoside O +
diphosphate O +
kinase O -
) O +
is O +
among O +
the O +
most O +
frequently O +
up O -
- O -
regulated O +
genes O +
in O +
this O +
region O -
. O +

Also O +
the O +
paralogous O +
genomic O +
neighbor O +
NME2 B-Gene +
which O +
acts O +
in O +
the O +
same O +
pathway O +
is O +
strongly O +
up O -
- O -
regulated O -
. O +

These O +
two O +
genes O +
are O +
possibly O +
the O +
primary O +
targets O +
of O +
regional O +
expression O +
up O -
- O -
regulation O -
. O +

However O -
, O +
up O -
- O -
regulation O +
of O +
several O +
other O +
genes O +
is O +
also O +
remarkable O -
. O +

The O +
up O -
- O -
regulation O +
of O +
the O +
mitochondrial O +
ribosomal O +
component O +
MRPS23 B-Gene +
is O +
notable O +
as O +
it O +
is O +
in O +
agreement O +
with O +
other O +
observations O +
of O +
up O -
- O -
regulation O +
of O +
genes O +
acting O +
in O +
translation O +
( O -
see O +
above O -
) O -
. O +

Additionally O -
, O +
the O +
RING O +
finger O +
gene O +
FLJ20315 B-Gene -
/ O -
RNF124 B-Gene -
, O +
possibly O +
encoding O +
a O +
novel O +
E3 O +
ubiquitin O +
ligase O -
, O +
and O +
the O +
suppressor O +
of O +
Ty O +
4 O +
homologue O +
1 O +
( O -
SUPT4H1 B-Gene -
) O -
, O +
a O +
putative O +
human O +
chromatin O +
regulator O +
that O +
alters O +
transcription O -
, O +
are O +
genes O +
that O +
are O +
strongly O +
up O -
- O -
regulated O +
and O +
could O +
have O +
the O +
potential O +
to O +
contribute O +
to O +
development O +
of O +
CRC O -
. O +

Up O -
- O -
regulation O +
of O +
mRNA O +
levels O +
in O +
human O +
chromosomal O +
region O +
17q21.33 O -
- O -
23.2 O +
( O -
T O -
/ O -
N O +
relative O +
expression O +
heat O +
map O -
) O -
. O +

Heat O +
map O +
of O +
fold O +
change O +
of O +
tumor O -
- O -
versus O -
- O -
normal O +
expression O -
. O +

Genes O +
are O +
given O +
in O +
chromosomal O +
order O +
on O +
the O +
horizontal O +
axis O -
. O +

Patient O +
codes O +
are O +
given O +
on O +
the O +
vertical O +
axis O -
. O +

The O +
legend O +
depicts O +
which O +
colors O +
code O +
for O +
which O +
expression O +
changes O +
on O +
a O +
loge O +
scale O +
( O -
green O -
: O +
down O +
in O +
tumor O -
; O +
red O -
: O +
up O +
in O +
tumor O -
) O -
. O +

View O +
in O +
conjunction O +
with O +
Figures O +
19 O +
and O +
20 O -
. O +

Up O -
- O -
regulation O +
of O +
mRNA O +
levels O +
in O +
human O +
chromosomal O +
region O +
17q21.33 O -
- O -
23.2 O +
( O -
patient O +
counts O +
with O +
coordinate O +
up O -
- O -
regulation O -
) O -
. O +

Grayscale O +
cross O -
- O -
comparison O +
plots O +
of O +
up O -
- O -
regulation O +
patterns O +
across O +
patients O +
( O -
analogous O +
to O +
Figures O +
7 O -
, O +
10 O -
, O +
13 O -
) O -
. O +

View O +
this O +
plot O +
in O +
conjunction O +
with O +
Figures O +
18 O +
and O +
20 O -
. O +

Note O -
, O +
that O +
many O +
more O +
patients O +
show O +
up O -
- O -
regulation O +
as O +
indicated O +
by O +
dark O +
spots O +
in O +
this O +
plot O +
than O +
down O -
- O -
regulation O +
as O +
indicated O +
by O +
dark O +
spots O +
in O +
Figure O +
20 O -
. O +

This O +
region O +
has O +
been O +
reported O +
in O +
other O +
studies O +
to O +
be O +
frequently O +
amplified O +
in O +
colon O +
cancer O +
( O -
see O +
Table O +
3 O -
) O -
. O +

Up O -
- O -
regulation O +
of O +
mRNA O +
levels O +
in O +
human O +
chromosomal O +
region O +
17q21.33 O -
- O -
23.2 O +
( O -
patient O +
counts O +
with O +
coordinate O +
down O -
- O -
regulation O -
) O -
. O +

Grayscale O +
cross O -
- O -
comparison O +
plots O +
of O +
down O -
- O -
regulation O +
patterns O +
across O +
patients O +
( O -
analogous O +
to O +
Figures O +
8 O -
, O +
11 O -
, O +
14 O -
) O -
. O +

View O +
this O +
plot O +
in O +
conjunction O +
with O +
Figures O +
18 O +
and O +
19 O -
. O +

Individual O +
chromosomal O +
islands O +
with O +
loss O +
of O +
expression O +
1p36.13 O -
- O -
1p36.11 O +
The O +
most O +
strongly O +
down O -
- O -
regulated O +
region O +
in O +
our O +
study O +
is O +
1p36.13 O -
- O -
1p36.11 O +
( O -
see O +
Figures O +
9 O -
, O +
10 O -
, O +
11 O -
) O -
. O +

A O +
larger O +
chromosome O +
region O +
comprising O +
this O +
fragment O +
has O +
recently O +
been O +
reported O +
to O +
be O +
frequently O +
deleted O +
in O +
CRC O +
( O -
see O +
Tables O +
1 O +
and O +
4 O -
) O -
. O +

No O +
tumor O +
suppressor O +
gene O +
has O +
been O +
found O +
yet O -
. O +

Our O +
data O +
suggest O +
multiple O +
genes O +
that O +
could O +
act O +
as O +
class O +
II O +
TSGs O -
. O +

Several O +
have O +
been O +
associated O +
with O +
proliferative O +
processes O +
or O +
even O +
cancer O +
before O -
. O +

The O +
PLA2G2A B-Gene +
encodes O +
phospholipase O +
A2 O +
group O +
IIA O +
which O +
has O +
been O +
proposed O +
as O +
a O +
TSG O +
and O +
a O +
marker O +
for O +
metastasis O +
and O +
patient O +
survival O +
in O +
gastric O +
cancer O +
[ O -
30 O -
] O -
. O +

The O +
E2F2 O +
transcription O +
factor O +
is O +
a O +
known O +
regulator O +
of O +
TSGs O +
and O +
interacts O +
specifically O +
with O +
the O +
RB O +
protein O -
. O +

It O +
plays O +
an O +
important O +
role O +
in O +
the O +
cell O +
cycle O -
. O +

The O +
CDC42 B-Gene +
protein O +
is O +
a O +
small O +
Rho O -
- O -
like O +
GTPase O -
. O +

It O +
acts O +
in O +
intracellular O +
signaling O +
and O +
is O +
involved O +
in O +
various O +
processes O +
like O +
control O +
of O +
morphology O -
, O +
migration O -
, O +
endocytosis O -
, O +
and O +
the O +
cell O +
cycle O -
. O +

Therefore O -
, O +
PLAG2A B-Gene -
, O +
E2F2 B-Gene +
and O +
CDC42 B-Gene +
are O +
the O +
primary O +
candidate O +
tumor O +
suppressors O +
in O +
this O +
region O -
. O +

Expression O +
in O +
Islands O +
frequently O +
deleted O +
in O +
CRC O -
. O +

Literature O +
survey O +
of O +
chromosomal O +
regions O +
with O +
evidence O +
for O +
deletions O +
in O +
colorectal O +
cancers O -
. O +

We O +
checked O +
all O +
regions O +
of O +
frequent O +
chromosomal O +
deletions O +
for O +
congruence O +
with O +
expression O +
patterns O -
. O +

Congruence O +
between O +
literature O +
CGH O +
data O +
and O +
our O +
expression O +
data O +
was O +
declared O +
on O +
the O +
presumption O +
that O +
allelic O +
loss O +
causes O +
mRNA O +
down O -
- O -
regulation O -
. O +

Down O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
1p36.13 O -
- O -
1p36.11 O +
( O -
T O -
/ O -
N O +
relative O +
expression O +
heat O +
map O -
) O -
. O +

Heat O +
map O +
of O +
fold O +
change O +
of O +
tumor O -
- O -
versus O -
- O -
normal O +
expression O -
. O +

Genes O +
are O +
given O +
in O +
chromosomal O +
order O +
on O +
the O +
horizontal O +
axis O -
. O +

Patient O +
codes O +
are O +
given O +
on O +
the O +
vertical O +
axis O -
. O +

The O +
legend O +
depicts O +
which O +
colors O +
code O +
for O +
which O +
expression O +
changes O +
on O +
a O +
loge O +
scale O +
( O -
green O -
: O +
down O +
in O +
tumor O -
; O +
red O -
: O +
up O +
in O +
tumor O -
) O -
. O +

View O +
in O +
conjunction O +
with O +
Figures O +
10 O +
and O +
11 O -
. O +

Down O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
1p36.13 O -
- O -
1p36.11 O +
( O -
patient O +
counts O +
with O +
coordinate O +
up O -
- O -
regulation O -
) O -
. O +

Grayscale O +
plot O +
of O +
cross O -
- O -
comparison O +
of O +
up O -
- O -
regulation O +
patterns O +
across O +
patients O +
for O +
gene O +
pairs O +
in O +
a O +
particular O +
region O -
. O +

Both O -
, O +
horizontal O +
and O +
vertical O +
axes O +
comprise O +
the O +
same O +
genes O +
in O +
chromosomal O +
order O -
. O +

In O +
each O +
square O +
total O +
counts O +
of O +
patients O +
with O +
consistent O +
up O -
- O -
regulation O +
in O +
two O +
genes O +
are O +
coded O +
by O +
different O +
shades O +
of O +
gray O -
. O +

Dark O +
squared O +
regions O +
along O +
the O +
diagonal O +
indicate O +
coordinated O +
regulation O +
in O +
patient O +
subgroups O -
. O +

View O +
this O +
plot O +
in O +
conjunction O +
with O +
Figures O +
9 O +
and O +
11 O -
. O +

Down O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
1p36.13 O -
- O -
1p36.11 O +
( O -
patient O +
counts O +
with O +
coordinate O +
down O -
- O -
regulation O -
) O -
. O +

Grayscale O +
plot O +
of O +
cross O -
- O -
comparison O +
of O +
down O -
- O -
regulation O +
patterns O +
across O +
patients O +
for O +
gene O +
pairs O +
in O +
a O +
particular O +
region O -
. O +

Both O -
, O +
horizontal O +
and O +
vertical O +
axes O +
comprise O +
the O +
same O +
genes O +
in O +
chromosomal O +
order O -
. O +

In O +
each O +
square O +
total O +
counts O +
of O +
patients O +
with O +
consistent O +
down O -
- O -
regulation O +
in O +
two O +
genes O +
are O +
coded O +
by O +
different O +
shades O +
of O +
gray O -
. O +

Dark O +
squared O +
regions O +
along O +
the O +
diagonal O +
indicate O +
coordinated O +
regulation O +
in O +
patient O +
subgroups O -
. O +

Note O -
, O +
that O +
many O +
more O +
patients O +
show O +
down O -
- O -
regulation O +
as O +
indicated O +
by O +
dark O +
spots O +
in O +
this O +
plot O +
than O +
up O -
- O -
regulation O +
as O +
indicated O +
by O +
dark O +
spots O +
in O +
Figure O +
10 O -
. O +

This O +
region O +
has O +
been O +
reported O +
in O +
other O +
studies O +
to O +
be O +
frequently O +
deleted O +
in O +
colorectal O +
cancer O +
( O -
see O +
Table O +
4 O -
) O -
. O +

This O +
is O +
the O +
most O +
significantly O +
down O -
- O -
regulated O +
region O +
of O +
our O +
analysis O -
. O +

Note O +
the O +
expression O +
of O +
potential O +
tumor O +
genes O +
PLA2G2A B-Gene -
, O +
E2F2 B-Gene -
, O +
and O +
CDC42 B-Gene -
. O +

4p15.31 O -
- O -
4p15.2 O +
The O +
region O +
4p15.31 O -
- O -
4p15.2 O +
is O +
part O +
of O +
a O +
larger O +
region O +
( O -
see O +
Table O +
1 O -
) O +
that O +
showed O +
marked O +
down O -
- O -
regulation O +
of O +
expression O +
in O +
our O +
tumor O +
samples O +
( O -
see O +
Figures O +
21 O -
, O +
22 O -
, O +
23 O -
) O -
. O +

Full O +
or O +
partial O +
losses O +
of O +
chromosome O +
4 O +
are O +
well O +
known O +
phenomena O +
in O +
the O +
development O +
of O +
CRC O +
[ O -
18,19,23,24 O -
] O -
. O +

One O +
of O +
the O +
strongly O +
down O -
- O -
regulated O +
genes O +
in O +
this O +
region O +
is O +
the O +
SLIT2 B-Gene +
gene O +
at O +
4p15.31 O +
that O +
encodes O +
a O +
membrane O +
protein O +
regulating O +
cellular O +
migration O -
. O +

It O +
has O +
recently O +
been O +
described O +
as O +
a O +
new O +
tumor O +
suppressor O +
gene O +
in O +
CRC O -
, O +
gliomas O -
, O +
lung O +
and O +
breast O +
tumors O +
and O +
seems O +
to O +
be O +
transcriptionally O +
inactivated O +
by O +
epigenetic O +
silencing O +
[ O -
31 O -
- O -
33 O -
] O -
. O +

In O +
addition O -
, O +
several O +
other O +
genes O +
of O +
this O +
region O +
could O +
serve O +
as O +
candidate O +
class O +
II O +
tumor O +
suppressor O +
genes O -
. O +

The O +
GPR125 B-Gene +
gene O +
encodes O +
an O +
orphan O +
G O -
- O -
protein O +
coupled O +
receptor O +
that O +
has O +
a O +
large O +
extracellular O +
N O -
- O -
terminus O +
with O +
an O +
immunoglobulin O +
domain O +
and O +
leucine O -
- O -
rich O +
repeats O -
, O +
similar O +
to O +
GPR49 B-Gene +
described O +
above O -
. O +

The O +
PCDH7 B-Gene +
gene O +
belongs O +
to O +
the O +
protocadherin O +
gene O +
family O -
. O +

It O +
encodes O +
a O +
transmembrane O +
protein O +
that O +
has O +
seven O +
extracellular O +
cadherin O +
repeats O -
, O +
suggesting O +
that O +
it O +
is O +
involved O +
in O +
cellular O +
adhesion O +
and O +
adhesion O -
- O -
dependent O +
intracellular O +
signaling O -
. O +

The O +
functions O +
of O +
genes O +
in O +
this O +
region O +
suggest O +
that O +
this O +
regional O +
expression O +
loss O +
influences O +
adhesion O +
and O +
migration O +
properties O +
of O +
cancer O +
cells O -
. O +

Both O -
, O +
epigenetic O +
silencing O +
and O +
chromosomal O +
aberrations O +
are O +
potential O +
mechanisms O +
leading O +
to O +
expression O +
loss O +
in O +
this O +
region O -
. O +

Down O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
4p15.31 O -
- O -
15.2 O +
( O -
T O -
/ O -
N O +
relative O +
expression O +
heat O +
map O -
) O -
. O +

Heat O +
map O +
of O +
fold O +
change O +
of O +
tumor O -
- O -
versus O -
- O -
normal O +
expression O -
. O +

Genes O +
are O +
given O +
in O +
chromosomal O +
order O +
on O +
the O +
horizontal O +
axis O -
. O +

Patient O +
codes O +
are O +
given O +
on O +
the O +
vertical O +
axis O -
. O +

The O +
legend O +
depicts O +
which O +
colors O +
code O +
for O +
which O +
expression O +
changes O +
on O +
a O +
loge O +
scale O +
( O -
green O -
: O +
down O +
in O +
tumor O -
; O +
red O -
: O +
up O +
in O +
tumor O -
) O -
. O +

View O +
in O +
conjunction O +
with O +
Figures O +
22 O +
and O +
23 O -
. O +

Down O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
4p15.31 O -
- O -
15.2 O +
( O -
patient O +
counts O +
with O +
coordinate O +
up O -
- O -
regulation O -
) O -
. O +

Grayscale O +
cross O -
- O -
comparison O +
plot O +
of O +
up O -
- O -
regulation O +
patterns O +
across O +
patients O +
( O -
analogous O +
to O +
Figures O +
7 O -
, O +
10 O -
, O +
13 O -
) O -
. O +

View O +
this O +
plot O +
in O +
conjunction O +
with O +
Figures O +
21 O +
and O +
23 O -
. O +

Down O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
4p15.31 O -
- O -
15.2 O +
( O -
patient O +
counts O +
with O +
coordinate O +
down O -
- O -
regulation O -
) O -
. O +

Grayscale O +
cross O -
- O -
comparison O +
plot O +
of O +
down O -
- O -
regulation O +
patterns O +
across O +
patients O +
( O -
analogous O +
to O +
Figures O +
8 O -
, O +
11 O -
, O +
14 O -
) O -
. O +

View O +
this O +
plot O +
in O +
conjunction O +
with O +
Figures O +
21 O +
and O +
22 O -
. O +

Note O -
, O +
that O +
many O +
more O +
patients O +
show O +
down O -
- O -
regulation O +
as O +
indicated O +
by O +
dark O +
spots O +
in O +
this O +
plot O +
than O +
up O -
- O -
regulation O +
as O +
indicated O +
by O +
dark O +
spots O +
in O +
Figure O +
22 O -
. O +

This O +
region O +
has O +
been O +
reported O +
in O +
other O +
studies O +
to O +
be O +
frequently O +
deleted O +
in O +
colon O +
cancer O +
( O -
see O +
Table O +
4 O -
) O -
. O +

Note O +
the O +
expression O +
down O -
- O -
regulation O +
of O +
SLIT2 B-Gene -
, O +
GPR125 B-Gene +
and O +
PCDH7 B-Gene -
. O +

18q21.2 O -
- O -
18q23 O +
There O +
are O +
several O +
reports O +
of O +
loss O +
of O +
chromosome O +
18q O +
in O +
CRC O +
( O -
see O +
Tables O +
1 O +
and O +
4 O -
) O -
. O +

We O +
found O +
a O +
smaller O +
region O +
of O +
expression O +
down O -
- O -
regulation O +
at O +
18q21.2 O -
- O -
18q23 O +
( O -
see O +
Figures O +
24 O -
, O +
25 O -
, O +
26 O -
) O -
. O +

There O +
is O +
a O +
hot O +
spot O +
for O +
down O -
- O -
regulation O +
in O +
direct O +
vicinity O +
of O +
the O +
BCL2 B-Gene +
gene O -
. O +

Its O +
special O +
role O +
in O +
cancer O +
qualified O +
the O +
anti O -
- O -
apoptotic O +
BCL2 B-Gene +
protein O +
as O +
a O +
therapeutic O +
target O +
molecule O +
[ O -
34,35 O -
] O -
. O +

Here O +
we O +
observed O +
down O -
- O -
regulation O +
of O +
BCL2 B-Gene +
and O +
its O +
neighbors O +
which O +
is O +
contradictory O +
to O +
its O +
known O +
anti O -
- O -
apoptotic O +
cancer O -
- O -
promoting O +
function O -
. O +

Distal O +
to O +
BCL2 B-Gene +
at O +
18q21.1 O -
- O -
18q21.2 O +
there O +
is O +
a O +
region O +
of O +
less O +
pronounced O +
down O -
- O -
regulation O +
between O +
ME2 B-Gene +
and O +
MBD2 B-Gene -
. O +

The O +
SMAD4 B-Gene +
( O -
Hs.298320 O -
) O +
is O +
only O +
weakly O +
down O -
- O -
regulated O +
and O +
the O +
biological O +
significance O +
is O +
questionable O -
. O +

The O +
DCC B-Gene +
( O -
deleted O +
in O +
colorectal O +
carcinoma O -
) O -
, O +
proximal O +
to O +
MBD2 B-Gene -
, O +
is O +
the O +
largest O +
gene O +
in O +
this O +
region O -
, O +
but O +
no O +
statements O +
about O +
its O +
expression O +
can O +
be O +
made O +
because O +
of O +
a O +
lack O +
of O +
informative O +
expression O +
measures O -
. O +

The O +
SMAD2 B-Gene +
and O +
SMAD7 B-Gene +
genes O +
are O +
in O +
close O +
vicinity O +
to O +
this O +
region O -
. O +

In O +
summary O -
, O +
we O +
do O +
not O +
have O +
direct O +
evidence O +
for O +
down O -
- O -
regulation O +
of O +
tumor O +
suppressor O +
genes O +
in O +
this O +
region O -
. O +

Instead O -
, O +
we O +
observed O +
down O -
- O -
regulation O +
of O +
the O +
cancer O -
- O -
promoting O +
BCL2 B-Gene +
gene O -
. O +

Therefore O -
, O +
the O +
biological O +
significance O +
of O +
this O +
domain O +
of O +
expression O +
loss O +
remains O +
elusive O -
. O +

Possibly O -
, O +
the O +
down O -
- O -
regulation O +
of O +
the O +
BCL2 B-Gene +
region O +
is O +
just O +
a O +
by O -
- O -
stander O +
effect O +
of O +
deletions O +
targeted O +
at O +
DCC B-Gene +
disruption O -
. O +

Alternatively O -
, O +
BCL2 B-Gene +
down O -
- O -
regulation O +
could O +
be O +
an O +
unsuccessful O +
attempt O +
of O +
the O +
tumor O +
cells O -
' O +
genetic O +
program O +
to O +
shift O +
the O +
cellular O +
homeostasis O +
towards O +
cell O +
death O -
. O +

Down O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
18q21.2 O -
- O -
18q23 O +
– O +
the O +
BCL2 O +
region O +
( O -
T O -
/ O -
N O +
relative O +
expression O +
heat O +
map O -
) O -
. O +

Heat O +
map O +
of O +
fold O +
change O +
of O +
tumor O -
- O -
versus O -
- O -
normal O +
expression O -
. O +

Genes O +
are O +
given O +
in O +
chromosomal O +
order O +
on O +
the O +
horizontal O +
axis O -
. O +

Patient O +
codes O +
are O +
given O +
on O +
the O +
vertical O +
axis O -
. O +

The O +
legend O +
depicts O +
which O +
colors O +
code O +
for O +
which O +
expression O +
changes O +
on O +
a O +
loge O +
scale O +
( O -
green O -
: O +
down O +
in O +
tumor O -
; O +
red O -
: O +
up O +
in O +
tumor O -
) O -
. O +

View O +
in O +
conjunction O +
with O +
Figures O +
25 O +
and O +
26 O -
. O +

Down O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
18q21.2 O -
- O -
18q23 O +
– O +
the O +
BCL2 B-Gene +
region O +
( O -
patient O +
counts O +
with O +
coordinate O +
up O -
- O -
regulation O -
) O -
. O +

Grayscale O +
cross O -
- O -
comparison O +
plot O +
of O +
up O -
- O -
regulation O +
patterns O +
across O +
patients O +
( O -
analogous O +
to O +
Figures O +
7 O -
, O +
10 O -
, O +
13 O -
) O -
. O +

View O +
this O +
plot O +
in O +
conjunction O +
with O +
Figures O +
24 O +
and O +
26 O -
. O +

Down O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
18q21.2 O -
- O -
18q23 O +
– O +
the O +
BCL2 O +
region O +
( O -
patient O +
counts O +
with O +
coordinate O +
down O -
- O -
regulation O -
) O -
. O +

Grayscale O +
cross O -
- O -
comparison O +
plot O +
of O +
down O -
- O -
regulation O +
patterns O +
across O +
patients O +
( O -
analogous O +
to O +
Figures O +
8 O -
, O +
11 O -
, O +
14 O -
) O -
. O +

View O +
this O +
plot O +
in O +
conjunction O +
with O +
Figures O +
24 O +
and O +
25 O -
. O +

Note O -
, O +
that O +
many O +
more O +
patients O +
show O +
down O -
- O -
regulation O +
as O +
indicated O +
by O +
dark O +
spots O +
in O +
this O +
plot O +
than O +
up O -
- O -
regulation O +
as O +
indicated O +
by O +
dark O +
spots O +
in O +
Figure O +
25 O -
. O +

This O +
region O +
has O +
been O +
reported O +
in O +
other O +
studies O +
to O +
be O +
frequently O +
deleted O +
in O +
colon O +
cancer O +
( O -
see O +
Table O +
4 O -
) O -
. O +

Note O +
the O +
expression O +
down O -
- O -
regulation O +
of O +
BCL2 B-Gene -
. O +

SMAD4 B-Gene +
( O -
Hs.298320 O -
) O +
and O +
TCF4 B-Gene +
are O +
only O +
weakly O +
down O -
- O -
regulated O -
. O +

The O +
DCC B-Gene +
gene O +
is O +
also O +
located O +
in O +
this O +
region O +
between O +
LOC51320 B-Gene +
and O +
MBD2 B-Gene +
but O +
no O +
informative O +
expression O +
measures O +
were O +
obtained O -
. O +

5q22.2 O -
- O -
5q23.1 O +
Not O +
unexpected O -
, O +
we O +
found O +
loss O +
of O +
expression O +
in O +
region O +
5q22.2 O -
- O -
5q23.1 O +
( O -
see O +
Figures O +
27 O -
, O +
28 O -
, O +
29 O -
) O -
. O +

This O +
interval O +
harbors O +
two O +
known O +
TSGs O +
in O +
colon O +
cancer O -
, O +
the O +
adenomatous O +
polyposis O +
coli O +
gene O +
( O -
APC B-Gene -
) O +
gene O +
and O +
the O +
mutated O +
in O +
colorectal O +
cancer O +
( O -
MCC O -
) O -
. O +

We O +
were O +
not O +
able O +
to O +
obtain O +
expression O +
values O +
for O +
APC B-Gene -
. O +

APC B-Gene +
is O +
located O +
at O +
the O +
border O +
of O +
a O +
region O +
at O +
5q22.2 O -
- O -
5q22.3 O +
that O +
harbors O +
several O +
drastically O +
down O -
- O -
regulated O +
genes O -
. O +

Central O +
in O +
this O +
region O +
is O +
the O +
MCC B-Gene +
gene O -
. O +

The O +
distal O +
border O +
is O +
the O +
CDO1 B-Gene +
gene O -
. O +

We O +
assume O +
that O +
deletion O +
or O +
epigenetic O +
silencing O +
of O +
this O +
region O +
is O +
a O +
frequent O +
mechanism O +
contributing O +
to O +
colorectal O +
tumorigenesis O -
. O +

It O +
is O +
possible O +
that O +
also O +
APC B-Gene +
or O +
MCC B-Gene +
show O +
reduced O +
expression O -
, O +
that O +
genes O +
in O +
this O +
region O +
other O +
than O +
APC B-Gene +
and O +
MCC B-Gene +
are O +
piggy O -
- O -
back O +
genes O -
, O +
and O +
that O +
their O +
misregulation O +
is O +
not O +
of O +
functional O +
significance O +
for O +
tumorigenesis O -
. O +

Down O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
5q22.2 O -
- O -
5q23.1 O +
– O +
the O +
APC B-Gene +
region O +
( O -
T O -
/ O -
N O +
relative O +
expression O +
heat O +
map O -
) O -
. O +

Heat O +
map O +
of O +
fold O +
change O +
of O +
tumor O -
- O -
versus O -
- O -
normal O +
expression O -
. O +

Genes O +
are O +
given O +
in O +
chromosomal O +
order O +
on O +
the O +
horizontal O +
axis O -
. O +

Patient O +
codes O +
are O +
given O +
on O +
the O +
vertical O +
axis O -
. O +

The O +
legend O +
depicts O +
which O +
colors O +
code O +
for O +
which O +
expression O +
changes O +
on O +
a O +
loge O +
scale O +
( O -
green O -
: O +
down O +
in O +
tumor O -
; O +
red O -
: O +
up O +
in O +
tumor O -
) O -
. O +

View O +
in O +
conjunction O +
with O +
Figures O +
28 O +
and O +
29 O -
. O +

Down O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
5q22.2 O -
- O -
5q23.1 O +
– O +
the O +
APC B-Gene +
region O +
( O -
patient O +
counts O +
with O +
coordinate O +
up O -
- O -
regulation O -
) O -
. O +

Grayscale O +
cross O -
- O -
comparison O +
plot O +
of O +
up O -
- O -
regulation O +
patterns O +
across O +
patients O +
( O -
analogous O +
to O +
Figures O +
7 O -
, O +
10 O -
, O +
13 O -
) O -
. O +

View O +
this O +
plot O +
in O +
conjunction O +
with O +
Figures O +
27 O +
and O +
29 O -
. O +

Down O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
5q22.2 O -
- O -
5q23.1 O +
– O +
the O +
APC B-Gene +
region O +
( O -
patient O +
counts O +
with O +
coordinate O +
down O -
- O -
regulation O -
) O -
. O +

Grayscale O +
cross O -
- O -
comparison O +
plot O +
of O +
down O -
- O -
regulation O +
patterns O +
across O +
patients O +
( O -
analogous O +
to O +
Figures O +
8 O -
, O +
11 O -
, O +
14 O -
) O -
. O +

View O +
this O +
plot O +
in O +
conjunction O +
with O +
Figures O +
27 O +
and O +
28 O -
. O +

Note O -
, O +
that O +
many O +
more O +
patients O +
show O +
down O -
- O -
regulation O +
as O +
indicated O +
by O +
dark O +
spots O +
in O +
this O +
plot O +
than O +
up O -
- O -
regulation O +
as O +
indicated O +
by O +
dark O +
spots O +
in O +
Figure O +
28 O -
. O +

This O +
region O +
has O +
been O +
reported O +
in O +
other O +
studies O +
to O +
be O +
frequently O +
deleted O +
in O +
colon O +
cancer O +
( O -
see O +
Table O +
4 O -
) O -
. O +

APC B-Gene +
itself O +
is O +
not O +
represented O +
in O +
this O +
plot O +
( O -
no O +
valid O +
expression O +
measures O -
) O -
. O +

It O +
is O +
located O +
down O -
- O -
stream O +
of O +
TIGA1 B-Gene +
and O +
up O -
- O -
stream O +
of O +
DP1 B-Gene +
and O +
DCP2 B-Gene -
. O +

Note O +
the O +
sharp O +
change O +
from O +
expression O +
up O -
- O -
regulation O +
( O -
TIGA1 B-Gene -
) O +
to O +
expression O +
down O -
- O -
regulation O +
( O -
DCP2 B-Gene +
to O +
DMXL1 B-Gene -
) O +
in O +
this O +
interval O -
. O +

14q24.3 O +
The O +
chromosomal O +
region O +
14q24.3 O +
has O +
been O +
implicated O +
in O +
colorectal O +
cancer O +
several O +
times O +
( O -
see O +
Table O +
1 O -
) O -
. O +

We O +
found O +
coordinated O +
down O -
- O -
regulation O +
of O +
expression O +
of O +
genes O +
in O +
14q24.1 O -
- O -
14q24.3 O +
( O -
see O +
Figures O +
30 O -
, O +
31 O -
, O +
32 O -
) O -
. O +

The O +
region O +
comprises O +
the O +
MLH3 B-Gene +
gene O +
that O +
is O +
linked O +
to O +
hereditary O +
non O -
- O -
polyposis O +
colorectal O +
cancer O +
type O +
7 O +
( O -
HNPCC7 O -
) O -
. O +

We O +
note O +
that O +
also O +
the O +
FOS B-Gene +
gene O +
encoding O +
one O +
half O +
of O +
the O +
bZIP O +
dimer O +
activator O +
protein O +
( O -
AP-1 O -
) O +
at O +
14q24.3 O +
is O +
strongly O +
down O -
- O -
regulated O -
. O +

FOS B-Gene +
is O +
known O +
as O +
an O +
oncogene O +
and O +
its O +
down O -
- O -
regulation O +
is O +
therefore O +
unexpected O -
. O +

However O -
, O +
deletions O +
of O +
14q24.3 O +
have O +
been O +
linked O +
to O +
metastatic O +
CRC O +
[ O -
36 O -
] O -
. O +

In O +
combination O -
, O +
these O +
results O +
suggest O +
that O +
there O +
is O +
a O +
class O +
II O +
tumor O +
metastasis O +
suppressor O +
in O +
this O +
region O -
. O +

This O +
class O +
II O +
TSG O +
is O +
probably O +
not O +
MLH3 B-Gene -
, O +
as O +
its O +
protein O +
function O +
is O +
hardly O +
related O +
to O +
cellular O +
functions O +
promoting O +
metastasis O -
. O +

The O +
functions O +
of O +
several O +
other O +
strongly O +
misregulated O +
proteins O -
, O +
however O -
, O +
make O +
them O +
better O +
candidates O +
for O +
metastasis O +
suppressors O -
. O +

KIAA0317 O +
codes O +
for O +
a O +
predicted O +
transmembrane O +
ubiquitin O +
ligase O -
. O +

Ubiquitin O +
ligases O +
can O +
help O +
to O +
tag O +
misfolded O +
transmembrane O +
proteins O +
in O +
the O +
ER O +
for O +
destruction O +
via O +
the O +
proteasome O +
system O +
[ O -
37 O -
] O -
. O +

Absence O +
of O +
such O +
a O +
function O +
could O +
result O +
in O +
misexpressed O +
proteins O +
at O +
the O +
cell O +
surface O +
which O +
could O +
promote O +
metastasis O -
. O +

Other O +
potential O +
candidates O +
for O +
metastasis O +
suppressor O +
genes O +
in O +
this O +
region O +
code O +
for O +
the O +
transmembrane O +
Alzheimer O +
protein O +
PSEN1 B-Gene -
, O +
the O +
GTPase O +
activating O +
protein O +
KIAA0440 O -
/ O -
SIPA1L1 O -
, O +
the O +
PDZ O -
- O -
domain O +
synaptojanin O +
2-binding O +
protein O +
SYNJ2BP B-Gene +
and O +
the O +
developmental O +
regulator O +
and O +
Notch O +
interaction O +
partner O +
NUMB B-Gene -
. O +

Down O -
- O -
regulation O +
of O +
mRNA O +
expression O +
in O +
human O +
chromosomal O +
region O +
14q24.1 O -
- O -
14q24.3 O +
– O +
the O +
FOS O +
region O +
( O -
T O -
/ O -
N O +
relative O +
expression O +
heat O +
map O -
) O -
. O +

Heat O +
map O +
of O +
fold O +
change O +
of O +
tumor O -
- O -
versus O -
- O -
normal O +
expression O -
. O +

Genes O +
are O +
given O +
in O +
chromosomal O +
order O +
on O +
the O +
horizontal O +
axis O -
. O +

Patient O +
codes O +
are O +
given O +
on O +
the O +
vertical O +
axis O -
. O +

The O +
legend O +
depicts O +
which O +
colors O +
code O +
for O +
which O +
expression O +
changes O +
on O +
a O +
loge O +
scale O +
( O -
green O -
: O +
down O +
in O +
tumor O -
; O +
red O -
: O +
up O +
in O +
tumor O -
) O -
. O +

View O +
in O +
conjunction O +
with O +
Figures O +
31 O +
and O +
32 O -
. O +

For O +
a O +
more O +
detailed O +
survey O +
of O +
congruence O +
between O +
gene O +
expression O +
and O +
chromosomal O +
aberrations O +
in O +
CRC O -
, O +
we O +
compared O +
our O +
results O +
to O +
six O +
previous O +
studies O +
reporting O +
chromosomal O +
gains O +
or O +
losses O +
in O +
distinct O +
chromosomal O +
regions O +
[ O -
18,19,21 O -
- O -
25 O -
] O +
( O -
see O +
Tables O +
3 O -
, O +
4 O -
) O -
. O +

We O +
considered O +
only O +
those O +
chromosomal O +
regions O +
that O +
were O +
reported O +
by O +
different O +
researchers O +
or O +
were O +
found O +
to O +
be O +
aberrant O +
in O +
> O +
20 O -
% O +
of O +
tumor O +
samples O -
. O +

In O +
summary O -
, O +
we O +
found O +
that O +
the O +
majority O +
of O +
deletion O +
regions O +
show O +
a O +
reduction O +
in O +
expression O -
. O +

This O +
suggests O +
that O +
regional O +
transcriptional O +
silencing O +
in O +
CRC O +
is O +
mainly O +
achieved O +
by O +
loss O +
of O +
genomic O +
DNA O -
. O +

In O +
contrast O -
, O +
amplified O +
regions O +
rather O +
show O +
heterogeneous O +
expression O +
changes O -
. O +

We O +
found O +
regions O +
of O +
expression O +
gain O +
in O +
the O +
most O +
frequently O +
reported O +
regions O +
of O +
chromosome O +
gain O +
on O +
7 O -
, O +
8q O -
, O +
13 O -
, O +
20q O -
. O +

These O +
regions O +
are O +
in O +
support O +
for O +
a O +
positive O +
correlation O +
of O +
DNA O +
copy O +
number O +
and O +
transcript O +
abundance O -
, O +
although O +
a O +
direct O +
causal O +
relationship O +
is O +
not O +
shown O +
in O +
this O +
study O -
. O +

Expression O +
in O +
Islands O +
frequently O +
amplified O +
in O +
CRC O -
. O +

Literature O +
survey O +
of O +
chromosomal O +
regions O +
with O +
evidence O +
for O +
amplifications O +
in O +
colorectal O +
cancers O -
. O +

We O +
checked O +
all O +
regions O +
of O +
frequent O +
chromosomal O +
amplifications O +
for O +
congruence O +
with O +
expression O +
patterns O -
. O +

Congruence O +
between O +
literature O +
CGH O +
data O +
and O +
our O +
expression O +
data O +
was O +
declared O +
on O +
the O +
presumption O +
that O +
allelic O +
gain O +
causes O +
mRNA O +
up O -
- O -
regulation O -
. O +

However O -
, O +
there O +
are O +
also O +
many O +
regions O +
of O +
frequent O +
deletions O +
that O +
did O +
not O +
show O +
alterations O +
in O +
expression O +
or O +
that O +
were O +
even O +
down O -
- O -
regulated O +
( O -
7q11.2 O -
- O -
7q12 O -
, O +
9q34 O -
, O +
12p13.1 O -
- O -
13.2 O -
, O +
15q22 O -
- O -
15q23 O -
, O +
16p12 O -
- O -
16p11 O -
, O +
22q11 O -
; O +
compare O +
Tables O +
3 O +
and O +
4 O -
) O -
. O +

One O +
possible O +
explanation O +
is O +
that O +
these O +
down O -
- O -
regulated O +
regions O +
are O +
not O +
amplified O +
in O +
our O +
tumor O +
samples O -
. O +

An O +
alternative O +
explanation O +
is O +
that O +
the O +
influence O +
of O +
chromosomal O +
amplification O +
on O +
transcription O +
levels O +
can O +
be O +
either O +
positive O +
or O +
negative O -
. O +

It O +
is O +
possible O +
that O +
amplification O +
of O +
a O +
particular O +
genomic O +
region O +
disrupts O +
transcription O +
of O +
amplified O +
genes O +
by O +
a O +
yet O +
unknown O +
mechanism O -
, O +
e.g. O +
by O +
induction O +
of O +
chromatin O -
- O -
based O +
silencing O -
, O +
or O +
by O +
separation O +
of O +
essential O +
enhancer O +
regions O +
from O +
transcription O +
starts O -
. O +

Platzer O +
et O +
al. O +
found O +
amplifications O +
in O +
7p O -
, O +
8q O -
, O +
13q O -
, O +
20q O +
in O +
26%–43 O -
% O +
of O +
their O +
CRC O +
patients O +
and O +
revealed O +
by O +
microarray O -
- O -
based O +
expression O +
analysis O +
that O +
only O +
81 O +
of O +
2146 O +
genes O +
in O +
amplified O +
regions O +
show O +
over O -
- O -
expression O +
( O -
3.8 O -
% O -
) O +
whereas O +
164 O +
of O +
2146 O +
genes O +
show O +
under O -
- O -
expression O +
( O -
7.7 O -
% O -
) O -
. O +

Using O +
a O +
different O +
approach O +
( O -
microdissection O -
, O +
oligo O +
arrays O -
, O +
analysis O +
aimed O +
at O +
the O +
identification O +
of O +
single O +
chromosomal O +
expression O +
domains O +
and O +
not O +
at O +
the O +
location O +
of O +
all O +
differentially O +
expressed O +
genes O +
in O +
chromosomes O -
) O +
we O +
found O +
several O +
smaller O +
up O -
- O -
regulated O +
regions O +
and O +
no O +
regions O +
of O +
down O -
- O -
regulation O +
in O +
the O +
same O +
chromosomal O +
regions O -
. O +

Therefore O -
, O +
our O +
data O +
partly O +
contradicts O +
the O +
findings O +
of O +
Platzer O +
et O +
al. O +
which O +
state O +
that O +
in O +
these O +
frequently O +
amplified O +
regions O +
gene O +
expression O +
is O +
rather O +
down O -
- O -
regulated O -
. O +

However O -
, O +
other O +
misregulated O +
expression O +
domains O +
( O -
see O +
above O -
) O +
of O +
our O +
study O +
confirmed O +
the O +
general O +
notion O +
by O +
Platzer O +
et O +
al. O +
that O +
frequently O +
amplified O +
regions O +
in O +
CRC O +
can O +
also O +
exhibit O +
down O -
- O -
regulation O +
of O +
transcript O +
levels O -
. O +

Aberrantly O +
expressed O +
chromosomal O +
islands O +
linked O +
to O +
hereditary O +
cancer O +
Roughly O +
5 O -
% O +
of O +
all O +
colorectal O +
carcinomas O +
are O +
hereditary O +
non O -
- O -
polyposis O +
colorectal O +
cancers O +
( O -
HNPCCs O -
) O -
. O +

In O +
HNPCC O -
, O +
histologically O +
verified O +
colorectal O +
carcinoma O +
is O +
found O +
in O +
at O +
least O +
three O +
relatives O +
from O +
two O +
or O +
more O +
successive O +
generations O -
. O +

In O +
at O +
least O +
one O +
patient O -
, O +
the O +
age O +
of O +
onset O +
should O +
be O +
less O +
than O +
50 O +
years O -
. O +

Seven O +
chromosomal O +
regions O +
have O +
been O +
linked O +
to O +
HNPCC O -
. O +

More O +
than O +
half O +
of O +
these O +
HNPCC O +
regions O +
show O +
misregulated O +
expression O +
in O +
our O +
patients O -
. O +

Three O +
regions O +
show O +
down O -
- O -
regulation O +
( O -
3p21.3 O -
, O +
2q31-q33 O +
comprising O +
PMS1 B-Gene -
, O +
14q24.3 O +
comprising O +
MLH3 B-Gene -
) O -
, O +
one O +
region O +
shows O +
up O -
- O -
regulation O +
( O -
7p22 O +
comprising O +
PMS2 B-Gene -
) O -
, O +
and O +
three O +
regions O +
do O +
not O +
show O +
significant O +
changes O +
in O +
expression O +
( O -
2p22.p21 O +
comprising O +
MSH2 B-Gene -
, O +
2p16 O +
comprising O +
MSH6 B-Gene -
, O +
3p22 O +
comprising O +
TGFBR2 B-Gene -
) O -
. O +

Eleven O +
further O +
chromosomal O +
regions O +
are O +
linked O +
to O +
hereditary O +
colorectal O +
carcinoma O +
under O +
a O +
common O +
entry O +
in O +
OMIM O +
( O -
14500 O -
) O -
. O +

More O +
than O +
50 O -
% O +
of O +
these O +
regions O +
show O +
significant O +
expression O +
changes O +
in O +
our O +
data O -
. O +

Five O +
regions O +
show O +
down O -
- O -
regulation O +
( O -
1p35 O -
, O +
14q24.3 O -
, O +
17p11.2 O -
, O +
17p13.1 O -
, O +
22q13 O -
) O -
, O +
one O +
region O +
shows O +
up O -
- O -
regulation O +
( O -
2p25 O -
) O -
, O +
and O +
five O +
regions O +
do O +
not O +
show O +
significant O +
expression O +
changes O +
in O +
our O +
data O +
( O -
3q26.3 O -
, O +
8p22-p21.3 O -
, O +
11p11.2 O -
, O +
15q15 O -
, O +
17q24 O -
) O -
. O +

In O +
combination O -
, O +
these O +
findings O +
strongly O +
suggest O +
that O +
expression O +
changes O +
in O +
regions O +
linked O +
to O +
hereditary O +
CRC O +
play O +
a O +
role O +
in O +
CRC O +
development O -
. O +

Congruence O +
of O +
our O +
study O +
with O +
the O +
genome O -
- O -
wide O +
copy O +
number O +
and O +
expression O +
analysis O +
of O +
Tsafrir O +
et O +
al O +
A O +
particular O +
focus O +
of O +
our O +
study O +
was O +
on O +
the O +
congruence O +
of O +
our O +
data O +
with O +
that O +
of O +
Tsafrir O +
et O +
al. O +
[ O -
17 O -
] O -
. O +

These O +
authors O +
described O +
11 O +
alterations O +
of O +
whole O +
chromosomes O +
or O +
chromosome O +
arms O -
. O +

Using O +
our O +
approach O +
based O +
solely O +
on O +
expression O +
data O +
we O +
found O +
precisely O +
defined O +
region O +
of O +
coordinated O +
up O -
- O -
regulation O +
in O +
all O +
four O +
regions O +
of O +
gene O +
expression O +
and O +
gDNA O +
copy O +
number O +
gain O +
that O +
they O +
reported O +
( O -
+ O -
7 O -
, O +
+ O -
8q O -
, O +
+ O -
13q O -
, O +
+ O -
20q O -
) O -
. O +

For O +
six O +
of O +
seven O +
aberrations O +
( O -
-1p O -
, O +
-4 O -
, O +
-5q O -
, O +
-14q O -
, O +
-15q O -
, O +
-18 O -
) O +
we O +
discovered O +
smaller O +
expression O +
islands O +
of O +
coordinated O +
down O -
- O -
regulation O -
. O +

We O +
were O +
not O +
able O +
to O +
reproduce O +
the O +
finding O +
of O +
expression O +
loss O +
on O +
8p O -
. O +

In O +
summary O -
, O +
this O +
large O +
congruence O +
of O +
our O +
results O +
with O +
that O +
of O +
Tsafrir O +
et O +
al. O +
can O +
be O +
regarded O +
as O +
an O +
external O +
validation O +
of O +
our O +
results O -
. O +

The O +
comparison O +
illustrates O +
the O +
power O +
of O +
our O +
data O +
analysis O +
approach O +
which O +
allows O +
to O +
define O +
expression O +
islands O +
on O +
a O +
single O -
- O -
gene O +
resolution O -
. O +

Most O +
importantly O +
it O +
confirms O +
our O +
confidence O +
in O +
the O +
use O +
of O +
the O +
chip O +
platform O +
( O -
Affymetrix O +
U133A O -
) O +
that O +
was O +
used O +
in O +
both O +
studies O +
and O +
apparently O +
can O +
lead O +
to O +
largely O +
congruent O +
results O +
in O +
different O +
patient O +
cohorts O +
and O +
laboratories O -
. O +

Preprocessing O +
of O +
expression O +
data O +
We O +
used O +
our O +
own O +
algorithm O +
to O +
condensate O +
the O +
probe O +
level O +
data O +
provided O +
by O +
Affymetrix O +
CEL O -
- O -
files O +
per O +
chip O +
experiment O -
: O +
Background O +
intensity O +
was O +
computed O +
as O +
the O +
mean O +
of O +
the O +
2 O -
% O +
darkest O +
feature O +
intensities O -
. O +

This O +
background O +
value O +
was O +
subtracted O +
from O +
each O +
feature O +
value O -
. O +

Subsequently O -
, O +
each O +
feature O +
value O +
was O +
divided O +
by O +
the O +
median O +
of O +
all O +
feature O +
values O -
. O +

As O +
a O +
representative O +
expression O +
value O +
( O -
PMQ O -
) O +
for O +
each O +
probe O +
set O -
, O +
the O +
third O +
quartile O +
( O -
75 O -
% O -
) O +
of O +
all O +
intensities O +
of O +
all O +
perfect O +
match O +
oligonucleotides O +
was O +
used O -
. O +

Furthermore O -
, O +
to O +
distinguish O +
real O +
expression O +
signals O +
from O +
noise O +
the O +
Wilcoxon O +
signed O +
rank O +
test O +
was O +
applied O +
to O +
each O +
probe O +
set O -
. O +

A O +
probe O +
set O +
was O +
called O +
detectable O +
if O +
the O +
result O +
of O +
the O +
Wilcoxon O +
signed O +
rank O +
test O +
applied O +
to O +
its O +
11 O +
probe O +
pairs O +
( O -
perfect O +
match O +
versus O +
mismatch O +
oligonucleotide O -
) O +
had O +
a O +
significance O +
level O +
of O +
p O +
< O +
0.1 O +
and O +
relative O +
expression O +
value O +
( O -
PMQ O -
) O +
of O +
> O +
4.0 O -
. O +

We O +
used O +
these O +
constraints O +
for O +
decision O +
whether O +
a O +
gene O +
is O +
expressed O +
or O +
not O +
due O +
to O +
validation O +
results O +
of O +
several O +
gene O +
expression O +
pattern O +
by O +
quantitative O +
RT O -
- O -
PCR O +
and/or O +
Northern O +
Blot O +
analysis O +
in O +
our O +
lab O +
( O -
data O +
not O +
shown O -
) O -
. O +

For O +
each O +
patient O +
and O +
probeset O +
an O +
expression O +
ratio O +
was O +
calculated O +
according O +
to O +
the O +
following O +
rules O -
: O +
If O +
expression O +
was O +
detectable O +
in O +
both O +
the O +
normal O +
and O +
tumor O +
sample O +
( O -
Wilcoxon O +
test O +
p O +
< O -
= O +
0.10 O +
and O +
relative O +
expression O +
value O +
PMQ O +
> O -
= O +
4 O -
) O -
, O +
the O +
ratio O +
PMQ O -
( O -
T O -
) O -
/ O -
PMQ O -
( O -
N O -
) O +
is O +
our O +
expression O +
ratio O +
( O -
hereafter O +
called O +
T O -
/ O -
N O -
) O -
. O +

If O +
expression O +
was O +
undetectable O +
in O +
either O +
the O +
normal O +
or O +
the O +
tumor O +
sample O -
, O +
the O +
expression O +
ratio O +
was O +
either O +
set O +
to O +
T O -
/ O -
N O +
= O +
2 O +
( O -
normal O +
absent O -
) O +
or O +
to O +
T O -
/ O -
N O +
= O +
0.5 O +
( O -
tumor O +
absent O -
) O -
. O +

If O +
expression O +
was O +
undetectable O +
in O +
both O +
the O +
normal O +
and O +
tumor O +
sample O -
, O +
no O +
expression O +
ratio O +
was O +
calculated O +
and O +
we O +
call O +
the O +
probe O +
set O +
not O +
informative O -
. O +

For O +
each O +
probe O +
set O +
the O +
number O +
of O +
cases O +
which O +
showed O +
an O +
up O -
- O -
regulation O +
( O -
T O -
/ O -
N O +
> O -
= O +
2 O -
) O -
, O +
a O +
down O -
- O -
regulation O +
( O -
T O -
/ O -
N O +
< O -
= O +
0.5 O -
) O +
or O +
the O +
number O +
of O +
unchanged O +
transcription O +
levels O +
( O -
0.5 O +
< O +
T O -
/ O -
N O +
< O +
2 O -
) O +
were O +
counted O -
. O +

We O +
filtered O +
out O +
those O +
probe O +
sets O +
which O +
are O +
not O +
informative O +
in O +
any O +
patient O -
, O +
reducing O +
the O +
number O +
of O +
probe O +
sets O +
to O +
19404 O -
. O +

To O +
eliminate O +
redundancy O +
of O +
probe O +
sets O +
with O +
respect O +
to O +
genes O -
, O +
we O +
kept O +
only O +
the O +
most O +
informative O +
probe O +
set O +
of O +
a O +
single O +
gene O -
, O +
i.e. O +
the O +
probe O +
set O +
which O +
is O +
informative O +
in O +
the O +
highest O +
number O +
of O +
matched O +
sample O +
pairs O -
. O +

Additionally O -
, O +
only O +
probe O +
sets O +
that O +
could O +
unambiguously O +
be O +
linked O +
to O +
a O +
particular O +
genomic O +
locus O +
were O +
considered O +
( O -
chromosome O +
band O +
and O +
position O -
; O +
see O +
Affymetrix O +
U133A O -
/ O -
B O +
annotation O +
files O -
) O -
. O +

Finally O -
, O +
the O +
pre O -
- O -
processing O +
resulted O +
in O +
a O +
total O +
number O +
of O +
10.935 O +
probe O +
sets O +
which O +
were O +
the O +
basis O +
of O +
all O +
further O +
analyses O -
. O +

Analysis O +
of O +
expression O +
along O +
chromosomes O +
In O +
each O +
graph O +
of O +
Figures O +
2 O -
, O +
3 O -
, O +
4 O -
, O +
5 O -
, O +
we O +
plotted O +
the O +
numbers O +
of O +
patient O +
samples O +
with O +
tumor O +
up O -
/ O -
down O +
regulation O +
( O -
percentage O +
on O +
informative O +
cases O -
) O +
for O +
all O +
genes O +
according O +
to O +
their O +
position O +
on O +
the O +
chromosome O -
. O +

In O +
these O +
plots O -
, O +
the O +
smoothing O +
of O +
the O +
curve O +
is O +
achieved O +
by O +
averaging O +
over O +
50 O +
consecutive O +
genes O -
. O +

Significant O +
deviations O +
from O +
average O +
expression O +
in O +
a O +
particular O +
chromosomal O +
region O +
is O +
not O +
sufficient O +
to O +
infer O +
coordinated O +
deregulation O -
. O +

This O +
is O +
because O +
it O +
does O +
not O +
allow O +
to O +
infer O +
whether O +
all O +
genes O +
of O +
a O +
region O +
are O +
actually O +
de O -
- O -
regulated O +
in O +
the O +
same O +
subset O +
of O +
patients O -
. O +

They O +
could O +
also O +
be O +
de O -
- O -
regulated O +
in O +
different O +
patients O -
. O +

Consider O +
three O +
genes O +
G1 O -
, O +
G2 O -
, O +
G3 O +
and O +
their O +
expression O +
in O +
patients O +
A O -
, O -
B O -
, O -
C O -
, O -
D. O +
Each O +
gene O +
is O +
up O -
- O -
regulated O +
in O +
50 O -
% O +
of O +
patients O -
. O +

If O +
the O +
genes O +
are O +
up O -
- O -
regulated O +
in O +
different O +
patients O +
( O -
G1 O +
is O +
up O -
- O -
regulated O +
in O +
A O -
/ O -
B O -
, O +
G2 O +
is O +
up O -
- O -
regulated O +
in O +
B O -
/ O -
C O -
, O +
G3 O +
is O +
up O -
- O -
regulated O +
in O +
C O -
/ O -
D O -
) O -
, O +
then O +
one O +
can O +
not O +
assume O +
that O +
there O +
is O +
a O +
regional O +
up O -
- O -
regulation O +
in O +
all O +
patients O -
. O +

However O -
, O +
if O +
the O +
genes O +
are O +
up O -
- O -
regulated O +
in O +
the O +
same O +
patients O +
( O -
G1 O -
, O +
G2 O +
and O +
G3 O +
are O +
all O +
up O -
- O -
regulated O +
in O +
A O +
and O +
B O -
) O -
, O +
then O +
it O +
is O +
fair O +
to O +
assume O +
that O +
they O +
have O +
undergone O +
coordinated O +
regional O +
up O -
- O -
regulation O -
. O +

Chance O +
effects O +
more O +
likely O +
create O +
non O -
- O -
coordinated O +
up O -
- O -
regulation O -
. O +

To O +
capture O +
such O +
a O +
gene O -
- O -
versus O -
- O -
gene O +
correlation O +
structure O -
, O +
we O +
performed O +
the O +
following O +
for O +
a O +
given O +
chromosome O +
region O -
: O +
For O +
each O +
pair O +
of O +
genes O +
of O +
a O +
given O +
chromosome O +
region O +
we O +
count O +
the O +
number O +
of O +
their O +
coordinated O +
( O -
simultaneous O -
) O +
up O -
- O -
regulations O +
( O -
based O +
on O +
the O +
above O +
computed O +
fold O +
changes O -
) O +
over O +
the O +
set O +
of O +
patients O +
and O +
the O +
number O +
of O +
coordinated O +
down O -
- O -
regulations O -
, O +
separately O -
. O +

These O +
values O +
can O +
be O +
represented O +
in O +
gray O -
- O -
scale O +
plots O -
: O +
one O +
gray O +
scale O +
plot O +
for O +
the O +
coordinated O +
up O -
- O -
regulation O +
and O +
a O +
similar O +
one O +
for O +
coordinated O +
down O -
- O -
regulation O -
. O +

Both O -
, O +
horizontal O +
and O +
vertical O +
axis O +
comprise O +
genes O +
of O +
the O +
chromosome O +
region O +
in O +
the O +
right O +
chromosomal O +
order O +
( O -
see O +
Figures O +
6 O -
, O +
7 O -
, O +
8 O -
, O +
9 O -
, O +
10 O -
, O +
11 O -
, O +
12 O -
, O +
13 O -
, O +
14 O -
, O +
15 O -
, O +
16 O -
, O +
17 O -
, O +
18 O -
, O +
19 O -
, O +
20 O -
, O +
21 O -
, O +
22 O -
, O +
23 O -
, O +
24 O -
, O +
25 O -
, O +
26 O -
, O +
27 O -
, O +
28 O -
, O +
29 O -
, O +
30 O -
, O +
31 O -
, O +
32 O -
) O -
. O +

The O +
darkness O +
of O +
squares O +
represents O +
the O +
number O +
of O +
coordinated O +
up- O +
or O +
down O -
- O -
regulations O -
, O +
respectively O -
. O +

Coordinately O +
up O -
- O -
regulated O +
regions O +
show O +
up O +
as O +
squares O +
with O +
high O +
" O -
correlation O -
" O +
measures O +
along O +
the O +
diagonal O -
. O +

Such O +
resulting O +
cross O -
- O -
comparison O +
matrices O +
can O +
be O +
visualized O +
interactively O +
for O +
any O +
chromosomal O +
region O +
on O +
our O +
supplementary O +
website O -
[ O -
41 O -
] O +
along O +
with O +
heat O +
maps O +
of O +
expression O +
intensities O +
and O +
are O +
used O +
in O +
Figures O +
6 O -
, O +
7 O -
, O +
8 O -
, O +
9 O -
, O +
10 O -
, O +
11 O -
, O +
12 O -
, O +
13 O -
, O +
14 O -
, O +
15 O -
, O +
16 O -
, O +
17 O -
, O +
18 O -
, O +
19 O -
, O +
20 O -
, O +
21 O -
, O +
22 O -
, O +
23 O -
, O +
24 O -
, O +
25 O -
, O +
26 O -
, O +
27 O -
, O +
28 O -
, O +
29 O -
, O +
30 O -
, O +
31 O -
, O +
32 O -
. O +

Alternatively O -
, O +
we O +
applied O +
" O -
correlation O -
" O +
measures O +
like O +
Pearson O +
correlation O +
coefficients O +
on O +
fold O +
changes O -
, O +
mutual O +
information O -
, O +
and O +
set O -
- O -
theoretic O +
coefficients O +
like O +
the O +
Dice O +
and O +
Jaccard O +
coefficients O +
on O +
binary O +
patterns O +
of O +
up O -
- O -
regulation O +
and O +
down O -
- O -
regulation O +
( O -
only O +
available O +
on O +
our O +
website O +
[ O -
41 O -
] O -
) O -
. O +

Although O +
this O +
analysis O +
is O +
already O +
instructive O +
for O +
the O +
visual O +
identification O +
of O +
general O +
up O -
/ O -
down O -
- O -
regulation O +
of O +
a O +
particular O +
region O -
, O +
it O +
does O +
not O +
allow O +
to O +
infer O +
the O +
precise O +
boundaries O +
of O +
deregulated O +
regions O -
. O +

Several O +
software O +
packages O +
for O +
the O +
analysis O +
of O +
array O +
CGH O +
data O +
exist O +
that O +
have O +
been O +
announced O +
to O +
also O +
be O +
suited O +
for O +
the O +
analysis O +
of O +
expression O +
data O +
[ O -
42 O -
- O -
44 O -
] O -
. O +

In O +
the O +
following O -
, O +
we O +
used O +
the O +
ChARM O +
software O +
package O +
[ O -
44 O -
] O -
. O +

ChARM O +
can O +
be O +
used O +
to O +
infer O +
intervals O +
of O +
variable O +
size O +
with O +
significant O +
positive O +
or O +
negative O +
signal O +
amplitudes O +
in O +
ordered O +
data O -
, O +
such O +
as O +
log O -
( O -
intensity O -
) O +
values O +
in O +
array O +
CGH O +
data O +
and O +
mRNA O +
expression O +
data O -
. O +

We O +
applied O +
the O +
ChARM O +
algorithm O +
on O +
different O +
data O +
sets O +
that O +
harbor O +
information O +
about O +
the O +
numbers O +
of O +
patients O +
with O +
coordinated O +
up- O +
and O +
down O -
- O -
regulation O +
of O +
expression O +
for O +
all O +
genes O +
on O +
human O +
autosomes O +
and O +
the O +
X O +
chromosome O -
. O +

For O +
each O +
chromosome O +
six O +
separate O +
data O +
sets O +
were O +
prepared O -
, O +
according O +
to O +
scanning O +
window O +
sizes O +
of O +
5 O -
, O +
11 O -
, O +
21 O -
, O +
31 O -
, O +
41 O -
, O +
51 O -
. O +

Within O +
each O +
window O +
all O +
possible O +
gene O +
pairs O +
( O -
excluding O +
self O +
comparisons O -
) O +
were O +
considered O -
. O +

For O +
each O +
gene O +
pair O -
, O +
the O +
number O +
of O +
coordinated O +
up O -
- O -
regulated O +
( O -
counted O +
as O +
+ O -
1 O -
) O +
and O +
down O -
- O -
regulated O +
( O -
counted O +
as O +
-1 O -
) O +
was O +
determined O -
. O +

For O +
each O +
window O +
the O +
sum O +
of O +
these O +
gene O +
pair O -
- O -
specific O +
values O +
divided O +
by O +
the O +
total O +
number O +
of O +
pairs O +
gave O +
the O +
cumulative O +
misregulation O +
score O +
( O -
CMS O -
) O -
. O +

In O +
a O +
sliding O +
window O +
approach O -
, O +
each O +
gene O +
was O +
associated O +
with O +
a O +
CMS O +
value O -
. O +

CMS O +
values O +
for O +
genes O +
at O +
the O +
edges O +
of O +
chromosomes O +
were O +
calculated O +
with O +
reduced O +
window O +
sizes O -
. O +

The O +
main O +
theoretical O +
advantage O +
of O +
the O +
use O +
of O +
CMS O +
scores O +
compared O +
to O +
raw O +
up O -
- O -
regulation O +
counts O +
or O +
averaged O +
expression O +
ratios O +
is O +
that O +
it O +
captures O +
only O +
information O +
from O +
co O -
- O -
regulated O +
neighboring O +
gene O +
pairs O -
: O +
Noise O +
signals O +
fluctuate O +
across O +
genes O +
and O +
may O +
more O +
often O +
lead O +
to O +
artificial O +
assignment O +
of O +
high O +
expression O +
ratios O +
between O +
two O +
genes O -
. O +

In O +
contrast O -
, O +
real O +
signals O +
of O +
regional O +
up- O -
/ O -
down O -
- O -
regulation O +
lead O +
to O +
consistent O +
changes O +
in O +
the O +
same O +
patients O +
for O +
two O +
genes O -
. O +

For O +
each O +
window O +
size O -
, O +
CMS O +
data O +
sets O +
of O +
each O +
chromosome O +
were O +
subject O +
to O +
ChARM O +
analysis O -
. O +

ChARM O +
determines O +
borders O +
of O +
regions O +
with O +
high O +
signal O +
amplitudes O +
in O +
ordered O +
data O -
, O +
here O +
regions O +
of O +
expression O +
imbalances O +
along O +
a O +
chromosome O -
, O +
by O +
an O +
expectation O -
- O -
maximization O +
approach O -
. O +

In O +
addition O -
, O +
ChARM O +
provides O +
different O +
statistical O +
estimates O +
to O +
judge O +
the O +
significance O +
of O +
expression O +
deregulation O +
in O +
a O +
particular O +
chromosomal O +
region O +
[ O -
44 O -
] O -
. O +

The O +
identified O +
deregulated O +
regions O +
were O +
further O +
evaluated O +
manually O +
using O +
heat O +
maps O +
and O +
the O +
above O +
mentioned O +
gene O -
- O -
versus O -
- O -
gene O +
" O -
correlation O -
" O +
plots O +
( O -
see O +
above O -
, O +
Figures O +
6 O -
, O +
7 O -
, O +
8 O -
, O +
9 O -
, O +
10 O -
, O +
11 O -
, O +
12 O -
, O +
13 O -
, O +
14 O -
, O +
15 O -
, O +
16 O -
, O +
17 O -
, O +
18 O -
, O +
19 O -
, O +
20 O -
, O +
21 O -
, O +
22 O -
, O +
23 O -
, O +
24 O -
, O +
25 O -
, O +
26 O -
, O +
27 O -
, O +
28 O -
, O +
29 O -
, O +
30 O -
, O +
31 O -
, O +
32 O +
and O +
accompanying O +
website O -
) O -
. O +

Availability O +
and O +
requirements O +
Project O +
name O -
: O +
Colorectal O +
carcinoma O +
comparative O +
chromosomal O +
gene O +
expression O +
analysis O +
( O -
CC O -
- O -
CCGEA O -
) O +
[ O -
41 O -
] O -
. O +

Project O +
home O +
page O -
: O +
Operating O +
system O -
( O -
s O -
) O -
: O +
all O +
Programming O +
language O -
: O +
Perl O -
- O -
CGI O +
Licence O -
: O +
GNU O +
GPL O +
Restrictions O +
to O +
use O +
by O +
non O -
- O -
academics O -
: O +
none O +

Advanced O +
colorectal O +
polyps O +
with O +
the O +
molecular O +
and O +
morphological O +
features O +
of O +
serrated O +
polyps O +
and O +
adenomas O -
: O +
concept O +
of O +
a O +
' O -
fusion O -
' O +
pathway O +
to O +
colorectal O +
cancer O +
Abstract O +
Jass O +
J O +
R O -
, O +
Baker O +
K O -
, O +
Zlobec O +
I O -
, O +
Higuchi O +
T O -
, O +
Barker O +
M O -
, O +
Buchanan O +
D O +
& O +
Young O +
J O +
( O -
2006 O -
) O +
Histopathology O +
49 O -
, O +
121–131 O +
Advanced O +
colorectal O +
polyps O +
with O +
the O +
molecular O +
and O +
morphological O +
features O +
of O +
serrated O +
polyps O +
and O +
adenomas O -
: O +
concept O +
of O +
a O +
' O -
fusion O -
' O +
pathway O +
to O +
colorectal O +
cancer O +
Aim O +
To O +
establish O +
and O +
explain O +
the O +
pattern O +
of O +
molecular O +
signatures O +
across O +
colorectal O +
polyps O -
. O +

Methods O +
and O +
results O +
Thirty O -
- O -
two O +
sessile O +
serrated O +
adenomas O +
( O -
SSA O -
) O -
, O +
10 O +
mixed O +
polyps O +
( O -
MP O -
) O -
, O +
15 O +
traditional O +
serrated O +
adenomas O +
( O -
SA O -
) O -
, O +
49 O +
hyperplastic O +
polyps O +
( O -
HP O -
) O +
and O +
84 O +
adenomas O +
were O +
assessed O +
for O +
mutation O +
of O +
KRAS B-Gene +
and O +
BRAF B-Gene +
and O +
aberrant O +
expression O +
of O +
p53 O -
. O +

The O +
findings O +
were O +
correlated O +
with O +
loss O +
of O +
expression O +
of O +
O-6-methylguanine B-Gene +
DNA I-Gene +
methyltransferase I-Gene +
( O -
MGMT B-Gene -
) O -
. O +

KRAS B-Gene +
mutation O +
occurred O +
more O +
frequently O +
( O -
26.5 O -
% O -
) O +
than O +
BRAF B-Gene +
mutation O +
( O -
4.8 O -
% O -
) O +
in O +
adenomas O +
( O -
P O +
< O +
0.001 O -
) O +
and O +
particularly O +
in O +
adenomas O +
with O +
villous O +
architecture O +
( O -
50 O -
% O -
) O -
. O +

Loss O +
of O +
expression O +
of O +
MGMT B-Gene +
correlated O +
with O +
KRAS B-Gene +
mutation O +
in O +
small O +
tubular O +
adenomas O +
( O -
P O +
< O +
0.04 O -
) O -
. O +

BRAF B-Gene +
mutation O +
was O +
frequent O +
in O +
HPs O +
( O -
67 O -
% O -
) O +
and O +
SSAs O +
( O -
81 O -
% O -
) O -
, O +
while O +
KRAS B-Gene +
mutation O +
was O +
infrequent O +
( O -
4 O -
% O +
and O +
3 O -
% O -
, O +
respectively O -
) O -
. O +

Of O +
MPs O +
and O +
SAs O -
, O +
72 O -
% O +
had O +
either O +
BRAF B-Gene +
or O +
KRAS B-Gene +
mutation O -
. O +

Aberrant O +
expression O +
of O +
p53 O +
was O +
uncommon O +
overall O -
, O +
but O +
occurred O +
more O +
frequently O +
in O +
MPs O +
and O +
SAs O +
( O -
12 O -
% O -
) O +
than O +
adenomas O +
( O -
1 O -
% O -
) O +
( O -
P O +
< O +
0.04 O -
) O +
and O +
there O +
was O +
concordant O +
loss O +
of O +
expression O +
of O +
MGMT B-Gene -
. O +

Conclusions O +
Molecular O +
alterations O +
that O +
are O +
characteristic O +
of O +
the O +
serrated O +
pathway O +
and O +
adenoma O -
– O -
carcinoma O +
sequence O +
can O +
co O -
- O -
occur O +
in O +
a O +
minority O +
of O +
advanced O +
colorectal O +
polyps O +
that O +
then O +
show O +
morphological O +
features O +
of O +
both O +
pathways O -
. O +

These O +
lesions O +
account O +
for O +
only O +
2 O -
% O +
of O +
colorectal O +
polyps O -
, O +
but O +
may O +
be O +
relatively O +
aggressive O -
. O +

Subsequently O -
, O +
it O +
was O +
argued O +
that O +
HP O +
and O +
SA O +
are O +
related O +
lesions.11 O +
The O +
latter O +
could O +
arise O +
within O +
the O +
former O +
( O -
giving O +
a O +
MP O -
) O +
or O +
could O +
develop O +
as O +
de O +
novo O +
SA O +
but O +
through O +
mechanisms O +
shared O +
with O +
HPs O -
. O +

This O +
proposal O +
subsequently O +
received O +
strong O +
support O +
through O +
the O +
demonstration O +
of O +
molecular O +
alterations O +
common O +
to O +
both O +
types O +
of O +
serrated O +
polyp O -
, O +
notably O +
mutation O +
of O +
BRAF B-Gene +
and O +
extensive O +
DNA O +
methylation.12 O +
This O +
viewpoint O +
was O +
consolidated O +
through O +
the O +
formal O +
recognition O +
of O +
two O +
largely O +
independent O +
pathways O +
of O +
colorectal O +
tumorigenesis O -
: O +
( O -
i O -
) O +
the O +
traditional O +
adenoma O -
– O -
carcinoma O +
sequence O +
associated O +
with O +
chomosomally O +
unstable O +
CRCs,13 O +
and O +
( O -
ii O -
) O +
the O +
' O -
serrated O +
pathway O -
' O +
culminating O +
in O +
CRCs O +
with O +
DNA O +
microsatellite O +
instability O +
( O -
MSI O -
) O -
, O +
mutation O +
of O +
BRAF B-Gene +
and O +
extensive O +
DNA O +
methylation.12,14–20 O +
This O +
paper O +
explores O +
the O +
possibility O +
that O +
the O +
early O +
evolution O +
of O +
colorectal O +
cancer O +
is O +
not O +
limited O +
to O +
two O +
essentially O +
independent O +
pathways O -
, O +
but O +
often O +
combines O +
components O +
of O +
these O +
pathways O -
. O +

Indeed O -
, O +
the O +
successful O +
' O -
fusion O -
' O +
of O +
the O +
hyperproliferation O +
and O +
crypt O +
fission O +
that O +
characterize O +
adenomas21 O +
with O +
the O +
inhibition O +
of O +
apoptosis O +
that O +
has O +
been O +
linked O +
with O +
serrated O +
polyps22,23 O +
may O +
generate O +
lesions O +
with O +
enhanced O +
aggressiveness O -
. O +

Specifically O -
, O +
it O +
is O +
suggested O +
that O +
methylation O +
of O +
the O +
DNA O +
repair O +
gene O +
O-6-methylguanine B-Gene +
DNA I-Gene +
methyltransferase I-Gene +
( O -
MGMT B-Gene -
) O -
, O +
mutation O +
of O +
KRAS B-Gene +
and O +
inactivation O +
of O +
TP53 B-Gene +
provide O +
critical O +
combinations O +
of O +
molecular O +
' O -
cross O -
- O -
over O -
' O +
between O +
the O +
two O +
pathways O +
that O +
occur O +
at O +
the O +
stage O +
of O +
precancerous O +
polyps O -
. O +

Materials O +
and O +
methods O +
Tissues O +
The O +
colorectal O +
polyps O +
used O +
in O +
this O +
study O +
were O +
from O +
a O +
previously O +
characterized O +
subset O +
of O +
a O +
consecutive O +
series O +
of O +
1250 O +
colonoscopically O +
derived O +
lesions.24 O +

The O +
study O +
group O +
included O +
all O +
SAs O +
( O -
sessile O +
and O +
traditional O -
) O +
and O +
MPs O +
and O +
a O +
subset O +
of O +
conventional O +
adenomas O +
and O +
HPs O -
. O +

The O +
previous O +
study O +
analysed O +
proliferative O +
indices O +
and O +
there O +
was O +
therefore O +
selection O +
of O +
HPs O +
that O +
were O +
large O +
and O +
well O -
- O -
oriented O +
and O +
likely O +
to O +
provide O +
sufficient O +
numbers O +
of O +
longitudinally O +
sectioned O +
crypts O -
. O +

Polyps O +
were O +
eliminated O +
from O +
the O +
present O +
study O +
if O +
there O +
was O +
insufficient O +
residual O +
tissue O -
, O +
blocks O +
contained O +
more O +
than O +
one O +
polyp O -
, O +
polyps O +
contained O +
foci O +
of O +
invasive O +
cancer O -
, O +
or O +
there O +
was O +
failure O +
of O +
DNA O +
amplification O +
for O +
both O +
the O +
BRAF B-Gene +
and O +
KRAS B-Gene +
mutation O +
assays O -
. O +

Fifteen O +
additional O +
polyps O +
from O +
the O +
parent O +
series O +
generated O +
a O +
total O +
study O +
group O +
of O +
190 O +
polyps O -
. O +

These O +
were O +
reviewed O +
by O +
the O +
first O +
author O +
and O +
classified O +
as O -
: O +
HPs O +
( O -
n O +
= O +
49 O -
) O -
, O +
tubular O +
adenomas O +
( O -
TAs O -
) O +
( O -
n O +
= O +
62 O -
) O -
, O +
tubulovillous O +
and O +
villous O +
adenomas O +
( O -
TVAs O -
/ O -
VAs O -
) O +
( O -
n O +
= O +
22 O -
) O -
, O +
sessile O +
SAs O +
( O -
SSAs O -
) O +
( O -
n O +
= O +
32 O -
) O -
, O +
MPs O +
( O -
n O +
= O +
10 O -
) O +
and O +
traditional O +
SAs O +
( O -
n O +
= O +
15 O -
) O -
. O +

SSA O +
has O +
also O +
been O +
termed O +
sessile O +
serrated O +
polyp O +
and O +
serrated O +
polyp O +
with O +
atypical O +
proliferation.17,25–27 O +
SSA O +
is O +
distinguished O +
from O +
HP O +
on O +
the O +
basis O +
of O +
greater O +
size O -
, O +
aberrant O +
architecture O -
, O +
atypical O +
proliferation O -
, O +
hypermucinous O +
epithelium O -
, O +
predilection O +
for O +
proximal O +
colon25 O +
and O +
molecular O +
features O +
including O +
a O +
higher O +
frequency O +
of O +
BRAF B-Gene +
mutation O +
and O +
more O +
extensive O +
DNA O +
methylation.14,16,17 O +
However O -
, O +
the O +
combination O +
of O +
architectural O +
and O +
cytological O +
changes O +
is O +
insufficient O +
for O +
a O +
diagnosis O +
of O +
dysplasia O -
. O +

Serrated O +
polyps O +
with O +
dysplasia O +
include O +
MPs O +
and O +
SAs O -
. O +

MPs O +
may O +
be O +
conceived O +
as O +
a O +
combined O +
lesion O +
that O +
includes O -
: O +
( O -
i O -
) O +
a O +
serrated O +
component O +
that O +
is O +
non O -
- O -
dysplastic O +
and O +
resembles O +
HP O +
or O +
SSA O -
, O +
and O +
( O -
ii O -
) O +
a O +
dysplastic O +
component O +
that O +
may O +
resemble O +
either O +
SA O +
or O +
conventional O +
adenoma.28 O +
For O +
the O +
purposes O +
of O +
this O +
study O -
, O +
lesions O +
were O +
also O +
included O +
as O +
MPs O +
if O +
they O +
comprised O +
separate O +
serrated O +
and O +
non O -
- O -
serrated O +
components O +
that O +
were O +
both O +
dysplastic O -
. O +

SAs O +
are O +
homogeneous O +
lesions O +
in O +
which O +
there O +
is O +
epithelial O +
serration O +
reminiscent O +
of O +
a O +
HP O +
or O +
SSA O +
together O +
with O +
architectural O +
and O +
cytological O +
changes O +
warranting O +
a O +
diagnosis O +
of O +
dysplasia O -
. O +

The O +
cytological O +
atypia O +
of O +
SA O +
may O +
appear O +
similar O +
to O +
that O +
of O +
conventional O +
adenoma O +
in O +
which O +
nuclei O +
are O +
elongated O -
, O +
hyperchromatic O +
and O +
pseudostratified O -
. O +

However O -
, O +
some O +
SAs O +
may O +
be O +
characterized O +
by O +
non O -
- O -
adenomatous O +
forms O +
of O +
dysplasia O +
in O +
which O +
the O +
nuclei O +
are O +
enlarged O -
, O +
ovoid O -
, O +
vesicular O +
and O +
contain O +
a O +
prominent O +
nucleolus O -
, O +
while O +
the O +
cytoplasm O +
is O +
relatively O +
abundant O +
and O +
eosinophilic O -
. O +

The O +
anatomical O +
site O +
of O +
polyps O +
was O +
grouped O +
as O +
proximal O +
colon O +
( O -
up O +
to O +
splenic O +
flexure O -
) O +
versus O +
distal O +
colon O +
and O +
rectum O +
combined O -
. O +

The O +
study O +
was O +
approved O +
by O +
the O +
Institutional O +
Review O +
Board O +
of O +
the O +
Faculty O +
of O +
Medicine O -
, O +
McGill O +
University O -
. O +

Dna O +
extraction O +
Genomic O +
DNA O +
was O +
extracted O +
from O +
archival O +
paraffin O -
- O -
embedded O +
tissue O +
sections O +
using O +
DNeasy O +
Tissue O +
Kit O +
( O -
Qiagen O -
, O +
Hilden O -
, O +
Germany O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
instructions O +
except O +
for O +
the O +
omission O +
of O +
xylene O +
treatment O -
. O +

Briefly O -
, O +
five O +
4-µm O +
non O -
- O -
microdissected O +
sections O +
( O -
polyps O +
were O +
generally O +
accompanied O +
by O +
little O +
normal O +
mucosa O -
) O +
and O +
180 O +
µl O +
of O +
ATL O +
buffer O +
were O +
dissolved O +
at O +
80 O -
° O -
C O +
and O +
then O +
digested O +
overnight O +
with O +
20 O +
µl O +
of O +
proteinase O +
K O +
at O +
55 O -
° O -
C O -
. O +

Following O +
centrifugation O +
at O +
2000 O +
r.p.m O -
. O +

( O -
300 O +
g O -
) O +
for O +
5 O +
min O -
, O +
the O +
lower O +
phase O +
was O +
applied O +
to O +
a O +
DNeasy O +
tissue O +
column O -
. O +

Bound O +
DNA O +
was O +
washed O +
by O +
centrifugation O +
through O +
ethanol O +
and O +
then O +
eluted O +
from O +
the O +
column O +
using O +
AE O +
buffer O -
. O +

KRAS B-Gene +
and O +
BRAF B-Gene +
mutations O +
KRAS B-Gene +
mutation O +
analysis O +
at O +
codons O +
12 O +
and O +
13 O +
was O +
performed O +
using O +
direct O +
automated O +
sequencing O +
of O +
a O +
fragment O +
containing O +
codon O +
12 O +
and O +
13 O +
in O +
exon O +
1 O +
of O +
the O +
KRAS B-Gene +
gene O -
, O +
amplified O +
using O +
a O +
touchdown O +
polymerase O +
chain O +
reaction O +
( O -
PCR O -
) O +
cycle O +
and O +
hotstart O +
protocol O -
. O +

PCR O +
products O +
were O +
initially O +
purified O +
and O +
then O +
directly O +
sequenced O +
using O +
BigDye O +
version O +
3.1 O +
dye O +
terminators O +
and O +
an O +
ABI O +
3100 O +
DNA O +
fragment O +
analyser O -
. O +

The O +
sequence O +
at O +
codon O +
12 O +
and O +
13 O +
was O +
determined O +
using O +
Mutation O +
Surveyor O +
( O -
SoftGenetics O -
, O +
State O +
College O -
, O +
PA O -
, O +
USA O -
) O +
software O -
. O +

BRAF B-Gene +
mutation O +
analysis O +
at O +
codon O +
600 O +
( O -
V600E O -
; O +
formerly O +
V599E O -
) O +
was O +
performed O +
by O +
a O +
real O -
- O -
time O +
PCR O -
- O -
based O +
allelic O +
discrimination O +
method O +
as O +
previously O +
described.29 O +
Briefly O -
, O +
real O -
- O -
time O +
PCR O +
was O +
performed O +
using O +
allele O -
- O -
specific O +
primers O +
designed O +
to O +
amplify O +
selectively O +
the O +
wild O -
- O -
type O +
( O -
T1796 O -
) O +
and O +
mutant O +
( O -
A1796 O -
) O +
BRAF B-Gene +
alleles O -
. O +

The O +
primer O +
sequences O +
were O +
as O +
follows O -
: O +
V O -
, O +
5′-GTGATTTTGGTCTAGCTACtGT O -
; O +
E O -
, O +
5′-CGCGGCCGGCCGCGGCGGTGATTTTGGTCTAGCTACcGA O -
; O +
AS O -
, O +
5′-TAGCCTCAATTCTTACCATCCAC O -
. O +

PCR O +
amplification O +
and O +
melting O +
curve O +
analysis O +
were O +
performed O +
on O +
a O +
Rotor O -
- O -
gene O +
3000 O +
( O -
Corbett O +
Research O -
, O +
NSW O -
, O +
Australia O -
) O -
. O +

Genomic O +
DNA O +
was O +
amplified O +
in O +
a O +
15-µl O +
volume O +
containing O +
1 O +
× O +
Platinum O +
SYBR O +
Green O +
qPCR O +
SuperMix O -
- O -
UDG O +
( O -
Invitrogen O -
, O +
Carlsbad O -
, O +
CA O -
, O +
USA O -
) O -
, O +
forward O +
primer O +
V O +
( O -
300 O +
nm O -
) O -
, O +
forward O +
primer O +
E O +
( O -
900 O +
nm O -
) O +
and O +
reverse O +
primer O +
AS O +
( O -
300 O +
nm O -
) O -
. O +

The O +
cycling O +
conditions O +
were O +
as O +
follows O -
: O +
50 O -
° O -
C O +
for O +
2 O +
min O -
, O +
95 O -
° O -
C O +
for O +
2 O +
min O -
, O +
40 O +
cycles O +
of O +
95 O -
° O -
C O +
for O +
15 O +
s O +
and O +
60 O -
° O -
C O +
for O +
60 O +
s. O +
After O +
amplification O -
, O +
samples O +
were O +
subjected O +
to O +
a O +
temperature O +
ramp O +
from O +
60 O -
° O -
C O +
to O +
99 O -
° O -
C O -
, O +
rising O +
1 O -
° O -
C O +
each O +
step O -
. O +

For O +
wild O -
- O -
type O +
samples O -
, O +
single O +
peaks O +
were O +
observed O +
at O +
80 O -
° O -
C O +
while O +
samples O +
containing O +
mutant O +
alleles O +
produced O +
single O +
peaks O +
at O +
85 O -
° O -
C O -
. O +

p53 O +
immunohistochemistry O +
and O +
scoring O +
This O +
was O +
undertaken O +
on O +
all O +
adenomas O +
and O +
all O +
serrated O +
polyps O +
with O +
dysplasia O +
( O -
traditional O +
SA O +
and O +
MP O -
) O -
. O +

Most O +
of O +
these O +
polyps O +
had O +
been O +
immunostained O +
previously O +
for O +
MGMT.24 B-Gene +
Following O +
deparaffinization O +
and O +
rehydration O +
of O +
4-µm O +
sections O +
and O +
antigen O +
retrieval O +
using O +
ethylene O +
diamine O +
tetra O -
- O -
acetic O +
acid O +
and O +
microwaving O -
, O +
the O +
sections O +
were O +
subjected O +
to O +
peroxidase O +
blockade O +
( O -
Dako O +
EnVision O +
bottle O +
1 O -
; O +
Mississauga O -
, O +
Canada O -
) O +
and O +
then O +
incubated O +
in O +
10 O -
% O +
goat O +
serum O +
to O +
minimize O +
non O -
- O -
specific O +
staining O -
. O +

They O +
were O +
subsequently O +
incubated O +
with O +
the O +
primary O +
anti O -
- O -
p53 O +
antibody O +
( O -
DO-7 O -
, O +
from O +
DakoCytomation O -
, O +
Mississauga O -
, O +
Canada O -
) O +
at O +
a O +
dilution O +
of O +
1 O +
: O +
100 O +
for O +
60 O +
min O +
at O +
37 O -
° O -
C O -
. O +

After O +
washing O -
, O +
the O +
sections O +
were O +
incubated O +
with O +
secondary O +
antibody O +
( O -
EnVision O +
bottle O +
2 O -
) O +
for O +
30 O +
min O -
, O +
washed O +
again O +
and O +
then O +
developed O +
with O +
the O +
chromogen O +
AEC O +
for O +
30 O +
min O -
. O +

Finally O -
, O +
the O +
sections O +
were O +
counterstained O +
with O +
Gill O -
's O +
haematoxylin O -
. O +

Polyps O +
were O +
scored O +
as O +
showing O +
loss O +
of O +
expression O +
of O +
MGMT B-Gene +
if O +
there O +
was O +
complete O +
absence O +
of O +
nuclear O +
expression O +
throughout O +
one O +
or O +
more O +
crypts O -
. O +

Polyps O +
were O +
scored O +
as O +
positive O +
for O +
aberrant O +
p53 B-Gene +
expression O +
if O +
there O +
were O +
distinct O +
subclones O +
characterized O +
by O +
strong O +
nuclear O +
expression O +
that O +
implicated O +
at O +
least O +
50 O -
% O +
of O +
nuclei O -
. O +

BRAF B-Gene +
and O +
KRAS B-Gene +
mutations O +
were O +
distributed O +
in O +
roughly O +
similar O +
proportions O +
across O +
MPs O +
( O -
90 O -
% O +
had O +
either O +
BRAF B-Gene +
or O +
KRAS B-Gene +
mutation O -
) O +
and O +
SAs O +
( O -
60 O -
% O +
had O +
either O +
BRAF B-Gene +
or O +
KRAS B-Gene +
mutation O -
) O +
( O -
Table O +
1 O -
) O -
. O +

The O +
frequent O +
finding O +
of O +
either O +
BRAF B-Gene +
or O +
KRAS B-Gene +
mutations O +
in O +
both O +
types O +
of O +
serrated O +
polyp O +
indicated O +
that O +
MPs O +
and O +
SAs O +
might O +
be O +
heterogeneous O +
lesions O -
. O +

These O +
25 O +
serrated O +
polyps O +
with O +
dysplasia O +
were O +
therefore O +
grouped O +
differently O -
. O +

Group O +
A O +
polyps O +
( O -
n O +
= O +
16 O -
) O +
included O +
a O +
non O -
- O -
dysplastic O +
serrated O +
component O +
and/or O +
dysplastic O +
epithelium O +
in O +
which O +
the O +
architectural O +
and O +
cytological O +
changes O +
were O +
more O +
reminiscent O +
of O +
HP O +
than O +
adenoma O +
( O -
Figure O +
1A O -
, O -
B O -
) O -
. O +

Group O +
B O +
polyps O +
( O -
n O +
= O +
9 O -
) O +
comprised O +
serrated O +
polyps O +
in O +
which O +
the O +
epithelial O +
dysplasia O +
appeared O +
adenomatous O +
( O -
Figure O +
1C O -
, O -
D O -
) O -
. O +

BRAF B-Gene +
mutation O +
occurred O +
in O +
10 O -
/ O -
16 O +
Group O +
A O +
polyps O +
but O +
only O +
1 O -
/ O -
9 O +
Group O +
B O +
polyps O +
( O -
P O +
< O +
0.03 O -
) O -
. O +

KRAS B-Gene +
mutation O +
occurred O +
in O +
only O +
3 O -
/ O -
16 O +
Group O +
A O +
polyps O +
but O +
in O +
5 O -
/ O -
9 O +
Group O +
B O +
polyps O +
( O -
P O +
= O +
0.06 O -
) O -
. O +

In O +
each O +
of O +
the O +
five O +
Group O +
B O +
polyps O +
with O +
KRAS B-Gene +
mutation O -
, O +
the O +
adenomatous O +
component O +
showed O +
both O +
villous O +
change O +
and O +
serration O -
. O +

A O -
, O +
Serrated O +
adenoma O +
( O -
SA O -
) O +
( O -
BRAF B-Gene +
mutation O -
) O +
with O +
a O +
' O -
hyperplastic O -
' O +
appearance O +
but O +
with O +
architectural O +
and O +
cytological O +
features O +
of O +
a O +
non O -
- O -
adenomatous O +
form O +
of O +
dysplasia O -
. O +

The O +
latter O +
include O +
marked O +
epithelial O +
serration O +
and O +
surface O +
papillarity O +
and O +
nuclei O +
that O +
are O +
ovoid O -
, O +
vesicular O +
and O +
contain O +
a O +
prominent O +
nucleolus O +
( O -
inset O -
) O -
. O +

The O +
columnar O +
cells O +
( O -
inset O -
) O +
contain O +
apical O +
mucin O +
droplets O -
, O +
similar O +
to O +
sessile O +
SA O +
( O -
SSA O -
) O -
. O +

B O -
, O +
Mixed O +
polyp O +
( O -
BRAF B-Gene +
mutation O -
) O +
comprising O +
SSA O +
( O -
left O -
) O +
and O +
SA O +
with O +
high O -
- O -
grade O +
dyplasia O +
showing O +
back O -
- O -
to O -
- O -
back O +
glands O +
( O -
right O -
) O +
and O +
aberrant O +
expression O +
of O +
p53 B-Gene +
( O -
inset O -
) O -
. O +

C O -
, O -
D O -
, O +
Two O +
mixed O +
polyps O +
( O -
MPs O -
) O +
( O -
both O +
SA O -
/ O -
tubulo O -
- O -
villous O +
adenoma O +
and O +
with O +
KRAS B-Gene +
mutation O -
) O +
in O +
which O +
the O +
serrated O +
epithelium O +
has O +
an O +
adenomatous O +
appearance O +
as O +
evidenced O +
by O +
elongated O +
hyperchomatic O +
nuclei O +
with O +
marked O +
stratification O +
and O +
a O +
dark O +
amphophilic O +
cytoplasm O -
. O +

The O +
pure O +
adenomatous O +
component O +
is O +
not O +
shown O -
. O +

E O -
, O -
F O -
, O +
Low- O +
and O +
medium O -
- O -
power O +
images O +
of O +
a O +
SA O +
( O -
KRAS B-Gene +
mutation O -
) O +
in O +
which O +
complex O +
microacini O +
have O +
resulted O +
in O +
markedly O +
serrated O +
epithelial O +
contours O -
. O +

The O +
epithelium O +
comprises O +
numerous O +
goblet O +
cells O +
and O +
absorptive O -
- O -
type O +
columnar O +
cells O +
with O +
eosinophilic O +
cytoplasm O +
and O +
is O +
reminiscent O +
of O +
the O +
goblet O +
cell O +
variant O +
of O +
hyperplastic O +
polyp O -
. O +

These O +
examples O +
illustrate O +
the O +
range O +
of O +
appearances O +
and O +
genetic O +
changes O +
that O +
are O +
encompassed O +
by O +
' O -
traditional O -
' O +
SA O -
. O +

With O +
respect O +
to O +
the O +
25 O +
serrated O +
polyps O +
with O +
dysplasia O -
, O +
only O +
five O +
occurred O +
in O +
the O +
proximal O +
colon O +
( O -
up O +
to O +
the O +
splenic O +
flexure O -
) O -
. O +

Two O +
of O +
these O +
had O +
BRAF B-Gene +
mutation O +
( O -
both O +
Group O +
A O -
) O +
and O +
two O +
had O +
KRAS B-Gene +
mutation O +
( O -
both O +
Group O +
B O -
) O -
. O +

Seven O +
of O +
the O +
11 O +
BRAF B-Gene +
mutations O +
occurred O +
in O +
polyps O +
derived O +
from O +
the O +
left O +
colon O +
or O +
rectum O +
( O -
remaining O +
two O +
polyps O +
with O +
BRAF B-Gene +
mutation O +
from O +
site O +
unknown O -
) O -
. O +

The O +
three O +
Group O +
A O +
SAs O +
with O +
KRAS B-Gene +
mutation O +
( O -
all O +
from O +
the O +
left O +
colon O +
or O +
rectum O -
) O +
comprised O +
numerous O +
goblet O +
cells O +
and O +
adjacent O +
cells O +
with O +
eosinophilic O +
cytoplasm O +
and O +
no O +
mucin O +
production O +
or O +
microvesicular O +
appearance O +
( O -
Figure O +
1E O -
, O -
F O -
) O -
. O +

These O +
SAs O +
therefore O +
resembled O +
the O +
goblet O +
cell O +
variant O +
of O +
HP O -
. O +

Loss O +
of O +
expression O +
of O +
mgmt O +
Loss O +
of O +
expression O +
of O +
MGMT B-Gene +
was O +
distributed O +
differently O +
( O -
P O +
< O +
0.001 O -
) O +
across O +
the O +
different O +
types O +
of O +
polyps O -
, O +
being O +
observed O +
most O +
frequently O +
among O +
MPs O -
, O +
TA O +
> O +
10 O +
mm O +
and O +
TVAs O -
/ O -
VAs O +
( O -
Table O +
1 O -
) O -
. O +

There O +
was O +
no O +
correlation O +
between O +
loss O +
of O +
expression O +
of O +
MGMT B-Gene +
and O +
either O +
KRAS B-Gene +
or O +
BRAF B-Gene +
mutation O +
across O +
the O +
full O +
range O +
of O +
polyp O +
types O -
. O +

However O -
, O +
among O +
TAs O +
< O +
10 O +
mm O -
, O +
KRAS B-Gene +
mutation O +
occurred O +
in O +
3 O -
/ O -
25 O +
( O -
12 O -
% O -
) O +
adenomas O +
with O +
no O +
MGMT B-Gene +
loss O +
but O +
in O +
4 O -
/ O -
8 O +
( O -
50 O -
% O -
) O +
adenomas O +
with O +
MGMT B-Gene +
loss O +
( O -
P O +
< O +
0.04 O -
) O -
. O +

Since O +
there O +
were O +
few O +
KRAS B-Gene +
mutations O +
in O +
this O +
subset O +
and O +
most O +
KRAS B-Gene +
mutations O +
( O -
5 O -
/ O -
7 O -
) O +
were O +
G→A O -
, O +
it O +
was O +
not O +
possible O +
to O +
demonstrate O +
an O +
association O +
between O +
MGMT B-Gene +
loss O +
and O +
G→A O +
mutation O +
in O +
KRAS B-Gene -
. O +

Aberrant O +
expression O +
of O +
p53 B-Gene +
and O +
correlation O +
with O +
MGMT B-Gene +
loss O +
Sixty O -
- O -
two O +
TAs O -
, O +
22 O +
TVAs O -
/ O -
VAs O -
, O +
15 O +
SAs O +
and O +
10 O +
MPs O +
were O +
immunostained O +
for O +
p53 B-Gene -
. O +

Weak O +
expression O +
of O +
nuclear O +
p53 B-Gene +
occurred O +
frequently O +
within O +
the O +
proliferative O +
compartment O +
in O +
all O +
types O +
of O +
polyps O +
and O +
was O +
ignored O -
. O +

Aberrant O +
p53 B-Gene +
expression O +
was O +
observed O +
in O +
only O +
four O +
polyps O -
: O +
one O +
TA O -
, O +
one O +
MP O +
( O -
Figure O +
1B O -
) O +
and O +
two O +
SAs O +
( O -
Figure O +
2 O -
) O -
. O +

Overall O -
, O +
only O +
1 O -
/ O -
84 O +
( O -
1 O -
% O -
) O +
conventional O +
adenomas O +
showed O +
aberrant O +
expression O +
of O +
p53 O +
compared O +
with O +
3 O -
/ O -
25 O +
( O -
12 O -
% O -
) O +
serrated O +
polyps O +
with O +
dysplasia O +
( O -
P O +
< O +
0.04 O -
) O -
. O +

In O +
the O +
latter O -
, O +
aberrant O +
p53 O +
expression O +
coincided O +
with O +
high O -
- O -
grade O +
dysplasia O +
and O +
reduced O +
or O +
complete O +
loss O +
of O +
expression O +
of O +
MGMT B-Gene +
( O -
Figures O +
1B O +
and O +
2 O -
) O -
. O +

The O +
TA O +
with O +
aberrant O +
p53 O +
expression O +
had O +
normal O +
expression O +
of O +
MGMT B-Gene -
. O +

High O -
- O -
power O +
field O +
of O +
a O +
serrated O +
adenoma O +
with O +
high O -
- O -
grade O +
dysplasia O +
( O -
A O -
) O +
in O +
which O +
there O +
is O +
aberrant O +
nuclear O +
expression O +
of O +
p53 O +
( O -
B O -
) O +
and O +
loss O +
of O +
nuclear O +
expression O +
of O +
O-6-methylguanine O +
DNA O +
methyltransferase O +
( O -
C O -
) O -
. O +

Discussion O +
The O +
scientific O +
basis O +
for O +
the O +
prevention O +
of O +
cancer O +
depends O +
upon O +
an O +
understanding O +
of O +
early O +
events O +
in O +
pathogenesis O -
, O +
including O +
the O +
mechanisms O +
underlying O +
initiation O +
and O +
growth O +
of O +
precancerous O +
polyps O -
. O +

Recommendations O +
for O +
the O +
management O +
of O +
patients O +
with O +
colorectal O +
polyps O +
currently O +
recognize O +
only O +
a O +
single O +
principal O +
type O +
of O +
clinically O +
important O +
polyp O -
: O +
the O +
adenoma O -
. O +

The O +
current O +
study O +
includes O +
additional O +
types O +
of O +
polyp O +
that O +
are O +
likely O +
to O +
have O +
malignant O +
potential O -
, O +
namely O +
serrated O +
polyps O +
with O +
( O -
MP O +
and O +
SA O -
) O +
and O +
without O +
( O -
SSA O -
) O +
dysplasia O -
. O +

This O +
discussion O +
will O +
focus O +
first O +
on O +
adenomas O -
, O +
second O +
on O +
non O -
- O -
dysplastic O +
serrated O +
polyps O +
and O +
will O +
then O +
conclude O +
with O +
the O +
concept O +
that O +
features O +
of O +
these O +
two O +
types O +
of O +
polyp O +
can O +
co O -
- O -
occur O +
or O +
become O +
' O -
fused O -
' O +
in O +
subtypes O +
of O +
advanced O +
polyps O +
with O +
mixed O +
cytomorphology O +
( O -
hyperplastic O +
and O +
dysplastic O -
) O +
and O +
a O +
serrated O +
and/or O +
villous O +
architecture O -
. O +

Adenomas O +
The O +
adenomas O +
in O +
this O +
study O +
were O +
grouped O +
as O +
TAs O +
< O +
10 O +
mm O -
, O +
TAs O +
> O +
10 O +
mm O +
and O +
TVAs O -
/ O -
VAs O -
. O +

Overall O -
, O +
KRAS B-Gene +
mutation O +
occurred O +
in O +
26.5 O -
% O +
of O +
adenomas O +
while O +
BRAF B-Gene +
mutation O +
was O +
detected O +
in O +
only O +
4.8 O -
% O -
. O +

Three O +
of O +
the O +
four O +
BRAF B-Gene +
mutations O +
occurred O +
in O +
adenomas O +
that O +
also O +
had O +
KRAS B-Gene +
mutation O -
. O +

It O +
is O +
well O +
established O +
that O +
BRAF B-Gene +
and O +
KRAS B-Gene +
mutation O +
rarely O +
occur O +
in O +
the O +
same O +
colorectal O +
neoplasm.12,16,30 O +
Furthermore O -
, O +
BRAF B-Gene +
mutations O +
are O +
much O +
more O +
typical O +
of O +
serrated O +
polyps O +
than O +
adenomas.14,31 O +
The O +
assay O +
for O +
BRAF B-Gene +
mutation O +
used O +
in O +
this O +
study O +
was O +
highly O +
sensitive O +
and O +
it O +
is O +
possible O +
that O +
the O +
mutation O +
was O +
being O +
identified O +
in O +
normal O +
mucosa O +
included O +
with O +
the O +
polyp O -
. O +

KRAS B-Gene +
mutation O +
may O +
occur O +
within O +
apparently O +
normal O +
colorectal O +
mucosa O +
and O +
the O +
same O +
could O +
apply O +
to O +
BRAF.32 B-Gene +
Therefore O -
, O +
the O +
finding O +
of O +
BRAF B-Gene +
mutation O +
in O +
a O +
small O +
subset O +
of O +
adenomas O +
could O +
be O +
spurious O +
and O +
the O +
true O +
incidence O +
of O +
BRAF B-Gene +
mutation O +
in O +
colorectal O +
adenomas O +
could O +
be O +
lower O +
than O +
4.8 O -
% O -
. O +

BRAF B-Gene +
mutation O +
frequencies O +
of O +
0%14 O +
and O +
3%31 O +
have O +
been O +
reported O +
in O +
other O +
series O +
of O +
colorectal O +
adenomas O -
. O +

In O +
previous O +
studies O +
of O +
KRAS B-Gene +
in O +
colorectal O +
adenomas O -
, O +
mutation O +
has O +
been O +
associated O +
negatively O +
with O +
flat O +
and O +
depressed O +
TAs O +
and O +
positively O +
with O +
polypoid O +
appearance O -
, O +
increasing O +
size O -
, O +
dysplasia O -
, O +
villous O +
change O +
and O +
synchronous O +
colorectal O +
cancer.6,33–35 O +
In O +
by O +
far O +
the O +
largest O +
study O -
, O +
which O +
included O +
738 O +
adenomas O +
obtained O +
from O +
639 O +
participants O +
in O +
a O +
dietary O +
intervention O +
trial O -
, O +
multivariate O +
analysis O +
showed O +
that O +
the O +
independent O +
predictors O +
of O +
KRAS B-Gene +
mutation O +
were O +
age O +
of O +
subject O -
, O +
presence O +
of O +
villous O +
architecture O +
and O +
high O -
- O -
grade O +
dysplasia O -
, O +
but O +
not O +
size O +
of O +
adenoma.6 O +
It O +
is O +
well O +
known O +
that O +
adenoma O +
size O -
, O +
dysplasia O +
and O +
villous O +
architecture O +
are O +
interrelated O +
and O +
account O +
has O +
to O +
be O +
taken O +
of O +
this O +
in O +
assessing O +
results O -
. O +

In O +
this O +
study O +
KRAS B-Gene +
mutation O +
occurred O +
with O +
the O +
same O +
frequency O +
in O +
small O +
( O -
18 O -
% O -
) O +
and O +
large O +
( O -
17 O -
% O -
) O +
adenomas O +
but O +
was O +
significantly O +
more O +
frequent O +
in O +
adenomas O +
that O +
included O +
a O +
villous O +
architecture O +
( O -
50 O -
% O -
) O -
. O +

A O +
previous O +
study O +
showed O +
a O +
very O +
high O +
frequency O +
of O +
KRAS B-Gene +
mutation O +
( O -
93 O -
% O -
) O +
in O +
flat O +
adenomas O +
with O +
a O +
tubulovillous O +
architecture.34 O +
We O +
would O +
agree O +
with O +
the O +
suggestion O +
that O +
KRAS B-Gene +
mutation O +
is O +
linked O +
with O +
the O +
development O +
of O +
villous O +
change O +
and O +
does O +
not O +
influence O +
adenoma O +
growth O +
in O +
an O +
independent O +
manner.6 O +
In O +
this O +
study O -
, O +
high O -
- O -
grade O +
dysplasia O +
was O +
diagnosed O +
only O +
when O +
it O +
amounted O +
to O +
carcinoma O +
in O +
situ O -
. O +

This O +
was O +
observed O +
in O +
none O +
of O +
the O +
84 O +
adenomas O +
but O +
in O +
four O +
serrated O +
polyps O -
, O +
of O +
which O +
three O +
showed O +
aberrant O +
expression O +
of O +
p53 O +
and O +
the O +
fourth O +
had O +
KRAS B-Gene +
mutation O -
. O +

Age O +
was O +
not O +
a O +
predictor O +
of O +
KRAS B-Gene +
mutation O +
in O +
this O +
study O -
. O +

However O -
, O +
many O +
of O +
the O +
patients O +
were O +
undergoing O +
continuing O +
colonoscopic O +
surveillance O +
for O +
colorectal O +
polyps O +
and O +
it O +
is O +
known O +
that O +
after O +
clearance O +
of O +
large O +
polyps O -
, O +
time O +
is O +
required O +
for O +
the O +
growth O +
of O +
newly O +
initiated O +
polyps.36 O +
This O +
could O +
explain O +
why O +
adenomas O +
were O +
smaller O +
in O +
subjects O +
aged O +
> O +
60 O +
years O +
than O +
in O +
subjects O +
aged O +
< O +
60 O +
years O +
( O -
data O +
not O +
shown O -
) O -
. O +

The O +
preceding O +
findings O +
indicate O +
that O +
serrated O +
polyps O +
with O +
dysplasia O +
evolve O +
through O +
at O +
least O +
two O +
independent O +
histogenetic O +
pathways O -
. O +

Group O +
A O +
polyps O +
are O +
likely O +
to O +
be O +
initiated O +
by O +
BRAF B-Gene +
mutation O +
and O +
are O +
serrated O +
lesions O +
at O +
the O +
outset O -
. O +

Group O +
B O +
polyps O +
may O +
begin O +
as O +
conventional O +
adenomas O +
and O +
then O +
become O +
serrated O +
and O +
villous O +
following O +
mutation O +
of O +
KRAS B-Gene -
. O +

There O +
may O +
be O +
instances O +
in O +
which O +
KRAS B-Gene +
mutation O +
can O +
initiate O +
lesions O +
which O +
are O +
serrated O +
at O +
the O +
outset O +
and O +
become O +
dysplastic O -
. O +

While O +
this O +
suggestion O +
remains O +
speculative O -
, O +
it O +
may O +
apply O +
to O +
the O +
Group O +
A O +
serrated O +
polyps O +
that O +
show O +
a O +
distinct O +
likeness O +
to O +
the O +
goblet O +
cell O +
variant O +
of O +
HP O +
in O +
which O +
columnar O +
cells O +
are O +
eosinophilic O +
and O +
lack O +
mucin O -
- O -
filled O +
microvesicles O +
and O +
KRAS B-Gene +
mutation O +
is O +
frequent O +
( O -
Figure O +
1E O -
, O -
F O -
) O -
.16,25 O +
The O +
literature O +
refers O +
to O +
the O +
concept O +
of O +
' O -
traditional O -
' O +
SA.43 O +
Based O +
on O +
the O +
current O +
findings O -
, O +
it O +
is O +
likely O +
that O +
several O +
mechanisms O +
can O +
account O +
for O +
adenomatous O +
lesions O +
with O +
glandular O +
serration O +
and O +
that O +
' O -
traditional O -
' O +
SA O +
is O +
not O +
a O +
single O +
entity O -
. O +

Concept O +
of O +
' O -
fusion O -
' O +
pathways O +
to O +
crc O +
Colorectal O +
polyps O +
have O +
traditionally O +
been O +
classified O +
into O +
distinct O +
histogenetic O +
types O +
that O +
may O +
progress O +
to O +
CRC O +
through O +
independent O +
pathways O +
of O +
colorectal O +
tumorigenesis O +
( O -
Table O +
2 O -
) O -
. O +

However O -
, O +
in O +
addition O +
to O +
the O +
two O +
' O -
classical O -
' O +
pathways O +
to O +
CRC O +
shown O +
in O +
Table O +
2 O -
, O +
there O +
may O +
be O +
' O -
fusion O -
' O +
pathways O +
that O +
combine O +
mechanisms O +
associated O +
with O +
both O +
adenomas O +
and O +
serrated O +
polyps O -
. O +

This O +
would O +
explain O +
why O +
many O +
CRCs O +
display O +
phenotypes O +
associated O +
with O +
serrated O +
polyps O +
as O +
well O +
as O +
adenomas.44 O +
Three O +
possible O +
examples O +
of O +
such O +
fusion O +
pathways O +
are O +
shown O +
in O +
Table O +
3 O -
. O +

It O +
is O +
difficult O +
to O +
observe O +
directly O +
the O +
actual O +
point O +
of O +
transition O +
from O +
benign O +
to O +
malignant O +
colorectal O +
lesions O -
. O +

Once O +
the O +
key O +
rate O -
- O -
limiting O +
step O +
is O +
achieved O +
it O +
is O +
likely O +
that O +
the O +
transition O +
to O +
cancer O +
occurs O +
rapidly O +
and O +
the O +
precursor O +
lesion O +
is O +
then O +
overtaken O +
by O +
the O +
malignancy O -
. O +

Changes O +
leading O +
to O +
inactivation O +
of O +
either O +
TP535 B-Gene +
or O +
the O +
DNA O +
mismatch O +
repair O +
gene O +
MLH113 B-Gene +
are O +
likely O +
to O +
be O +
two O +
such O +
rate O -
- O -
limiting O +
mechanisms O -
. O +

Only O +
a O +
single O +
instance O +
of O +
loss O +
of O +
expression O +
of O +
MLH1 B-Gene +
was O +
observed O +
in O +
the O +
present O +
series O +
of O +
polyps O +
and O +
the O +
adenoma O +
in O +
question O +
was O +
inferred O +
to O +
be O +
from O +
a O +
patient O +
with O +
Lynch O +
syndrome.24 O +
Concept O +
of O +
discrete O +
colorectal O +
lesions O +
and O +
progression O +
to O +
colorectal O +
cancer O +
via O +
independent O +
pathways O +
ACF O -
, O +
Aberrant O +
crypt O +
foci O +
( O -
hyperplastic O +
or O +
dysplastic O -
) O -
; O +
HP O -
, O +
hyperplastic O +
polyp O -
; O +
SSA O -
, O +
sessile O +
serrated O +
adenoma O -
; O +
SA O -
, O +
serrated O +
adenoma O -
; O +
TA O -
, O +
tubular O +
adenoma O -
. O +

Inactivation O +
of O +
MLH1 B-Gene +
and O +
TP53 B-Gene +
is O +
associated O +
with O +
malignant O +
progression O -
. O +

' O -
Fusion O -
' O +
pathways O +
brought O +
about O +
by O +
the O +
sequential O +
alteration O +
of O +
genes O +
( O -
linked O +
to O +
separate O +
lesions O +
and O +
pathways O +
in O +
Table O +
2 O -
) O +
and O +
with O +
the O +
second O +
alteration O +
associated O +
with O +
a O +
superimposed O +
morphology O +

MGMT B-Gene +
inactivation O +
predisposes O +
to O +
G O -
: O -
T O +
mismatches O +
and O +
chromosomal O +
instability O +
through O +
futile O +
cycles O +
of O +
excision O +
and O +
repair O +
as O +
well O +
as O +
to O +
mutation O +
of O +
KRAS B-Gene +
and O +
TP53.9 B-Gene +
Partial O +
methylation O +
of O +
MLH1 B-Gene +
may O +
also O +
lead O +
to O +
low O -
- O -
level O +
microsatellite O +
instability.37 O +
The O +
interpretation O +
of O +
immunostaining O +
for O +
p53 B-Gene +
is O +
problematic O +
insofar O +
as O +
increased O +
expression O +
of O +
the O +
wild O -
- O -
type O +
protein O +
occurs O +
in O +
areas O +
of O +
increased O +
proliferation O +
and O +
must O +
be O +
distinguished O +
from O +
the O +
diffuse O +
and O +
strong O +
nuclear O +
staining O +
associated O +
with O +
retained O +
mutant O +
protein O -
. O +

However O -
, O +
several O +
studies O +
have O +
described O +
low O +
frequencies O +
of O +
p53 O +
expression O +
in O +
TAs O +
with O +
low O -
- O -
grade O +
dysplasia45,46 O +
and O +
even O +
in O +
VAs.47 O +
Conversely O -
, O +
there O +
is O +
general O +
agreement O +
that O +
aberrant O +
p53 O +
expression O +
is O +
closely O +
associated O +
with O +
the O +
presence O +
of O +
high O -
- O -
grade O +
dysplasia O +
amounting O +
to O +
carcinoma O +
in O +
situ.34,46,48 O +
Aberrant O +
retention O +
of O +
presumed O +
mutant O +
nuclear O +
p53 O +
was O +
rarely O +
observed O +
in O +
the O +
present O +
series O -
, O +
although O +
it O +
occurred O +
more O +
frequently O +
in O +
serrated O +
polyps O +
with O +
dysplasia O +
( O -
12 O -
% O -
) O +
than O +
in O +
adenomas O +
( O -
1 O -
% O -
) O -
. O +

One O +
of O +
the O +
polyps O +
with O +
aberrant O +
expression O +
of O +
p53 O +
was O +
a O +
mixed O +
polyp O +
with O +
BRAF B-Gene +
mutation O +
( O -
Figure O +
1B O -
) O -
. O +

Had O +
it O +
not O +
been O +
removed O -
, O +
this O +
polyp O +
may O +
have O +
progressed O +
within O +
a O +
short O +
time O +
frame O +
to O +
the O +
subset O +
of O +
CRC O +
with O +
BRAF B-Gene +
mutation O -
, O +
DNA O +
methylation O -
, O +
TP53 B-Gene +
mutation O +
and O +
DNA O +
microsatellite O +
stable O +
status O +
( O -
a O +
' O -
fusion O -
' O +
pathway O +
shown O +
in O +
Table O +
3 O -
) O -
.49,50 O +
Loss O +
of O +
expression O +
of O +
the O +
DNA O +
repair O +
gene O +
MGMT B-Gene +
is O +
associated O +
with O +
methylation O +
of O +
the O +
promoter O +
region45,51,52 O +
and O +
the O +
latter O +
change O +
has O +
been O +
linked O +
causatively O +
with O +
G O -
: O -
C O +
to O +
A O -
: O -
T O +
transition O +
mutations O +
in O +
TP53.53 B-Gene +
In O +
the O +
present O +
study O -
, O +
complete O +
or O +
partial O +
loss O +
of O +
expression O +
of O +
MGMT B-Gene +
coincided O +
with O +
aberrant O +
nuclear O +
expression O +
of O +
p53 O +
in O +
three O +
serrated O +
polyps O +
with O +
dysplasia O +
( O -
Figure O +
2 O -
) O -
, O +
but O +
not O +
in O +
the O +
single O +
tubular O +
adenoma O +
with O +
aberrant O +
p53 O +
expression O -
. O +

Only O +
one O +
previous O +
study O +
has O +
attempted O +
to O +
correlate O +
MGMT B-Gene +
and O +
p53 O +
expression O +
in O +
colorectal O +
polyps.45 O +
In O +
that O +
study O -
, O +
4.3 O -
% O +
of O +
adenomas O +
showed O +
aberrant O +
p53 O +
expression O +
but O +
none O +
had O +
loss O +
of O +
MGMT B-Gene -
. O +

It O +
is O +
possible O +
that O +
the O +
link O +
between O +
MGMT B-Gene +
silencing O +
and O +
TP53 B-Gene +
mutation O +
is O +
more O +
evident O +
in O +
the O +
serrated O +
pathway O +
than O +
in O +
the O +
adenoma O -
– O -
carcinoma O +
sequence O -
. O +

The O +
frequency O +
of O +
TP53 B-Gene +
mutation O +
in O +
SAs O +
has O +
ranged O +
from O +
5 O +
to O +
50 O -
% O +
in O +
the O +
literature.39,41,54 O +
Although O +
a O +
link O +
between O +
MGMT B-Gene +
loss O +
and O +
aberrant O +
expression O +
of O +
p53 B-Gene +
is O +
supported O +
by O +
the O +
present O +
findings O -
, O +
it O +
should O +
be O +
noted O +
that O +
only O +
a O +
small O +
number O +
of O +
polyps O +
showed O +
these O +
changes O +
concurrently O -
. O +

KRAS B-Gene +
mutation O +
has O +
been O +
linked O +
to O +
the O +
initiation O +
of O +
hyperplastic O +
aberrant O +
crypt O +
foci O +
and O +
small O +
HPs7,38,55 O +
and O +
is O +
therefore O +
closely O +
associated O +
with O +
the O +
development O +
of O +
glandular O +
serration O -
. O +

While O +
the O +
acquisition O +
of O +
KRAS B-Gene +
mutation O +
is O +
also O +
observed O +
in O +
adenomas O -
, O +
this O +
change O +
is O +
correlated O +
with O +
the O +
development O +
of O +
a O +
villous O +
architecture O +
and O +
in O +
some O +
cases O +
the O +
presence O +
of O +
epithelial O +
serration O +
( O -
see O +
Discussion O +
of O +
Group O +
B O +
serrated O +
polyps O +
above O -
) O -
. O +

It O +
may O +
therefore O +
be O +
conceptually O +
correct O +
to O +
view O +
KRAS B-Gene +
mutation O +
as O +
adding O +
a O +
serrated O +
molecular O +
signature O +
to O +
the O +
traditional O +
adenoma O +
and O +
hence O +
providing O +
an O +
additional O +
' O -
fusion O -
' O +
pathway O -
. O +

However O -
, O +
a O +
mechanistic O +
link O +
between O +
KRAS B-Gene +
mutation O +
and O +
the O +
morphogenesis O +
of O +
serration O +
and O +
villous O +
change O +
remains O +
to O +
be O +
established O -
. O +

MGMT B-Gene +
is O +
again O +
implicated O +
in O +
this O +
second O +
type O +
of O +
' O -
fusion O -
' O +
since O +
methylation O +
and O +
inactivation O +
of O +
this O +
DNA O +
repair O +
gene O +
has O +
been O +
linked O +
to O +
G O -
: O -
C O +
to O +
A O -
: O -
T O +
transitions O +
in O +
KRAS.56–58 B-Gene +
In O +
this O +
study O +
there O +
was O +
an O +
association O +
between O +
loss O +
of O +
expression O +
of O +
MGMT B-Gene +
and O +
KRAS B-Gene +
mutation O +
among O +
small O +
TAs O +
( O -
P O +
= O +
0.04 O -
) O +
but O +
not O +
in O +
the O +
other O +
polyp O +
categories O -
. O +

Methylation O +
of O +
MGMT B-Gene +
occurs O +
in O +
normal O +
colorectal O +
mucosa,59 O +
as O +
well O +
as O +
in O +
polyps O -
, O +
and O +
is O +
therefore O +
unlikely O +
to O +
serve O +
as O +
a O +
key O +
rate O -
- O -
limiting O +
step O +
in O +
the O +
transition O +
to O +
malignancy O -
. O +

A O +
possible O +
third O +
' O -
fusion O -
' O +
pathway O +
implicating O +
KRAS B-Gene +
and O +
methylation O +
of O +
APC60 B-Gene +
is O +
included O +
in O +
Table O +
3 O -
. O +

A O +
procedure O +
for O +
the O +
detection O +
of O +
linkage O +
with O +
high O +
density O +
SNP O +
arrays O +
in O +
a O +
large O +
pedigree O +
with O +
colorectal O +
cancer O +
Abstract O +
Background O +
The O +
apparent O +
dominant O +
model O +
of O +
colorectal O +
cancer O +
( O -
CRC O -
) O +
inheritance O +
in O +
several O +
large O +
families O -
, O +
without O +
mutations O +
in O +
known O +
CRC O +
susceptibility O +
genes O -
, O +
suggests O +
the O +
presence O +
of O +
so O +
far O +
unidentified O +
genes O +
with O +
strong O +
or O +
moderate O +
effect O +
on O +
the O +
development O +
of O +
CRC O -
. O +

Linkage O +
analysis O +
could O +
lead O +
to O +
identification O +
of O +
susceptibility O +
genes O +
in O +
such O +
families O -
. O +

In O +
comparison O +
to O +
classical O +
linkage O +
analysis O +
with O +
multi O -
- O -
allelic O +
markers O -
, O +
single O +
nucleotide O +
polymorphism O +
( O -
SNP O -
) O +
arrays O +
have O +
increased O +
information O +
content O +
and O +
can O +
be O +
processed O +
with O +
higher O +
throughput O -
. O +

Therefore O -
, O +
SNP O +
arrays O +
can O +
be O +
excellent O +
tools O +
for O +
linkage O +
analysis O -
. O +

However O -
, O +
the O +
vast O +
number O +
of O +
SNPs O +
on O +
the O +
SNP O +
arrays O -
, O +
combined O +
with O +
large O +
informative O +
pedigrees O +
( O -
e.g. O +
> O -
35–40 O +
bits O -
) O -
, O +
presents O +
us O +
with O +
a O +
computational O +
complexity O +
that O +
is O +
challenging O +
for O +
existing O +
statistical O +
packages O +
or O +
even O +
exceeds O +
their O +
capacity O -
. O +

We O +
therefore O +
setup O +
a O +
procedure O +
for O +
linkage O +
analysis O +
in O +
large O +
pedigrees O +
and O +
validated O +
the O +
method O +
by O +
genotyping O +
using O +
SNP O +
arrays O +
of O +
a O +
colorectal O +
cancer O +
family O +
with O +
a O +
known O +
MLH1 B-Gene +
germ O +
line O +
mutation O -
. O +

Methods O +
Quality O +
control O +
of O +
the O +
genotype O +
data O +
was O +
performed O +
in O +
Alohomora O -
, O +
Mega2 O +
and O +
SimWalk2 O -
, O +
with O +
removal O +
of O +
uninformative O +
SNPs O -
, O +
Mendelian O +
inconsistencies O +
and O +
Mendelian O +
consistent O +
errors O -
, O +
respectively O -
. O +

Linkage O +
disequilibrium O +
was O +
measured O +
by O +
SNPLINK O +
and O +
Merlin O -
. O +

Parametric O +
linkage O +
analysis O +
using O +
two O +
flanking O +
markers O +
was O +
performed O +
using O +
MENDEL O -
. O +

For O +
multipoint O +
parametric O +
linkage O +
analysis O +
and O +
haplotype O +
analysis O -
, O +
SimWalk2 O +
was O +
used O -
. O +

Results O +
On O +
chromosome O +
3 O -
, O +
in O +
the O +
MLH1-region B-Gene -
, O +
a O +
LOD O +
score O +
of O +
1.9 O +
was O +
found O +
by O +
parametric O +
linkage O +
analysis O +
using O +
two O +
flanking O +
markers O -
. O +

On O +
chromosome O +
11 O +
a O +
small O +
region O +
with O +
LOD O +
1.1 O +
was O +
also O +
detected O -
. O +

Upon O +
linkage O +
disequilibrium O +
removal O -
, O +
multipoint O +
linkage O +
analysis O +
yielded O +
a O +
LOD O +
score O +
of O +
2.1 O +
in O +
the O +
MLH1 B-Gene +
region O -
, O +
whereas O +
the O +
LOD O +
score O +
dropped O +
to O +
negative O +
values O +
in O +
the O +
region O +
on O +
chromosome O +
11 O -
. O +

Subsequent O +
haplotype O +
analysis O +
in O +
the O +
MLH1 B-Gene +
region O +
perfectly O +
matched O +
the O +
mutation O +
status O +
of O +
the O +
family O +
members O -
. O +

Conclusion O +
We O +
developed O +
a O +
workflow O +
for O +
linkage O +
analysis O +
in O +
large O +
families O +
using O +
high O -
- O -
density O +
SNP O +
arrays O +
and O +
validated O +
this O +
workflow O +
in O +
a O +
family O +
with O +
colorectal O +
cancer O -
. O +

Linkage O +
disequilibrium O +
has O +
to O +
be O +
removed O +
when O +
using O +
SNP O +
arrays O -
, O +
because O +
it O +
can O +
falsely O +
inflate O +
the O +
LOD O +
score O -
. O +

Haplotype O +
analysis O +
is O +
adequate O +
and O +
can O +
predict O +
the O +
carrier O +
status O +
of O +
the O +
family O +
members O -
. O +

Several O +
programs O +
are O +
suitable O +
for O +
linkage O +
analysis O +
with O +
bi O -
- O -
allelic O +
markers O -
. O +

Genehunter O +
and O +
Merlin O +
can O +
handle O +
a O +
relative O +
large O +
numbers O +
of O +
markers O -
, O +
however O +
the O +
analysis O +
is O +
restricted O +
to O +
pedigrees O +
of O +
up O +
to O +
~30-bits O +
[ O -
25,26 O -
] O -
. O +

Both O +
programs O +
are O +
based O +
on O +
the O +
Lander O -
- O -
Green O +
Hidden O +
Markov O +
Model O +
algorithm O +
and O +
can O +
perform O +
non O -
- O -
parametric O +
as O +
well O +
as O +
parametric O +
linkage O +
analysis O -
. O +

In O +
Genehunter O -
, O +
the O +
Elston O -
- O -
Stewart O +
algorithm O +
is O +
also O +
implemented O -
, O +
allowing O +
the O +
performance O +
of O +
simultaneous O +
analysis O +
of O +
several O +
markers O +
as O +
well O +
as O +
analysis O +
of O +
pedigrees O +
of O +
moderate O +
size O -
. O +

A O +
third O +
program O +
based O +
on O +
the O +
Lander O -
- O -
Green O +
Hidden O +
Markov O +
Model O +
algorithm O +
is O +
Allegro O +
2 O -
. O +

This O +
program O +
can O +
handle O +
large O +
pedigrees O +
( O -
up O +
to O +
~40 O +
bits O -
) O -
, O +
although O +
the O +
computational O +
costs O +
increase O +
substantially O +
when O +
not O +
all O +
genotype O +
information O +
of O +
the O +
family O +
is O +
available O +
[ O -
27,28 O -
] O -
. O +

Allegro O +
calculates O +
parametric O +
LOD O +
scores O +
as O +
well O +
as O +
NPL O +
scores O +
and O +
allele O -
- O -
sharing O +
LOD O +
scores O -
. O +

Another O +
program O -
, O +
SNPLINK O +
[ O -
28,29 O -
] O +
can O +
perform O +
automated O +
linkage O +
analysis O +
with O +
LD O +
removal O +
using O +
either O +
Allegro O +
or O +
Merlin O -
. O +

However O -
, O +
for O +
all O +
the O +
above O +
mentioned O +
programs O +
the O +
different O +
branches O +
of O +
large O +
families O +
( O -
i.e. O +
> O -
35–40 O +
bits O -
) O +
need O +
to O +
be O +
analyzed O +
separately O -
. O +

This O +
will O +
lead O +
to O +
substantial O +
loss O +
of O +
information O +
and O +
potential O +
undetected O +
linkage O -
. O +

MENDEL O +
[ O -
30 O -
] O +
is O +
a O +
program O +
that O +
is O +
suitable O +
for O +
linkage O +
analysis O +
with O +
SNPs O +
in O +
large O +
pedigrees O -
. O +

It O +
allows O +
adjusting O +
the O +
maximum O +
number O +
of O +
meioses O -
, O +
though O +
the O +
computation O +
time O +
will O +
increase O +
in O +
that O +
case O -
. O +

Both O +
parametric O +
and O +
non O -
- O -
parametric O +
linkage O +
analysis O +
can O +
be O +
performed O +
in O +
MENDEL O -
. O +

The O +
program O +
will O +
either O +
use O +
the O +
Lander O -
- O -
Green O +
or O +
the O +
Elston O -
- O -
Stewart O +
algorithm O -
, O +
depending O +
on O +
whichever O +
is O +
more O +
efficient O +
for O +
the O +
pedigree O -
. O +

SimWalk2 O +
is O +
a O +
program O +
that O +
can O +
perform O +
multipoint O +
parametric O +
linkage O +
analysis O -
, O +
haplotype O +
analysis O +
and O +
a O +
few O +
other O +
analyses O +
in O +
large O +
pedigrees O +
using O +
bi O -
- O -
allelic O +
markers O -
. O +

It O +
uses O +
Markov O +
chain O +
Monte O +
Carlo O +
methods O +
to O +
compute O +
the O +
likelihood O +
[ O -
31 O -
] O -
. O +

Simwalk2 O +
uses O +
the O +
MENDEL O +
program O +
for O +
computing O +
location O +
scores O -
. O +

With O +
the O +
aim O +
to O +
detect O +
linkage O +
in O +
CRC O +
families O +
exceeding O +
40 O +
bits O +
we O +
established O +
a O +
procedure O +
using O +
freely O +
available O +
software O +
packages O +
and O +
validated O +
this O +
in O +
a O +
large O +
colorectal O +
cancer O +
family O -
, O +
with O +
a O +
known O +
causal O +
MLH1 B-Gene +
germ O +
line O +
mutation O +
on O +
chromosome O +
3 O -
. O +

Mendelian O +
consistent O +
errors O +
Mendelian O +
consistent O +
errors O +
were O +
identified O +
by O +
mistyping O +
analysis O -
. O +

Since O +
this O +
analysis O +
is O +
computationally O +
complex O +
and O +
therefore O +
time O +
consuming O +
( O -
2 O +
1 O -
/ O -
4 O +
hours O +
for O +
35 O +
SNPs O -
) O -
, O +
only O +
the O +
regions O +
of O +
interest O +
were O +
analyzed O +
for O +
Mendelian O +
consistent O +
errors O -
. O +

All O +
chromosomal O +
regions O +
with O +
LOD O +
scores O +
exceeding O +
1 O +
and O +
lacking O +
negative O +
LOD O +
scores O +
were O +
defined O +
as O +
regions O +
of O +
interest O +
( O -
ROI O -
) O -
. O +

SimWalk2 O +
[ O -
31 O -
] O +
was O +
used O +
to O +
check O +
all O +
ROI O +
for O +
Mendelian O +
consistent O +
errors O +
by O +
performing O +
mistyping O +
analysis O -
. O +

An O +
error O +
model O +
with O +
a O +
uniform O +
error O +
rate O +
for O +
all O +
mistypings O +
was O +
used O -
. O +

The O +
overall O +
rate O +
of O +
mistyping O +
was O +
set O +
at O +
0.004 O +
[ O -
34,35 O -
] O -
. O +

The O +
threshold O +
for O +
the O +
posterior O +
probability O +
of O +
mistyping O +
was O +
set O +
at O +
0.5 O +
[ O -
36 O -
] O -
. O +

Linkage O +
disequilibrium O +
estimation O +
In O +
the O +
ROI O +
the O +
pair O -
- O -
wise O +
correlation O +
coefficient O +
r2 O -
, O +
as O +
a O +
measure O +
of O +
linkage O +
disequilibrium O +
( O -
LD O -
) O +
between O +
adjacent O +
SNPs O -
, O +
was O +
estimated O +
using O +
SNPLINK O +
[ O -
29 O -
] O +
and O +
Merlin O +
[ O -
26 O -
] O -
. O +

Since O +
we O +
are O +
only O +
interested O +
in O +
estimates O +
of O +
r2 O -
, O +
we O +
split O +
the O +
large O +
family O +
into O +
nuclear O +
families O -
. O +

In O +
addition O +
to O +
the O +
family O +
under O +
study O -
, O +
genotypes O +
from O +
12 O +
Dutch O +
nuclear O +
families O +
from O +
other O +
studies O +
( O -
unpublished O +
results O -
) O +
were O +
used O +
to O +
calculate O +
LD O -
. O +

The O +
program O +
SNPLINK O +
provides O +
a O +
list O +
of O +
SNPs O +
to O +
be O +
removed O -
. O +

We O +
used O +
as O +
cut O +
off O +
value O +
for O +
LD O +
removal O +
an O +
r2 O +
≥ O +
0.4 O -
. O +

The O +
information O +
content O +
was O +
computed O +
before O +
and O +
after O +
removal O +
of O +
the O +
SNPs O +
using O +
Merlin O -
. O +

Linkage O +
analysis O +
To O +
determine O +
the O +
power O +
to O +
detect O +
linkage O +
in O +
the O +
MLH1 B-Gene +
family O -
, O +
we O +
performed O +
a O +
simulation O +
study O +
using O +
Simlink O +
[ O -
37 O -
] O +
under O +
the O +
assumption O +
of O +
a O +
dominant O +
trait O +
with O +
a O +
piecewise O +
linear O +
penetrance O -
. O +

Subsequently O -
, O +
we O +
performed O +
an O +
affected O -
- O -
only O +
linkage O +
analysis O +
and O +
modeled O +
a O +
dominant O +
trait O +
with O +
an O +
allele O +
frequency O +
of O +
0.001 O -
. O +

For O +
parametric O +
linkage O +
analysis O -
, O +
the O +
proper O +
assignment O +
of O +
affected O +
status O +
to O +
family O +
members O +
is O +
crucial O +
since O -
, O +
due O +
to O +
the O +
surveillance O +
of O +
the O +
families O -
, O +
adenomas O +
will O +
be O +
detected O +
and O +
removed O +
before O +
they O +
can O +
develop O +
into O +
a O +
carcinoma O -
. O +

Additionally O -
, O +
the O +
risk O +
of O +
cancer O +
increases O +
with O +
age O -
. O +

And O +
the O +
risk O +
of O +
developing O +
an O +
adenoma O +
is O +
different O +
from O +
the O +
risk O +
of O +
developing O +
a O +
carcinoma O -
. O +

To O +
adjust O +
for O +
these O +
phenomena O -
, O +
we O +
defined O +
10 O +
liability O +
classes O -
: O +
four O +
classes O +
were O +
defined O +
with O +
different O +
penetrances O +
for O +
colorectal O +
cancer O -
; O +
four O +
classes O +
for O +
polyp O +
carriers O +
and O +
two O +
more O +
liability O +
classes O +
for O +
spouses O -
, O +
that O +
carry O +
a O +
population O +
risk O +
of O +
developing O +
polyps O +
or O +
colorectal O +
cancer O +
and O +
one O +
for O +
the O +
family O +
members O +
of O +
which O +
the O +
disease O +
status O +
is O +
not O +
known O -
. O +

These O +
liability O +
classes O +
are O +
based O +
on O +
the O +
incidences O +
of O +
CRC O +
and O +
adenomas O +
in O +
the O +
members O +
of O +
HNPCC O +
families O +
in O +
the O +
Netherlands O -
, O +
that O +
do O +
not O +
carry O +
the O +
disease O +
causing O +
mutation O +
[ O -
38 O -
] O -
. O +

In O +
MENDEL O +
[ O -
30 O -
] O -
, O +
an O +
affected O -
- O -
only O +
parametric O +
linkage O +
analysis O +
was O +
performed O +
using O +
two O +
flanking O +
markers O +
( O -
computation O +
time O -
: O +
~20 O +
sec O +
per O +
chromosome O -
) O -
. O +

In O +
this O +
analysis O +
only O +
family O +
members O +
with O +
colorectal O +
cancer O +
were O +
defined O +
as O +
affected O +
and O +
all O +
other O +
persons O +
were O +
set O +
to O +
unknown O -
. O +

Parametric O +
linkage O +
analysis O +
with O +
liability O +
classes O +
was O +
performed O +
thereafter O -
, O +
using O +
two O +
flanking O +
markers O +
( O -
computation O +
time O -
: O +
~20 O +
sec O +
per O +
chromosome O -
) O -
. O +

Cancers O +
other O +
than O +
colorectal O +
cancer O +
were O +
not O +
considered O +
to O +
be O +
part O +
of O +
the O +
syndrome O -
. O +

In O +
the O +
ROIs O +
appearing O +
from O +
this O +
linkage O +
analysis O -
, O +
possible O +
Mendelian O +
consistent O +
errors O +
were O +
removed O +
as O +
well O +
as O +
the O +
possible O +
presence O +
of O +
linkage O +
disequilibrium O -
. O +

Subsequently O -
, O +
multipoint O +
parametric O +
linkage O +
analysis O +
was O +
performed O +
in O +
SimWalk2 O +
[ O -
31 O -
] O -
, O +
using O +
the O +
ten O +
liability O +
classes O -
. O +

In O +
this O +
multipoint O +
analysis O +
no O +
more O +
than O +
30 O +
SNPs O +
were O +
analyzed O -
, O +
limited O +
by O +
the O +
computational O +
complexity O +
( O -
analysis O +
time O -
: O +
1 O +
3 O -
/ O -
4 O +
hours O +
for O +
30 O +
SNPs O -
) O -
. O +

Haplotype O +
analysis O +
Haplotype O +
analysis O +
was O +
performed O +
in O +
the O +
ROI O -
, O +
using O +
SimWalk2 O -
. O +

All O +
SNPs O +
in O +
the O +
region O +
of O +
interest O +
( O -
~18 O -
) O +
were O +
included O +
in O +
this O +
analysis O +
( O -
computation O +
time O -
: O +
1 O +
1 O -
/ O -
3 O +
hours O +
for O +
18 O +
SNPs O -
) O -
. O +

The O +
results O +
of O +
the O +
haplotyping O +
were O +
visualized O +
in O +
HaploPainter O +
[ O -
39 O -
] O -
. O +

The O +
haplotype O +
segregation O +
in O +
the O +
family O +
could O +
then O +
be O +
compared O +
to O +
the O +
segregation O +
of O +
the O +
mutation O +
in O +
MLH1 B-Gene +
in O +
this O +
family O -
. O +

Results O +
and O +
discussion O +
Linkage O +
analysis O +
using O +
bi O -
- O -
allelic O +
genotype O +
data O +
from O +
SNP O +
arrays O +
and O +
large O +
families O +
is O +
a O +
computational O +
challenge O +
using O +
commonly O +
used O -
, O +
freely O +
available O +
analysis O +
software O -
. O +

For O +
the O +
different O +
steps O +
of O +
the O +
linkage O +
analysis O -
; O +
e.g. O +
data O +
formatting O -
, O +
detection O +
of O +
Mendelian O +
inconsistencies O -
, O +
mistyping O +
analysis O -
, O +
LD O +
removal O +
and O +
single O +
to O +
multipoint O +
linkage O +
analysis O -
, O +
we O +
have O +
chosen O +
the O +
following O +
programs O +
that O +
can O +
handle O +
large O +
pedigrees O +
and O +
many O +
SNPs O +
where O +
required O -
; O +
Alohomora O +
[ O -
32 O -
] O -
, O +
Mega2 O +
[ O -
33 O -
] O -
, O +
MENDEL O +
[ O -
30 O -
] O -
, O +
SNPLINK O +
[ O -
29 O -
] O +
and O +
SimWalk2 O +
[ O -
31 O -
] O -
. O +

In O +
advance O +
of O +
the O +
linkage O +
analysis O +
we O +
performed O +
a O +
simulation O +
study O +
to O +
calculate O +
the O +
power O +
using O +
Simlink O -
. O +

The O +
mean O +
LOD O +
score O +
in O +
1000 O +
simulations O +
in O +
this O +
family O +
was O +
2.0 O -
. O +

The O +
Alohomora O +
program O +
[ O -
32 O -
] O +
was O +
used O +
first O +
to O +
combine O +
the O +
genotype O +
data O +
generated O +
with O +
the O +
SNP O +
arrays O -
, O +
and O +
the O +
pedigree O +
and O +
SNP O +
information O +
and O +
secondly O -
, O +
to O +
convert O +
these O +
data O +
into O +
the O +
appropriate O +
format O +
for O +
further O +
analysis O -
. O +

In O +
addition O -
, O +
1256 O +
of O +
the O +
10053 O +
SNPs O +
were O +
uninformative O +
and O +
were O +
therefore O +
removed O +
from O +
analysis O +
by O +
Alohomora O -
. O +

Since O +
errors O +
in O +
genotyping O +
can O +
easily O +
mask O +
linkage O -
, O +
the O +
data O +
were O +
checked O +
for O +
different O +
types O +
of O +
errors O -
. O +

First O -
, O +
we O +
have O +
estimated O +
the O +
genotyping O +
error O +
rate O +
in O +
five O +
duplicate O +
experiments O -
. O +

The O +
mean O +
genotyping O +
error O +
rate O +
between O +
the O +
duplicates O +
was O +
only O +
0.0051 O -
. O +

Mega2 O +
was O +
then O +
used O +
for O +
several O +
data O +
validation O +
checks O -
, O +
including O +
errors O +
in O +
the O +
pedigree O +
data O +
or O +
Mendelian O +
inconsistent O +
errors O -
. O +

Mega2 O +
was O +
used O +
since O +
it O +
supports O +
28 O +
different O +
programs O -
, O +
including O +
the O +
programs O +
MENDEL O +
and O +
SimWalk2 O -
, O +
which O +
we O +
have O +
used O +
for O +
linkage O +
analysis O +
and O +
haplotype O +
analysis O -
. O +

The O +
genotypes O +
of O +
18 O +
SNPs O +
( O -
0.21 O -
% O -
) O +
were O +
removed O +
from O +
analysis O -
, O +
because O +
of O +
Mendelian O +
inconsistencies O -
. O +

However O -
, O +
with O +
bi O -
- O -
allelic O +
markers O +
not O +
all O +
errors O +
appear O +
as O +
Mendelian O +
inconsistent O +
errors O +
[ O -
40 O -
] O -
. O +

The O +
data O +
were O +
therefore O +
also O +
checked O +
for O +
Mendelian O +
consistent O +
errors O -
. O +

Because O +
of O +
the O +
computational O +
complexity O +
of O +
these O +
multipoint O +
analyses O -
, O +
this O +
error O +
check O +
was O +
performed O +
only O +
in O +
the O +
regions O +
of O +
interest O -
. O +

The O +
mistyping O +
analysis O +
option O +
in O +
SimWalk2 O +
was O +
used O -
, O +
since O +
this O +
program O +
can O +
handle O +
such O +
a O +
complex O +
analysis O +
in O +
a O +
large O +
pedigree O -
. O +

No O +
Mendelian O +
consistent O +
errors O +
were O +
identified O +
in O +
the O +
ROI O -
. O +

Affected O -
- O -
only O +
parametric O +
linkage O +
analysis O +
and O +
parametric O +
linkage O +
analysis O +
using O +
liability O +
classes O +
was O +
performed O +
in O +
MENDEL O -
, O +
using O +
two O +
flanking O +
markers O -
. O +

This O +
analysis O +
showed O +
a O +
maximum O +
LOD O +
score O +
of O +
1.8 O +
in O +
the O +
affected O -
- O -
only O +
analysis O +
and O +
1.9 O +
using O +
liability O +
classes O +
for O +
a O +
1.7 O +
Mb O +
region O +
around O +
the O +
MLH1 B-Gene +
gene O +
on O +
chromosome O +
3 O +
( O -
Figure O +
2 O -
) O -
. O +

A O +
second O +
region O +
with O +
a O +
LOD O +
1.1 O +
was O +
found O -
, O +
both O +
in O +
the O +
affected O -
- O -
only O +
analysis O +
and O +
using O +
liability O +
classes O -
, O +
near O +
the O +
centromere O +
on O +
chromosome O +
11 O -
. O +

Current O +
linkage O +
analysis O +
programs O +
assume O +
LD O +
between O +
markers O +
and O +
a O +
disease O +
locus O +
and O +
importantly O -
, O +
linkage O +
equilibrium O +
between O +
markers O -
. O +

The O +
presence O +
of O +
linkage O +
disequilibrium O +
between O +
two O +
markers O +
can O +
falsely O +
inflate O +
the O +
LOD O +
score O +
and O +
missing O +
genotypes O +
can O +
increase O +
this O +
effect O -
. O +

Therefore O -
, O +
the O +
r2 O +
as O +
a O +
measure O +
of O +
LD O +
was O +
computed O +
in O +
Merlin O +
and O +
SNPLINK O -
. O +

Using O +
the O +
threshold O +
r2 O +
≥ O +
0.4 O -
, O +
5 O +
of O +
the O +
27 O +
SNPs O +
in O +
the O +
region O +
on O +
chromosome O +
3 O +
were O +
removed O +
from O +
the O +
analysis O -
. O +

From O +
the O +
region O +
of O +
interest O +
on O +
chromosome O +
11 O -
, O +
14 O +
of O +
the O +
30 O +
SNPs O +
with O +
an O +
r2 O +
≥ O +
0.4 O +
were O +
removed O +
from O +
the O +
analysis O -
. O +

After O +
LD O +
removal O -
, O +
multipoint O +
linkage O +
analysis O +
in O +
the O +
region O +
on O +
chromosome O +
3 O +
yielded O +
a O +
LOD O +
score O +
of O +
2.1 O -
, O +
whereas O +
on O +
chromosome O +
11 O +
negative O +
LOD O +
scores O +
were O +
seen O +
by O +
multipoint O +
linkage O +
analysis O +
after O +
LD O +
was O +
removed O -
. O +

This O +
indicates O +
that O +
the O +
strong O +
LD O +
in O +
the O +
region O +
on O +
chromosome O +
11 O +
was O +
responsible O +
for O +
the O +
peak O +
in O +
the O +
LOD O +
in O +
that O +
region O -
. O +

On O +
both O +
chromosomes O -
, O +
the O +
removal O +
of O +
SNPs O +
with O +
high O +
LD O +
had O +
no O +
significant O +
effect O +
on O +
the O +
information O +
content O +
( O -
not O +
shown O -
) O -
. O +

We O +
inferred O +
the O +
haplotypes O +
of O +
the O +
family O +
members O -
, O +
using O +
SimWalk2 O +
for O +
the O +
linkage O +
region O +
on O +
chromosome O +
3 O -
. O +

All O +
known O +
affected O +
MLH1-mutation B-Gene +
carriers O +
share O +
the O +
same O +
haplotype O -
, O +
as O +
well O +
as O +
the O +
affected O +
obligate O +
carriers O -
. O +

Therefore O -
, O +
this O +
haplotype O +
perfectly O +
co O -
- O -
segregates O +
with O +
the O +
clinical O +
phenotype O +
of O +
the O +
family O +
members O +
( O -
Figure O +
1 O -
) O -
. O +

Case O +
23 O -
, O +
who O +
had O +
developed O +
polyps O +
at O +
age O +
60 O -
, O +
does O +
not O +
share O +
this O +
haplotype O -
. O +

Subsequent O +
mutation O +
analysis O +
showed O +
that O +
this O +
individual O +
indeed O +
did O +
not O +
carry O +
the O +
disease O +
causing O +
mutation O +
in O +
MLH1 B-Gene -
. O +

Therefore O -
, O +
this O +
case O +
showed O +
to O +
be O +
a O +
phenocopy O -
. O +

Another O +
family O +
member O -
, O +
case O +
39 O -
, O +
has O +
to O +
date O +
not O +
developed O +
clinical O +
symptoms O +
of O +
HNPCC O -
, O +
although O +
he O +
did O +
inherit O +
the O +
disease O +
causing O +
allele O +
according O +
to O +
the O +
haplotype O +
analysis O -
. O +

Indeed O -
, O +
sequence O +
analysis O +
showed O +
that O +
this O +
person O +
carries O +
the O +
mutation O -
. O +

Conclusion O +
In O +
conclusion O -
, O +
we O +
show O +
that O +
we O +
can O +
perform O +
linkage O +
analysis O +
with O +
high O -
- O -
density O +
10 O -
K O +
SNP O +
arrays O +
in O +
large O +
families O +
for O +
which O +
not O +
all O +
members O +
could O +
be O +
genotyped O -
. O +

We O +
developed O +
a O +
workflow O +
with O +
different O +
publicly O +
available O +
software O +
to O +
perform O +
the O +
analyses O -
: O +
removal O +
of O +
Mendelian O +
consistent O +
and O +
Mendelian O +
inconsistent O +
errors O -
, O +
two O +
and O +
multipoint O +
parametric O +
linkage O +
analysis O -
, O +
removal O +
of O +
linkage O +
disequilibrium O +
and O +
haplotype O +
analysis O -
. O +

The O +
procedure O +
was O +
validated O +
in O +
a O +
large O +
CRC O +
family O +
carrying O +
a O +
known O +
germ O +
line O +
mutation O +
in O +
MLH1 B-Gene -
. O +

Linkage O +
was O +
found O +
with O +
the O +
MLH1 B-Gene +
gene O +
and O +
subsequent O +
haplotype O +
analysis O +
corresponds O +
to O +
the O +
mutation O +
status O +
of O +
the O +
family O +
members O -
. O +

This O +
procedure O +
can O +
now O +
be O +
used O +
for O +
linkage O +
analysis O +
of O +
large O +
families O +
with O +
an O +
inherited O +
condition O -
, O +
such O +
as O +
hereditary O +
colorectal O +
cancer O -
. O +

HNPCC O +
sporadic O +
microsatellite O -
- O -
unstable O +
colon O +
cancers O +
follow O +
different O +
routes O +
toward O +
loss O +
of O +
HLA O +
class O +
I O +
expression O +
Abstract O +
Background O +
Abnormalities O +
in O +
Human O +
Leukocyte O +
Antigen O +
( O -
HLA O -
) O +
class O +
I O +
expression O +
are O +
common O +
in O +
colorectal O +
cancer O -
. O +

Since O +
HLA B-Gene +
expression O +
is O +
required O +
to O +
activate O +
tumor O +
antigen O -
- O -
specific O +
cytotoxic O +
T O -
- O -
lymphocytes O +
( O -
CTL O -
) O -
, O +
HLA B-Gene +
class I-Gene +
I I-Gene +
abnormalities O +
represent O +
a O +
mechanism O +
by O +
which O +
tumors O +
circumvent O +
immune O +
surveillance O -
. O +

Tumors O +
with O +
high O +
microsatellite O +
instability O +
( O -
MSI O -
- O -
H O -
) O +
are O +
believed O +
to O +
face O +
strong O +
selective O +
pressure O +
to O +
evade O +
CTL O +
activity O +
since O +
they O +
produce O +
large O +
amounts O +
of O +
immunogenic O +
peptides O -
. O +

Previous O +
studies O +
identified O +
the O +
prevalence O +
of O +
HLA O +
class O +
I O +
alterations O +
in O +
MSI O -
- O -
H O +
tumors O -
. O +

However O -
, O +
those O +
reports O +
did O +
not O +
compare O +
the O +
frequency O +
of O +
alterations O +
between O +
hereditary O +
and O +
sporadic O +
MSI O -
- O -
H O +
tumors O +
neither O +
the O +
mechanisms O +
that O +
led O +
to O +
HLA O +
class O +
I O +
alterations O +
in O +
each O +
subgroup O -
. O +

Methods O +
To O +
characterize O +
the O +
HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
among O +
sporadic O +
MSI O -
- O -
H O +
and O +
microsatellite O -
- O -
stable O +
( O -
MSS O -
) O +
tumors O -
, O +
and O +
HNPCC O +
tumors O +
we O +
compared O +
immunohistochemically O +
the O +
expression O +
of O +
HLA B-Gene +
class I-Gene +
I I-Gene -
, O +
β2-microglobulin B-Gene +
( O -
β2 B-Gene -
m I-Gene -
) O -
, O +
and O +
Antigen O +
Processing O +
Machinery O +
( O -
APM B-Gene -
) O +
components O +
in O +
81 O +
right O -
- O -
sided O +
sporadic O +
and O +
75 O +
HNPCC O +
tumors O -
. O +

Moreover O -
, O +
we O +
investigated O +
the O +
genetic O +
basis O +
for O +
these O +
changes O -
. O +

Results O +
HLA O +
class O +
I O +
loss O +
was O +
seen O +
more O +
frequently O +
in O +
MSI O -
- O -
H O +
tumors O +
than O +
in O +
MSS O +
tumors O +
( O -
p O +
< O +
0.0001 O -
) O -
. O +

Distinct O +
mechanisms O +
were O +
responsible O +
for O +
HLA O +
class O +
I O +
loss O +
in O +
HNPCC O +
and O +
sporadic O +
MSI O -
- O -
H O +
tumors O -
. O +

Loss O +
of O +
HLA O +
class O +
I O +
expression O +
was O +
associated O +
with O +
β2 O -
m O +
loss O +
in O +
HNPCC O +
tumors O -
, O +
but O +
was O +
correlated O +
with O +
APM O +
component O +
defects O +
in O +
sporadic O +
MSI O -
- O -
H O +
tumors O +
( O -
p O +
< O +
0.0001 O -
) O -
. O +

In O +
about O +
half O +
of O +
the O +
cases O -
, O +
loss O +
of O +
expression O +
of O +
HLA O +
class O +
I O +
was O +
concordant O +
with O +
the O +
detection O +
of O +
one O +
or O +
more O +
mutations O +
in O +
the O +
β2 B-Gene -
m I-Gene +
and O +
APM B-Gene +
components I-Gene +
genes O -
. O +

Conclusion O +
HLA O +
class O +
I O +
aberrations O +
are O +
found O +
at O +
varying O +
frequencies O +
in O +
different O +
colorectal O +
tumor O +
types O +
and O +
are O +
caused O +
by O +
distinct O +
genetic O +
mechanisms O -
. O +

Chiefly O -
, O +
sporadic O +
and O +
hereditary O +
MSI O -
- O -
H O +
tumors O +
follow O +
different O +
routes O +
toward O +
HLA O +
class O +
I O +
loss O +
of O +
expression O +
supporting O +
the O +
idea O +
that O +
these O +
tumors O +
follow O +
different O +
evolutionary O +
pathways O +
in O +
tumorigenesis O -
. O +

The O +
resulting O +
variation O +
in O +
immune O +
escape O +
mechanisms O +
may O +
have O +
repercussions O +
in O +
tumor O +
progression O +
and O +
behavior O -
. O +

Background O +
During O +
cancer O +
development O -
, O +
tumor O +
cells O +
may O +
elicit O +
cytotoxic O +
T O -
- O -
lymphocyte O +
( O -
CTL O -
) O -
-mediated O +
immune O +
responses O -
– O -
partly O +
a O +
consequence O +
of O +
accumulated O +
gene O +
mutations O +
that O +
are O +
translated O +
into O +
altered O +
peptides O +
[ O -
1 O -
] O -
. O +

Tumor O +
cell O +
expression O +
of O +
HLA B-Gene +
class I-Gene +
I I-Gene -
- O -
antigen O +
complexes O +
is O +
essential O +
for O +
CTL O +
recognition O +
of O +
aberrant O +
peptides O +
and O +
subsequent O +
activation O +
[ O -
2 O -
] O -
. O +

Consequently O -
, O +
alteration O +
of O +
HLA B-Gene +
class I-Gene +
I I-Gene +
cell O +
surface O +
expression O +
provides O +
an O +
effective O +
mechanism O +
by O +
which O +
tumors O +
can O +
escape O +
immune O +
detection O +
[ O -
3,4 O -
] O -
. O +

Multiple O +
mechanisms O +
have O +
been O +
shown O +
to O +
underlie O +
defects O +
in O +
HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
by O +
tumor O +
cells O -
. O +

They O +
include O +
mutations O +
in O +
the O +
individual O +
HLA B-Gene +
class I-Gene +
I I-Gene +
genes O +
HLA B-Gene -
- I-Gene -
A I-Gene -
, O +
-B B-Gene +
and O +
-C B-Gene -
, O +
located O +
on O +
chromosome O +
6p21.3 O -
) O +
[ O -
5 O -
] O -
; O +
mutations O +
in O +
β2-microglobulin B-Gene +
( O -
β2 B-Gene -
m I-Gene -
) O +
[ O -
6 O -
- O -
9 O -
] O -
, O +
molecule O +
required O +
for O +
cell O +
surface O +
expression O +
of O +
HLA B-Gene +
class I-Gene +
I I-Gene +
antigens O -
; O +
and O +
defects O +
in O +
components B-Gene +
of I-Gene +
the I-Gene +
HLA I-Gene +
class I-Gene +
I I-Gene -
- I-Gene -
associated I-Gene +
antigen I-Gene -
- I-Gene -
processing I-Gene +
machinery I-Gene +
( O -
APM B-Gene -
) O +
[ O -
9 O -
- O -
11 O -
] O -
. O +

The O +
APM B-Gene +
consists O +
of O +
proteasome O +
components O +
delta O -
, O +
MB1 B-Gene +
and O +
Z B-Gene -
; O +
the O +
immunoproteasome O +
components O +
LMP2 B-Gene -
, O +
LMP7 B-Gene +
and O +
LMP10 B-Gene -
; O +
peptide O +
transporters O +
TAP1 B-Gene +
and O +
TAP2 B-Gene -
; O +
and O +
chaperones O +
Calnexin B-Gene -
, O +
Calreticulin B-Gene -
, O +
ERp57 B-Gene -
, O +
and O +
Tapasin B-Gene -
. O +

The O +
immunoproteasome O +
generates O +
peptides O +
mostly O -
, O +
although O +
not O +
exclusively O +
from O +
endogenous O +
proteins O -
, O +
TAP1 B-Gene +
and O +
TAP2 B-Gene +
facilitate O +
peptide O +
translocation O +
from O +
the O +
cytosol O +
into O +
the O +
lumen O +
of O +
the O +
endoplasmic O +
reticulum O -
, O +
where O +
the O +
peptides O +
are O +
loaded O +
onto O +
the O +
HLA B-Gene +
class I-Gene +
I I-Gene +
molecules O +
with O +
the O +
aid O +
from O +
the O +
several O +
chaperones O +
[ O -
12 O -
] O -
. O +

Chromosomal O +
instability O +
( O -
CIN O -
) O +
and O +
microsatellite O +
instability O +
( O -
MIN O -
) O +
are O +
the O +
two O +
major O +
forms O +
of O +
genetic O +
instability O +
in O +
colorectal O +
cancer O -
. O +

Combined O +
with O +
distinct O +
somatic O +
mutation O +
patterns O +
and O +
epigenetic O +
modifications O -
, O +
CIN O +
and O +
MIN O +
lead O +
to O +
the O +
development O +
of O +
sporadic O +
colorectal O +
cancer O +
[ O -
13 O -
] O -
. O +

MIN O +
sporadic O +
tumors O -
, O +
which O +
constitute O +
approximately O +
15 O -
% O +
of O +
all O +
colorectal O +
cancer O +
cases O +
and O +
up O +
to O +
40 O -
% O +
of O +
the O +
tumors O +
localized O +
on O +
the O +
right O +
side O +
( O -
preceding O +
the O +
splenic O +
flexure O -
) O +
of O +
the O +
colon O +
[ O -
14 O -
] O -
, O +
have O +
a O +
phenotype O +
resulting O +
from O +
the O +
epigenetic O +
inactivation O +
of O +
the O +
mismatch O +
repair O +
gene O +
hMLH1 B-Gene -
. O +

Its O +
inactivation O +
destroys O +
a O +
cell O -
's O +
ability O +
to O +
repair O +
base O -
- O -
base O +
mismatches O +
and O +
small O +
insertions O +
or O +
deletions O +
in O +
repetitive O +
stretches O -
, O +
leading O +
to O +
an O +
accumulation O +
of O +
frameshift O +
mutations O +
that O +
get O +
translated O +
into O +
abnormal O +
peptide O +
sequences O -
. O +

When O +
these O +
mutations O +
are O +
accumulated O +
to O +
large O +
extent O +
in O +
the O +
cell O +
genome O +
the O +
tumors O +
are O +
said O +
to O +
possess O +
high O -
- O -
microsatellite O +
instability O +
( O -
MSI O -
- O -
H O -
) O +
[ O -
15 O -
] O -
. O +

Hence O -
, O +
it O +
is O +
expected O +
that O +
genes O +
containing O +
microsatellite O +
sequences O +
within O +
their O +
coding O +
regions O +
are O +
more O +
susceptible O +
to O +
somatic O +
mutations O -
, O +
as O +
seen O +
in O +
the O +
TGFβ B-Gene -
- I-Gene -
RII I-Gene +
gene O -
. O +

TGFβ B-Gene -
- I-Gene -
RII I-Gene -
's O +
third O +
exon O +
contains O +
a O +
microsatellite O +
repeat O +
of O +
10 O +
adenines O +
that O +
is O +
frequently O +
targeted O +
by O +
frameshift O +
mutations O +
in O +
MSI O -
- O -
H O +
tumors O +
[ O -
16 O -
] O -
. O +

MSI O -
- O -
H O +
is O +
also O +
the O +
hallmark O +
of O +
hereditary O +
non O -
- O -
polyposis O +
colorectal O +
cancer O +
( O -
HNPCC O -
) O -
, O +
in O +
which O +
germline O +
mutations O +
of O +
hMLH1 B-Gene -
, O +
hMSH2 B-Gene -
, O +
hMSH6 B-Gene +
and O +
PMS2 B-Gene +
can O +
be O +
found O -
. O +

HNPCC O +
constitutes O +
approximately O +
2–4 O -
% O +
of O +
all O +
CRC O +
cases O +
[ O -
17 O -
] O -
. O +

Tumors O +
with O +
MSI O -
- O -
H O +
are O +
thought O +
to O +
be O +
more O +
able O +
to O +
stimulate O +
a O +
CTL O -
- O -
mediated O +
immune O +
response O +
due O +
to O +
their O +
frequent O +
generation O +
of O +
the O +
aberrant O +
frameshift O +
peptides O +
[ O -
18 O -
] O -
. O +

Therefore O -
, O +
these O +
tumors O +
are O +
subjected O +
to O +
a O +
greater O +
selective O +
pressure O +
which O +
favors O +
the O +
outgrowth O +
of O +
tumor O +
cells O +
with O +
the O +
ability O +
to O +
escape O +
from O +
recognition O +
and O +
destruction O +
by O +
host O +
immune O +
system O -
. O +

Various O +
studies O +
have O +
identified O +
HLA O +
alterations O +
in O +
colorectal O +
cancer O +
[ O -
19 O -
- O -
21 O -
] O -
, O +
including O +
the O +
prevalence O +
of O +
HLA O +
class O +
I O +
alterations O +
in O +
MSI O -
- O -
H O +
tumors O +
[ O -
8,22 O -
] O -
. O +

However O -
, O +
the O +
latter O +
studies O +
did O +
not O +
compare O +
the O +
frequency O +
of O +
alterations O +
between O +
hereditary O +
and O +
sporadic O +
MSI O -
- O -
H O +
tumors O +
neither O +
the O +
mechanisms O +
that O +
led O +
to O +
HLA O +
class O +
I O +
alterations O +
in O +
each O +
subgroup O -
. O +

It O +
was O +
suggested O +
that O +
MSI O -
- O -
H O +
sporadic O +
and O +
hereditary O +
tumors O +
follow O +
parallel O +
evolutionary O +
pathways O +
during O +
tumorigenesis O +
in O +
terms O +
of O +
both O +
genotype O +
and O +
phenotype O +
[ O -
23 O -
] O -
. O +

As O +
far O +
as O +
HLA B-Gene +
class I-Gene +
I I-Gene +
defects O +
are O +
concerned O +
it O +
was O +
never O +
investigated O +
whether O +
these O +
different O +
tumors O +
present O +
distinct O +
escape O +
mechanisms O +
from O +
the O +
immune O +
system O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
compared O +
the O +
frequency O +
of O +
defects O +
in O +
HLA O +
class O +
I O +
expression O +
in O +
right O -
- O -
sided O +
sporadic O +
( O -
MSI O -
- O -
H O +
and O +
microsatellite O -
- O -
stable O +
( O -
MSS O -
) O +
sub O -
- O -
groups O -
) O +
colon O +
tumors O +
and O +
in O +
HNPCC O +
tumors O +
and O +
studied O +
the O +
mechanisms O +
underlying O +
any O +
abnormalities O +
in O +
these O +
subgroups O -
. O +

Methods O +
Patient O +
material O +
and O +
tissue O +
microarrays O +
Two O +
tissue O +
microarrays O +
were O +
constructed O +
from O +
formalin O -
- O -
fixed O -
, O +
paraffin O -
- O -
embedded O +
tissues O +
as O +
described O +
previously O +
[ O -
24 O -
] O -
. O +

One O +
array O -
, O +
previously O +
described O +
[ O -
25 O -
] O -
, O +
included O +
colorectal O +
tumor O +
specimens O +
from O +
129 O +
suspected O +
HNPCC O +
patients O +
with O +
MSI O -
- O -
H O +
colon O +
tumors O +
of O +
which O +
75 O +
cases O +
were O +
analyzed O +
in O +
the O +
present O +
study O +
after O +
confirmation O +
of O +
their O +
HNPCC O +
status O -
: O +
73.3 O -
% O +
( O -
n O +
= O +
55 O -
) O +
of O +
the O +
latter O +
possessed O +
a O +
germline O +
pathogenic O +
mutation O +
in O +
hMLH1 B-Gene +
( O -
n O +
= O +
24 O -
) O -
, O +
hMSH2 B-Gene +
( O -
n O +
= O +
18 O -
) O -
, O +
hMSH6 B-Gene +
( O -
n O +
= O +
12 O -
) O +
or O +
PMS2 B-Gene +
( O -
n O +
= O +
1 O -
) O -
, O +
the O +
remaining O +
were O +
MSI O -
- O -
H O -
, O +
without O +
methylation O +
of O +
the O +
hMLH1 B-Gene +
promoter O +
and/or O +
with O +
immunohistochemical O +
loss O +
of O +
the O +
MSH2 B-Gene -
/ O -
MSH6 B-Gene +
heterodimer O +
and/or O +
possessed O +
a O +
very O +
young O +
age O +
at O +
diagnosis O +
of O +
colon O +
cancer O +
( O -
< O -
50 O +
yrs O +
old O -
) O -
. O +

All O +
cases O +
possessed O +
a O +
positive O +
family O +
history O +
for O +
MSI O -
- O -
H O +
tumors O -
. O +

The O +
second O +
tissue O +
array O +
included O +
3 O +
tumor O +
tissue O +
cores O +
from O +
81 O +
sporadic O +
right O -
- O -
sided O +
colon O +
cancer O +
cases O +
resected O +
between O +
1990 O +
and O +
2005 O +
at O +
the O +
Leiden O +
University O +
Medical O +
Center O +
( O -
Leiden O -
, O +
The O +
Netherlands O -
) O +
and O +
at O +
the O +
Rijnland O +
Hospital O +
( O -
Leiderdorp O -
, O +
The O +
Netherlands O -
) O -
. O +

The O +
81 O +
patients O +
in O +
the O +
latter O +
array O +
consisted O +
of O +
47 O +
females O +
and O +
34 O +
males O +
with O +
a O +
mean O +
age O +
of O +
71.15 O +
years O +
( O -
SD= O +
9.958 O -
) O -
. O +

Approximately O +
60 O -
% O +
( O -
n O +
= O +
48 O -
) O +
of O +
these O +
cases O +
were O +
classified O +
as O +
MSS O +
while O +
the O +
remaining O +
( O -
n O +
= O +
33 O -
) O +
possessed O +
a O +
MSI O -
- O -
H O +
phenotype O -
. O +

The O +
microsatellite O +
instability O +
status O +
of O +
the O +
tumors O +
was O +
determined O +
according O +
to O +
recommendations O +
of O +
the O +
National O +
Cancer O +
Institute O -
/ O -
ICG O -
- O -
HNPCC O +
[ O -
15 O -
] O -
. O +

Moreover O +
all O +
MSI O -
- O -
H O +
sporadic O +
cases O +
have O +
lost O +
the O +
expression O +
of O +
the O +
MLH1 B-Gene -
/ O -
PMS2 B-Gene +
heterodimer O +
as O +
assessed O +
by O +
immunohistochemistry O -
. O +

The O +
sporadic O +
status O +
of O +
the O +
MSI O -
- O -
H O +
right O -
- O -
sided O +
tumors O +
( O -
RST O -
) O +
was O +
confirmed O +
by O +
methylation O +
analysis O +
of O +
the O +
hMLH1 B-Gene +
promoter O +
using O +
a O +
methylation O -
- O -
specific O +
MLPA O +
assay O +
as O +
previously O +
described O +
[ O -
26 O -
] O -
. O +

All O +
MSI O -
- O -
H O +
sporadic O +
cases O +
presented O +
with O +
hypermethylation O +
at O +
the O +
hMLH1 B-Gene +
promoter O -
. O +

The O +
present O +
study O +
falls O +
under O +
approval O +
by O +
the O +
Medical O +
Ethical O +
Committee O +
of O +
the O +
LUMC O +
( O -
protocol O +
P01–019 O -
) O -
. O +

Cases O +
were O +
analyzed O +
following O +
the O +
medical O +
ethnical O +
guidelines O +
described O +
in O +
the O +
Code O +
Proper O +
Secondary O +
Use O +
of O +
Human O +
Tissue O +
established O +
by O +
the O +
Dutch O +
Federation O +
of O +
Medical O +
Sciences O +
[ O -
27 O -
] O -
. O +

Immunohistochemistry O +
Standard O +
three O -
- O -
step O -
, O +
indirect O +
immunohistochemistry O +
was O +
performed O +
on O +
4-μm O +
tissue O +
sections O +
transferred O +
to O +
glass O +
slides O +
using O +
a O +
tape O -
- O -
transfer O +
system O +
( O -
Instrumedics O -
, O +
Hackensack O -
, O +
NJ O -
) O -
, O +
including O +
citrate O +
antigen O +
retrieval O -
, O +
blockage O +
of O +
endogenous O +
peroxidase O +
and O +
endogenous O +
avidin O -
- O -
binding O +
activity O -
, O +
and O +
di O -
- O -
aminobenzidine O +
development O -
. O +

The O +
following O +
primary O +
antibodies O +
were O +
used O -
: O +
the O +
mAb O +
HCA2 O +
which O +
recognizes O +
β2m O -
- O -
free O +
HLA B-Gene -
- I-Gene -
A I-Gene +
( O -
except O +
-A24 O -
) O -
, O +
-B7301 O +
and O +
-G O +
heavy O +
chains O +
[ O -
28,29 O -
] O +
; O +
the O +
mAb O +
HC10 O -
, O +
which O +
recognizes O +
a O +
determinant O +
expressed O +
on O +
all O +
β2m O -
- O -
free O +
HLA B-Gene -
- I-Gene -
B I-Gene +
and O +
C O +
heavy O +
chains O +
and O +
on O +
β2m O -
- O -
free O +
HLA B-Gene -
- O -
A10 O -
, O +
-A28 O -
, O +
-A29 O -
, O +
-A30 O -
, O +
-A31 O -
, O +
-A32 O +
and O +
-A33 O +
heavy O +
chains O +
( O -
supernatant O +
kindly O +
provided O +
by O +
Dr. O +
J. O +
Neefjes O -
, O +
NKI O -
, O +
Amsterdam O -
, O +
The O +
Netherlands O +
and O +
Dr. O +
H. O +
L. O +
Ploegh O -
, O +
MIT O -
, O +
Boston O -
, O +
MA O -
) O +
[ O -
28,30 O -
] O -
; O +
TAP1 B-Gene +
specific O +
mAb O +
NOB1 O -
; O +
LMP2-specific B-Gene +
mAb O +
SY-1 O -
; O +
LMP7-specific B-Gene +
mAb O +
HB2 O -
; O +
LPM10-specific B-Gene +
mAb O +
TO-7 O -
; O +
Calnexin B-Gene -
- O -
specific O +
mAb O +
TO-5 O -
; O +
Calreticulin B-Gene -
- O -
specific O +
mAb O +
TO-11 O -
; O +
Tapasin B-Gene -
- O -
specific O +
mAb O +
TO-3 O -
; O +
ERp57-specific B-Gene +
mAb O +
TO-2 O +
[ O -
31 O -
- O -
33 O -
] O -
; O +
TAP2-specific B-Gene +
mAb O +
( O -
BD O +
Biosciences O +
Pharmingen O -
, O +
San O +
Diego O -
, O +
CA O -
) O -
; O +
rabbit O +
anti O -
- O -
β2 B-Gene -
m I-Gene +
polyclonal O +
Ab O +
( O -
A O +
072 O -
; O +
DAKO O +
Cytomation O -
, O +
Glostrup O -
, O +
Denmark O -
) O -
; O +
anti O -
- O -
MLH1 O +
( O -
clone O +
G168–728 O -
; O +
BD O +
Biosciences O -
) O +
and O +
anti O -
- O -
PMS2 B-Gene +
( O -
clone O +
A16 O -
- O -
4 O -
; O +
BD O +
Biosciences O -
) O -
. O +

Secondary O +
reagents O +
used O +
were O +
biotinylated O +
rabbit O +
anti O -
- O -
mouse O +
IgG O +
antibodies O +
( O -
DAKO O +
Cytomation O -
) O -
, O +
goat O +
anti O -
- O -
rabbit O +
IgG O +
antibodies O +
( O -
DAKO O +
Cytomation O -
) O -
, O +
and O +
biotinylated O -
- O -
peroxidase O +
streptavidin O +
complex O +
( O -
SABC O -
; O +
DAKO O +
Cytomation O -
) O -
. O +

Loss O +
of O +
expression O +
was O +
defined O +
by O +
complete O +
lack O +
of O +
staining O +
in O +
membrane O +
and O +
cytoplasm O +
( O -
HCA2 O -
, O +
HC10 O -
, O +
and O +
anti O -
- O -
β2 O -
m O -
) O -
, O +
in O +
the O +
nucleus O +
( O -
anti O -
- O -
MLH1 O +
and O +
anti O -
- O -
PMS2 O -
) O -
, O +
in O +
the O +
peri O -
- O -
nucleus O -
/ O -
endoplasmic O +
reticulum O +
( O -
NOB1 O -
, O +
anti O -
- O -
TAP2 O -
, O +
TO-2 O -
, O +
TO-3 O -
, O +
TO-5 O -
, O +
TO-7 O -
, O +
and O +
TO-11 O -
) O -
, O +
or O +
in O +
the O +
cytoplasm O +
( O -
SY-1 O -
, O +
HB2 O -
, O +
and O +
TO-7 O -
) O -
, O +
but O +
with O +
concurrent O +
staining O +
in O +
normal O +
epithelium O -
, O +
stroma O +
or O +
infiltrating O +
leukocytes O -
. O +

HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
was O +
considered O +
to O +
be O +
lost O +
when O +
one O +
of O +
the O +
HLA B-Gene +
class I-Gene +
I I-Gene +
antigen O -
- O -
specific O +
antibodies O +
gave O +
a O +
negative O +
result O +
alongside O +
a O +
positive O +
internal O +
control O +
( O -
lymphocytic O +
infiltrate O -
) O -
. O +

Flow O +
cytometric O +
sorting O +
The O +
flow O +
cytometric O +
sorting O +
procedure O -
, O +
including O +
tissue O +
preparation O -
, O +
staining O +
and O +
flow O +
cytometry O +
analysis O +
was O +
performed O +
as O +
described O +
previously O +
[ O -
34 O -
] O -
. O +

Briefly O -
, O +
2 O +
mm O +
diameter O +
punches O +
from O +
selected O +
areas O +
of O +
formalin O -
- O -
fixed O +
paraffin O +
embedded O +
colorectal O +
carcinomas O +
were O +
digested O +
enzymatically O +
in O +
a O +
mixture O +
of O +
0.1 O -
% O +
collagenase O +
I O -
- O -
A O +
( O -
Sigma O -
- O -
Aldrich O -
, O +
St O +
Louis O -
, O +
MO O -
, O +
USA O -
) O +
and O +
0.1 O -
% O +
dispase O +
( O -
Gibco O +
BRL O -
, O +
Paisley O -
, O +
UK O -
) O -
. O +

After O +
determination O +
of O +
cell O +
concentration O -
, O +
one O +
million O +
cells O +
were O +
incubated O +
with O +
100 O +
μl O +
of O +
mAb O +
mixture O +
directed O +
against O +
keratin O +
and O +
vimentin O +
containing O +
clones O +
MNF116 O +
( O -
anti O -
- O -
keratin O -
; O +
IgG1 O -
; O +
DAKOCytomation O -
, O +
Golstrup O -
, O +
Denmark O -
) O -
, O +
AE1 O -
/ O -
AE3 O +
( O -
anti O -
- O -
keratin O -
; O +
IgG1 O -
; O +
Chemicon O +
International O +
Inc O -
, O +
Temecula O -
, O +
CA O -
, O +
USA O -
) O -
, O +
and O +
V9 O -
- O -
2b O +
( O -
anti O -
- O -
vimentin O -
; O +
IgG2b O -
; O +
Department O +
of O +
Pathology O -
, O +
LUMC O +
[ O -
35 O -
] O -
) O -
. O +

Next O +
day O -
, O +
cells O +
were O +
incubated O +
with O +
100 O +
μl O +
of O +
premixed O +
FITC O +
and O +
RPE O -
- O -
labelled O +
goat O +
F O -
( O -
ab' O -
) O -
2 O +
anti O -
- O -
mouse O +
subclass O -
- O -
specific O +
secondary O +
reagents O +
( O -
Southern O +
Biotechnology O +
Associates O -
, O +
Birmingham O -
, O +
AL O -
, O +
USA O -
) O -
. O +

After O +
washing O -
, O +
cells O +
were O +
incubated O +
with O +
10 O +
μM O +
propidium O +
iodide O +
( O -
PI O -
) O +
and O +
0.1 O -
% O +
DNase O -
- O -
free O +
RNase O +
( O -
Sigma O -
) O -
. O +

The O +
next O +
day O +
cells O +
were O +
analyzed O +
by O +
flow O +
cytometry O -
. O +

A O +
standard O +
FACSCalibur O +
( O -
BD O +
Biosciences O -
) O +
was O +
used O +
for O +
the O +
simultaneous O +
measurement O +
of O +
FITC O -
, O +
RPE O -
, O +
and O +
PI O -
. O +

Tumor O +
and O +
normal O +
cell O +
populations O +
were O +
flow O -
- O -
sorted O +
using O +
a O +
FACSVantage O +
flow O -
- O -
sorter O +
( O -
BD O +
Biosciences O -
) O +
using O +
the O +
FACSCalibur O +
filter O +
settings O -
. O +

Sorting O +
was O +
only O +
performed O +
on O +
samples O +
included O +
in O +
the O +
RST O +
array O +
due O +
to O +
shortage O +
of O +
material O +
from O +
the O +
HNPCC O +
cases O -
. O +

DNA O +
from O +
flow O -
- O -
sorted O +
tumor O +
material O +
was O +
isolated O +
as O +
described O +
by O +
Jordanova O +
et O +
al. O +
[ O -
36 O -
] O -
. O +

DNA O +
from O +
non O -
- O -
sorted O +
material O +
was O +
isolated O +
using O +
Chelex O +
extraction O +
as O +
described O +
previously O +
[ O -
37 O -
] O -
. O +

LOH O +
and O +
fragment O +
analysis O +
Markers O +
for O +
loss O +
of O +
heterozygosity O +
( O -
LOH O -
) O +
analysis O +
were O +
chosen O +
from O +
the O +
dbMHC O +
database O +
[ O -
38 O -
] O +
to O +
map O +
the O +
chromosome O +
6p21.3 O +
region O +
between O +
HLA B-Gene -
- I-Gene -
A I-Gene +
and O +
TAP2 B-Gene -
. O +

They O +
were O +
MOGc B-Gene -
, O +
D6S510 B-Gene -
, O +
C125 B-Gene -
, O +
C141 B-Gene -
, O +
D6S2444 B-Gene -
, O +
TAP1 B-Gene +
and O +
M2426 B-Gene -
. O +

A O +
" O -
linker O -
" O +
sequence O +
of O +
5'-GTTTCTT O +
was O +
added O +
to O +
the O +
5 O -
' O +
terminus O +
of O +
all O +
reverse O +
primers O +
[ O -
39 O -
] O -
. O +

LOH O +
was O +
defined O +
as O +
allelic O +
imbalance O +
> O -
2 O +
in O +
the O +
HNPCC O +
cases O +
( O -
non O -
- O -
sorted O -
) O +
and O +
allelic O +
imbalance O +
> O -
5 O +
in O +
the O +
sorted O +
RST O +
[ O -
40 O -
] O -
. O +

To O +
detect O +
frame O -
- O -
shift O +
mutations O +
in O +
the O +
HLA B-Gene -
- I-Gene -
A I-Gene -
, O +
HLA B-Gene -
- I-Gene -
B I-Gene -
, O +
β2 B-Gene -
m I-Gene -
, O +
LMP2 B-Gene -
, O +
LMP7 B-Gene -
, O +
LMP10 B-Gene -
, O +
TAP1 B-Gene -
, O +
TAP2 B-Gene -
, O +
Calnexin B-Gene -
, O +
Calreticulin B-Gene -
, O +
ERp57 B-Gene +
and O +
Tapasin B-Gene +
genes O -
, O +
28 O +
pairs O +
of O +
primers O +
( O -
Table O +
1 O -
) O +
were O +
constructed O +
surrounding O +
non O -
- O -
polymorphic O +
microsatellite O +
regions O +
within O +
the O +
coding O +
regions O -
. O +

Frameshift O +
mutation O +
screening O +
of O +
the O +
microsatellite O +
sequences O +
present O +
in O +
the O +
coding O +
regions O +
of O +
the O +
HLA B-Gene +
class I-Gene +
I I-Gene -
, O +
APM B-Gene +
components I-Gene +
and O +
β2 B-Gene -
m I-Gene +
genes O +
was O +
performed O +
on O +
all O +
cases O +
with O +
aberrant O +
HLA O +
class O +
I O +
expression O +
( O -
Figure O +
5B O -
, O -
C. O +
However O +
specific O +
genes O +
were O +
only O +
analyzed O +
when O +
lack O +
of O +
expression O +
of O +
the O +
encoded O +
proteins O +
was O +
detected O +
by O +
immunohistochemistry O -
. O +

Of O +
the O +
classical O +
HLA B-Gene +
class I-Gene +
I I-Gene +
genes O +
only O +
HLA B-Gene -
- I-Gene -
A I-Gene +
and O +
-B B-Gene +
were O +
analyzed O +
since O +
HLA B-Gene -
- I-Gene -
C I-Gene +
does O +
not O +
carry O +
any O +
microsatellite O +
repeat O +
in O +
its O +
coding O +
region O -
. O +

Ten O +
RST O +
cases O +
and O +
20 O +
HNPCC O +
control O +
cases O +
with O +
normal O +
expression O +
of O +
β2 B-Gene -
m I-Gene +
and O +
APM B-Gene +
components O +
were O +
screened O +
for O +
frameshift O +
mutations O +
and O +
none O +
was O +
detected O -
. O +

Frameshift O +
mutations O +
were O +
mainly O +
found O +
in O +
the O +
MSI O -
- O -
H O +
cases O +
( O -
both O +
sporadic O +
and O +
hereditary O +
forms O -
) O -
. O +

At O +
least O +
one O +
mutation O +
in O +
an O +
APM B-Gene +
component I-Gene +
gene O +
was O +
found O +
in O +
6 O +
of O +
7 O +
sporadic O +
MSI O -
- O -
H O +
tumors O +
that O +
lost O +
expression O +
of O +
one O +
or O +
more O +
APM O +
components O -
. O +

The O +
single O +
sporadic O +
MSI O -
- O -
H O +
case O +
that O +
lost O +
β2 O -
m O +
expression O +
also O +
presented O +
with O +
a O +
single O +
frameshift O +
mutation O +
in O +
the O +
β2 B-Gene -
m I-Gene +
gene O -
. O +

Of O +
the O +
13 O +
sporadic O +
MSI O -
- O -
H O +
cases O +
in O +
which O +
loss O +
of O +
HLA O +
class O +
I O +
expression O +
was O +
associated O +
neither O +
with O +
APM B-Gene +
component I-Gene +
nor O +
with O +
β2 B-Gene -
m I-Gene +
loss O +
as O +
detected O +
by O +
immunohistochemical O +
staining O -
, O +
one O +
presented O +
with O +
a O +
frameshift O +
in O +
an O +
HLA B-Gene +
gene O +
( O -
case O +
39 O -
, O +
Figure O +
3 O -
, O +
Table O +
3 O -
) O +
while O +
3 O +
other O +
cases O +
showed O +
LOH O +
of O +
the O +
markers O +
adjacent O +
the O +
HLA B-Gene +
genes O +
( O -
cases O +
7 O -
, O +
44 O +
and O +
67 O -
) O -
. O +

One O +
frameshift O +
mutation O +
was O +
found O +
in O +
the O +
Tapasin B-Gene +
gene O +
in O +
a O +
MSS O +
case O +
( O -
case O +
62 O -
) O -
. O +

From O +
15 O +
HNPCC O +
tumors O +
that O +
lost O +
β2 B-Gene -
m I-Gene +
expression O +
at O +
least O +
one O +
mutation O +
was O +
found O +
in O +
8 O +
cases O +
( O -
Figure O +
4 O -
) O -
. O +

Three O +
of O +
the O +
latter O +
showed O +
2 O +
mutations O +
localized O +
in O +
different O +
stretches O -
. O +

In O +
the O +
remaining O +
17 O +
HNPCC O +
cases O +
that O +
solely O +
lost O +
HLA O +
class O +
I O +
expression O -
, O +
only O +
4 O +
showed O +
genetic O +
abnormalities O -
. O +

LOH O +
was O +
found O +
in O +
the O +
HLA B-Gene +
region O +
in O +
cases O +
h16 O -
, O +
h56 O +
and O +
h120 O +
( O -
data O +
not O +
shown O -
) O -
. O +

A O +
frameshift O +
mutation O +
in O +
one O +
of O +
the O +
HLA B-Gene +
genes O +
( O -
HLA B-Gene +
B I-Gene -
) O +
was O +
found O +
in O +
one O +
case O +
( O -
h99 O -
, O +
Figure O +
4 O -
) O -
. O +

In O +
neither O +
of O +
the O +
2 O +
HNPCC O +
cases O +
that O +
immunohistochemically O +
lost O +
the O +
expression O +
of O +
one O +
of O +
the O +
APM B-Gene +
components O +
an O +
APM B-Gene +
frameshift O +
mutation O +
was O +
found O -
. O +

The O +
reason O +
sporadic O +
MSI O -
- O -
H O +
tumors O +
would O +
target O +
APM B-Gene +
members O +
for O +
inactivation O +
and O +
HNPCC O +
would O +
target O +
the O +
β2 B-Gene -
m I-Gene +
chaperon O +
is O +
unclear O -
. O +

One O +
possibility O +
worth O +
further O +
exploration O +
is O +
that O +
the O +
various O +
mutations O +
suggest O +
different O +
immune O -
- O -
escape O +
mechanisms O +
for O +
thwarting O +
distinct O +
anti O -
- O -
tumor O +
responses O -
. O +

HNPCC O +
tumors O +
can O +
have O +
an O +
age O +
of O +
onset O +
before O +
the O +
5th O +
decade O +
of O +
life O +
while O +
sporadic O +
MSI O -
- O -
H O +
tumors O +
appear O +
generally O +
around O +
the O +
7th O +
decade O +
of O +
life O +
[ O -
43 O -
] O -
; O +
one O +
would O +
therefore O +
predict O +
that O +
the O +
alertness O +
and O +
robustness O +
of O +
the O +
immune O +
system O +
would O +
be O +
higher O +
in O +
HNPCC O +
patients O +
leading O +
to O +
a O +
stronger O -
, O +
or O +
at O +
least O +
different O +
selective O +
pressure O +
on O +
the O +
latter O -
. O +

Furthermore O +
it O +
has O +
been O +
recently O +
suggested O +
that O +
the O +
JC O +
polyoma O +
virus O +
plays O +
a O +
role O +
in O +
the O +
oncogenicity O +
of O +
colon O +
tumors O +
with O +
an O +
identical O +
phenotype O +
to O +
sporadic O +
MSI O -
- O -
H O +
tumors O +
[ O -
44 O -
] O -
. O +

Although O +
speculative O -
, O +
the O +
presence O +
of O +
the O +
JC O +
virus O +
might O +
be O +
implicated O +
in O +
a O +
different O +
immune O +
response O +
between O +
sporadic O +
MSI O -
- O -
H O +
and O +
HNPCC O +
tumors O -
. O +

The O +
advantages O +
of O +
different O +
escape O +
mechanisms O +
( O -
loss O +
of O +
APM O +
members O +
vs. O +
abrogation O +
of O +
β2 B-Gene -
m I-Gene -
) O +
are O +
not O +
understood O -
. O +

The O +
only O +
known O +
function O +
of O +
APM B-Gene +
members O +
is O +
facilitating O +
the O +
expression O +
of O +
HLA B-Gene +
classical O +
molecules O +
in O +
complex O +
with O +
endogenous O +
peptides O -
. O +

Thus O -
, O +
one O +
would O +
expect O +
that O +
only O +
these O +
HLA B-Gene +
molecules O +
would O +
be O +
affected O +
by O +
failure O +
of O +
the O +
antigen O +
processing O +
machinery O -
. O +

On O +
the O +
other O +
hand O -
, O +
it O +
is O +
accepted O +
that O +
cell O +
surface O +
expression O +
of O +
non O -
- O -
classical O +
HLA B-Gene +
molecules O +
( O -
e.g. O +
HLA B-Gene +
-G I-Gene -
, O +
-E O -
) O +
also O +
depends O +
on O +
β2 B-Gene -
m I-Gene -
, O +
so O +
the O +
function O +
of O +
these O +
highly O +
specialized O +
molecules O +
would O +
be O +
compromised O +
if O +
β2 B-Gene -
m I-Gene +
were O +
mutated O +
or O +
lost O -
. O +

These O +
molecules O +
might O +
play O +
an O +
important O +
role O +
in O +
regulation O +
of O +
immune O +
cell O +
activity O +
by O +
inhibiting O +
or O +
activating O +
its O +
function O -
. O +

Therefore O -
, O +
MSI O -
- O -
H O +
sporadic O +
tumors O +
that O +
have O +
lost O +
expression O +
of O +
both O +
HLA B-Gene +
and O +
an O +
APM O +
component O +
and O +
HNPCC O +
tumors O +
with O +
lost O +
β2 B-Gene -
m I-Gene +
expression O +
might O +
behave O +
differently O +
or O +
present O +
a O +
different O +
kind O +
of O +
interaction O +
with O +
cells O +
from O +
the O +
immune O +
system O -
. O +

For O +
instance O -
, O +
Yamamoto O +
et O +
al. O +
have O +
described O +
a O +
correlation O +
between O +
β2 B-Gene -
m I-Gene +
mutations O +
and O +
unfavorable O +
prognosis O +
in O +
colorectal O +
cancer O +
[ O -
45 O -
] O -
. O +

We O +
separately O +
analyzed O +
the O +
presence O +
of O +
the O +
characteristic O +
BRAF B-Gene +
V600E O +
somatic O +
mutations O +
in O +
the O +
RST O +
cohort O +
( O -
data O +
not O +
shown O -
) O -
. O +

Forty O -
- O -
percent O +
of O +
MSI O -
- O -
H O +
sporadic O +
tumors O +
presented O +
with O +
this O +
mutation O +
which O +
was O +
absent O +
in O +
the O +
MSS O +
tumors O -
. O +

It O +
was O +
previously O +
described O +
that O +
this O +
mutation O +
is O +
also O +
absent O +
in O +
HNPCC O +
tumors O +
[ O -
46 O -
] O -
. O +

V600E O +
was O +
distributed O +
equally O +
between O +
tumors O +
that O +
lost O +
vs. O +
retained O +
expression O +
of O +
HLA B-Gene +
class I-Gene +
I I-Gene +
in O +
the O +
sporadic O +
MSI O -
- O -
H O +
cases O -
. O +

Conclusion O +
HLA O +
class O +
I O +
aberrations O +
are O +
found O +
at O +
varying O +
frequencies O +
in O +
different O +
colorectal O +
tumor O +
types O +
and O +
are O +
caused O +
by O +
distinct O +
genetic O +
mechanisms O -
. O +

Chiefly O -
, O +
sporadic O +
and O +
hereditary O +
MSI O -
- O -
H O +
tumors O +
follow O +
different O +
routes O +
toward O +
HLA O +
class O +
I O +
loss O +
of O +
expression O +
supporting O +
the O +
idea O +
that O +
these O +
tumors O +
follow O +
different O +
evolutionary O +
pathways O +
in O +
tumorigenesis O -
. O +

The O +
resulting O +
variation O +
in O +
immune O +
escape O +
mechanisms O +
may O +
have O +
repercussions O +
in O +
tumor O +
progression O +
and O +
behavior O -
. O +

Introduction O +
Although O +
dietary O +
fat O +
has O +
been O +
implicated O +
in O +
the O +
etiology O +
of O +
colorectal O +
cancer O +
[ O -
1 O -
] O -
, O +
results O +
from O +
epidemiological O +
studies O +
are O +
inconsistent O +
[ O -
2 O -
, O +
3 O -
] O +
and O +
often O +
do O +
not O +
support O +
an O +
association O -
, O +
as O +
observed O +
recently O +
in O +
the O +
Women O -
's O +
Health O +
Study O +
[ O -
4 O -
] O -
. O +

Fortunately O -
, O +
current O +
molecular O +
techniques O +
to O +
detect O +
DNA O +
alterations O +
on O +
a O +
large O +
scale O +
allow O +
studying O +
molecular O +
endpoints O +
for O +
colorectal O +
cancer O -
, O +
characterized O +
by O +
acquired O +
( O -
epi O -
) O +
genetic O +
defects O +
in O +
tumor O +
DNA O +
[ O -
5 O -
] O -
. O +

This O +
approach O +
may O +
improve O +
our O +
ability O +
to O +
observe O +
associations O +
between O +
dietary O +
factors O +
and O +
cancer O +
that O +
may O +
otherwise O +
remain O +
undetected O -
. O +

A O +
multistep O +
model O +
linking O +
sporadic O +
colorectal O +
carcinogenesis O +
to O +
molecular O +
aberrations O +
has O +
been O +
proposed O +
[ O -
6–8 O -
] O -
, O +
with O +
DNA O +
repair O +
genes O -
, O +
tumor O +
suppressor O +
genes O +
and O +
oncogenes O -
, O +
operating O +
in O +
multiple O +
genetic O +
pathways O -
. O +

About O +
10–20 O -
% O +
of O +
sporadic O +
colon O +
carcinomas O +
are O +
characterized O +
by O +
microsatellite O +
instability O -
, O +
predominantly O +
due O +
to O +
promoter O +
methylation O +
of O +
the O +
MLH1 B-Gene +
( O -
mutL B-Gene +
homolog I-Gene +
1 I-Gene -
, O +
colon O +
cancer O -
, O +
nonpolyposis O +
type O +
2 O -
) O +
DNA O +
mismatch O +
repair O +
gene O -
, O +
which O +
prevents O +
expression O +
of O +
the O +
enzyme O +
[ O -
9 O -
] O -
. O +

Up O +
to O +
90 O -
% O +
of O +
colon O +
and O +
rectum O +
carcinomas O +
are O +
chromosomally O +
instable O +
[ O -
10 O -
, O +
11 O -
] O +
and O +
are O +
associated O +
with O +
mutations O +
in O +
the O +
APC B-Gene +
( O -
adenomatous B-Gene +
polyposis I-Gene +
coli I-Gene -
) O +
and O +
TP53 B-Gene +
( O -
tumor B-Gene +
protein I-Gene +
53 I-Gene -
) O +
tumor O +
suppressor O +
genes O +
and O +
in O +
the O +
KRAS B-Gene +
( O -
v B-Gene -
- I-Gene -
Ki I-Gene -
- I-Gene -
ras2 I-Gene +
Kirsten I-Gene +
rat I-Gene +
sarcoma I-Gene +
viral I-Gene +
oncogene I-Gene +
homolog I-Gene -
) O +
oncogene O +
[ O -
12 O -
] O -
. O +

However O -
, O +
simultaneous O +
occurrence O +
of O +
mutations O +
in O +
these O +
three O +
genes O +
is O +
rare O +
suggesting O +
that O -
, O +
even O +
within O +
this O +
group O +
of O +
chromosomally O +
instable O +
tumors O -
, O +
different O +
genetic O +
pathways O +
to O +
colorectal O +
cancer O +
exist O +
[ O -
13 O -
, O +
14 O -
] O -
. O +

Mutations O +
in O +
the O +
APC B-Gene +
gene O +
are O +
found O +
to O +
occur O +
relatively O +
early O +
in O +
colorectal O +
tumorigenesis O +
and O +
are O +
observed O +
in O +
up O +
to O +
80 O -
% O +
of O +
both O +
adenomas O +
and O +
carcinomas O +
[ O -
8 O -
, O +
15 O -
] O -
. O +

Mutations O +
in O +
the O +
KRAS B-Gene +
gene O +
are O +
observed O +
in O +
approximately O +
10–20 O -
% O +
of O +
small O +
adenomas O +
and O +
40–50 O -
% O +
of O +
larger O +
adenomas O +
and O +
carcinomas O -
, O +
suggesting O +
it O +
to O +
be O +
an O +
important O +
event O +
in O +
the O +
progression O +
of O +
adenoma O +
to O +
carcinoma O +
[ O -
15 O -
] O -
. O +

Mutations O +
in O +
the O +
TP53 B-Gene +
gene O +
are O +
postulated O +
to O +
affect O +
relatively O +
late O +
stages O +
of O +
colorectal O +
carcinogenesis O +
[ O -
15 O -
] O -
. O +

Breivik O +
et O +
al. O +
proposed O +
that O +
the O +
type O +
of O +
genetic O +
instability O +
in O +
cancer O +
cells O +
reflects O +
the O +
selection O +
pressures O +
exerted O +
by O +
specific O +
carcinogens O +
[ O -
16 O -
] O -
. O +

Bardelli O +
et O +
al. O +
subsequently O +
tested O +
this O +
hypothesis O +
in O +
immortal O +
genetically O +
stable O +
human O +
cells O +
and O +
concluded O +
that O +
exposure O +
to O +
specific O +
carcinogens O +
can O +
indeed O +
select O +
for O +
tumor O +
cells O +
with O +
distinct O +
forms O +
of O +
genetic O +
instability O +
and O +
vice O +
versa O +
[ O -
17 O -
] O -
. O +

Therefore O -
, O +
DNA O +
adducts O +
derived O +
from O +
dietary O +
fat O +
metabolism O +
could O +
also O +
be O +
associated O +
with O +
colorectal O +
tumors O +
exhibiting O +
chromosomal O +
instability O -
. O +

This O +
is O +
supported O +
by O +
the O +
observations O +
that O +
malondialdehyde O +
( O -
MDA O -
) O -
, O +
generated O +
during O +
lipid O +
peroxidation O +
and O +
arachidonic O +
acid O +
metabolism O -
, O +
can O +
form O +
DNA O +
adducts O +
and O +
induce O +
G→T O +
transversions O +
and O +
G→A O +
transitions O +
in O +
DNA O +
[ O -
18 O -
, O +
19 O -
] O -
. O +

In O +
addition O -
, O +
higher O +
levels O +
of O +
MDA O -
- O -
DNA O +
adducts O +
have O +
been O +
observed O +
in O +
colorectal O +
tissue O +
of O +
adenoma O +
patients O +
than O +
in O +
tissue O +
of O +
controls O +
[ O -
20 O -
] O -
. O +

MDA O +
levels O +
are O +
modulated O +
by O +
dietary O +
factors O -
, O +
with O +
polyunsaturated O +
fatty O +
acids O -
, O +
and O +
specifically O +
ω-6 O +
polyunsaturated O +
fatty O +
acids O -
, O +
presumably O +
increasing O +
MDA O +
levels O +
[ O -
21 O -
] O -
. O +

This O +
is O +
in O +
line O +
with O +
our O +
previous O +
report O +
of O +
a O +
significant O +
association O +
between O +
the O +
intake O +
of O +
linoleic O +
acid O -
, O +
the O +
most O +
abundant O +
ω-6 O +
polyunsaturated O +
fatty O +
acid O +
in O +
the O +
diet O -
, O +
and O +
increased O +
risk O +
of O +
colon O +
carcinomas O +
with O +
a O +
mutated O +
KRAS B-Gene +
gene O +
within O +
the O +
Netherlands O +
Cohort O +
Study O +
( O -
NLCS O -
) O +
on O +
diet O +
and O +
cancer O +
[ O -
22 O -
] O -
. O +

Tissue O +
samples O +
Approval O +
for O +
collection O +
of O +
archival O +
tissue O +
samples O +
from O +
colorectal O +
cancer O +
patients O +
was O +
obtained O +
from O +
the O +
Ethical O +
Review O +
Board O +
of O +
University O +
Maastricht O -
, O +
the O +
NCR O +
and O +
PALGA O -
. O +

The O +
tissue O +
specimen O +
collection O +
started O +
in O +
August O +
1999 O +
and O +
was O +
completed O +
in O +
December O +
of O +
2001 O -
. O +

For O +
five O +
percent O +
of O +
patients O -
, O +
tissue O +
samples O +
could O +
not O +
be O +
retrieved O +
( O -
44 O -
/ O -
819 O -
) O +
due O +
to O +
administrative O +
inconsistencies O -
. O +

Of O +
775 O +
available O +
tissue O +
samples O -
, O +
737 O +
( O -
95 O -
% O -
) O +
contained O +
sufficient O +
tumor O +
material O +
for O +
molecular O +
analyses O +
of O +
MLH1 B-Gene +
expression O +
and O +
mutations O +
in O +
APC B-Gene +
and O +
KRAS B-Gene +
genes O -
. O +

Since O +
the O +
rectosigmoid O +
can O +
be O +
considered O +
as O +
a O +
clinically O +
applied O +
term O +
rather O +
than O +
an O +
anatomically O +
defined O +
transitional O +
zone O +
between O +
the O +
colon O +
and O +
rectum O -
, O +
the O +
85 O +
patients O +
with O +
a O +
rectosigmoid O +
tumor O +
were O +
excluded O +
from O +
data O +
analysis O -
. O +

Moreover O -
, O +
the O +
group O +
of O +
patients O +
with O +
a O +
rectosigmoid O +
tumor O +
was O +
too O +
small O +
for O +
adequate O +
stratified O +
analysis O -
. O +

MLH1 B-Gene +
expression O +
analysis O +
Formalin O -
- O -
fixed O -
, O +
paraffin O -
- O -
embedded O +
tissues O +
were O +
sectioned O +
at O +
4 O +
μm O +
and O +
contained O +
tumor O +
tissue O +
and O +
normal O +
adjacent O +
mucosa O -
. O +

Endogeneous O +
peroxidase O +
activity O +
was O +
blocked O +
with O +
3 O -
% O +
H2O2 O -
. O +

Slides O +
were O +
submitted O +
to O +
microwave O +
antigen O +
retrieval O +
in O +
1mM O +
EDTA O +
buffer O +
( O -
pH O +
8.0 O -
) O +
and O +
incubated O +
with O +
10 O -
% O +
normal O +
horse O +
serum O +
for O +
10 O +
min O +
at O +
room O +
temperature O -
. O +

Then O -
, O +
sections O +
were O +
incubated O +
overnight O +
at O +
4 O -
° O -
C O +
with O +
mouse O +
monoclonal O +
antibodies O +
against O +
MLH1 B-Gene +
protein O +
( O -
clone O +
G168–15 O -
, O +
PharMingen O -
, O +
San O +
Diego O -
, O +
CA O -
) O +
at O +
a O +
1:100 O +
dilution O -
. O +

Antibody O +
binding O +
was O +
detected O +
by O +
incubating O +
the O +
sections O +
at O +
room O +
temperature O +
with O +
the O +
peroxidase O -
- O -
labeled O +
DAKO O +
Envision O +
System O +
( O -
DAKO O -
, O +
Carpinteris O -
, O +
CA O -
) O +
and O +
using O +
DAB O +
as O +
a O +
chromogen O -
. O +

Sections O +
were O +
counterstained O +
with O +
haematoxylin O -
. O +

Lesions O +
were O +
considered O +
to O +
lack O +
MLH1 B-Gene +
protein O +
expression O +
when O +
unequivocal O +
absence O +
of O +
nuclear O +
staining O +
of O +
the O +
tumor O +
epithelial O +
cells O +
was O +
observed O -
. O +

Nuclear O +
staining O +
of O +
normal O +
epithelial O +
and O +
stromal O +
cells O +
or O +
lymphocytes O +
served O +
as O +
internal O +
positive O +
control O -
. O +

Two O +
investigators O +
reviewed O +
the O +
immunohistochemical O +
staining O +
independently O +
and O +
discrepancies O +
were O +
re O -
- O -
examined O +
and O +
discussed O +
with O +
a O +
pathologist O +
until O +
consensus O +
was O +
reached O -
. O +

MLH1 B-Gene +
expression O +
status O +
was O +
determined O +
successfully O +
in O +
98 O -
% O +
of O +
samples O -
, O +
i.e. O -
, O +
468 O +
colon O +
tumors O +
and O +
173 O +
rectum O +
tumors O +
( O -
Fig. O +
1 O -
) O -
. O +

APC B-Gene +
mutation O +
analysis O +
The O +
majority O +
of O +
somatic O +
mutations O +
in O +
APC B-Gene +
occur O +
within O +
the O +
mutation O +
cluster O +
region O -
. O +

Mutation O +
analysis O +
of O +
the O +
mutation O +
cluster O +
region O +
( O -
codons O +
1,286–1,520 O -
) O -
, O +
was O +
performed O +
on O +
archival O +
adenocarcinoma O +
specimens O -
, O +
using O +
macrodissection O +
followed O +
by O +
extraction O +
of O +
tumor O +
DNA O -
. O +

Then O +
nested O +
PCR O +
was O +
used O +
to O +
amplify O +
the O +
mutation O +
cluster O +
region O +
in O +
four O +
overlapping O +
DNA O +
fragments O +
and O +
the O +
purified O +
fragments O +
were O +
sequenced O -
. O +

This O +
procedure O +
has O +
been O +
described O +
in O +
detail O +
elsewhere O +
[ O -
25 O -
] O -
. O +

In O +
brief O -
, O +
in O +
a O +
first O +
round O +
of O +
PCR O -
, O +
two O +
overlapping O +
fragments O +
were O +
generated O -
, O +
that O +
served O +
as O +
templates O +
for O +
a O +
second O +
round O +
of O +
PCR O +
to O +
amplify O +
four O +
overlapping O +
biotin O -
- O -
labeled O +
PCR O +
fragments O +
that O +
were O +
subsequently O +
used O +
for O +
direct O +
sequencing O -
. O +

The O +
sequence O +
profile O +
was O +
analyzed O +
on O +
ALFexpress O +
DNA O +
Analysis O +
System O +
using O +
ALFwin O +
software O +
( O -
Amersham O +
Biosciences O -
, O +
Roosendaal O -
, O +
The O +
Netherlands O -
) O -
. O +

Evaluation O +
of O +
the O +
sequence O +
patterns O +
and O +
data O +
entry O +
were O +
independently O +
performed O +
by O +
two O +
observers O -
. O +

Sensitivity O +
and O +
specificity O +
was O +
assessed O +
by O +
analyzing O +
the O +
mutational O +
status O +
of O +
APC B-Gene +
in O +
six O +
colorectal O +
cancer O +
cell O +
lines O -
. O +

Both O +
sensitivity O +
and O +
specificity O +
were O +
regarded O +
to O +
be O +
satisfactory O +
since O +
specific O +
mutations O +
in O +
the O +
mutation O +
cluster O +
region O +
of O +
APC B-Gene +
were O +
confirmed O +
in O +
CaCo2 O +
cells O -
, O +
SW480 O +
cells O +
and O +
LOVO O +
cells O -
, O +
as O +
previously O +
described O +
[ O -
25 O -
, O +
26 O -
] O -
, O +
and O +
wild O +
type O +
sequences O +
were O +
confirmed O +
in O +
HCT116 O -
, O +
Colo205 O +
and O +
HT29 O -
, O +
for O +
the O +
mutation O +
cluster O +
region O +
of O +
APC B-Gene +
[ O -
25 O -
] O -
. O +

In O +
addition O -
, O +
the O +
detection O +
limit O +
was O +
5 O -
% O +
of O +
mutated O +
DNA O +
[ O -
25 O -
] O -
. O +

Reproducibility O +
of O +
mutation O +
analysis O +
was O +
regarded O +
to O +
be O +
satisfactory O +
since O +
85 O -
% O +
of O +
duplicate O +
analyses O -
, O +
from O +
flank O +
PCR O +
of O +
genomic O +
DNA O +
to O +
sequencing O +
of O +
the O +
four O +
fragments O +
( O -
i.e. O -
, O +
61 O +
out O +
of O +
72 O +
fragments O -
) O -
, O +
revealed O +
identical O +
mutation O +
status O +
of O +
APC B-Gene +
[ O -
25 O -
] O -
. O +

From O +
47 O +
colon O +
cancer O +
patients O +
and O +
25 O +
rectum O +
cancer O +
patients O -
, O +
one O +
or O +
more O +
fragments O +
of O +
the O +
APC B-Gene +
gene O +
mutation O +
cluster O +
region O +
could O +
not O +
be O +
amplified O +
and O +
these O +
patients O +
were O +
not O +
included O +
in O +
this O +
study O -
, O +
leaving O +
429 O +
colon O +
and O +
151 O +
rectum O +
cancer O +
cases O +
with O +
successful O +
analysis O +
of O +
the O +
mutation O +
cluster O +
region O +
of O +
the O +
APC B-Gene +
gene O +
( O -
Fig. O +
1 O -
) O -
. O +

KRAS B-Gene +
mutation O +
analysis O +
Mutation O +
analysis O +
of O +
the O +
exon1 O +
fragment O +
of O +
the O +
KRAS B-Gene +
oncogene O -
, O +
spanning O +
codons O +
8–29 O -
, O +
was O +
performed O +
on O +
archival O +
adenocarcinoma O +
specimens O -
, O +
using O +
nested O +
PCR O -
, O +
followed O +
by O +
direct O +
sequencing O +
of O +
purified O +
fragments O +
[ O -
27 O -
] O -
. O +

The O +
detection O +
limit O +
was O +
5 O -
% O +
mutated O +
DNA O -
. O +

Reproducibility O +
was O +
regarded O +
to O +
be O +
satisfactory O -
, O +
since O +
88 O -
% O +
of O +
duplicate O +
analyses O -
, O +
from O +
tissue O +
sectioning O +
to O +
DNA O +
sequencing O +
( O -
i.e. O -
, O +
28 O +
out O +
of O +
32 O -
) O -
, O +
revealed O +
identical O +
mutation O +
status O +
of O +
KRAS B-Gene +
[ O -
27 O -
] O -
. O +

Mutation O +
analysis O +
was O +
performed O +
with O +
success O +
on O +
476 O +
colon O +
and O +
176 O +
rectum O +
cancer O +
cases O +
( O -
Fig. O +
1 O -
) O -
. O +

Exposure O +
assessment O +

The O +
150–item O +
semi O -
- O -
quantitative O +
food O +
frequency O +
questionnaire O +
concentrated O +
on O +
habitual O +
consumption O +
of O +
food O +
and O +
beverages O +
during O +
the O +
year O +
preceding O +
the O +
start O +
of O +
the O +
study O -
. O +

Mean O +
individual O +
nutrient O +
intakes O +
per O +
day O +
were O +
computed O +
using O +
the O +
computerized O +
Dutch O +
food O +
composition O +
table O +
of O +
1986 O +
[ O -
28 O -
] O -
. O +

The O +
questionnaire O +
was O +
validated O +
against O +
a O +
9-day O +
diet O +
record O +
[ O -
29 O -
] O -
. O +

Crude O +
and O +
energy O -
- O -
gender O -
- O -
adjusted O +
( O -
in O +
parentheses O -
) O +
correlation O +
coefficients O +
were O +
0.72 O +
( O -
0.52 O -
) O +
for O +
total O +
fat O -
, O +
0.73 O +
( O -
0.58 O -
) O +
for O +
saturated O +
fat O +
and O +
0.73 O +
( O -
0.75 O -
) O +
for O +
polyunsaturated O +
fat O +
[ O -
29 O -
] O -
. O +

For O +
energy O +
intake O +
the O +
correlation O +
coefficient O +
was O +
0.74 O -
. O +

On O +
average O -
, O +
the O +
questionnaire O +
covered O +
91 O -
% O +
of O +
the O +
energy O +
intake O +
assessed O +
by O +
the O +
record O +
intake O -
. O +

Questionnaire O +
data O +
were O +
key O -
- O -
entered O +
twice O +
and O +
processed O +
for O +
all O +
incident O +
cases O +
in O +
the O +
cohort O +
and O +
for O +
all O +
subcohort O +
members O +
in O +
a O +
manner O +
blinded O +
with O +
respect O +
to O +
case O -
/ O -
subcohort O +
status O -
. O +

For O +
7 O -
% O +
of O +
subjects O +
( O -
either O +
cases O +
or O +
subcohort O +
members O -
) O -
, O +
dietary O +
data O +
were O +
incomplete O +
or O +
inconsistent O -
, O +
and O +
they O +
were O +
excluded O +
from O +
the O +
analyses O -
. O +

Questionnaires O +
were O +
considered O +
incomplete O +
when O +
either O -
: O +
( O -
1 O -
) O +
more O +
than O +
60 O +
items O +
were O +
left O +
blank O +
and O +
less O +
than O +
35 O +
items O +
were O +
eaten O +
at O +
least O +
once O +
a O +
month O -
; O +
or O +
( O -
2 O -
) O +
one O +
or O +
more O +
item O +
blocks O +
( O -
groups O +
of O +
items O -
, O +
e.g. O -
, O +
beverages O -
) O +
were O +
left O +
blank O -
. O +

Additional O +
details O +
are O +
given O +
elsewhere O +
[ O -
29 O -
] O -
. O +

This O +
resulted O +
in O +
the O +
availability O +
of O +
3,048 O +
subcohort O +
members O -
, O +
441 O +
colon O +
cancer O +
cases O +
for O +
whom O +
MLH1 B-Gene +
expression O +
status O +
was O +
known O -
, O +
and O +
414 O +
colon O +
and O +
136 O +
rectal O +
cancer O +
cases O +
for O +
whom O +
APC B-Gene +
and O +
KRAS B-Gene +
mutation O +
status O +
was O +
known O -
. O +

No O +
data O -
- O -
analyses O +
were O +
conducted O +
for O +
lack O +
of O +
MLH1 B-Gene +
expression O +
in O +
rectal O +
cancer O +
cases O +
since O +
there O +
were O +
only O +
two O +
such O +
cases O +
in O +
the O +
cohort O +
( O -
Fig. O +
1 O -
) O -
. O +

Intake O +
of O +
specific O +
fatty O +
acids O +
was O +
based O +
on O +
a O +
food O +
composition O +
database O +
with O +
specific O +
fatty O +
acids O +
derived O +
from O +
the O +
TRANSFAIR O +
study O +
[ O -
30 O -
] O -
. O +

For O +
this O +
database O -
, O +
the O +
hundred O +
foods O +
that O +
contributed O +
most O +
to O +
fat O +
intake O +
in O +
the O +
Dutch O +
dietary O +
pattern O +
were O +
sampled O +
and O +
analyzed O +
as O +
methyl O +
esters O +
of O +
the O +
fatty O +
acids O +
present O +
in O +
the O +
foods O -
. O +

In O +
the O +
database O -
, O +
total O +
fat O +
includes O +
triglycerides O +
and O +
other O +
lipids O +
such O +
as O +
phospholipids O +
and O +
sterols O -
. O +

The O +
percentage O +
of O +
triglycerides O +
in O +
total O +
fat O +
is O +
assumed O +
to O +
be O +
93 O -
% O +
on O +
average O -
, O +
but O +
varies O +
across O +
food O +
sources O -
. O +

Daily O +
intakes O +
of O +
total O +
fat O +
( O -
g O -
/ O -
day O -
) O -
, O +
saturated O +
fat O +
( O -
g O -
/ O -
day O -
) O -
, O +
monounsaturated O +
fat O +
( O -
g O -
/ O -
day O -
) O -
, O +
polyunsaturated O +
fat O +
( O -
g O -
/ O -
day O -
) O -
, O +
and O +
linoleic O +
acid O +
( O -
C18:2 O -
, O +
C9 O -
, O +
12 O -
) O +
( O -
g O -
/ O -
day O -
) O +
and O +
linolenic O +
acid O +
( O -
C18:3 O -
, O +
C9 O -
, O +
12 O -
, O +
15 O -
) O +
( O -
g O -
/ O -
day O -
) O +
as O +
the O +
main O +
constituents O +
of O +
polyunsaturated O +
fat O -
, O +
were O +
used O +
as O +
exposure O +
variables O -
. O +

Linoleic O +
and O +
linolenic O +
acid O +
were O +
used O +
as O +
the O +
most O +
abundant O +
sources O +
of O +
ω-6 O +
polyunsaturated O +
fatty O +
acids O +
and O +
ω-3 O +
polyunsaturated O +
fatty O +
acids O +
in O +
the O +
diet O -
. O +

In O +
all O +
analyses O -
, O +
the O +
values O +
for O +
fat O +
intake O +
variables O +
are O +
adjusted O +
for O +
energy O +
intake O +
by O +
the O +
residual O +
method O +
[ O -
31 O -
] O -
. O +

For O +
data O +
analyses O -
, O +
quartiles O +
of O +
the O +
intake O +
of O +
fat O +
and O +
different O +
types O +
of O +
fats O +
were O +
computed O +
based O +
on O +
the O +
distribution O +
of O +
subcohort O +
members O -
. O +

Daily O +
intake O +
of O +
dietary O +
fiber O +
( O -
g O -
/ O -
day O -
) O -
, O +
alcohol O +
( O -
g O -
/ O -
day O -
) O -
, O +
fruit O +
( O -
g O -
/ O -
day O -
) O -
, O +
vegetables O +
( O -
g O -
/ O -
day O -
) O +
and O +
total O +
energy O +
( O -
kJ O -
/ O -
day O -
) O +
and O +
age O +
at O +
baseline O +
( O -
years O -
) O -
, O +
sex O +
( O -
men O -
/ O -
women O -
) O -
, O +
body O +
mass O +
index O +
( O -
kg O -
/ O -
m2 O -
) O -
, O +
non O -
- O -
occupational O +
physical O +
activity O +
( O -
< O -
30 O +
min O -
/ O -
day O -
, O +
30–60 O +
min O -
/ O -
day O -
, O +
60–90 O +
min O -
/ O -
day O -
, O +
> O -
90 O +
min O -
/ O -
day O -
) O -
, O +
family O +
history O +
of O +
colorectal O +
cancer O +
( O -
yes O -
/ O -
no O -
) O +
and O +
smoking O +
status O +
( O -
never O -
/ O -
ex O -
/ O -
current O -
) O +
were O +
regarded O +
as O +
potential O +
confounders O -
. O +

Statistical O +
analysis O +
Data O +
analyses O +
were O +
based O +
on O +
study O +
participants O +
for O +
whom O +
data O +
on O +
fat O +
intake O +
and O +
confounding O +
variables O +
were O +
complete O -
, O +
i.e. O -
, O +
2,948 O +
subcohort O +
members O -
, O +
428 O +
colon O +
cancer O +
patients O +
for O +
whom O +
MLH1 B-Gene +
expression O +
status O +
was O +
known O -
, O +
and O +
401 O +
colon O +
cancer O +
and O +
130 O +
rectal O +
cancer O +
patients O +
for O +
whom O +
APC B-Gene +
and O +
KRAS B-Gene +
mutation O +
status O +
was O +
known O +
( O -
Fig. O +
1 O -
) O -
. O +

Data O +
analyses O +
were O +
conducted O +
separately O +
for O +
overall O +
colon O +
and O +
rectal O +
cancer O -
, O +
colon O +
cancer O +
lacking O +
MLH1 B-Gene +
expression O -
, O +
colon O +
and O +
rectal O +
cancer O +
with O +
or O +
without O +
a O +
truncating O +
APC B-Gene +
mutation O -
, O +
described O +
here O +
as O +
APC+ B-Gene +
and O +
APC− B-Gene +
tumors O +
respectively O -
. O +

Truncating O +
APC B-Gene +
mutations O +
lead O +
to O +
the O +
introduction O +
of O +
a O +
stop O +
codon O +
and O +
result O +
in O +
a O +
truncated O +
and O +
therefore O -
, O +
inactive O +
APC B-Gene +
protein O -
. O +

The O +
analyses O +
with O +
truncating O +
APC B-Gene +
mutations O +
were O +
also O +
conducted O +
separately O +
for O +
the O +
most O +
common O +
point O +
mutations O +
resulting O +
in O +
the O +
introduction O +
of O +
a O +
stop O +
codon O -
, O +
i.e. O -
, O +
C O -
: O -
G O +
→ O +
T O -
: O -
A O +
or O +
G O -
: O -
C O +
→ O +
T O -
: O -
A O +
point O +
mutations O -
. O +

As O +
indicated O +
previously O -
, O +
associations O +
between O +
fat O +
intake O +
and O +
KRAS B-Gene +
mutated O +
tumors O +
have O +
been O +
described O +
in O +
this O +
population O +
previously O -
, O +
and O +
a O +
positive O +
association O +
between O +
the O +
intake O +
of O +
linoleic O +
acid O +
and O +
KRAS B-Gene +
mutated O +
colon O +
tumors O +
was O +
observed O +
[ O -
22 O -
] O -
. O +

Therefore O -
, O +
when O +
( O -
borderline O -
) O +
significant O +
associations O +
were O +
observed O +
with O +
any O +
of O +
the O +
colon O +
tumor O +
endpoints O -
, O +
analyses O +
were O +
repeated O +
excluding O +
tumors O +
harboring O +
mutations O +
in O +
KRAS B-Gene -
. O +

Since O +
tumors O +
may O +
harbor O +
multiple O +
mutations O +
it O +
is O +
difficult O +
to O +
assess O +
whether O +
observed O +
associations O +
are O +
specific O +
for O +
tumors O +
with O +
a O +
particular O +
gene O +
defect O -
. O +

We O +
therefore O -
, O +
conducted O +
additional O +
analyses O +
when O +
( O -
borderline O -
) O +
significant O +
associations O +
were O +
observed O -
. O +

In O +
these O +
analyses O +
subgroups O +
of O +
tumors O +
were O +
formed O +
characterized O +
by O +
either O +
the O +
absence O +
of O +
the O +
three O +
gene O +
defects O -
, O +
or O +
by O +
defects O +
in O +
a O +
single O +
gene O -
, O +
i.e. O -
, O +
either O +
only O +
lack O +
of O +
MLH1 B-Gene +
expression O -
, O +
only O +
a O +
truncating O +
APC B-Gene +
mutation O +
or O +
only O +
an O +
activating O +
KRAS B-Gene +
mutations O -
. O +

Activating O +
KRAS B-Gene +
mutations O +
are O +
defined O +
as O +
mutations O +
in O +
codons O +
12 O +
and O +
13 O +
of O +
the O +
KRAS B-Gene +
gene O +
leading O +
to O +
an O +
altered O +
amino O +
acid O -
. O +

Mean O +
values O +
of O +
the O +
intake O +
of O +
fat O +
variables O +
( O -
g O -
/ O -
day O -
) O -
, O +
and O +
possible O +
confounding O +
variables O +
including O +
age O +
at O +
baseline O +
( O -
years O -
) O -
, O +
dietary O +
fiber O +
( O -
g O -
/ O -
day O -
) O -
, O +
alcohol O +
( O -
g O -
/ O -
day O -
) O -
, O +
intake O +
of O +
fruit O +
( O -
g O -
/ O -
day O -
) O -
, O +
vegetable O +
( O -
g O -
/ O -
day O -
) O -
, O +
energy O +
( O -
kJ O -
/ O -
day O -
) O -
, O +
and O +
BMI O +
( O -
kg O -
/ O -
m2 O -
) O -
, O +
as O +
well O +
as O +
distributions O +
of O +
the O +
variables O +
sex O -
, O +
family O +
history O +
of O +
colorectal O +
cancer O +
( O -
yes O -
/ O -
no O -
) O -
, O +
smoking O +
status O +
( O -
never O -
/ O -
ex O -
/ O -
current O +
smoker O -
) O +
and O +
physical O +
activity O +
in O +
leisure O +
time O +
( O -
< O -
30 O -
, O +
30–60 O -
, O +
60–90 O -
, O +
> O -
90 O +
min O -
/ O -
day O -
) O +
were O +
evaluated O +
for O +
subcohort O +
members O -
, O +
colon O +
and O +
rectal O +
cancer O +
patients O +
with O +
or O +
without O +
a O +
truncating O +
APC B-Gene +
mutation O +
and O +
colon O +
cancer O +
patients O +
lacking O +
MLH1 B-Gene +
expression O -
. O +

Differences O +
in O +
mean O +
values O +
of O +
the O +
continuous O +
variables O +
between O +
patients O +
with O +
or O +
without O +
truncating O +
nonsense O +
or O +
frameshift O +
mutations O +
in O +
the O +
mutation O +
cluster O +
region O +
of O +
the O +
APC B-Gene +
gene O -
, O +
and O +
between O +
patients O +
with O +
or O +
without O +
MLH1 B-Gene +
expression O -
, O +
were O +
tested O +
using O +
the O +
Mann O -
– O -
Whitney O -
- O -
U O -
- O -
test O +
since O +
the O +
variables O +
were O +
not O +
normally O +
distributed O +
among O +
cases O -
. O +

The O +
distributions O +
of O +
the O +
categorical O +
variables O +
between O +
patients O +
with O +
and O +
without O +
truncating O +
APC B-Gene +
mutations O +
were O +
tested O +
with O +
the O +
χ2–test O -
. O +

Incidence O +
rate O +
ratios O +
( O -
RR O -
) O +
and O +
corresponding O +
95 O -
% O +
confidence O +
intervals O +
( O -
CI O -
) O +
for O +
colon O +
and O +
rectal O +
cancer O +
patients O +
were O +
estimated O +
according O +
to O +
quartiles O +
of O +
intake O +
of O +
fat O +
variables O -
, O +
and O +
one O +
standard O +
deviation O +
increment O +
of O +
intake O -
, O +
using O +
Cox O +
proportional O +
hazards O +
regression O +
models O -
. O +

In O +
addition O -
, O +
associations O +
were O +
estimated O +
for O +
specific O +
molecular O +
endpoints O +
of O +
the O +
tumors O -
. O +

Standard O +
errors O +
were O +
estimated O +
using O +
the O +
robust O +
Huber O -
– O -
White O +
sandwich O +
estimator O +
to O +
account O +
for O +
additional O +
variance O +
introduced O +
by O +
sampling O +
the O +
subcohort O +
from O +
the O +
entire O +
cohort O +
[ O -
32 O -
, O +
33 O -
] O -
. O +

The O +
proportional O +
hazards O +
assumption O +
was O +
tested O +
using O +
the O +
scaled O +
Schoenfeld O +
residuals O +
[ O -
34 O -
] O -
. O +

Tests O +
for O +
dose O +
response O +
trends O +
over O +
the O +
different O +
quartiles O +
and O +
categories O +
of O +
fat O +
intake O +
were O +
estimated O +
by O +
fitting O +
the O +
ordinal O +
exposure O +
variables O +
as O +
continuous O +
variables O +
and O +
evaluated O +
using O +
the O +
Wald O +
test O -
. O +

The O +
covariates O +
included O +
in O +
the O +
multivariate O +
analyses O +
were O +
those O +
found O +
to O +
significantly O +
( O -
p O +
< O +
0.05 O -
) O +
contribute O +
to O +
the O +
multivariate O +
model O +
for O +
colon O +
and/or O +
rectal O +
cancer O +
( O -
age O +
at O +
baseline O -
, O +
sex O -
, O +
body O +
mass O +
index O -
, O +
family O +
history O +
of O +
colorectal O +
cancer O -
, O +
and O +
smoking O +
status O -
) O +
or O +
to O +
influence O +
the O +
RR O +
by O +
more O +
than O +
ten O +
percent O -
, O +
as O +
well O +
as O +
energy O +
intake O -
. O +

Results O +
Lack O +
of O +
expression O +
in O +
MLH1 B-Gene +
was O +
observed O +
in O +
13 O -
% O +
( O -
54 O +
out O +
of O +
428 O -
) O +
of O +
tumors O +
from O +
colon O +
cancer O +
patients O +
( O -
Table O +
1 O -
) O -
. O +

APC B-Gene +
truncating O +
mutations O +
were O +
observed O +
in O +
tumors O +
from O +
32 O -
% O +
of O +
colon O +
cancer O +
patients O +
( O -
127 O +
out O +
of O +
401 O -
) O +
and O +
44 O -
% O +
of O +
rectal O +
cancer O +
patients O +
( O -
57 O +
out O +
of O +
130 O -
) O +
( O -
Table O +
1 O -
) O -
. O +

C O -
: O -
G→T O -
: O -
A O +
transitions O +
or O +
G O -
: O -
C→T O -
: O -
A O +
transversions O +
that O +
would O +
result O +
in O +
a O +
stop O +
codon O +
were O +
observed O +
in O +
10 O -
% O +
and O +
5 O -
% O +
of O +
colon O +
cancer O +
patients O +
and O +
12 O -
% O +
and O +
5 O -
% O +
of O +
rectal O +
cancer O +
patients O -
, O +
respectively O -
. O +

These O +
figures O +
are O +
similar O +
to O +
the O +
percentages O +
reported O +
for O +
the O +
total O +
group O +
of O +
colon O +
and O +
rectal O +
cancer O +
patients O +
for O +
whom O +
APC B-Gene +
mutation O +
status O +
was O +
available O -
, O +
but O +
for O +
whom O +
dietary O +
intake O +
data O +
were O +
not O +
always O +
complete O +
[ O -
25 O -
] O -
. O +

Table O +
1Baseline O +
dietary O +
intake O +
and O +
other O +
characteristics O +
of O +
the O +
subcohort O +
and O +
colon O +
and O +
rectum O +
cancer O +
patients O +
from O +
The O +
Netherlands O +
cohort O +
studySubcohortColon O +
cancer O +
( O -
n O +
= O +
428 O -
) O -
p O -
- O -
valuebColon O +
cancer O +
( O -
n O +
= O +
401 O -
) O -
p O -
- O -
valuebRectal O +
cancer O +
( O -
n O +
= O +
130 O -
) O -
p O -
- O -
valuebMLH1 O +
expressionaNo O +
MLH1 B-Gene +
expressionaAPC O +
− O +
cAPC O +
+ O -
cAPC O +
−cAPC O +
+ O -
cN2,948374542741277357 O +
Sex O +
( O -
% O -
men O -
) O -
4856410.0452560.4964670.79 O +
Age O +

( O -
years O -
) O -
61.3 O +
± O +
4.263.0 O +
± O +
4.062.8 O +
± O +
4.50.9163.1 O +
± O +
4.062.7 O +
± O +
4.00.3462.2 O +
± O +
4.462.6 O +
± O +
3.50.63Fat O +
variables O +
( O -
g O -
/ O -
day O -
) O -
d O +
Total O +
fat83.8 O +
± O +
15.885.1 O +
± O +
14.784.1 O +
± O +
17.50.5785.2 O +
± O +
15.084.8 O +
± O +
14.90.8085.1 O +
± O +
14.286.7 O +
± O +
14.80.52 O +
Saturated O +
fat33.2 O +
± O +
7.533.5 O +
± O +
6.633.3 O +
± O +
7.60.6433.3 O +
± O +
6.733.5 O +
± O +
7.00.9233.0 O +
± O +
5.835.5 O +
± O +
7.70.05 O +
MUFAe31.4 O +
± O +
7.031.9 O +
± O +
6.531.1 O +
± O +
7.50.4531.8 O +
± O +
6.631.9 O +
± O +
6.60.9831.8 O +
± O +
6.132.8 O +
± O +
6.20.37 O +
PUFAf17.3 O +
± O +
7.517.9 O +
± O +
7.517.4 O +
± O +
6.80.8518.2 O +
± O +
7.317.8 O +
± O +
7.60.4418.6 O +
± O +
8.716.5 O +
± O +
6.90.27 O +
Linoleic O +
acid16.0 O +
± O +
7.516.7 O +
± O +
7.516.6 O +
± O +
7.00.7617.0 O +
± O +
7.416.6 O +
± O +
7.70.3617.5 O +
± O +
8.815.2 O +
± O +
7.20.15 O +
Linolenic O +
acid1.3 O +
± O +
0.61.2 O +
± O +
0.51.3 O +
± O +
0.60.981.2 O +
± O +
0.51.3 O +
± O +
0.50.571.3 O +
± O +
0.61.3 O +
± O +
0.60.79Other O +
dietary O +
factors O +
Fibre O +
( O -
g O -
/ O -
day O -
) O -
27.0 O +
± O +
8.224.5 O +
± O +
8.125.2 O +
± O +
7.10.1326.7 O +
± O +
7.927.9 O +
± O +
8.10.2028.1 O +
± O +
7.028.2 O +
± O +
9.00.78 O +
Alcohol O +
( O -
g O -
/ O -
day O -
) O -
g10.1 O +
± O +
14.111.0 O +
± O +
14.810.7 O +
± O +
17.00.4911.0 O +
± O +
14.911.3 O +
± O +
16.50.8912.2 O +
± O +
14.914.5 O +
± O +
18.10.53 O +
Fruit O +
( O -
g O -
/ O -
day O -
) O -
177.0 O +
± O +
118.0178.8 O +
± O +
122.1160.5 O +
± O +
137.70.07169.7 O +
± O +
121.9187.5 O +
± O +
132.20.11197.4 O +
± O +
155.1205.0 O +
± O +
118.30.21 O +
Vegetables O +
( O -
g O -
/ O -
day O -
) O -
193.8 O +
± O +
82.2191.3 O +
± O +
82.3185.4 O +
± O +
73.80.80187.9 O +
± O +
80.7192.7 O +
± O +
85.20.71186.3 O +
± O +
68.5169.0 O +
± O +
122.20.69 O +
Energy O +
( O -
kj O -
/ O -
day O -
) O -
8,028 O +
± O +
2,1648,080 O +
± O +
2,0597,505 O +
± O +
1,7180.077,845 O +
± O +
1,8998,335 O +
± O +
2,3060.098,433 O +
± O +
1,9248,449 O +
± O +
1,6160.92Other O +
characteristics O +
BMIh O +
( O -
kg O -
/ O -
m2 O -
) O -
25.1 O +
± O +
3.125.6 O +
± O +
3.225.6 O +
± O +
3.50.5725.5 O +
± O +
3.2825.8 O +
± O +
3.10.3025.3 O +
± O +
3.125.1 O +
± O +
2.80.92 O +
Family O +
history O +
of O +
CRCi O +
( O -
% O +
yes O -
) O -
61390.4911110.9810110.86Smoker O +
( O -
% O -
) O +
Never37373336382633 O +
Ex O -
- O -
smoker35453746434739 O +
Current O +
smoker2818300.1218190.8827280.59Physical O +
activity O +
( O -
% O -
) O -
g O +
< O -
30 O +
min O -
/ O -
day21212219261726 O +
30 O -
- O -
60 O +
min O -
/ O -
day32332233282832 O +
60 O -
- O -
90 O +
min O -
/ O -
day21211922182418 O +
> O -
90 O +
min O -
/ O -
day2725370.2026270.3132250.43aFor O +
rectal O +
cancer O +
there O +
were O +
only O +
two O +
patients O +
without O +
MLH1 B-Gene +
expression O -
, O +
these O +
are O +
not O +
shown O +
separately O +
in O +
this O +
tablebp O -
- O -
value O +
for O +
the O +
difference O +
between O +
cancer O +
patients O +
with O +
and O +
without O +
MLH1 B-Gene +
expression O +
and O +
colon O +
and O +
rectal O +
cancer O +
patients O +
with O +
and O +
without O +
a O +
mutation O +
leading O +
to O +
the O +
introduction O +
of O +
a O +
stop O +
codon O +
in O +
APCcAPC B-Gene +
− O -
: O +
cancer O +
patients O +
without O +
a O +
mutation O +
in O +
the O +
MCR O +
of O +
the O +
APC B-Gene +
gene O +
leading O +
to O +
a O +
stop O +
codon O -
; O +
APC B-Gene +
+ O +
: O +
cancer O +
patients O +
with O +
a O +
mutation O +
in O +
the O +
MCR O +
of O +
the O +
APC B-Gene +
gene O +
leading O +
to O +
a O +
stop O +
codondAdjusted O +
for O +
energy O +
intakeeMonounsaturated O +
fatfPolyunsaturated O +
fatgFor O +
alcohol O +
intake O +
and O +
physical O +
activity O +
the O +
mean O +
levels O +
in O +
the O +
subcohort O +
are O +
based O +
on O +
2,862 O +
and O +
2,915 O +
subjects O +
respectively O -
. O +

Four O +
and O +
six O +
colon O +
cancer O +
cases O +
had O +
missing O +
values O +
for O +
alcohol O +
intake O +
and O +
physical O +
activity O +
respectively O -
. O +

Two O +
and O +
one O +
rectal O +
cancer O +
case O +
had O +
missing O +
values O +
for O +
alcohol O +
intake O +
and O +
physical O +
activity O +
respectivelyhBMI O -
: O +
body O +
mass O +
indexiCRC O -
: O +
colorectal O +
cancer O +

Colon O +
and O +
rectal O +
cancer O +
patients O +
were O +
generally O +
older O +
and O +
more O +
frequently O +
men O +
than O +
subcohort O +
members O +
( O -
Table O +
1 O -
) O -
. O +

Colon O +
cancer O +
patients O +
lacking O +
MLH1 B-Gene +
expression O +
in O +
their O +
tumor O +
were O +
significantly O +
less O +
often O +
men O +
than O +
patients O +
with O +
expression O +
of O +
the O +
gene O +
( O -
41 O -
% O +
vs. O +
56 O -
% O -
) O -
. O +

There O +
were O +
no O +
striking O +
differences O +
in O +
fat O +
intake O +
between O +
patients O +
and O +
subcohort O +
members O +
or O +
between O +
patients O +
with O +
or O +
without O +
MLH1 B-Gene +
expression O +
or O +
APC B-Gene +
mutations O +
in O +
their O +
tumors O -
. O +

Only O +
rectal O +
cancer O +
patients O +
with O +
a O +
tumor O +
harboring O +
a O +
truncating O +
APC B-Gene +
mutation O +
had O +
a O +
higher O +
intake O +
of O +
saturated O +
fat O +
than O +
rectal O +
cancer O +
patients O +
without O +
a O +
truncating O +
APC B-Gene +
mutation O +
( O -
p O +
= O +
0.05 O -
) O -
. O +

Neither O +
total O +
fat O +
nor O +
different O +
types O +
of O +
fat O +
appeared O +
to O +
be O +
associated O +
with O +
overall O +
colon O +
cancer O +
risk O +
in O +
this O +
population O +
( O -
Table O +
2 O -
) O -
. O +

For O +
different O +
subgroups O +
of O +
colon O +
cancer O +
based O +
on O +
absence O +
of O +
MLH1 B-Gene +
expression O +
or O +
absence O +
or O +
presence O +
of O +
APC B-Gene +
truncating O +
mutations O +
in O +
their O +
tumors O -
, O +
total O +
fat O +
intake O +
and O +
most O +
of O +
the O +
specific O +
types O +
of O +
fat O +
intake O +
variables O +
were O +
also O +
not O +
associated O +
with O +
risk O -
. O +

However O -
, O +
polyunsaturated O +
fat O +
intake O -
, O +
and O +
especially O +
linoleic O +
acid O +
intake O -
, O +
appeared O +
to O +
be O +
associated O +
with O +
an O +
increased O +
risk O +
of O +
colon O +
tumors O +
without O +
MLH1 B-Gene +
expression O +
and O +
with O +
colon O +
tumors O +
without O +
APC B-Gene +
truncating O +
mutations O -
, O +
but O +
not O +
with O +
colon O +
tumors O +
with O +
APC B-Gene +
truncating O +
mutations O +
( O -
Table O +
2 O -
) O -
. O +

For O +
colon O +
tumors O +
without O +
MLH1 B-Gene +
expression O -
, O +
the O +
RR O +
according O +
to O +
the O +
quartiles O +
of O +
linoleic O +
acid O +
intake O +
were O +
increased O -
, O +
though O +
not O +
significantly O -
, O +
for O +
all O +
the O +
categories O +
of O +
intake O +
above O +
the O +
reference O +
( O -
lowest O +
quartile O +
of O +
intake O -
) O -
, O +
i.e. O -
, O +
1.66 O +
( O -
95 O -
% O +
CI O +
0.69–3.98 O -
) O -
, O +
2.14 O +
( O -
95 O -
% O +
CI O +
0.91–5.00 O -
) O +
and O +
2.02 O +
( O -
95 O -
% O +
CI O +
0.86–4.76 O -
) O +
for O +
the O +
second O +
through O +
the O +
fourth O +
quartiles O +
respectively O -
, O +
and O +
the O +
test O +
for O +
linear O +
trend O +
was O +
borderline O +
significant O +
( O -
p O +
= O +
0.08 O -
) O -
. O +

A O +
similar O +
trend O +
was O +
observed O +
for O +
the O +
risk O +
of O +
colon O +
tumors O +
without O +
APC B-Gene +
truncating O +
mutations O +
( O -
RR O +
over O +
the O +
quartiles O +
of O +
linoleic O +
acid O +
intake O -
: O +
1.50 O +
( O -
95 O -
% O +
CI O +
1.02–2.21 O -
) O -
, O +
1.68 O +
( O -
95 O -
% O +
CI O +
1.15–2.45 O -
) O +
and O +
1.44 O +
( O -
95 O -
% O +
CI O +
0.99–2.11 O -
) O +
respectively O -
, O +
p O -
- O -
trend O +
= O +
0.05 O +
( O -
Table O +
2 O -
) O -
. O +

Additional O +
analyses O +
for O +
subgroups O +
of O +
colon O +
tumors O +
with O +
specific O +
truncating O +
point O +
mutations O +
in O +
APC B-Gene +
did O +
not O +
show O +
any O +
associations O +
with O +
the O +
intake O +
of O +
fat O +
or O +
different O +
types O +
of O +
fat O +
( O -
results O +
not O +
shown O -
) O -
. O +

Table O +
2Adjusted O +
incidence O +
rate O +
ratios O +
and O +
95 O -
% O +
confidence O +
intervals O +
for O +
colon O +
cancer O +
patients O +
overall O -
, O +
without O +
MLH1 B-Gene +
expression O -
, O +
and O +
with O +
and O +
without O +
an O +
APC B-Gene +
mutation O +
leading O +
to O +
a O +
stop O +
codon O -
, O +
according O +
to O +
the O +
intake O +
of O +
fat O +
variables O +
( O -
The O +
Netherlands O +
Cohort O +
Study O -
) O -
Dietary O +
fat O +
intakeMedian O +
intake O +
( O -
g O -
/ O -
day O -
) O -
Person O +
yearsbColon O +
cancerOverallNo O +
MLH1 B-Gene +
expressionAPC O +
–aAPC O +
+ O -
aMenWomenNumber O +
of O +
patientsRRc O -
( O -
95 O -
% O +
CI O -
) O -
cNumber O +
of O +
patientsRRc O -
( O -
95 O -
% O +
CI O -
) O -
cNumber O +
of O +
patientsRRc O -
( O -
95 O -
% O +
CI O -
) O -
cNumber O +
of O +
patientsRRc O -
( O -
95 O -
% O +
CI O -
) O -
cTotal O +
fat O +
Q178.063.03,5491101.00 O -
( O -
reference O -
) O -
111.00 O -
( O -
reference O -
) O -
611.00 O -
( O -
reference O -
) O -
401.00 O -
( O -
reference O -
) O +
Q290.271.43,5561251.09 O -
( O -
0.82–1.44 O -
) O -
171.47 O -
( O -
0.69–3.14 O -
) O -
871.34 O -
( O -
0.94–1.90 O -
) O -
320.80 O -
( O -
0.49–1.28 O -
) O +
Q398.577.63,579890.75 O -
( O -
0.55–1.01 O -
) O -
110.94 O -
( O -
0.40–2.17 O -
) O -
550.82 O -
( O -
0.56–1.21 O -
) O -
240.57 O -
( O -
0.33–0.96 O -
) O +
Q4108.885.33,5881100.96 O -
( O -
0.72–1.28 O -
) O -
151.30 O -
( O -
0.59–2.86 O -
) O -
711.11 O -
( O -
0.77–1.59 O -
) O -
310.74 O -
( O -
0.46–1.20 O -
) O +
p O -
- O -
valued0.290.820.710.13 O +
1SD O +
incremente1.00 O -
( O -
0.88–1.13 O -
) O -
1.21 O -
( O -
0.82–1.77 O -
) O -
1.04 O -
( O -
0.89–1.22 O -
) O -
0.93 O -
( O -
0.76–1.14 O -
) O -
Saturated O +
fat O +
Q128.923.93,567991.00 O -
( O -
reference O -
) O -
91.00 O -
( O -
reference O -
) O -
591.00 O -
( O -
reference O -
) O -
331.00 O -
( O -
reference O -
) O +
Q233.727.83,5501201.20 O -
( O -
0.89–1.61 O -
) O -
141.48 O -
( O -
0.63–3.49 O -
) O -
841.38 O -
( O -
0.97–1.97 O -
) O -
300.94 O -
( O -
0.55–1.61 O -
) O +
Q338.330.93,5831151.11 O -
( O -
0.82–1.49 O -
) O -
191.93 O -
( O -
0.86–4.32 O -
) O -
731.15 O -
( O -
0.79–1.66 O -
) O -
331.01 O -
( O -
0.60–1.68 O -
) O +
Q445.836.63,5711000.94 O -
( O -
0.69–1.27 O -
) O -
121.25 O -
( O -
0.52–3.00 O -
) O -
580.90 O -
( O -
0.62–1.32 O -
) O -
310.89 O -
( O -
0.53–1.48 O -
) O +
p O -
- O -
valued0.540.480.350.72 O +
1SD O +
incremente0.97 O -
( O -
0.87–1.08 O -
) O -
1.12 O -
( O -
0.82–1.51 O -
) O -
0.95 O -
( O -
0.83–1.09 O -
) O -
0.95 O -
( O -
0.79–1.14 O -
) O -
MUFAf O +
Q128.222.43,546981.00 O -
( O -
reference O -
) O -
111.00 O -
( O -
reference O -
) O -
561.00 O -
( O -
reference O -
) O -
311.00 O -
( O -
reference O -
) O +
Q233.226.03,5461221.20 O -
( O -
0.89–1.61 O -
) O -
141.15 O -
( O -
0.52–2.53 O -
) O -
791.33 O -
( O -
0.92–1.91 O -
) O -
361.18 O -
( O -
0.72–1.95 O -
) O +
Q336.928.93,5801131.12 O -
( O -
0.83–1.52 O -
) O -
141.15 O -
( O -
0.52–2.54 O -
) O -
761.30 O -
( O -
0.89–1.89 O -
) O -
311.03 O -
( O -
0.60–1.77 O -
) O +
Q442.533.13,6001010.99 O -
( O -
0.73–1.34 O -
) O -
151.25 O -
( O -
0.58–2.71 O -
) O -
631.08 O -
( O -
0.74–1.57 O -
) O -
290.90 O -
( O -
0.54–1.52 O -
) O +

p O -
- O -
valued0.790.590.800.57 O +
1SD O +
incremente0.99 O -
( O -
0.88–1.12 O -
) O -
1.04 O -
( O -
0.73–1.46 O -
) O -
1.01 O -
( O -
0.87–1.17 O -
) O -
0.98 O -
( O -
0.81–1.18 O -
) O -
PUFAg O +
Q111.68.83,507911.00 O -
( O -
reference O -
) O -
81.00 O -
( O -
reference O -
) O -
491.00 O -
( O -
reference O -
) O -
321.00 O -
( O -
reference O -
) O +

Q216.012.43,5621181.37 O -
( O -
1.02–1.86 O -
) O -
162.03 O -
( O -
0.86–4.81 O -
) O -
731.55 O -
( O -
1.06–2.28 O -
) O -
331.13 O -
( O -
0.68–1.89 O -
) O +
Q320.916.23,6181131.24 O -
( O -
0.91–1.68 O -
) O -
162.00 O -
( O -
0.84–4.76 O -
) O -
781.57 O -
( O -
1.07–2.31 O -
) O -
300.96 O -
( O -
0.57–1.62 O -
) O +
Q429.322.53,5801121.21 O -
( O -
0.89–1.63 O -
) O -
141.75 O -
( O -
0.72–4.24 O -
) O -
741.47 O -
( O -
1.01–2.16 O -
) O -
320.98 O -
( O -
0.59–1.63 O -
) O +
p O -
- O -
valued0.380.260.060.79 O +
1SD O +
incremente1.03 O -
( O -
0.94–1.14 O -
) O -
1.07 O -
( O -
0.82–1.38 O -
) O -
1.09 O -
( O -
0.97–1.23 O -
) O -
1.00 O -
( O -
0.84–1.19 O -
) O -
Linoleic O +
acid O +
Q110.07.53,509861.00 O -
( O -
reference O -
) O -
81.00 O -
( O -
reference O -
) O -
491.00 O -
( O -
reference O -
) O -
261.00 O -
( O -
reference O -
) O +

Q214.811.23,5861221.49 O -
( O -
1.10–2.02 O -
) O -
131.66 O -
( O -
0.69–3.98 O -
) O -
711.50 O -
( O -
1.02–2.21 O -
) O -
401.65 O -
( O -
0.99–2.76 O -
) O +
Q319.514.93,5991121.32 O -
( O -
0.97–1.79 O -
) O -
172.14 O -
( O -
0.91–5.00 O -
) O -
821.68 O -
( O -
1.15–2.45 O -
) O -
251.00 O -
( O -
0.57–1.76 O -
) O +
Q428.021.23,5741141.30 O -
( O -
0.96–1.77 O -
) O -
162.02 O -
( O -
0.86–4.76 O -
) O -
721.44 O -
( O -
0.99–2.11 O -
) O -
361.35 O -
( O -
0.80–2.28 O -
) O +
p O -
- O -
valued0.200.080.050.65 O +
1SD O +
incremente1.06 O -
( O -
0.96–1.17 O -
) O -
1.15 O -
( O -
0.90–1.48 O -
) O -
1.12 O -
( O -
0.99–1.26 O -
) O -
1.02 O -
( O -
0.86–1.21 O -
) O -
Linolenic O +
acid O +
Q10.80.63,5181071.00 O -
( O -
reference O -
) O -
111.00 O -
( O -
reference O -
) O -
681.00 O -
( O -
reference O -
) O -
311.00 O -
( O -
reference O -
) O +
Q21.20.93,5741040.95 O -
( O -
0.70–1.30 O -
) O -
171.32 O -
( O -
0.60–2.89 O -
) O -
720.99 O -
( O -
0.68–1.43 O -
) O -
240.84 O -
( O -
0.47–1.49 O -
) O +
Q31.51.23,5711171.10 O -
( O -
0.82–1.48 O -
) O -
110.91 O -
( O -
0.40–2.10 O -
) O -
620.89 O -
( O -
0.62–1.29 O -
) O -
431.48 O -
( O -
0.91–2.40 O -
) O +
Q42.01.63,6041061.01 O -
( O -
0.76–1.36 O -
) O -
151.32 O -
( O -
0.61–2.84 O -
) O -
721.08 O -
( O -
0.76–1.53 O -
) O -
290.97 O -
( O -
0.57–1.65 O -
) O +
p O -
- O -
valued0.680.730.820.52 O +
1SD O +
incremente0.98 O -
( O -
0.89–1.09 O -
) O -
1.07 O -
( O -
0.79–1.44 O -
) O -
0.97 O -
( O -
0.85–1.10 O -
) O -
1.01 O -
( O -
0.86–1.19 O -
) O -
aAPC O +
− O -
: O +
cancer O +
patients O +
without O +
a O +
mutation O +
in O +
the O +
MCR O +
of O +
the O +
APC B-Gene +
gene O +
leading O +
to O +
a O +
stop O +
codon O -
; O +
APC B-Gene +
+ O -
: O +
cancer O +
patients O +
with O +
a O +
mutation O +
in O +
the O +
MCR O +
of O +
the O +
APC B-Gene +
gene O +
leading O +
to O +
a O +
stop O +
codonbPerson O +
years O +
at O +
risk O +
are O +
estimated O +
from O +
the O +
subcohortcIncidence O +
rate O +
ratios O +
( O -
RR O -
) O +
and O +
95 O -
% O +
confidence O +
intervals O +
( O -
95 O -
% O +
CI O -
) O +
are O +
adjusted O +
for O +
age O -
, O +
sex O -
, O +
body O +
mass O +
index O -
, O +
smoking O -
, O +
energy O +
intake O +
and O +
family O +
history O +
of O +
colorectal O +
cancerdp O -
- O -
value O +
for O +
trend O +
over O +
the O +
quartiles O +
of O +
intake O +
of O +
fat O +
variableseFor O +
1 O +
standard O +
deviation O +
of O +
intake O +
of O +
fat O +
in O +
the O +
subcohort O +
( O -
see O +
Table O +
1 O -
) O -
; O +
i.e. O -
, O +
15.8 O +
g O -
/ O -
day O +
for O +
total O +
fat O -
, O +
7.5 O +
g O -
/ O -
day O +
for O +
saturated O +
fat O -
, O +
7.0 O +
g O -
/ O -
day O +
for O +
monounsaturated O +
fat O -
, O +
7.5 O +
g O -
/ O -
day O +
for O +
polyunsaturated O +
fat O -
, O +
7.5 O +
g O -
/ O -
day O +
for O +
linoleic O +
acid O +
and O +
0.6 O +
g O -
/ O -
day O +
for O +
linolenic O +
acidfMonounsaturated O +
fatgPolyunsaturated O +
fat O +

For O +
overall O +
rectal O +
cancer O -
, O +
associations O +
with O +
the O +
intake O +
of O +
total O +
fat O +
or O +
different O +
types O +
of O +
fat O +
were O +
not O +
observed O +
( O -
Table O +
3 O -
) O -
. O +

Also O +
after O +
taking O +
account O +
of O +
truncating O +
APC B-Gene +
mutations O +
in O +
rectal O +
tumors O -
, O +
none O +
of O +
the O +
fat O +
intake O +
variables O +
were O +
significantly O +
associated O +
with O +
risk O +
of O +
rectal O +
cancer O -
. O +

Only O +
the O +
intake O +
of O +
saturated O +
fat O +
appeared O +
to O +
be O +
inversely O +
associated O +
with O +
rectal O +
tumors O +
without O +
APC B-Gene +
truncating O +
mutations O +
( O -
RR O +
for O +
the O +
highest O +
versus O +
the O +
lowest O +
quartile O +
of O +
intake O -
: O +
0.46 O +
( O -
95 O -
% O +
CI O +
0.22–0.97 O -
) O -
, O +
p O -
- O -
trend O +
= O +
0.07 O -
) O +
( O -
Table O +
3 O -
) O -
. O +

For O +
rectal O +
tumors O +
with O +
specific O +
types O +
of O +
APC B-Gene +
truncating O +
mutations O +
no O +
associations O +
were O +
observed O +
with O +
any O +
of O +
the O +
fat O +
intake O +
variables O +
( O -
results O +
not O +
shown O -
) O -
. O +

Table O +
3Adjusted O +
incidence O +
rate O +
ratios O +
and O +
95 O -
% O +
confidence O +
intervals O +
for O +
rectal O +
cancer O +
patients O +
overall O -
, O +
and O +
with O +
and O +
without O +
an O +
APC B-Gene +
mutation O +
leading O +
to O +
a O +
stop O +
codon O -
, O +
according O +
to O +
the O +
intake O +
of O +
fat O +
variables O -
. O +

( O -
The O +
Netherlands O +
Cohort O +
Study O -
) O -
Dietary O +
fat O +
intakeMedian O +
intake O +
( O -
g O -
/ O -
day O -
) O -
Person O +
yearsbRectal O +
cancerOverallAPC O +
−aAPC O +
+ O -
aMenWomenNumber O +
of O +
patientsRRc O -
( O -
95 O -
% O +
CI O -
) O -
cNumber O +
of O +
patientsRRc O -
( O -
95 O -
% O +
CI O -
) O -
cNumber O +
of O +
patientsRRc O -
( O -
95 O -
% O +
CI O -
) O -
cTotal O +
fat O +
Q178.063.03,549431.00 O -
( O -
reference O -
) O -
241.00 O -
( O -
reference O -
) O -
151.00 O -
( O -
reference O -
) O +
Q290.271.43,556390.89 O -
( O -
0.56–1.39 O -
) O -
170.70 O -
( O -
0.37–1.34 O -
) O -
120.79 O -
( O -
0.36–1.70 O -
) O +

Q398.577.63,579330.74 O -
( O -
0.46–1.19 O -
) O -
160.65 O -
( O -
0.33–1.26 O -
) O -
140.91 O -
( O -
0.43–1.90 O -
) O +
Q4108.885.33,588380.87 O -
( O -
0.55–1.36 O -
) O -
150.60 O -
( O -
0.31–1.16 O -
) O -
161.06 O -
( O -
0.51–2.19 O -
) O +

p O -
- O -
valued0.420.130.80 O +
1SD O +
incremente0.91 O -
( O -
0.76–1.09 O -
) O -
0.84 O -
( O -
0.65–1.08 O -
) O -
0.94 O -
( O -
0.69–1.28 O -
) O -
Saturated O +
fat O +
Q128.923.93,567431.00 O -
( O -
reference O -
) O -
231.00 O -
( O -
reference O -
) O -
141.00 O -
( O -
reference O -
) O +

Q233.727.83,550340.80 O -
( O -
0.49–1.29 O -
) O -
180.81 O -
( O -
0.42–1.56 O -
) O -
120.87 O -
( O -
0.39–1.91 O -
) O +

Q338.330.93,583441.02 O -
( O -
0.66–1.59 O -
) O -
210.92 O -
( O -
0.49–1.73 O -
) O -
120.86 O -
( O -
0.40–1.88 O -
) O +

Q445.836.63,571330.74 O -
( O -
0.46–1.18 O -
) O -
110.46 O -
( O -
0.22–0.97 O -
) O -
191.30 O -
( O -
0.65–2.63 O -
) O +
p O -
- O -
valued0.380.070.47 O +
1SD O +
incremente0.95 O -
( O -
0.81–1.12 O -
) O -
0.81 O -
( O -
0.65–1.02 O -
) O -
1.16 O -
( O -
0.89–1.50 O -
) O -
MUFAf O +
Q128.222.43,546441.00 O -
( O -
reference O -
) O -
231.00 O -
( O -
reference O -
) O -
151.00 O -
( O -
reference O -
) O +

Q233.226.03,546310.70 O -
( O -
0.44–1.13 O -
) O -
180.79 O -
( O -
0.41–1.49 O -
) O -
90.62 O -
( O -
0.27–1.43 O -
) O +
Q336.928.93,580400.91 O -
( O -
0.58–1.44 O -
) O -
150.67 O -
( O -
0.34–1.33 O -
) O -
201.36 O -
( O -
0.67–2.78 O -
) O +
Q442.533.13,600390.88 O -
( O -
0.56–1.37 O -
) O -
170.72 O -
( O -
0.38–1.36 O -
) O -
130.88 O -
( O -
0.40–1.90 O -
) O +
p O -
- O -
valued0.820.280.76 O +
1SD O +
incremente0.94 O -
( O -
0.78–1.12 O -
) O -
0.85 O -
( O -
0.67–1.08 O -
) O -
1.00 O -
( O -
0.76–1.33 O -
) O -
PUFAg O +
Q111.68.83,507451.00 O -
( O -
reference O -
) O -
171.00 O -
( O -
reference O -
) O -
211.00 O -
( O -
reference O -
) O +
Q216.012.43,562320.74 O -
( O -
0.46–1.18 O -
) O -
191.17 O -
( O -
0.60–2.28 O -
) O -
100.49 O -
( O -
0.23–1.07 O -
) O +

Q320.916.23,618390.86 O -
( O -
0.55–1.34 O -
) O -
160.94 O -
( O -
0.47–1.88 O -
) O -
160.76 O -
( O -
0.39–1.48 O -
) O +

Q429.322.53,580380.82 O -
( O -
0.53–1.29 O -
) O -
211.20 O -
( O -
0.63–2.29 O -
) O -
100.47 O -
( O -
0.22–1.00 O -
) O +
p O -
- O -
valued0.530.730.11 O +
1SD O +
incremente0.98 O -
( O -
0.83–1.16 O -
) O -
1.06 O -
( O -
0.84–1.34 O -
) O -
0.78 O -
( O -
0.60–1.03 O -
) O -
Linoleic O +
acid O +
Q110.07.53,509391.00 O -
( O -
reference O -
) O -
181.00 O -
( O -
reference O -
) O -
181.00 O -
( O -
reference O -
) O +
Q214.811.23,586391.03 O -
( O -
0.65–1.64 O -
) O -
170.98 O -
( O -
0.50–1.92 O -
) O -
140.80 O -
( O -
0.40–1.63 O -
) O +
Q319.514.93,599350.90 O -
( O -
0.56–1.44 O -
) O -
160.90 O -
( O -
0.45–1.79 O -
) O -
150.84 O -
( O -
0.42–1.68 O -
) O +
Q428.021.23,574411.03 O -
( O -
0.65–1.62 O -
) O -
221.19 O -
( O -
0.63–2.24 O -
) O -
100.54 O -
( O -
0.25–1.18 O -
) O +
p O -
- O -
valued0.950.650.15 O +
1SD O +
incremente0.99 O -
( O -
0.84–1.17 O -
) O -
1.09 O -
( O -
0.86–1.38 O -
) O -
0.79 O -
( O -
0.60–1.04 O -
) O -
Linolenic O +
acid O +
Q10.80.63,518421.00 O -
( O -
reference O -
) O -
181.00 O -
( O -
reference O -
) O -
181.00 O -
( O -
reference O -
) O +
Q21.20.93,574380.92 O -
( O -
0.57–1.48 O -
) O -
201.16 O -
( O -
0.58–2.31 O -
) O -
100.55 O -
( O -
0.25–1.24 O -
) O +
Q31.51.23,571360.87 O -
( O -
0.55–1.38 O -
) O -
150.87 O -
( O -
0.43–1.75 O -
) O -
130.72 O -
( O -
0.35–1.48 O -
) O +
Q42.01.63604380.92 O -
( O -
0.58–1.44 O -
) O -
201.13 O -
( O -
0.60–2.14 O -
) O -
160.90 O -
( O -
0.45–1.80 O -
) O +
p O -
- O -
valued0.680.930.91 O +
1SD O +
incremente0.95 O -
( O -
0.81–1.12 O -
) O -
0.98 O -
( O -
0.77–1.24 O -
) O -
1.03 O -
( O -
0.81–1.31 O -
) O -
aAPC O +
− O -
: O +
cancer O +
patients O +
without O +
a O +
mutation O +
in O +
the O +
MCR O +
of O +
the O +
APC B-Gene +
gene O +
leading O +
to O +
a O +
stop O +
codon O -
; O +
APC B-Gene +
+ O -
: O +
cancer O +
patients O +
with O +
a O +
mutation O +
in O +
the O +
MCR O +
of O +
the O +
APC B-Gene +
gene O +
leading O +
to O +
a O +
stop O +
codonbPerson O +
years O +
at O +
risk O +
are O +
estimated O +
from O +
the O +
subcohortcIncidence O +
rate O +
ratios O +
( O -
RR O -
) O +
and O +
95 O -
% O +
confidence O +
intervals O +
( O -
95 O -
% O +
CI O -
) O +
are O +
adjusted O +
for O +
age O -
, O +
sex O -
, O +
body O +
mass O +
index O -
, O +
smoking O -
, O +
energy O +
intake O +
and O +
family O +
history O +
of O +
colorectal O +
cancerdp O -
- O -
value O +
for O +
trend O +
over O +
the O +
quartiles O +
of O +
intake O +
of O +
fat O +
variableseFor O +
1 O +
standard O +
deviation O +
of O +
intake O +
of O +
fat O +
in O +
the O +
subcohort O +
( O -
see O +
Table O +
1 O -
) O -
; O +
i.e. O -
, O +
15.8 O +
g O -
/ O -
day O +
for O +
total O +
fat O -
, O +
7.5 O +
g O -
/ O -
day O +
for O +
saturated O +
fat O -
, O +
7.0 O +
g O -
/ O -
day O +
for O +
monounsaturated O +
fat O -
, O +
7.5 O +
g O -
/ O -
day O +
for O +
polyunsaturated O +
fat O -
, O +
7.5 O +
g O -
/ O -
day O +
for O +
linoleic O +
acid O +
and O +
0.6 O +
g O -
/ O -
day O +
for O +
linolenic O +
acidfMonounsaturated O +
fatgPolyunsaturated O +
fat O +
Additional O +
analyses O +
were O +
conducted O +
to O +
assess O +
whether O +
the O +
observed O +
associations O +
of O +
polyunsaturated O +
fat O +
intake O -
, O +
and O +
especially O +
linoleic O +
acid O +
intake O -
, O +
with O +
the O +
increased O +
risk O +
of O +
colon O +
tumors O +
lacking O +
MLH1 B-Gene +
expression O +
and O +
with O +
the O +
increased O +
risk O +
of O +
colon O +
tumors O +
without O +
APC B-Gene +
truncating O +
mutations O -
, O +
were O +
observed O +
because O +
of O +
an O +
underlying O +
association O +
with O +
colon O +
tumors O +
harboring O +
a O +
KRAS B-Gene +
mutation O -
, O +
as O +
previously O +
observed O +
[ O -
22 O -
] O -
. O +

Excluding O +
tumors O +
with O +
a O +
KRAS B-Gene +
mutation O +
resulted O +
in O +
the O +
absence O +
of O +
a O +
statistically O +
significant O +
association O +
of O +
polyunsaturated O +
fat O +
intake O +
and O +
linoleic O +
acid O +
intake O +
with O +
colon O +
tumors O +
lacking O +
MLH1 B-Gene +
expression O +
( O -
p O -
- O -
trend O +
= O +
0.34 O +
and O +
0.12 O -
, O +
respectively O -
) O +
and O +
those O +
lacking O +
APC B-Gene +
tuncating O +
mutations O +
( O -
p O -
- O -
trend O +
= O +
0.77 O +
and O +
0.99 O -
, O +
respectively O -
) O -
. O +

Intake O +
of O +
polyunsaturated O +
fat O +
or O +
linoleic O +
acid O +
was O +
neither O +
associated O +
with O +
the O +
risk O +
of O +
colon O +
cancer O +
without O +
any O +
of O +
the O +
three O +
gene O +
defects O -
, O +
nor O +
with O +
the O +
risk O +
of O +
colon O +
cancer O +
only O +
lacking O +
MLH1 B-Gene +
expression O -
, O +
nor O +
with O +
the O +
risk O +
of O +
colon O +
cancer O +
with O +
only O +
truncating O +
APC B-Gene +
mutations O +
( O -
Table O +
4 O -
) O -
. O +

With O +
increasing O +
intake O +
of O +
polyunsaturated O +
fat O +
and O +
of O +
linoleic O +
acid O -
, O +
a O +
strongly O +
increased O +
risk O +
of O +
colon O +
cancer O +
with O +
only O +
activating O +
KRAS B-Gene +
mutations O +
was O +
observed O +
( O -
Table O +
4 O -
) O +
( O -
p O -
- O -
trend O +
≤ O +
0.001 O +
for O +
both O +
polyunsaturated O +
fat O +
and O +
linoleic O +
acid O +
intake O -
) O -
. O +

The O +
RRs O +
for O +
one O +
standard O +
deviation O +
increase O +
in O +
intake O +
were O +
1.40 O +
( O -
95 O -
% O +
CI O +
1.17–1.68 O -
) O +
and O +
1.41 O +
( O -
95 O -
% O +
CI O +
1.18–1.69 O -
) O -
, O +
respectively O -
. O +

The O +
RRs O +
for O +
polyunsaturated O +
fat O +
( O -
not O +
shown O -
) O +
and O +
linoleic O +
acid O +
intake O +
were O +
of O +
similar O +
size O +
when O +
estimated O +
separately O +
for O +
men O +
( O -
1.41 O -
, O +
95 O -
% O +
CI O +
1.15–1.72 O +
for O +
1 O +
standard O +
deviation O +
increase O +
in O +
linoleic O +
acid O +
intake O -
) O +
and O +
women O +
( O -
1.42 O -
, O +
95 O -
% O +
CI O +
0.96–2.10 O -
) O -
, O +
and O +
were O +
elevated O +
for O +
proximal O +
( O -
1.23 O -
, O +
95 O -
% O +
CI O +
0.99–1.53 O -
) O +
and O +
distal O +
colon O +
cancer O +
( O -
1.53 O -
, O +
95 O -
% O +
CI O +
1.21–1.95 O -
) O -
. O +

Likewise O -
, O +
a O +
positive O +
association O +
was O +
observed O +
for O +
all O +
colorectal O +
cancers O +
( O -
1.24 O -
, O +
95 O -
% O +
CI O +
1.06–1.47 O +
and O +
p O -
- O -
trend O +
= O +
0.01 O -
) O -
, O +
based O +
on O +
a O +
total O +
of O +
87 O +
cases O +
( O -
i.e. O -
, O +
including O +
the O +
rectosigmoid O -
) O -
. O +

Table O +
4Adjusted O +
incidence O +
rate O +
ratios O +
and O +
95 O -
% O +
confidence O +
intervals O +
for O +
colon O +
cancer O +
patients O +
without O +
any O +
of O +
the O +
gene O +
defects O +
or O +
with O +
only O +
a O +
single O +
gene O +
defect O -
, O +
i.e. O -
, O +
either O +
lack O +
of O +
MLH1 B-Gene +
expression O -
, O +
a O +
truncating O +
APC B-Gene +
gene O +
mutation O +
or O +
an O +
activating O +
KRAS B-Gene +
gene O +
mutation O -
, O +
according O +
to O +
the O +
intake O +
of O +
polyunsaturated O +
fat O +
and O +
linoleic O +
acid O +
intake O +
( O -
The O +
Netherlands O +
Cohort O +
Study O -
) O -
Dietary O +
fat O +
intakePerson O +
yearseColon O +
cancerNo O +
gene O +
defectsaOnly O +
lack O +
of O +
MLH1 B-Gene +
expressionbOnly O +
truncating O +
APC B-Gene +
mutationscOnly O +
activating O +
KRAS B-Gene +
mutationsdNumber O +
of O +
patientsRRf O -
( O -
95 O -
% O +
CI O -
) O -
fNumber O +
of O +
patientsRRf O -
( O -
95 O -
% O +
CI O -
) O -
fNumber O +
of O +
patientsRRf O -
( O -
95 O -
% O +
CI O -
) O -
fNumber O +
of O +
patientsRRf O -
( O -
95 O -
% O +
CI O -
) O -
fPUFAgQ13,507391.00 O -
( O -
reference O -
) O -
61.00 O -
( O -
reference O -
) O -
181.00 O -
( O -
reference O -
) O -
41.00 O -
( O -
reference O -
) O -
Q23,562441.15 O -
( O -
0.73–1.81 O -
) O -
142.48 O -
( O -
0.94–6.54 O -
) O -
211.31 O -
( O -
0.68–2.53 O -
) O -
143.76 O -
( O -
1.21–11.69 O -
) O -
Q33,618451.10 O -
( O -
0.70–1.73 O -
) O -
111.89 O -
( O -
0.69–5.16 O -
) O -
150.86 O -
( O -
0.43–1.74 O -
) O -
195.00 O -
( O -
1.67–14.99 O -
) O -
Q43,580350.86 O -
( O -
0.54–1.38 O -
) O -
101.72 O -
( O -
0.61–4.81 O -
) O -
130.70 O -
( O -
0.34–1.45 O -
) O -
286.74 O -
( O -
2.36–19.51 O -
) O -
p O -
- O -
valueh0.510.480.19≤0.0011SD O +
incrementi0.96 O -
( O -
0.82–1.13 O -
) O -
1.01 O -
( O -
0.72–1.40 O -
) O -
0.90 O -
( O -
0.71–1.14 O -
) O -
1.40 O -
( O -
1.17–1.68 O -
) O -
Linoleic O +
acidQ13,509381.00 O -
( O -
reference O -
) O -
71.00 O -
( O -
reference O -
) O -
141.00 O -
( O -
reference O -
) O -
41.00 O -
( O -
reference O -
) O -
Q23,586451.20 O -
( O -
0.77–1.90 O -
) O -
101.51 O -
( O -
0.58–0.93 O -
) O -
262.03 O -
( O -
1.03–3.99 O -
) O -
154.06 O -
( O -
1.32–12.46 O -
) O -
Q33,599451.15 O -
( O -
0.73–1.81 O -
) O -
142.08 O -
( O -
0.84–5.19 O -
) O -
130.99 O -
( O -
0.46–2.13 O -
) O -
215.61 O -
( O -
1.88–16.68 O -
) O -
Q43,574350.90 O -
( O -
0.56–1.44 O -
) O -
101.49 O -
( O -
0.56–3.97 O -
) O -
140.97 O -
( O -
0.46–2.06 O -
) O -
256.02 O -
( O -
2.09–17.41 O -
) O -
p O -
- O -
valueh0.620.300.38≤0.0011SD O +
incrementi0.98 O -
( O -
0.84–1.15 O -
) O -
1.08 O -
( O -
0.79–1.49 O -
) O -
0.91 O -
( O -
0.73–1.14 O -
) O -
1.41 O -
( O -
1.18–1.69 O -
) O -
aColon O +
cancer O +
patients O +
with O +
MLH1 B-Gene +
expression O +
and O +
without O +
truncating O +
APC B-Gene +
or O +
activating O +
KRAS B-Gene +
gene O +
mutationsbColon O +
cancer O +
patients O +
lacking O +
MLH1 B-Gene +
expression O +
but O +
without O +
truncating O +
APC B-Gene +
or O +
activating O +
KRAS B-Gene +
gene O +
mutationscColon O +
cancer O +
patients O +
with O +
a O +
truncating O +
APC B-Gene +
gene O +
mutation O +
but O +
with O +
MLH1 B-Gene +
expression O +
and O +
without O +
activating O +
KRAS B-Gene +
gene O +
mutationsdColon O +
cancer O +
patients O +
with O +
an O +
activating O +
KRAS B-Gene +
gene O +
mutations O +
but O +
with O +
MLH1 B-Gene +
expression O +
and O +
without O +
truncating O +
APC B-Gene +
gene O +
mutationsePerson O +
years O +
at O +
risk O +
are O +
estimated O +
from O +
the O +
subcohort.fIncidence O +
rate O +
ratios O +
( O -
RR O -
) O +
and O +
95 O -
% O +
confidence O +
intervals O +
( O -
95 O -
% O +
CI O -
) O +
are O +
adjusted O +
for O +
age O -
, O +
sex O -
, O +
body O +
mass O +
index O -
, O +
smoking O -
, O +
energy O +
intake O +
and O +
family O +
history O +
of O +
colorectal O +
cancer.gPolyunsaturated O +
fathp O -
- O -
value O +
for O +
trend O +
over O +
the O +
quartiles O +
of O +
intake O +
of O +
fat O +
variablesiFor O +
1standard O +
deviation O +
if O +
intake O +
of O +
fat O +
in O +
the O +
subcohort O +
( O -
see O +
Table O +
1 O -
) O -
; O +
i.e. O -
, O +
7.5 O +
g O -
/ O -
day O +
for O +
polyunsaturated O +
fat O +
and O +
7.5 O +
g O -
/ O -
day O +
for O +
linoleic O +
acid O +

Likewise O -
, O +
additional O +
analyses O +
were O +
conducted O +
for O +
saturated O +
fat O +
intake O +
in O +
relation O +
to O +
risk O +
of O +
rectal O +
cancer O +
without O +
APC B-Gene +
truncating O +
mutations O -
, O +
also O +
excluding O +
individuals O +
with O +
a O +
KRAS B-Gene +
mutation O +
and O +
lack O +
of O +
MLH1 B-Gene +
expression O -
. O +

The O +
association O +
did O +
not O +
change O +
substantially O -
. O +

Again O -
, O +
only O +
the O +
highest O +
level O +
of O +
intake O +
showed O +
a O +
significant O +
reduced O +
risk O +
of O +
cancer O +
compared O +
to O +
the O +
reference O +
category O +
( O -
RR O +
0.40 O +
95 O -
% O +
CI O +
0.14–1.15 O -
, O +
p O -
- O -
trend O +
= O +
0.09 O -
) O -
. O +

Discussion O +
In O +
this O +
prospective O +
study O -
, O +
we O +
observed O +
that O +
the O +
intake O +
of O +
total O -
, O +
saturated O +
and O +
monounsaturated O +
fat O +
was O +
not O +
associated O +
with O +
the O +
risk O +
of O +
colon O +
cancer O -
, O +
rectal O +
cancer O -
, O +
or O +
the O +
different O +
molecular O +
subgroups O +
of O +
cancer O +
based O +
on O +
lack O +
of O +
MLH1 B-Gene +
expression O +
or O +
truncating O +
mutations O +
in O +
the O +
APC B-Gene +
gene O -
. O +

This O +
was O +
also O +
found O +
for O +
polyunsaturated O +
fat O +
intake O +
and O +
rectal O +
cancer O -
. O +

However O -
, O +
linoleic O +
acid O +
showed O +
an O +
association O +
with O +
increased O +
risk O +
of O +
colon O +
tumors O +
with O +
only O +
an O +
activated O +
KRAS B-Gene +
mutation O +
and O +
no O +
additional O +
truncating O +
APC B-Gene +
mutation O +
or O +
lack O +
of O +
MLH1 B-Gene +
expression O -
. O +

None O +
of O +
the O +
other O +
epidemiological O +
studies O +
report O +
on O +
specific O +
fatty O +
acids O +
and O +
the O +
risk O +
of O +
molecular O +
surrogate O +
end O -
- O -
points O +
for O +
colon O +
or O +
rectal O +
cancer O +
or O +
adenomas O +
[ O -
35–43 O -
] O -
. O +

Some O +
of O +
these O +
studies O +
report O +
on O +
various O +
types O +
of O +
fat O +
depending O +
on O +
saturation O +
level O -
, O +
but O +
the O +
results O +
are O +
inconsistent O +
across O +
the O +
studies O +
[ O -
35 O -
, O +
38 O -
, O +
41 O -
, O +
42 O -
] O +
including O +
the O +
current O +
study O -
. O +

Diergaarde O +
et O +
al. O +
observed O +
unsaturated O +
fat O +
intake O +
to O +
be O +
associated O +
with O +
increased O +
colon O +
carcinomas O +
with O +
a O +
truncating O +
APC B-Gene +
mutation O +
[ O -
38 O -
] O -
. O +

No O +
distinction O +
was O +
made O +
between O +
mono- O +
and O +
polyunsaturated O +
fats O -
. O +

In O +
our O +
study O -
, O +
we O +
did O +
not O +
observe O +
any O +
association O +
between O +
various O +
types O +
of O +
fat O +
intake O +
and O +
risk O +
of O +
colon O +
or O +
rectal O +
cancer O +
with O +
or O +
without O +
truncating O +
APC B-Gene +
mutations O +
after O +
patients O +
also O +
harboring O +
a O +
KRAS B-Gene +
mutation O +
in O +
their O +
tumor O +
were O +
excluded O +
from O +
the O +
analyses O -
. O +

We O +
observed O +
a O +
possible O +
inverse O +
association O +
between O +
saturated O +
fat O +
intake O +
and O +
risk O +
of O +
rectal O +
tumors O +
without O +
a O +
truncating O +
APC B-Gene +
mutation O -
. O +

However O -
, O +
the O +
association O +
was O +
weak O -
, O +
did O +
not O +
increase O +
gradually O +
according O +
to O +
the O +
quartiles O +
of O +
intake O +
and O +
was O +
only O +
a O +
result O +
of O +
the O +
reduced O +
risk O +
in O +
the O +
highest O +
category O +
of O +
intake O -
. O +

Furthermore O -
, O +
in O +
absence O +
of O +
a O +
biological O +
explanation O +
for O +
this O +
finding O +
and O +
considering O +
the O +
large O +
number O +
of O +
associations O +
investigated O -
, O +
the O +
observation O +
may O +
best O +
be O +
attributed O +
to O +
chance O -
. O +

Slattery O +
et O +
al. O +
observed O +
saturated O +
and O +
monounsaturated O +
fats O -
, O +
but O +
not O +
polyunsaturated O +
fat O -
, O +
to O +
be O +
associated O +
with O +
increased O +
risk O +
of O +
colon O +
tumors O +
with O +
specific O +
KRAS B-Gene +
mutations O -
, O +
i.e. O -
, O +
a O +
G→T O +
transversion O +
at O +
codon O +
12 O +
[ O -
41 O -
] O -
. O +

No O +
distinction O +
was O +
made O +
between O +
ω-6 O +
and O +
ω-3 O +
fatty O +
acids O -
. O +

We O +
observed O +
an O +
association O +
between O +
polyunsaturated O +
fat O +
intake O -
, O +
especially O +
linoleic O +
acid O -
, O +
and O +
increased O +
risk O +
of O +
colon O +
tumors O +
with O +
a O +
KRAS B-Gene +
mutation O -
, O +
regardless O +
of O +
the O +
type O +
of O +
mutations O +
[ O -
22 O -
] O -
. O +

Finally O -
, O +
Bautista O +
et O +
al. O +
observed O +
an O +
inverse O +
association O +
between O +
monounsaturated O +
fats O -
, O +
mostly O +
derived O +
from O +
olive O +
oil O +
in O +
the O +
Spanish O +
diet O -
, O +
and O +
risk O +
of O +
colon O +
cancer O +
without O +
KRAS B-Gene +
mutations O +
[ O -
35 O -
] O -
. O +

Since O +
olive O +
oil O +
was O +
rarely O +
consumed O +
by O +
this O +
elderly O +
Dutch O +
population O +
in O +
the O +
years O +
preceding O +
1986 O +
( O -
the O +
cohort O +
baseline O -
) O -
, O +
this O +
could O +
explain O +
the O +
lack O +
of O +
association O +
for O +
this O +
type O +
of O +
fat O +
in O +
our O +
study O -
. O +

However O -
, O +
a O +
recent O +
Dutch O +
case O -
– O -
control O +
study O +
on O +
risk O +
factors O +
for O +
colorectal O +
adenomas O +
showed O +
a O +
significant O +
positive O +
association O +
between O +
monounsaturated O +
fats O +
and O +
adenoma O +
risk O +
[ O -
42 O -
] O -
. O +

Several O +
factors O +
hamper O +
comparisons O +
between O +
our O +
findings O +
and O +
those O +
of O +
other O +
epidemiological O +
studies O +
and O +
may O +
in O +
part O +
explain O +
observed O +
inconsistencies O -
. O +

First O -
, O +
our O +
study O +
is O +
the O +
first O +
large O +
prospective O +
cohort O +
study O +
incorporating O +
molecular O +
end O -
- O -
points O +
for O +
colon O +
and O +
rectal O +
cancer O -
. O +

One O +
of O +
the O +
other O +
studies O +
was O +
a O +
cross O -
- O -
sectional O +
case O -
– O -
case O +
comparison O +
study O +
[ O -
40 O -
] O -
, O +
and O +
the O +
others O +
were O +
case O -
– O -
control O +
studies O +
of O +
varying O +
size O +
( O -
ranging O +
from O +
108 O +
to O +
1,510 O +
cases O -
) O +
[ O -
35–39 O -
, O +
41–43 O -
] O -
. O +

Second O -
, O +
varying O +
end O -
- O -
points O +
were O +
considered O -
. O +

Three O +
of O +
the O +
other O +
studies O +
focused O +
on O +
adenomas O +
instead O +
of O +
carcinomas O +
[ O -
37 O -
, O +
40 O -
, O +
42 O -
] O -
, O +
and O +
three O +
studies O +
also O +
incorporated O +
rectal O +
tumors O +
but O +
did O +
not O +
distinguish O +
between O +
colon O +
and O +
rectum O +
[ O -
35 O -
, O +
37 O -
, O +
42 O -
] O -
. O +

Previously O -
, O +
we O +
reported O +
the O +
association O +
between O +
linoleic O +
acid O +
intake O +
and O +
increased O +
risk O +
of O +
colon O +
tumors O +
with O +
KRAS B-Gene +
mutations O +
( O -
adjusted O +
RR O +
for O +
one O +
standard O +
deviation O +
of O +
increase O +
1.22 O +
( O -
95 O -
% O +
CI O +
1.05–1.42 O -
) O -
) O +
[ O -
22 O -
] O -
. O +

Now O -
, O +
we O +
report O +
that O +
the O +
association O +
appears O +
to O +
be O +
confined O +
to O +
those O +
colon O +
tumors O +
with O +
activating O +
KRAS B-Gene +
mutations O +
and O +
an O +
otherwise O +
intact O +
APC B-Gene +
gene O +
and O +
with O +
MLH1 B-Gene +
expression O -
. O +

In O +
addition O -
, O +
the O +
association O +
appears O +
to O +
be O +
robust O +
since O +
RRs O +
clearly O +
increase O +
over O +
the O +
quartiles O +
of O +
linoleic O +
acid O +
intake O +
and O +
the O +
RRs O +
for O +
one O +
standard O +
deviation O +
increase O +
in O +
linoleic O +
acid O +
intake O +
are O +
similar O +
for O +
men O +
and O +
women O -
, O +
and O +
is O +
increased O +
for O +
proximal O +
and O +
distal O +
colon O +
cancer O +
as O +
well O +
as O +
for O +
overall O +
colorectal O +
cancer O -
, O +
including O +
the O +
rectosigmoid O -
. O +

The O +
activating O +
KRAS B-Gene +
mutations O +
at O +
codons O +
12 O +
and O +
13 O +
are O +
predominantly O +
G→T O +
and O +
G→A O +
mutations O +
[ O -
27 O -
] O +
which O +
could O +
be O +
a O +
result O +
of O +
MDA O +
DNA O +
adduct O +
formation O +
[ O -
18 O -
, O +
19 O -
] O +
associated O +
with O +
increased O +
ω-6 O +
polyunsaturated O +
fat O +
intake O +
[ O -
21 O -
] O -
. O +

Therefore O -
, O +
even O +
though O +
chance O +
can O -
not O +
be O +
ruled O +
out O +
and O +
verification O +
by O +
others O +
is O +
warranted O -
, O +
the O +
association O +
seems O +
quite O +
plausible O -
. O +

Still O +
several O +
issues O +
remain O +
puzzling O -
. O +

First O -
, O +
why O +
is O +
the O +
observed O +
association O +
for O +
linoleic O +
acid O +
confined O +
to O +
colon O +
cancer O +
and O +
not O +
rectum O +
cancer O +
with O +
only O +
a O +
KRAS B-Gene +
mutation O -
? O +

The O +
multistep O +
model O +
for O +
molecular O +
aberrations O +
underlying O +
colorectal O +
carcinogenesis O +
is O +
likely O +
to O +
apply O +
equally O +
for O +
both O +
tumor O +
subsites O +
[ O -
7 O -
, O +
8 O -
, O +
15 O -
] O -
. O +

However O -
, O +
lack O +
of O +
MLH1 B-Gene +
expression O +
in O +
our O +
study O +
is O +
rare O +
among O +
rectum O +
cancer O +
patients O +
and O +
there O +
is O +
growing O +
evidence O +
for O +
differences O +
in O +
the O +
etiology O +
of O +
colon O +
and O +
rectal O +
tumors O +
[ O -
33 O -
] O -
. O +

Second O -
, O +
why O +
is O +
the O +
association O +
with O +
linoleic O +
acid O +
observed O +
for O +
KRAS B-Gene +
and O +
not O +
for O +
truncating O +
APC B-Gene +
gene O +
mutations O -
? O +

It O +
is O +
unlikely O +
that O +
adduct O +
formation O +
selectively O +
occurs O +
in O +
one O +
gene O +
but O +
not O +
in O +
the O +
other O -
. O +

However O -
, O +
KRAS B-Gene +
is O +
an O +
oncogene O +
requiring O +
only O +
one O +
mutation O +
for O +
the O +
gene O +
to O +
be O +
activated O -
, O +
whereas O +
APC B-Gene +
is O +
a O +
tumor O +
suppressor O +
gene O +
requiring O +
an O +
additional O +
aberration O +
in O +
the O +
other O +
allele O +
for O +
loss O +
of O +
function O -
. O +

In O +
addition O -
, O +
more O +
than O +
half O +
of O +
the O +
patients O +
with O +
an O +
APC B-Gene +
mutation O +
had O +
multiple O +
mutations O +
in O +
this O +
gene O +
[ O -
25 O -
] O -
, O +
complicating O +
data O +
analyses O +
and O +
interpretation O -
. O +

Additional O +
analyses O +
for O +
subgroups O +
of O +
colon O +
tumors O +
with O +
specific O +
truncating O +
point O +
mutations O +
in O +
APC B-Gene +
did O +
not O +
show O +
any O +
associations O +
with O +
the O +
intake O +
of O +
fat O +
or O +
different O +
types O +
of O +
fat O -
. O +

mRNA O -
/ O -
microRNA O +
gene O +
expression O +
profile O +
in O +
microsatellite O +
unstable O +
colorectal O +
cancer O +
Abstract O +
Background O +
Colorectal O +
cancer O +
develops O +
through O +
two O +
main O +
genetic O +
instability O +
pathways O +
characterized O +
by O +
distinct O +
pathologic O +
features O +
and O +
clinical O +
outcome O -
. O +

Results O +
We O +
investigated O +
colon O +
cancer O +
samples O +
( O -
23 O +
characterized O +
by O +
microsatellite O +
stability O -
, O +
MSS O -
, O +
and O +
16 O +
by O +
high O +
microsatellite O +
instability O -
, O +
MSI O -
- O -
H O -
) O +
for O +
genome O -
- O -
wide O +
expression O +
of O +
microRNA O +
( O -
miRNA O -
) O +
and O +
mRNA O -
. O +

Based O +
on O +
combined O +
miRNA O +
and O +
mRNA O +
gene O +
expression O -
, O +
a O +
molecular O +
signature O +
consisting O +
of O +
twenty O +
seven O +
differentially O +
expressed O +
genes O -
, O +
inclusive O +
of O +
8 O +
miRNAs O -
, O +
could O +
correctly O +
distinguish O +
MSI O -
- O -
H O +
versus O +
MSS O +
colon O +
cancer O +
samples O -
. O +

Among O +
the O +
differentially O +
expressed O +
miRNAs O -
, O +
various O +
members O +
of O +
the O +
oncogenic O +
miR-17 O -
- O -
92 O +
family O +
were O +
significantly O +
up O -
- O -
regulated O +
in O +
MSS O +
cancers O -
. O +

The O +
majority O +
of O +
protein O +
coding O +
genes O +
were O +
also O +
up O -
- O -
regulated O +
in O +
MSS O +
cancers O -
. O +

Their O +
functional O +
classification O +
revealed O +
that O +
they O +
were O +
most O +
frequently O +
associated O +
with O +
cell O +
cycle O -
, O +
DNA O +
replication O -
, O +
recombination O -
, O +
repair O -
, O +
gastrointestinal O +
disease O +
and O +
immune O +
response O -
. O +

Conclusion O +
This O +
is O +
the O +
first O +
report O +
that O +
indicates O +
the O +
existence O +
of O +
differences O +
in O +
miRNA O +
expression O +
between O +
MSS O +
versus O +
MSI O -
- O -
H O +
colorectal O +
cancers O -
. O +

In O +
addition O -
, O +
the O +
work O +
suggests O +
that O +
the O +
combination O +
of O +
mRNA O -
/ O -
miRNA O +
expression O +
signatures O +
may O +
represent O +
a O +
general O +
approach O +
for O +
improving O +
bio O -
- O -
molecular O +
classification O +
of O +
human O +
cancer O -
. O +

Background O +
Colorectal O +
cancer O +
develops O +
through O +
two O +
main O +
genetic O +
pathways O +
characterized O +
by O +
different O +
forms O +
of O +
genomic O +
instability O +
[ O -
1 O -
] O -
. O +

Most O +
tumors O +
are O +
generated O +
by O +
the O +
chromosomal O +
instability O +
( O -
CIN O -
) O +
pathway O +
and O +
display O +
marked O +
cytogenetic O +
abnormalities O -
, O +
aneuploidy O +
and O +
allelic O +
losses O +
at O +
multiple O +
chromosomal O +
arms O -
. O +

CIN O +
is O +
probably O +
caused O +
by O +
various O +
molecular O +
mechanisms O -
, O +
but O +
the O +
underlying O +
genetic O +
alterations O +
are O +
still O +
poorly O +
defined O -
. O +

About O +
15 O -
% O +
of O +
colorectal O +
carcinomas O +
develop O +
through O +
the O +
microsatellite O +
instability O +
( O -
MSI O -
) O +
pathway O -
. O +

MSI O +
tumors O +
show O +
stable O +
karyotype O -
, O +
low O +
frequencies O +
of O +
allelic O +
losses O +
and O +
diploid O +
nuclear O +
DNA O +
content O -
. O +

MSI O +
results O +
from O +
defects O +
in O +
the O +
DNA O +
mismatch O +
repair O +
system O +
( O -
MMR B-Gene -
) O +
[ O -
2 O -
] O -
. O +

In O +
HNPCC O -
, O +
MSI O +
is O +
produced O +
by O +
germline O +
mutations O +
of O +
one O +
of O +
the O +
MMR B-Gene +
genes O +
( O -
MLH1 B-Gene -
, O +
MSH2 B-Gene +
and O +
less O +
frequently O +
MSH6 B-Gene +
and O +
PMS2 B-Gene -
) O +
with O +
somatic O +
inactivation O +
of O +
the O +
wild O -
- O -
type O +
allele O +
[ O -
3,4 O -
] O -
. O +

In O +
sporadic O +
tumors O -
, O +
MMR O +
deficiency O +
is O +
near O +
always O +
determined O +
by O +
epigenetic O +
inactivation O +
of O +
the O +
MLH1 B-Gene +
gene O +
by O +
biallelic O +
promoter O +
methylation O +
[ O -
5 O -
- O -
7 O -
] O -
. O +

MSI O +
colorectal O +
adenocarcinomas O +
display O +
distinctive O +
pathologic O +
features O -
, O +
such O +
as O +
proximal O +
location O -
, O +
poor O +
differentiation O -
, O +
frequent O +
mucinous O +
and O +
medullary O +
phenotype O -
, O +
and O +
marked O +
peritumoral O +
and O +
intratumoral O +
lymphocytic O +
infiltration O +
[ O -
8 O -
- O -
10 O -
] O -
. O +

MSI O +
carcinomas O +
have O +
a O +
more O +
favorable O +
clinical O +
outcome O +
than O +
non O -
- O -
MSI O +
tumors O +
and O +
the O +
survival O +
advantage O +
conferred O +
by O +
the O +
MSI O +
phenotype O +
is O +
independent O +
of O +
tumor O +
stage O +
and O +
other O +
clinical O +
and O +
pathological O +
variables O +
[ O -
11 O -
- O -
13 O -
] O -
. O +

In O +
addition O -
, O +
MMR O -
- O -
deficient O +
cancer O +
cells O +
are O +
thought O +
to O +
be O +
less O +
responsive O +
to O +
5-fluorouracil O +
and O +
other O +
chemotherapeutic O +
agents O +
in O +
vitro O +
and O +
in O +
vivo O +
[ O -
14 O -
- O -
16 O -
] O -
. O +

Gene O +
expression O +
analysis O +
based O +
on O +
genome O -
- O -
wide O +
microarrays O +
has O +
been O +
largely O +
used O +
to O +
characterize O +
human O +
cancers O -
. O +

This O +
approach O +
allowed O +
the O +
identification O +
of O +
genes O +
important O +
in O +
tumorigenesis O -
. O +

Furthermore O -
, O +
the O +
discovery O +
of O +
gene O +
expression O +
signatures O +
characteristic O +
of O +
distinctive O +
clinico O -
- O -
pathological O +
features O +
suggested O +
that O +
expression O +
profiles O +
could O +
be O +
used O +
for O +
molecular O +
classification O +
of O +
human O +
cancer O +
[ O -
17 O -
- O -
20 O -
] O -
. O +

Microarray O +
tools O +
have O +
been O +
recently O +
enriched O +
by O +
the O +
development O +
of O +
platforms O +
for O +
the O +
analysis O +
of O +
microRNAs O +
( O -
miRNA O -
) O +
expression O +
[ O -
21,22 O -
] O -
. O +

miRNAs O +
are O +
a O +
class O +
of O +
small O +
non O -
- O -
coding O +
RNAs O +
involved O +
in O +
temporal O +
and O +
tissue O -
- O -
specific O +
eukaryotic O +
gene O +
regulation O +
[ O -
23 O -
] O -
. O +

Comparison O +
between O +
human O +
cancers O +
and O +
their O +
normal O +
counterparts O +
revealed O +
that O +
miRNAs O +
exhibit O +
differential O +
expression O +
profiles O +
in O +
normal O +
versus O +
cancer O +
tissues O +
[ O -
24 O -
- O -
29 O -
] O -
. O +

These O +
studies O +
revealed O +
that O +
some O +
human O +
miRNAs O +
are O +
consistently O +
deregulated O +
in O +
human O +
cancer O -
, O +
suggesting O +
a O +
role O +
in O +
tumorigenesis O +
either O +
as O +
oncogenes O +
or O +
tumor O +
suppressor O +
genes O +
[ O -
30 O -
- O -
32 O -
] O -
. O +

Unique O +
miRNA O +
expression O +
signatures O +
were O +
found O +
to O +
be O +
associated O +
with O +
bio O -
- O -
molecular O +
and O +
prognostic O +
characteristics O +
of O +
human O +
lung O +
cancer O +
and O +
chronic O +
lymphocytic O +
leukemia O +
[ O -
24,33 O -
] O -
, O +
indicating O +
that O +
miRNA O +
signatures O +
could O +
be O +
used O +
to O +
define O +
biological O +
or O +
clinical O +
features O +
of O +
human O +
cancers O -
. O +

Known O +
function O +
of O +
mammalian O +
miRNAs O +
is O +
to O +
post O -
- O -
transcriptionally O +
regulate O +
target O +
mRNAs O -
, O +
implying O +
that O +
the O +
combination O +
of O +
miRNAs O +
and O +
mRNAs O +
expression O +
may O +
better O +
represent O +
the O +
transcriptional O +
program O +
that O +
dictates O +
normal O +
and O +
tumor O +
cell O +
characteristics O -
. O +

Here O -
, O +
we O +
identified O +
differentially O +
expressed O +
miRNAs O +
and O +
mRNAs O +
able O +
to O +
distinguish O +
colon O +
cancers O +
with O +
or O +
without O +
microsatellite O +
instability O -
. O +

Results O +
We O +
analyzed O +
miRNA O +
and O +
mRNA O +
expression O +
using O +
microarrays O +
in O +
a O +
set O +
of O +
microsatellite O +
stable O +
( O -
MSS O -
) O +
and O +
unstable O +
( O -
MSI O -
- O -
H O -
) O +
colorectal O +
cancers O +
( O -
23 O +
MSS O +
and O +
16 O +
MSI O -
- O -
H O -
) O +
( O -
Table O +
1 O -
) O +
with O +
the O +
aim O +
of O +
recognizing O +
the O +
most O +
significant O +
differences O +
in O +
gene O +
expression O -
. O +

In O +
particular O -
, O +
this O +
is O +
the O +
first O +
study O +
that O +
investigates O +
the O +
differences O +
in O +
miRNAs O +
expression O +
between O +
MSS O +
and O +
MSI O +
tumors O -
. O +

Clinical O +
and O +
bio O -
- O -
pathological O +
features O +
of O +
colorectal O +
carcinomas O +
employed O +
in O +
the O +
study O -
. O +

* O +
Evaluated O +
with O +
Chi O -
- O -
square O +
test O +
or O +
the O +
Fisher O -
's O +
Exact O +
test O +
NS O -
, O +
not O +
significant O +
We O +
carried O +
out O +
initial O +
studies O +
on O +
miRNA O +
and O +
mRNA O -
- O -
chip O +
data O +
separately O -
. O +

The O +
analysis O +
of O +
miRNA O +
expression O +
profiles O +
of O +
MSI O -
- O -
H O +
versus O +
MSS O +
tumors O +
identified O +
14 O +
differentially O +
expressed O +
miRNAs O +
( O -
p O +
< O +
0.05 O -
) O -
. O +

Additional O +
file O +
1 O +
provides O +
the O +
list O +
of O +
deregulated O +
miRNAs O +
and O +
their O +
mean O +
expression O +
values O +
and O +
standard O +
errors O +
in O +
the O +
two O +
groups O -
. O +

The O +
analysis O +
of O +
mRNA O +
expression O +
profiles O +
of O +
MSI O -
- O -
H O +
versus O +
MSS O +
identified O +
a O +
large O +
number O +
of O +
differentially O +
expressed O +
genes O +
( O -
451 O +
genes O +
at O +
p O +
< O +
0.05 O -
; O +
Additional O +
file O +
2 O -
) O -
. O +

By O +
using O +
the O +
more O +
stringent O +
Bonferroni O +
multiple O +
testing O +
correction O +
at O +
p O +
< O +
0.05 O -
, O +
a O +
sub O -
- O -
list O +
of O +
72 O +
differentially O +
expressed O +
mRNAs O +
was O +
identified O +
( O -
Additional O +
file O +
3 O -
) O -
. O +

To O +
visually O +
assess O +
the O +
ability O +
of O +
the O +
differentially O +
expressed O +
miRNAs O +
and O +
mRNAs O +
to O +
distinguish O +
MSS O +
versus O +
MSI O -
- O -
H O +
tumors O -
, O +
we O +
applied O +
the O +
combination O +
of O +
the O +
86 O +
differentially O +
expressed O +
miRNAs O +
and O +
mRNAs O +
to O +
perform O +
a O +
supervised O +
cluster O +
analysis O -
. O +

Using O +
this O +
combined O +
set O +
of O +
genes O -
, O +
a O +
perfect O +
classification O +
of O +
the O +
tumor O +
samples O +
resulted O +
( O -
Figure O +
1 O -
) O -
. O +

The O +
combination O +
of O +
the O +
two O +
sets O +
of O +
genes O +
resulted O +
also O +
in O +
an O +
improvement O +
in O +
the O +
separation O +
of O +
the O +
MSS O +
versus O +
the O +
MSI O +
tumor O +
samples O +
in O +
comparison O +
to O +
the O +
individual O +
sets O +
( O -
see O +
Additional O +
files O +
4 O +
and O +
5 O -
) O -
. O +

Supervised O +
hierarchical O +
clustering O +
of O +
39 O +
colon O +
cancer O +
samples O +
( O -
23 O +
MSS O +
and O +
16 O +
MSI O -
- O -
H O -
) O +
using O +
expression O +
data O +
from O +
the O +
list O +
of O +
86 O +
differentially O +
expressed O +
mRNA O -
/ O -
miRNA O +
genes O +
described O +
in O +
Supplemental O +
Tables O +
1 O +
and O +
3 O -
. O +

Columns O +
display O +
the O +
clustering O +
of O +
tumor O +
samples O -
; O +
rows O +
the O +
clustering O +
of O +
genes O -
. O +

MSI O +
status O +
is O +
indicated O +
by O +
colored O +
squares O -
: O +
red O +
for O +
MSS O +
and O +
yellow O +
for O +
MSI O -
- O -
H O +
tumor O +
samples O -
. O +

All O +
sample O +
were O +
properly O +
assigned O +
to O +
the O +
correct O +
class O -
. O +

The O +
expression O +
intensity O +
of O +
each O +
gene O +
in O +
each O +
sample O +
varies O +
from O +
red O +
to O +
green O -
: O +
red O +
color O +
means O +
an O +
expression O +
value O +
over O +
the O +
average O +
across O +
samples O -
, O +
green O +
color O +
the O +
opposite O -
. O +

For O +
quantification O +
of O +
color O +
codes O -
, O +
see O +
color O -
- O -
bar O +
on O +
the O +
right O -
. O +

A O +
smaller O +
selected O +
signature O +
of O +
best O +
predictors O +
of O +
microsatellite O +
status O +
was O +
generated O +
by O +
applying O +
Support O +
Vector O +
Machine O +
( O -
SVM O -
) O +
( O -
GeneSpring O +
software O -
) O +
and O +
Prediction O +
Analysis O +
of O +
Microarrays O +
( O -
PAM O -
) O +
algorithms O +
to O +
the O +
86 O +
differentially O +
expressed O +
miRNAs O +
and O +
mRNAs O -
: O +
27 O +
genes O +
( O -
inclusive O +
of O +
mRNAs O +
and O +
miRNAs O -
) O +
were O +
identified O +
as O +
predictors O +
by O +
at O +
least O +
one O +
of O +
the O +
two O +
algorithms O +
( O -
Table O +
2 O -
) O -
. O +

Cluster O +
analysis O +
with O +
these O +
27 O +
miRNA O -
/ O -
mRNAs O +
still O +
produced O +
a O +
perfect O +
separation O +
between O +
the O +
two O +
tumor O +
classes O -
, O +
and O +
a O +
PAM O +
plot O +
displayed O +
a O +
correct O +
predictions O +
for O +
all O +
the O +
samples O +
( O -
Figure O +
2 O -
) O -
. O +

The O +
prediction O +
of O +
MSI O +
status O +
obtained O +
with O +
72 O +
mRNAs O +
or O +
14 O +
miRNAs O +
signatures O +
did O +
not O +
perform O +
equally O +
well O +
when O +
tested O +
independently O -
. O +

Of O +
the O +
39 O +
samples O -
, O +
the O +
miRNA O -
- O -
only O +
signature O +
could O +
correctly O +
predict O +
36 O +
samples O +
using O +
SVM O +
or O +
33 O +
using O +
PAM O +
algorithms O -
, O +
and O +
the O +
mRNA O -
- O -
only O +
signature O +
could O +
correctly O +
predict O +
38 O +
samples O +
using O +
SVM O +
or O +
39 O +
using O +
PAM O -
. O +

Predictors O +
of O +
microsatellite O +
status O +
identified O +
by O +
Support O +
Vector O +
Machine O +
and O +
PAM O +
algorithms O -
. O +

* O +
SVM O -
: O +
Support O +
Vector O +
Machine O -
; O +
PAM O -
: O +
Prediction O +
Analysis O +
of O +
Microarray O +
Prediction O +
of O +
microsatellite O +
instability O -
. O +

( O -
A O -
) O +
Prediction O +
of O +
MSI O +
status O +
for O +
39 O +
samples O +
using O +
the O +
PAM O +
cross O -
- O -
validation O +
procedure O -
. O +

The O +
graphical O +
representation O +
shows O +
the O +
probabilities O +
( O -
0.0 O +
to O +
1.0 O -
) O +
of O +
each O +
tumor O +
for O +
being O +
MSS O +
( O -
pink O +
dot O -
) O +
or O +
MSI O -
- O -
H O +
( O -
blue O +
dot O -
) O -
. O +

All O +
tumors O +
were O +
correctly O +
assigned O -
. O +

( O -
B O -
) O +
Supervised O +
hierarchical O +
clustering O +
of O +
colon O +
cancer O +
samples O +
using O +
expression O +
data O +
from O +
the O +
27 O +
predictor O +
mRNA O -
/ O -
miRNA O +
genes O +
described O +
in O +
Table O +
2 O -
. O +

Using O +
the O +
predictors O +
for O +
the O +
cluster O +
analysis O -
, O +
a O +
good O +
separation O +
among O +
colorectal O +
cancers O +
in O +
MSS O +
( O -
red O -
) O +
and O +
MSI O -
- O -
H O +
( O -
yellow O -
) O +
groups O +
was O +
achieved O -
. O +

Expression O +
intensity O +
is O +
shown O +
as O +
described O +
in O +
Figure O +
1 O -
. O +

Confirmation O +
of O +
the O +
differential O +
expression O +
for O +
some O +
of O +
the O +
signature O +
genes O +
was O +
achieved O +
by O +
Northern O +
blot O +
to O +
validate O +
miRNA O +
expression O +
and O +
Real O +
time O +
RT O -
- O -
PCR O +
to O +
validate O +
expression O +
of O +
mRNAs O -
. O +

Figure O +
3A O +
shows O +
the O +
expression O +
of O +
miR-25 O +
and O +
miR-92 O +
as O +
detected O +
by O +
Northern O +
blot O -
. O +

This O +
analysis O +
confirmed O +
that O +
the O +
expression O +
of O +
these O +
miRNAs O +
is O +
increased O +
in O +
MSS O +
samples O +
as O +
detected O +
by O +
microarray O +
analysis O -
. O +

Similarly O -
, O +
the O +
evaluation O +
of O +
expression O +
of O +
5 O +
protein O -
- O -
coding O +
genes O +
showed O +
an O +
overlap O +
with O +
the O +
expression O +
values O +
obtained O +
by O +
microarray O +
analysis O +
( O -
Figure O +
3B O -
) O -
. O +

Confirmation O +
of O +
microarray O +
data O -
. O +

( O -
A O -
) O +
Northern O +
blot O +
analysis O +
of O +
miRNAs O +
miR-25 O +
and O +
miR-92 O -
. O +

As O +
expected O +
from O +
microarray O +
data O -
, O +
Northern O +
blot O +
analysis O +
confirmed O +
that O +
these O +
miRNAs O +
were O +
up O -
- O -
regulated O +
in O +
MSS O +
samples O -
. O +

miRNA O -
/ O -
U6 O +
ratio O +
of O +
densitometric O +
intensities O +
is O +
shown O +
below O +
each O +
miRNA O +
lane O -
. O +

( O -
B O -
) O +
Quantitative O +
Real O +
time O +
RT O -
- O -
PCR O +
validation O +
of O +
microarray O +
results O -
. O +

Microarray O +
expression O +
values O +
of O +
a O +
selected O +
panel O +
of O +
5 O +
genes O +
differentially O +
expressed O +
between O +
MSS O +
and O +
MSI O -
- O -
H O +
groups O +
of O +
colorectal O +
cancers O +
were O +
validated O +
with O +
quantitative O +
real O -
- O -
time O +
PCR O -
. O +

Values O +
for O +
microarray O +
data O +
were O +
normalized O +
on O +
chip O +
50th O +
percentile O +
while O +
for O +
real O -
- O -
time O +
PCR O +
values O +
are O +
equal O +
to O +
ΔCt*10 O -
^ O -
6 O -
. O +

In O +
this O +
report O -
, O +
quantitative O +
real O +
time O +
PCRs O +
for O +
differentially O +
expressed O +
mRNAs O +
and O +
Northern O +
blot O +
for O +
differentially O +
expressed O +
miRNAs O +
were O +
performed O +
to O +
validate O +
microarray O +
expression O +
data O -
. O +

These O +
methods O +
confirmed O +
the O +
differential O +
expression O +
detected O +
by O +
microarray O -
- O -
based O +
expression O +
methods O -
. O +

Additional O +
evidence O +
for O +
the O +
robustness O +
of O +
data O +
was O +
the O +
finding O +
that O +
the O +
MLH1 B-Gene +
gene O +
is O +
among O +
the O +
most O +
significantly O +
( O -
P O +
< O +
0.001 O -
) O +
down O -
- O -
regulated O +
genes O +
in O +
MSI O -
- O -
H O +
tumors O +
versus O +
the O +
MSS O +
cancer O +
set O +
( O -
Additional O +
file O +
2 O -
) O -
. O +

Indeed O -
, O +
this O +
gene O +
represents O +
a O +
sort O +
of O +
internal O +
control O -
, O +
since O +
it O +
is O +
well O -
- O -
known O +
that O +
the O +
loss O +
of O +
MLH1 B-Gene +
function O -
, O +
which O +
confers O +
the O +
microsatellite O +
instability O +
phenotype O +
to O +
tumor O +
samples O -
, O +
is O +
caused O +
by O +
transcriptional O +
silencing O +
due O +
to O +
promoter O +
methylation O +
in O +
MSI O +
tumors O +
[ O -
5,6 O -
] O -
. O +

In O +
addition O +
to O +
their O +
role O +
as O +
discriminating O +
markers O +
of O +
MSS O +
versus O +
MSI O -
- O -
H O +
tumors O -
, O +
some O +
of O +
the O +
gene O -
- O -
associated O +
functions O +
may O +
possibly O +
be O +
involved O +
in O +
the O +
different O +
phenotypes O +
that O +
characterize O +
the O +
two O +
types O +
of O +
colon O +
cancers O -
. O +

In O +
fact O -
, O +
analysis O +
of O +
the O +
functions O +
associated O +
with O +
212 O +
( O -
for O +
which O +
annotation O +
was O +
present O -
) O +
of O +
the O +
451 O +
differentially O +
expressed O +
genes O +
revealed O +
that O +
the O +
most O +
frequently O +
associated O +
classes O +
were O +
cell O +
cycle O -
, O +
DNA O +
replication O -
, O +
recombination O -
, O +
repair O -
, O +
gastrointestinal O +
disease O +
and O +
immune O +
response O +
( O -
Additional O +
file O +
7 O -
) O -
, O +
suggesting O +
that O +
these O +
molecular O +
differences O +
may O +
be O +
responsible O +
for O +
traits O +
that O +
distinguish O +
MSS O +
and O +
MSI O -
- O -
H O +
tumors O -
. O +

Additional O +
studies O +
on O +
the O +
molecular O +
and O +
biological O +
functions O +
of O +
these O +
differentially O +
expressed O +
genes O +
will O +
be O +
required O +
to O +
substantiate O +
this O +
hypothesis O -
. O +

Among O +
the O +
differentially O +
expressed O +
genes O -
, O +
it O +
is O +
interesting O +
to O +
note O +
the O +
detection O +
of O +
the O +
up O -
- O -
regulation O +
of O +
several O +
members O +
of O +
the O +
mir-17 O -
- O -
92 O +
family O +
in O +
the O +
MSS O +
colon O +
cancers O -
. O +

This O +
family O +
includes O +
fourteen O +
homologous O +
miRNAs O +
organized O +
in O +
three O +
gene O +
clusters O +
[ O -
38 O -
] O -
. O +

Our O +
study O +
revealed O +
that O -
, O +
among O +
these O -
, O +
miR-17 O -
- O -
5p O -
, O +
miR-20 O -
, O +
miR-25 O -
, O +
miR-92 O -
- O -
1 O -
, O +
miR-92 O -
- O -
2 O -
, O +
miR-93 O -
- O -
1 O +
and O +
miR-106a O +
were O +
significantly O +
up O -
- O -
regulated O +
in O +
MSS O +
versus O +
MSI O -
- O -
H O +
colon O +
cancer O -
. O +

The O +
chromosomes O +
13 O +
and O +
X O +
gene O +
clusters O +
were O +
previously O +
found O +
up O -
- O -
regulated O +
in O +
B O -
- O -
cell O +
lymphoma O +
[ O -
39 O -
] O -
. O +

It O +
was O +
also O +
shown O +
that O +
c O -
- O -
MYC O +
promotes O +
their O +
transcription O +
[ O -
40 O -
] O +
and O -
, O +
interestingly O -
, O +
enforced O +
expression O +
of O +
the O +
mir-17 O -
- O -
92 O +
cluster O +
acted O +
with O +
c O -
- O -
myc O +
to O +
accelerate O +
tumour O +
development O +
in O +
a O +
mouse O +
B O -
- O -
cell O +
lymphoma O +
model O +
[ O -
39 O -
] O -
. O +

In O +
human O +
solid O +
tumors O -
, O +
the O +
chromosome O +
13 O +
mir-17 O -
- O -
92 O +
cluster O +
was O +
found O +
up O -
- O -
regulated O +
in O +
small O -
- O -
cell O +
lung O +
cancer O +
[ O -
41 O -
] O +
and O +
its O +
ectopic O +
over O -
- O -
expression O +
enhanced O +
lung O +
cancer O +
cell O +
growth O +
[ O -
41 O -
] O -
. O +

Since O +
these O +
data O +
indicate O +
that O +
members O +
of O +
the O +
mir-17 O -
- O -
92 O +
family O +
can O +
act O +
as O +
oncogenes O +
to O +
promote O +
cell O +
growth O +
and O +
inhibit O +
apoptosis O -
, O +
our O +
data O +
suggests O +
that O +
up O -
- O -
regulation O +
of O +
these O +
miRNAs O +
may O +
have O +
a O +
role O +
in O +
the O +
more O +
aggressive O +
clinical O +
behavior O +
of O +
MSS O +
versus O +
MSI O -
- O -
H O +
tumors O -
. O +

For O +
mRNA O -
- O -
chip O +
hybridization O -
, O +
5 O +
ug O +
of O +
total O +
RNA O +
were O +
used O +
for O +
the O +
production O +
of O +
biotinylated O +
cRNA O -
. O +

Labeled O +
cRNA O +
was O +
synthesized O +
following O +
the O +
Ambion O +
cRNA O +
Synthesis O +
Protocol O +
and O +
purified O +
using O +
an O +
RNeasy O -
® O +
Kit O +
( O -
Qiagen O -
) O -
. O +

cRNA O +
yield O +
was O +
quantified O +
by O +
measuring O +
the O +
UV O +
absorbance O +
at O +
260 O +
nm O -
. O +

Unfragmented O +
biotinylated O +
cRNA O +
( O -
about O +
50 O +
ug O -
) O +
was O +
used O +
for O +
hybridization O +
on O +
custom O +
made O +
high O +
density O +
oligonucleotide O +
arrays O -
. O +

The O +
array O +
was O +
the O +
human O +
18.5 O -
K O +
Expression O +
Bioarray O +
( O -
Compugen O +
Human O +
Oligo O +
Set O +
1.0 O -
, O +
http://www.labonweb.com/chips/libraries.html O -
) O -
, O +
which O +
contains O +
18,861 O +
probes O +
corresponding O +
to O +
approximately O +
17,260 O +
unique O +
human O +
gene O +
clusters O +
and O +
18 O +
bacterial O +
control O +
probes O -
. O +

All O +
probes O +
on O +
these O +
microarrays O +
are O +
65-mer O +
oligonucleotides O +
spotted O +
by O +
contacting O +
technologies O +
and O +
covalently O +
attached O +
to O +
a O +
polymeric O +
matrix O -
. O +

Microarrays O +
were O +
hybridized O +
in O +
6 O +
× O +
SSPE O -
/ O -
40 O -
% O +
formamide O +
using O +
a O +
Tecan O +
HS4800 O +
hybridization O +
station O +
at O +
37 O -
° O -
C O +
for O +
20 O +
hours O -
, O +
post O -
- O -
hybridization O +
washed O +
in O +
46 O -
° O -
C O +
pre O -
- O -
warmed O +
0.75 O +
× O +
TNT O +
( O -
1 O +
× O +
TNT:0.1 O +
M O +
Tris O -
- O -
HCL O -
, O +
pH7.5 O -
/ O -
0.15 O +
M O +
NaCL O -
/ O -
0.05 O -
% O +
Tween-20 O -
) O +
at O +
46 O -
° O -
C O +
for O +
one O +
hour O -
, O +
and O +
processed O +
using O +
a O +
direct O +
detection O +
method O +
of O +
the O +
biotin O -
- O -
containing O +
transcripts O +
by O +
a O +
Streptavidin O -
- O -
Alexa647 O +
conjugate O +
( O -
1:500 O +
diluted O -
) O +
in O +
TNB O +
( O -
0.1 O +
M O +
Tris O -
- O -
HCL O -
, O +
pH7.5 O -
/ O -
0.15 O +
M O +
NaCL O -
/ O -
0.5 O -
% O +
Blocking O +
Reagent O -
- O -
PerkinElmer O -
) O +
at O +
RT O +
for O +
30 O +
min O -
. O +

Post O -
- O -
staining O +
washing O +
in O +
1 O +
× O +
TNT O +
for O +
one O +
hour O -
. O +

Processed O +
slides O +
were O +
scanned O +
using O +
Axon O +
4000B O +
scanner O +
( O -
Molecular O +
Device O -
, O +
CA O -
) O -
. O +

Image O +
were O +
quantified O +
by O +
GenePix O +
Pro O +
6.0 O +
software O -
. O +

Microarray O +
data O +
analysis O +
MiRNA O -
- O -
chip O +
and O +
mRNA O +
chip O +
raw O +
data O +
were O +
normalized O +
separately O +
using O +
the O +
GeneSpring O +
software O +
version O +
7.2 O +
( O -
Agilent O -
) O -
. O +

Both O +
on O +
chip O +
and O +
on O +
gene O +
median O +
methods O +
were O +
used O +
to O +
normalize O +
gene O +
expression O +
data O -
. O +

Microarray O +
data O +
were O +
then O +
joined O +
into O +
one O +
GeneSpring O +
genome O +
and O +
samples O +
were O +
assigned O +
to O +
one O +
of O +
two O +
groups O -
. O +

The O +
comparative O +
analysis O +
between O +
MSI O -
- O -
H O +
and O +
MSS O +
samples O +
was O +
carried O +
out O +
using O +
the O +
Welch O -
's O +
t O -
- O -
test O +
and O +
the O +
Benjamini O +
& O +
Hochberg O +
or O +
Bonferroni O +
( O -
for O +
a O +
more O +
stringent O +
analysis O -
) O +

False O +
Discovery O +
Rate O +
correction O -
. O +

Cluster O +
analysis O +
was O +
performed O +
using O +
the O +
Pearson O +
correlation O +
as O +
a O +
measure O +
of O +
similarity O -
. O +

Predictions O +
were O +
made O +
using O +
both O +
Support O +
Vector O +
Machine O +
algorithm O +
and O +
PAM O +
software O +
[ O -
44 O -
] O -
. O +

The O +
Gene O +
Ontology O +
analysis O +
of O +
the O +
gene O +
lists O +
of O +
interest O +
was O +
generated O +
by O +
using O +
the O +
web O -
- O -
delivered O +
tools O +
of O +
Ingenuity O +
Pathway O +
Analysis O -
. O +

Data O +
have O +
been O +
submitted O +
to O +
Array O +
Express O +
( O -
Accession O +
number O +
E O -
- O -
MEXP-326 O -
) O -
. O +

Northern O +
blot O +
of O +
miRNAs O +
RNA O +
samples O +
( O -
10 O +
μg O +
each O -
) O +
were O +
electrophoresed O +
on O +
15 O -
% O +
acrylamide O -
, O +
7 O +
M O +
urea O +
Criterion O +
precasted O +
gels O +
( O -
Bio O -
- O -
Rad O -
, O +
Hercules O -
, O +
CA O -
) O +
and O +
transferred O +
onto O +
Hybond O +
N+ O +
membrane O +
( O -
Amersham O +
Bioscience O -
, O +
Piscataway O -
, O +
NJ O -
) O -
. O +

Membranes O +
were O +
hybridized O +
with O +
oligonucleotide O +
probes O -
, O +
corresponding O +
to O +
the O +
complementary O +
sequences O +
of O +
the O +
following O +
mature O +
miRNAs O -
: O +
miR-25 O +
( O -
TCA O +
GAC O +
CGA O +
GAC O +
AAG O +
TGC O +
AAT O +
G O -
) O +
and O +
miR-92 O +
( O -
CAG O +
GCC O +
GGG O +
ACA O +
AGT O +
GCA O +
ATA O -
) O -
. O +

Probes O +
were O +
5'-end O +
labeled O +
using O +
the O +
polynucleotide O +
kinase O +
in O +
the O +
presence O +
of O +
P32-gamma O -
- O -
ATP O -
. O +

Hybridization O +
was O +
performed O +
at O +
37 O -
° O -
C O +
in O +
7 O -
% O +
SDS O -
/ O -
0.2 O +
mol O -
/ O -
L O +
Na2PO4 O +
( O -
pH O +
7.0 O -
) O +
for O +
16 O +
hours O -
. O +

Membranes O +
were O +
washed O +
at O +
42 O -
° O -
C O -
, O +
twice O +
with O +
2 O +
× O +
standard O +
saline O +
phosphate O +
( O -
0.18 O +
mol O -
/ O -
L O +
NaCl O -
/ O -
10 O +
mmol O -
/ O -
L O +
phosphate O +
pH O +
7.4 O -
) O -
, O +
1 O +
mmol O -
/ O -
L O +
EDTA O +
( O -
saline O -
- O -
sodium O +
phosphate O -
- O -
EDTA O -
, O +
SSPE O -
) O -
, O +
and O +
0.1 O -
% O +
SDS O +
and O +
twice O +
with O +
0.5 O +
× O +
SSPE O -
/ O -
0.1 O -
% O +
SDS O -
. O +

Northern O +
blots O +
were O +
re O -
- O -
hybridized O +
after O +
stripping O +
the O +
oligonucleotides O +
used O +
as O +
probes O +
in O +
boiling O +
0.1 O -
% O +
SDS O +
for O +
10 O +
minutes O -
. O +

As O +
a O +
control O +
for O +
normalization O +
of O +
RNA O +
expression O +
levels O -
, O +
we O +
hybridized O +
blots O +
with O +
an O +
oligonucleotide O +
probe O +
complementary O +
to O +
the O +
U6 O +
RNA O +
( O -
5'-GCA O +
GGG O +
GCC O +
ATG O +
CTA O +
ATC O +
TTC O +
TCT O +
GTA O +
TCG-3 O -
' O -
) O -
. O +

Quantitative O +
Real O +
time O +
PCR O +
for O +
mRNAs O +
The O +
RT O +
reaction O +
was O +
perfomed O +
using O +
200 O +
ng O +
of O +
total O +
RNA O +
for O +
each O +
sample O +
according O +
to O +
the O +
manufacturer O +
instructions O +
( O -
SuperScript O +
First O +
Strand O +
Invitrogen O -
) O -
. O +

The O +
Real O +
Time O +
reactions O +
were O +
performed O +
using O +
Taqman O +
Gene O +
Expression O +
Assay O +
on O +
a O +
ABI O +
PRISM O +
7900HT O -
. O +

For O +
each O +
gene O +
one O +
set O +
of O +
primers O +
and O +
a O +
probe O +
were O +
chosen O +
from O +
the O +
Applied O +
Biosystems O +
list O +
of O +
TaqMan O -
® O +
Gene O +
Expression O +
Assays O -
. O +

Hs02379661_g1 O +
for O +
MTA2 O -
, O +
Hs00228732_m1 O +
for O +
CTCL O +
tumor O +
antigen O -
, O +
Hs00228336_m1 O +
for O +
C13orf18 O -
, O +
Hs00196125_m1 O +
for O +
VAV3 B-Gene +
oncogene O -
, O +
Hs00914163_m1 O +
for O +
GGH O -
, O +
Hs00214886_m1 O +
for O +
FLJ20315 B-Gene -
. O +

Expression O +
analysis O +
was O +
performed O +
in O +
triplicate O +
for O +
each O +
sample O -
. O +

Expression O +
of O +
18S O +
rRNA O -
, O +
which O +
displayed O +
the O +
most O +
constant O +
expression O +
among O +
tested O +
housekeeping O +
genes O +
between O +
different O +
samples O -
, O +
was O +
used O +
as O +
endogenous O +
reference O +
control O -
. O +

The O +
fold O +
difference O +
for O +
each O +
sample O +
was O +
obtained O +
using O +
the O +
following O +
equation O +
2-dCt O -
. O +

Ct O +
is O +
the O +
Threshold O +
Cycle O -
, O +
the O +
cycle O +
number O +
at O +
which O +
the O +
fluorescence O +
generated O +
within O +
a O +
reaction O +
crosses O +
the O +
threshold O -
; O +
dCt O +
= O +
Ct O +
average O +
sample O +
gene O +
- O +
Ct O +
average O +
18S O -
. O +

Correlation O +
between O +
CpG O +
methylation O +
profiles O +
and O +
hormone O +
receptor O +
status O +
in O +
breast O +
cancers O +
Abstract O +
Introduction O +
Aberrant O +
DNA O +
methylation O +
has O +
been O +
found O +
frequently O +
in O +
human O +
breast O +
cancers O -
, O +
associated O +
with O +
the O +
loss O +
of O +
expression O +
of O +
a O +
number O +
of O +
regulatory O +
genes O +
for O +
growth O +
and O +
correlated O +
to O +
clinical O +
outcomes O -
. O +

The O +
present O +
study O +
was O +
undertaken O +
to O +
determine O +
whether O +
methylation O +
of O +
a O +
set O +
of O +
growth O -
- O -
suppressor O +
genes O +
would O +
correlate O +
to O +
the O +
expression O +
of O +
estrogen O +
receptors O +
( O -
ERs B-Gene -
) O +
and O +
progesterone O +
receptors O +
( O -
PRs B-Gene -
) O -
. O +

Methods O +
We O +
used O +
a O +
pyrosequencing O +
methylation O +
analysis O +
to O +
study O +
the O +
methylation O +
of O +
12 O +
known O +
growth O -
- O -
suppressor O +
genes O +
in O +
90 O +
pairs O +
of O +
malignant O -
/ O -
normal O +
breast O +
tissues O -
. O +

We O +
also O +
examined O +
the O +
expression O +
of O +
ERs B-Gene +
and O +
PRs B-Gene +
in O +
those O +
specimens O +
by O +
immunohistochemistry O -
. O +

Mutations O +
of O +
p53 B-Gene +
in O +
tumor O +
cells O +
were O +
detected O +
by O +
direct O +
sequencing O -
. O +

Results O +
Twelve O +
tumor O -
- O -
suppressor O +
genes O -
: O +
ARHI B-Gene -
, O +
RASSF1A B-Gene -
, O +
HIN-1 B-Gene -
, O +
RARβ2 B-Gene -
, O +
hMLH1 B-Gene -
, O +
14 B-Gene -
- I-Gene -
3 I-Gene -
- I-Gene -
3 I-Gene +
σ I-Gene -
, O +
RIZ1 B-Gene -
, O +
p16 B-Gene -
, O +
E B-Gene -
- I-Gene -
cadherin I-Gene -
, O +
RIL B-Gene -
, O +
CDH13 B-Gene -
, O +
and O +
NKD2 B-Gene +
were O +
selected O +
for O +
this O +
methylation O +
study O -
. O +

Five O +
of O +
them O +
( O -
RIL B-Gene -
, O +
HIN-1 B-Gene -
, O +
RASSF1A B-Gene -
, O +
CDH13 B-Gene -
, O +
and O +
RARβ2 B-Gene -
) O +
were O +
frequently O +
methylated O +
in O +
breast O +
cancers O +
( O -
57 O -
% O -
, O +
49 O -
% O -
, O +
58 O -
% O -
, O +
44 O -
% O -
, O +
and O +
17 O -
% O -
, O +
respectively O -
) O +
but O +
not O +
the O +
normal O +
breast O +
( O -
0–4 O -
% O -
) O -
. O +

Two O +
panels O +
of O +
methylation O +
profiles O +
were O +
defined O -
. O +

The O +
methylation O +
of O +
the O +
HIN-1 B-Gene -
/ O -
RASSFIA B-Gene +
panel O +
strongly O +
correlated O +
to O +
the O +
expression O +
of O +
ERs B-Gene -
, O +
PRs B-Gene -
, O +
and O +
hormone O +
receptors O +
( O -
HRs B-Gene -
; O +
which O +
were O +
defined O +
as O +
' O -
positive O -
' O +
if O +
ERs B-Gene +
and/or O +
PRs B-Gene +
were O +
positive O -
; O +
p O +
< O +
0.001 O -
) O -
. O +

Conversely O -
, O +
the O +
methylation O +
of O +
the O +
RIL B-Gene -
/ O -
CDH13 B-Gene +
panel O +
strongly O +
correlated O +
to O +
negative O +
ER B-Gene -
, O +
PR B-Gene -
, O +
and O +
HR B-Gene +
expression O +
( O -
p O +
= O +
0.001 O -
, O +
0.025 O -
, O +
and O +
0.001 O -
, O +
respectively O -
) O -
. O +

The O +
subset O +
of O +
triple O -
- O -
negative O +
breast O +
cancers O +
( O -
in O +
other O +
words O -
, B-Gene +
those I-Gene +
with O +
negative O +
ER B-Gene -
, O +
PR B-Gene -
, O +
and O +
HER-2 B-Gene -
/ I-Gene -
neu I-Gene +
status O -
) O +
was O +
positively O +
associated O +
with O +
the O +
methylation O +
of O +
the O +
RIL B-Gene -
/ O -
CDH13 B-Gene +
panel O +
and O +
negatively O +
associated O +
with O +
the O +
HIN-1 B-Gene -
/ O -
RASSF1A B-Gene +
panel O -
. O +

Mutations O +
of O +
p53 B-Gene +
were O +
found O +
in O +
nine O +
breast O +
tumors O +
( O -
11 O -
% O -
) O -
, O +
seven O +
of O +
which O +
lacked O +
methylation O +
in O +
both O +
panels O -
. O +

Conclusion O +

We O +
have O +
defined O +
two O +
panels O +
( O -
HIN-1 B-Gene -
/ O -
RASSFIA B-Gene -
, O +
and O +
RIL B-Gene -
/ O -
CDH13 B-Gene -
) O +
of O +
methylation O +
profiles O -
, O +
which O +
correlated O -
, O +
either O +
positively O +
or O +
negatively O -
, O +
to O +
HR B-Gene +
status O -
. O +

Materials O +
and O +
methods O +
Cell O +
lines O +
Human O +
breast O +
cancer O +
cell O +
lines O +
SKBr3 O -
, O +
MDA O -
- O -
MB-435 O -
, O +
MDA O -
- O -
MB-468 O -
, O +
BT-20 O -
, O +
MDA O -
- O -
MB-231 O -
, O +
and O +
MCF-7 O +
were O +
maintained O +
in O +
RPMI O +
1640 O +
medium O +
supplemented O +
with O +
10 O -
% O +
fetal O +
bovine O +
serum O -
. O +

Normal O +
breast O +
epithelial O +
cells O -
, O +
HMEC O +
231 O +
and O +
HMEC234 O -
, O +
were O +
cultured O +
in O +
a O +
1:1 O +
solution O +
of O +
MCDB O +
105 O +
and O +
medium O +
199 O +
with O +
15 O -
% O +
fetal O +
bovine O +
serum O +
and O +
10 O +
ng O -
/ O -
ml O +
epithelial O +
growth O +
factor O +
( O -
Sigma O -
, O +
St O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
, O +
as O +
described O +
elsewhere O +
[ O -
21 O -
] O -
. O +

Tissue O +
samples O +
We O +
used O +
90 O +
samples O -
, O +
consisting O +
of O +
paired O +
tissues O +
and O +
associated O +
clinicopathologic O +
data O +
from O +
the O +
Breast O +
Tumor O +
Bank O +
at O +
The O +
University O +
of O +
Texas O +
MD O +
Anderson O +
Cancer O +
Center O +
( O -
Houston O -
, O +
TX O -
, O +
USA O -
) O -
. O +

The O +
samples O +
of O +
breast O +
tumors O +
and O +
corresponding O +
adjacent O +
normal O -
- O -
appearing O +
tissues O +
( O -
from O +
tissues O +
located O +
at O +
least O +
3 O +
cm O +
away O +
from O +
the O +
site O +
at O +
which O +
the O +
tumor O +
was O +
sampled O -
) O +
came O +
from O +
80 O +
patients O +
who O +
had O +
undergone O +
surgery O +
at O +
The O +
University O +
of O +
Texas O +
MD O +
Anderson O +
Cancer O +
Center O +
in O +
2004 O +
or O +
2005 O +
and O +
10 O +
patients O +
who O +
had O +
been O +
diagnosed O +
with O +
breast O +
cancer O +
between O +
1995 O +
and O +
2003 O -
. O +

All O +
tissue O +
samples O +
had O +
been O +
fresh O -
- O -
frozen O +
and O +
stored O +
at O +
-80 O -
° O -
C O -
. O +

No O +
patient O +
was O +
recruited O +
specifically O +
for O +
this O +
study O -
. O +

All O +
patients O +
gave O +
written O +
informed O +
consent O +
permitting O +
the O +
use O +
of O +
their O +
breast O +
tissue O +
for O +
research O +
at O +
the O +
time O +
specimens O +
were O +
collected O -
. O +

This O +
study O +
was O +
approved O +
by O +
The O +
University O +
of O +
Texas O +
MD O +
Anderson O +
Cancer O +
Center O -
's O +
Institutional O +
Review O +
Board O -
. O +

Histopathologic O +
analysis O +
All O +
breast O +
specimens O +
were O +
reviewed O +
by O +
experienced O +
pathologists O -
. O +

Slides O +
were O +
subject O +
to O +
immunoperoxidase O +
staining O +
for O +
estrogen O +
receptors O +
( O -
ERs B-Gene -
; O +
clone O +
6F11 O -
, O +
Novocastra O +
Laboratories O +
Ltd O -
, O +
Benton O +
Lane O -
, O +
UK O -
) O +
and O +
progesterone O +
receptors O +
( O -
PRs B-Gene -
; O +
clone1A6 O -
, O +
Novocastra O +
Laboratories O +
Ltd O -
) O -
, O +
according O +
to O +
the O +
manufacturer O -
's O +
recommendations O -
. O +

Cancers O +
were O +
considered O +
receptor O -
- O -
positive O +
if O +
> O +
10 O -
% O +
of O +
malignant O +
cells O +
showed O +
nuclear O +
staining O -
. O +

Cancers O +
were O +
classified O +
as O +
HR O -
- O -
positive O +
if O +
the O +
ER B-Gene +
and/or O +
PR B-Gene +
status O +
was O +
positive O -
. O +

HER-2 B-Gene -
/ I-Gene -
neu I-Gene +
gene O +
amplification O +
was O +
assessed O +
by O +
interphase O +
fluorescence O +
in O +
situ O +
hybridization O +
( O -
FISH O -
) O +
using O +
the O +
PathVysion O +
HER-2 B-Gene -
/ I-Gene -
neu I-Gene +
probe O +
kit O +
( O -
Vysis O +
Inc. O -
, O +
Downers O +
Grove O -
, O +
IL O -
, O +
USA O -
) O -
, O +
according O +
to O +
the O +
manufacturer O -
's O +
recommendations O -
. O +

Levels O +
of O +
the O +
HER-2 B-Gene -
/ I-Gene -
neu I-Gene -
: O -
CEP17 B-Gene +
signal O +
ratio O +
were O +
considered O +
normal O +
if O +
FISH O +
detected O +
≤ O +
2.0 O +
copies O +
per O +
cell O -
. O +

Microdissection O -
, O +
DNA O +
extraction O -
, O +
and O +
sodium O +
bisulfite O +
treatment O +
To O +
avoid O +
contamination O +
with O +
normal O +
tissues O +
in O +
the O +
methylation O +
analysis O -
, O +
we O +
isolated O +
breast O +
cancer O +
cells O +
and O +
paired O +
normal O +
breast O +
epithelial O +
cells O +
from O +
tissues O +
by O +
manual O +
microdissection O -
, O +
following O +
the O +
National O +
Cancer O +
Institutes O +
( O -
Bethesda O -
, O +
MA O -
, O +
USA O -
) O +
protocols O +
[ O -
22 O -
] O -
. O +

In O +
brief O -
, O +
5–10 O +
μm O +
sections O +
were O +
cut O +
from O +
each O +
archival O +
fresh O -
- O -
frozen O +
tissue O +
block O -
. O +

For O +
each O +
pair O +
of O +
tissues O -
, O +
the O +
presence O +
of O +
tumor O +
cells O +
in O +
malignant O +
tissues O +
and O +
absence O +
of O +
cancer O +
cells O +
in O +
normal O +
tissues O +
were O +
confirmed O +
by O +
histopathologic O +
examination O -
. O +

Frozen O +
tissue O +
sections O +
were O +
fixed O +
with O +
ethanol O -
, O +
stained O +
with O +
H O +
& O +
E O -
, O +
and O +
microdissected O +
using O +
a O +
needle O -
. O +

Each O +
tumor O +
sample O +
contained O +
> O +
70 O -
% O +
tumor O +
cells O +
after O +
microdissection O -
. O +

Genomic O +
DNA O +
was O +
extracted O +
from O +
patient O +
samples O -
, O +
breast O +
cancer O +
cell O +
lines O -
, O +
and O +
normal O +
breast O +
epithelial O +
cells O +
using O +
the O +
Dneasy O +
tissue O +
kit O +
( O -
Qiagen O -
, O +
Valencia O -
, O +
CA O -
, O +
USA O -
) O -
. O +

Bisulfite O +
treatment O +
of O +
1–2 O +
μg O +
of O +
genomic O +
DNA O +
was O +
performed O -
, O +
as O +
previously O +
described O +
[ O -
3 O -
] O -
. O +

Genes O +
studied O +
Twelve O +
tumor O -
- O -
suppressor O +
genes O +
were O +
selected O +
for O +
this O +
study O -
. O +

ARHI B-Gene +
( O -
CpG O +
I O +
and O +
II O -
) O -
, O +
RASSF1A B-Gene -
, O +
HIN-1 B-Gene +
( O -
SCGB3A1 B-Gene -
) O -
, O +
RARβ2 B-Gene -
, O +
hMLH1 B-Gene -
, O +
the O +
14 B-Gene -
- I-Gene -
3 I-Gene -
- I-Gene -
3 I-Gene +
σ I-Gene +
gene O -
, O +
RIZ1 B-Gene -
, O +
p16 B-Gene +
( O -
CDKN2A B-Gene -
) O -
, O +
and O +
the O +
E B-Gene -
- I-Gene -
cadherin I-Gene +
gene O +
( O -
CDH1 B-Gene -
) O +
were O +
selected O +
on O +
the O +
basis O +
of O +
previous O +
reports O +
of O +
elevated O +
methylation O +
rates O +
in O +
breast O +
cancers O +
[ O -
3 O -
- O -
12 O -
] O -
. O +

RIL B-Gene +
( O -
PDLIM4 B-Gene -
) O +
[ O -
23 O -
] O -
, O +
CDH13 B-Gene -
, O +
and O +
NKD2 B-Gene +
were O +
identified O +
as O +
hypermethylated O +
genes O +
using O +
genome O -
- O -
wide O +
methylated O +
CpG O +
island O +
amplification O +
( O -
MCA O -
) O +
from O +
multiple O +
tumors O +
( O -
24 O -
) O -
. O +

Global O +
methylation O +
was O +
estimated O +
by O +
testing O +
methylation O +
levels O +
of O +
LINE1 B-Gene +
repetitive O +
elements O +
[ O -
25 O -
] O -
. O +

We O +
also O +
assessed O +
the O +
methylation O +
of O +
ERα B-Gene +
and O +
PGRB B-Gene +
genes O -
. O +

Pyrosequencing O +
methylation O +
analysis O +
Bisulfite O +
pyrosequencing O +
was O +
used O +
to O +
detect O +
methylation O +
of O +
all O +
15 O +
genes O -
. O +

Pyrosequencing O +
primers O +
were O +
designed O +
using O +
Assay O +
Design O +
software O +
1.0 O +
( O -
Biotage O -
, O +
Westborough O -
, O +
MA O -
, O +
USA O -
) O -
. O +

For O +
each O +
gene O -
, O +
we O +
selected O +
the O +
CpG O +
island O +
region O +
flanking O +
the O +
transcription O +
start O +
site O +
at O +
the O +
5'UTR O -
. O +

Two O +
to O +
six O +
CpG O +
sites O +
were O +
studied O +
for O +
each O +
particular O +
CpG O +
island O -
. O +

The O +
primers O +
for O +
pyrosequencing O +
and O +
PCR O +
conditions O +
are O +
listed O +
in O +
Additional O +
file O +
1 O -
. O +

Bisulfite O -
- O -
treated O +
DNA O +
( O -
1 O +
μl O -
) O +
was O +
amplified O +
in O +
50 O +
μl O +
of O +
reaction O +
mixture O -
, O +
containing O +
primers O +
and O +
0.2 O +
U O +
of O +
Taq O +
polymerase O +
( O -
New O +
England O +
Biolabs O -
, O +
Ipswich O -
, O +
MA O -
, O +
USA O -
) O -
. O +

For O +
the O +
amplification O +
of O +
HIN-1 B-Gene -
, O +
RARβ2 B-Gene -
, O +
hMLH1 B-Gene -
, O +
the O +
14 B-Gene -
- I-Gene -
3 I-Gene -
- I-Gene -
3 I-Gene +
σ I-Gene +
gene O -
, O +
RIZ1 B-Gene -
, O +
the O +
E B-Gene -
- I-Gene -
cadherin I-Gene +
gene O -
, O +
NKD2 B-Gene -
, O +
and O +
PGRB B-Gene -
, O +
we O +
used O +
a O +
universal O +
primer O +
approach O +
[ O -
18 O -
] O -
. O +

The O +
PCR O +
product O +
was O +
purified O +
and O +
methylation O +
was O +
quantitated O +
using O +
the O +
PSQ O +
HS O +
96A O +
pyrosequencing O +
system O +
and O +
Pyro O +
gold O +
reagents O +
( O -
Biotage O -
) O -
. O +

Methylation O +
data O +
are O +
presented O +
as O +
the O +
percentage O +
of O +
average O +
methylation O +
in O +
all O +
observed O +
CpG O +
sites O -
. O +

To O +
set O +
the O +
controls O +
for O +
pyrosequencing O -
, O +
we O +
used O +
cancer O +
cell O +
lines O +
and O +
normal O +
cells O +
that O +
were O +
consistently O +
positive O +
or O +
negative O +
with O +
stable O +
levels O +
of O +
methylation O -
. O +

In O +
this O +
study O -
, O +
each O +
PCR O +
assay O +
included O +
a O +
positive O +
control O +
( O -
the O +
MDA O -
- O -
MB-231 O +
breast O +
cancer O +
cell O +
line O -
, O +
which O +
is O +
highly O +
methylated O +
in O +
most O +
genes O -
) O +
and O +
a O +
negative O +
control O +
( O -
normal O +
breast O +
epithelial O +
cells O -
, O +
HMEC231 O -
, O +
which O +
are O +
unmethylated O +
in O +
all O +
genes O -
, O +
except O +
LINE1 B-Gene -
, O +
ARHI B-Gene -
, O +
and O +
the O +
14 B-Gene -
- I-Gene -
3 I-Gene -
- I-Gene -
3 I-Gene +
σ I-Gene +
gene O -
) O -
. O +

RKO O -
, O +
a O +
colon O +
cancer O +
cell O +
line O +
that O +
is O +
highly O +
methylated O +
in O +
hMLH1 B-Gene +
and O +
p16 B-Gene -
, O +
was O +
also O +
used O +
as O +
a O +
positive O +
control O -
. O +

p53 B-Gene +
mutation O +
detection O +
Genomic O +
DNA O +
was O +
extracted O +
from O +
microdissected O +
tumor O +
tissue O +
using O +
the O +
QIAGEN O +
DNA O +
purification O +
kit O +
( O -
Qiagen O -
) O -
. O +

PCR O +
was O +
performed O +
using O +
primers O +
that O +
amplify O +
p53 B-Gene +
exons O +
5–6 O +
and O +
7–9 O -
. O +

The O +
PCR O +
products O +
were O +
then O +
purified O +
by O +
the O +
gel O +
purification O +
system O +
( O -
Qiagen O -
) O +
or O +
Exonuclease O +
I O +
and O +
shrimp O +
alkaline O +
phosphatase O +
( O -
USB O -
, O +
Cleveland O -
, O +
OH O -
, O +
USA O -
) O -
. O +

Mutations O +
were O +
determined O +
by O +
direct O +
sequencing O -
. O +

Results O +
Patients O -
' O +
clinical O +
data O +
Patient O +
characteristics O +
are O +
presented O +
in O +
Table O +
1 O -
. O +

Normal O +
paired O +
tissues O +
were O +
unavailable O +
in O +
two O +
cases O -
. O +

Information O +
regarding O +
the O +
grade O -
, O +
HER-2 B-Gene -
/ I-Gene -
neu I-Gene +
status O -
, O +
and O +
ER B-Gene +
and O +
PR B-Gene +
status O +
were O +
unavailable O +
for O +
one O -
, O +
ten O -
, O +
and O +
three O +
patients O -
, O +
respectively O -
. O +

Patient O +
characteristics O +
BNG O -
, O +
Black O -
's O +
nuclear O +
grade O -
; O +
ER B-Gene -
, O +
estrogen O +
receptor O -
; O +
PR B-Gene -
, O +
progesterone O +
receptor O -
. O +

Accuracy O -
, O +
reproducibility O -
, O +
and O +
quantitation O +
of O +
results O +
with O +
bisulfite O +
pyrosequencing O +
To O +
confirm O +
the O +
reliability O +
of O +
bisulfite O +
pyrosequencing O +
for O +
the O +
quantitation O +
of O +
methylation O +
levels O -
, O +
we O +
measured O +
the O +
methylation O +
of O +
ARHI B-Gene +
CpG O +
islands O +
I O +
and O +
II O +
using O +
pyrosequencing O +
and O +
COBRA O +
and O +
compared O +
the O +
resulting O +
data O -
. O +

COBRA O +
detected O +
only O +
one O +
CpG O +
site O -
, O +
whereas O +
pyrosequencing O +
detected O +
four O +
to O +
eight O +
CpG O +
sites O +
in O +
one O +
CpG O +
island O +
( O -
Figure O +
1 O -
) O -
. O +

From O +
six O +
breast O +
cancer O +
cell O +
lines O +
and O +
two O +
cultures O +
of O +
normal O +
breast O +
epithelial O +
cells O -
, O +
methylation O +
data O +
were O +
matched O +
in O +
CpG O +
island O +
II O +
but O +
not O +
completely O +
matched O +
in O +
CpG O +
island O +
I. O +
COBRA O +
showed O +
two O +
breast O +
cancer O +
cell O +
lines O +
were O +
partially O +
methylated O +
in O +
CpG O +
island O +
I O +
( O -
50 O -
% O +
and O +
54 O -
% O +
in O +
one O +
CpG O +
site O -
) O -
, O +
but O +
they O +
were O +
shown O +
to O +
be O +
hypermethylated O +
in O +
CpG O +
island O +
I O +
by O +
pyrosequencing O +
( O -
the O +
mean O +
of O +
four O +
CpG O +
sites O +
per O +
island O +
was O +
92 O -
% O +
and O +
91 O -
% O -
, O +
respectively O -
) O -
. O +

On O +
the O +
basis O +
of O +
these O +
results O -
, O +
pyrosequencing O +
was O +
more O +
sensitive O +
for O +
methylation O +
detection O +
than O +
COBRA O -
. O +

Pyrosequencing O +
analysis O +
for O +
ARHI B-Gene +
methylation O -
. O +

( O -
a O -
) O +
Design O +
of O +
pyrosequencing O +
primers O +
for O +
ARHI B-Gene +
CpG O +
islands O +
I O +
and O +
II O -
. O +

The O +
vertical O +
bars O +
indicate O +
CpG O +
sites O +
in O +
PCR O +
products O -
. O +

COBRA O +
indicated O +
the O +
restriction O +
enzyme O +
cutting O +
site O -
. O +

( O -
b O -
) O +
Pyrosequencing O +
results O +
for O +
ARHI B-Gene +
CpG O +
island O +
II O +
methylation O +
in O +
MB O -
- O -
MDA-231 O +
cells O +
using O +
two O +
detection O +
primers O +
( O -
Pyro O +
F1 O +
and O +
F2 O -
) O -
. O +

Methylation O +
levels O +
ranged O +
from O +
65 O -
% O +
to O +
100 O -
% O -
, O +
with O +
a O +
mean O +
of O +
84 O -
% O -
. O +

Gray O +
highlighting O +
marks O +
the O +
CpG O +
sites O +
tested O +
and O +
the O +
percentage O +
reading O +
of O +
C O +
and O +
T. O +
COBRA O -
, O +
combined O +
bisulfite O +
restriction O +
analysis O -
. O +

To O +
confirm O +
the O +
reproducibility O +
of O +
pyrosequencing O -
, O +
the O +
methylation O +
of O +
HIN-1 B-Gene +
and O +
RIL B-Gene +
was O +
measured O +
repeatedly O +
in O +
22 O +
samples O +
using O +
bisulfite O +
treatment O +
and O +
pyrosequencing O +
assays O -
. O +

The O +
correlation O +
between O +
repeated O +
and O +
initial O +
values O +
was O +
high O +
( O -
for O +
HIN-1 B-Gene -
, O +
Pearson O -
's O +
correlation O +
coefficient O +
R O +
= O +
0.99 O +
and O +
p O +
< O +
0.0001 O -
; O +
for O +
RIL B-Gene -
, O +
R O +
= O +
0.99 O +
and O +
p O +
< O +
0.0001 O -
) O -
. O +

In O +
addition O -
, O +
the O +
variation O +
between O +
individual O +
assays O +
was O +
< O +
6 O -
% O -
: O +
the O +
mean O +
differences O +
and O +
95 O -
% O +
confidence O +
intervals O +
( O -
CIs O -
) O +
for O +
HIN-1 B-Gene +
and O +
RIL B-Gene +
were O +
1.9 O -
% O +
with O +
95 O -
% O +
CIs O +
of O +
-0.1 O -
% O +
to O +
3.9 O -
% O +
and O +
3.0 O -
% O +
with O +
95 O -
% O +
CIs O +
of O +
0.1 O -
% O +
to O +
6.0 O -
% O -
, O +
respectively O -
. O +

Frequent O +
methylation O +
of O +
RIL B-Gene -
, O +
HIN-1 B-Gene -
, O +
RASSF1A B-Gene -
, O +
CDH13 B-Gene -
, O +
and O +
RARβ2 B-Gene +
We O +
evaluated O +
the O +
methylation O +
status O +
of O +
12 O +
putative O +
tumor O -
- O -
suppressor O +
genes O +
( O -
ARHI B-Gene -
, O +
RASSF1A B-Gene -
, O +
HIN-1 B-Gene -
, O +
RARβ2 B-Gene -
, O +
hMLH1 B-Gene -
, O +
the O +
14 B-Gene -
- I-Gene -
3 I-Gene -
- I-Gene -
3 I-Gene +
σ I-Gene +
gene O -
, O +
RIZ1 B-Gene -
, O +
p16 B-Gene -
, O +
the O +
E B-Gene -
- I-Gene -
cadherin I-Gene +
gene O -
, O +
RIL B-Gene -
, O +
CDH13 B-Gene -
, O +
and O +
NKD2 B-Gene -
) O -
, O +
LINE1 B-Gene -
, O +
ER B-Gene -
, O +
and O +
PGRB B-Gene +
in O +
both O +
culture O +
cell O +
lines O +
and O +
primary O +
cancer O +
tissues O -
. O +

The O +
results O +
from O +
the O +
analysis O +
of O +
six O +
breast O +
cancer O +
cell O +
lines O +
and O +
two O +
normal O +
breast O +
epithelial O +
cell O +
samples O +
( O -
Additional O +
file O +
2 O -
) O +
indicated O +
that O +
7 O +
of O +
12 O +
genes O +
( O -
RIL B-Gene -
, O +
HIN-1 B-Gene -
, O +
RASSF1A B-Gene -
, O +
ARHI B-Gene -
, O +
CDH13 B-Gene -
, O +
RARβ2 B-Gene -
, O +
and O +
NKD2 B-Gene -
) O +
were O +
densely O +
methylated O +
( O -
marked O +
bold O -
) O +
in O +
cancer O +
cell O +
lines O +
but O +
not O +
in O +
normal O +
breast O +
epithelial O +
cell O +
lines O -
. O +

We O +
also O +
tested O +
the O +
methylation O +
profiles O +
of O +
the O +
12 O +
genes O +
in O +
breast O +
cancer O +
and O +
the O +
adjacent O +
normal O +
breast O +
tissues O +
from O +
the O +
same O +
patients O -
. O +

In O +
our O +
pilot O +
study O -
, O +
we O +
screened O +
12 O +
tumor O -
- O -
suppressor O +
genes O +
in O +
32–37 O +
paired O +
tissues O -
. O +

Five O +
tumor O -
- O -
suppressor O +
genes O +
( O -
RASSF1A B-Gene -
, O +
RIL B-Gene -
, O +
HIN-1 B-Gene -
, O +
CDH13 B-Gene -
, O +
and O +
RARβ2 B-Gene -
) O +
were O +
frequently O +
methylated O +
in O +
breast O +
cancer O +
tissues O +
( O -
the O +
positive O +
rate O +
ranged O +
from O +
17 O -
% O +
to O +
58 O -
% O -
) O +
but O +
not O +
in O +
normal O +
breast O +
tissues O +
( O -
the O +
positive O +
rate O +
ranged O +
from O +
0 O -
% O +
to O +
4.5 O -
% O -
) O -
. O +

Another O +
five O +
genes O +
( O -
RIZ1 B-Gene -
, O +
the O +
E B-Gene -
- I-Gene -
cadherin I-Gene +
gene O -
, O +
p16 B-Gene -
, O +
hMLH1 B-Gene -
, O +
and O +
NKD2 B-Gene -
) O +
were O +
not O +
frequently O +
methylated O +
in O +
either O +
malignant O +
or O +
normal O +
breast O +
tissue O +
( O -
the O +
positive O +
rate O +
ranged O +
from O +
0 O -
% O +
to O +
9 O -
% O -
, O +
all O +
< O +
10 O -
% O -
) O -
. O +

The O +
14 B-Gene -
- I-Gene -
3 I-Gene -
- I-Gene -
3 I-Gene +
σ I-Gene +
gene O +
is O +
highly O +
methylated O +
in O +
both O +
malignant O +
and O +
normal O +
breast O +
tissues O -
. O +

ARHI B-Gene -
, O +
as O +
an O +
imprinted O +
gene O -
, O +
is O +
at O +
least O +
partially O +
methylated O +
in O +
all O +
cases O +
( O -
Figure O +
2 O +
and O +
Table O +
2 O -
) O -
. O +

Consequently O -
, O +
seven O +
genes O +
were O +
unsuitable O +
for O +
development O +
of O +
methylation O +
profiles O -
. O +

To O +
correlate O +
the O +
methylation O +
profile O +
to O +
clinical O +
outcomes O -
, O +
we O +
focused O +
on O +
the O +
five O +
highly O +
methylated O +
genes O +
by O +
assaying O +
53 O +
more O +
paired O +
samples O -
. O +

PGRB B-Gene +
was O +
not O +
frequently O +
methylated O +
in O +
the O +
48 O +
cases O +
of O +
breast O +
tumor O +
or O +
normal O +
breast O +
tissue O -
. O +

ER B-Gene +
was O +
not O +
highly O +
methylated O +
in O +
the O +
40 O +
cases O +
of O +
breast O +
tumor O +
or O +
normal O +
breast O +
tissue O -
, O +
but O +
higher O +
methylation O +
levels O +
were O +
observed O +
in O +
normal O +
tissues O -
. O +

LINE1 B-Gene -
, O +
a O +
global O +
methylation O +
marker O -
, O +
was O +
highly O +
methylated O +
in O +
all O +
normal O +
and O +
malignant O +
tissues O -
, O +
but O +
the O +
methylation O +
levels O +
were O +
significant O +
lower O +
in O +
tumors O +
( O -
60.0 O +
± O +
8.8 O -
) O +
than O +
normal O +
tissues O +
( O -
68.2 O +
± O +
3.5 O -
; O +
p O +
< O +
0.001 O -
) O -
. O +

Methylation O +
levels O +
of O +
15 O +
genes O +
from O +
pairs O +
of O +
normal O +
and O +
malignant O +
breast O +
tissues O +
* O -
Positive O +
rate O +
using O +
the O +
sample O +
mean O +
plus O +
two O +
times O +
the O +
SD O +
of O +
the O +
pooled O +
normal O +
samples O +
( O -
and O +
minimum O +
10 O -
% O +
methylation O -
) O +
as O +
a O +
cut O -
- O -
off O +
point O -
. O +

* O -
* O -
p O +
value O +
computed O +
using O +
the O +
Wilcoxon O +
signed O +
rank O +
test O +
for O +
paired O +
data O -
. O +

SD O -
, O +
standard O +
deviation O -
. O +

Comparison O +
of O +
promoter O +
methylation O +
levels O +
of O +
15 O +
genes O +
in O +
paired O +
normal O +
and O +
malignant O +
breast O +
tissue O +
samples O -
. O +

Correlation O +
of O +
methylation O +
between O +
different O +
genes O +
and O +
to O +
age O +
On O +
the O +
basis O +
of O +
data O +
from O +
continuous O +
marker O +
methylation O +
analyses O +
in O +
normal O +
tissues O -
, O +
the O +
methylation O +
levels O +
of O +
RASSF1A B-Gene +
and O +
HIN-1 B-Gene +
exhibited O +
a O +
strong O +
correlation O +
to O +
each O +
other O +
( O -
R O +
= O +
0.66 O -
, O +
p O +
< O +
0.001 O -
) O -
. O +

Some O +
moderate O +
correlations O +
were O +
found O +
between O +
RARβ2 B-Gene +
and O +
CDH13 B-Gene +
( O -
R O +
= O +
0.40 O -
, O +
p O +
< O +
0.001 O -
) O +
and O +
between O +
RIL B-Gene +
and O +
CDH13 B-Gene +
( O -
R O +
= O +
0.30 O -
, O +
p O +
= O +
0.004 O -
) O -
. O +

Similarly O -
, O +
in O +
tumor O +
tissues O -
, O +
a O +
moderate O +
correlation O +
existed O +
between O +
RASSF1A B-Gene +
and O +
HIN-1 B-Gene +
( O -
R O +
= O +
0.51 O -
, O +
p O +
< O +
0.001 O -
) O +
and O +
a O +
weak O +
correlation O +
existed O +
between O +
RIL B-Gene +
and O +
CDH13 B-Gene +
( O -
R O +
= O +
0.19 O -
, O +
p O +
= O +
0.068 O -
) O -
. O +

In O +
addition O -
, O +
the O +
global O +
methylation O +
marker O +
LINE1 B-Gene +
was O +
negatively O +
correlated O +
to O +
RIL B-Gene +
( O -
R O +
= O +
-0.25 O -
, O +
p O +
= O +
0.019 O -
) O +
and O +
RASSF1A B-Gene +
( O -
R O +
= O +
-0.26 O -
, O +
p O +
= O +
0.014 O -
) O +
in O +
breast O +
cancer O +
samples O -
. O +

In O +
normal O +
tissues O -
, O +
RIL B-Gene +
methylation O +
levels O +
increased O +
with O +
age O +
( O -
R O +
= O +
0.336 O -
, O +
p O +
= O +
0.001 O -
) O -
, O +
whereas O +
other O +
markers O +
had O +
little O +
correlation O +
to O +
age O -
. O +

In O +
the O +
cancer O +
tissues O -
, O +
HIN-1 B-Gene +
levels O +
exhibited O +
a O +
weak O +
correlation O +
to O +
age O +
( O -
R O +
= O +
0.229 O -
, O +
p O +
= O +
0.03 O -
) O -
, O +
whereas O +
other O +
markers O +
had O +
little O +
correlation O +
to O +
age O -
. O +

Correlation O +
between O +
methylation O +
in O +
malignant O +
and O +
adjacent O +
normal O +
tissues O +
To O +
study O +
whether O +
gene O +
methylation O +
in O +
cancer O +
would O +
affect O +
adjacent O +
normal O -
- O -
appearing O +
mammary O +
gland O +
tissues O -
, O +
the O +
pair O -
- O -
wise O +
correlation O +
between O +
paired O +
tumor O +
and O +
adjacent O +
normal O +
breast O +
tissues O +
was O +
estimated O +
for O +
each O +
marker O -
. O +

Methylation O +
of O +
RIL B-Gene -
, O +
HIN-1 B-Gene -
, O +
RASSF1A B-Gene -
, O +
and O +
CDH13 B-Gene +
exhibited O +
a O +
positive O +
correlation O +
between O +
breast O +
cancer O +
and O +
normal O +
tissues O -
. O +

The O +
Pearson O +
correlation O +
values O +
ranged O +
from O +
0.25 O +
to O +
0.38 O +
( O -
p O +
values O +
ranged O +
from O +
0.02 O +
to O +
0.0002 O -
) O -
. O +

Relationship O +
between O +
methylation O +
of O +
individual O +
genes O +
and O +
clinical O +
characteristics O +
Using O +
the O +
ANOVA O +
model O -
, O +
no O +
statistically O +
significant O +
associations O +
were O +
found O +
between O +
clinical O +
stage O -
, O +
tumor O +
size O -
, O +
or O +
node O +
status O -
. O +

Tumors O +
that O +
were O +
poorly O +
differentiated O +
( O -
grade O +
3 O -
) O +
according O +
to O +
Black O -
's O +
nuclear O +
grade O +
( O -
BNG O -
) O +
had O +
lower O +
methylation O +
levels O +
of O +
HIN-1 B-Gene +
than O +
well- O +
and O +
moderately O +
differentiated O +
tumors O +
( O -
grade O +
1 O +
+ O +
2 O -
; O +
p O +
= O +
0.01 O -
) O -
. O +

Similarly O -
, O +
RASSF1A B-Gene +
methylation O +
levels O +
were O +
lower O +
in O +
poorly O +
differentiated O +
cancers O +
than O +
well- O +
and O +
moderately O +
differentiated O +
tumors O +
( O -
p O +
= O +
0.053 O -
) O -
. O +

In O +
addition O -
, O +
CDH13 B-Gene +
and O +
RIL B-Gene +
methylation O +
levels O +
cancers O +
were O +
marginally O +
higher O +
in O +
poorly O +
differentiated O +
than O +
well- O +
and O +
moderately O +
differentiated O +
cancers O +
( O -
p O +
= O +
0.059 O +
and O +
0.096 O -
, O +
respectively O -
) O -
. O +

Relationship O +
between O +
methylation O +
of O +
individual O +
genes O +
and O +
ER B-Gene -
, O +
PR B-Gene -
, O +
HR B-Gene -
, O +
and O +
HER-2 B-Gene -
/ I-Gene -
neu I-Gene +
status O +
In O +
univariate O +
analyses O -
, O +
the O +
ER B-Gene +
status O +
was O +
positively O +
associated O +
with O +
high O +
HIN-1 B-Gene +
and O +
RASSF1A B-Gene +
methylation O +
levels O +
but O +
negatively O +
correlated O +
to O +
high O +
RIL B-Gene +
methylation O +
levels O +
( O -
p O +
< O +
0.001 O -
, O +
0.002 O -
, O +
and O +
0.01 O -
, O +
respectively O -
) O -
. O +

Specifically O -
, O +
patients O +
with O +
a O +
positive O +
ER B-Gene +
status O +
had O +
higher O +
methylation O +
levels O +
of O +
HIN-1 B-Gene +
( O -
mean O +
of O +
29 O -
% O +
in O +
ER B-Gene -
- O -
positive O +
tumors O +
versus O +
9 O -
% O +
in O +
ER B-Gene -
- O -
negative O +
tumors O -
) O -
, O +
whereas O +
patients O +
with O +
a O +
negative O +
ER B-Gene +
status O +
had O +
higher O +
methylation O +
levels O +
of O +
RIL B-Gene +
( O -
mean O +
of O +
36 O -
% O +
in O +
ER B-Gene -
- O -
negative O +
tumors O +
versus O +
22 O -
% O +
in O +
ER B-Gene -
- O -
positive O +
tumors O -
) O -
. O +

In O +
addition O -
, O +
the O +
PR B-Gene +
status O +
was O +
positively O +
associated O +
with O +
high O +
HIN-1 B-Gene +
methylation O +
levels O +
( O -
p O +
< O +
0.001 O -
) O +
and O +
negatively O +
associated O +
with O +
high O +
CDH13 B-Gene +
methylation O +
levels O +
( O -
p O +
= O +
0.03 O -
) O -
. O +

By O +
defining O +
the O +
HR B-Gene +
status O +
as O +
positive O +
if O +
the O +
status O +
of O +
ERs B-Gene +
and/or O +
PRs B-Gene +
is O +
positive O -
, O +
the O +
associations O +
between O +
the O +
methylation O +
markers O +
and O +
HRs B-Gene +
are O +
similar O +
to O +
those O +
between O +
the O +
methylation O +
markers O +
and O +
ERs B-Gene -
. O +

In O +
multivariate O +
logistic O +
models O -
, O +
high O +
levels O +
of O +
both O +
HIN-1 B-Gene +
and O +
RIL B-Gene +
methylation O +
are O +
independent O +
predictors O +
of O +
the O +
status O +
of O +
ERs B-Gene +
and O +
HRs B-Gene -
, O +
and O +
high O +
levels O +
of O +
HIN-1 B-Gene +
and O +
CDH13 B-Gene +
methylation O +
are O +
independent O +
predictors O +
of O +
PR B-Gene +
status O +
( O -
Table O +
3 O -
) O -
. O +

Higher O +
methylation O +
levels O +
of O +
HIN-1 B-Gene +
were O +
more O +
likely O +
to O +
be O +
associated O +
with O +
ER B-Gene -
- O -
positive O +
than O +
ER B-Gene -
- O -
negative O +
tumors O -
, O +
whereas O +
higher O +
methylation O +
levels O +
of O +
RIL B-Gene +
were O +
more O +
likely O +
to O +
be O +
associated O +
with O +
ER B-Gene -
- O -
negative O +
than O +
ER B-Gene -
- O -
positive O +
tumors O -
. O +

Using O +
multivariable O +
logistic O +
models O -
, O +
we O +
have O +
assessed O +
the O +
effect O +
of O +
each O +
gene O +
( O -
LINE1 B-Gene -
, O +
RIL B-Gene -
, O +
HIN-1 B-Gene -
, O +
RASFF1A B-Gene -
, O +
CDH13 B-Gene -
, O +
and O +
RARβ2 B-Gene -
) O +
on O +
HR B-Gene +
( O -
adjusted O +
for O +
age O -
) O -
, O +
ER B-Gene +
( O -
adjusted O +
for O +
age O +
and O +
PR B-Gene +
status O -
) O -
, O +
or O +
PR B-Gene +
( O -
adjusted O +
for O +
age O +
and O +
ER B-Gene +
status O -
) O +
status O +
( O -
Additional O +
file O +
3 O -
) O -
. O +

The O +
results O +
shown O +
in O +
Additional O +
file O +
3 O +
are O +
similar O +
to O +
those O +
in O +
Table O +
3 O -
. O +

Among O +
the O +
markers O +
studied O -
, O +
the O +
higher O +
methylation O +
levels O +
of O +
HIN-1 B-Gene +
were O +
significantly O +
correlated O +
to O +
a O +
lack O +
of O +
HER-2 B-Gene -
/ I-Gene -
neu I-Gene +
amplification O +
( O -
p O +
= O +
0.014 O -
) O -
. O +

Fitted O +
multivariate O +
logistic O +
models O +
for O +
ER B-Gene -
, O +
PR B-Gene -
, O +
and O +
HR B-Gene +
expression O +
CI O -
, O +
confidence O +
interval O -
; O +
ER B-Gene -
, O +
estrogen O +
receptor O -
; O +
HR B-Gene -
, O +
hormone O +
receptor O -
; O +
PR B-Gene -
, O +
progesterone O +
receptor O -
. O +

Correlation O +
of O +
two O +
panels O +
of O +
methylation O +
profiles O +
to O +
opposite O +
hormone O +
status O +
Because O +
of O +
a O +
correlation O +
between O +
the O +
methylation O +
levels O +
of O +
several O +
of O +
the O +
genes O +
studied O -
, O +
we O +
assembled O +
four O +
potential O +
markers O +
into O +
two O +
panels O -
: O +
HIN-1 B-Gene -
/ O -
RASSFIA B-Gene +
and O +
RIL B-Gene -
/ O -
CDH13 B-Gene -
. O +

A O +
univariate O +
analysis O +
was O +
performed O +
and O +
a O +
multivariate O +
logistic O +
model O +
was O +
fitted O +
to O +
the O +
two O +
panels O -
. O +

The O +
results O +
of O +
the O +
univariate O +
analysis O +
for O +
each O +
panel O +
indicated O +
that O +
the O +
panels O +
had O +
a O +
greater O +
power O +
to O +
predict O +
ER B-Gene -
, O +
PR B-Gene -
, O +
and O +
HR B-Gene +
status O +
( O -
Table O +
4 O +
and O +
Figure O +
3 O -
) O +
than O +
the O +
methylation O +
of O +
individual O +
genes O +
( O -
Table O +
3 O -
) O -
. O +

Methylation O +
of O +
the O +
HIN-1 B-Gene -
/ O -
RASSFIA B-Gene +
panel O +
was O +
strongly O +
correlated O +
to O +
positive O +
ER B-Gene -
, O +
PR B-Gene -
, O +
and O +
HR B-Gene +
expression O -
; O +
88 O -
% O +
of O +
HIN-1 B-Gene -
/ O -
RASSFIA B-Gene -
- O -
positive O +
breast O +
cancers O +
were O +
ER B-Gene -
- O -
positive O +
and O +
only O +
12 O -
% O +
of O +
breast O +
cancers O +
were O +
ER B-Gene -
- O -
negative O +
( O -
p O +
< O +
0.001 O -
) O -
. O +

Conversely O -
, O +
methylation O +
of O +
the O +
RIL B-Gene -
/ O -
CDH13 B-Gene +
panel O +
was O +
strongly O +
correlated O +
to O +
negative O +
ER B-Gene -
, O +
PR B-Gene -
, O +
and O +
HR B-Gene +
expression O -
, O +
because O +
69 O -
% O +
of O +
methylation O -
- O -
positive O +
tumors O +
were O +
ER B-Gene -
- O -
negative O +
and O +
only O +
31 O -
% O +
were O +
ER B-Gene -
- O -
positive O +
( O -
p O +
= O +
0.001 O -
) O -
. O +

Univariate O +
analysis O +
of O +
clinical O +
variables O +
by O +
HIN-1 B-Gene -
/ O -
RASSF1A B-Gene +
and O +
RIL B-Gene -
/ O -
CDH13panels B-Gene -
, O +
according O +
to O +
Fisher O -
's O +
exact O +
test O +
BNG O -
, O +
Black O -
's O +
nuclear O +
grade O -
; O +
ER B-Gene -
, O +
estrogen O +
receptor O -
; O +
HR B-Gene -
, O +
hormone O +
receptor O -
; O +
PR B-Gene -
, O +
progesterone O +
receptor O -
. O +

Comparison O +
of O +
two O +
methylation O +
panels O +
with O +
hormone O +
receptor O +
status O -
. O +

( O -
a O -
) O +
Dichotomous O +
heat O +
map O +
representing O +
DNA O +
methylation O +
in O +
the O +
HIN-1 B-Gene -
/ O -
RASSF1A B-Gene +
panel O +
( O -
left O -
) O +
and O +
hormone O +
status O +
of O +
each O +
tumor O +
( O -
right O -
) O -
. O +

( O -
b O -
) O +
Dichotomous O +
heat O +
map O +
representing O +
DNA O +
methylation O +
data O +
in O +
the O +
RIL B-Gene -
/ O -
CDH13 B-Gene +
panel O +
( O -
left O -
) O +
and O +
hormone O +
receptor O +
status O +
of O +
each O +
tumor O +
( O -
right O -
) O -
. O +

Dark O +
gray O -
, O +
positive O -
; O +
light O +
gray O -
, O +
negative O -
. O +

We O +
summarize O +
the O +
fitted O +
multivariate O +
logistic O +
models O +
of O +
the O +
HIN-1 B-Gene -
/ O -
RASSF1A B-Gene +
and O +
RIL B-Gene -
/ O -
CDH13 B-Gene +
panels O +
by O +
categorical O +
variables O +
( O -
Table O +
3 O -
) O -
. O +

Specifically O -
, O +
a O +
patient O +
with O +
a O +
positive O +
value O +
in O +
the O +
RIL B-Gene -
/ O -
CDH13 B-Gene +
panel O +
is O +
ten O +
times O +
more O +
likely O +
to O +
have O +
an O +
ER B-Gene -
- O -
negative O +
tumor O +
than O +
a O +
patient O +
with O +
a O +
negative O +
value O -
. O +

By O +
contrast O -
, O +
a O +
patient O +
with O +
a O +
positive O +
value O +
in O +
the O +
HIN-1 B-Gene -
/ O -
RASSF1A B-Gene +
panel O +
is O +
17 O +
times O +
more O +
likely O +
to O +
have O +
an O +
ER B-Gene -
- O -
positive O +
tumor O +
than O +
a O +
patient O +
with O +
a O +
negative O +
value O -
. O +

Interestingly O -
, O +
we O +
found O +
that O +
triple O -
- O -
negative O +
breast O +
cancers O +
( O -
in O +
other O +
words O -
, O +
those O +
with O +
negative O +
ER B-Gene -
, O +
PR B-Gene -
, O +
and O +
HER-2 O -
/ O -
neu O +
status O -
) O +
were O +
positively O +
correlated O +
to O +
methylation O +
of O +
the O +
RIL B-Gene -
/ O -
CDH13 B-Gene +
panel O +
and O +
negatively O +
correlated O +
to O +
methylation O +
of O +
the O +
HIN-1 B-Gene -
/ O -
RASSFIA B-Gene +
panel O +
( O -
Table O +
4 O -
) O -
. O +

In O +
particular O -
, O +
58 O -
% O +
( O -
15 O +
out O +
of O +
26 O -
) O +
of O +
triple O -
- O -
negative O +
cancers O +
exhibited O +
methylation O +
of O +
the O +
RIL B-Gene -
/ O -
CDH13 B-Gene +
panel O -
, O +
whereas O +
17 O -
% O +
( O -
11 O +
out O +
of O +
64 O -
) O +
of O +
triple O -
- O -
negative O +
cancers O +
failed O +
to O +
methylate O +
in O +
this O +
panel O +
( O -
p O +
< O +
0.001 O -
) O -
. O +

Only O +
9 O -
% O +
( O -
3 O +
out O +
of O +
34 O -
) O +
of O +
triple O -
- O -
negative O +
cancers O +
exhibited O +
HIN-1 B-Gene -
/ O -
RASSFIA B-Gene +
panel O +
methylation O -
, O +
whereas O +
41 O -
% O +
( O -
23 O +
out O +
of O +
56 O -
) O +
of O +
triple O -
- O -
negative O +
cancers O +
failed O +
to O +
methylate O +
in O +
this O +
panel O +
( O -
p O +
= O +
0.001 O -
) O -
. O +

In O +
addition O -
, O +
triple O -
- O -
negative O +
cancers O +
were O +
significantly O +
associated O +
with O +
advanced O +
tumor O +
grade O +
( O -
24 O -
% O +
in O +
grade O +
1 O +
and O +
2 O +
versus O +
76 O -
% O +
in O +
grade O +
3 O -
; O +
p O +
= O +
0.001 O -
) O -
. O +

Breast O +
tumors O +
with O +
p53 B-Gene +
mutations O +
lacked O +
methylation O +
We O +
studied O +
the O +
mutation O +
status O +
of O +
p53 B-Gene +
in O +
the O +
84 O +
tumors O +
in O +
which O +
DNA O +
sequences O +
were O +
available O +
for O +
analysis O -
. O +

Overall O -
, O +
p53 B-Gene +
mutations O +
were O +
found O +
in O +
9 O +
out O +
of O +
84 O +
( O -
11 O -
% O -
) O +
cases O -
. O +

Seven O +
cases O +
with O +
p53 B-Gene +
mutations O +
belonged O +
to O +
the O +
group O +
that O +
lacked O +
methylation O +
in O +
both O +
panels O -
; O +
one O +
case O +
was O +
positive O +
in O +
the O +
HIN-1 B-Gene -
/ O -
RASSF1A B-Gene +
panel O +
and O +
one O +
case O +
was O +
positive O +
in O +
the O +
RIL B-Gene -
/ O -
CDH13 B-Gene +
panel O -
. O +

In O +
the O +
methylation O -
- O -
negative O +
group O +
( O -
both O +
panels O +
were O +
negative O -
) O -
, O +
18 O -
% O +
( O -
7 O +
out O +
of O +
38 O -
) O +
of O +
the O +
specimens O +
had O +
p53 B-Gene +
mutations O -
; O +
in O +
the O +
methylation O -
- O -
positive O +
group O +
( O -
either O +
panel O +
or O +
both O +
panels O +
were O +
positive O -
) O -
, O +
only O +
4 O -
% O +
( O -
2 O +
out O +
of O +
46 O -
) O +
of O +
specimens O +
had O +
p53 B-Gene +
mutation O +
( O -
p O +
= O +
0.072 O +
in O +
Fisher O -
's O +
exact O +
test O -
) O -
. O +

Interestingly O -
, O +
five O +
of O +
the O +
cases O +
with O +
p53 B-Gene +
mutations O +
occurred O +
in O +
triple O -
- O -
negative O +
( O -
ER- B-Gene -
, O +
PR- B-Gene -
, O +
and O +
HER2-negative B-Gene -
) O +
cancers O -
. O +

Interestingly O -
, O +
ERs B-Gene +
and O +
PRs B-Gene +
were O +
not O +
frequently O +
methylated O +
in O +
breast O +
cancers O +
at O +
levels O +
comparable O +
with O +
those O +
observed O +
in O +
the O +
five O +
tumor O -
- O -
suppressor O +
genes O -
. O +

Consequently O -
, O +
alterations O +
in O +
methylation O +
do O +
not O +
seem O +
to O +
have O +
silenced O +
these O +
receptors O +
directly O -
. O +

Increased O +
methylation O +
of O +
certain O +
genes O +
was O +
associated O +
with O +
the O +
expression O +
of O +
ERs B-Gene +
and O +
PRs B-Gene -
, O +
suggesting O +
that O +
silencing O +
of O -
, O +
at O +
least O +
some O -
, O +
tumor O +
suppressors O +
might O +
affect O +
the O +
transcriptional O +
regulation O +
of O +
HRs B-Gene -
, O +
possibly O +
by O +
upregulating O +
HR B-Gene +
co O -
- O -
stimulators O -
. O +

Conversely O -
, O +
the O +
downregulation O +
of O +
ERs B-Gene +
or O +
PRs B-Gene +
might O +
relate O +
to O +
the O +
increased O +
expression O +
of O +
HR O +
co O -
- O -
repressors O -
. O +

These O +
hypotheses O +
will O +
be O +
tested O +
in O +
future O +
studies O -
. O +

Recently O -
, O +
on O +
the O +
basis O +
of O +
the O +
microarray O +
profiling O +
of O +
invasive O +
breast O +
carcinomas O -
, O +
five O +
distinct O +
subtypes O +
of O +
tumors O +
( O -
luminal O +
A O -
, O +
luminal O +
B O -
, O +
normal O +
breast O -
- O -
like O -
, O +
HER-2 B-Gene -
/ I-Gene -
neu I-Gene +
overexpressing O -
, O +
and O +
basal O -
) O +
associated O +
with O +
different O +
clinical O +
outcomes O +
have O +
been O +
identified O +
[ O -
29,30 O -
] O -
. O +

The O +
basal O +
subtype O +
is O +
associated O +
with O +
poor O +
clinical O +
outcomes O +
and O +
the O +
subtype O +
observed O +
in O +
BRCA1-related B-Gene +
breast O +
cancers O -
. O +

All O +
basal O -
- O -
like O +
tumors O +
tested O +
in O +
the O +
current O +
study O +
were O +
triple O -
- O -
negative O +
( O -
that O +
is O +
to O +
say O -
, O +
negative O +
for O +
ER B-Gene -
, O +
PR B-Gene -
, O +
and O +
HER-2 B-Gene -
/ I-Gene -
neu I-Gene +
expression O -
) O -
, O +
poorly O +
differentiated O -
, O +
and O +
high O -
- O -
grade O +
[ O -
29,30 O -
] O -
. O +

An O +
early O +
study O +
of O +
HIN-1 B-Gene +
methylation O +
revealed O +
lower O +
frequencies O +
of O +
HIN-1 B-Gene +
promoter O +
methylation O +
in O +
sporadic O +
breast O +
tumors O +
with O +
a O +
' O -
BRCA1-like B-Gene -
' O +
histopathologic O +
phenotype O +
[ O -
31 O -
] O -
. O +

In O +
the O +
90 O +
cases O +
we O +
tested O -
, O +
76 O -
% O +
of O +
the O +
26 O +
triple O -
- O -
negative O +
tumors O +
were O +
high O -
- O -
grade O -
. O +

Interestingly O -
, O +
we O +
found O +
these O +
tumors O +
to O +
be O +
positively O +
associated O +
with O +
methylation O +
of O +
the O +
RIL B-Gene -
/ O -
CDH13 B-Gene +
panel O +
but O +
negatively O +
correlated O +
to O +
methylation O +
of O +
the O +
HIN-1 B-Gene -
/ O -
RASSFIA B-Gene +
panel O -
. O +

Our O +
results O +
suggested O +
that O +
methylation O +
reflected O +
by O +
the O +
RIL B-Gene -
/ O -
CDH13 B-Gene +
panel O +
might O +
have O +
a O +
role O +
in O +
the O +
phenotype O +
of O +
basal O -
- O -
like O +
breast O +
tumors O -
. O +

Recent O +
advances O +
in O +
molecular O +
biology O +
have O +
revealed O +
numerous O +
genetic O +
alterations O +
involved O +
in O +
breast O +
tumorigenesis O -
; O +
p53 B-Gene +
mutation O +
is O +
among O +
the O +
most O +
important O +
of O +
those O +
alterations O -
, O +
and O +
studies O +
have O +
reported O +
that O +
p53 B-Gene +
mutations O +
are O +
strongly O +
associated O +
with O +
poor O +
prognoses O +
in O +
breast O +
cancer O +
[ O -
32 O -
] O -
. O +

In O +
colorectal O +
cancer O -
, O +
methylation O +
phenotypes O +
define O +
two O +
groups O +
with O +
significantly O +
different O +
genetic O +
lesions O +
( O -
K B-Gene -
- I-Gene -
RAS I-Gene +
and O +
p53 B-Gene +
mutations O -
) O +
[ O -
33 O -
] O -
. O +

In O +
this O +
study O -
, O +
we O +
have O +
identified O +
11 O -
% O +
of O +
breast O +
tumors O +
that O +
had O +
p53 B-Gene +
mutations O -
. O +

Equivalent O +
to O +
the O +
observation O +
in O +
colorectal O +
cancers O -
, O +
most O +
cases O +
with O +
p53 B-Gene +
mutations O +
belong O +
to O +
the O +
group O +
that O +
lack O +
methylation O -
, O +
suggesting O +
that O +
p53 B-Gene +
mutation O +
and O +
methylation O +
can O +
be O +
two O +
distinct O +
mechanisms O +
that O +
deactivate O +
tumor O -
- O -
suppressor O +
genes O +
in O +
breast O +
cancer O -
. O +

The O +
correlation O +
of O +
p53 B-Gene +
mutation O +
to O +
hypomethylation O +
is O +
also O +
likely O +
to O +
be O +
owing O +
to O +
the O +
fact O +
that O +
p53 B-Gene +
mutations O +
and O +
hypomethylation O +
both O +
occur O +
in O +
basal O -
- O -
like O +
triple O -
- O -
negative O +
breast O +
cancers O -
. O +

The O +
methylation O +
of O +
multiple O +
tumor O -
- O -
suppressor O +
genes O +
has O +
been O +
correlated O +
to O +
poor O +
prognoses O +
in O +
cancers O +
[ O -
34 O -
] O -
. O +

The O +
use O +
of O +
epigenetic O +
information O +
has O +
shown O +
promise O +
in O +
the O +
identification O +
of O +
patients O +
with O +
gastrointestinal O +
cancers O +
who O +
have O +
poor O +
prognoses O +
[ O -
35 O -
] O -
. O +

In O +
esophageal O +
carcinoma O -
, O +
the O +
cancers O +
with O +
frequent O +
methylation O +
had O +
significantly O +
poorer O +
survival O -
, O +
and O +
methylation O +
was O +
a O +
better O +
predictor O +
of O +
outcome O +
than O +
the O +
disease O +
stage O +
or O +
patient O +
age O +
[ O -
36 O -
] O -
. O +

Methylation O -
, O +
as O +
a O +
prognosis O +
factor O -
, O +
has O +
also O +
been O +
described O +
in O +
bladder O +
cancer O +
[ O -
37 O -
] O -
, O +
head O +
and O +
neck O +
cancer O +
[ O -
38 O -
] O -
, O +
ovarian O +
cancer O +
[ O -
39 O -
] O -
, O +
and O +
acute O +
lymphocytic O +
leukemia O +
[ O -
40 O -
] O -
. O +

In O +
our O +
study O -
, O +
we O +
did O +
not O +
have O +
sufficient O +
survival O +
data O +
to O +
correlate O +
methylation O +
to O +
prognosis O +
( O -
most O +
patients O +
were O +
treated O +
in O +
2004 O +
and O +
2005 O -
) O -
, O +
but O +
we O +
did O +
confirm O +
that O +
the O +
methylation O +
of O +
multiple O +
tumor O -
- O -
suppressor O +
genes O +
was O +
an O +
early O +
event O +
in O +
the O +
subgroups O +
of O +
patients O +
with O +
breast O +
cancer O -
. O +

To O +
understand O +
whether O +
methylation O +
is O +
a O +
prognostic O +
factor O +
in O +
breast O +
cancer O -
, O +
we O +
must O +
conduct O +
studies O +
with O +
longer O +
follow O -
- O -
up O +
times O +
to O +
obtain O +
adequate O +
survival O +
data O -
. O +

Finally O -
, O +
epigenetic O +
therapy O -
, O +
including O +
the O +
use O +
of O +
demethylating O +
agents O +
( O -
for O +
example O -
, O +
5-aza O -
- O -
cytidine O +
and O +
5-aza-2'-deoxycytidine O -
) O +
and O +
histone O +
deacetylase O +
inhibitors O +
( O -
for O +
example O -
, O +
suberoylanilide O +
hydroxamic O +
acid O +
and O +
valproic O +
acid O -
) O -
, O +
is O +
currently O +
in O +
clinical O +
trials O +
for O +
myelodysplastic O +
syndrome O -
, O +
leukemia O -
, O +
ovarian O +
cancer O -
, O +
and O +
lung O +
cancer O -
. O +

Previous O +
reports O +
indicate O +
that O +
the O +
' O -
cross O -
- O -
talk O -
' O +
between O +
inhibitors O +
of O +
DNA O +
methylation O +
and O +
histone O +
deacetylase O +
can O +
result O +
in O +
synergistic O +
activation O +
of O +
silent O +
tumor O -
- O -
suppressor O +
genes O +
in O +
breast O +
cancer O -
. O +

These O +
observations O +
suggest O +
that O +
combination O +
of O +
these O +
inhibitors O +
might O +
be O +
an O +
effective O +
form O +
of O +
epigenetic O +
therapy O +
for O +
breast O +
cancer O -
. O +

It O +
is O +
possible O +
that O +
epigenetic O +
therapy O +
will O +
have O +
a O +
role O +
in O +
the O +
management O +
of O +
breast O +
cancer O -
. O +

The O +
information O +
from O +
this O +
study O +
of O +
methylation O +
profiles O +
will O +
be O +
useful O +
for O +
the O +
study O +
of O +
the O +
biology O +
of O +
breast O +
cancer O +
and O +
refining O +
epigenetic O +
therapy O -
. O +

Conclusion O +
By O +
pyrosequencing O +
methylation O +
analysis O -
, O +
we O +
have O +
examined O +
the O +
methylation O +
profile O +
of O +
90 O +
normal O -
/ O -
breast O +
cancer O +
paired O +
samples O -
. O +

Our O +
data O +
indicated O +
that O +
5 O +
out O +
of O +
12 O +
tumor O -
- O -
suppressor O +
genes O +
were O +
frequently O +
methylated O +
in O +
breast O +
cancers O +
but O +
not O +
the O +
normal O +
breast O -
. O +

We O +
have O +
defined O +
two O +
panels O +
( O -
HIN-1 B-Gene -
/ O -
RASSFIA B-Gene +
and O +
RIL B-Gene -
/ O -
CDH13 B-Gene -
) O +
of O +
methylation O +
profiles O -
, O +
which O +
correlated O -
, O +
either O +
positively O +
or O +
negatively O -
, O +
to O +
HR B-Gene +
status O -
. O +

Clinical O +
impact O +
of O +
HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
in O +
rectal O +
cancer O +
Abstract O +
Purpose O +
To O +
determine O +
the O +
clinical O +
impact O +
of O +
human B-Gene +
leukocyte I-Gene +
antigen I-Gene +
( I-Gene -
HLA I-Gene -
) I-Gene +
class I-Gene +
I I-Gene +
expression O +
in O +
irradiated O +
and O +
non O -
- O -
irradiated O +
rectal O +
carcinomas O -
. O +

Experimental O +
design O +
Tumor O +
samples O +
in O +
tissue O +
micro O +
array O +
format O +
were O +
collected O +
from O +
1,135 O +
patients O -
. O +

HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
was O +
assessed O +
after O +
immunohistochemical O +
staining O +
with O +
two O +
antibodies O +
( O -
HCA2 O +
and O +
HC10 O -
) O -
. O +

Results O +
Tumors O +
were O +
split O +
into O +
two O +
groups O -
: O +
( O -
1 O -
) O +
tumors O +
with O +
> O -
50 O -
% O +
of O +
tumor O +
cells O +
expressing O +
HLA B-Gene +
class I-Gene +
I I-Gene +
( O -
high O -
) O +
and O +
( O -
2 O -
) O +
tumors O +
with O +
≤50 O -
% O +
of O +
tumor O +
cells O +
expressing O +
HLA B-Gene +
class I-Gene +
I I-Gene +
( O -
low O -
) O -
. O +

No O +
difference O +
in O +
distribution O +
or O +
prognosis O +
of O +
HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
was O +
found O +
between O +
irradiated O +
and O +
non O -
- O -
irradiated O +
patients O -
. O +

Patients O +
with O +
low O +
expression O +
of O +
HLA B-Gene +
class I-Gene +
I I-Gene +
( O -
15 O -
% O +
of O +
all O +
patients O -
) O +
showed O +
an O +
independent O +
significantly O +
worse O +
prognosis O +
with O +
regard O +
to O +
overall O +
survival O +
and O +
disease O -
- O -
free O +
survival O -
. O +

HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
had O +
no O +
effect O +
on O +
cancer O -
- O -
specific O +
survival O +
or O +
recurrence O -
- O -
free O +
survival O -
. O +

Conclusions O +
Down O -
- O -
regulation O +
of O +
HLA B-Gene +
class I-Gene +
I I-Gene +
in O +
rectal O +
cancer O +
is O +
associated O +
with O +
poor O +
prognosis O -
. O +

In O +
contrast O +
to O +
our O +
results O -
, O +
previous O +
reports O +
on O +
HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
in O +
colorectal O +
cancer O +
described O +
a O +
large O +
population O +
of O +
patients O +
with O +
HLA B-Gene +
class I-Gene +
I I-Gene +
negative O +
tumors O -
, O +
having O +
a O +
good O +
prognosis O -
. O +

This O +
difference O +
might O +
be O +
explained O +
by O +
the O +
fact O +
that O +
a O +
large O +
proportion O +
of O +
HLA B-Gene +
negative O +
colon O +
tumors O +
are O +
microsatellite O +
instable O +
( O -
MSI O -
) O -
. O +

MSI O +
tumors O +
are O +
associated O +
with O +
a O +
better O +
prognosis O +
than O +
microsatellite O +
stable O +
( O -
MSS O -
) O -
. O +

As O +
rectal O +
tumors O +
are O +
mainly O +
MSS O -
, O +
our O +
results O +
suggest O +
that O +
it O +
is O +
both O -
, O +
oncogenic O +
pathway O +
and O +
HLA B-Gene +
class I-Gene +
I I-Gene +
expression O -
, O +
that O +
dictates O +
patient O -
's O +
prognosis O +
in O +
colorectal O +
cancer O -
. O +

Therefore O -
, O +
to O +
prevent O +
confounding O +
in O +
future O +
prognostic O +
analysis O +
on O +
the O +
impact O +
of O +
HLA B-Gene +
expression O +
in O +
colorectal O +
tumors O -
, O +
separate O +
analysis O +
of O +
MSI O +
and O +
MSS O +
tumors O +
should O +
be O +
performed O -
. O +

Materials O +
and O +
methods O +
Study O +
population O +
Patients O +
were O +
obtained O +
from O +
the O +
Dutch O +
TME O +
trial O -
, O +
a O +
multicenter O +
trial O +
that O +
evaluated O +
total O +
mesorectal O +
excision O +
( O -
TME O -
) O +
surgery O +
with O +
or O +
without O +
preoperative O +
radiotherapy O +
( O -
5 O +
× O +
5 O +
Gray O -
) O +
[ O -
15 O -
] O -
. O +

Radiotherapeutical O -
, O +
surgical O +
and O +
pathological O +
procedures O +
were O +
standardized O +
and O +
quality O -
- O -
controlled O +
[ O -
15 O -
, O +
21 O -
] O -
. O +

Tumor O +
staging O +
was O +
determined O +
using O +
the O +
tumor O +
node O +
metastasis O +
( O -
TNM O -
) O +
classification O +
[ O -
29 O -
] O -
. O +

Patients O +
with O +
the O +
hereditary O +
Lynch O +
syndrome O +
also O +
known O +
as O +
hereditary O +
non O -
- O -
polyposis O +
colorectal O +
cancer O +
( O -
HNPCC O -
) O +
were O +
excluded O +
from O +
the O +
TME O +
trial O -
. O +

Sufficient O +
formalin O -
- O -
fixed O +
paraffin O -
- O -
embedded O +
tumor O +
material O +
was O +
available O +
for O +
1,135 O +
Dutch O +
patients O -
. O +

Three O +
2 O +
mm O +
cores O +
of O +
each O +
tumor O +
sample O +
were O +
arrayed O +
into O +
tissue O +
microarrays O +
( O -
TMA O -
) O +
as O +
previously O +
described O +
[ O -
5 O -
] O -
. O +

Immunohistochemistry O +
and O +
microscopic O +
analysis O +
TMAs O +
[ O -
5 O -
] O +
were O +
immunohistochemically O +
stained O +
for O +
HLA B-Gene +
class I-Gene +
I I-Gene +
using O +
the O +
mAb O +
antibodies O +
HCA2 O +
and O +
HC10 O +
and O +
the O +
rabbit O +
anti O -
- O -
β2 O +
m O +
polyclonal O +
Ab O +
( O -
A O +
072 O -
; O +
DAKO O +
Cytomation O -
, O +
Glostrup O -
, O +
Denmark O -
) O -
. O +

The O +
HCA2 O +
and O +
HC10 O +
antibodies O +
were O +
applied O +
in O +
immunohistochemistry O +
as O +
hybridoma O +
culture O +
supernatant O -
, O +
kindly O +
provided O +
by O +
Prof. O +
J.J. O +
Neefjes O +
from O +
the O +
Netherlands O +
Cancer O +
Institute O +
( O -
Amsterdam O -
, O +
The O +
Netherlands O -
) O -
. O +

The O +
reactivity O +
spectrum O +
of O +
HCA2 O +
includes O +
HLA B-Gene -
- I-Gene -
A I-Gene +
( O -
except O +
HLA B-Gene -
- O -
A24 O -
) O -
, O +
HLA B-Gene -
- O -
B73 O +
and O +
HLA B-Gene -
- I-Gene -
C I-Gene +
molecules O +
as O +
well O +
as O +
HLA B-Gene -
- O -
E O -
, O +
HLA B-Gene -
- O -
F O +
and O +
HLA B-Gene -
- I-Gene -
G I-Gene +
antigens O +
[ O -
27 O -
, O +
28 O -
, O +
31 O -
] O -
. O +

HC10 O +
reacts O +
with O +
HLA B-Gene -
- I-Gene -
B I-Gene +
and O +
HLA B-Gene -
- I-Gene -
C I-Gene +
molecules O +
and O +
HLA B-Gene -
- O -
A10 O -
, O +
-A28 O -
, O +
-A29 O -
, O +
-A30 O -
, O +
-A31 O -
, O +
-A32 O +
and O +
-A33 O +
heavy O +
chains O +
[ O -
13 O -
, O +
23 O -
, O +
31 O -
, O +
32 O -
] O -
. O +

The O +
immunohistochemical O +
procedures O +
are O +
described O +
in O +
detail O +
elsewhere O +
[ O -
18 O -
] O -
. O +

All O +
tumor O +
specimens O +
were O +
stained O +
simultaneously O +
to O +
avoid O +
intra O -
- O -
assay O +
variation O -
. O +

Microscopic O +
analysis O +
was O +
assessed O +
by O +
two O +
independent O +
observers O +
( O -
M.M. O +
v. O +
B. O +
and O +
M. O +
v. O +
V. O -
) O +
in O +
a O +
blinded O +
manner O -
. O +

HCA2 O -
, O +
HC10 O +
and O +
β2 O +
m O +
stainings O +
were O +
scored O +
in O +
six O +
categories O -
. O +

Essentially O -
, O +
the O +
scoring O +
was O +
divided O +
into O +
quartiles O +
but O +
for O +
tumors O +
with O +
less O +
than O +
25 O -
% O +
stained O +
cells O -
, O +
there O +
was O +
a O +
distinction O +
made O +
between O +
those O +
with O +
6–25 O -
% O +
positively O +
stained O +
tumor O +
cells O -
, O +
those O +
with O +
approximately O +
1–5 O -
% O +
positively O +
stained O +
cells O +
and O +
those O +
with O +
absolute O +
no O +
positively O +
stained O +
tumor O +
cells O +
[ O -
3 O -
, O +
11 O -
] O -
. O +

Where O +
discrepancies O +
arose O +
between O +
the O +
staining O +
of O +
cores O +
from O +
the O +
same O +
tumor O -
, O +
an O +
average O +
of O +
the O +
scores O +
was O +
taken O -
, O +
with O +
confirmation O +
by O +
two O +
observers O +
using O +
a O +
double O -
- O -
headed O +
microscope O +
with O +
a O +
consensus O +
decision O +
taken O +
in O +
all O +
cases O -
. O +

Tissue O +
stromal O +
cells O -
, O +
normal O +
epithelium O +
or O +
lymph O +
follicles O +
served O +
as O +
positive O +
internal O +
controls O +
to O +
ascertain O +
the O +
quality O +
of O +
the O +
staining O -
. O +

Patients O +
were O +
excluded O +
if O +
stromal O +
cells O +
of O +
tumor O +
were O +
not O +
stained O +
for O +
HCA2 O +
or O +
HC10 O -
. O +

Twenty O -
- O -
five O +
tumors O +
with O +
negative O +
staining O +
of O +
the O +
stromal O +
cells O +
for O +
HCA2 O +
were O +
excluded O -
. O +

HC10 O +
showed O +
in O +
all O +
tumors O +
staining O +
of O +
the O +
stromal O +
cells O -
. O +

Also O +
TNM O +
stage O +
0 O +
patients O -
, O +
tumors O +
lost O +
due O +
to O +
technical O +
failure O +
and O +
ineligible O +
patients O +
were O +
excluded O -
, O +
leaving O +
1,092 O +
tumors O +
in O +
which O +
HC10 O -
, O +
and O +
1,035 O +
in O +
which O +
HCA2 O +
could O +
be O +
evaluated O -
. O +

Combining O +
the O +
results O +
for O +
HCA2 O +
and O +
HC10 O +
staining O +
resulted O +
in O +
1,008 O +
eligible O +
stage O +
I O -
– O -
IV O +
rectal O +
cancer O +
patients O +
for O +
analyses O +
of O +
clinical O +
impact O +
of O +
HLA B-Gene +
class I-Gene +
I I-Gene +
expression O -
. O +

Results O +
Scoring O +
methods O +
Several O +
methods O +
are O +
described O +
to O +
analyze O +
HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
in O +
cancer O -
. O +

The O +
standard O +
is O +
defined O +
by O +
the O +
International O +
HLA B-Gene +
and O +
Immunogenetics O +
Workshop O +
( O -
IHIW O -
) O +
[ O -
3 O -
, O +
11 O -
] O -
. O +

A O +
recent O +
paper O +
describing O +
HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
in O +
colorectal O +
cancer O +
used O +
an O +
adjusted O +
form O +
of O +
this O +
scoring O +
method O +
[ O -
35 O -
] O -
. O +

Our O +
scoring O +
was O +
primarily O +
adapted O +
from O +
IWIH O -
, O +
i.e. O +
division O +
into O +
quartiles O -
, O +
but O +
for O +
tumors O +
with O +
less O +
than O +
25 O -
% O +
stained O +
cells O +
a O +
distinction O +
was O +
made O +
between O +
those O +
with O +
6–25 O -
% O +
positive O +
tumor O +
cells O -
, O +
those O +
with O +
approximately O +
1–5 O -
% O +
positive O +
tumor O +
cells O +
and O +
those O +
with O +
absolute O +
no O +
HLA B-Gene +
class I-Gene +
I I-Gene +
positive O -
- O -
stained O +
tumor O +
cells O -
. O +

After O +
scoring O +
and O +
analyzing O +
this O +
method O +
we O +
found O +
that O +
patients O +
in O +
the O +
groups O +
with O +
absolute O +
numbers O -
, O +
1–5 O -
% O -
, O +
6–25 O -
% O +
and O +
26–50 O -
% O +
HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
of O +
tumor O +
cells O +
did O +
not O +
differ O +
in O +
prognosis O +
but O +
had O +
a O +
worse O +
prognosis O +
as O +
compared O +
to O +
patients O +
with O +
HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
in O +
groups O +
with O +
50–75 O -
% O +
and O +
> O -
75 O -
% O +
of O +
tumor O +
cells O +
expressing O +
HLA B-Gene +
class I-Gene +
I. I-Gene +
Therefore O -
, O +
we O +
distinguished O +
two O +
categories O -
. O +

These O +
two O +
categories O +
were O +
( O -
1 O -
) O +
0–50 O -
% O -
; O +
and O +
( O -
2 O -
) O +
> O -
50–100 O -
% O +
of O +
tumor O +
cells O +
expressing O +
HLA B-Gene +
class I-Gene +
I. I-Gene +
HCA-2 O +
and O +
HC10 O +
staining O +
in O +
rectal O +
cancer O +
Immunohistochemical O +
staining O +
with O +
HCA2 O +
and O +
HC10 O +
antibodies O +
demonstrated O +
strong O +
positive O +
membrane O +
staining O +
of O +
stromal O +
cells O +
and O +
tumor O -
- O -
infiltrating O +
inflammatory O +
cells O -
, O +
indicating O +
the O +
success O +
of O +
the O +
staining O -
. O +

A O +
total O +
of O +
1,035 O +
and O +
1,092 O +
tumors O +
were O +
evaluated O +
with O +
HCA2 O +
and O +
HC10 O -
; O +
324 O +
( O -
65 O -
% O -
) O +
irradiated O +
tumors O +
and O +
312 O +
( O -
58 O -
% O -
) O +
non O -
- O -
irradiated O +
tumors O +
showed O +
at O +
least O +
50 O -
% O +
of O +
all O +
tumor O +
cells O +
positive O +
for O +
HCA2 O -
. O +

Staining O +
with O +
HC10 O +
resulted O +
in O +
403 O +
( O -
76 O -
% O -
) O +
irradiated O +
tumors O +
and O +
436 O +
( O -
77 O -
% O -
) O +
non O -
- O -
irradiated O +
tumors O +
that O +
showed O +
more O +
than O +
50 O -
% O +
positive O +
tumor O +
cells O -
. O +

The O +
complete O +
results O +
are O +
shown O +
in O +
Table O +
1 O -
. O +

Representative O +
examples O +
of O +
the O +
immunohistochemical O +
stainings O +
of O +
tumors O +
are O +
displayed O +
in O +
Fig. O +
1a O -
– O -
f O -
. O +

These O +
results O +
show O +
that O +
about O +
35 O -
% O +
of O +
irradiated O +
and O +
42 O -
% O +
of O +
non O -
- O -
irradiated O +
patients O +
showed O +
less O +
than O +
50 O -
% O +
of O +
the O +
tumor O +
cells O +
expressing O +
HCA2 O -
. O +

HC10 O +
is O +
expressed O +
in O +
less O +
than O +
50 O -
% O +
of O +
the O +
tumor O +
cells O +
in O +
about O +
25 O -
% O +
of O +
both O +
irradiated O +
and O +
non O -
- O -
irradiated O +
rectal O +
cancer O +
patients O -
. O +

Table O +
1Most O +
rectal O +
tumors O +
have O +
high O +
numbers O +
of O +
tumor O +
cells O +
positive O +
for O +
HCA2 O +
or O +
HC10Irradiated O +
patients O +
N O +
( O -
% O -
) O -
Non O -
- O -
irradiated O +
patients O +
N O +
( O -
% O -
) O -
HCA2 O +
High324 O +
( O -
65% O -
) O -
312 O +
( O -
58 O -
% O -
) O +
Low142 O +
( O -
28% O -
) O -
174 O +
( O -
32 O -
% O -
) O +
Absence31 O +
( O -
6.2% O -
) O -
52 O +
( O -
9.7% O -
) O -
HC10 O +
High403 O +
( O -
76% O -
) O -
436 O +
( O -
77 O -
% O -
) O +
Low117 O +
( O -
22% O -
) O -
116 O +
( O -
21 O -
% O -
) O +
Absence8 O +
( O -
1.5% O -
) O -
12 O +
( O -
2.1% O -
) O -
Numbers O +
( O -
N O -
) O +
of O +
patients O +
are O +
indicated O +
with O +
percentages O +
shown O +
in O +
parentheses O -
, O +
showing O -
: O +
expression O +
of O +
HCA2 O +
and O +
HC10 O +
in O +
more O +
than O +
50 O -
% O +
of O +
the O +
tumor O +
cells O +
( O -
high O -
) O -
, O +
expression O +
in O +
less O +
than O +
50 O -
% O +
of O +
the O +
tumor O +
cells O +
( O -
low O -
) O +
and O +
total O +
absence O +
( O -
absence O -
) O -
Fig O -
. O +

1Examples O +
of O +
HCA2 O +
and O +
HC10 O +
immunohistochemical O +
staining O +
of O +
rectal O +
tumors O -
; O +
a O -
– O -
c O +
HCA2 O -
, O +
d O -
– O -
f O +
HC10 O +
expression O -
. O +

a O -
, O +
d O +
Expression O +
of O +
HLA B-Gene +
class I-Gene +
I I-Gene +
in O +
> O -
50 O -
% O +
tumor O +
cells O -
; O +
b O -
, O +
e O +
expression O +
of O +
HLA B-Gene +
class I-Gene +
I I-Gene +
in O +
< O -
50 O -
% O +
tumor O +
cells O -
; O +
c O -
, O +
f O +
epithelial O +
cells O +
show O +
total O +
absence O +
for O +
HCA2 O +
or O +
HC10 O +
and O +
only O +
stromal O +
and O +
infiltrative O +
cells O +
show O +
positive O +
staining O +
for O +
HCA2 O +
or O +
HC10 O -
; O +
Original O +
magnification O +
×20 O +

Multivariate O +
analysis O +
confirms O +
independent O +
better O +
overall O -
, O +
and O +
disease O +
free O +
survival O +
for O +
rectal O +
cancer O +
patients O +
with O +
high O +
expression O +
of O +
HLA B-Gene +
class I-Gene +
I I-Gene +
Multivariate O +
analysis O +
for O +
cancer O +
specific O -
, O +
overall O +
and O +
disease O +
free O +
survival O +
was O +
performed O +
to O +
identify O +
factors O +
with O +
independent O +
prognostic O +
significance O +
and O +
to O +
calculate O +
hazard O +
ratios O +
( O -
HR O -
) O +
with O +
95 O -
% O +
confidence O +
intervals O +
( O -
CI O -
) O +
shown O +
in O +
parentheses O -
. O +

HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
in O +
more O +
than O +
50 O -
% O +
of O +
the O +
tumor O +
cells O +
( O -
high O -
) O +
versus O +
expression O +
in O +
less O +
than O +
50 O -
% O +
of O +
the O +
tumor O +
cells O +
( O -
low O -
) O -
, O +
total O +
mesorectal O +
excision O +
( O -
TME O -
) O -
, O +
Radiotherapy O +
( O -
RT O -
) O -
; O +
circumferential O +
margin O +
( O -
CRM O -
) O -
; O +
P O +
value O +
is O +
based O +
on O +
Cox O -
' O +
regression O +
analyses O +
* O +
Statistical O +
significant O +
P O +
values O +
and O +
HR O +
are O +
in O +
bold O +

We O +
showed O +
that O +
tumors O +
that O +
do O +
not O +
stain O +
HC10 O +
can O +
stain O +
positive O +
for O +
HCA2 O +
and O +
thus O +
are O +
still O +
able O +
to O +
present O +
antigens O -
. O +

Therefore O -
, O +
an O +
explanation O +
for O +
the O +
differences O +
with O +
the O +
results O +
of O +
Watson O +
et O +
al. O +
is O +
that O +
we O +
used O +
strict O +
criteria O +
to O +
classify O +
tumors O +
as O +
HLA B-Gene +
class I-Gene +
I I-Gene +
absent O +
( O -
defined O +
as O +
both O +
HCA2 O +
and O +
HC10 O +
negative O -
) O +
as O +
compared O +
to O +
Watson O +
et O +
al. O +
( O -
defined O +
as O +
negative O +
for O +
HC10 O +
or O +
negative O +
for O +
β2 O +
m O +
instead O +
of O +
negative O +
for O +
both O -
) O -
. O +

Another O +
important O +
explanation O +
is O +
that O +
we O +
examined O +
HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
in O +
a O +
relative O +
more O +
homogeneous O +
population O +
of O +
patients O +
with O +
a O +
rectal O +
tumor O -
, O +
while O +
the O +
other O +
cohorts O +
are O +
more O +
heterogeneous O -
, O +
consisting O +
of O +
both O +
colon O +
and O +
rectal O +
cancer O -
. O +

Although O +
combining O +
results O +
from O +
colon O +
and O +
rectum O +
is O +
generally O +
accepted O +
when O +
predicting O +
prognosis O -
, O +
this O +
might O +
influence O +
results O +
[ O -
14 O -
] O -
. O +

In O +
colon O +
cancer O +
patients O -
, O +
approximately O +
50 O -
% O +
of O +
all O +
proximal O +
colon O +
tumors O +
show O +
MSI O -
, O +
whereas O +
almost O +
all O +
distal O +
colon O +
and O +
rectal O +
cancers O +
are O +
MSS O +
tumors O +
[ O -
24 O -
, O +
30 O -
] O -
. O +

Loss O +
of O +
HLA B-Gene +
class I-Gene +
I I-Gene +
has O +
been O +
described O +
in O +
at O +
least O +
60 O -
% O +
of O +
all O +
sporadic O +
right O -
- O -
sided O +
MSI O +
colorectal O +
tumors O +
but O +
in O +
only O +
17 O -
% O +
of O +
MSS O +
right O -
- O -
sided O +
colon O +
tumors O +
loss O +
of O +
HLA B-Gene +
class I-Gene +
I I-Gene +
is O +
found O +
[ O -
8 O -
, O +
16 O -
] O -
. O +

In O +
our O +
cohort O -
, O +
only O +
1 O +
out O +
of O +
11 O +
HLA O +
negative O +
tumors O +
and O +
2 O +
out O +
of O +
81 O +
tumors O +
negative O +
for O +
HCA2 O +
or O +
HC10 O +
did O +
not O +
express O +
MLH1 B-Gene +
and O +
PMS2 O +
and O +
were O +
thus O +
likely O +
MSI O +
tumors O -
. O +

This O +
indicates O +
that O +
rectal O +
cancers O +
are O +
mainly O +
MSS O +
tumors O -
, O +
as O +
has O +
previously O +
been O +
described O +
[ O -
4 O -
, O +
14 O -
, O +
25 O -
] O -
. O +

Of O +
the O +
multiple O +
mechanisms O +
that O +
have O +
been O +
shown O +
to O +
underlie O +
defects O +
in O +
HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
in O +
colorectal O +
cancer O +
( O -
mutations O +
in O +
the O +
individual O +
HLA B-Gene +
class I-Gene +
I I-Gene +
genes O -
, O +
mutations O +
in O +
β2 B-Gene +
m I-Gene +
[ O -
16 O -
] O -
, O +
and O +
defects O +
in O +
components O +
of O +
the O +
HLA B-Gene +
class I-Gene +
I I-Gene -
- B-Gene -
associated I-Gene +
antigen I-Gene +
processing I-Gene +
machinery I-Gene +
( O -
APM B-Gene -
) O +
[ O -
2 O -
, O +
16 O -
] O -
) O -
, O +
only O +
the O +
first O +
will O +
result O +
in O +
allele O -
- O -
specific O +
aberrancies O +
while O +
the O +
other O +
affect O +
total O +
HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
and O +
may O +
result O +
in O +
total O +
absence O +
in O +
a O +
tumor O +
cell O -
. O +

These O +
observations O +
imply O +
that O +
a O +
population O +
of O +
colorectal O +
tumors O +
with O +
total O +
absence O +
of O +
HLA B-Gene +
class I-Gene +
I I-Gene +
probably O +
contains O +
a O +
disproportionate O +
large O +
number O +
of O +
MSI O +
tumors O +
when O +
compared O +
to O +
colorectal O +
tumors O +
expressing O +
HLA B-Gene +
class I-Gene +
I. I-Gene +
In O +
addition O -
, O +
MSI O +
colorectal O +
tumors O +
have O +
a O +
better O +
prognosis O +
when O +
compared O +
to O +
MSS O +
colorectal O +
tumors O +
[ O -
12 O -
, O +
24 O -
] O -
. O +

Therefore O -
, O +
HLA B-Gene +
class I-Gene +
I I-Gene +
negative O +
tumors O +
are O +
more O +
likely O +
to O +
be O +
MSI O +
tumors O +
with O +
a O +
different O +
clinical O +
behavior O +
as O +
compared O +
to O +
MSS O +
colorectal O +
tumors O -
. O +

It O +
is O +
likely O +
that O +
MSI O +
influences O +
prognostic O +
results O +
when O +
considering O +
HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
in O +
colorectal O +
tumors O -
. O +

Our O +
results O +
show O +
that O +
HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
in O +
rectal O +
cancer O +
affects O +
the O +
patient O -
's O +
prognosis O -
. O +

We O +
hypothesize O +
that O +
both O +
oncogenic O +
pathway O +
and O +
HLA B-Gene +
class I-Gene +
I I-Gene +
expression O +
dictate O +
clinical O +
tumor O +
progression O -
. O +

We O +
suggest O +
that O +
in O +
future O +
prognostic O +
studies O -
, O +
analyzing O +
expression O +
of O +
HLA B-Gene +
class I-Gene +
I I-Gene +
or O +
other O +
biomarkers O +
in O +
colorectal O +
cancer O -
, O +
the O +
impact O +
of O +
MSI O +
should O +
be O +
considered O -
. O +

Lynch O +
syndrome O -
: O +
still O +
not O +
a O +
familiar O +
picture O +
Abstract O +
Background O +
Germ O +
line O +
mutations O +
in O +
mismatch B-Gene +
repair I-Gene +
genes I-Gene +
underlie O +
Lynch O +
syndrome O +
and O +
predispose O +
carriers O +
for O +
colorectal O +
carcinoma O +
and O +
malignancies O +
in O +
many O +
other O +
organ O +
systems O -
. O +

Case O +
presentation O +
A O +
large O +
Lynch O +
syndrome O +
family O +
with O +
15 O +
affected O +
family O +
members O +
and O +
involvement O +
in O +
7 O +
organs O +
is O +
reported O -
. O +

It O +
illustrates O +
a O +
lack O +
of O +
awareness O +
and O +
knowledge O +
about O +
this O +
hereditary O +
tumor O +
syndrome O +
among O +
doctors O +
as O +
well O +
as O +
patients O -
. O +

None O +
of O +
the O +
described O +
family O +
members O +
underwent O +
presymptomatic O +
screening O +
on O +
the O +
basis O +
of O +
the O +
family O +
history O -
. O +

Conclusion O +
Hereditary O +
features O -
, O +
like O +
young O +
age O +
at O +
diagnosis O -
, O +
multiple O +
tumors O +
in O +
multiple O +
organs O +
and O +
a O +
positive O +
family O +
history O -
, O +
should O +
lead O +
to O +
timely O +
referral O +
of O +
suspected O +
cases O +
for O +
genetic O +
counseling O +
and O +
diagnostics O -
. O +

For O +
Lynch O +
syndrome O -
, O +
these O +
features O +
can O +
be O +
found O +
in O +
the O +
Amsterdam O +
and O +
Bethesda O +
criteria O -
. O +

Subsequently O -
, O +
early O +
identification O +
of O +
mutation O +
carriers O +
might O +
have O +
diminished O -
, O +
at O +
least O +
in O +
part O -
, O +
the O +
high O +
and O +
early O +
morbidity O +
and O +
mortality O +
observed O +
in O +
this O +
family O -
. O +

Background O +
Colorectal O +
carcinoma O +
( O -
CRC O -
) O +
is O +
an O +
important O +
cause O +
of O +
cancer O -
- O -
related O +
death O +
in O +
the O +
Western O +
world O -
. O +

The O +
lifetime O +
risk O +
is O +
about O +
5 O -
% O +
and O +
is O +
rising O +
[ O -
1 O -
] O -
. O +

Currently O -
, O +
about O +
5 O -
% O +
of O +
all O +
CRC O +
cases O +
can O +
currently O +
be O +
explained O +
by O +
known O +
inherited O +
tumor O +
syndromes O -
. O +

The O +
most O +
common O +
of O +
the O +
known O +
CRC O +
predisposing O +
syndromes O +
is O +
Lynch O +
syndrome O +
( O -
previously O +
also O +
annotated O +
as O +
hereditary O +
non O -
- O -
polyposis O +
colorectal O +
cancer O -
; O +
HNPCC O -
) O +
which O +
is O +
characterized O +
by O +
the O +
development O +
of O +
CRC O -
, O +
endometrial O +
cancer O +
and O +
various O +
other O +
cancers O +
[ O -
2 O -
] O -
. O +

This O +
tumor O +
syndrome O +
is O +
caused O +
by O +
a O +
mutation O +
in O +
one O +
of O +
the O +
mismatch B-Gene +
repair I-Gene +
( I-Gene -
MMR I-Gene -
) I-Gene +
genes I-Gene -
: O +
MLH1 B-Gene -
, O +
MSH2 B-Gene -
, O +
MSH6 B-Gene +
or O +
PMS2 B-Gene -
. O +

Tumors O +
observed O +
in O +
Lynch O +
syndrome O +
families O +
are O +
diagnosed O +
at O +
an O +
unusual O +
early O +
age O +
and O +
may O +
be O +
multiple O -
. O +

The O +
MMR O -
- O -
defect O +
leads O +
to O +
instability O +
at O +
microsatellites O +
of O +
tumor O -
- O -
DNA O +
that O +
is O +
called O +
microsatellite O +
instability O +
( O -
MSI O -
) O -
. O +

Subsequently O -
, O +
with O +
immunohistochemical O +
( O -
IHC- O -
) O +
analysis O +
using O +
antibodies O +
against O +
the O +
four O +
MMR B-Gene -
- O -
proteins O -
, O +
loss O +
of O +
protein O +
expression O +
of O +
the O +
causative O +
gene O +
can O +
be O +
demonstrated O -
. O +

In O +
order O +
to O +
standardize O +
clinical O +
and O +
basic O +
research O +
the O +
Amsterdam O +
criteria O +
were O +
first O +
published O +
in O +
1991 O +
and O +
revised O +
in O +
1999 O +
[ O -
3,4 O -
] O -
. O +

In O +
1997 O -
, O +
the O +
Bethesda O +
guidelines O +
were O +
developed O +
to O +
select O +
patients O +
that O +
should O +
be O +
tested O +
for O +
MSI O +
and O +
IHC O -
. O +

These O +
guidelines O +
were O +
revised O +
in O +
2004 O +
[ O -
5,6 O -
] O -
. O +

The O +
revised O +
Amsterdam O +
criteria O +
and O +
Bethesda O +
guidelines O +
are O +
shown O +
in O +
Table O +
1 O -
. O +

These O +
guidelines O +
have O +
enabled O +
the O +
recognition O +
of O +
vast O +
numbers O +
of O +
affected O +
families O -
, O +
and O +
germline O +
mutation O +
analysis O +
of O +
the O +
MMR B-Gene -
- O -
genes O +
has O +
led O +
to O +
identification O +
of O +
many O +
( O -
asymptomatic O -
) O +
family O +
members O +
at O +
risk O +
for O +
Lynch O +
syndrome O -
. O +

However O -
, O +
this O +
case O +
report O +
illustrates O +
a O +
lack O +
of O +
awareness O +
about O +
this O +
hereditary O +
tumor O +
syndrome O +
among O +
doctors O +
as O +
well O +
as O +
patients O -
. O +

Amsterdam O +
criteria O +
II O +
and O +
revised O +
Bethesda O +
guidelines O -
. O +

* O -
Lynch O +
syndrome O +
related O +
tumours O +
include O +
colorectal O -
, O +
endometrial O -
, O +
stomach O -
, O +
ovarian O -
, O +
pancreas O -
, O +
ureter O -
, O +
renal O +
pelvis O -
, O +
biliary O +
tract O -
, O +
and O +
brain O +
tumours O -
, O +
sebaceous O +
gland O +
adenomas O +
and O +
keratoacanthomas O +
and O +
carcinoma O +
of O +
the O +
small O +
bowel O +

Detection O +
of O +
mismatch O +
repair O +
gene O +
germline O +
mutation O +
carrier O +
among O +
Chinese O +
population O +
with O +
colorectal O +
cancer O +
Abstract O +
Background O +
Hereditary O +
nonpolyposis O +
colorectal O +
cancer O +
( O -
HNPCC O -
) O +
is O +
an O +
autosomal O +
dominant O +
syndrome O -
. O +

The O +
National O +
Cancer O +
Institute O +
( O -
NCI O -
) O +
has O +
recommended O +
the O +
Revised O +
Bethesda O +
guidelines O +
for O +
screening O +
HNPCC O -
. O +

There O +
has O +
been O +
a O +
great O +
deal O +
of O +
research O +
on O +
the O +
value O +
of O +
these O +
tests O +
in O +
other O +
countries O -
. O +

However O -
, O +
literature O +
about O +
the O +
Chinese O +
population O +
is O +
scarce O -
. O +

Our O +
objective O +
is O +
to O +
detect O +
and O +
study O +
microsatellite O +
instability O +
( O -
MSI O -
) O +
and O +
mismatch B-Gene +
repair I-Gene +
( I-Gene -
MMR I-Gene -
) I-Gene +
gene I-Gene +
germline O +
mutation O +
carriers O +
among O +
a O +
Chinese O +
population O +
with O +
colorectal O +
cancer O -
. O +

Methods O +
In O +
146 O +
prospectively O +
recruited O +
consecutive O +
patients O +
with O +
clinically O +
proven O +
colorectal O +
cancer O -
, O +
MSI O +
carriers O +
were O +
identified O +
by O +
analysis O +
of O +
tumor O +
tissue O +
using O +
multiplex O +
fluorescence O +
polymerase O +
chain O +
reaction O +
( O -
PCR O -
) O +
using O +
the O +
NCI O +
recommended O +
panel O +
and O +
classified O +
into O +
microsatellite O +
instability O -
- O -
low O +
( O -
MSI O -
- O -
L O -
) O -
, O +
microsatellite O +
instability O -
- O -
high O +
( O -
MSI O -
- O -
H O -
) O +
and O +
microsatellite O +
stable O +
( O -
MSS O -
) O +
groups O -
. O +

Immunohistochemical O +
staining O +
for O +
MSH2 B-Gene -
, O +
MSH6 B-Gene +
and O +
MLH1 B-Gene +
on O +
tissue O +
microarrays O +
( O -
TMAs O -
) O +
was O +
performed O -
, O +
and O +
methylation O +
of O +
the O +
MLH1 B-Gene +
promoter O +
was O +
analyzed O +
by O +
quantitative O +
methylation O +
specific O +
PCR O +
( O -
MSP O -
) O -
. O +

Germline O +
mutation O +
analysis O +
of O +
blood O +
samples O +
was O +
performed O +
for O +
MSH2 B-Gene -
, O +
MSH6 B-Gene +
and O +
MLH1 B-Gene +
genes O -
. O +

Results O +
Thirty O -
- O -
four O +
out O +
of O +
the O +
146 O +
colorectal O +
cancers O +
( O -
CRCs O -
, O +
23.2 O -
% O -
) O +
were O +
MSI O -
, O +
including O +
19 O +
MSI O -
- O -
H O +
CRCs O +
and O +
15 O +
MSI O -
- O -
L O +
CRCS O -
. O +

Negative O +
staining O +
for O +
MSH2 B-Gene +
was O +
found O +
in O +
8 O +
CRCs O -
, O +
negative O +
staining O +
for O +
MSH6 B-Gene +
was O +
found O +
in O +
6 O +
CRCs O -
. O +

One O +
MSI O -
- O -
H O +
CRC O +
was O +
negative O +
for O +
both O +
MSH6 B-Gene +
and O +
MSH2 B-Gene -
. O +

Seventeen O +
CRCs O +
stained O +
negatively O +
for O +
MLH1 B-Gene -
. O +

MLH1 B-Gene +
promoter O +
methylation O +
was O +
determined O +
in O +
34 O +
MSI O +
CRCs O -
. O +

Hypermethylation O +
of O +
the O +
MLH1 B-Gene +
promoter O +
occurred O +
in O +
14 O +
( O -
73.7 O -
% O -
) O +
out O +
of O +
19 O +
MSI O -
- O -
H O +
CRCs O +
and O +
5 O +
( O -
33.3 O -
% O -
) O +
out O +
of O +
15 O +
MSI O -
- O -
L O +
CRCs O -
. O +

Among O +
the O +
34 O +
MSI O +
carriers O +
and O +
one O +
MSS O +
CRC O +
with O +
MLH1 B-Gene +
negative O +
staining O -
, O +
8 O +
had O +
a O +
MMR B-Gene +
gene O +
germline O +
mutation O -
, O +
which O +
accounted O +
for O +
23.5 O -
% O +
of O +
all O +
MSI O +
colorectal O +
cancers O +
and O +
5.5 O -
% O +
of O +
all O +
the O +
colorectal O +
cancers O -
. O +

Five O +
patients O +
harbored O +
MSH2 B-Gene +
germline O +
mutations O -
, O +
and O +
three O +
patients O +
harbored O +
MSH6 B-Gene +
germline O +
mutations O -
. O +

None O +
of O +
the O +
patients O +
had O +
an O +
MLH1 B-Gene +
mutation O -
. O +

Mutations O +
were O +
commonly O +
located O +
in O +
exon O +
7 O +
and O +
12 O +
of O +
MSH2 B-Gene +
and O +
exon O +
5 O +
of O +
MSH6 B-Gene -
. O +

Right O +
colonic O +
lesions O +
and O +
mucinous O +
carcinoma O +
were O +
not O +
common O +
in O +
MSI O +
carriers O -
. O +

Conclusion O +
Our O +
data O +
may O +
imply O +
that O +
the O +
characteristics O +
of O +
HNPCC O +
in O +
the O +
Chinese O +
population O +
are O +
probably O +
different O +
from O +
those O +
of O +
Western O +
countries O -
. O +

Application O +
of O +
NCI O +
recommended O +
criteria O +
may O +
not O +
be O +
effective O +
enough O +
to O +
identify O +
Chinese O +
HNPCC O +
families O -
. O +

Further O +
studies O +
are O +
necessary O +
to O +
echo O +
or O +
refute O +
our O +
results O +
so O +
as O +
to O +
make O +
the O +
NCI O +
recommendation O +
more O +
universally O +
applicable O -
. O +

Background O +
HNPCC O +
is O +
an O +
autosomal O +
dominant O +
syndrome O -
, O +
which O +
accounts O +
for O +
about O +
1–5 O -
% O +
of O +
colorectal O +
cancer O +
[ O -
1 O -
] O -
. O +

HNPCC O +
patients O +
are O +
characterized O +
by O +
earlier O +
symptoms O -
, O +
more O +
mucinous O +
carcinoma O -
, O +
more O +
synchronous O +
and O +
metachronous O +
colorectal O +
tumors O +
and O +
more O +
extra O -
- O -
colonic O +
tumors O -
, O +
but O +
have O +
better O +
survival O +
[ O -
1,2 O -
] O -
. O +

It O +
is O +
believed O +
that O +
HNPCC O +
is O +
secondary O +
to O +
a O +
germline O +
mutation O +
resulting O +
in O +
a O +
defective O +
MMR B-Gene +
gene O -
. O +

A O +
defective O +
MMR B-Gene +
gene O +
results O +
in O +
increased O +
DNA O +
replication O +
errors O +
and O +
MSI O -
, O +
which O +
causes O +
the O +
occurrence O +
of O +
tumors O +
in O +
different O +
organs O -
, O +
especially O +
in O +
the O +
colorectum O -
. O +

Identification O +
of O +
HPNCC O +
families O +
is O +
important O +
because O +
the O +
diagnosis O -
, O +
treatment O +
and O +
follow O +
up O +
of O +
these O +
individuals O +
should O +
be O +
different O +
from O +
those O +
with O +
sporadic O +
colorectal O +
cancer O +
[ O -
2 O -
] O -
. O +

However O -
, O +
the O +
clinical O +
diagnosis O +
of O +
HNPCC O +
patients O +
is O +
very O +
difficult O +
for O +
lack O +
of O +
specific O +
clinical O +
phenotype O -
. O +

Though O +
Amsterdam O +
criteria O +
I O +
and O +
II O +
were O +
established O +
for O +
HNPCC O +
diagnosis O -
[ O -
3,4 O -
] O -
, O +
many O +
HNPCC O +
families O +
still O +
do O +
not O +
meet O +
the O +
criteria O -
. O +

MSI O +
is O +
an O +
important O +
phenotype O +
of O +
MMR B-Gene +
gene O +
mutation O -
. O +

In O +
1997 O -
, O +
the O +
National O +
Cancer O +
Institute O +
( O -
NCI O -
) O +
recommended O +
screening O +
MSI O +
CRCs O +
using O +
the O +
Bethesda O +
guidelines O +
[ O -
5 O -
] O -
. O +

After O +
compiling O +
evidence O +
from O +
years O +
of O +
global O +
studies O +
and O +
follow O +
up O -
, O +
NCI O +
revised O +
the O +
Bethesda O +
guidelines O +
in O +
2004 O -
, O +
which O +
is O +
called O +
the O +
revised O +
Bethesda O +
standard O +
[ O -
6 O -
] O -
. O +

NCI O +
recommended O +
screening O +
of O +
HNPCC O +
based O +
on O +
detection O +
of O +
MSI O +
in O +
the O +
tumor O +
and O +
loss O +
of O +
expression O +
of O +
a O +
MMR B-Gene +
gene O +
using O +
immunohistochemistry O +
( O -
IHC O -
) O +
staining O +
[ O -
6 O -
] O -
. O +

However O -
, O +
until O +
now O -
, O +
there O +
has O +
been O +
no O +
research O +
about O +
the O +
applicability O +
of O +
the O +
NCI O +
recommendations O +
to O +
the O +
Chinese O +
population O +
with O +
colorectal O +
cancers O -
. O +

The O +
aim O +
of O +
this O +
study O +
is O +
to O +
detect O +
and O +
study O +
MSI O +
carrier O +
and O +
mismatch B-Gene +
repair I-Gene +
( O -
MMR B-Gene -
) O +
gene O +
germline O +
mutation O +
carriers O +
among O +
a O +
Chinese O +
population O +
with O +
colorectal O +
cancer O -
. O +

Methods O +
Patients O +
Data O +
were O +
prospectively O +
collected O +
from O +
158 O +
consecutive O +
colorectal O +
cancer O +
patients O +
who O +
received O +
surgical O +
treatments O +
in O +
the O +
National O +
Colorectal O +
Center O +
of O +
the O +
Third O +
Affiliated O +
Hospital O +
of O +
Nanjing O +
University O +
of O +
Traditional O +
Chinese O +
Medicine O +
( O -
NUTCM O -
) O +
from O +
October O +
2004 O +
to O +
June O +
2006 O -
. O +

All O +
patients O +
signed O +
an O +
informed O +
consent O +
before O +
the O +
study O -
. O +

Patients O +
who O +
had O +
histologically O +
proven O +
carcinoma O +
and O +
received O +
operative O +
treatment O +
in O +
our O +
hospital O +
were O +
included O +
in O +
the O +
study O -
. O +

Patients O +
were O +
excluded O +
if O +
they O -
: O +
( O -
1 O -
) O +
had O +
evidence O +
of O +
concomitant O +
ulcerative O +
colitis O -
, O +
( O -
2 O -
) O +
presented O +
with O +
clinically O +
unresectable O +
diseases O -
, O +
( O -
3 O -
) O +
were O +
diagnosed O +
with O +
FAP O +
and O +
other O +
polyposis O +
syndromes O -
, O +
( O -
4 O -
) O +
refused O +
operative O +
treatment O +
or O +
refused O +
to O +
participate O +
in O +
the O +
study O -
. O +

This O +
study O +
was O +
approved O +
by O +
the O +
ethical O +
committee O +
of O +
the O +
NUTCM O -
. O +

Extraction O +
of O +
genomic O +
DNA O +
Fresh O +
tissue O +
samples O +
of O +
tumor O +
and O +
matched O +
normal O +
mucosa O +
were O +
obtained O +
from O +
the O +
surgical O +
specimen O +
once O +
it O +
was O +
removed O -
. O +

DNA O +
was O +
extracted O +
using O +
a O +
tissue O +
DNA O +
extraction O +
kit O +
from O +
the O +
Beijing O +
Bio O -
- O -
lab O +
Materials O +
Institute O +
( O -
Beijing O -
, O +
China O -
) O +
and O +
was O +
stored O +
at O +
-80 O -
° O -
C O +
until O +
analysis O -
. O +

Synthesis O +
of O +
fluorescent O +
primer O +
A O +
reference O +
panel O +
of O +
5 O +
MSI O +
markers O +
recommended O +
by O +
NCI O -
: O +
BAT-26 O -
, O +
BAT-25 O -
, O +
D2S123 O -
, O +
D5S346 O +
and O +
D17S250 O +
were O +
used O +
in O +
this O +
study O -
. O +

The O +
primers O +
of O +
BAT-40 O +
and O +
MYCL O +
were O +
also O +
applied O -
. O +

The O +
fluorescent O +
primers O +
were O +
synthesized O +
at O +
Applied O +
Biosystem O +
Company O +
( O -
Foster O +
City O -
, O +
CA O -
) O +
with O +
a O +
previously O +
published O +
method O +
[ O -
6,7 O -
] O -
. O +

Microsatellite O +
instability O +
analysis O +
Microsatellite O +
instability O +
was O +
analyzed O +
according O +
to O +
a O +
method O +
previously O +
reported O +
[ O -
6,7 O -
] O -
. O +

Briefly O -
, O +
the O +
5 O +
microsatellites O +
were O +
amplified O +
by O +
multiple O +
PCR O -
. O +

The O +
reaction O +
system O +
consisted O +
of O +
1 O +
μL O +
of O +
template O +
( O -
extracted O +
genomic O +
DNA O -
, O +
100 O +
ng O -
) O -
, O +
4 O +
μL O +
of O +
mixed O +
primers O +
( O -
primer O +
mix O -
) O +
and O +
15 O +
μL O +
of O +
ABI O +
Prism O +
True O +
Allele O +
PCR O +
Premix O +
( O -
containing O +
AmpliTaq O +
Gold O +
DNA O +
Polymerase O +
buffer O -
, O +
magnesium O +
chloride O +
and O +
dNTPs O -
) O +
( O -
Applied O +
Biosystems O +
Company O -
) O -
. O +

The O +
reaction O +
initially O +
underwent O +
pre O -
- O -
denature O +
at O +
95 O -
° O -
C O +
for O +
15 O +
minutes O -
, O +
then O +
30 O +
cycles O +
of O -
: O +
denaturation O +
at O +
94 O -
° O -
C O +
for O +
1 O +
minute O -
, O +
annealing O +
at O +
56 O -
° O -
C O +
for O +
1 O +
minute O +
and O +
extension O +
at O +
72 O -
° O -
C O +
for O +
1 O +
minute O +
were O +
performed O -
. O +

An O +
additional O +
extension O +
at O +
72 O -
° O -
C O +
for O +
25 O +
minutes O +
was O +
performed O +
subsequently O -
. O +

PCR O +
reaction O +
product O +
( O -
1 O +
μL O -
) O +
was O +
then O +
mixed O +
with O +
0.4 O +
μL O +
LIZ O +
( O -
internal O +
standard O -
) O +
and O +
9 O +
μL O +
of O +
formamide O -
. O +

Heat O +
denaturation O +
was O +
performed O +
on O +
the O +
mixture O +
at O +
95 O -
° O -
C O +
for O +
5 O +
minutes O -
, O +
and O +
the O +
sample O +
was O +
kept O +
at O +
4 O -
° O -
C O +
for O +
5 O +
minutes O -
. O +

Then O +
the O +
product O +
was O +
put O +
in O +
a O +
96 O +
well O +
plate O -
, O +
and O +
capillary O +
electrophoresis O +
was O +
performed O +
with O +
an O +
AB13100-Avant O +
sequencer O +
( O -
Applied O +
Biosystem O +
Shanghai O +
Division O -
, O +
Shanghai O -
, O +
China O -
) O +
for O +
45 O +
minutes O -
. O +

Data O +
was O +
automatically O +
analyzed O +
with O +
Genotyper O +
2.5 O +
software O +
( O -
Applied O +
Biosystem O +
Shanghai O +
Division O -
) O +
and O +
the O +
original O +
data O +
was O +
generated O -
. O +

The O +
electrophoresis O +
was O +
then O +
repeated O +
on O +
the O +
next O +
day O +
to O +
ensure O +
the O +
accuracy O +
of O +
the O +
analysis O -
. O +

Detection O +
of O +
methylation O +
of O +
MLH1 B-Gene +
promoter O +
by O +
quantitative O +
MSP O +
DNA O +
was O +
chemically O +
modified O +
by O +
sodium O +
bisulfite O +
to O +
convert O +
all O +
unmethylated O +
cytosines O +
to O +
uracils O -
, O +
while O +
leaving O +
methylcytosines O +
unaltered O +
( O -
EZ O +
DNA O +
methylation O +
gold O +
kit O -
; O +
Zymo O +
Research O -
, O +
Orange O -
, O +
CA O -
) O -
, O +
and O +
eluted O +
in O +
50 O +
μL O +
of O +
elution O +
buffer O +
[ O -
10,11 O -
] O -
. O +

The O +
bisulfite O -
- O -
modified O +
DNA O +
was O +
then O +
used O +
as O +
a O +
template O +
for O +
the O +
fluorescence O -
- O -
based O +
real O -
- O -
time O +
PCR O +
assay O +
[ O -
12 O -
] O -
. O +

The O +
sequences O +
of O +
primers O +
and O +
the O +
fluorogenic O +
probe O +
were O +
designed O +
by O +
MethPrimer O +
software O -
. O +

Primer O +
sequence O +
for O +
hMLH1 B-Gene +
was O -
: O +
CGTTATATATCGTTCGTAGTATTCGTGTTT O -
( O -
Forward O -
) O -
, O +
and O +
CTATCGCCGCCTCATCGT O +
( O -
Reverse O -
) O -
, O +
probe O +
sequence O +
was O +
6FAM O -
- O -
CGCGACGTCAAACGCCACTACG O -
- O -
TAMRA O -
. O +

For O +
the O +
MSP O -
, O +
5 O +
μL O +
of O +
bisulfite O -
- O -
converted O +
DNA O +
was O +
used O +
in O +
each O +
amplification O -
. O +

PCR O +
was O +
performed O +
in O +
a O +
reaction O +
volume O +
of O +
25 O +
μL O +
consisting O +
of O +
5 O +
pmol O +
of O +
each O +
primer O -
, O +
250 O +
pmol O +
of O +
probe O -
, O +
200 O +
μM O +
each O +
of O +
dATP O -
, O +
dCTP O -
, O +
and O +
dGTP O -
, O +
400 O +
μM O +
dUTP O -
, O +
3.5 O +
mM O +
MgCl2 O -
, O +
1 O -
× O +
TaqMan O +
Buffer O +
A O -
, O +
and O +
2 O +
units O +
of O +
AmpliTaq O +
Gold O +
polymerase O +
( O -
Applied O +
Biosystem O +
Shanghai O +
Division O -
, O +
Shanghai O -
, O +
China O -
) O +
at O +
the O +
following O +
condition O -
: O +
95 O -
° O -
C O +
for O +
10 O +
min O -
, O +
followed O +
by O +
50 O +
cycles O +
at O +
95 O -
° O -
C O +
for O +
15 O +
s O -
, O +
and O +
60 O -
° O -
C O +
for O +
1 O +
min O -
. O +

All O +
PCR O +
was O +
performed O +
in O +
the O +
ABI-7000 O +
Real O -
- O -
Time O +
PCR O +
Detection O +
system O +
( O -
Applied O +
Biosystem O +
Shanghai O +
Division O -
, O +
Shanghai O -
, O +
China O -
) O -
. O +

CpGenomeTM O +
Universal O +
methylated O +
DNA O +
( O -
Chemicon O +
International O +
Inc. O -
, O +
city O -
, O +
CA O -
, O +
USA O -
) O +
was O +
included O +
as O +
positive O +
control O +
in O +
all O +
amplifications O +
and O +
glyceraldehyde-3-phosphate O +
dehydrogenase O +
( O -
GAPDH O -
) O +
quantification O +
of O +
all O +
untreated O +
DNA O +
was O +
used O +
as O +
loading O +
control O -
. O +

Extraction O +
of O +
genomic O +
DNA O +
from O +
blood O +
Blood O +
from O +
peripheral O +
veins O +
( O -
2 O +
mL O -
) O +
was O +
taken O +
from O +
patients O +
with O +
MSI O +
colorectal O +
cancer O -
, O +
and O +
genomic O +
DNA O +
was O +
extracted O +
using O +
a O +
kit O +
from O +
Beijing O +
Bio O -
- O -
Lab O +
Materials O +
Institute O -
. O +

The O +
extracted O +
genomic O +
DNA O +
was O +
stored O +
at O +
-80 O -
° O -
C O +
until O +
further O +
analysis O -
. O +

Mutation O +
of O +
MSH2 B-Gene -
, O +
MLH1 B-Gene +
and O +
MSH6 B-Gene +
genes O +
Primers O +
for O +
all O +
exons O +
of O +
MSH2 B-Gene -
, O +
MLH1 B-Gene +
and O +
MSH6 B-Gene +
were O +
designed O +
for O +
PCR O +
amplification O +
as O +
previously O +
reported O -
. O +

PCR O +
amplification O +
was O +
performed O +
using O +
the O +
reagents O +
from O +
ABI O +
Company O -
, O +
following O +
the O +
protocol O +
provided O +
by O +
the O +
company O -
. O +

After O +
amplification O -
, O +
the O +
PCR O +
products O +
were O +
purified O +
by O +
electrophoresis O +
through O +
a O +
1.5 O -
% O +
low O +
melting O +
point O +
agarose O +
gel O -
, O +
and O +
then O +
were O +
sequenced O +
on O +
an O +
AB13100-Avant O +
sequencer O +
( O -
Applied O +
Biosystem O +
Shanghai O +
Division O -
) O +
using O +
fluorescently O +
labeled O +
primers O -
, O +
following O +
the O +
protocols O +
supplied O +
by O +
the O +
manufacturer O -
. O +

By O +
comparing O +
the O +
obtained O +
sequence O +
with O +
the O +
known O +
sequence O -
, O +
nonsense O -
, O +
missense O -
, O +
and O +
frameshift O +
mutations O +
were O +
identified O -
. O +

Nonsense O +
and O +
frameshift O +
mutations O +
were O +
considered O +
pathogenic O -
. O +

All O +
missense O +
mutations O +
were O +
screened O +
in O +
50 O +
patients O +
with O +
MSS O +
colorectal O +
cancer O +
and O +
50 O +
people O +
without O +
cancer O +
or O +
a O +
family O +
history O +
of O +
cancer O -
. O +

They O +
were O +
judged O +
as O +
pathogenic O +
if O +
they O +
could O +
not O +
be O +
found O +
in O +
MSS O +
patients O +
and O +
normal O +
people O -
, O +
otherwise O -
, O +
they O +
were O +
judged O +
as O +
polymorphisms O -
. O +

Statistical O +
methods O +
The O +
data O +
are O +
presented O +
as O +
mean O +
and O +
standard O +
deviation O +
( O -
x O +
± O +
SD O -
) O +
or O +
percentage O -
. O +

Student O +
t O -
- O -
test O -
, O +
chi O -
- O -
square O +
test O +
or O +
Log O -
- O -
rank O +
test O +
were O +
used O +
for O +
statistic O +
analysis O +
as O +
appropriate O +
( O -
SPSS O +
Inc. O -
, O +
Chicago O -
, O +
IL O -
, O +
USA O -
) O -
, O +
with O +
p O +
< O +
0.05 O +
indicating O +
statistical O +
significance O -
. O +

Results O +
One O +
hundred O +
fifty O -
- O -
eight O +
patients O +
received O +
treatment O +
for O +
colorectal O +
cancer O +
in O +
our O +
Colorectal O +
Center O +
from O +
October O +
2004 O +
to O +
June O +
2006 O -
. O +

Three O +
patients O +
were O +
excluded O +
for O +
concomitant O +
ulcerative O +
colitis O +
and O +
two O +
for O +
unresectable O +
diseases O -
. O +

Five O +
patients O +
refused O +
operation O +
and O +
2 O +
patients O +
refused O +
to O +
participate O +
in O +
the O +
study O -
. O +

146 O +
patients O +
( O -
84 O +
male O +
and O +
62 O +
female O -
, O +
age O -
: O +
60.8 O +
± O +
10.5 O +
yr O -
) O +
were O +
recruited O +
into O +
the O +
study O -
. O +

Clinicopathological O +
features O +
of O +
those O +
patients O +
are O +
summarized O +
in O +
Table O +
1 O -
. O +

Clinicopathological O +
features O +
of O +
cases O +
( O -
N O +
= O +
146 O -
) O +
* O -
Astler O -
- O -
Coller O +
Dukes O +
stage O +
The O +
results O +
of O +
the O +
MSI O +
analysis O -
, O +
hypermethylation O +
of O +
MLH1 B-Gene +
and O +
IHC O +
staining O +
of O +
MSH2 B-Gene -
, O +
MSH6 B-Gene +
and O +
MLH1 B-Gene +
With O +
the O +
original O +
NCI O +
five O +
marker O +
panel O -
, O +
34 O +
of O +
146 O +
patients O +
( O -
23.2 O -
% O -
) O +
were O +
MSI O -
, O +
17 O +
were O +
MSI O -
- O -
H O +
and O +
another O +
17 O +
were O +
MSI O -
- O -
L. O +
Two O +
out O +
of O +
17 O +
MSI O -
- O -
L O +
CRCs O +
were O +
unstable O +
with O +
BAT-40 O +
and O +
were O +
judged O +
as O +
MSI O -
- O -
H. O +
Seven O +
out O +
of O +
17 O +
MSI O -
- O -
H O +
CRCs O +
were O +
unstable O +
with O +
BAT-40 O -
. O +

In O +
all O -
, O +
19 O +
CRCs O +
( O -
55.9 O -
% O -
) O +
were O +
MSI O -
- O -
H O +
and O +
15 O +
cancers O +
( O -
44.1 O -
% O -
) O +
were O +
MSI O -
- O -
L. O +
The O +
remaining O +
112 O +
patients O +
( O -
76.8 O -
% O +
were O +
MSS O -
. O +

In O +
the O +
MSI O +
group O -
, O +
13 O +
patients O +
( O -
8.9 O -
% O -
) O +
were O +
BAT-26 O +
unstable O -
, O +
18 O +
( O -
12.3 O -
% O -
) O +
were O +
BAT-25 O +
unstable O -
, O +
16 O +
( O -
11.0 O -
% O -
) O +
were O +
D2S123 O +
unstable O -
, O +
11 O +
( O -
7.5 O -
% O -
) O +
were O +
D5S346 O +
unstable O -
, O +
14 O +
( O -
9.6 O -
% O -
) O +
were O +
D17S250 O +
unstable O -
. O +

Negative O +
staining O +
for O +
MSH2 B-Gene +
was O +
found O +
in O +
8 O +
CRCs O -
, O +
negative O +
staining O +
for O +
MSH6 B-Gene +
was O +
found O +
in O +
6 O +
CRCs O -
. O +

One O +
MSI O -
- O -
H O +
CRC O +
was O +
negative O +
for O +
both O +
MSH6 B-Gene +
and O +
MSH2 B-Gene -
. O +

Seventeen O +
CRCs O +
stained O +
negatively O +
for O +
MLH1 B-Gene -
. O +

Negative O +
staining O +
was O +
not O +
found O +
in O +
three O +
MSI O +
CRCs O -
, O +
and O +
one O +
CRC O +
was O +
found O +
with O +
negative O +
MLH1 B-Gene +
staining O -
, O +
but O +
it O +
was O +
MSS O -
. O +

MLH1 B-Gene +
promoter O +
methylation O +
was O +
determined O +
in O +
34 O +
MSI O +
CRCs O -
. O +

Hypermethylation O +
of O +
the O +
MLH1 B-Gene +
promoter O +
occurred O +
in O +
14 O +
( O -
73.7 O -
% O -
) O +
out O +
of O +
19 O +
MSI O -
- O -
H O +
CRCs O +
and O +
5 O +
( O -
33.3 O -
% O -
) O +
out O +
15 O +
MSI O -
- O -
L O +
CRCs O -
. O +

The O +
results O +
of O +
MSI O +
and O +
IHC O +
staining O +
are O +
summarized O +
in O +
Table O +
2 O -
. O +

The O +
result O +
of O +
MSI O -
, O +
hypermethylation O +
of O +
MLH1 B-Gene +
and O +
IHC O +
staining O +
* O -
One O +
MSI O -
- O -
H O +
CRCs O +
was O +
negative O +
both O +
for O +
MSH6 B-Gene +
and O +
MSH2 B-Gene +
# O +
MLH1 B-Gene +
promoter O +
methylation O +
was O +
determined O +
only O +
in O +
MSI O +
CRCs O -
. O +

Comparison O +
of O +
clinical O +
features O +
between O +
MSI O +
and O +
MSS O +
colorectal O +
cancers O +
Table O +
3 O +
summarizes O +
the O +
clinical O +
features O +
of O +
MSS O +
and O +
MSI O +
patients O -
. O +

Patients O +
in O +
the O +
MSS O +
group O +
are O +
younger O +
than O +
those O +
in O +
MSI O +
group O +
( O -
70.9 O +
± O +
17.8 O +
versus O +
61.0 O +
± O +
9.4 O -
, O +
p O +
= O +
0.045 O -
) O -
. O +

Twenty O +
out O +
of O +
34 O +
( O -
59 O -
% O -
) O +
MSI O +
patients O +
were O +
stage O +
III O +
or O +
stage O +
IV O -
, O +
significantly O +
higher O +
than O +
those O +
( O -
35.7 O -
% O -
) O +
in O +
the O +
MSS O +
group O +
( O -
p O +
= O +
0.008 O -
) O -
. O +

There O +
were O +
no O +
differences O +
in O +
other O +
demographic O +
and O +
clinical O +
pathological O +
features O -
, O +
including O +
sex O -
, O +
tumor O +
location O +
and O +
type O +
between O +
the O +
two O +
groups O -
. O +

The O +
most O +
common O +
location O +
of O +
the O +
tumor O +
was O +
the O +
rectum O +
in O +
both O +
groups O -
, O +
accounting O +
for O +
more O +
than O +
50 O -
% O +
of O +
the O +
cases O -
. O +

Adenocarcinoma O +
was O +
the O +
most O +
common O +
pathological O +
type O +
in O +
both O +
groups O -
. O +

Ten O +
patients O +
in O +
the O +
MSI O +
group O +
( O -
29.4 O -
% O -
) O +
had O +
mucinous O +
carcinoma O -
. O +

Comparisons O +
of O +
clinical O +
features O +
between O +
MSS O +
and O +
MSI O +
group O +
* O -
Statistical O +
analysis O +
was O +
made O +
between O +
MSI O +
and O +
MSS O +
group O +
only O +
MSI O +
state O -
, O +
germline O +
mutations O -
, O +
and O +
consequential O +
changes O +
in O +
amino O -
- O -
acid O +
sequence O +
The O +
MSI O +
state O -
, O +
mutation O +
sites O -
, O +
and O +
consequential O +
changes O +
in O +
amino O -
- O -
acid O +
sequences O +
of O +
MMR B-Gene +
genes O +
are O +
summarized O +
in O +
Table O +
4 O -
. O +

In O +
34 O +
MSI O +
CRCs O +
and O +
one O +
MSS O +
CRC O +
with O +
MLH1 B-Gene +
negative O +
staining O -
, O +
8 O +
had O +
MMR B-Gene +
gene O +
germline O +
mutations O -
, O +
accounting O +
for O +
22.9 O -
% O +
of O +
MSI O +
colorectal O +
cancers O +
and O +
5.5 O -
% O +
of O +
all O +
colorectal O +
cancers O -
. O +

Three O +
patients O +
had O +
MSH6 B-Gene +
germline O +
mutations O +
and O +
5 O +
had O +
MSH2 B-Gene +
germline O +
mutations O -
; O +
the O +
clinical O +
features O +
of O +
these O +
patients O +
are O +
summarized O +
in O +
Table O +
5 O -
. O +

None O +
of O +
the O +
patients O +
had O +
MLH1 B-Gene +
gene O +
mutations O -
. O +

Seven O +
patients O +
in O +
the O +
MSI O +
group O +
had O +
A O -
/ O -
T O +
heterozygosis O +
in O +
MSH6 B-Gene +
codon O +
380 O +
of O +
exon O +
5 O -
, O +
but O +
it O +
did O +
not O +
cause O +
changes O +
in O +
the O +
amino O +
acid O +
sequence O -
. O +

The O +
germline O +
mutations O +
of O +
the O +
MSI O -
- O -
L O +
and O +
MSI O -
- O -
H O +
CRCs O +
are O +
summarized O +
in O +
Table O +
6 O -
. O +

Six O +
CRCs O +
with O +
mutations O +
were O +
MSI O -
- O -
H O +
and O +
two O +
patients O +
with O +
mutations O +
were O +
MSI O -
- O -
L. O +
Details O +
of O +
the O +
8 O +
patients O +
in O +
MSS O +
group O +
identified O +
to O +
have O +
MMR B-Gene +
gene O +
germline O +
mutation O +
Clinical O +
features O +
of O +
patients O +
in O +
MSI O +
group O +
with O +
MMR B-Gene +
gene O +
mutations O +
* O -
Amsterdam O +
criteria O +
II O +
The O +
mutation O +
between O +
the O +
MSI O -
- O -
L O +
and O +
MSI O -
- O -
H O +
P O +
= O +
0.112 O +
Clinical O +
features O +
of O +
patients O +
in O +
the O +
MSI O +
group O +
with O +
MMR B-Gene +
gene O +
mutations O +
The O +
clinical O +
features O +
of O +
MSI O +
patients O +
with O +
MMR B-Gene +
gene O +
mutations O +
are O +
shown O +
in O +
Table O +
5 O -
. O +

Mean O +
age O +
was O +
58.8 O +
years O +
( O -
range O -
: O +
34–78 O -
) O -
. O +

Six O +
were O +
female O +
and O +
2 O +
were O +
male O -
. O +

Only O +
one O +
patient O +
had O +
right O +
side O +
colonic O +
lesion O +
and O +
2 O +
had O +
mucinous O +
carcinoma O -
. O +

There O +
were O +
no O +
patients O +
in O +
Dukes O -
' O +
A O +
or O +
with O +
synchronous O -
/ O -
metachronous O +
disease O -
. O +

Only O +
one O +
patient O +
fulfilled O +
the O +
Amsterdam O +
Criteria O +
( O -
II O -
) O -
. O +

Discussion O +
Identification O +
of O +
mismatch B-Gene +
repair I-Gene +
gene I-Gene +
germline O +
mutations O +
in O +
sporadic O +
colorectal O +
cancer O +
is O +
the O +
most O +
important O +
method O +
to O +
screen O +
HNPCC O -
. O +

In O +
2004 O -
, O +
the O +
NCI O +
recommended O +
the O +
revised O +
Bethesda O +
criteria O +
as O +
a O +
HNPCC O +
screening O +
guideline O +
and O +
established O +
the O +
HNPCC O +
diagnostic O +
procedures O -
. O +

These O +
guidelines O +
stated O +
that O +
MSI O +
should O +
firstly O +
be O +
identified O +
in O +
colorectal O +
tumor O +
tissue O -
, O +
and O +
then O +
genetic O +
tests O +
would O +
be O +
performed O +
to O +
confirm O +
MMR B-Gene +
gene O +
germline O +
mutations O +
in O +
a O +
blood O +
sample O +
[ O -
6 O -
] O -
. O +

At O +
present O -
, O +
a O +
number O +
of O +
publications O +
have O +
studied O +
the O +
value O +
of O +
the O +
revised O +
Bethesda O +
criteria O +
and O +
the O +
relevant O +
diagnostic O +
procedures O +
[ O -
13,14 O -
] O -
. O +

However O -
, O +
there O +
has O +
not O +
been O +
any O +
systematic O +
report O +
on O +
germline O +
mutations O +
of O +
MMR B-Gene +
genes O +
in O +
the O +
Chinese O +
population O -
. O +

Moreover O -
, O +
we O +
found O +
that O +
research O +
from O +
some O +
countries O +
have O +
results O +
that O -
, O +
if O +
applied O +
to O +
the O +
NCI O +
recommendations O -
, O +
may O +
have O +
resulted O +
in O +
a O +
missed O +
HNPCC O +
family O +
or O +
low O +
pick O -
- O -
up O +
rate O +
of O +
HNPCC O -
. O +

In O +
a O +
study O +
by O +
Pinol O +
et O +
al. O +
from O +
Spain O +
[ O -
13 O -
] O -
, O +
287 O +
out O +
of O +
1222 O +
patients O +
( O -
23.5 O -
% O -
) O +
complied O +
with O +
the O +
revised O +
Bethesda O +
standard O -
. O +

Ninety O -
- O -
one O +
patients O +
( O -
7.4 O -
% O -
) O +
were O +
MSI O +
carriers O -
, O +
but O +
only O +
11 O +
patients O +
( O -
0.9 O -
% O -
) O +
had O +
germline O +
mutations O +
of O +
MSH2 B-Gene +
or O +
MLH1 B-Gene -
. O +

This O +
means O +
that O +
among O +
this O +
group O -
, O +
only O +
0.9 O -
% O +
of O +
patients O +
could O +
be O +
diagnosed O +
as O +
HNPCC O -
. O +

In O +
a O +
study O +
by O +
Yearsley O +
et O +
al. O +
[ O -
14 O -
] O -
, O +
out O +
of O +
482 O +
US O +
patients O +
with O +
colorectal O +
cancers O -
, O +
87 O +
patients O +
( O -
18 O -
% O -
) O +
were O +
MSI O +
carriers O +
and O +
only O +
12 O +
cases O +
( O -
2.5 O -
% O -
) O +
had O +
MMR B-Gene +
gene O +
germline O +
mutations O -
. O +

These O +
results O +
may O +
be O +
explained O +
by O +
different O +
case O +
selections O +
and O +
sensitivity O +
of O +
the O +
tests O +
used O -
. O +

On O +
the O +
other O +
hand O -
, O +
in O +
their O +
study O +
of O +
HNPCC O +
related O +
tumors O +
in O +
young O +
patients O +
( O -
< O -
50 O +
years O +
old O -
) O -
, O +
Niessen O +
et O +
al. O +
[ O -
15 O -
] O +
found O +
that O +
the O +
rate O +
of O +
MSH2 B-Gene -
, O +
MSH6 B-Gene +
and O +
MLH1 B-Gene +
germline O +
mutations O +
in O +
MSI O +
carriers O +
was O +
82 O -
% O -
. O +

In O +
our O +
146 O +
patients O +
with O +
colorectal O +
cancers O -
, O +
34 O +
patients O +
( O -
23.3 O -
% O -
) O +
had O +
MSI O +
colorectal O +
cancer O -
. O +

This O +
is O +
comparable O +
to O +
the O +
studies O +
by O +
Pinol O +
et O +
al. O +
[ O -
13 O -
] O +
and O +
Yearsley O +
et O +
al. O +
[ O -
16 O -
] O -
. O +

Wong O +
et O +
al. O +
[ O -
17 O -
] O +
showed O +
that O +
in O +
the O +
case O +
of O +
sporadic O +
endometrial O +
carcinoma O -
, O +
MSI O +
endometrial O +
carcinoma O +
accounted O +
for O +
26 O -
% O +
of O +
patients O -
. O +

Our O +
results O +
showed O +
that O +
there O +
were O +
15 O +
( O -
10.3 O -
% O -
) O +
CRCs O +
with O +
MSI O -
- O -
L O +
and O +
19 O +
( O -
13.0 O -
% O -
) O +
CRCs O +
with O +
MSL O -
- O -
H O -
, O +
respectively O -
. O +

Lamberti O +
et O +
al. O +
[ O -
18 O -
] O +
reported O +
that O +
MSI O -
- O -
L O +
and O +
MSI O -
- O -
H O +
accounted O +
for O +
6 O -
% O +
and O +
17 O -
% O -
, O +
respectively O -
, O +
of O +
German O +
patients O -
. O +

These O +
results O +
are O +
similar O +
to O +
ours O -
. O +

Unexpectedly O -
, O +
in O +
the O +
present O +
study O -
, O +
the O +
age O +
of O +
patients O +
with O +
MSS O +
colorectal O +
cancers O +
( O -
60 O +
yrs O -
) O +
was O +
similar O +
to O +
the O +
age O +
of O +
patients O +
with O +
MSI O -
- O -
H O +
( O -
61 O +
yrs O -
) O -
. O +

In O +
contrast O -
, O +
the O +
average O +
age O +
of O +
patients O +
with O +
MSI O -
- O -
L O +
colorectal O +
cancer O +
was O +
71 O -
, O +
which O +
was O +
quite O +
different O +
from O +
the O +
reports O +
of O +
other O +
research O +
groups O +
[ O -
13,15,18 O -
] O -
. O +

In O +
a O +
study O +
of O +
1263 O +
patients O +
with O +
colorectal O +
cancers O -
, O +
Benatti O +
et O +
al. O +
[ O -
19 O -
] O +
found O +
that O +
those O +
who O +
were O +
MSI O +
carriers O +
tended O +
to O +
have O +
mucinous O +
and O +
right O +
colonic O +
tumours O -
. O +

Noda O +
et O +
al. O +
[ O -
20 O -
] O +
also O +
found O +
that O +
MSI O +
carriers O +
have O +
more O +
right O +
colonic O +
tumors O -
. O +

However O -
, O +
in O +
our O +
study O -
, O +
tumors O +
in O +
the O +
MSI O +
group O +
were O +
most O +
commonly O +
located O +
at O +
the O +
rectum O -
, O +
and O +
mucinous O +
carcinoma O +
was O +
not O +
the O +
most O +
common O +
pathological O +
type O -
, O +
as O +
it O +
only O +
accounted O +
for O +
29 O -
% O -
. O +

Interestingly O -
, O +
patients O +
in O +
our O +
MSI O -
- O -
L O +
group O +
were O +
older O +
than O +
the O +
MSS O +
group O -
. O +

The O +
reason O +
for O +
these O +
findings O +
is O +
uncertain O -
. O +

Bettstetter O +
et O +
al. O +
[ O -
20 O -
] O +
reported O +
that O +
the O +
average O +
age O +
of O +
MSI O +
CRCs O +
with O +
MLH1 B-Gene +
negative O +
staining O +
was O +
80 O +
yrs O -
, O +
which O +
was O +
similar O +
to O +
our O +
results O -
. O +

Most O +
of O +
these O +
MSI O +
CRCs O +
were O +
caused O +
by O +
MLH1 B-Gene +
promoter O +
hypermethylation O -
. O +

In O +
our O +
group O -
, O +
out O +
of O +
34 O +
MSI O +
CRCs O -
, O +
19 O +
CRCs O +
( O -
55.9 O -
% O -
) O +
were O +
hypermethylated O +
at O +
the O +
MLH1 B-Gene +
promoter O -
, O +
which O +
accounted O +
for O +
73.7 O -
% O +
of O +
MSI O -
- O -
H O +
CRCs O +
and O +
33.3 O -
% O +
of O +
MSI O +
CRCs O -
. O +

Anacleto O +
et O +
al. O +
[ O -
21 O -
] O +
reported O +
that O +
8 O +
out O +
of O +
15 O +
MSI O +
CRCs O +
had O +
MLH1 B-Gene +
promoter O +
hypermethylation O -
, O +
which O +
was O +
similar O +
to O +
our O +
results O -
. O +

Kim O +
et O +
al. O +
[ O -
10 O -
] O +
found O +
that O +
in O +
MSI O -
- O -
H O +
gastric O +
cancers O -
, O +
the O +
MLH1 B-Gene +
hypermethylation O +
occurred O +
in O +
89 O -
% O +
of O +
patients O -
. O +

Bettstetter O +
et O +
al. O +
[ O -
20 O -
] O +
showed O +
that O +
all O +
sporadic O +
MSI O -
- O -
H O +
CRCs O +
were O +
hypermethylated O +
at O +
the O +
MLH1 B-Gene +
promoter O -
. O +

These O +
results O +
were O +
similar O +
to O +
ours O -
. O +

Fourteen O +
out O +
of O +
16 O +
MLH1 B-Gene +
negatively O +
staining O +
CRCs O +
were O +
hypermethylated O +
at O +
the O +
MLH1promoter B-Gene -
. O +

Mutation O +
analysis O +
revealed O +
that O +
8 O +
patients O +
( O -
23.5 O -
% O -
) O +
had O +
MMR B-Gene +
gene O +
germline O +
mutations O +
out O +
of O +
34 O +
MSI O +
patients O -
. O +

Five O +
patients O +
had O +
MSH2 B-Gene +
mutations O +
and O +
3 O +
had O +
MSH6 B-Gene +
mutations O -
, O +
while O +
no O +
MLH1 B-Gene +
mutation O +
was O +
found O -
. O +

There O +
were O +
2 O +
and O +
6 O +
patients O +
who O +
had O +
mutations O +
in O +
MSH2 B-Gene +
and O +
MSH6 B-Gene +
in O +
the O +
MSI O -
- O -
L O +
and O +
MSI O -
- O -
H O +
groups O -
, O +
respectively O -
. O +

Yearsley O +
et O +
al. O +
[ O -
15 O -
] O -
, O +
in O +
their O +
study O +
of O +
87 O +
patients O +
with O +
MSI O +
colorectal O +
cancers O -
, O +
found O +
12 O +
patients O +
( O -
13.8 O -
% O -
) O +
with O +
MLH1 B-Gene +
and O +
MSH2 B-Gene +
germline O +
mutations O -
. O +

Niessen O +
et O +
al. O +
[ O -
16 O -
] O -
, O +
however O -
, O +
found O +
that O +
the O +
rate O +
of O +
MSH2 B-Gene -
, O +
MSH6 B-Gene +
and O +
MLH1 B-Gene +
germline O +
mutations O +
was O +
82 O -
% O +
in O +
the O +
young O +
age O +
group O +
( O -
< O -
50 O +
years O +
old O -
) O -
. O +

This O +
was O +
quite O +
different O +
from O +
our O +
group O -
. O +

This O +
difference O +
might O +
be O +
due O +
to O +
different O +
case O +
selections O +
of O +
the O +
two O +
groups O -
. O +

Our O +
study O +
was O +
more O +
representative O +
of O +
the O +
patient O +
population O +
because O +
it O +
was O +
a O +
successive O +
cohort O +
study O -
. O +

Most O +
importantly O -
, O +
the O +
above O +
differences O +
may O +
also O +
be O +
explained O +
by O +
underlying O +
differences O +
in O +
genetic O +
background O +
between O +
Chinese O +
and O +
Western O +
populations O -
. O +

Conclusion O +
Our O +
results O +
imply O +
that O +
HNPCC O +
in O +
the O +
Chinese O +
population O +
may O +
have O +
distinct O +
clinicopathological O +
characteristics O +
and O +
underlying O +
MMR B-Gene +
germline O +
mutations O -
, O +
as O +
compared O +
to O +
patients O +
from O +
Western O +
countries O -
. O +

Application O +
of O +
NCI O +
recommendations O +
on O +
the O +
Chinese O +
population O +
may O +
not O +
enable O +
the O +
screening O +
of O +
all O +
HNPCC O +
families O -
. O +

Further O +
studies O +
are O +
necessary O +
to O +
echo O +
or O +
refute O +
our O +
results O +
so O +
as O +
to O +
make O +
the O +
NCI O +
recommendation O +
more O +
universally O +
applicable O -
. O +

Transcriptional O +
recapitulation O +
and O +
subversion O +
of O +
embryonic O +
colon O +
development O +
by O +
mouse O +
colon O +
tumor O +
models O +
and O +
human O +
colon O +
cancer O +
Abstract O +
Colon O +
tumors O +
from O +
four O +
independent O +
mouse O +
models O +
and O +
100 O +
human O +
colorectal O +
cancers O +
all O +
exhibited O +
striking O +
recapitulation O +
of O +
embryonic O +
colon O +
gene O +
expression O +
from O +
embryonic O +
days O +
13.5 O -
- O -
18.5 O -
. O +

Abstract O +
Background O +
The O +
expression O +
of O +
carcino O -
- O -
embryonic O +
antigen O +
by O +
colorectal O +
cancer O +
is O +
an O +
example O +
of O +
oncogenic O +
activation O +
of O +
embryonic O +
gene O +
expression O -
. O +

Hypothesizing O +
that O +
oncogenesis O -
- O -
recapitulating O -
- O -
ontogenesis O +
may O +
represent O +
a O +
broad O +
programmatic O +
commitment O -
, O +
we O +
compared O +
gene O +
expression O +
patterns O +
of O +
human O +
colorectal O +
cancers O +
( O -
CRCs O -
) O +
and O +
mouse O +
colon O +
tumor O +
models O +
to O +
those O +
of O +
mouse O +
colon O +
development O +
embryonic O +
days O +
13.5 O -
- O -
18.5 O -
. O +

Results O +
We O +
report O +
here O +
that O +
39 O +
colon O +
tumors O +
from O +
four O +
independent O +
mouse O +
models O +
and O +
100 O +
human O +
CRCs O +
encompassing O +
all O +
clinical O +
stages O +
shared O +
a O +
striking O +
recapitulation O +
of O +
embryonic O +
colon O +
gene O +
expression O -
. O +

Compared O +
to O +
normal O +
adult O +
colon O -
, O +
all O +
mouse O +
and O +
human O +
tumors O +
over O -
- O -
expressed O +
a O +
large O +
cluster O +
of O +
genes O +
highly O +
enriched O +
for O +
functional O +
association O +
to O +
the O +
control O +
of O +
cell O +
cycle O +
progression O -
, O +
proliferation O -
, O +
and O +
migration O -
, O +
including O +
those O +
encoding O +
MYC B-Gene -
, O +
AKT2 B-Gene -
, O +
PLK1 B-Gene +
and O +
SPARC B-Gene -
. O +

Mouse O +
tumors O +
positive O +
for O +
nuclear O +
β O -
- O -
catenin O +
shifted O +
the O +
shared O +
embryonic O +
pattern O +
to O +
that O +
of O +
early O +
development O -
. O +

Human O +
and O +
mouse O +
tumors O +
differed O +
from O +
normal O +
embryonic O +
colon O +
by O +
their O +
loss O +
of O +
expression O +
modules O +
enriched O +
for O +
tumor O +
suppressors O +
( O -
EDNRB B-Gene -
, O +
HSPE B-Gene -
, O +
KIT B-Gene +
and O +
LSP1 B-Gene -
) O -
. O +

Human O +
CRC O +
adenocarcinomas O +
lost O +
an O +
additional O +
suppressor O +
module O +
( O -
IGFBP4 B-Gene -
, O +
MAP4K1 B-Gene -
, O +
PDGFRA B-Gene -
, O +
STAB1 B-Gene +
and O +
WNT4 B-Gene -
) O -
. O +

Many O +
human O +
tumor O +
samples O +
also O +
gained O +
expression O +
of O +
a O +
coordinately O +
regulated O +
module O +
associated O +
with O +
advanced O +
malignancy O +
( O -
ABCC1 B-Gene -
, O +
FOXO3A B-Gene -
, O +
LIF B-Gene -
, O +
PIK3R1 B-Gene -
, O +
PRNP B-Gene -
, O +
TNC B-Gene -
, O +
TIMP3 B-Gene +
and O +
VEGF B-Gene -
) O -
. O +

Conclusion O +
Cross O -
- O -
species O -
, O +
developmental O -
, O +
and O +
multi O -
- O -
model O +
gene O +
expression O +
patterning O +
comparisons O +
provide O +
an O +
integrated O +
and O +
versatile O +
framework O +
for O +
definition O +
of O +
transcriptional O +
programs O +
associated O +
with O +
oncogenesis O -
. O +

This O +
approach O +
also O +
provides O +
a O +
general O +
method O +
for O +
identifying O +
pattern O -
- O -
specific O +
biomarkers O +
and O +
therapeutic O +
targets O -
. O +

This O +
delineation O +
and O +
categorization O +
of O +
developmental O +
and O +
non O -
- O -
developmental O +
activator O +
and O +
suppressor O +
gene O +
modules O +
can O +
thus O +
facilitate O +
the O +
formulation O +
of O +
sophisticated O +
hypotheses O +
to O +
evaluate O +
potential O +
synergistic O +
effects O +
of O +
targeting O +
within- O +
and O +
between O -
- O -
modules O +
for O +
next O -
- O -
generation O +
combinatorial O +
therapeutics O +
and O +
improved O +
mouse O +
models O -
. O +

Two O +
other O +
mouse O +
models O +
that O +
carry O +
different O +
genetic O +
alterations O +
leading O +
to O +
colon O +
tumor O +
formation O +
are O +
based O +
on O +
the O +
observation O +
that O +
transforming B-Gene +
growth I-Gene +
factor I-Gene +
( I-Gene -
TGF I-Gene -
) I-Gene -
β I-Gene +
type I-Gene +
II I-Gene +
receptor I-Gene +
( O -
TGFBR2 B-Gene -
) O +
gene O +
mutations O +
are O +
present O +
in O +
up O +
to O +
30 O -
% O +
of O +
sporadic O +
CRCs O +
and O +
in O +
more O +
than O +
90 O -
% O +
of O +
tumors O +
that O +
occur O +
in O +
patients O +
with O +
the O +
DNA O +
mismatch O +
repair O +
deficiency O +
associated O +
with O +
hereditary O +
non O -
- O -
polyposis O +
colon O +
cancer O +
( O -
HNPCC O -
) O +
[ O -
12 O -
] O -
. O +

In O +
the O +
mouse O -
, O +
a O +
deficiency O +
of O +
TGFβ1 B-Gene +
combined O +
with O +
an O +
absence O +
of O +
T O -
- O -
cells O +
( O -
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O -
) O +
results O +
in O +
a O +
high O +
occurrence O +
of O +
colon O +
cancer O +
[ O -
13 O -
] O -
. O +

These O +
mice O +
develop O +
adenomas O +
by O +
two O +
months O +
of O +
age O -
, O +
and O +
adenocarcinomas O -
, O +
often O +
mucinous O -
, O +
by O +
three O +
to O +
six O +
months O +
of O +
age O -
. O +

Immunohistochemical O +
analyses O +
of O +
these O +
tumors O +
are O +
negative O +
for O +
nuclear O +
β O -
- O -
catenin O -
, O +
suggesting O +
that O +
TGFβ1 B-Gene +
does O +
not O +
suppress O +
tumors O +
via O +
a O +
canonical O +
WNT O +
signaling O -
- O -
dependent O +
pathway O -
. O +

The O +
SMAD B-Gene +
family O +
proteins O +
are O +
critical O +
downstream O +
transcription O +
regulators O +
activated O +
by O +
TGFβ O +
signaling O -
, O +
in O +
part O +
through O +
the O +
TGFβ B-Gene +
type I-Gene +
II I-Gene +
receptor I-Gene -
. I-Gene +

Smad3- B-Gene -
/ O -
- O +
mice O +
also O +
develop O +
intestinal O +
lesions O +
that O +
include O +
colon O +
adenomas O +
and O +
adenocarcinomas O +
by O +
six O +
months O +
of O +
age O +
[ O -
14 O -
] O -
. O +

To O +
identify O +
transcriptional O +
programs O +
that O +
are O +
significantly O +
activated O +
or O +
repressed O +
in O +
different O +
colon O +
tumor O +
models O -
, O +
we O +
compared O +
gene O +
expression O +
profiles O +
of O +
100 O +
human O +
CRCs O +
and O +
39 O +
colonic O +
tumors O +
from O +
the O +
four O +
models O +
of O +
colon O +
cancer O +
to O +
mouse O +
embryonic O +
and O +
mouse O +
and O +
human O +
adult O +
colon O -
. O +

The O +
results O +
of O +
these O +
analyses O +
demonstrate O +
that O +
tumors O +
from O +
the O +
mouse O +
models O +
extensively O +
adopt O +
embryonic O +
gene O +
expression O +
patterns O -
, O +
irrespective O +
of O +
the O +
initiating O +
mutation O -
. O +

Although O +
two O +
of O +
the O +
mouse O +
tumor O +
subtypes O +
were O +
distinguishable O +
by O +
their O +
relative O +
shifts O +
towards O +
early O +
or O +
later O +
stages O +
of O +
embryonic O +
gene O +
expression O +
( O -
driven O +
principally O +
by O +
localization O +
of O +
β O -
- O -
catenin O +
to O +
the O +
nucleus O +
versus O +
the O +
plasma O +
membrane O -
) O -
, O +
Myc O +
was O +
over O -
- O -
expressed O +
in O +
tumors O +
from O +
all O +
four O +
tumor O +
models O -
. O +

Further O -
, O +
by O +
mapping O +
mouse O +
genes O +
to O +
their O +
corresponding O +
human O +
orthologs O -
, O +
we O +
further O +
show O +
that O +
human O +
CRCs O +
share O +
in O +
the O +
broad O +
over O -
- O -
expression O +
of O +
genes O +
characteristic O +
of O +
colon O +
embryogenesis O +
and O +
the O +
up O -
- O -
regulation O +
of O +
MYC O -
, O +
consistent O +
with O +
a O +
fundamental O +
relationship O +
between O +
embryogenesis O +
and O +
tumorigenesis O -
. O +

Large O +
scale O +
similarities O +
could O +
also O +
be O +
found O +
at O +
the O +
level O +
of O +
developmental O +
genes O +
that O +
were O +
not O +
activated O +
in O +
either O +
mouse O +
or O +
human O +
tumors O -
. O +

In O +
addition O -
, O +
there O +
were O +
transcriptional O +
modules O +
consistently O +
activated O +
and O +
repressed O +
in O +
human O +
CRCs O +
that O +
were O +
not O +
found O +
in O +
the O +
mouse O +
models O -
. O +

Taken O +
together O -
, O +
this O +
cross O -
- O -
species O -
, O +
cross O -
- O -
models O +
analytical O +
approach O +
- O +
filtered O +
through O +
the O +
lens O +
of O +
embryonic O +
colon O +
development O +
- O +
provides O +
an O +
integrated O +
view O +
of O +
gene O +
expression O +
patterning O +
that O +
implicates O +
the O +
adoption O +
of O +
a O +
broad O +
program O +
encompassing O +
embryonic O +
activation O -
, O +
developmental O +
arrest O -
, O +
and O +
failed O +
differentiation O +
as O +
a O +
fundamental O +
feature O +
of O +
the O +
biology O +
of O +
human O +
CRC O -
. O +

Detailed O +
cluster O +
analysis O -
: O +
differential O +
and O +
statistically O +
significant O +
biological O +
functions O +
in O +
clusters O +
C1-C7 O +
A O -
, O +
AOM O -
- O -
induced O -
; O +
M O -
, O +
ApcMin B-Gene -
/ O -
+ O -
; O +
S O -
, O +
Smad3- B-Gene -
/ O -
- O -
; O +
T O -
, O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O -
. O +

Active O +
canonical O +
WNT O +
signaling O +
( O -
as O +
determined O +
by O +
nuclear O +
β O -
- O -
catenin O -
) O +
stratifies O +
the O +
four O +
murine O +
colon O +
tumor O +
models O +
into O +
two O +
groups O -
. O +

( O -
a O -
) O +
Hierarchical O +
clustering O +
of O +
gene O +
transcripts O +
separates O +
the O +
four O +
models O +
into O +
two O +
groups O -
. O +

The O +
upper O +
panel O +
shows O +
1,798 O +
gene O +
transcripts O +
identified O +
as O +
differentially O +
expressed O +
among O +
any O +
of O +
the O +
four O +
mouse O +
tumor O +
models O +
( O -
Kruskal O -
- O -
Wallis O +
test O +
+ O +
Student O -
- O -
Newman O -
- O -
Keuls O +
test O +
+ O +
FDR O +
< O +
5.10 O -
- O -
5 O -
) O -
. O +

Results O +
demonstrate O +
that O +
AOM B-Gene +
( O -
A O -
) O +
and O +
ApcMin B-Gene -
/ O -
+ O +
( O -
M O -
) O +
tumors O +
are O +
transcriptionally O +
more O +
similar O +
to O +
each O +
other O +
than O +
to O +
tumors O +
from O +
Smad3- B-Gene -
/ O -
- O +
( O -
S O -
) O +
and O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O +
( O -
T O -
) O +
mice O -
. O +

Five O +
clusters O +
have O +
been O +
identified O +
( O -
C1-C5 O -
) O +
that O +
correspond O +
to O +
the O +
K O -
- O -
means O +
functional O +
clusters O +
listed O +
in O +
Table O +
1 O -
. O +

Please O +
refer O +
to O +
Table O +
1 O +
for O +
an O +
in O -
- O -
depth O +
description O +
of O +
the O +
functional O +
classification O +
of O +
the O +
genes O +
found O +
in O +
these O +
clusters O -
. O +

The O +
lower O +
panel O +
illustrates O +
the O +
extent O +
of O +
the O +
similarity O +
between O +
A O -
/ O -
M O +
and O +
S O -
/ O -
T O +
tumors O +
by O +
identifying O +
the O +
top O -
- O -
ranked O +
1,265 O +
transcripts O +
of O +
the O +
1,798 O +
that O +
were O +
higher O +
or O +
lower O +
in O +
the O +
two O +
tumor O +
super O -
- O -
groups O +
( O -
rank O +
based O +
on O +
Wilcoxon O -
- O -
Mann O -
- O -
Whitney O +
test O +
for O +
between O -
- O -
group O +
differences O +
with O +
a O +
FDR O +
< O +
5.10 O -
- O -
5 O +
cutoff O -
) O -
. O +

Up O -
- O -
regulated O +
transcripts O +
in O +
A O -
/ O -
M O +
tumors O +
are O +
highly O +
enriched O +
for O +
genes O +
associated O +
with O +
canonical O +
WNT O +
signaling O +
activity O -
, O +
cell O +
proliferation O -
, O +
chromatin O +
remodeling O -
, O +
cell O +
cycle O +
progression O +
and O +
mitosis O -
; O +
transcripts O +
over O -
- O -
expressed O +
in O +
S O -
/ O -
T O +
tumors O +
are O +
highly O +
enriched O +
for O +
genes O +
related O +
to O +
immune O +
and O +
defense O +
responses O -
, O +
endocytosis O -
, O +
transport O -
, O +
oxidoreductase O +
activity O -
, O +
signal O +
transduction O +
and O +
metabolism O -
. O +

( O -
b O -
) O +
Representative O +
histologies O +
for O +
each O +
of O +
the O +
four O +
tumor O +
models O -
. O +

The O +
lower O +
panel O +
illustrates O +
the O +
model O -
- O -
dependent O +
localization O +
of O +
β O -
- O -
catenin O -
. O +

Tumors O +
from O +
M O +
( O -
bottom O +
left O -
) O +
and O +
A O +
( O -
not O +
shown O -
) O +
mice O +
exhibited O +
prominent O +
nuclear O +
β O -
- O -
catenin O +
accumulation O +
and O +
reduced O +
cell O +
surface O +
staining O -
. O +

Conversely O -
, O +
tumors O +
from O +
S O +
( O -
bottom O +
right O -
) O +
and O +
T O -
( O -
not O +
shown O -
) O +
mice O +
exhibited O +
retention O +
of O +
plasma O +
membrane O +
β O -
- O -
catenin O +
immunoreactivity O -
. O +

A O +
and O +
M O +
in O +
top O +
panel O +
100 O -
× O +
magnification O -
; O +
S O +
and O +
T O +
200 O -
× O +
magnification O -
. O +

M O +
and O +
S O +
in O +
lower O +
panel O +
both O +
400 O -
× O +
magnification O -
. O +

From O +
the O +
1,798 O +
transcripts O +
differentially O +
expressed O +
among O +
the O +
four O +
mouse O +
models O +
of O +
CRC O -
, O +
more O +
than O +
70 O -
% O +
( O -
n O +
= O +
1265 O -
) O +
distinguished O +
ApcMin B-Gene -
/ O -
+ O +
and O +
AOM O +
tumors O +
versus O +
Smad3- B-Gene -
/ O -
- O +
and O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O +
tumors O +
( O -
Figure O +
2a O -
, O +
bottom O -
) O -
. O +

If O +
a O +
random O +
or O +
equivalent O +
degree O +
of O +
variance O +
occurred O +
among O +
all O +
classes O -
, O +
there O +
would O +
be O +
far O +
less O +
overlap O -
. O +

The O +
majority O +
of O +
this O +
signature O +
( O -
approximately O +
75 O -
% O -
, O +
n O +
= O +
904 O +
features O -
) O +
derived O +
from O +
genes O +
over O -
- O -
expressed O +
in O +
ApcMin B-Gene -
/ O -
+ O +
and O +
AOM O +
tumors O +
relative O +
to O +
the O +
Smad3- B-Gene -
/ O -
- O +
and O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O +
tumors O +
( O -
cluster O +
C6 O -
) O -
. O +

Cluster O +
C6 O +
was O +
functionally O +
enriched O +
for O +
genes O +
linked O +
to O +
canonical O +
WNT O +
signaling O +
( O -
Table O +
1 O -
) O -
. O +

These O +
included O +
genes O +
previously O +
identified O +
to O +
be O +
part O +
of O +
this O +
pathway O +
( O -
Cd44 B-Gene -
, O +
Myc B-Gene -
, O +
Stra6 B-Gene -
, O +
Tcf1 B-Gene -
, O +
Tcf4 B-Gene +
[ O -
16 O -
] O -
, O +
Id2 B-Gene -
, O +
Lef1 B-Gene -
, O +
Nkd1 B-Gene -
, O +
Nlk B-Gene -
, O +
Twist1 B-Gene +
[ O -
17 O -
] O -
, O +
Catnb B-Gene -
, O +
Csnk1a1 B-Gene -
, O +
Csnk1d B-Gene -
, O +
Csnk1e B-Gene -
, O +
Plat B-Gene -
, O +
Wif1 B-Gene -
) O +
as O +
well O +
as O +
genes O +
that O +
appear O +
to O +
be O +
novel O +
canonical O +
WNT O +
signaling O +
targets O +
( O -
for O +
example O -
, O +
Cryl1 B-Gene -
, O +
Expi B-Gene -
, O +
Ifitm3l B-Gene -
, O +
Pacsin2 B-Gene -
, O +
Sox4 B-Gene +
[ O -
16 O -
] O -
, O +
Ets2 B-Gene -
, O +
Hnrnpg B-Gene -
, O +
Hnrpa1 B-Gene -
, O +
Id3 B-Gene -
, O +
Kpnb3 B-Gene -
, O +
Pais B-Gene -
, O +
Pcna B-Gene -
, O +
Ranbp11 B-Gene -
, O +
Rbbp4 B-Gene -
, O +
Yes B-Gene +
[ O -
18 O -
] O -
, O +
Hdac2 B-Gene +
[ O -
19 O -
] O -
) O -
. O +

Moreover O -
, O +
consistent O +
with O +
the O +
over O -
- O -
expression O +
of O +
Myc B-Gene +
in O +
tumors O +
from O +
the O +
ApcMin B-Gene -
/ O -
+ O +
and O +
AOM O +
models O -
, O +
we O +
detected O +
enrichment O +
of O +
Myc O +
targets O -
, O +
such O +
as O +
Apex B-Gene -
, O +
Eef1d B-Gene -
, O +
Eif2a B-Gene -
, O +
Eif4e B-Gene -
, O +
Hsp90 B-Gene -
, O +
Mif B-Gene -
, O +
Mitf B-Gene -
, O +
Npm1 B-Gene +
[ O -
20 O -
] O -
, O +
and O +
the O +
repression O +
of O +
Nibam B-Gene +
[ O -
20 O -
] O -
. O +

Nuclear O +
β O -
- O -
catenin O +
expression O +
distinguishes O +
murine O +
models O +
To O +
establish O +
a O +
molecular O +
basis O +
for O +
over O -
- O -
expression O +
of O +
canonical O +
WNT O +
target O +
genes O +
in O +
ApcMin B-Gene -
/ O -
+ O +
and O +
AOM B-Gene +
tumors O -
, O +
we O +
used O +
immunohistochemistry O +
to O +
characterize O +
the O +
relative O +
cellular O +
distribution O +
of O +
β O -
- O -
catenin O -
. O +

Tumors O +
from O +
ApcMin B-Gene -
/ O -
+ O +
( O -
Figure O +
2b O -
, O +
bottom O +
left O +
panel O -
) O +
and O +
AOM B-Gene +
( O -
not O +
shown O -
) O +
mice O +
exhibited O +
strong O +
nuclear O +
β O -
- O -
catenin O +
immunoreactivity O +
and O +
reduced O +
membrane O +
staining O +
( O -
see O +
inset O -
) O -
, O +
whereas O +
tumors O +
from O +
Smad3- B-Gene -
/ O -
- O +
( O -
Figure O +
2b O -
, O +
bottom O +
right O +
panel O -
) O +
and O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O +
( O -
not O +
shown O -
) O +
mice O +
showed O +
strong O +
plasma O +
membrane O +
β O -
- O -
catenin O +
staining O +
with O +
no O +
nuclear O +
accumulation O +
( O -
see O +
inset O -
) O -
. O +

Additional O +
tests O +
to O +
confirm O +
the O +
microarray O +
results O +
were O +
also O +
carried O +
out O +
using O +
an O +
independent O +
set O +
of O +
C57BL O -
/ O -
6 O +
ApcMin B-Gene -
/ O -
+ O +
colon O +
tumor O +
samples O +
analyzed O +
by O +
quantitative O +
real O -
- O -
time O +
PCR O +
( O -
qRT O -
- O -
PCR O -
; O +
Figure O +
3a O -
) O +
and O +
immunohistochemistry O +
( O -
Figure O +
3b O -
) O -
. O +

All O +
expression O +
patterns O +
identified O +
via O +
microarray O +
analysis O +
were O +
consistent O +
with O +
the O +
qRT O -
- O -
PCR O +
results O +
( O -
n O +
= O +
9 O +
transcripts O -
, O +
chosen O +
for O +
their O +
demonstration O +
of O +
a O +
range O +
of O +
differential O +
expression O +
characteristics O -
) O -
. O +

In O +
situ O +
hybridization O +
analyses O +
using O +
C57BL O -
/ O -
6 O +
ApcMin B-Gene -
/ O -
+ O +
colon O +
tumor O +
samples O +
also O +
validated O +
that O +
Wif B-Gene -
, O +
Tesc B-Gene -
, O +
Spock2 B-Gene +
and O +
Casp6 B-Gene +
were O +
strongly O +
expressed O +
in O +
dysplastic O +
cells O +
of O +
the O +
tumors O +
( O -
data O +
not O +
shown O -
) O -
. O +

At O +
the O +
protein O +
level O -
, O +
immunohistochemical O +
analyses O +
confirmed O +
relatively O +
greater O +
expression O +
of O +
the O +
oncoprotein O +
stathmin B-Gene +
1 I-Gene +
in O +
ApcMin B-Gene -
/ O -
+ O +
mice O +
and O +
tyrosine B-Gene +
phosphatase I-Gene +
4a2 I-Gene +
in O +
Smad3- B-Gene -
/ O -
- O +
mice O +
( O -
Figure O +
3b O -
) O -
. O +

Selective O +
validation O +
of O +
microarray O +
results O +
by O +
qRT O -
- O -
PCR O +
and O +
immunohistochemistry O -
. O +

Differential O +
expression O +
of O +
transcripts O +
identified O +
by O +
the O +
microarray O +
analyses O +
was O +
examined O +
using O +
( O -
a O -
) O +
qRT O -
- O -
PCR O +
and O +
( O -
b O -
) O +
immunohistochemistry O -
. O +

Additional O +
colon O +
tumors O +
from O +
five O +
ApcMin B-Gene -
/ O -
+ O +
( O -
M O -
; O +
nuclear O +
β O -
- O -
catenin O -
- O -
positive O -
) O +
mice O +
and O +
four O +
Smad3- B-Gene -
/ O -
- O +
( O -
S O -
; O +
nuclear O +
β O -
- O -
catenin O -
- O -
negative O -
) O +
mice O +
were O +
harvested O -
, O +
and O +
qRT O -
- O -
PCR O +
was O +
performed O +
on O +
nine O +
genes O +
that O +
exhibited O +
representative O +
strong O +
or O +
subtle O +
patterns O +
in O +
the O +
microarray O +
analyses O -
. O +

All O +
nine O +
patterns O +
detected O +
in O +
the O +
microarray O +
set O +
were O +
validated O +
by O +
the O +
qRT O -
- O -
PCR O +
results O -
. O +

Alox12 B-Gene -
, O +
Arachidonate B-Gene +
12-lipoxygenase I-Gene -
; O +
Casp6 B-Gene -
, O +
Caspase B-Gene +
6 I-Gene -
; O +
Matn2 B-Gene -
, O +
Matrilin B-Gene +
2 I-Gene -
; O +
Ptplb B-Gene -
, O +
Protein B-Gene +
tyrosine I-Gene +
phosphatase I-Gene -
- I-Gene -
like I-Gene +
B I-Gene -
; O +
Sox21 B-Gene -
, O +
SRY B-Gene +
( I-Gene -
sex I-Gene +
determining I-Gene +
region I-Gene +
Y I-Gene -
) I-Gene -
-box I-Gene +
21 I-Gene -
; O +
Spock2 B-Gene -
, O +
Sparc B-Gene -
/ I-Gene -
osteonectin I-Gene -
, O +
CWCV B-Gene -
, O +
and O +
Kazal B-Gene -
- I-Gene -
like I-Gene +
domains I-Gene +
proteoglycan I-Gene +
( I-Gene -
testican I-Gene -
) I-Gene +
2 I-Gene -
; O +
Tesc B-Gene -
, O +
Tescalcin B-Gene -
; O +
Tpm2 B-Gene -
, O +
Tropomysin B-Gene +
2 I-Gene -
; O +
Wif1 B-Gene -
, O +
WNT B-Gene +
inhibitory I-Gene +
factor I-Gene -
; O +
Stmn1 B-Gene -
, O +
stathmin B-Gene +
1 I-Gene -
; O +
Ptp4a2 B-Gene -
, O +
phosphatase B-Gene +
4a2 I-Gene -
. O +

In O +
( O -
a O -
) O -
, O +

* O -
p O +
< O +
0.05 O +
and O +

* O +

* O -
p O +
< O +
0.01 O -
. O +

Overall O -
, O +
cluster O +
C6 O +
genes O +
( O -
that O +
is O -
, O +
genes O +
with O +
greater O +
up O -
- O -
regulation O +
in O +
tumors O +
from O +
ApcMin B-Gene -
/ O -
+ O +
and O +
AOM B-Gene +
models O +
than O +
in O +
Smad3- B-Gene -
/ O -
- O +
and O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O -
) O +
were O +
consistent O +
with O +
increased O +
tumor O +
cell O +
proliferation O +
( O -
for O +
example O -
, O +
Myc B-Gene -
, O +
Pcna B-Gene -
) O -
, O +
cytokinesis O +
( O -
for O +
example O -
, O +
Amot B-Gene -
, O +
Cxcl5 B-Gene -
) O -
, O +
chromatin O +
remodeling O +
( O -
for O +
example O -
, O +
Ets2 B-Gene -
, O +
Hdac2 B-Gene -
, O +
Set B-Gene -
) O +
as O +
well O +
as O +
cell O +
cycle O +
progression O +
and O +
mitosis O +
( O -
for O +
example O -
, O +
Cdk1 B-Gene -
, O +
Cdk4 B-Gene -
, O +
Cul1 B-Gene -
, O +
Plk1 B-Gene -
) O -
. O +

It O +
is O +
important O +
to O +
note O +
that O +
Myc B-Gene +
is O +
up O -
- O -
regulated O +
in O +
all O +
four O +
mouse O +
tumor O +
models O +
relative O +
to O +
normal O +
colon O +
tissue O +
( O -
see O +
below O -
) O -
. O +

Biological O +
processes O +
showing O +
increased O +
transcription O +
in O +
tumors O +
from O +
the O +
Smad3- B-Gene -
/ O -
- O +
and O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O +
models O +
( O -
cluster O +
C7 O -
) O +
included O +
immune O +
and O +
defense O +
responses O +
( O -
for O +
example O -
, O +
Il18 B-Gene -
, O +
Irf1 B-Gene -
, O +
Myd88 B-Gene -
) O -
, O +
endocytosis O +
( O -
for O +
example O -
, O +
Lrp1 B-Gene -
, O +
Ldlr B-Gene -
, O +
Rac1 B-Gene -
) O -
, O +
transport O +
( O -
for O +
example O -
, O +
Abca3 B-Gene -
, O +
Slc22a5 B-Gene -
, O +
Slc30a4 B-Gene -
) O -
, O +
and O +
oxidoreductase O +
activity O +
( O -
for O +
example O -
, O +
Gcdh B-Gene -
, O +
Prdx6 B-Gene -
, O +
Xdh B-Gene -
) O +
( O -
Table O +
1 O -
) O -
. O +

Taken O +
together O -
, O +
these O +
transcriptional O +
observations O +
are O +
both O +
consistent O +
with O +
and O +
extend O +
our O +
understanding O +
of O +
the O +
histological O +
features O +
of O +
the O +
CRC O +
models O +
[ O -
7 O -
] O -
. O +

For O +
example O -
, O +
while O +
ApcMin B-Gene -
/ O -
+ O +
and O +
AOM B-Gene +
tumors O +
are O +
characterized O +
by O +
cytologic O +
atypia O +
( O -
that O +
is O -
, O +
nuclear O +
crowding O -
, O +
hyperchromasia O -
, O +
increased O +
nucleus O -
- O -
to O -
- O -
cytoplasm O +
ratios O +
and O +
minimal O +
inflammation O -
) O -
, O +
tumors O +
from O +
Smad3- B-Gene -
/ O -
- O +
and O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O +
mice O +
show O +
less O +
overt O +
dysplastic O +
changes O +
but O +
exhibit O +
a O +
significant O +
inflammatory O +
component O -
. O +

Large O -
- O -
scale O +
activation O +
of O +
the O +
embryonic O +
colon O +
transcriptome O +
in O +
mouse O +
tumor O +
models O +
We O +
hypothesized O +
that O +
comparisons O +
of O +
genes O +
over O -
- O -
expressed O +
in O +
both O +
colon O +
tumors O +
and O +
embryonic O +
mouse O +
colon O +
could O +
provide O +
valuable O +
insights O +
into O +
tumor O +
programs O +
important O +
for O +
fundamental O +
aspects O +
of O +
tumor O +
growth O +
and O +
regulation O +
of O +
differentiation O -
. O +

To O +
identify O +
genes O +
and O +
observe O +
regulatory O +
patterns O +
that O +
were O +
shared O +
or O +
differed O +
between O +
colon O +
tumors O +
and O +
embryonic O +
development O -
, O +
we O +
applied O +
a O +
global O +
quantitative O +
referencing O +
strategy O +
to O +
both O +
tumor O +
and O +
embryonic O +
samples O +
by O +
calculating O +
the O +
relative O +
expression O +
of O +
each O +
gene O +
as O +
the O +
ratio O +
of O +
its O +
expression O +
in O +
any O +
sample O +
as O +
that O +
relative O +
to O +
its O +
mean O +
level O +
in O +
adult O +
colon O -
. O +

From O +
this O +
adult O +
baseline O +
reference O -
, O +
genes O +
over O -
- O -
expressed O +
in O +
the O +
four O +
mouse O +
tumor O +
models O +
appeared O +
strikingly O +
similar O -
. O +

Moreover O -
, O +
the O +
vast O +
majority O +
of O +
genes O +
over O -
- O -
expressed O +
in O +
tumors O +
were O +
also O +
over O -
- O -
expressed O +
in O +
embryonic O +
colon O +
( O -
Figure O +
4a O -
) O -
. O +

If O +
the O +
fraction O +
of O +
fetal O +
over O -
- O -
expressed O +
genes O +
from O +
the O +
entire O +
microarray O +
( O -
5,796 O +
of O +
20,393 O +
features O -
; O +
28.4 O -
% O -
) O +
was O +
maintained O +
at O +
a O +
similar O +
occurrence O +
frequency O +
in O +
the O +
tumor O +
over O -
- O -
expressed O +
fraction O +
( O -
8,804 O +
of O +
20,393 O -
) O -
, O +
one O +
would O +
expect O +
an O +
overlap O +
of O +
2,502 O +
transcripts O +
( O -
( O -
8,804 O -
/ O -
20,393 O -
) O +
× O +
28.4 O -
% O -
) O -
. O +

Rather O -
, O +
4,693 O +
out O +
of O +
the O +
5,796 O +
fetal O +
over O -
- O -
expressed O +
transcripts O +
were O +
observed O +
to O +
be O +
over O -
- O -
expressed O +
in O +
the O +
8,804 O +
tumor O +
over O -
- O -
expressed O +
genes O +
( O -
Figure O +
4b O -
) O -
. O +

The O +
probability O +
calculated O +
by O +
Fisher O -
's O +
exact O +
test O +
is O +
p O +
< O +
1 O -
- O -
300 O -
, O +
and O +
thus O +
represents O +
highly O +
significant O +
over O -
- O -
representation O +
of O +
fetal O +
genes O +
among O +
the O +
tumor O +
over O -
- O -
expressed O +
genes O -
. O +

Similarly O -
, O +
genes O +
under O -
- O -
expressed O +
in O +
developing O +
colon O +
were O +
disproportionately O +
underexpressed O +
in O +
tumors O +
relative O +
to O +
normal O +
adult O +
colon O +
( O -
3,282 O +
of O +
3,541 O -
; O +
p O +
< O +
1 O -
- O -
300 O -
) O -
. O +

Combining O +
these O +
results O -
, O +
approximately O +
85 O -
% O +
of O +
the O +
developmentally O +
regulated O +
transcripts O +
( O -
7,975 O +
out O +
of O +
9,337 O +
features O -
) O +
were O +
recapitulated O +
in O +
tumor O +
expression O +
patterns O +
relative O +
to O +
adult O +
colon O +
( O -
Figure O +
4a O -
, O -
b O -
, O +
green O +
and O +
red O +
markers O +
represent O +
the O +
corresponding O +
7,975 O +
features O -
) O -
. O +

All O +
four O +
murine O +
tumor O +
models O +
exhibit O +
reactivation O +
of O +
embryonic O +
gene O +
expression O -
. O +

The O +
expression O +
level O +
of O +
each O +
gene O +
in O +
each O +
sample O +
was O +
calculated O +
relative O +
to O +
that O +
in O +
adult O +
colon O -
. O +

Genes O +
and O +
samples O +
were O +
subjected O +
to O +
unsupervised O +
hierarchical O +
tree O +
clustering O +
for O +
similarities O +
among O +
genes O +
and O +
tumors O -
. O +

( O -
a O -
) O +
Heatmap O +
shows O +
the O +
relative O +
behaviors O +
of O +
20,393 O +
transcripts O +
that O +
passed O +
basic O +
signal O +
quality O +
filters O +
with O +
gene O +
transcripts O +
shown O +
as O +
separate O +
rows O +
and O +
samples O +
as O +
separate O +
columns O -
. O +

Note O +
that O +
the O +
majority O +
of O +
genes O +
over O -
- O -
expressed O +
in O +
tumors O +
( O -
red O -
) O +
are O +
also O +
over O -
- O -
expressed O +
in O +
embryonic O +
colon O -
; O +
similarly O -
, O +
the O +
genes O +
under O -
- O -
expressed O +
in O +
tumors O +
( O -
blue O -
) O +
are O +
under O -
- O -
expressed O +
in O +
embryonic O +
colon O -
. O +

The O +
color O +
bars O +
to O +
the O +
right O +
indicate O +
the O +
position O +
of O +
4,693 O +
transcripts O +
over O -
- O -
expressed O +
in O +
both O +
tumors O +
and O +
development O +
( O -
red O -
) O +
or O +
under O -
- O -
expressed O +
in O +
both O +
( O -
green O -
) O -
. O +

In O +
addition O -
, O +
there O +
are O +
genes O +
over O -
- O -
expressed O +
in O +
embryonic O +
colon O +
that O +
are O +
under O -
- O -
expressed O +
in O +
tumors O +
and O +
vice O +
versa O +
( O -
asterisks O -
) O -
. O +

( O -
b O -
) O +
The O +
genes O +
represented O +
in O +
( O -
a O -
) O +
were O +
divided O +
into O +
those O +
over O -
- O -
expressed O +
and O +
under O -
- O -
expressed O +
in O +
embryonic O +
colon O +
and O +
in O +
the O +
tumors O -
, O +
respectively O -
. O +

Fisher O -
's O +
exact O +
test O +
was O +
used O +
to O +
calculate O +
expected O +
overlaps O +
between O +
lists O +
and O +
confirmed O +
significant O +
over O -
- O -
representation O +
of O +
development O -
- O -
regulated O +
signatures O +
among O +
the O +
tumors O +
( O -
* O -
p O +
< O +
1 O -
- O -
300 O -
, O +
* O +

* O -
p O +
< O +
1.3 O -
- O -
19 O -
, O +

* O +

* O -
* O -
p O +
< O +
4 O -
- O -
296 O -
, O +

* O +

* O +

* O +

* O -
p O +
< O +
1 O -
- O -
300 O -
) O -
. O +

( O -
c O -
) O +
Heatmap O +
showing O +
the O +
behavior O +
of O +
a O +
subset O +
of O +
the O +
transcripts O +
in O +
( O -
a O -
) O +
( O -
n O +
= O +
4,693 O +
features O -
) O +
that O +
were O +
over O -
- O -
expressed O +
in O +
both O +
embryonic O +
colon O +
and O +
tumor O +
samples O -
. O +

Refer O +
to O +
Table O +
2 O +
for O +
a O +
complete O +
description O +
of O +
the O +
genes O +
associated O +
with O +
these O +
clusters O -
. O +

( O -
d O -
) O +
Embryonic O +
gene O +
expression O +
can O +
be O +
further O +
refined O +
into O +
genes O +
expressed O +
differentially O +
during O +
early O +
( O -
ED O -
; O +
E13.5 O -
- O -
15.5 O -
) O +
and O +
late O +
( O -
LD O -
; O +
E16.5 O -
- O -
18.5 O -
) O +
embryonic O +
development O -
. O +

Heatmap O +
showing O +
the O +
relative O +
behaviors O +
of O +
750 O +
transcripts O +
that O +
are O +
highest O -
- O -
ranked O +
for O +
early O +
versus O +
late O +
embryonic O +
regulation O -
. O +

Overall O -
, O +
transcripts O +
with O +
the O +
highest O +
early O +
embryonic O +
expression O +
were O +
expressed O +
at O +
higher O +
levels O +
in O +
nuclear O +
β O -
- O -
catenin O -
- O -
positive O +
tumors O +
( O -
A O +
and O +
M O -
) O -
, O +
whereas O +
nuclear O +
β O -
- O -
catenin O -
- O -
negative O +
tumors O +
( O -
S O +
and O +
T O -
) O +
were O +
representative O +
of O +
later O +
stages O +
of O +
embryonic O +
development O -
. O +

Sample O +
groups O -
: O +
ED O -
, O +
early O +
development O +
( O -
E13.5-E15.5 O -
) O -
; O +
LD O -
, O +
late O +
development O +
( O -
E16.5-E18.5 O -
) O -
; O +
A O -
, O +
AOM O -
- O -
induced O -
; O +
M O -
, O +
ApcMin B-Gene -
/ O -
+ O -
; O +
T O -
, O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O -
; O +
S O -
, O +
Smad3- B-Gene -
/ O -
- O -
. O +

Staging O -
: O +
nAC O -
, O +
normal O +
colon O -
. O +

Clusters O +
C8-C10 O +
to O +
the O +
right O +
of O +
the O +
heatmap O +
correspond O +
to O +
the O +
K O -
- O -
means O +
functional O +
clusters O +
listed O +
in O +
Table O +
2 O -
. O +

To O +
explore O +
the O +
potential O +
biological O +
significance O +
of O +
genes O +
over O -
- O -
expressed O +
in O +
both O +
embryonic O +
colon O +
development O +
and O +
mouse O +
tumors O -
, O +
we O +
used O +
K O -
- O -
means O +
clustering O +
to O +
generate O +
C8-C10 O +
cluster O +
patterns O +
as O +
shown O +
in O +
a O +
hierarchical O +
tree O +
heatmap O +
( O -
Figure O +
4c O -
; O +
Table O +
2 O -
) O -
. O +

Several O +
sub O -
- O -
patterns O +
were O +
evident O -
, O +
some O +
of O +
which O +
clearly O +
separated O +
ApcMin B-Gene -
/ O -
+ O +
and O +
AOM O +
from O +
Smad3- B-Gene -
/ O -
- O +
and O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O +
tumors O -
. O +

One O +
strong O +
cluster O -
, O +
cluster O +
C8 O -
, O +
consisted O +
of O +
genes O +
more O +
strongly O +
expressed O +
in O +
ApcMin B-Gene -
/ O -
+ O +
and O +
AOM O +
than O +
Smad3- B-Gene -
/ O -
- O +
and O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O +
tumors O -
. O +

This O +
group O +
of O +
genes O +
represented O +
a O +
large O +
fraction O +
of O +
all O +
differences O +
found O +
between O +
nuclear O +
β O -
- O -
catenin O -
- O -
positive O +
( O -
ApcMin B-Gene -
/ O -
+ O +
and O +
AOM O -
) O +
and O +
negative O +
( O -
Smad3- B-Gene -
/ O -
- O +
and O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O -
) O +
tumors O +
( O -
approximately O +
45 O -
% O -
; O +
1,636 O +
out O +
of O +
3,592 O +
features O -
) O -
, O +
as O +
well O +
as O +
differences O +
detected O +
between O +
early O +
( O -
that O +
is O -
, O +
E13.5-E15.5 O -
, O +
ED O -
) O +
and O +
late O +
( O -
E.16.5-E18.5 O -
, O +
LD O -
) O +
embryonic O +
colon O +
developmental O +
stages O -
. O +

Thus O -
, O +
the O +
fraction O +
of O +
developmentally O +
regulated O +
genes O +
that O +
are O +
more O +
characteristic O +
of O +
the O +
earlier O +
stages O +
of O +
normal O +
colon O +
development O +
( O -
E13.5-E15.5 O -
) O -
, O +
are O +
clearly O +
expressed O +
at O +
higher O +
levels O +
in O +
nuclear O +
β O -
- O -
catenin O -
- O -
positive O +
tumors O -
. O +

This O +
observation O +
is O +
illustrated O +
by O +
750 O +
transcripts O +
selected O +
solely O +
for O +
stronger O +
expression O +
in O +
ED O +
versus O +
LD O +
( O -
Figure O +
4d O -
) O -
. O +

Note O +
that O +
most O +
of O +
these O +
transcripts O +
overlap O +
with O +
cluster O +
C6 O +
containing O +
230 O +
features O +
( O -
Figure O +
2a O -
, O +
lower O +
panel O -
) O +
and O +
illustrate O +
the O +
tendency O +
of O +
the O +
earlier O -
- O -
expressed O +
developmental O +
genes O +
to O +
be O +
more O +
strongly O +
expressed O +
in O +
ApcMin B-Gene -
/ O -
+ O +
and O +
AOM O +
mice O -
. O +

In O +
addition O -
, O +
transcripts O +
associated O +
with O +
increased O +
differentiation O +
and O +
maturation O -
, O +
observed O +
at O +
later O +
stages O +
of O +
colon O +
development O +
E16.5-E18.5 O +
( O -
for O +
example O -
, O +
Klf4 B-Gene +
[ O -
21 O -
] O -
, O +
Crohn O -
's O +
disease O -
- O -
related O +
Slc22a5 B-Gene -
/ O -
Octn2 B-Gene +
[ O -
22 O -
] O -
, O +
Slc30a4 B-Gene -
/ O -
Znt4 B-Gene +
[ O -
23 O -
] O -
, O +
Sst B-Gene +
[ O -
24 O -
] O -
) O -
, O +
were O +
expressed O +
at O +
higher O +
levels O +
by O +
tumors O +
from O +
Smad3- B-Gene -
/ O -
- O +
and O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O +
mice O -
. O +

Detailed O +
cluster O +
analysis O -
: O +
differential O +
and O +
statistically O +
significant O +
biological O +
functions O +
in O +
clusters O +
C8-C10 O +
PS O -
, O +
ProbeSets O -
. O +

Human O +
CRCs O +
reactivate O +
an O +
embryonic O +
gene O +
signature O +
Since O +
mouse O +
tumors O +
recapitulated O +
developmental O +
signatures O +
irrespective O +
of O +
their O +
etiology O -
, O +
we O +
asked O +
whether O +
a O +
similar O +
commitment O +
to O +
embryonic O +
gene O +
programming O +
was O +
shared O +
by O +
sporadic O +
human O +
CRCs O -
. O +

Tumor O +
classification O +
by O +
microarray O +
profiling O +
is O +
usually O +
accomplished O +
by O +
referencing O +
relative O +
gene O +
expression O +
levels O +
to O +
the O +
median O +
value O +
for O +
each O +
gene O +
across O +
a O +
series O +
of O +
tumor O +
samples O -
. O +

Using O +
this O +
' O -
between O -
- O -
tumors O +
median O +
normalization O -
' O +
approach O -
, O +
as O +
well O +
as O +
a O +
gene O +
filtering O +
strategy O +
that O +
detects O +
significantly O +
regulated O +
genes O +
in O +
at O +
least O +
10 O -
% O +
of O +
the O +
cases O -
, O +
led O +
to O +
the O +
identification O +
of O +
a O +
set O +
of O +
3,285 O +
probe O +
sets O +
corresponding O +
to O +
transcripts O +
whose O +
expression O +
was O +
highly O +
varied O +
between O +
independent O +
human O +
tumor O +
cases O -
. O +

As O +
shown O +
in O +
Figure O +
5 O -
, O +
there O +
was O +
striking O +
heterogeneity O +
of O +
gene O +
expression O +
among O +
100 O +
human O +
CRCs O -
. O +

For O +
example O -
, O +
cluster O +
15 O +
contained O +
a O +
set O +
of O +
genes O +
( O -
principally O +
metallothionein O +
genes O -
) O +
recently O +
identified O +
to O +
be O +
predictive O +
of O +
microsatellite O +
instability O +
[ O -
25,26 O -
] O -
. O +

This O +
analysis O +
indicates O +
that O +
human O +
CRCs O +
have O +
a O +
greater O +
level O +
of O +
complexity O +
than O +
the O +
mouse O +
colon O +
tumors O +
studied O +
here O +
( O -
compare O +
Figures O +
2 O +
and O +
5 O -
) O -
. O +

There O +
was O +
no O +
correlation O +
between O +
these O +
distinguishing O +
clusters O +
and O +
the O +
stage O +
of O +
the O +
tumor O +
( O -
note O +
the O +
broad O +
overlapping O +
distributions O +
of O +
Dukes O +
stages O +
A O -
- O -
D O +
across O +
these O +
different O +
clusters O -
) O -
. O +

However O -
, O +
as O +
shown O +
in O +
Table O +
3 O -
, O +
gene O +
ontology O +
and O +
network O +
analysis O +
of O +
the O +
individual O +
gene O +
clusters O +
( O -
clusters O +
C11-C17 O -
) O +
that O +
were O +
differentially O +
active O +
in O +
subgroups O +
of O +
the O +
tumors O -
, O +
map O +
to O +
genes O +
highly O +
associated O +
with O +
a O +
diverse O +
set O +
of O +
biological O +
functions O -
, O +
including O +
lipid O +
metabolism O -
, O +
digestive O +
tract O +
development O +
and O +
function O -
, O +
immune O +
response O +
and O +
cancer O +

Discussion O +
Numerous O +
mouse O +
models O +
of O +
intestinal O +
neoplasia O +
have O +
been O +
developed O -
, O +
each O +
with O +
unique O +
characteristics O -
. O +

The O +
models O +
constructed O +
to O +
date O -
, O +
however O -
, O +
do O +
not O +
fully O +
represent O +
the O +
complexity O +
of O +
human O +
CRCs O +
principally O +
because O +
most O +
are O +
unigenic O +
in O +
origin O +
and O +
produce O +
primarily O +
adenomas O +
and O +
early O +
stage O +
cancers O -
. O +

Although O +
models O +
like O +
ApcMin B-Gene -
/ O -
+ O +
show O +
molecular O +
similarities O +
to O +
human O +
CRCs O -
, O +
such O +
as O +
initiation O +
of O +
adenoma O +
formation O +
by O +
inactivation O +
of O +
Apc B-Gene -
, O +
little O +
is O +
known O +
about O +
the O +
molecular O +
similarities O +
of O +
tumors O +
from O +
the O +
different O +
mouse O +
models O -
. O +

It O +
is O +
also O +
unknown O +
how O +
such O +
common O +
and O +
perhaps O +
large O -
- O -
scale O +
molecular O +
changes O +
in O +
mouse O +
models O +
relate O +
to O +
the O +
molecular O +
programming O +
of O +
human O +
CRC O -
. O +

To O +
shed O +
light O +
on O +
the O +
underlying O +
molecular O +
changes O +
in O +
tumors O +
from O +
mouse O +
models O +
and O +
human O +
CRC O -
, O +
we O +
assessed O +
the O +
relationship O +
at O +
the O +
molecular O +
level O +
of O +
four O +
widely O +
used O -
, O +
but O +
genetically O +
distinct O -
, O +
mouse O +
models O +
that O +
develop O +
colon O +
tumors O -
. O +

A O +
subsequent O +
analysis O +
of O +
the O +
models O +
in O +
the O +
context O +
of O +
embryonic O +
mouse O +
colon O +
development O +
was O +
also O +
undertaken O -
. O +

Finally O -
, O +
to O +
identify O +
consensus O +
species O -
- O -
independent O +
cancer O +
signatures O +
that O +
may O +
define O +
gene O +
expression O +
changes O +
common O +
to O +
all O +
CRCs O -
, O +
we O +
projected O +
relevant O +
mouse O +
model O +
signatures O +
onto O +
a O +
large O +
set O +
of O +
human O +
primary O +
CRCs O +
of O +
varied O +
histopathology O +
and O +
stage O -
. O +

Differential O +
canonical O +
WNT O +
signaling O +
activity O +
discriminates O +
two O +
major O +
classes O +
of O +
mouse O +
models O +
of O +
CRC O +
with O +
distinct O +
molecular O +
characteristics O +
Tumors O +
from O +
mouse O +
models O +
of O +
CRC O +
exhibit O +
significant O +
phenotypic O +
diversity O +
[ O -
6 O -
] O -
, O +
and O -
, O +
therefore O -
, O +
were O +
expected O +
to O +
exhibit O +
differential O +
gene O +
expression O +
patterns O -
. O +

Using O +
a O +
combination O +
of O +
inter O -
- O -
model O +
and O +
normal O +
adult O +
gene O +
expression O +
level O +
referencing O -
, O +
our O +
analysis O +
of O +
tumors O +
from O +
mouse O +
models O +
of O +
CRC O +
has O +
revealed O +
a O +
low O +
complexity O +
between O +
models O +
and O +
strains O -
, O +
and O +
has O +
identified O +
common O +
and O +
unique O +
transcriptional O +
patterns O +
associated O +
with O +
a O +
variety O +
of O +
biological O +
processes O +
and O +
pathway O -
- O -
associated O +
activities O -
. O +

Our O +
results O +
demonstrate O +
an O +
imbalance O +
between O +
proliferation O +
and O +
differentiation O -
, O +
with O +
nuclear O +
β O -
- O -
catenin O -
- O -
positive O +
tumors O +
being O +
more O +
proliferative O -
, O +
less O +
differentiated O +
and O +
with O +
lower O +
immunogenic O +
characteristics O +
than O +
tumors O +
from O +
nuclear O +
β O -
- O -
catenin O -
- O -
negative O +
tumors O -
. O +

Mouse O +
tumors O +
characterized O +
by O +
signatures O +
of O +
relative O +
up O -
- O -
regulation O +
of O +
genes O +
associated O +
with O +
cell O +
cycle O +
progression O +
also O +
showed O +
increased O +
canonical O +
WNT O +
signaling O +
activity O +
( O -
ApcMin B-Gene -
/ O -
+ O +
and O +
AOM B-Gene -
) O -
. O +

Tumors O +
from O +
mouse O +
models O +
not O +
showing O +
canonical O +
WNT O +
signaling O +
pathway O +
activation O +
( O -
Smad3- B-Gene -
/ O -
- O +
and O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O -
) O +
were O +
characterized O +
by O +
up O -
- O -
regulation O +
of O +
genes O +
associated O +
with O +
inflammatory O +
and O +
innate O +
immunological O +
responses O -
, O +
and O +
intestinal O +
epithelial O +
cell O +
differentiation O -
. O +

Recent O +
studies O +
have O +
indicated O +
that O +
chronic O +
inflammation O +
caused O +
either O +
by O +
infection O +
with O +
Helicobacter O +
pylori O +
[ O -
32 O -
] O +
or O +
Helicobacter O +
hepaticus O +
[ O -
13 O -
] O +
is O +
a O +
prerequisite O +
for O +
intestinal O +
tumor O +
development O +
in O +
Smad3- B-Gene -
/ O -
- O +
and O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O +
mice O -
, O +
respectively O -
. O +

The O +
activation O +
of O +
canonical O +
WNT O +
signaling O +
in O +
AOM B-Gene +
tumors O +
was O +
identified O +
using O +
a O +
between O -
- O -
tumor O +
global O +
median O +
normalization O +
to O +
gene O +
expression O +
data O -
. O +

However O -
, O +
when O +
tumor O +
sample O +
expression O +
was O +
referenced O +
to O +
that O +
of O +
normal O +
adult O +
intestinal O +
tissue O -
, O +
many O +
more O +
genes O +
are O +
up O -
- O -
regulated O -
, O +
including O +
developmental O +
genes O +
that O +
are O +
not O +
dependent O +
on O +
nuclear O +
β O -
- O -
catenin O -
. O +

That O +
canonical O +
WNT O +
signaling O -
- O -
related O +
genes O +
are O +
altered O +
similarly O +
in O +
both O +
AOM B-Gene +
and O +
ApcMin B-Gene -
/ O -
+ O +
tumors O +
suggests O +
biological O +
similarities O +
between O +
the O +
two O +
models O -
. O +

In O +
addition O -
, O +
the O +
relatively O +
consistent O +
programming O +
within O +
the O +
AOM O +
model O +
also O +
emphasizes O +
its O +
value O +
for O +
examining O +
the O +
more O +
complicated O +
genetics O +
that O +
result O +
in O +
strain O -
- O -
specific O +
sensitivity O +
to O +
environmental O +
agents O +
that O +
induce O +
cancer O -
. O +

Activation O +
of O +
canonical O +
WNT O +
signaling O +
leads O +
to O +
nuclear O +
translocation O +
of O +
β O -
- O -
catenin O +
and O -
, O +
through O +
its O +
interaction O +
with O +
LEF B-Gene -
/ O -
TCF B-Gene -
, O +
the O +
regulation O +
of O +
genes O +
relevant O +
to O +
embryonic O +
development O +
and O +
proliferation O +
[ O -
16 O -
] O -
, O +
as O +
well O +
as O +
stem O +
cell O +
self O -
- O -
renewal O +
[ O -
33 O -
] O -
. O +

Consequently O -
, O +
the O +
activated O +
canonical O +
WNT O +
signaling O +
observed O +
in O +
ApcMin B-Gene -
/ O -
+ O +
and O +
AOM B-Gene +
models O +
suggests O +
that O +
tumors O +
may O +
arise O +
as O +
a O +
consequence O +
of O +
proliferation O +
of O +
the O +
stem O +
cell O +
or O +
' O -
transient O +
amplifying O -
' O +
compartment O -
. O +

In O +
the O +
colonic O +
crypt O -
, O +
loss O +
of O +
TCF4 B-Gene +
[ O -
34 O -
] O +
or O +
DKK1 B-Gene +
over O -
- O -
expression O +
[ O -
35 O -
] O +
promotes O +
loss O +
of O +
stem O +
cells O -
, O +
suggesting O +
that O +
canonical O +
WNT O +
signaling O +
is O +
required O +
for O +
the O +
maintenance O +
of O +
the O +
intestinal O +
stem O +
cell O +
compartment O +
[ O -
34 O -
- O -
36 O -
] O -
. O +

Conversely O -
, O +
increased O +
nuclear O +
β O -
- O -
catenin O -
/ O -
TCF4 B-Gene +
activity O +
imposes O +
a O +
crypt O +
progenitor O +
phenotype O +
on O +
tumor O +
cells O +
[ O -
18 O -
] O -
. O +

In O +
this O +
study O -
, O +
we O +
identified O +
transcriptional O +
activation O +
of O +
the O +
canonical O +
WNT O +
signaling O +
pathway O +
in O +
tumors O +
from O +
ApcMin B-Gene -
/ O -
+ O +
and O +
AOM B-Gene +
mice O -
. O +

This O +
was O +
confirmed O +
by O +
immunohistochemistry O +
( O -
Figure O +
2b O -
) O -
. O +

In O +
colon O +
tumors O +
and O +
perhaps O +
intestinal O +
stem O +
cells O -
, O +
activation O +
of O +
canonical O +
WNT O +
signaling O +
promotes O +
a O +
hyperproliferative O +
state O -
. O +

Proliferation O -
- O -
related O +
characteristics O +
of O +
nuclear O +
β O -
- O -
catenin O -
- O -
positive O +
tumors O +
include O +
increased O +
expression O +
of O +
CCND1 B-Gene -
, O +
MYC B-Gene -
, O +
PCNA B-Gene +
[ O -
18 O -
] O -
, O +
and O +
Sox4 B-Gene +
[ O -
16 O -
] O -
. O +

These O +
genes O +
were O +
also O +
identified O +
as O +
a O +
component O +
of O +
our O +
nuclear O -
- O -
β O -
- O -
catenin O -
- O -
positive O +
signatures O -
. O +

In O +
turn O -
, O +
increased O +
MYC B-Gene +
decreases O +
intestinal O +
cell O +
differentiation O +
by O +
binding O +
to O +
and O +
repressing O +
the O +
Cdkn1a B-Gene +
( O -
coding O +
for O +
p21CIP1 B-Gene -
/ O -
WAF1 B-Gene -
) O +
promoter O +
[ O -
37 O -
] O -
, O +
the O +
gene O +
encoding O +
Wnt B-Gene -
- O -
inhibitory O +
factor O +
Wif1 B-Gene -
, O +
the O +
gene O +
encoding O +
the O +
negative O +
regulator O +
of O +
WNT O +
Naked1 B-Gene +
[ O -
38 O -
] O -
, O +
and O +
the O +
gene O +
encoding O +
the O +
Tak1 O -
/ O -
Nemo O -
- O -
like O +
kinase O -
, O +
Nlk B-Gene +
[ O -
39 O -
] O -
. O +

Wif1 B-Gene +
displays O +
a O +
graded O +
expression O +
in O +
colonic O +
tissue O -
, O +
with O +
higher O +
expression O +
in O +
the O +
stem O +
cell O +
compartments O +
and O +
lower O +
expression O +
in O +
the O +
more O +
differentiated O +
cells O +
at O +
the O +
luminal O +
surface O -
, O +
suggesting O +
that O +
Wif1 B-Gene +
may O +
contribute O +
to O +
stem O +
cell O +
pool O +
maintenance O +
independent O +
of O +
WNT O +
signaling O +
inhibition O -
. O +

[ O -
40 O -
] O -
. O +

Canonical O +
WNT O +
signaling O +
not O +
only O +
governs O +
intestinal O +
cell O +
proliferation O -
, O +
but O +
also O +
cell O +
differentiation O +
and O +
cell O +
positioning O +
along O +
the O +
crypt O -
- O -
lumen O +
axis O +
of O +
epithelial O +
differentiation O -
. O +

Increased O +
canonical O +
WNT O +
signaling O +
activity O +
enhances O +
MATH1-mediated B-Gene +
amplification O +
of O +
the O +
gut O +
secretory O +
lineages O +
[ O -
41 O -
] O -
. O +

Canonical O +
WNT O +
signaling O +
also O +
influences O +
cell O +
positioning O +
by O +
regulating O +
the O +
gradient O +
of O +
EPHB2 B-Gene -
/ I-Gene -
EPHB3 B-Gene +
and O +
EPHB1 B-Gene +
ligand O +
expression O +
[ O -
42,43 O -
] O -
. O +

Together O -
, O +
our O +
data O +
suggest O +
a O +
complex O +
imbalance O +
of O +
crypt O +
homeostasis O +
due O +
to O +
enhanced O +
canonical O +
WNT O +
activity O -
. O +

Our O +
results O +
indicate O +
that O +
tumors O +
arising O +
in O +
response O +
to O +
abnormal O +
TGFβ1 B-Gene -
/ O -
SMAD B-Gene +
signaling O +
[ O -
14,44 O -
] O +
are O +
similar O +
to O +
one O +
another O +
in O +
their O +
specific O +
gene O +
signatures O +
and O +
broadly O +
distinct O +
from O +
those O +
with O +
activated O +
canonical O +
WNT O +
signaling O +
by O +
their O +
absence O +
of O +
nuclear O +
β O -
- O -
catenin O -
. O +

Unique O +
to O +
the O +
dysregulated O +
TGFβ1 B-Gene -
/ O -
SMAD4 B-Gene +
signaling O +
models O +
is O +
the O +
strong O +
signature O +
of O +
an O +
immunologically O +
altered O +
state O -
, O +
with O +
up O -
- O -
regulation O +
of O +
genes O +
determining O +
immune O +
and O +
defense O +
responses O -
, O +
such O +
as O +
Il18 B-Gene -
, O +
Irf1 B-Gene +
and O +
mucin O +
pathway O -
- O -
associated O +
genes O -
. O +

Again O -
, O +
these O +
tumors O +
are O +
usually O +
characterized O +
by O +
a O +
strong O +
inflammatory O +
component O +
when O +
evaluated O +
histopathologically O -
, O +
even O +
in O +
the O +
absence O +
of O +
T- O +
and O +
B O -
- O -
cells O +
such O +
as O +
in O +
the O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O +
background O -
. O +

This O +
report O +
constitutes O +
a O +
comprehensive O +
molecular O +
evaluation O +
and O +
comparison O +
of O +
mouse O +
and O +
human O +
colon O +
tumor O +
gene O +
expression O +
profiles O -
. O +

We O +
have O +
greatly O +
improved O +
our O +
ability O +
to O +
compare O +
tumor O +
gene O +
expression O +
profiles O +
between O +
mouse O +
and O +
human O +
tumors O +
by O +
using O +
a O +
referencing O +
strategy O +
in O +
which O +
gene O +
expression O +
levels O +
in O +
the O +
tumor O +
samples O +
are O +
analyzed O +
in O +
relation O +
to O +
gene O +
expression O +
in O +
corresponding O +
normal O +
colon O +
epithelium O -
. O +

This O +
approach O +
has O +
revealed O +
that O +
gene O +
expression O +
patterns O +
are O +
both O +
shared O +
and O +
distinct O +
between O +
mouse O +
models O +
and O +
human O +
CRCs O -
. O +

Although O +
several O +
recent O +
studies O +
have O +
suggested O +
that O +
tumors O +
recapitulate O +
embryonic O +
gene O +
expression O +
[ O -
16,27,54,55 O -
] O -
, O +
the O +
present O +
study O +
demonstrates O +
the O +
magnitude O +
of O +
this O +
similarity O -
. O +

Finally O -
, O +
our O +
results O +
suggest O +
that O +
comparisons O +
made O +
between O +
mouse O +
tumor O +
models O -
, O +
developing O +
embryonic O +
tissues O -
, O +
and O +
human O +
CRCs O +
provides O +
a O +
powerful O +
biological O +
framework O +
from O +
which O +
to O +
observe O +
shared O +
and O +
unique O +
genetic O +
programs O +
associated O +
with O +
human O +
cancer O -
. O +

While O +
ortholog O -
- O -
gene O +
based O +
analyses O +
have O +
been O +
used O +
previously O +
to O +
obtain O +
direct O +
comparison O +
of O +
the O +
molecular O +
features O +
of O +
mouse O +
and O +
human O +
hepatocellular O +
carcinomas O +
[ O -
56 O -
] O -
, O +
our O +
results O +
provide O +
striking O +
support O +
for O +
the O +
hypothesis O +
that O +
cancer O +
represents O +
a O +
subversion O +
of O +
normal O +
embryonic O +
development O -
. O +

By O +
inclusion O +
of O +
detailed O +
mouse O +
embryonic O +
and O +
developmental O +
profile O +
information O -
, O +
our O +
results O +
have O +
revealed O +
critical O +
similarities O +
and O +
differences O +
between O +
the O +
mouse O +
and O +
human O +
tumors O +
that O +
are O +
particularly O +
revealing O +
of O +
oncogenic O +
and O +
tumor O +
suppressor O +
programs O -
, O +
some O +
genes O +
from O +
which O +
should O +
be O +
useful O +
for O +
development O +
of O +
diagnostic O +
biomarkers O +
and O +
identification O +
of O +
therapeutic O +
targets O +
and O +
pathways O -
. O +

Materials O +
and O +
methods O +
Mouse O +
models O -
, O +
human O +
CRC O +
patients O +
and O +
tumor O +
collection O +
Mouse O +
tumors O +
All O +
tumors O +
were O +
isolated O +
as O +
spontaneously O +
occurring O +
lesions O +
in O +
ApcMin B-Gene -
/ O -
+ O +
[ O -
57 O -
] O -
, O +
Smad3- B-Gene -
/ O -
- O +
[ O -
58 O -
] O -
, O +
and O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O -
, O +
collected O +
at O +
three O -
- O -
to O -
- O -
nine O +
months O +
of O +
age O +
depending O +
on O +
the O +
model O +
( O -
for O +
a O +
review O -
, O +
see O +
[ O -
6 O -
] O -
) O -
. O +

The O +
only O +
exceptions O +
were O +
two O +
ApcMin B-Gene -
/ O -
+ O +
tumors O -
, O +
UW_3_2778 O +
and O +
UW_6_2748 O -
, O +
that O +
were O +
13 O +
and O +
14 O +
months O +
and O +
the O +
three O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O +
tumors O -
, O +
all O +
five O +
of O +
which O +
had O +
histological O +
features O +
of O +
locally O +
invasive O +
carcinoma O +
[ O -
7 O -
] O -
. O +

Three- O +
to O +
four O -
- O -
month O +
old O +
mice O +
from O +
various O +
AXB O +
recombinant O +
inbred O +
lines O +
were O +
treated O +
with O +
AOM O +
doses O +
chosen O +
for O +
enhancement O +
of O +
inter O -
- O -
strain O +
differences O +
in O +
susceptibility O +
[ O -
11 O -
] O -
. O +

Mice O +
were O +
given O +
four O +
weekly O +
i.p O -
. O +

injections O +
of O +
10 O +
mg O +
AOM O +
per O +
kg O +
body O +
weight O -
, O +
and O +
tumors O +
were O +
collected O +
six O +
months O +
after O +
the O +
first O +
injection O -
. O +

Animals O +
were O +
euthanized O +
with O +
CO2 O -
, O +
colons O +
removed O -
, O +
flushed O +
with O +
1 O -
× O +
phosphate O -
- O -
buffered O +
saline O +
( O -
PBS O -
) O -
, O +
and O +
laid O +
out O +
on O +
Whatman O +
3 O +
MM O +
paper O -
. O +

A O +
summary O +
of O +
the O +
mouse O +
strains O -
, O +
mutant O +
alleles O +
and O +
source O +
laboratories O +
is O +
presented O +
in O +
Table O +
5 O -
. O +

All O +
tumors O +
were O +
obtained O +
from O +
the O +
colon O +
only O -
, O +
the O +
particular O +
segment O +
of O +
which O +
is O +
indicated O +
in O +
the O +
Gene O +
Expression O +
Omnibus O +
( O -
GEO O -
) O +
database O +
[ O -
59 O -
] O +
reposited O +
sample O +
information O +
( O -
GSE5261 O -
) O -
. O +

The O +
majority O +
of O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O +
and O +
Smad3- B-Gene -
/ O -
- O +
tumors O +
occur O +
in O +
the O +
cecum O +
and O +
proximal O +
colon O +
and O +
all O +
samples O +
isolated O +
for O +
characterization O +
were O +
obtained O +
from O +
there O -
. O +

In O +
contrast O -
, O +
tumors O +
isolated O +
from O +
ApcMin B-Gene -
/ O -
+ O +
and O +
AOM B-Gene +
mice O +
occurred O +
predominantly O +
in O +
the O +
mid- O +
and O +
distal O +
colon O -
. O +

A O +
small O +
portion O +
of O +
the O +
tumor O +
was O +
placed O +
in O +
formalin O +
for O +
histology O -
, O +
with O +
the O +
remainder O +
finely O +
dissected O +
into O +
RNAlater O +
( O -
Ambion O +
Inc. O -
, O +
Austin O -
, O +
TX O -
, O +
USA O -
) O +
and O +
stored O +
at O +
-20 O -
° O -
C O -
. O +

Normal O +
adult O +
colon O +
RNA O +
for O +
reference O +
was O +
obtained O +
from O +
whole O +
colon O +
samples O +
harvested O +
from O +
ten O +
eight O -
- O -
week O -
- O -
old O +
C57BL O -
/ O -
6 O +
male O +
mice O -
. O +

The O +
tissue O +
was O +
lysed O +
in O +
Trizol O +
Reagent O +
( O -
Invitrogen O +
Systems O +
Inc. O -
, O +
Carlsbad O -
, O +
CA O -
, O +
USA O -
) O +
and O +
homogenized O -
. O +

Total O +
RNA O +
was O +
purified O +
using O +
a O +
Qiagen O +
kit O +
( O -
USA O -
- O -
Qiagen O +
Inc. O -
, O +
Valencia O -
, O +
CA O -
, O +
USA O -
) O -
. O +

Mouse O +
models O +
of O +
colon O +
cancer O +
Tumors O +
from O +
four O +
established O +
mouse O +
models O +
of O +
CRC O +
( O -
ApcMin B-Gene -
/ O -
+ O -
, O +
AOM B-Gene -
, O +
Smad3- B-Gene -
/ O -
- O +
and O +
Tgfb1- B-Gene -
/ O -
- O -
; O +
Rag2- B-Gene -
/ O -
- O +
were O +
analyzed O -
. O +

The O +
table O +
provides O +
details O +
on O +
the O +
mouse O +
strains O +
used O +
for O +
the O +
four O +
models O -
, O +
as O +
well O +
as O +
information O +
on O +
the O +
number O +
of O +
samples O +
generated O +
per O +
model O +
and O +
sample O -
- O -
originating O +
laboratory O -
. O +

Human O +
samples O -
: O +
collection O -
/ O -
biopsies O -
, O +
regulatory O +
aspects O -
, O +
compliance O +
and O +
informed O +
consents O +
Sample O +
collection O +
protocol O +
and O +
analyses O +
at O +
the O +
H O +
Lee O +
Moffitt O +
Cancer O +
Center O +
and O +
Research O +
Institute O +
have O +
been O +
described O +
previously O +
[ O -
37 O -
] O -
. O +

Information O +
collected O +
with O +
the O +
samples O +
for O +
this O +
study O +
includes O +
solid O +
tumor O +
staging O +
criteria O +
for O +
tumor O -
, O +
nodes O -
, O +
and O +
metastases O +
( O -
TNM O -
) O -
, O +
Dukes O +
staging O -
/ O -
presentation O +
criteria O -
, O +
pathological O +
diagnosis O -
, O +
and O +
differentiation O +
criteria O -
. O +

RNA O +
isolation O +
All O +
RNA O +
samples O +
were O +
purified O +
using O +
Trizol O +
Reagent O +
from O +
finely O +
dissected O +
tumors O +
and O +
were O +
subjected O +
to O +
quality O +
control O +
screening O +
using O +
the O +
Agilent O +
BioAnalyzer O +
2100 O +
( O -
Agilent O +
Technologies O -
, O +
Santa O +
Clara O -
, O +
CA O -
, O +
USA O -
) O -
. O +

Microarray O +
procedures O +
and O +
data O +
analysis O +
Mouse O +
cDNA O +
arrays O +
Mouse O +
tumors O +
were O +
analyzed O +
on O +
Vanderbilt O +
University O +
Microarray O +
Core O +
( O -
VUMC O -
) O -
-printed O +
20 O +
K O +
mouse O +
cDNA O +
arrays O -
, O +
composed O +
principally O +
of O +
PCR O +
products O +
derived O +
from O +
three O +
sources O -
: O +
the O +
15 O +
K O +
National O +
Institute O +
of O +
Aging O +
mouse O +
cDNA O +
library O -
; O +
the O +
Research O +
Genetics O +
mouse O +
5 O +
K O +
set O -
; O +
and O +
an O +
additional O +
set O +
of O +
cDNAs O +
mapped O +
to O +
RefSeq O +
transcripts O -
. O +

Labeling O -
, O +
hybridization O -
, O +
scanning O -
, O +
and O +
quantitative O +
evaluation O +
of O +
these O +
two O -
- O -
color O +
channel O +
arrays O +
were O +
performed O +
according O +
to O +
VUMC O +
protocols O +
[ O -
60 O -
] O +
using O +
a O +
whole O +
mouse O +
Universal O +
Reference O +
standard O +
( O -
E17.5 O +
whole O +
fetal O +
mouse O +
RNA O -
) O -
. O +

Arrays O +
were O +
analyzed O +
by O +
GenePix O +
version O +
3.0 O +
( O -
MDS O +
Inc. O -
, O +
Sunnyvale O -
, O +
CA O -
, O +
USA O -
) O -
, O +
flagged O +
and O +
filtered O +
for O +
unreliable O +
measurements O -
, O +
with O +
dye O +
channel O +
ratios O +
corrected O +
using O +
Lowess O +
and O +
dye O -
- O -
specific O +
correction O +
normalization O +
as O +
previously O +
described O +
[ O -
15 O -
] O -
. O +

Human O +
Affymetrix O +
oligonucleotide O +
arrays O +
Human O +
RNA O +
samples O +
were O +
labeled O +
for O +
hybridization O +
to O +
Affymetrix O +
HG O -
- O -
U133plus2 O +
microarrays O +
using O +
the O +
Affymetrix O -
- O -
recommended O +
standard O +
labeling O +
protocol O +
( O -
Small O -
- O -
scale O +
labeling O +
protocol O +
version O +
2.0 O +
with O +
0.5 O +
μg O +
of O +
total O +
RNA O -
; O +
Affymetrix O +
Technical O +
Bulletin O -
) O -
. O +

Microarrays O +
were O +
scanned O +
with O +
MicroarraySuite O +
version O +
5.0 O +
to O +
generate O +
' O -
CEL O -
' O +
files O +
that O +
were O +
processed O +
using O +
the O +
RMA O +
algorithm O +
as O +
implemented O +
by O +
Bioconductor O +
[ O -
15 O -
] O -
. O +

Analysis O +
strategy O +
The O +
four O +
different O +
mouse O +
models O +
of O +
CRC O +
were O +
compared O +
for O +
model O -
- O -
specific O +
differences O -
, O +
then O +
compared O +
to O +
mouse O +
colon O +
development O +
stages O -
, O +
and O +
then O +
to O +
human O +
CRC O +
samples O +
( O -
Figure O +
1 O -
) O -
. O +

The O +
mouse O +
tumor O +
sample O +
array O +
data O +
are O +
composed O +
of O +
Lowess O -
- O -
normalized O +
Cy3 O -
: O -
Cy5 O +
labeling O +
ratios O +
of O +
each O +
individual O +
tumor O +
sample O +
versus O +
a O +
universal O +
E17.5 O +
whole O +
fetal O +
mouse O +
reference O +
RNA O +
( O -
described O +
using O +
MIAME O +
guidelines O +
in O +
the O +
NCBI O +
GEO O +
database O +
under O +
series O +
accession O +
number O +
GSE5261 O -
) O -
. O +

The O +
first O +
approach O +
to O +
referencing O +
was O +
to O +
compare O +
normalized O +
ratios O +
across O +
the O +
tumor O +
series O -
. O +

To O +
do O +
this O -
, O +
for O +
each O +
gene O -
, O +
the O +
Lowess O -
- O -
corrected O +
ratio O +
for O +
each O +
probe O +
element O +
( O -
sample O +
versus O +
E17.5 O +
whole O +
fetal O +
mouse O +
reference O -
) O +
was O +
divided O +
by O +
the O +
median O +
ratio O +
for O +
that O +
probe O +
across O +
the O +
entire O +
tumor O +
sample O +
series O -
. O +

This O +
is O +
termed O +
the O +
median O -
- O -
per O -
- O -
tumor O +
expression O +
ratio O +
and O +
was O +
useful O +
for O +
identifying O -
, O +
clustering O +
and O +
visualizing O +
differences O +
that O +
occur O +
between O +
the O +
different O +
tumor O +
samples O -
. O +

Since O +
we O +
previously O +
collected O +
mouse O +
expression O +
data O +
for O +
normal O +
E13.5-E18.5 O +
colon O +
samples O +
from O +
inbred O +
C57BL O -
/ O -
6J O +
and O +
outbred O +
CD-1 O +
mice O +
[ O -
15 O -
] O +
using O +
the O +
identical O +
E17.5 O +
whole O +
fetal O +
mouse O +
reference O -
, O +
this O +
allowed O +
us O +
to O +
combine O +
the O +
data O +
directly O -
. O +

Differential O +
expression O +
profiles O +
in O +
the O +
tumors O +
were O +
combined O +
with O +
relative O +
developmental O +
gene O +
expression O +
levels O +
by O +
direct O +
comparisons O +
of O +
ratios O +
determined O +
within O +
each O +
experimental O +
series O -
. O +

Initial O +
comparisons O +
were O +
made O +
between O +
median O +
normalized O +
tumor O +
data O +
to O +
gene O +
expression O +
levels O +
observed O +
in O +
the O +
E13.5-E18.5 O +
and O +
adult O +
( O -
eight O +
week O +
post O -
- O -
natal O -
) O +
colon O +
samples O -
, O +
which O +
were O +
referenced O +
to O +
either O +
E13.5 O +
samples O +
or O +
to O +
the O +
adult O +
colon O -
. O +

The O +
latter O +
approach O +
subsequently O +
allowed O +
for O +
the O +
broadest O +
comparison O +
of O +
mouse O +
and O +
human O +
data O +
using O +
gene O +
ortholog O +
mapping O -
. O +

Correlated O +
phenomena O +
could O +
be O +
observed O +
from O +
any O +
of O +
the O +
different O +
referencing O +
strategies O -
. O +

qRT O -
- O -
PCR O +
To O +
confirm O +
the O +
validity O +
of O +
data O +
normalization O +
and O +
referencing O +
procedures O +
as O +
well O +
as O +
the O +
cDNA O +
gene O +
assignments O +
of O +
the O +
printed O +
arrays O +
used O +
in O +
the O +
microarray O +
analyses O -
, O +
we O +
used O +
qRT O -
- O -
PCR O +
to O +
measure O +
relative O +
levels O +
of O +
nine O +
genes O +
found O +
by O +
microarray O +
data O +
analysis O +
to O +
be O +
differentially O +
expressed O +
( O -
FDR O +
< O +
5.10 O -
- O -
5 O -
) O +
in O +
tumors O +
from O +
ApcMin B-Gene -
/ O -
+ O +
and O +
Smad3- B-Gene -
/ O -
- O +
mice O -
. O +

Total O +
RNAs O +
from O +
C57BL6 O +
ApcMin B-Gene -
/ O -
+ O +
and O +
129 O +
Smad3- B-Gene -
/ O -
- O +
tumor O +
samples O +
( O -
20 O +
μg O -
) O +
were O +
reverse O -
- O -
transcribed O +
to O +
cDNA O +
using O +
the O +
High O +
Capacity O +
cDNA O +
Archive O +
Kit O +
( O -
oligo O -
- O -
dT O +
primed O -
; O +
Applied O +
Biosystems O -
, O +
Foster O +
City O -
, O +
CA O -
, O +
USA O -
) O -
. O +

qRT O -
- O -
PCR O +
reactions O +
( O -
20 O +
μl O -
) O +
were O +
set O +
up O +
in O +
96-well O +
MicroAmp O +
Reaction O +
Plates O +
( O -
Applied O +
Biosystems O -
) O +
using O +
10 O +
ng O +
of O +
cDNA O +
template O +
in O +
Taqman O +
Universal O +
PCR O +
Master O +
Mix O +
and O +
6-FAM O -
- O -
labeled O +
Assays O -
- O -
on O -
- O -
Demand O +
primer O -
- O -
probe O +
sets O +
( O -
Applied O +
Biosystems O -
) O -
. O +

Reactions O +
were O +
run O +
on O +
an O +
MX3000P O +
( O -
Stratagene O -
, O +
a O +
division O +
of O +
Agilent O +
Technologies O -
) O +
with O +
integrated O +
analysis O +
software O -
. O +

Threshold O +
cycle O +
numbers O +
( O -
Ct O -
) O +
were O +
determined O +
for O +
each O +
target O +
gene O +
using O +
an O +
algorithm O +
that O +
assigns O +
a O +
fluorescence O +
baseline O +
based O +
on O +
measurements O +
prior O +
to O +
exponential O +
amplification O -
. O +

Relative O +
gene O +
expression O +
levels O +
were O +
calculated O +
using O +
the O +
ΔΔCt O +
method O +
[ O -
75 O -
] O -
, O +
with O +
the O +
Gusb O +
gene O +
as O +
a O +
control O -
. O +

Fold O -
- O -
change O +
was O +
determined O +
relative O +
to O +
expression O +
in O +
normal O +
adult O +
colon O +
from O +
two O +
C57BL O -
/ O -
6J O +
mice O -
. O +

Immunohistochemistry O +
Immunohistochemical O +
procedures O +
were O +
performed O +
as O +
described O +
[ O -
15 O -
] O -
. O +

ApcMin B-Gene -
/ O -
+ O +
and O +
Smad3- B-Gene -
/ O -
- O +
colon O +
tumors O +
were O +
rapidly O +
dissected O -
, O +
fixed O +
in O +
4 O -
% O +
paraformaldehyde O -
, O +
and O +
embedded O +
in O +
paraffin O +
before O +
cutting O +
10 O +
μm O +
thick O +
sections O -
. O +

Antigen O +
retrieval O +
was O +
performed O +
by O +
boiling O +
for O +
20 O +
minutes O +
in O +
citrate O +
buffer O -
, O +
pH O +
6.0 O -
. O +

Sections O +
were O +
treated O +
with O +
0.3 O -
% O +
hydrogen O +
peroxide O +
in O +
PBS O +
for O +
30 O +
minutes O -
, O +
washed O +
in O +
PBS O -
, O +
blocked O +
in O +
PBS O +
plus O +
3 O -
% O +
goat O +
serum O +
and O +
0.1 O -
% O +
Triton O +
X-100 O -
, O +
and O +
then O +
incubated O +
with O +
primary O +
antibodies O +
and O +
HRP O -
- O -
conjugated O +
goat O +
anti O -
- O -
rabbit O +
secondary O +
antibody O +
( O -
Sigma O -
, O +
St O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O +

Antigen O -
- O -
antibody O +
complexes O +
were O +
detected O +
with O +
a O +
DAB O +
peroxidase O +
substrate O +
kit O +
( O -
Vector O +
Laboratories O -
, O +
Burlingame O -
, O +
CA O -
, O +
USA O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
protocol O -
. O +

Digital O +
MS O -
- O -
HRM O +
was O +
developed O +
to O +
confirm O +
the O +
results O +
of O +
the O +
BRCA1 B-Gene +
MethyLight O +
and O +
MS O -
- O -
HRM O +
assays O -
. O +

Serial O +
10-fold O +
dilutions O +
of O +
bisulfite O +
modified O +
DNA O +
from O +
the O +
methylation O +
positive O +
samples O +
were O +
made O +
and O +
replicates O +
of O +
each O +
dilution O +
were O +
amplified O +
by O +
MS O -
- O -
HRM O -
. O +

The O +
dilution O +
at O +
which O +
amplification O +
of O +
some O +
replicates O +
dropped O +
out O +
was O +
then O +
chosen O +
for O +
further O +
analysis O -
. O +

Multiple O +
replicate O +
amplifications O +
for O +
the O +
selected O +
dilution O +
were O +
performed O +
and O +
compared O +
to O +
0 O -
% O +
and O +
100 O -
% O +
methylated O +
control O +
DNA O -
. O +

Reactions O +
or O +
' O -
clones O -
' O +
resembling O +
fully O +
methylated O +
and O +
unmethylated O +
DNA O +
were O +
then O +
used O +
in O +
a O +
second O +
round O +
amplification O +
with O +
M13 O +
tagged O +
primers O -
. O +

The O +
products O +
were O +
then O +
sequenced O +
using O +
M13 O +
primers O +
using O +
the O +
BigDye O +
terminator O +
kit O +
( O -
Applied O +
Biosystems O -
, O +
Foster O +
City O -
, O +
CA O -
, O +
USA O -
) O -
. O +

Results O +
We O +
examined O +
the O +
peripheral O +
blood O +
leukocyte O +
DNA O +
of O +
seven O +
breast O +
cancer O +
cases O +
( O -
KCF1 O +
to O +
KCF7 O -
) O +
( O -
ages O +
of O +
onset O +
ranging O +
from O +
35 O +
to O +
51 O +
years O -
) O +
for O +
BRCA1 B-Gene +
methylation O -
. O +

Each O +
of O +
these O +
cases O -
, O +
from O +
the O +
kConFab O +
familial O +
cancer O +
repository O -
, O +
had O +
a O +
family O +
history O +
of O +
breast O +
or O +
ovarian O +
cancer O +
with O +
BRCA1-like B-Gene +
breast O +
pathology O +
as O +
defined O +
by O +
kConFab O +
criteria O -
, O +
but O +
were O +
negative O +
for O +
mutations O +
in O +
the O +
coding O +
regions O +
of O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene -
. O +

We O +
used O +
both O +
real O -
- O -
time O +
methylation O +
specific O +
PCR O +
( O -
MethyLight O -
) O +
[ O -
19 O -
] O +
and O +
methylation O -
- O -
sensitive O +
high O +
resolution O +
melting O +
( O -
MS O -
- O -
HRM O -
) O +
[ O -
20 O -
] O +
to O +
assess O +
methylation O +
levels O -
. O +

The O +
primers O +
for O +
each O +
assay O +
spanned O +
the O +
proximal O +
BRCA1 B-Gene +
promoter O +
region O +
and O +
were O +
carefully O +
designed O +
so O +
that O +
the O +
methylation O +
status O +
of O +
the O +
highly O +
homologous O +
pseudo O +
BRCA1 B-Gene +
region O +
[ O -
22 O -
] O +
was O +
not O +
assessed O +
( O -
Figure O +
1 O -
) O -
. O +

Three O +
of O +
the O +
individuals O +
showed O +
detectable O +
BRCA1 B-Gene +
methylation O +
in O +
DNA O +
from O +
their O +
peripheral O +
blood O +
leukocytes O -
, O +
but O +
unexpectedly O +
all O +
showed O +
less O +
than O +
the O +
50 O -
% O +
methylation O +
that O +
would O +
be O +
expected O +
for O +
methylation O +
at O +
one O +
allele O +
in O +
every O +
cell O -
. O +

KCF3 O +
was O +
the O +
sample O +
showing O +
the O +
highest O +
level O +
of O +
methylation O +
of O +
BRCA1 B-Gene -
. O +

BRCA1 B-Gene +
methylation O +
was O +
detected O +
in O +
the O +
peripheral O +
blood O +
DNA O +
at O +
approximately O +
14 O -
% O +
methylated O +
alleles O +
estimated O +
by O +
MethyLight O -
, O +
and O +
10 O -
% O +
methylated O +
alleles O +
estimated O +
by O +
MS O -
- O -
HRM O +
( O -
Figure O +
2 O -
) O -
. O +

Buccal O +
mucosal O +
DNA O +
from O +
this O +
patient O +
showed O +
approximately O +
10 O -
% O +
methylated O +
alleles O +
estimated O +
by O +
MethyLight O +
and O +
5 O -
% O +
methylated O +
alleles O +
estimated O +
by O +
MS O -
- O -
HRM O -
. O +

Thus O -
, O +
both O +
methods O +
gave O +
a O +
similar O +
estimate O +
of O +
methylation O -
. O +

Methylation O +
analysis O +
of O +
BRCA1 B-Gene +
in O +
KCF3 O -
. O +

( O -
a O -
) O +
MethyLight O +
results O +
for O +
BRCA1 B-Gene +
and O +
control O +
gene O +
HMBS B-Gene +
for O +
samples O +
from O +
KCF3 O -
. O +

The O +
BRCA1 B-Gene +
MethyLight O +
assay O +
indicates O +
the O +
presence O +
of O +
methylated O +
DNA O +
for O +
the O +
peripheral O +
blood O +
leukocyte O +
( O -
PBL O -
) O -
, O +
buccal O +
mucosa O +
( O -
BUC O -
) O +
and O +
tumour O +
( O -
TUM O -
) O +
of O +
KCF3 O -
. O +

The O +
HMBS B-Gene +
control O +
gene O +
indicates O +
the O +
amount O +
of O +
bisulfite O +
modified O +
DNA O +
for O +
each O +
sample O +
of O +
KCF3 O -
. O +

( O -
b O -
) O +
Methylation O -
- O -
sensitive O +
high O +
resolution O +
melting O +
( O -
MS O -
- O -
HRM O -
) O +
results O +
for O +
samples O +
from O +
KCF3 O -
. O +

The O +
PBL O +
sample O +
( O -
pink O +
curve O -
) O +
and O +
the O +
BUC O +
sample O +
( O -
green O +
curve O -
) O +
show O +
methylation O +
levels O +
close O +
to O +
the O +
10 O -
% O +
methylated O +
control O -
. O +

The O +
TUM O +
sample O +
( O -
orange O +
curve O -
) O +
shows O +
a O +
much O +
higher O +
level O +
of O +
methylation O -
. O +

To O +
verify O +
that O +
the O +
deviation O +
from O +
the O +
expected O +
50 O -
% O +
methylation O +
was O +
not O +
due O +
to O +
PCR O +
bias O +
or O +
other O +
artefacts O -
, O +
we O +
developed O +
a O +
third O +
methodology O +
specifically O +
to O +
accurately O +
quantify O +
the O +
levels O +
of O +
methylation O -
. O +

Digital O +
MS O -
- O -
HRM O +
is O +
an O +
adaptation O +
of O +
MS O -
- O -
HRM O +
that O +
enables O +
rapid O +
counting O +
of O +
methylated O +
and O +
unmethylated O +
alleles O -
. O +

The O +
digital O +
approach O +
to O +
quantification O +
has O +
been O +
described O +
previously O +
[ O -
23 O -
] O -
. O +

However O -
, O +
previous O +
methods O +
have O +
relied O +
on O +
subsequent O +
secondary O +
analysis O +
whereas O +
HRM O +
uses O +
in O -
- O -
tube O +
analysis O +
with O +
a O +
consequent O +
rapid O +
generation O +
of O +
results O -
. O +

Patient O +
KCF3 O +
developed O +
two O +
breast O +
cancers O +
in O +
her O +
lifetime O -
, O +
the O +
first O +
at O +
43 O +
years O +
and O +
the O +
second O +
at O +
51 O +
years O -
. O +

DNA O +
from O +
the O +
first O +
tumour O +
was O +
available O +
for O +
analysis O +
and O +
both O +
MethyLight O +
and O +
MS O -
- O -
HRM O +
assays O +
indicated O +
that O +
BRCA1 B-Gene +
methylation O +
was O +
present O -
. O +

Analysis O +
using O +
digital O +
MS O -
- O -
HRM O +
estimated O +
the O +
tumour O +
methylation O +
at O +
61 O -
% O +
( O -
14 O -
/ O -
23 O +
clones O -
) O -
. O +

We O +
examined O +
the O +
peripheral O +
blood O +
and O +
tumour O +
DNA O +
of O +
KCF3 O +
for O +
methylation O +
at O +
other O +
loci O +
that O +
are O +
commonly O +
methylated O +
in O +
breast O +
cancer O +
to O +
assess O +
whether O +
the O +
observed O +
BRCA1 B-Gene +
methylation O +
was O +
due O +
to O +
a O +
propensity O +
to O +
methylate O +
at O +
a O +
global O +
level O -
. O +

The O +
samples O +
were O +
screened O +
with O +
MethyLight O -
. O +

None O +
of O +
RASSF1A B-Gene -
, O +
RARB B-Gene -
, O +
GSTP1 B-Gene -
, O +
TWIST B-Gene -
, O +
CDH1 B-Gene -
, O +
HIC1 B-Gene +
and O +
HIN1 B-Gene +
proved O +
to O +
be O +
methylated O +
( O -
results O +
not O +
shown O -
) O +
indicating O +
that O +
the O +
methylation O +
in O +
this O +
patient O +
seen O +
is O +
not O +
part O +
of O +
an O +
overall O +
increased O +
methylation O +
of O +
CpG O +
islands O -
. O +

In O +
two O +
of O +
the O +
remaining O +
cases O -
, O +
KCF1 O +
and O +
KCF4 O -
, O +
methylation O +
of O +
BRCA1 B-Gene +
was O +
detected O +
at O +
approximately O +
1 O -
% O +
in O +
the O +
peripheral O +
blood O +
DNA O +
using O +
MethyLight O +
and O +
MS O -
- O -
HRM O +
( O -
Figure O +
4 O -
) O -
. O +

Digital O +
MS O -
- O -
HRM O +
was O +
used O +
to O +
confirm O +
the O +
observed O +
methylation O +
in O +
these O +
samples O +
and O +
1 O +
of O +
33 O +
clones O +
for O +
KCF1 O +
and O +
1 O +
of O +
44 O +
for O +
KCF4 O +
showed O +
a O +
fully O +
methylated O +
peak O -
. O +

Analysis O +
of O +
tumour O +
material O +
from O +
both O +
of O +
these O +
individuals O +
demonstrated O +
close O +
to O +
100 O -
% O +
methylation O +
using O +
MethyLight O +
and O +
MS O -
- O -
HRM O -
. O +

Methylation O +
analysis O +
of O +
BRCA1 B-Gene +
in O +
KCF1 O +
and O +
KCF4 O -
. O +

( O -
a O -
) O +
MethyLight O +
results O +
for O +
BRCA1 B-Gene +
and O +
the O +
control O +
gene O +
HMBS B-Gene +
for O +
samples O +
from O +
KCF1 O +
and O +
KCF4 O -
. O +

The O +
BRCA1 B-Gene +
MethyLight O +
assay O +
indicates O +
the O +
presence O +
of O +
methylated O +
DNA O +
for O +
the O +
peripheral O +
blood O +
( O -
PBL O -
) O +
and O +
tumour O +
( O -
TUM O -
) O +
for O +
both O +
individuals O -
. O +

( O -
b O -
) O +
The O +
methylation O -
- O -
sensitive O +
high O +
resolution O +
melting O +
( O -
MS O -
- O -
HRM O -
) O +
assay O +
also O +
shows O +
the O +
presence O +
of O +
methylation O +
in O +
the O +
peripheral O +
blood O +
and O +
tumour O +
for O +
both O +
individuals O -
. O +

Tumour O +
material O +
was O +
available O +
from O +
two O +
of O +
the O +
four O +
patients O +
that O +
did O +
not O +
have O +
any O +
detectable O +
levels O +
of O +
methylation O +
in O +
peripheral O +
blood O +
DNA O -
. O +

These O +
tumours O +
showed O +
no O +
BRCA1 B-Gene +
methylation O +
using O +
MethyLight O +
or O +
MS O -
- O -
HRM O -
, O +
indicating O +
that O +
methylation O +
of O +
BRCA1 B-Gene +
in O +
the O +
peripheral O +
blood O +
corresponds O +
to O +
tumour O +
methylation O -
. O +

The O +
peripheral O +
blood O +
leukocyte O +
DNA O +
of O +
seven O +
age O -
- O -
matched O +
normal O +
controls O +
was O +
examined O +
for O +
BRCA1 B-Gene +
methylation O +
for O +
comparison O +
to O +
the O +
breast O +
cancer O +
patients O -
. O +

Six O +
of O +
the O +
seven O +
control O +
samples O +
did O +
not O +
have O +
any O +
detectable O +
BRCA1 B-Gene +
methylation O +
by O +
MethyLight O +
or O +
MS O -
- O -
HRM O -
. O +

One O +
sample O +
produced O +
a O +
methylated O +
signal O +
for O +
two O +
of O +
three O +
replicates O +
by O +
MethyLight O +
only O -
, O +
estimated O +
at O +
the O +
level O +
of O +
0.1 O -
% O +
relative O +
to O +
the O +
100 O -
% O +
methylated O +
control O -
. O +

It O +
is O +
pertinent O +
to O +
consider O +
the O +
region O +
that O +
was O +
spanned O +
by O +
the O +
primers O +
in O +
each O +
of O +
our O +
assays O +
( O -
Figure O +
1 O -
) O -
. O +

In O +
all O +
cases O -
, O +
we O +
designed O +
primers O +
that O +
would O +
not O +
amplify O +
the O +
highly O +
homologous O +
duplication O +
of O +
the O +
BRCA1 B-Gene +
promoter O +
region O +
and O +
exons O +
1 O +
and O +
2 O +
[ O -
22 O -
] O -
. O +

The O +
MS O -
- O -
HRM O +
assay O +
overlaid O +
the O +
proximal O +
promoter O +
region O +
and O +
assessed O +
the O +
CpGs O +
at O +
-37 O -
, O +
-29 O -
, O +
-21 O +
and O +
-19 O +
according O +
to O +
the O +
nomenclature O +
of O +
Rice O +
et O +
al. O +
[ O -
24 O -
] O -
. O +

Previous O +
authors O +
have O +
shown O +
some O +
methylation O +
in O +
this O +
region O -
, O +
commonly O +
at O +
-37 O +
and O +
-29 O +
in O +
peripheral O +
blood O +
in O +
individuals O +
with O +
and O +
without O +
breast O +
cancer O +
[ O -
24,25 O -
] O -
. O +

We O +
observed O +
methylation O +
in O +
only O +
three O +
individuals O +
using O +
both O +
MS O -
- O -
HRM O +
and O +
MethyLight O +
assays O -
. O +

The O +
MethyLight O +
assay O -
, O +
while O +
overlapping O +
this O +
region O +
( O -
the O +
3 O -
' O +
ends O +
of O +
each O +
primer O +
being O +
at O +
-37 O +
and O +
+ O -
27 O -
) O -
, O +
would O +
only O +
give O +
a O +
positive O +
result O +
if O +
there O +
were O +
methylation O +
at O +
the O +
probe O +
binding O +
site O +
covering O +
CpGs O +
at O +
+ O -
14 O -
, O +
+ O -
16 O +
and O +
+ O -
19 O -
. O +

This O +
indicates O +
that O +
the O +
three O +
peripheral O +
blood O +
DNAs O +
with O +
detectable O +
methylation O +
were O +
all O +
methylated O +
over O +
a O +
wider O +
region O +
than O +
just O +
-37 O +
and O +
-29 O -
. O +

Remarkably O -
, O +
all O +
three O +
patients O +
had O +
tumours O +
that O +
were O +
methylated O +
for O +
BRCA1 B-Gene +
as O +
measured O +
by O +
both O +
assays O -
. O +

The O +
-37 O +
and O +
-29 O +
CpG O +
sites O +
could O +
possibly O +
represent O +
a O +
seeding O +
area O +
where O +
under O +
conditions O +
of O +
epigenetic O +
instability O -
, O +
methylation O +
of O +
this O +
small O +
region O +
would O +
spread O +
to O +
the O +
entire O +
promoter O +
causing O +
inactivation O +
of O +
the O +
entire O +
BRCA1 B-Gene +
promoter O +
region O -
. O +

Detailed O +
analysis O +
of O +
the O +
digital O +
HRM O +
assay O +
was O +
also O +
instructive O -
. O +

Whereas O +
the O +
region O +
assessed O +
included O +
-37 O +
and O +
-29 O -
, O +
it O +
also O +
included O +
the O +
CpGs O +
at O +
-21 O +
and O +
-19 O +
that O +
tend O +
not O +
to O +
be O +
methylated O -
. O +

When O +
the O +
individual O +
sequences O +
of O +
the O +
amplified O +
alleles O +
were O +
examined O -
, O +
all O +
but O +
one O +
showed O +
methylation O +
at O +
all O +
four O +
sites O -
. O +

Discussion O +
In O +
this O +
study O -
, O +
we O +
demonstrate O +
the O +
presence O +
of O +
BRCA1 B-Gene +
promoter O +
methylation O +
in O +
normal O +
non O -
- O -
epithelial O +
tissues O +
of O +
patients O +
that O +
developed O +
breast O +
cancer O -
. O +

The O +
levels O +
of O +
BRCA1 B-Gene +
methylation O +
in O +
the O +
peripheral O +
blood O +
( O -
and O +
buccal O +
mucosa O +
for O +
KCF3 O -
) O +
were O +
confirmed O +
by O +
three O +
independent O +
methods O -
, O +
MethyLight O -
, O +
MS O -
- O -
HRM O +
and O +
digital O +
MS O -
- O -
HRM O -
. O +

The O +
observed O +
methylation O +
is O +
not O +
due O +
to O +
disseminated O +
breast O +
cancer O +
cells O +
in O +
the O +
blood O +
because O +
these O +
do O +
not O +
occur O +
at O +
sufficiently O +
high O +
levels O +
to O +
be O +
detected O +
by O +
our O +
assay O -
. O +

Chen O +
et O +
al. O +
have O +
also O +
looked O +
for O +
BRCA1 B-Gene +
methylation O +
in O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
mutation O -
- O -
negative O +
women O +
with O +
a O +
family O +
history O +
of O +
breast O +
cancer O +
[ O -
25 O -
] O -
. O +

They O +
did O +
not O +
detect O +
any O +
methylation O +
in O +
41 O +
patients O -
. O +

Each O +
of O +
these O +
patients O +
had O +
approximately O +
10 O +
clones O +
examined O -
, O +
which O +
would O +
have O +
made O +
it O +
difficult O +
to O +
detect O +
low O +
numbers O +
of O +
fully O +
methylated O +
alleles O +
especially O +
if O +
there O +
was O +
any O +
PCR O +
bias O +
in O +
the O +
amplification O +
prior O +
to O +
cloning O -
. O +

It O +
should O +
also O +
be O +
noted O +
that O +
these O +
women O +
were O +
unselected O +
for O +
BRCA1-like B-Gene +
features O +
and O +
that O +
the O +
BRCA1 B-Gene +
methylation O +
status O +
of O +
their O +
tumours O +
was O +
unknown O -
. O +

We O +
observed O +
one O +
peripheral O +
blood O +
leukocyte O +
DNA O +
sample O +
in O +
our O +
age O -
- O -
matched O +
control O +
panel O +
that O +
had O +
an O +
extremely O +
low O +
level O +
of O +
BRCA1 B-Gene +
methylation O -
. O +

This O +
low O +
level O +
of O +
methylation O +
was O +
not O +
detectable O +
by O +
the O +
MS O -
- O -
HRM O +
assay O -
. O +

However O -
, O +
this O +
result O +
does O +
raise O +
the O +
question O +
of O +
whether O +
this O +
individual O +
does O +
have O +
an O +
elevated O +
risk O +
of O +
developing O +
breast O +
cancer O +
in O +
the O +
future O -
. O +

Many O +
other O +
questions O +
remain O +
to O +
be O +
addressed O +
in O +
future O +
research O +
following O +
the O +
intriguing O +
findings O +
presented O +
here O -
. O +

Our O +
results O +
raise O +
the O +
possibility O +
that O +
methylation O +
and O +
associated O +
silencing O +
of O +
BRCA1 B-Gene +
could O +
represent O +
a O +
germline O +
alteration O +
that O +
underlies O +
some O +
cases O +
of O +
familial O +
breast O +
cancer O -
. O +

DNA O +
from O +
the O +
parents O +
of O +
individual O +
KCF3 O +
were O +
not O +
available O -
, O +
so O +
we O +
were O +
unable O +
to O +
determine O +
if O +
this O +
was O +
an O +
epimutation O +
that O +
may O +
have O +
been O +
inherited O -
. O +

In O +
retrospect O -
, O +
patients O +
from O +
cancer O +
families O +
may O +
not O +
be O +
the O +
best O +
subjects O +
to O +
examine O +
for O +
somatic O +
methylation O +
because O +
of O +
the O +
likely O +
limited O +
transmissibility O +
through O +
the O +
germline O +
[ O -
10 O -
] O -
. O +

It O +
is O +
unclear O +
why O +
the O +
levels O +
of O +
methylation O +
in O +
the O +
somatic O +
tissues O +
were O +
not O +
at O +
the O +
50 O -
% O +
level O +
that O +
we O +
expected O -
. O +

An O +
interesting O +
parallel O +
may O +
be O +
drawn O +
to O +
a O +
recent O +
study O +
showing O +
somatic O +
methylation O +
in O +
a O +
hereditary O +
non O -
- O -
polyposis O +
colorectal O +
cancer O +
family O -
. O +

About O +
10 O -
% O +
of O +
the O +
MSH2 B-Gene +
gene O +
alleles O +
that O +
segregated O +
with O +
the O +
disease O +
were O +
methylated O +
in O +
DNA O +
from O +
peripheral O +
blood O +
[ O -
26 O -
] O -
. O +

The O +
alteration O +
was O +
stably O +
inherited O +
in O +
numerous O +
individuals O +
with O +
the O +
disease O +
haplotype O -
. O +

The O +
inheritance O +
was O +
not O +
of O +
a O +
methylated O +
allele O +
per O +
se O -
, O +
but O +
of O +
a O +
propensity O +
to O +
methylate O +
that O +
was O +
presumably O +
associated O +
with O +
the O +
allelic O +
sequence O -
. O +

Although O +
a O +
methylation O +
propensity O +
could O +
explain O +
the O +
deviation O +
seen O +
from O +
expected O +
allelic O +
methylation O +
ratios O +
in O +
our O +
results O -
, O +
upstream O +
sequencing O +
of O +
KCF3 O +
( O -
data O +
not O +
shown O -
) O +
did O +
not O +
detect O +
any O +
possible O +
variation O +
that O +
could O +
account O +
for O +
this O -
. O +

Conclusion O +
Our O +
findings O +
represent O +
a O +
new O +
paradigm O +
for O +
somatic O +
methylation O +
leading O +
to O +
disease O +
predisposition O -
. O +

Rather O +
than O +
an O +
allelic O +
methylation O +
as O +
has O +
previously O +
been O +
reported O +
for O +
MLH1 B-Gene -
, O +
a O +
mosaic O +
level O +
of O +
BRCA1 B-Gene +
methylation O +
has O +
been O +
identified O +
in O +
the O +
somatic O +
tissues O +
of O +
some O +
breast O +
cancer O +
patients O -
. O +

We O +
believe O +
it O +
will O +
be O +
important O +
to O +
examine O +
individuals O +
with O +
early O +
onset O +
or O +
multifocal O +
breast O +
cancer O +
for O +
BRCA1 B-Gene +
methylation O +
lacking O +
a O +
strong O +
family O +
history O -
. O +

We O +
consider O +
that O +
widespread O +
somatic O +
methylation O +
of O +
BRCA1 B-Gene +
is O +
an O +
important O +
and O +
as O +
yet O +
unrecognised O +
cause O +
of O +
some O +
BRCA1-like B-Gene +
cancers O -
. O +

Further O +
studies O +
will O +
be O +
required O +
to O +
determine O +
the O +
frequency O +
and O +
functional O +
significance O +
of O +
widespread O +
somatic O +
BRCA1 B-Gene +
methylation O -
. O +

and O +
Missense O +
Variants O +
of O +
High O +
and O +
Low O +
Clinical O +
Significance O +
Influence O +
Lymphoblastoid O +
Cell O +
Line O +
Post O -
- O -
Irradiation O +
Gene O +
Expression O +
Abstract O +

The O +
functional O +
consequences O +
of O +
missense O +
variants O +
in O +
disease O +
genes O +
are O +
difficult O +
to O +
predict O -
. O +

We O +
assessed O +
if O +
gene O +
expression O +
profiles O +
could O +
distinguish O +
between O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
pathogenic O +
truncating O +
and O +
missense O +
mutation O +
carriers O +
and O +
familial O +
breast O +
cancer O +
cases O +
whose O +
disease O +
was O +
not O +
attributable O +
to O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
mutations O +
( O -
BRCAX B-Gene +
cases O -
) O -
. O +

72 O +
cell O +
lines O +
from O +
affected O +
women O +
in O +
high O -
- O -
risk O +
breast O +
ovarian O +
families O +
were O +
assayed O +
after O +
exposure O +
to O +
ionising O +
irradiation O -
, O +
including O +
23 O +
BRCA1 B-Gene +
carriers O -
, O +
22 O +
BRCA2 B-Gene +
carriers O -
, O +
and O +
27 O +
BRCAX B-Gene +
individuals O -
. O +

A O +
subset O +
of O +
10 O +
BRCAX B-Gene +
individuals O +
carried O +
rare O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
sequence O +
variants O +
considered O +
to O +
be O +
of O +
low O +
clinical O +
significance O +
( O -
LCS O -
) O -
. O +

BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
mutation O +
carriers O +
had O +
similar O +
expression O +
profiles O -
, O +
with O +
some O +
subclustering O +
of O +
missense O +
mutation O +
carriers O -
. O +

The O +
majority O +
of O +
BRCAX B-Gene +
individuals O +
formed O +
a O +
distinct O +
cluster O -
, O +
but O +
BRCAX B-Gene +
individuals O +
with O +
LCS O +
variants O +
had O +
expression O +
profiles O +
similar O +
to O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
mutation O +
carriers O -
. O +

Gaussian O +
Process O +
Classifier O +
predicted O +
BRCA1 B-Gene -
, O +
BRCA2 B-Gene +
and O +
BRCAX O +
status O -
, O +
with O +
a O +
maximum O +
of O +
62 O -
% O +
accuracy O -
, O +
and O +
prediction O +
accuracy O +
decreased O +
with O +
inclusion O +
of O +
BRCAX O +
samples O +
carrying O +
an O +
LCS O +
variant O -
, O +
and O +
inclusion O +
of O +
pathogenic O +
missense O +
carriers O -
. O +

Similarly O -
, O +
prediction O +
of O +
mutation O +
status O +
with O +
gene O +
lists O +
derived O +
using O +
Support O +
Vector O +
Machines O +
was O +
good O +
for O +
BRCAX B-Gene +
samples O +
without O +
an O +
LCS O +
variant O +
( O -
82–94 O -
% O -
) O -
, O +
poor O +
for O +
BRCAX O +
with O +
an O +
LCS O +
( O -
40–50 O -
% O -
) O -
, O +
and O +
improved O +
for O +
pathogenic O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
mutation O +
carriers O +
when O +
the O +
gene O +
list O +
used O +
for O +
prediction O +
was O +
appropriate O +
to O +
mutation O +
effect O +
being O +
tested O +
( O -
71–100 O -
% O -
) O -
. O +

This O +
study O +
indicates O +
that O +
mutation O +
effect O -
, O +
and O +
presence O +
of O +
rare O +
variants O +
possibly O +
associated O +
with O +
a O +
low O +
risk O +
of O +
cancer O -
, O +
must O +
be O +
considered O +
in O +
the O +
development O +
of O +
array O -
- O -
based O +
assays O +
of O +
variant O +
pathogenicity O -
. O +

Abstract O +
Author O +
Summary O +
Inherited O +
mutations O +
in O +
the O +
genes O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
increase O +
risk O +
of O +
breast O +
cancer O +
and O +
contribute O +
to O +
a O +
proportion O +
of O +
breast O +
cancer O +
families O -
. O +

However O -
, O +
more O +
than O +
half O +
of O +
the O +
reported O +
sequence O +
alterations O +
in O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
are O +
currently O +
of O +
unknown O +
clinical O +
significance O -
. O +

We O +
analysed O +
gene O +
expression O +
in O +
lymphoblastoid O +
cell O +
lines O +
derived O +
from O +
blood O +
of O +
patients O +
with O +
sequence O +
alterations O +
in O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
and O +
compared O +
these O +
to O +
lymphoblastoid O +
cells O +
from O +
familial O +
breast O +
cancer O +
patients O +
without O +
such O +
alterations O -
. O +

We O +
then O +
classified O +
these O +
lymphoblastoid O +
cells O +
based O +
on O +
their O +
gene O +
profiles O -
. O +

We O +
found O +
that O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
samples O +
were O +
more O +
similar O +
to O +
each O +
other O +
than O +
to O +
familial O +
breast O +
cancer O +
patients O +
without O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
mutations O -
, O +
and O +
that O +
the O +
type O +
of O +
sequence O +
change O +
in O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
( O -
missense O +
or O +
truncating O -
) O +
influenced O +
gene O +
expression O -
. O +

We O +
included O +
in O +
the O +
study O +
ten O +
familial O +
breast O +
cancer O +
samples O -
, O +
which O +
carried O +
sequence O +
changes O +
in O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene -
, O +
that O +
are O +
believed O +
to O +
be O +
of O +
little O +
clinical O +
significance O -
. O +

Interestingly O +
these O +
samples O +
were O +
distinct O +
from O +
other O +
familial O +
breast O +
cancer O +
cases O +
without O +
any O +
sequence O +
alteration O +
in O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene -
, O +
indicating O +
that O +
further O +
work O +
needs O +
to O +
be O +
performed O +
to O +
determine O +
the O +
possible O +
association O +
of O +
these O +
" O -
low O +
clinical O +
significance O -
� O -
? O +
sequence O +
changes O +
with O +
a O +
low O +
to O +
moderate O +
risk O +
of O +
cancer O -
. O +

Introduction O +
Approximately O +
7 O -
% O +
of O +
breast O +
cancer O +
cases O +
occur O +
in O +
women O +
with O +
a O +
strong O +
family O +
history O +
of O +
the O +
disease O +
[ O -
1 O -
] O -
. O +

Mutations O +
in O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
account O +
for O +
a O +
considerable O +
proportion O +
of O +
these O +
familial O +
breast O +
cancer O +
cases O -
, O +
with O +
the O +
average O +
cumulative O +
risk O +
in O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
mutation O +
carriers O +
by O +
age O +
70 O +
years O +
estimated O +
at O +
65 O -
% O +
and O +
45 O -
% O -
, O +
respectively O +
[ O -
2 O -
] O -
. O +

The O +
Breast O +
Cancer O +
Information O +
Core O +
( O -
BIC O -
) O +
database O +
( O -
http://research.nhgri.nih.gov/bic/ O -
) O +
currently O +
has O +
more O +
than O +
1400 O +
and O +
1800 O +
unique O +
sequence O +
variants O +
listed O +
in O +
the O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
genes O -
, O +
respectively O -
. O +

These O +
include O +
frameshift O -
, O +
nonsense O -
, O +
missense O -
, O +
splice O +
site O +
alterations O +
and O +
polymorphisms O -
. O +

Greater O +
than O +
a O +
third O +
of O +
the O +
BRCA1 B-Gene +
and O +
greater O +
than O +
half O +
of O +
the O +
BRCA2 B-Gene +
unique O +
variants O +
are O +
" O -
unclassified O +
variants O -
� O -
? O +
without O +
compelling O +
evidence O +
of O +
pathogenicity O +
or O +
functional O +
significance O -
. O +

The O +
majority O +
of O +
unclassified O +
variants O +
recorded O +
in O +
the O +
BIC O +
database O +
are O +
predicted O +
missense O +
changes O +
( O -
more O +
than O +
400 O +
BRCA1 B-Gene +
and O +
800 O +
BRCA2 B-Gene -
) O -
. O +

However O +
other O +
variants O +
which O +
may O +
be O +
categorised O +
as O +
unclassified O +
variants O +
are O +
in O -
- O -
frame O +
deletions O +
or O +
duplications O -
, O +
variants O +
that O +
may O +
disrupt O +
splicing O -
, O +
or O +
variants O +
in O +
the O +
3′UTR O +
that O +
may O +
affect O +
RNA O +
stability O +
( O -
www.kconfab.org O -
) O -
. O +

BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
unclassified O +
variants O +
represent O +
a O +
problem O +
in O +
the O +
clinical O +
setting O +
as O +
it O +
is O +
not O +
known O +
which O +
variants O +
are O +
associated O +
with O +
the O +
high O +
risk O +
of O +
disease O +
reported O +
for O +
classical O +
truncating O +
mutations O -
. O +

Several O +
functional O +
assays O +
may O +
be O +
used O +
to O +
determine O +
the O +
significance O +
of O +
unclassified O +
variants O -
, O +
including O +
transcription O +
activation O +
and O +
complementation O +
assays O +
[ O -
3 O -
] O -
– O -
[ O -
9 O -
] O -
, O +
but O +
a O +
disadvantage O +
of O +
biochemical O +
assays O +
is O +
that O +
they O +
rely O +
on O +
the O +
functions O +
of O +
specific O +
domains O +
of O +
the O +
protein O -
, O +
require O +
specialized O +
laboratory O +
skills O -
, O +
and O +
are O +
time O -
– O -
consuming O +
to O +
perform O -
. O +

Other O +
methods O +
for O +
classifying O +
variants O +
include O +
the O +
analysis O +
of O +
clinical O +
and O +
histopathological O +
data O +
[ O -
10 O -
] O -
, O +
loss O +
of O +
heterozygosity O +
analysis O +
[ O -
11 O -
] O +
and O +
bioinformatic O +
analysis O +
to O +
predict O +
the O +
effect O +
of O +
the O +
amino O +
acid O +
change O +
on O +
structure O +
and O +
multiple O +
sequence O +
alignment O +
strategies O +
[ O -
12 O -
] O -
; O +
[ O -
13 O -
] O -
– O -
[ O -
15 O -
] O -
. O +

Integrated O +
evaluation O +
of O +
unclassified O +
variants O +
which O +
combines O +
several O +
approaches O -
, O +
such O +
as O +
the O +
analysis O +
of O +
co O -
- O -
segregation O +
of O +
the O +
mutation O +
with O +
disease O -
, O +
co O -
- O -
occurrence O +
of O +
the O +
variant O +
with O +
a O +
deleterious O +
mutation O -
, O +
sequence O +
conservation O +
of O +
the O +
amino O +
acid O +
change O -
, O +
severity O +
of O +
amino O +
acid O +
change O -
, O +
tumor O +
loss O +
of O +
heterozygosity O -
, O +
and O +
tumor O +
histopathology O +
classification O -
, O +
provides O +
a O +
quantitative O +
tool O +
for O +
the O +
classification O +
of O +
variants O +
[ O -
16 O -
] O -
– O -
[ O -
22 O -
] O -
. O +

This O +
multifactorial O +
method O +
was O +
developed O +
to O +
classify O +
such O +
rare O +
unclassified O +
variants O +
into O +
two O +
categories O -
, O +
variants O +
with O +
features O +
of O +
classical O +
high O -
- O -
risk O +
mutations O +
( O -
termed O +
pathogenic O -
) O -
, O +
and O +
variants O +
that O +
do O +
not O +
have O +
the O +
features O +
of O +
a O +
high O -
- O -
risk O +
mutation O +
( O -
termed O +
neutral O +
or O +
low O +
clinical O +
significance O +
( O -
LCS O -
) O -
) O -
. O +

While O +
the O +
availability O +
of O +
appropriate O +
biospecimens O +
( O -
e.g. O +
number O +
of O +
families O +
and O +
tumors O -
) O +
for O +
inclusion O +
in O +
likelihood O +
prediction O +
is O +
a O +
major O +
factor O +
determining O +
the O +
classification O +
of O +
any O +
single O +
variant O -
, O +
another O +
major O +
caveat O +
of O +
the O +
multifactorial O +
approach O +
is O +
that O +
it O +
is O +
not O +
appropriate O +
for O +
the O +
evaluation O +
of O +
possible O +
moderate O +
or O +
low O +
risk O +
variants O -
, O +
since O +
it O +
uses O +
high O -
- O -
risk O +
mutations O +
as O +
reference O +
for O +
the O +
underlying O +
assumptions O +
[ O -
16 O -
] O -
, O -
[ O -
19 O -
] O -
, O -
[ O -
20 O -
] O -
. O +

Therefore O -
, O +
the O +
current O +
multifactorial O +
method O +
can O -
not O +
exclude O +
the O +
possibility O +
that O +
rare O +
variants O +
classified O +
to O +
be O +
of O +
low O +
clinical O +
significance O +
may O +
be O +
associated O +
with O +
a O +
moderate O +
or O +
low O +
risk O +
of O +
cancer O -
. O +

Gene O +
expression O +
profiling O +
has O +
increased O +
our O +
understanding O +
of O +
the O +
molecular O +
events O +
in O +
breast O +
tumor O +
development O -
, O +
has O +
been O +
used O +
to O +
predict O +
prognosis O -
, O +
and O +
has O +
characterised O +
breast O +
tumors O +
into O +
subtypes O +
[ O -
23 O -
] O -
– O -
[ O -
27 O -
] O -
. O +

The O +
value O +
of O +
expression O +
profiling O +
for O +
identifying O +
underlying O +
high O -
- O -
risk O +
gene O +
mutation O +
status O +
is O +
indicated O +
by O +
a O +
number O +
of O +
studies O -
. O +

A O +
distinct O +
gene O +
expression O +
profile O +
has O +
been O +
reported O +
for O +
breast O +
tumors O +
of O +
BRCA1 B-Gene +
mutation O +
carriers O +
[ O -
23 O -
] O -
, O -
[ O -
28 O -
] O -
, O -
[ O -
29 O -
] O -
, O +
expected O +
to O +
be O +
homozygous O +
for O +
loss O +
of O +
BRCA1 B-Gene +
function O +
at O +
the O +
somatic O +
level O -
. O +

In O +
addition O -
, O +
the O +
existence O +
of O +
distinct O +
gene O +
expression O +
profiles O +
for O +
heterozygous O +
loss O +
of O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
function O +
is O +
supported O +
by O +
accurate O +
separation O +
of O +
short O -
- O -
term O +
cultures O +
of O +
fibroblasts O +
carrying O +
a O +
germline O +
mutation O +
in O +
the O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
genes O -
, O +
compared O +
to O +
healthy O +
women O +
undergoing O +
reduction O +
mammoplastic O +
surgery O +
with O +
no O +
family O +
or O +
personal O +
history O +
of O +
any O +
cancer O +
or O +
sporadic O +
breast O -
- O -
cancer O -
- O -
affected O +
controls O +
[ O -
30 O -
] O -
, O -
[ O -
31 O -
] O -
. O +

Lymphoblastoid O +
cell O +
lines O +
( O -
LCLs O -
) O +
have O +
also O +
been O +
shown O +
to O +
have O +
distinct O +
mRNA O +
expression O +
phenotypes O +
for O +
heterozygous O +
carriers O +
of O +
ATM B-Gene +
mutations O -
, O +
some O +
of O +
which O +
are O +
known O +
to O +
be O +
associated O +
with O +
an O +
increased O +
risk O +
in O +
breast O +
cancer O +
[ O -
32 O -
] O -
, O -
[ O -
33 O -
] O -
. O +

These O +
findings O +
suggest O +
that O +
germline O +
gene O +
expression O +
signatures O -
, O +
including O +
those O +
from O +
fibroblasts O +
or O +
LCLs O -
, O +
may O +
be O +
used O +
to O +
define O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
mutation O +
status O +
and O +
to O +
assist O +
in O +
assessing O +
the O +
clinical O +
significance O +
of O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
unclassified O +
variants O -
. O +

In O +
this O +
study O +
we O +
compared O +
LCL O +
gene O +
expression O +
signatures O +
of O +
breast O +
cancer O +
cases O +
carrying O +
pathogenic O +
mutations O +
in O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene -
, O +
to O +
familial O +
breast O +
cancer O +
cases O +
with O +
no O +
known O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
mutations O +
( O -
BRCAX O -
) O -
. O +

We O +
also O +
considered O +
the O +
possibility O +
that O +
BRCAX B-Gene +
individuals O +
with O +
a O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
sequence O +
variant O +
classified O +
to O +
be O +
neutral O -
/ O -
low O +
clinical O +
significance O +
( O -
LCS O -
) O +
using O +
multifactorial O +
likelihood O +
analysis O +
may O +
differ O +
in O +
gene O +
expression O +
profile O +
from O +
BRCAX B-Gene +
individuals O +
without O +
such O +
sequence O +
variants O -
. O +

In O +
addition O -
, O +
since O +
truncating O +
alterations O +
comprise O +
the O +
majority O +
of O +
known O +
pathogenic O +
mutations O +
but O +
most O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
unclassified O +
variants O +
are O +
predicted O +
missense O +
alterations O -
, O +
we O +
compared O +
profiles O +
from O +
individuals O +
with O +
known O +
missense O +
or O +
truncating O +
mutations O +
to O +
determine O +
if O +
mutation O +
effect O +
will O +
affect O +
the O +
mutation O -
- O -
associated O +
expression O +
profile O +
for O +
each O +
gene O -
. O +

We O +
derived O +
gene O +
lists O +
to O +
predict O +
mutation O +
status O +
defined O +
by O +
gene O +
and O +
mutation O +
effect O -
, O +
and O +
then O +
tested O +
the O +
efficacy O +
of O +
these O +
gene O +
lists O +
to O +
predict O +
the O +
gene O +
mutation O +
status O +
of O +
LCLs O -
. O +

We O +
provide O +
evidence O +
that O +
gene O +
lists O +
differ O +
according O +
to O +
gene O +
and O +
mutation O +
effect O -
, O +
and O +
according O +
to O +
the O +
presence O +
of O +
sequence O +
variants O +
of O +
low O +
clinical O +
significance O -
. O +

We O +
also O +
demonstrate O +
that O +
the O +
use O +
of O +
appropriately O -
- O -
derived O +
gene O +
lists O +
improves O +
the O +
prediction O +
of O +
pathogenicity O +
of O +
known O +
mutations O -
. O +

Results O +
Differences O +
in O +
LCL O +
Post O -
- O -
Irradiation O +
Gene O +
Expression O +
between O +
BRCAX B-Gene +
Individuals O +
with O +
or O +
without O +
a O +
Sequence O +
Variant O +
of O +
Low O +
Clinical O +
Significance O +

The O +
ultimate O +
aim O +
of O +
this O +
experiment O +
was O +
to O +
establish O +
if O +
gene O +
expression O +
profiles O +
could O +
distinguish O +
between O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
pathogenic O +
mutation O +
carriers O +
and O +
familial O +
breast O +
cancer O +
cases O +
whose O +
disease O +
was O +
not O +
attributable O +
to O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
mutations O +
( O -
BRCAX B-Gene +
cases O -
) O -
. O +

BRCAX B-Gene +
breast O +
cancer O +
families O +
are O +
likely O +
to O +
result O +
from O +
mutations O +
in O +
several O +
other O +
genes O -
, O +
and O +
thus O +
represent O +
a O +
heterogeneous O +
group O -
. O +

Moreover O -
, O +
included O +
in O +
the O +
BRCAX B-Gene +
group O +
were O +
a O +
subset O +
of O +
10 O +
BRCAX B-Gene +
individuals O +
who O +
carried O +
a O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
variant O +
previously O +
classified O +
to O +
be O +
of O +
low O +
clinical O +
significance O +
using O +
multifactorial O +
likelihood O +
approaches O +
[ O -
8 O -
] O -
, O -
[ O -
19 O -
] O -
, O -
[ O -
21 O -
] O -
, O -
[ O -
22 O -
] O -
. O +

Unsupervised O +
hierarchical O +
clustering O +
showed O +
that O +
BRCAX O +
LCLs O +
containing O +
a O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
variant O +
of O +
low O +
clinical O +
significance O +
clustered O +
away O +
from O +
the O +
majority O +
of O +
remaining O +
BRCAX O +
samples O +
( O -
Figure O +
1 O -
) O -
. O +

A O +
t O -
- O -
test O +
with O +
Benjamini O +
and O +
Hochberg O +
multiple O +
testing O +
correction O +
[ O -
34 O -
] O +
was O +
performed O +
to O +
determine O +
if O +
there O +
were O +
gene O +
expression O +
differences O +
between O +
the O +
BRCAX B-Gene +
individuals O +
with O +
an O +
LCS O +
variant O +
and O +
those O +
without O +
an O +
LCS O +
variant O -
. O +

Expression O +
of O +
631 O +
genes O +
differed O +
between O +
the O +
two O +
BRCAX B-Gene +
subgroups O +
( O -
5 O -
% O +
of O +
the O +
631 O +
genes O +
identified O +
would O +
be O +
expected O +
to O +
pass O +
this O +
restriction O +
by O +
chance O -
) O -
. O +

For O +
this O +
reason O -
, O +
BRCAX O +
samples O +
were O +
stratified O +
according O +
to O +
the O +
presence O +
of O +
an O +
LCS O +
variant O +
for O +
further O +
analyses O -
. O +

Unsupervised O +
Hierarchical O +
cluster O +
of O +
differences O +
between O +
BRCAX O +
samples O +
with O +
or O +
without O +
a O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
sequence O +
variant O +
of O +
Low O +
Clinical O +
Significance O -
. O +

Unsupervised O +
cluster O +
analysis O +
was O +
performed O +
using O +
1778 O +
genes O +
that O +
varied O +
in O +
expression O +
2-fold O +
from O +
the O +
mean O +
in O +
10 O -
% O +
of O +
BRCAX O +
without O +
a O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
LCS O +
variant O +
and O +
BRCAX O +
samples O +
with O +
an O +
LCS O -
. O +

The O +
tree O +
structure O +
at O +
the O +
top O +
of O +
the O +
cluster O +
shows O +
how O +
related O +
the O +
samples O +
are O +
to O +
each O +
other O -
. O +

The O +
majority O +
of O +
BRCAX B-Gene +
samples O +
without O +
an O +
LCS O +
( O -
black O -
) O +
clustered O +
in O +
a O +
distinct O +
group O +
away O +
from O +
BRCAX O +
with O +
an O +
LCS O +
variant O +
( O -
red O -
) O -
. O +

Gene O +
expression O +
is O +
similar O +
for O +
carriers O +
of O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
truncating O +
mutations O +
and O +
rare O +
sequence O +
variants O +
of O +
low O +
clinical O +
significance O -
, O +
but O +
differs O +
from O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
missense O +
mutations O +
and O +
BRCAX B-Gene +
non B-Gene -
- I-Gene -
BRCA1 I-Gene -
/ I-Gene -
2 I-Gene +
familial O +
cases O -
. O +

Unsupervised O +
hierarchical O +
clustering O +
( O -
Figure O +
2 O -
) O +
of O +
LCL O +
expression O +
data O +
from O +
all O +
samples O +
revealed O +
that O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
samples O +
were O +
more O +
similar O +
to O +
each O +
other O +
than O +
BRCAX B-Gene +
samples O +
without O +
an O +
LCS O +
variant O -
. O +

This O +
result O +
suggests O +
that O +
germline O +
effects O +
of O +
heterozygous O +
mutations O +
in O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
can O -
not O +
easily O +
be O +
separated O +
using O +
the O +
experimental O +
conditions O +
used O +
in O +
this O +
study O -
. O +

Although O +
BRCAX B-Gene +
samples O +
tended O +
to O +
cluster O +
distinctly O +
from O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
samples O -
, O +
nine O +
of O +
ten O +
BRCAX B-Gene +
individuals O +
who O +
carried O +
a O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
variant O +
previously O +
classified O +
to O +
be O +
of O +
low O +
clinical O +
significance O +
fell O +
within O +
the O +
major O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
mutation O +
cluster O -
. O +

In O +
contrast O -
, O +
six O +
of O +
the O +
nine O +
pathogenic O +
missense O +
mutations O +
of O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
fell O +
into O +
a O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
outlier O +
group O -
, O +
which O +
clustered O +
closer O +
to O +
the O +
BRCAX B-Gene +
samples O -
. O +

Unsupervised O +
Hierarchical O +
Cluster O +
of O +
Differences O +
between O +
BRCA1 B-Gene -
, O +
BRCA2 B-Gene +
and O +
BRCAX B-Gene +
samples O -
. O +

Clustering O +
was O +
based O +
on O +
4751 O +
genes O +
which O +
varied O +
2-fold O +
difference O +
in O +
gene O +
expression O +
in O +
at O +
least O +
10 O -
% O +
of O +
samples O -
. O +

There O +
are O +
two O +
main O +
clusters O -
, O +
the O +
BRCAX B-Gene +
samples O +
without O +
a O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
LCS O +
variant O +
( O -
black O -
) O +
cluster O +
to O +
the O +
right O -
, O +
whereas O +
BRCA1 B-Gene +
( O -
green O -
) O -
, O +
BRCA2 B-Gene +
( O -
blue O -
) O +
and O +
BRCAX B-Gene +
samples O +
with O +
a O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
LCS O +
variant O +
( O -
red O -
) O +
are O +
predominantly O +
located O +
in O +
the O +
left O +
cluster O -
. O +

The O +
missense O +
pathogenic O +
mutations O +
of O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
are O +
indicated O +
with O +
arrows O +
and O +
6 O -
/ O -
9 O +
cluster O +
closest O +
to O +
the O +
BRCAX O +
LCLs O -
. O +

Gaussian O +
Process O +
Classifier O +
Prediction O +
of O +
BRCA1 B-Gene -
, O +
BRCA2 B-Gene +
and O +
BRCAX O +
Mutation O +
Status O +
To O +
determine O +
the O +
accuracy O +
of O +
using O +
gene O +
expression O +
data O +
from O +
LCLs O +
to O +
predict O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
pathogenic O +
carriers O +
and O +
BRCAX B-Gene +
individuals O -
, O +
we O +
used O +
a O +
Gaussian O +
Process O +
Classifier O +
( O -
GPC O -
) O -
. O +

GPC O +
analysis O +
was O +
used O +
previously O +
in O +
an O +
analysis O +
of O +
microarray O +
profiles O +
from O +
irradiated O +
short O -
- O -
term O +
fibroblasts O +
of O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
mutation O +
carriers O +
[ O -
31 O -
] O -
, O +
and O +
allows O +
for O +
multiway O +
comparison O +
of O +
groups O -
. O +

For O +
GPC O +
analysis O +
2031 O +
genes O +
which O +
were O +
significantly O +
over O -
/ O -
under O -
- O -
expressed O +
at O +
the O +
5 O -
% O +
significance O +
level O +
were O +
selected O -
. O +

The O +
GPC O +
was O +
used O +
in O +
a O +
three O +
way O +
comparison O +
to O +
compare O +
BRCA1 B-Gene +
truncating O +
mutation O +
carriers O +
to O +
BRCA2 B-Gene +
truncating O +
mutation O +
carriers O -
, O +
and O +
to O +
BRCAX B-Gene +
samples O +
without O +
an O +
LCS O +
variant O -
. O +

Samples O +
with O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
pathogenic O +
missense O +
mutations O +
or O +
classified O +
as O +
BRCAX O +
with O +
an O +
LCS O +
variant O +
were O +
then O +
included O +
to O +
determine O +
their O +
affect O +
on O +
the O +
prediction O +
accuracy O -
. O +

A O +
summary O +
of O +
the O +
prediction O +
accuracy O +
is O +
shown O +
in O +
Table O +
1 O -
. O +

The O +
highest O +
prediction O +
accuracy O +
( O -
62.26 O -
% O -
) O +
was O +
achieved O +
when O +
the O +
analysis O +
excluded O +
samples O +
classified O +
as O +
BRCAX O +
with O +
an O +
LCS O -
, O +
and O +
samples O +
with O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
missense O +
mutations O -
. O +

This O +
prediction O +
accuracy O +
is O +
above O +
the O +
expected O +
performance O -
, O +
as O +
a O +
random O +
prediction O +
with O +
three O +
classes O +
comprised O +
of O +
a O +
similar O +
sample O +
number O +
would O +
be O +
33 O -
% O +
accuracy O -
. O +

When O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
samples O +
were O +
compared O +
to O +
only O +
BRCAX B-Gene +
samples O +
with O +
an O +
LCS O +
variant O -
, O +
the O +
prediction O +
dropped O +
to O +
43.46 O -
% O -
, O +
and O +
the O +
addition O +
of O +
the O +
BRCAX B-Gene +
samples O +
without O +
an O +
LCS O +
variant O +
improved O +
the O +
accuracy O -
. O +

In O +
all O +
comparisons O +
the O +
inclusion O +
of O +
the O +
pathogenic O +
non O -
- O -
truncating O +
mutations O +
of O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
lowered O +
the O +
prediction O +
accuracy O -
. O +

Accuracy O +
of O +
Prediction O +
of O +
Mutation O +
Status O +
using O +
a O +
Gaussian O +
Process O +
Classifier O +

* O +
2031 O +
genes O +
were O +
used O +
to O +
predict O +
mutation O +
status O +
between O +
groups O -
, O +
as O +
described O +
in O +
the O +
methods O +
section O -
. O +

Comparison O +
of O +
Gene O +
Expression O +
Profiles O +
between O +
BRCAX O +
and O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
LCLs O +
In O +
the O +
clinical O +
setting O -
, O +
unclassified O +
sequence O +
variants O +
of O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
are O +
generally O +
identified O +
after O +
full O +
sequencing O +
of O +
both O +
genes O -
. O +

Therefore O +
the O +
most O +
common O +
clinical O +
question O +
is O +
whether O +
a O +
variant O +
in O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
is O +
pathogenic O +
or O +
not O -
. O +

We O +
thus O +
performed O +
pair O +
wise O +
analyses O +
to O +
determine O +
if O +
BRCAX B-Gene +
samples O +
could O +
be O +
distinguished O +
from O +
those O +
with O +
pathogenic O +
mutations O +
in O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene -
. O +

Based O +
on O +
observations O +
from O +
hierarchical O +
clustering O +
analyses O +
and O +
the O +
GPC O +
analysis O -
, O +
we O +
also O +
considered O +
the O +
possibility O +
that O +
the O +
effect O +
of O +
pathogenic O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
mutations O +
( O -
truncating O +
or O +
missense O -
) O +
affected O +
LCL O +
gene O +
expression O -
. O +

T O -
- O -
tests O +
were O +
performed O +
using O +
the O +
20,874 O +
detected O +
probes O +
to O +
elucidate O +
gene O +
differences O +
between O +
i O -
) O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
truncating O +
mutations O +
vs O +
BRCAX O +
without O +
an O +
LCS O +
variant O -
; O +
ii O -
) O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
missense O +
mutations O +
vs O +
BRCAX O +
without O +
an O +
LCS O +
variant O -
. O +

The O +
number O +
of O +
genes O +
which O +
passed O +
these O +
restrictions O +
and O +
the O +
overlap O +
between O +
them O +
is O +
outlined O +
in O +
Figure O +
3A O +
and O +
3C O -
. O +

The O +
comparisons O +
were O +
then O +
repeated O +
with O +
BRCAX O +
with O +
an O +
LCS O +
variant O +
( O -
Figure O +
3B O +
and O +
3D O -
) O -
. O +

As O +
expected O +
when O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
were O +
compared O +
to O +
BRCAX B-Gene +
samples O +
without O +
an O +
LCS O +
variant O -
, O +
a O +
greater O +
number O +
of O +
genes O +
were O +
deemed O +
significant O +
compared O +
to O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
vs O +
BRCAX B-Gene +
samples O +
with O +
an O +
LCS O +
variant O -
. O +

Venn O +
Diagrams O +
of O +
Differences O +
between O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
and O +
BRCAX O +
LCLs O +
with O +
or O +
without O +
a O +
LCS O -
. O +

T O -
- O -
tests O +
( O -
p O -
- O -
value<0.05 O -
) O +
were O +
performed O +
to O +
determine O +
genes O +
that O +
differed O +
between O +
LCLs O +
as O +
follows O -
: O +
A O -
) O +
BRCA1 B-Gene +
Truncating O +
mutations O +
vs O +
BRCAX O +
with O +
no O +
LCS O -
, O +
and O +
BRCA1 B-Gene +
missense O +
mutations O +
vs O +
BRCAX O +
with O +
no O +
LCS O -
; O +
B O -
) O +
BRCA1 B-Gene +
Truncating O +
mutations O +
vs O +
BRCAX O +
with O +
an O +
LCS O -
, O +
and O +
BRCA1 B-Gene +
missense O +
mutations O +
vs O +
BRCAX O +
with O +
an O +
LCS O -
. O +

C O -
) O +
BRCA2 B-Gene +
Truncating O +
mutations O +
vs O +
BRCAX O +
with O +
no O +
LCS O -
, O +
and O +
BRCA2 B-Gene +
missense O +
mutations O +
vs O +
BRCAX O +
with O +
no O +
LCS O -
; O +
D O -
) O +
BRCA2 B-Gene +
Truncating O +
mutations O +
vs O +
BRCAX O +
with O +
an O +
LCS O -
, O +
and O +
BRCA1 B-Gene +
missense O +
mutations O +
vs O +
BRCAX O +
with O +
an O +
LCS O -
. O +

For O +
each O +
comparison O -
, O +
the O +
overlap O +
of O +
genes O +
is O +
shown O -
. O +

Support O +
Vector O +
Machines O +
Prediction O +
of O +
BRCA1 B-Gene -
, O +
BRCA2 B-Gene +
and O +
BRCAX O +
Mutation O +
Status O +
SVM O +
is O +
a O +
widely O +
accepted O +
classification O +
approach O +
for O +
assessing O +
differences O +
in O +
mRNA O +
expression O -
, O +
and O +
was O +
used O +
to O +
compare O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
individually O +
to O +
BRCAX B-Gene +
samples O -
. O +

Since O +
our O +
detailed O +
analysis O +
of O +
gene O +
lists O +
showed O +
that O +
mutation O +
effect O +
( O -
truncating O +
or O +
missense O +
substitution O -
) O +
appears O +
to O +
affect O +
the O +
genes O +
that O +
are O +
differentially O +
expressed O +
in O +
the O +
carriers O +
after O +
IR O +
( O -
Figure O +
3 O -
) O -
, O +
we O +
assessed O +
if O +
these O +
gene O +
differences O +
will O +
affect O +
the O +
predictions O -
. O +

We O +
used O +
SVM O +
with O +
the O +
top O +
200 O +
genes O +
from O +
the O +
comparison O +
of O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
truncating O +
mutations O +
to O +
BRCAX O -
, O +
and O +
the O +
top O +
200 O +
genes O +
from O +
the O +
comparison O +
of O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
missense O +
mutations O +
to O +
BRCAX O +
( O -
Figure O +
3A O +
and O +
3C O -
) O -
. O +

The O +
genes O +
which O +
differed O +
between O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
and O +
BRCAX O +
with O +
an O +
LCS O +
variant O +
were O +
not O +
used O +
in O +
this O +
comparison O +
as O +
too O +
few O +
genes O +
passed O +
the O +
restriction O +
( O -
Figure O +
3B O +
and O +
3D O -
) O -
. O +

The O +
top O +
200 O +
genes O +
are O +
listed O +
in O +
Tables O +
S2 O -
, O +
S3 O -
, O +
S4 O -
, O +
and O +
S5 O +
and O +
the O +
overlap O +
of O +
the O +
top O +
200 O +
genes O +
used O +
for O +
prediction O +
from O +
[ O -
BRCA1 B-Gene +
( O -
missense O -
) O +
vs O +
BRCAX O +
( O -
noLCS O -
) O -
] O +
and O +
[ O -
BRCA1 B-Gene +
( O -
truncating O -
) O +
vs O +
BRCAX O +
( O -
noLCS O -
) O -
] O +
was O +
16 O +
transcripts O -
, O +
with O +
no O +
overlap O +
between O +
the O +
top O +
200 O +
genes O +
from O +
[ O -
BRCA2 B-Gene +
( O -
missense O -
) O +
vs O +
BRCAX O +
( O -
noLCS O -
) O -
] O +
and O +
[ O -
BRCA2 B-Gene +
( O -
truncating O -
) O +
vs O +
BRCAX O +
( O -
noLCS O -
) O -
] O -
. O +

A O +
total O +
of O +
715 O +
different O +
genes O +
were O +
represented O +
in O +
the O +
four O +
lists O +
of O +
top O +
200 O +
gene O -
- O -
lists O +
from O +
comparison O +
of O +
BRCAX O +
( O -
no O +
LCS O -
) O +
to O +
the O +
different O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
groups O +
above O -
. O +

The O +
results O +
are O +
summarised O +
in O +
Tables O +
2 O +
and O +
3 O -
. O +

The O +
BRCA2 B-Gene +
truncating O +
pathogenic O +
carriers O +
were O +
consistently O +
predicted O +
with O +
higher O +
accuracy O +
compared O +
to O +
BRCA1 B-Gene +
truncating O +
pathogenic O +
carriers O -
. O +

The O +
accuracy O +
of O +
prediction O +
was O +
improved O +
when O +
the O +
gene O +
list O +
used O +
for O +
prediction O +
was O +
appropriate O +
to O +
the O +
mutation O +
effect O +
( O -
truncating O +
or O +
missense O -
) O +
being O +
tested O -
. O +

When O +
the O +
missense O -
- O -
associated O +
gene O +
list O +
was O +
used O -
, O +
pathogenic O +
truncating O +
mutations O +
were O +
predicted O +
with O +
35 O -
% O +
and O +
68 O -
% O +
accuracy O +
for O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene -
, O +
respectively O -
. O +

Predictions O +
increased O +
to O +
71 O -
% O +
and O +
84 O -
% O +
for O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene -
, O +
respectively O -
, O +
using O +
the O +
truncating O -
- O -
associated O +
genes O -
. O +

Similarly O -
, O +
the O +
pathogenic O +
missense O +
mutation O +
carriers O +
were O +
predicted O +
with O +
83 O -
% O +
and O +
100 O -
% O +
accuracy O +
when O +
the O +
missense O -
- O -
associated O +
gene O +
list O +
is O +
used O -
, O +
but O +
this O +
accuracy O +
was O +
lower O +
or O +
remained O +
the O +
same O +
when O +
the O +
truncating O -
- O -
specific O +
gene O +
list O +
was O +
used O +
( O -
83 O -
% O +
and O +
0 O -
% O -
) O -
. O +

Prediction O +
of O +
BRCAX B-Gene +
samples O +
that O +
did O +
not O +
carry O +
an O +
LCS O +
variant O +
was O +
high O +
in O +
all O +
comparisons O +
( O -
82–94 O -
% O -
) O -
. O +

In O +
contrast O -
, O +
prediction O +
of O +
BRCAX B-Gene +
samples O +
that O +
did O +
carry O +
an O +
LCS O +
variant O +
was O +
poor O +
( O -
40–50 O -
% O -
) O -
. O +

Mutation O +
Prediction O +
of O +
BRCA1 B-Gene +
and O +
BRCAX B-Gene +
samples O +
based O +
on O +
SVM O +
Lists O +
included O +
the O +
200 O +
Highest O +
Ranked O +
Genes O +
from O +
the O +
comparison O +
of O +
BRCA1 B-Gene +
to O +
BRCAX B-Gene +
samples O +
without O +
an O +
LCS O +
variant O -
, O +
as O +
described O +
in O +
the O +
methods O -
. O +

Mutation O +
Prediction O +
of O +
BRCA2 B-Gene +
and O +
BRCAX B-Gene +
samples O +
based O +
on O +
SVM O +
Lists O +
included O +
the O +
200 O +
Highest O +
Ranked O +
Genes O +
from O +
the O +
comparison O +
of O +
BRCA2 B-Gene +
to O +
BRCAX B-Gene +
samples O +
without O +
an O +
LCS O +
variant O -
, O +
as O +
described O +
in O +
the O +
methods O -
. O +

When O +
using O +
SVM O -
, O +
the O +
significance O +
of O +
the O +
predictions O +
can O +
also O +
be O +
represented O +
by O +
the O +
distance O +
the O +
prediction O +
is O +
from O +
the O +
plane O -
, O +
where O +
predictions O +
called O +
with O +
greater O +
confidence O +
are O +
further O +
from O +
the O +
plane O +
that O +
separates O +
the O +
BRCA1 B-Gene +
( O -
or O +
BRCA2 B-Gene -
) O +
and O +
BRCAX B-Gene +
samples O -
. O +

The O +
significance O +
of O +
the O +
predictions O +
for O +
the O +
BRCA1 B-Gene +
pathogenic O +
missense O +
mutations O +
is O +
summarised O +
in O +
Figure O +
4 O -
. O +

Although O +
both O +
missense O +
and O +
truncating O +
gene O +
lists O +
correctly O +
predicted O +
5 O +
of O +
6 O +
missense O +
mutations O -
, O +
the O +
results O +
show O +
that O +
there O +
is O +
much O +
greater O +
confidence O +
in O +
the O +
5 O +
correctly O +
predicted O +
missense O +
mutations O +
when O +
using O +
the O +
missense O -
- O -
derived O +
list O -
. O +

Confidence O +
of O +
Predictions O +
for O +
Missense O +
BRCA1 B-Gene +
LCLs O +
as O +
Determined O +
by O +
Distance O +
from O +
the O +
SVM O +
Plane O -
. O +

The O +
SVM O +
plane O +
separating O +
BRCA1 B-Gene +
from O +
BRCAX O +
is O +
shown O +
by O +
the O +
red O +
line O -
. O +

If O +
the O +
sample O +
falls O +
over O +
the O +
line O +
( O -
black O +
point O -
) O +
the O +
missense O +
mutation O +
is O +
correctly O +
predicted O +
as O +
pathogenic O +
for O +
BRCA1 B-Gene +
mutation O -
. O +

If O +
the O +
sample O +
falls O +
under O +
the O +
line O +
( O -
red O +
point O -
) O +
the O +
missense O +
mutation O +
is O +
incorrectly O +
predicted O +
as O +
BRCAX O -
. O +

The O +
gene O +
lists O +
used O +
for O +
the O +
predictions O +
are O +
the O +
top O +
200 O +
genes O +
from O +
BRCA1 B-Gene +
missense O +
vs O +
BRCAX O -
, O +
and O +
the O +
top O +
200 O +
genes O +
from O +
BRCA1 B-Gene +
Truncating O +
vs O +
BRCAX O -
. O +

Pathway O +
Analysis O +
of O +
Genes O +
Associated O +
with O +
Pathogenic O +
Mutations O +
in O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
Ingenuity O +
Pathway O +
Analysis O +
of O +
genes O +
which O +
differed O +
between O +
the O +
LCLs O +
carrying O +
pathogenic O +
truncating O +
or O +
missense O +
mutations O +
of O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
compared O +
to O +
BRCAX B-Gene +
samples O +
without O +
an O +
LCS O +
variant O +
was O +
performed O +
to O +
determine O +
the O +
potential O +
functional O +
relevance O +
of O +
the O +
differentially O +
expressed O +
genes O -
. O +

All O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
pathogenic O +
mutations O +
resulted O +
in O +
gene O +
expression O +
changes O +
relating O +
to O +
cell O +
cycle O -
, O +
cancer O +
and O +
cellular O +
growth O +
and O +
development O -
, O +
while O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
missense O +
mutations O +
shared O +
some O +
additional O +
similarities O +
( O -
cell O +
death O +
and O +
cell O +
development O +
pathways O -
) O -
. O +

There O +
were O +
also O +
alterations O +
in O +
several O +
pathways O +
that O +
were O +
unique O +
to O +
BRCA1 B-Gene +
truncating O +
mutations O -
, O +
BRCA2 B-Gene +
truncating O +
mutations O -
, O +
BRCA1 B-Gene +
missense O +
mutations O -
, O +
or O +
BRCA2 B-Gene +
missense O +
mutations O +
( O -
Figure O +
S1 O -
) O -
. O +

Discussion O +
It O +
is O +
difficult O +
to O +
counsel O +
patients O +
with O +
a O +
strong O +
family O +
history O +
of O +
breast O +
cancer O +
who O +
are O +
found O +
to O +
carry O +
an O +
unclassified O +
variant O +
in O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene -
. O +

While O +
management O +
at O +
the O +
level O +
of O +
the O +
family O +
should O +
remain O +
unchanged O +
from O +
that O +
of O +
a O +
BRCAX B-Gene +
family O +
with O +
no O +
knowledge O +
of O +
a O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
mutation O -
, O +
some O +
individuals O +
from O +
high O -
- O -
risk O +
families O +
may O +
nevertheless O +
interpret O +
information O +
about O +
an O +
unclassified O +
variant O +
to O +
alter O +
their O +
choices O +
regarding O +
prophylactic O +
surgery O +
for O +
example O -
, O +
and O +
so O +
require O +
careful O +
counselling O -
. O +

Gene O +
expression O +
profiling O +
can O +
be O +
used O +
to O +
classify O +
samples O +
based O +
on O +
phenotype O -
, O +
and O +
its O +
frequent O +
use O +
in O +
laboratories O +
world O -
- O -
wide O +
holds O +
great O +
promise O +
for O +
clinical O +
application O -
, O +
to O +
the O +
extent O +
that O +
profiling O +
tools O +
are O +
being O +
developed O +
for O +
diagnostic O +
use O +
e.g. O +
Agendia O +
Inc. O +
( O -
http://www.agendia.com/ O -
) O -
. O +

Expression O +
profiles O +
of O +
short O -
- O -
term O +
fibroblasts O +
have O +
previously O +
been O +
reported O +
to O +
separate O +
carriers O +
of O +
a O +
heterozygous O +
mutation O +
in O +
the O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
genes O +
from O +
sporadic O +
breast O -
- O -
cancer O -
- O -
affected O +
controls O +
[ O -
30 O -
] O -
, O -
[ O -
31 O -
] O -
. O +

We O +
wished O +
to O +
determine O +
if O +
expression O +
profiling O +
of O +
LCLs O +
could O +
similarly O +
be O +
used O +
to O +
predict O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
mutation O +
status O -
, O +
with O +
the O +
ultimate O +
aim O +
of O +
predicting O +
the O +
significance O +
of O +
unclassified O +
variants O +
of O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene -
. O +

We O +
chose O +
LCLs O +
as O +
a O +
minimally O +
invasive O +
source O +
of O +
germline O +
material O +
that O +
can O +
be O +
maintained O +
as O +
long O +
term O +
cultures O -
, O +
and O +
because O +
previous O +
studies O +
have O +
shown O +
that O +
LCL O +
array O +
profiling O +
is O +
robust O +
to O +
sourcing O +
of O +
LCLs O +
established O +
in O +
different O +
laboratories O +
[ O -
33 O -
] O -
. O +

We O +
compared O +
expression O +
profiles O +
of O +
irradiated O +
LCLs O +
from O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
carriers O +
to O +
those O +
of O +
non B-Gene -
- I-Gene -
BRCA1 I-Gene -
/ I-Gene -
2 I-Gene +
BRCAX B-Gene +
familial O +
breast O +
cancer O +
patients O -
, O +
an O +
appropriate O +
reference O +
group O +
for O +
the O +
proposed O +
evaluation O +
of O +
unclassified O +
variants O +
identified O +
in O +
familial O +
breast O +
cancer O +
patients O -
. O +

A O +
relatively O +
early O +
time O -
- O -
point O +
of O +
30 O +
minutes O +
post O -
- O -
irradiation O +
was O +
chosen O +
to O +
capture O +
gene O +
expression O +
initiation O -
, O +
and O +
minimize O +
possible O +
downstream O +
compensation O +
effects O -
. O +

It O +
has O +
previously O +
been O +
shown O +
that O +
10Gy O +
IR O +
treatment O +
of O +
normal O +
LCLs O +
has O +
an O +
effect O +
on O +
the O +
transcriptional O +
response O -
, O +
with O +
greatest O +
change O +
in O +
mRNA O +
levels O +
for O +
most O +
genes O +
within O +
one O +
hour O +
post O -
- O -
treatment O +
[ O -
35 O -
] O -
, O +
and O +
studies O +
of O +
mouse O +
brain O +
gene O +
expression O +
after O +
whole O -
- O -
body O +
low O -
- O -
dose O +
irradiation O +
have O +
shown O +
that O +
a O +
large O +
number O +
of O +
early O +
IR O +
response O +
genes O +
can O +
be O +
measured O +
at O +
the O +
30 O +
minute O +
time O +
point O +
[ O -
36 O -
] O -
. O +

A O +
number O +
of O +
BRCAX B-Gene +
cases O +
carried O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
sequence O +
variants O +
that O +
had O +
been O +
previously O +
classified O +
using O +
multifactorial O +
likelihood O +
modelling O +
methods O +
to O +
be O +
neutral O +
or O +
of O +
low O +
clinical O +
significance O -
- O -
that O +
is O -
, O +
these O +
rare O +
variants O +
are O +
extremely O +
unlikely O +
to O +
be O +
a O +
high O -
- O -
risk O +
mutation O +
in O +
either O +
of O +
these O +
genes O -
, O +
but O +
the O +
modelling O +
methods O +
used O +
can O -
not O +
assess O +
whether O +
they O +
are O +
truly O +
neutral O +
or O +
associated O +
with O +
a O +
much O +
lower O +
risk O +
of O +
disease O -
. O +

We O +
found O +
that O +
the O +
BRCAX B-Gene +
samples O +
with O +
such O +
LCS O +
variants O +
were O +
separated O +
from O +
the O +
majority O +
of O +
BRCAX B-Gene +
samples O +
without O +
such O +
LCS O +
variants O +
using O +
unsupervised O +
hierarchical O +
clustering O -
. O +

This O +
result O +
indicates O +
that O +
LCS O +
samples O +
differ O +
in O +
expression O +
profile O +
as O +
a O +
result O +
of O +
their O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
sequence O +
variant O -
, O +
and O +
was O +
substantiated O +
by O +
the O +
class O +
prediction O +
methods O -
: O +
GPC O +
prediction O +
of O +
the O +
BRCAX B-Gene +
samples O +
decreased O +
in O +
accuracy O +
when O +
BRCAX B-Gene +
samples O +
with O +
an O +
LCS O +
were O +
included O -
. O +

In O +
addition O -
, O +
SVM O +
to O +
detect O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
mutation O -
- O -
related O +
gene O +
lists O +
yielded O +
differences O +
in O +
the O +
significant O +
genes O +
for O +
comparisons O +
to O +
BRCAX B-Gene +
samples O +
without O +
an O +
LCS O +
variant O -
, O +
compared O +
to O +
BRCAX B-Gene +
samples O +
with O +
an O +
LCS O +
variant O -
. O +

Accordingly O -
, O +
prediction O +
of O +
BRCAX O +
subgroup O +
status O +
based O +
on O +
the O +
more O +
robust O +
gene O +
list O +
derived O +
from O +
comparisons O +
to O +
BRCAX B-Gene +
individuals O +
without O +
an O +
LCS O +
variant O +
was O +
generally O +
poorer O +
for O +
BRCAX B-Gene +
samples O +
with O +
an O +
LCS O +
( O -
40–50 O -
% O -
) O +
compared O +
to O +
those O +
without O +
an O +
LCS O +
( O -
82%–94 O -
% O -
) O -
. O +

These O +
rather O +
provocative O +
results O +
indicate O +
that O +
the O +
possible O +
effect O +
of O +
all O +
rare O +
variants O +
should O +
be O +
considered O +
in O +
development O +
of O +
assays O +
to O +
assess O +
which O +
variants O +
have O +
features O +
of O +
high O -
- O -
risk O +
mutations O -
. O +

Moreover O -
, O +
the O +
similarity O +
in O +
expression O +
profile O +
of O +
these O +
variants O +
to O +
other O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
pathogenic O +
mutations O +
suggests O +
that O +
at O +
least O +
some O +
of O +
these O +
LCS O +
variants O +
may O +
confer O +
small O -
- O -
moderate O +
risks O +
of O +
breast O +
cancer O -
, O +
presumably O +
acting O +
in O +
concert O +
with O +
alterations O +
in O +
other O +
genes O +
in O +
the O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
pathway O +
to O +
lead O +
to O +
breast O +
cancer O -
. O +

Given O +
the O +
rarity O +
of O +
these O +
variants O -
, O +
alternative O +
statistical O +
approaches O +
will O +
be O +
required O +
to O +
assess O +
the O +
risk O +
of O +
cancer O +
associated O +
with O +
them O -
. O +

Pathway O +
analysis O +
confirming O +
altered O +
expression O +
of O +
cancer O -
, O +
cell O +
proliferation O +
and O +
cell O +
cycle O +
pathways O +
in O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
mutation O +
carrier O +
groups O +
is O +
consistent O +
with O +
the O +
known O +
functions O +
of O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
[ O -
38 O -
] O -
, O -
[ O -
39 O -
] O -
. O +

The O +
pathway O +
differences O +
by O +
mutation O +
type O +
such O +
as O +
cell O +
death O +
and O +
development O +
may O +
reflect O +
that O +
the O +
majority O +
of O +
truncating O +
mutations O +
result O +
in O +
activation O +
of O +
the O +
nonsense O +
mediated O +
decay O +
pathway O +
[ O -
40 O -
] O +
and O +
complete O +
loss O +
of O +
protein O -
, O +
whereas O +
most O +
missense O +
mutations O +
are O +
likely O +
to O +
result O +
in O +
more O +
subtle O +
effects O +
through O +
ablation O +
of O +
individual O +
functional O +
domains O -
. O +

Some O +
pathways O +
identified O +
were O +
unexpected O +
and O +
are O +
only O +
present O +
in O +
a O +
single O +
mutation O +
type O -
, O +
and O +
it O +
is O +
thus O +
likely O +
that O +
at O +
least O +
some O +
of O +
these O +
pathways O +
were O +
generated O +
by O +
chance O +
alone O -
. O +

In O +
conclusion O -
, O +
we O +
have O +
provided O +
evidence O +
that O +
carriers O +
of O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
variants O +
considered O +
to O +
be O +
of O +
low O +
clinical O +
significance O +
have O +
array O +
profiles O +
distinct O +
from O +
other O +
non B-Gene -
- I-Gene -
BRCA1 I-Gene -
/ I-Gene -
2 I-Gene +
familial O +
cases O -
, O +
but O +
resembling O +
profiles O +
of O +
pathogenic O +
BRCA1 B-Gene -
/ I-Gene -
2 I-Gene +
cases O -
, O +
indicating O +
that O +
further O +
work O +
will O +
be O +
required O +
to O +
evaluate O +
their O +
possible O +
association O +
with O +
a O +
low O -
- O -
moderate O +
risk O +
of O +
cancer O -
. O +

We O +
have O +
also O +
shown O +
that O +
it O +
will O +
be O +
important O +
to O +
consider O +
mutation O +
effect O +
when O +
developing O +
array O -
- O -
based O +
assays O +
for O +
predicting O +
the O +
clinical O +
significance O +
of O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
unclassified O +
variants O -
. O +

Lastly O -
, O +
our O +
findings O +
demonstrate O +
the O +
ability O +
of O +
array O +
profiling O +
of O +
immortalized O +
lines O +
derived O +
from O +
lymphoblastoid O +
cells O +
to O +
detect O +
germline O +
mutations O +
in O +
genes O +
that O +
result O +
in O +
breast O +
and O +
ovarian O +
cancer O -
, O +
and O +
thus O +
have O +
relevance O +
to O +
the O +
investigation O +
of O +
other O +
genetic O +
diseases O +
irrespective O +
of O +
the O +
organs O +
or O +
tissues O +
they O +
affect O -
. O +

Materials O +
and O +
Methods O +
Subjects O +
and O +
Lymphoblastoid O +
Cell O +
Lines O +
LCLs O +
were O +
derived O +
from O +
breast O +
cancer O -
- O -
affected O +
women O +
recruited O +
into O +
the O +
Kathleen O +
Cuningham O +
Foundation O +
for O +
Research O +
into O +
Breast O +
Cancer O +
( O -
kConFab O -
) O -
, O +
a O +
consortium O +
which O +
ascertains O +
multiple O -
- O -
case O +
breast O +
cancer O +
families O +
[ O -
41 O -
] O -
. O +

These O +
include O +
families O +
in O +
which O +
one O +
or O +
more O +
carriers O +
of O +
a O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
mutation O +
have O +
been O +
identified O -
, O +
and O +
families O +
in O +
which O +
no O +
predisposing O +
mutation O +
has O +
been O +
identified O +
( O -
BRCAX O -
) O -
. O +

The O +
recruitment O +
criteria O +
for O +
BRCAX B-Gene +
families O +
are O -
: O +
1 O -
) O +
at O +
least O +
one O +
member O +
of O +
the O +
family O +
at O +
high O -
- O -
risk O +
according O +
to O +
the O +
National O +
Breast O +
Cancer O +
Centre O +
Category O +
III O +
guidelines O +
( O -
http://www.nbcc.org.au O -
) O -
, O +
and O +
four O +
or O +
more O +
cases O +
of O +
breast O +
or O +
ovarian O +
cancer O +
( O -
on O +
one O +
side O +
of O +
the O +
family O -
) O -
, O +
and O +
two O +
or O +
more O +
living O +
affecteds O +
with O +
breast O +
or O +
ovarian O +
cancer O -
, O +
and O +
four O +
or O +
more O +
living O +
first O +
or O +
second O +
degree O +
unaffected O +
female O +
relatives O +
of O +
affected O +
cases O -
, O +
over O +
the O +
age O +
of O +
18 O +
; O +
2 O -
) O +
two O +
or O +
three O +
cases O +
of O +
breast O +
or O +
ovarian O +
cancer O +
( O -
on O +
one O +
side O +
of O +
the O +
family O -
) O +
in O +
same O +
or O +
adjacent O +
generations O -
, O +
if O +
at O +
least O +
one O +
of O +
these O +
cases O +
is O +
' O -
high O +
risk O -
' O +
( O -
i.e. O +
male O +
breast O +
cancer O -
, O +
bilateral O +
breast O +
cancer O -
, O +
breast O +
plus O +
ovarian O +
cancer O +
in O +
the O +
same O +
individual O -
, O +
or O +
breast O +
cancer O +
with O +
onset O +
less O +
than O +
40 O +
years O -
) O -
, O +
and O +
two O +
or O +
more O +
living O +
affected O +
cases O +
with O +
breast O +
or O +
ovarian O +
cancer O -
, O +
and O +
four O +
or O +
more O +
living O +
first O +
or O +
second O +
degree O +
unaffected O +
female O +
relatives O +
of O +
affected O +
cases O -
, O +
over O +
the O +
age O +
of O +
18 O -
. O +

Classifications O +
for O +
BRCA1 B-Gene +
and O +
BRCA2 B-Gene +
pathogenic O +
mutations O +
and O +
variants O +
of O +
low O +
clinical O +
significance O +
( O -
LCS O -
) O +
are O +
described O +
on O +
http://www.kconfab.org/Progress/Classification.shtml O -
. O +

Briefly O -
, O +
LCS O +
variants O +
include O +
BRCA1 B-Gene +
or O +
BRCA2 B-Gene +
variants O +
described O +
in O +
trans O +
with O +
a O +
deleterious O +
mutation O +
in O +
the O +
same O +
gene O +
in O +
an O +
individual O +
and O +
occur O +
at O +
a O +
frequency O +
of O +
less O +
than O +
1 O -
% O +
in O +
unaffected O +
controls O -
, O +
or O +
considered O +
neutral O -
/ O -
low O +
clinical O +
significance O +
as O +
measured O +
using O +
multifactorial O +
likelihood O +
approaches O +
[ O -
16 O -
] O -
, O -
[ O -
19 O -
] O -
, O -
[ O -
21 O -
] O -
, O -
[ O -
22 O -
] O -
. O +

A O +
cohort O +
of O +
72 O +
LCLs O +
were O +
used O +
in O +
this O +
study O -
. O +

The O +
full O +
listing O +
of O +
mutation O +
details O +
for O +
LCLs O +
is O +
shown O +
in O +
Table O +
S1 O -
. O +

In O +
brief O -
, O +
the O +
study O +
included O -
: O +
23 O +
LCLs O +
from O +
women O +
carrying O +
a O +
pathogenic O +
mutation O +
in O +
BRCA1 B-Gene -
, O +
17 O +
of O +
which O +
are O +
predicted O +
to O +
lead O +
to O +
a O +
truncated O +
protein O -
, O +
and O +
six O +
of O +
which O +
were O +
missense O +
mutations O +
( O -
2 O -
× O +
300 O +
T O -
> O -
G O +
C61 O -
G O -
; O +
2 O -
× O +
5242 O +
C O -
> O -
A O +
A1708E O -
; O +
1 O -
× O +
5331 O +
G O -
> O -
A O +
G1738R O -
; O +
1 O -
× O +
5632 O +
T O -
> O -
A O +
V1838E O -
) O -
; O +
22 O +
LCLs O +
from O +
women O +
carrying O +
a O +
pathogenic O +
mutation O +
in O +
BRCA2 B-Gene -
, O +
19 O +
of O +
which O +
are O +
predicted O +
to O +
lead O +
to O +
a O +
truncated O +
protein O -
, O +
and O +
three O +
of O +
which O +
were O +
missense O +
mutations O +
( O -
3 O -
× O +
8395 O +
G O -
> O -
C O +
D2723H O -
, O +
one O +
of O +
which O +
also O +
carried O +
the O +
LCS O +
variant O +
9079 O +
G O -
> O -
A O +
A2951 O -
T O -
) O -
; O +

Clinical O +
characterization O +
and O +
the O +
mutation O +
spectrum O +
in O +
Swedish O +
adenomatous O +
polyposis O +
families O +
Abstract O +

Background O +
The O +
dominantly O +
inherited O +
condition O +
familial O +
adenomatous O +
polyposis O +
( O -
FAP O -
) O +
is O +
caused O +
by O +
germline O +
mutations O +
in O +
the O +
APC B-Gene +
gene O -
. O +

Finding O +
the O +
causative O +
mutations O +
has O +
great O +
implications O +
for O +
the O +
families O -
. O +

Correlating O +
the O +
genotypes O +
to O +
the O +
phenotypes O +
could O +
help O +
to O +
improve O +
the O +
diagnosis O +
and O +
follow O -
- O -
up O +
of O +
patients O -
. O +

Methods O +
Mutation O +
screening O +
of O +
APC B-Gene +
and O +
the O +
clinical O +
characterization O +
of O +
96 O +
unrelated O +
FAP O +
patients O +
from O +
the O +
Swedish O +
Polyposis O +
Registry O +
was O +
performed O -
. O +

In O +
addition O +
to O +
generally O +
used O +
mutation O +
screening O +
methods O -
, O +
analyses O +
of O +
splicing O -
- O -
affecting O +
mutations O +
and O +
investigations O +
of O +
the O +
presence O +
of O +
low O -
- O -
frequency O +
mutation O +
alleles O -
, O +
indicating O +
mosaics O -
, O +
have O +
been O +
performed O -
, O +
as O +
well O +
as O +
quantitative O +
real O -
- O -
time O +
polymerase O +
chain O +
reaction O +
to O +
detect O +
lowered O +
expression O +
of O +
APC B-Gene -
. O +

Results O +
Sixty O -
- O -
one O +
different O +
APC B-Gene +
mutations O +
in O +
81 O +
of O +
the O +
96 O +
families O +
were O +
identified O +
and O +
27 O +
of O +
those O +
are O +
novel O -
. O +

We O +
have O +
previously O +
shown O +
that O +
6 O +
of O +
the O +
96 O +
patients O +
carried O +
biallelic O +
MUTYH B-Gene +
mutations O -
. O +

The O +
9 O +
mutation O -
- O -
negative O +
cases O +
all O +
display O +
an O +
attenuated O +
or O +
atypical O +
phenotype O -
. O +

Probands O +
with O +
a O +
genotype O +
( O -
codon O +
1250–1464 O -
) O +
predicting O +
a O +
severe O +
phenotype O +
had O +
a O +
median O +
age O +
at O +
diagnosis O +
of O +
21.8 O +
( O -
range O -
, O +
11–49 O -
) O +
years O +
compared O +
with O +
34.4 O +
( O -
range O -
, O +
14–57 O -
) O +
years O +
among O +
those O +
with O +
mutations O +
outside O +
this O +
region O +
( O -
P O +
< O +
0.017 O -
) O -
. O +

Dense O +
polyposis O +
( O -
> O +
1000 O -
) O +
occurred O +
in O +
75 O -
% O +
of O +
the O +
probands O +
with O +
a O +
severe O +
phenotype O +
compared O +
with O +
30 O -
% O +
in O +
those O +
with O +
mutations O +
outside O +
this O +
region O -
. O +

The O +
morbidity O +
in O +
colorectal O +
cancer O +
among O +
probands O +
was O +
25 O -
% O +
at O +
a O +
mean O +
age O +
of O +
37.5 O +
years O +
and O +
29 O -
% O +
at O +
a O +
mean O +
age O +
of O +
46.6 O +
years O -
. O +

Conclusion O +
Using O +
a O +
variety O +
of O +
mutation O -
- O -
detection O +
techniques O -
, O +
we O +
have O +
achieved O +
a O +
100 O -
% O +
detection O +
frequency O +
in O +
classical O +
FAP O -
. O +

Probands O +
with O +
APC B-Gene +
mutations O +
outside O +
codon O +
1250–1464 O -
, O +
although O +
exhibiting O +
a O +
less O -
- O -
severe O +
phenotype O -
, O +
are O +
at O +
high O +
risk O +
of O +
having O +
a O +
colorectal O +
cancer O +
at O +
diagnosis O +
indicating O +
that O +
age O +
at O +
diagnosis O +
is O +
as O +
important O +
as O +
the O +
severity O +
of O +
the O +
disease O +
for O +
colorectal O +
cancer O +
morbidity O -
. O +

Background O +
The O +
dominantly O +
inherited O +
condition O +
familial O +
adenomatous O +
polyposis O +
( O -
FAP O -
) O +
is O +
caused O +
by O +
germline O +
mutations O +
in O +
the O +
APC B-Gene +
gene O +
( O -
5q21-q22 O -
; O +
MIM#175100 O -
) O +
[ O -
1,2 O -
] O -
. O +

The O +
classical O +
FAP O +
phenotype O +
is O +
defined O +
by O +
hundreds O +
to O +
thousands O +
of O +
adenomatous O +
polyps O +
that O +
develop O +
in O +
the O +
large O +
intestine O -
, O +
conferring O +
a O +
high O +
risk O +
of O +
colorectal O +
cancer O +
( O -
CRC O -
) O -
. O +

A O +
variety O +
of O +
extra O -
- O -
colonic O +
manifestations O +
exist O +
in O +
FAP O -
. O +

Duodenal O +
adenomas O +
are O +
common O +
and O +
carcinomas O +
of O +
the O +
duodenum O +
are O +
a O +
main O +
cause O +
of O +
death O +
in O +
FAP O +
patients O -
. O +

Patients O +
also O +
have O +
an O +
increased O +
risk O +
of O +
developing O +
extra O -
- O -
intestinal O +
tumors O -
, O +
for O +
example O -
, O +
desmoids O -
. O +

Recently O -
, O +
a O +
new O +
type O +
of O +
colorectal O +
adenomatous O +
polyposis O +
has O +
been O +
described O -
, O +
MUTYH B-Gene -
- O -
associated O +
polyposis O +
( O -
MAP O -
) O +
[ O -
3 O -
] O +
or O +
MUTYH B-Gene -
- O -
associated O +
CRC O +
( O -
MIM#608456 O -
) O -
. O +

MAP O +
is O +
caused O +
by O +
biallelic O +
mutations O +
in O +
the O +
MUTYH B-Gene +
( O -
mutY O +
homologue O -
; O +
MIM*604933 O -
) O +
gene O +
( O -
1p32.1-p34.3 B-Gene -
) O +
and O +
is O +
inherited O +
in O +
a O +
recessive O +
manner O +
[ O -
4,5 O -
] O -
. O +

The O +
majority O +
of O +
germline O +
APC B-Gene +
mutations O +
identified O +
in O +
FAP O +
families O +
cause O +
truncations O +
in O +
this O +
multifunctional O +
protein O +
[ O -
6,7 O -
] O -
. O +

The O +
APC B-Gene +
truncations O +
most O +
often O +
occur O +
as O +
the O +
result O +
of O +
nonsense O +
APC B-Gene +
mutations O +
or O +
frameshifts O +
caused O +
by O +
small O +
deletions O -
/ O -
insertions O -
. O +

Large O +
APC B-Gene +
deletions O +
are O +
found O +
in O +
a O +
limited O +
number O +
of O +
FAP O +
cases O -
. O +

By O +
using O +
methods O +
such O +
as O +
quantitative O +
real O -
- O -
time O +
PCR O +
( O -
polymerase O +
chain O +
reaction O -
) O +
or O +
MLPA O +
( O -
multiplex O +
ligation O -
- O -
dependent O +
probe O +
amplification O -
) O +
rather O +
than O +
conventional O +
mutation O -
- O -
detection O +
techniques O -
, O +
we O +
can O +
achieve O +
higher O +
detection O +
rates O +
of O +
large O +
deletions O +
[ O -
8 O -
- O -
12 O -
] O -
. O +

The O +
number O +
of O +
reported O +
characterized O +
APC B-Gene +
splice O -
- O -
site O +
mutations O +
is O +
comparatively O +
low O +
[ O -
13 O -
- O -
17 O -
] O -
. O +

Approximately O +
10–15 O -
% O +
of O +
the O +
FAP O +
patients O +
could O +
have O +
a O +
reduced O +
or O +
absent O +
APC B-Gene +
expression O +
[ O -
18 O -
] O -
. O +

The O +
cause O +
of O +
the O +
reduced O +
expression O +
is O +
not O +
known O +
but O +
the O +
patients O +
show O +
a O +
similar O +
phenotype O +
to O +
those O +
with O +
an O +
identified O +
truncating O +
APC B-Gene +
mutation O +
[ O -
19 O -
- O -
21 O -
] O -
. O +

It O +
has O +
been O +
shown O +
that O +
a O +
decrease O +
of O +
approximately O +
50 O -
% O +
of O +
the O +
expression O +
of O +
an O +
allele O +
can O +
result O +
in O +
a O +
predisposition O +
to O +
FAP O +
[ O -
20 O -
] O -
. O +

Germline O +
APC B-Gene -
- O -
mutation O +
mosaicism O +
in O +
FAP O +
patients O +
has O +
been O +
reported O +
[ O -
22 O -
- O -
25 O -
] O +
but O +
is O +
not O +
generally O +
included O +
in O +
the O +
mutation O +
screening O +
procedure O +
provided O +
by O +
most O +
labs O +
owing O +
to O +
the O +
technical O +
difficulties O +
encountered O +
with O +
these O +
analyses O -
. O +

Different O +
genotype O -
- O -
phenotype O +
correlations O +
in O +
FAP O +
have O +
been O +
suggested O +
[ O -
26 O -
- O -
28 O -
] O -
. O +

The O +
classic O +
phenotype O +
is O +
primarily O +
caused O +
by O +
mutations O +
in O +
the O +
central O +
part O +
of O +
the O +
APC B-Gene +
gene O -
. O +

Mutations O +
around O +
codon O +
1309 O +
cause O +
a O +
severe O +
course O +
of O +
disease O +
with O +
early O +
onset O +
and O +
profuse O +
polyposis O -
. O +

The O +
milder O -
, O +
attenuated O +
form O +
of O +
disease O +
( O -
AFAP O -
) O -
, O +
characterized O +
by O +
less O +
than O +
100 O +
adenomas O +
and O +
later O +
onset O +
of O +
adenomatosis O +
and O +
CRC O -
, O +
is O +
often O +
caused O +
by O +
mutations O +
in O +
the O +
far O +
5 O -
' O +
and O +
3 O -
' O +
regions O +
of O +
the O +
APC B-Gene +
gene O -
, O +
as O +
well O +
as O +
in O +
the O +
part O +
excluded O +
by O +
alternative O +
splicing O +
of O +
exon O +
9 O +
[ O -
29 O -
] O -
. O +

Molecular O +
genetic O +
analysis O +
of O +
the O +
APC B-Gene +
gene O +
Mutational O +
screening O +
of O +
APC B-Gene +
was O +
initialized O +
with O +
DNA O +
( O -
exon O +
15 O -
) O +
and O -
, O +
whenever O +
possible O -
, O +
RNA O -
- O -
based O +
( O -
exons O +
1–14 O -
) O +
PTT O +
( O -
protein O +
truncation O +
test O -
) O -
. O +

SSCP O -
/ O -
HD O +
( O -
single O -
- O -
strand O +
conformational O +
polymorphism O -
/ O -
heteroduplex O -
) O -
, O +
D O -
- O -
HPLC O +
( O -
denaturing O +
high O -
- O -
performance O +
liquid O +
chromatography O -
) O +
on O +
the O +
Wave O +
instrument O +
( O -
Transgenomic O -
, O +
Omaha O -
, O +
NE O -
) O -
, O +
and/or O +
DNA O +
sequencing O +
was O +
applied O +
for O +
screening O +
of O +
exons O +
1–14 O -
. O +

DNA O +
sequencing O +
of O +
exon O +
15 O +
was O +
performed O +
when O +
no O +
mutation O +
had O +
been O +
detected O +
in O +
the O +
initial O +
search O -
. O +

Patients O +
C107 O -
, O +
C257 O +
and O +
C505 O +
with O +
no O +
documented O +
inheritance O +
of O +
FAP O +
and O +
where O +
no O +
mutation O +
in O +
the O +
entire O +
APC B-Gene +
or O +
MUTYH B-Gene +
genes O +
could O +
be O +
detected O -
, O +
were O +
subjected O +
to O +
analyses O +
for O +
mosaic O +
mutations O +
using O +
SSCP O -
/ O -
HD O -
. O +

PCR O -
, O +
RT O -
- O -
PCR O +
( O -
reverse O +
transcriptase O +
PCR O -
) O -
, O +
SSCP O -
/ O -
HD O -
, O +
and O +
PTT O +
were O +
carried O +
out O +
as O +
described O +
previously O +
[ O -
33 O -
] O +
with O +
the O +
following O +
changes O -
: O +
the O +
Criterion O +
Tris O -
- O -
HCl O +
8–16 O -
% O +
gels O +
and O +
Criterion O +
Gel O +
Electrophoresis O +
System O +
( O -
BioRad O +
Laboratories O -
, O +
Hercules O -
, O +
CA O -
) O +
were O +
used O +
for O +
the O +
PTT O -
. O +

Primers O +
used O +
for O +
PCR O +
amplification O +
of O +
genomic O +
DNA O +
for O +
subsequent O +
DNA O +
sequencing O +
or O +
PTT O +
are O +
available O +
from O +
the O +
authors O +
upon O +
request O -
. O +

Taq O +
DNA O +
polymerase O +
( O -
Amersham O +
Biosciences O +
Corp O -
, O +
Piscataway O -
, O +
NJ O +
or O +
Promega O +
Corporation O -
, O +
Madison O -
, O +
WI O -
) O +
was O +
used O +
for O +
PCR O +
amplification O +
prior O +
to O +
DNA O +
sequencing O -
. O +

DNA O +
sequencing O +
was O +
performed O +
on O +
PCR O +
products O +
purified O +
with O +
ExoSAP O -
- O -
IT O +
( O -
USB O -
, O +
Cleveland O -
, O +
OH O -
) O -
. O +

Sequence O +
reactions O +
were O +
carried O +
out O +
using O +
ABI O +
Prism O +
Big O +
Dye O +
Terminator O +
Cycle O +
Sequencing O +
kit O +
( O -
Applied O +
Biosystems O -
, O +
Foster O +
City O -
, O +
CA O -
) O +
and O +
analyzed O +
on O +
the O +
ABI O +
Prism O +
3100 O +
Genetic O +
Analyzer O +
( O -
Applied O +
Biosystems O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
protocol O -
. O +

MLPA O +
[ O -
34 O -
] O +
was O +
used O +
to O +
detect O +
deletions O -
/ O -
duplications O +
of O +
one O +
or O +
more O +
exons O +
and O +
was O +
carried O +
out O +
as O +
described O +
by O +
Meuller O +
et O +
al O +
[ O -
10 O -
] O -
. O +

All O +
MLPA O +
analyses O +
were O +
carried O +
out O +
in O +
duplicates O +
and O +
normalized O +
against O +
two O +
different O +
control O +
individuals O -
. O +

All O +
mutations O +
described O +
in O +
this O +
study O +
were O +
verified O +
in O +
a O +
second O +
independent O +
analysis O +
using O -
, O +
as O +
far O +
as O +
possible O -
, O +
an O +
alternative O +
mutation O -
- O -
detection O +
technique O -
. O +

Analyses O +
of O +
APC B-Gene +
expression O +
The O +
level O +
of O +
APC B-Gene +
mRNA O +
expression O +
in O +
peripheral O +
blood O +
cells O +
was O +
investigated O +
by O +
TaqMan O +
quantitative O +
real O -
- O -
time O +
PCR O +
( O -
RT O -
- O -
PCR O -
) O +
analysis O +
in O +
29 O +
patients O +
from O +
18 O +
families O -
. O +

RT O -
- O -
PCR O +
was O +
carried O +
out O +
using O +
ABI O +
Prism O +
7900HT O +
Sequence O +
Detection O +
System O +
( O -
Applied O +
Biosystems O -
) O +
at O +
the O +
Gothenburg O +
Genomics O +
Core O +
Facility O -
. O +

Primers O +
and O +
probe O +
for O +
the O +
APC B-Gene +
gene O +
as O +
well O +
as O +
for O +
GAPD B-Gene -
, O +
which O +
was O +
used O +
as O +
internal O +
control O -
, O +
were O +
obtained O +
from O +
[ O -
35 O -
] O -
. O +

Amplification O +
reactions O +
were O +
performed O +
for O +
the O +
two O +
genes O +
separately O +
in O +
a O +
volume O +
of O +
10 O +
μl O +
containing O +
1 O +
μl O +
template O +
cDNA O +
diluted O +
1:10 O -
, O +
1 O +
× O +
FAM O -
- O -
labeled O +
Assay O -
- O -
on O -
- O -
Demand O +
Gene O +
Expression O +
Assay O +
Mix O -
, O +
and O +
1 O +
× O +
TaqMan O +
Universal O +
PCR O +
Master O +
Mix O +
( O -
Applied O +
Biosystems O -
) O -
. O +

Thermal O +
cycling O +
was O +
performed O +
according O +
to O +
the O +
standard O +
protocol O -
. O +

Triple O +
samples O +
of O +
each O +
patient O +
were O +
analyzed O +
and O +
no O -
- O -
template O +
controls O +
were O +
included O +
in O +
the O +
experiments O -
. O +

As O +
the O +
standard O +
curve O +
method O +
for O +
quantification O +
of O +
RT O -
- O -
PCR O +
products O +
would O +
be O +
used O -
, O +
a O +
series O +
of O +
dilutions O +
of O +
calibrator O +
cDNA O +
were O +
also O +
included O -
. O +

The O +
fluorescence O +
intensities O +
detected O +
during O +
the O +
PCR O +
process O +
were O +
analyzed O +
and O +
converted O +
into O +
threshold O +
cycle O +
values O +
( O -
Ct O -
- O -
values O -
) O +
using O +
the O +
SDS O +
2.0 O +
software O +
( O -
Applied O +
Biosystems O -
) O -
. O +

Using O +
the O +
obtained O +
standard O +
curve O +
for O +
each O +
gene O -
, O +
the O +
concentration O +
of O +
APC B-Gene +
and O +
GAPD B-Gene +
in O +
each O +
sample O +
was O +
calculated O +
from O +
the O +
mean O +
Ct O +
value O +
of O +
each O +
triplicate O -
. O +

The O +
APC B-Gene +
value O +
was O +
then O +
normalized O +
against O +
the O +
housekeeping O +
gene O +
GAPD B-Gene +
to O +
obtain O +
a O +
relative O +
measurement O +
of O +
the O +
level O +
of O +
APC B-Gene +
expression O +
in O +
the O +
blood O +
of O +
the O +
patient O -
. O +

The O +
Dunnett O +
t O -
- O -
test O +
was O +
used O +
to O +
calculate O +
statistical O +
significance O -
. O +

To O +
verify O +
the O +
expression O +
data O -
, O +
cDNA O +
from O +
the O +
positive O +
individuals O +
was O +
sequenced O +
over O +
an O +
informative O +
heterozygous O +
cSNP O +
position O +
( O -
c.5465A O +
> O +
T O -
) O -
. O +

The O +
level O +
of O +
expression O +
of O +
each O +
allele O +
could O +
then O +
be O +
estimated O -
. O +

Statistics O +
Student O -
's O +
t O -
- O -
test O +
was O +
used O +
to O +
analyze O +
continuous O +
data O -
, O +
and O +
Fisher O -
's O +
exact O +
test O +
was O +
used O +
to O +
analyze O +
categorical O +
data O -
. O +

Differences O +
were O +
considered O +
statistically O +
significant O +
at O +
a O +
level O +
of O +
P O +
< O +
0.05 O -
. O +

Results O +
Sixty O -
- O -
one O +
different O +
APC B-Gene +
mutations O -
, O +
27 O +
novel O +
and O +
34 O +
recurrent O -
, O +
were O +
detected O +
among O +
81 O +
of O +
the O +
96 O +
Swedish O +
families O +
studied O +
as O +
shown O +
in O +
Additional O +
files O +
1 O +
and O +
2 O -
. O +

A O +
mutation O +
spectrum O +
displaying O +
the O +
distribution O +
between O +
novel O +
and O +
previously O +
reported O +
mutations O +
is O +
shown O +
in O +
Figure O +
1 O -
. O +

The O +
frequency O +
of O +
APC B-Gene +
de O +
novo O +
mutation O +
cases O +
among O +
the O +
families O +
was O +
16 O -
% O -
. O +

In O +
three O +
of O +
the O +
families O +
parents O +
were O +
tested O +
negative O +
for O +
the O +
mutation O +
and O +
in O +
the O +
remaining O +
seven O +
families O +
we O +
where O +
unable O +
to O +
obtain O +
samples O +
to O +
test O +
parents O -
. O +

Thirty O -
- O -
two O +
of O +
the O +
81 O +
patients O +
with O +
APC B-Gene +
mutations O +
were O +
probands O -
. O +

Probands O +
with O +
mutations O +
in O +
the O +
region O +
from O +
codon O +
1250 O +
to O +
1464 O +
of O +
the O +
APC B-Gene +
gene O +
which O +
predicts O +
a O +
severe O +
phenotype O +
[ O -
36 O -
] O +
had O +
a O +
median O +
age O +
at O +
diagnosis O +
of O +
21.8 O +
( O -
range O -
, O +
11–49 O -
) O +
years O +
compared O +
with O +
34.4 O +
( O -
range O -
, O +
14–57 O -
) O +
years O +
among O +
those O +
with O +
mutations O +
outside O +
this O +
region O +
( O -
P O +
< O +
0.017 O -
) O -
. O +

Available O +
data O +
on O +
colorectal O +
polyp O +
number O +
shows O +
that O -
, O +
in O +
spite O +
of O +
higher O +
age O +
at O +
diagnosis O -
, O +
dense O +
polyposis O +
( O -
> O +
1000 O -
) O +
only O +
occurred O +
in O +
30 O -
% O +
of O +
the O +
probands O +
compared O +
with O +
75 O -
% O +
in O +
those O +
with O +
mutations O +
between O +
codon O +
1250 O +
and O +
1464 O -
. O +

In O +
the O +
former O +
group O +
29 O -
% O +
( O -
7 O +
out O +
of O +
24 O -
) O +
had O +
CRC O +
at O +
diagnosis O +
compared O +
with O +
25 O -
% O +
( O -
2 O +
out O +
of O +
8) O +
in O +
the O +
latter O +
group O -
. O +

The O +
mean O +
age O +
at O +
CRC O +
was O +
46.6 O +
( O -
range O +
28–57 O -
) O +
and O +
37.5 O +
( O -
range O +
26–49 O -
) O +
years O -
, O +
respectively O -
. O +

The O +
total O +
morbidity O +
in O +
CRC O +
among O +
probands O +
was O +
34 O -
% O +
( O -
11 O +
out O +
of O +
32 O -
) O -
. O +

Of O +
all O +
probands O +
diagnosed O +
after O +
1996 O -
, O +
four O +
out O +
of O +
nine O +
( O -
44 O -
% O -
) O +
had O +
cancer O +
at O +
diagnosis O -
. O +

The O +
median O +
age O +
in O +
this O +
group O +
was O +
47.5 O +
( O -
range O +
45–51 O -
) O +
years O +
and O +
none O +
had O -
, O +
despite O +
high O +
age O +
at O +
diagnosis O +
of O +
CRC O -
, O +
dense O +
colorectal O +
polyposis O +
at O +
diagnosis O +
indicating O +
a O +
less O -
- O -
severe O +
phenotype O -
. O +

A O +
compilation O +
of O +
clinical O +
status O +
of O +
all O +
patients O +
analyzed O +
in O +
this O +
study O +
is O +
shown O +
in O +
Additional O +
file O +
1 O -
. O +

Mutation O +
spectrum O +
of O +
the O +
APC B-Gene +
gene O -
. O +

( O -
A O -
) O +
The O +
spectrum O +
of O +
APC B-Gene +
mutations O +
identified O +
among O +
families O +
from O +
the O +
Swedish O +
Polyposis O +
Registry O +
showing O +
the O +
distribution O +
between O +
previously O +
reported O +
and O +
novel O +
mutations O +
in O +
our O +
patients O -
. O +

( O -
B O -
) O +
A O +
schematic O +
representation O +
of O +
the O +
APC B-Gene +
coding O +
region O -
, O +
shown O +
in O +
the O +
same O +
scale O +
as O +
in O +
( O -
A O -
) O -
. O +

The O +
arrow O +
with O +
an O +
asterisk O +
indicates O +
codon O +
24 O +
and O +
the O +
second O +
arrow O +
points O +
at O +
codon O +
184 O -
. O +

( O -
C O -
) O +
Distribution O +
of O +
six O +
large O +
deletions O +
found O +
in O +
seven O +
unrelated O +
patients O +
of O +
the O +
Swedish O +
Polyposis O +
Registry O -
. O +

Novel O +
deletions O +
are O +
marked O +
with O +
an O +
asterisk O -
. O +

Patient O +
numbers O +
are O +
shown O +
to O +
the O +
left O -
. O +

Scale O +
as O +
in O +
( O -
A O -
) O -
. O +

Large O +
deletions O +
of O +
the O +
APC B-Gene +
gene O +

Splice O -
- O -
site O +
affecting O +
mutations O +
When O +
investigating O +
patient O +
C496 O +
with O +
RNA O -
- O -
based O +
PTT O -
, O +
an O +
aberrant O +
APC B-Gene +
polypeptide O +
pattern O +
was O +
detected O +
( O -
data O +
not O +
shown O -
) O -
. O +

Sequencing O +
of O +
the O +
corresponding O +
cDNA O +
fragment O +
identified O +
a O +
change O +
in O +
the O +
beginning O +
of O +
exon O +
8 O +
( O -
Figure O +
3 O -
) O -
. O +

Genomic O +
sequencing O +
of O +
exon O +
8 O +
and O +
the O +
flanking O +
intron O +
sequences O +
lead O +
to O +
the O +
discovery O +
of O +
the O +
c.835 O -
- O -
7 O -
T O +
> O +
G O +
mutation O +
( O -
Figure O +
3A O -
) O -
. O +

The O +
base O +
substitution O +
introduces O +
a O +
new O +
AG O +
splice O -
- O -
acceptor O +
site O +
eight O +
bases O +
upstream O +
of O +
exon O +
8 O -
. O +

Owing O +
to O +
the O +
use O +
of O +
this O +
new O +
splice O +
site O +
the O +
last O +
six O +
bases O +
of O +
intron O +
7 O +
are O +
included O +
in O +
the O +
transcript O -
, O +
resulting O +
in O +
premature O +
truncation O +
( O -
Figure O +
3B O -
) O -
. O +

The O +
entire O +
APC B-Gene +
coding O +
region O +
of O +
the O +
patient O +
was O +
sequenced O +
and O +
no O +
other O +
pathogenic O +
variants O +
were O +
detected O -
. O +

A O +
search O +
for O +
deletion O +
or O +
duplication O +
of O +
one O +
or O +
more O +
exon O +
in O +
the O +
APC B-Gene +
gene O +
by O +
MLPA O +
was O +
also O +
carried O +
out O +
with O +
negative O +
result O -
. O +

Characterization O +
of O +
the O +
mutation O +
in O +
patient O +
C496 O -
. O +

( O -
A O -
) O +
Genomic O +
sequence O +
of O +
the O +
patient O +
showing O +
the O +
c.835 O -
- O -
7 O -
T O +
> O +
G O +
mutation O -
. O +

The O +
new O +
splice O +
site O +
generated O +
by O +
the O +
T O +
> O +
G O +
substitution O +
is O +
indicated O +
with O +
a O +
dashed O +
line O -
, O +
the O +
wildtype O +
acceptor O -
- O -
splice O +
site O +
is O +
underlined O -
, O +
and O +
the O +
regular O +
start O +
of O +
exon O +
8 O +
is O +
indicated O +
with O +
an O +
arrow O -
. O +
( O -
B O -
) O +
cDNA O +
sequence O +
covering O +
the O +
exon O +
7–8 O +
boundary O -
, O +
indicated O +
with O +
a O +
dashed O +
line O -
. O +

Shown O +
below O +
the O +
sequence O +
diagram O +
is O +
the O +
interpretation O +
of O +
the O +
sequence O +
reflecting O +
the O +
two O +
mRNA O +
species O +
present O +
in O +
the O +
sample O -
. O +

The O +
insertion O +
of O +
6 O +
bp O +
owing O +
to O +
the O +
introduction O +
of O +
a O +
new O +
splice O +
site O +
in O +
the O +
mutant O +
allele O +
is O +
shown O +
as O +
a O +
shaded O +
area O -
. O +

Predicted O +
amino O -
- O -
acid O +
sequence O +
of O +
translation O +
products O +
are O +
shown O +
above O +
and O +
below O +
the O +
respective O +
cDNA O +
sequence O -
. O +

The O +
APC B-Gene +
mutation O +
in O +
patient O +
C633 O +
was O +
also O +
detected O +
by O +
RNA O -
- O -
based O +
PTT O -
, O +
followed O +
by O +
cDNA O +
sequencing O +
and O +
genomic O +
sequencing O +
of O +
APC B-Gene +
exon O +
7 O +
( O -
Figure O +
4 O -
) O -
. O +

The O +
c.834 O -
G O +
> O +
C O +
mutation O +
changes O +
the O +
normal O +
splice O +
donor O +
site O +
of O +
exon O +
7 O -
. O +

This O +
substitution O +
reduces O +
the O +
score O +
for O +
usage O +
of O +
the O +
wild O -
- O -
type O +
splice O +
donor O +
site O +
according O +
to O +
[ O -
37 O -
] O -
. O +

An O +
alternative O +
cryptic O +
splice O +
donor O +
site O +
11 O +
bp O +
upstream O +
in O +
exon O +
7 O +
is O +
used O +
in O +
the O +
mutant O +
allele O -
, O +
leading O +
to O +
the O +
aberrant O +
splicing O +
of O +
exon O +
7 O -
. O +

The O +
resulting O +
APC B-Gene +
mRNA O +
carries O +
a O +
frameshift O -
, O +
caused O +
by O +
the O +
11-bp O +
deletion O +
in O +
the O +
3 O -
' O +
end O +
of O +
exon O +
7 O -
, O +
which O +
leads O +
to O +
the O +
premature O +
truncation O +
of O +
the O +
protein O +
in O +
exon O +
8 O -
. O +

A O +
third O +
novel O +
mutation O +
affecting O +
splicing O +
of O +
the O +
APC B-Gene +
gene O +
was O +
detected O +
by O +
PTT O +
analysis O +
and O +
genomic O +
sequencing O +
of O +
patient O +
C232 O -
. O +

A O +
complex O +
deletion O -
/ O -
insertion O +
was O +
detected O +
that O +
affects O +
the O +
splicing O +
of O +
APC B-Gene +
intron O +
3 O -
, O +
APC B-Gene +
c.423 O -
- O -
6del8ins13 O +
( O -
in O +
detail O +
APC B-Gene +
c. O +
423 O +
-6delAAATAGGTinsGAAGCAAGATCAG O -
) O -
. O +

Characterization O +
of O +
mutation O +
in O +
patient O +
C633 O -
. O +

Diagram O +
of O +
genomic O +
DNA O +
sequence O +
at O +
the O +
exon O -
/ O -
intron O +
7 O +
boundary O -
. O +

The O +
line O +
arrow O +
indicates O +
the O +
c.834 O -
G O +
> O +
C O +
mutation O +
and O +
the O +
wildtype O +
5 O -
' O +
donor O +
splice O +
site O +
of O +
intron O +
7 O +
is O +
underlined O +
in O +
the O +
sequence O +
diagram O -
. O +

The O +
wildtype O +
cDNA O +
and O +
the O +
resulting O +
amino O +
acid O +
sequence O +
from O +
the O +
corresponding O +
transcript O +
are O +
shown O +
above O +
the O +
diagram O -
. O +

The O +
G O +
that O +
is O +
substituted O +
in O +
one O +
allele O +
in O +
the O +
patient O +
is O +
indicated O +
in O +
bold O -
. O +

The O +
cryptic O +
splice O +
site O +
used O +
as O +
a O +
result O +
of O +
the O +
mutation O +
is O +
underlined O +
with O +
a O +
dashed O +
line O +
and O +
the O +
shaded O +
area O +
corresponds O +
to O +
the O +
mRNA O +
sequence O +
deleted O +
in O +
the O +
mutant O +
transcript O -
. O +

Beneath O +
the O +
genomic O +
sequence O +
the O +
cDNA O +
sequence O +
derived O +
from O +
the O +
mutant O +
allele O +
is O +
displayed O -
, O +
showing O +
the O +
resulting O +
frameshift O +
and O +
premature O +
termination O +
of O +
the O +
translation O +
product O -
. O +

A O +
family O +
with O +
reduced O +
APC B-Gene +
expression O +
Lowered O +
APC B-Gene +
expression O +
was O +
observed O +
in O +
samples O +
from O +
two O +
affected O +
individuals O +
from O +
family O +
1 O +
in O +
the O +
Swedish O +
Polyposis O +
Registry O +
( O -
index O +
case O -
, O +
C152 O -
) O -
. O +

The O +
level O +
of O +
APC B-Gene +
mRNA O +
expression O +
in O +
peripheral O +
blood O +
cells O +
from O +
these O +
two O +
individuals O +
where O +
investigated O +
by O +
TaqMan O +
quantitative O +
RT O -
- O -
PCR O +
analysis O -
. O +

In O +
total O -
, O +
29 O +
patients O +
including O +
all O +
9 O +
mutation O -
- O -
negative O +
cases O +
were O +
analyzed O -
. O +

APC- B-Gene +
and O +
MUTYH B-Gene -
- O -
mutation O +
positive O +
patients O +
as O +
well O +
as O +
healthy O +
individuals O +
where O +
included O +
as O +
controls O -
. O +

Reduced O +
APC B-Gene +
expression O +
was O +
only O +
observed O +
in O +
two O +
samples O +
from O +
affected O +
individuals O +
and O +
both O +
of O +
those O +
where O +
from O +
family O +
1 O +
( O -
Figure O +
5A O -
) O -
. O +

The O +
APC B-Gene -
- O -
mutation O +
positive O +
samples O +
used O +
as O +
controls O +
did O +
not O +
show O +
reduced O +
expression O +
of O +
APC B-Gene -
. O +

To O +
verify O +
the O +
expression O +
data O -
, O +
cDNA O +
from O +
the O +
individuals O +
was O +
sequenced O +
over O +
an O +
informative O +
heterozygous O +
cSNP O +
position O +
( O -
c.5465A O +
> O +
T O -
) O -
. O +

By O +
sequencing O +
cDNA O +
and O +
monitoring O +
the O +
level O +
of O +
expression O +
of O +
each O +
allele O +
as O +
shown O +
by O +
the O +
sequence O +
diagram O +
( O -
Figure O +
5B O -
) O -
, O +
the O +
level O +
of O +
the O +
T O -
- O -
allele O +
was O +
found O +
to O +
be O +
lowered O +
in O +
the O +
two O +
FAP O -
- O -
affected O +
members O +
of O +
the O +
family O -
, O +
compared O +
with O +
control O +
individuals O +
who O +
had O +
displayed O +
normal O +
APC B-Gene +
expression O +
in O +
the O +
quantitative O +
RT O -
- O -
PCR O +
experiment O +
( O -
Figure O +
5A O -
) O -
. O +

Linkage O +
to O +
the O +
APC B-Gene +
locus O +
on O +
chromosome O +
5 O +
has O +
also O +
been O +
investigated O +
in O +
this O +
family O -
. O +

Positive O +
linkage O +
in O +
two O +
different O +
branches O +
of O +
the O +
family O +
was O +
determined O -
. O +

Individuals O +
who O +
have O +
shown O +
positive O +
linkage O +
to O +
APC B-Gene +
are O +
indicated O +
in O +
Figure O +
6 O -
, O +
which O +
shows O +
a O +
pedigree O +
presenting O +
only O +
a O +
part O +
of O +
the O +
complete O +
pedigree O +
of O +
the O +
large O +
family O +
1 O -
. O +

In O +
total O -
, O +
this O +
family O +
includes O +
150 O +
individuals O +
of O +
whom O +
57 O +
are O +
affected O +
by O +
the O +
disease O -
. O +

mRNA O +
expression O +
analysis O +
of O +
family O +
1 O +
of O +
the O +
Swedish O +
Polyposis O +
Registry O -
. O +

( O -
A O -
) O +
Diagram O +
of O +
part O +
of O +
the O +
results O +
from O +
the O +
TaqMan O +
APC B-Gene +
mRNA O +
expression O +
analysis O -
, O +
showing O +
the O +
relative O +
mRNA O +
levels O +
calculated O +
by O +
the O +
standard O +
curve O +
method O +
of O +
two O +
affected O +
members O +
of O +
family O +
1 O +
( O -
A O +
and O +
B O -
) O +
and O +
two O +
control O +
individuals O +
( O -
C O +
and O +
D O -
) O -
. O +

( O -
B O -
) O +
Diagrams O +
of O +
cDNA O +
sequences O +
of O +
the O +
above O +
indicated O +
patients O +
and O +
controls O +
covering O +
the O +
APC B-Gene +
c.5465A O +
> O +
T O +
polymorphism O -
. O +

Discussion O +
The O +
APC B-Gene +
mutations O +
identified O +
in O +
the O +
Swedish O +
patients O +
are O +
scattered O +
along O +
the O +
APC B-Gene +
gene O +
( O -
Figure O +
1 O -
) O -
. O +

The O +
most O +
5 O -
' O +
situated O +
pathogenic O +
germ O +
line O +
APC B-Gene +
mutation O +
identified O +
in O +
this O +
study O -
, O +
in O +
codon O +
24 O +
of O +
exon O +
1 O +
( O -
c.70C O +
> O +
T O -
) O -
, O +
was O +
detected O +
when O +
analyzing O +
patient O +
C157 O -
. O +

This O +
may O +
be O +
the O +
most O +
5 O -
' O +
location O +
of O +
any O +
mutation O +
detected O +
in O +
the O +
coding O +
region O +
of O +
APC B-Gene +
( O -
Figure O +
1 O -
[ O -
38 O -
] O -
) O -
. O +

Codon O +
24 O +
is O +
within O +
the O +
oligomerization O +
domain O +
at O +
the O +
N O -
- O -
terminus O +
of O +
APC B-Gene -
, O +
encoded O +
by O +
amino O +
acids O +
6–57 O +
[ O -
39 O -
] O -
. O +

The O +
most O +
3 O -
' O +
situated O +
mutation O +
identified O +
in O +
the O +
present O +
study O +
( O -
C159 O -
) O +
is O +
a O +
frameshift O +
at O +
codon O +
1920 O -
. O +

The O +
most O +
frequently O +
found O +
mutation O +
was O +
the O +
well O -
- O -
known O +
c.3927_3931del O +
AAAGA O +
( O -
amino O +
acid O +
position O +
1309 O -
) O +
mutation O +
detected O +
in O +
10 O +
out O +
of O +
the O +
95 O +
patients O -
. O +

The O +
recurrent O +
mutation O +
c.3183_3187delACAAA O +
( O -
amino O +
acid O +
1061 O -
) O +
was O +
found O +
in O +
four O +
patients O -
. O +

The O +
frequency O +
of O +
de O +
novo O +
mutation O +
cases O +
was O +
16 O -
% O +
which O +
is O +
lower O +
than O +
the O +
estimation O +
of O +
20–25 O -
% O +
reported O +
by O +
Bisgaard O +
et O +
al O +
[ O -
40 O -
] O -
. O +

The O +
most O +
frequent O +
mutation O +
occurring O +
de O +
novo O +
was O +
c.3927_3931del O +
AAAGA O +
( O -
3 O +
out O +
of O +
10 O +
cases O -
, O +
30 O -
% O -
) O +
compared O +
with O +
mutations O +
at O +
other O +
sites O +
in O +
the O +
gene O +
( O -
7 O +
out O +
of O +
55 O +
cases O -
, O +
12.7 O -
% O -
) O -
. O +

Genotype O -
- O -
phenotype O +
The O +
clinical O +
characterization O +
of O +
the O +
APC B-Gene -
- O -
mutation O +
positive O +
patients O +
is O +
summarized O +
in O +
Additional O +
file O +
1 O +
and O +
the O +
characterization O +
of O +
APC- B-Gene +
and O +
MUTYH B-Gene -
- O -
mutation O +
negative O +
patients O +
are O +
presented O +
in O +
Table O +
1 O -
. O +

Probands O +
with O +
mutations O +
between O +
codon O +
1250 O +
and O +
1468 O +
in O +
the O +
APC B-Gene +
gene O -
, O +
which O +
predict O +
a O +
severe O +
course O +
of O +
the O +
colorectal O +
polyposis O +
[ O -
41 O -
] O +
were O +
significantly O +
younger O +
at O +
diagnosis O +
compared O +
with O +
those O +
with O +
mutations O +
outside O +
this O +
region O +
and O +
seem O +
to O +
have O +
more O +
colorectal O +
polyps O -
. O +

Despite O +
a O +
lower O +
fraction O +
of O +
patients O +
with O +
dense O +
polyposis O +
among O +
those O +
with O +
mutations O +
outside O +
codon O +
1250–1464 O -
, O +
CRC O +
at O +
diagnosis O +
occurred O +
often O -
. O +

High O +
age O +
at O +
diagnosis O +
can O +
probably O +
explain O +
the O +
relatively O +
high O +
risk O +
of O +
having O +
CRC O +
at O +
diagnosis O +
in O +
this O +
subgroup O +
of O +
probands O -
. O +

Early O +
detection O +
because O +
of O +
short O +
patients O +
and O +
delay O +
by O +
doctors O +
may O +
explain O +
the O +
relatively O +
low O +
fraction O +
of O +
patients O +
having O +
CRC O +
at O +
diagnosis O +
among O +
those O +
where O +
the O +
site O +
of O +
the O +
mutation O +
and O +
clinical O +
features O +
indicate O +
a O +
more O +
severe O +
phenotype O -
. O +

Overall O -
, O +
the O +
risk O +
for O +
a O +
proband O +
of O +
having O +
a O +
CRC O +
at O +
diagnosis O +
was O +
lower O +
than O +
previously O +
reported O +
by O +
Björk O +
et O +
al O +
[ O -
33 O -
] O +
where O +
67 O -
% O +
of O +
the O +
probands O +
diagnosed O +
between O +
1912 O +
and O +
1996 O +
had O +
CRC O +
at O +
diagnosis O -
. O +

In O +
this O +
previous O +
study O +
a O +
continued O +
decrease O +
in O +
CRC O +
morbidity O +
among O +
probands O +
was O +
seen O +
over O +
time O +
being O +
48 O -
% O +
in O +
the O +
last O +
period O +
studied O +
( O -
1977–1996 O -
) O -
. O +

In O +
this O +
current O +
study O +
84 O -
% O +
( O -
27 O +
out O +
of O +
32 O -
) O +
of O +
the O +
probands O +
were O +
diagnosed O +
with O +
FAP O +
during O +
that O +
period O +
or O +
later O +
( O -
after O +
1976 O -
) O -
. O +

Nine O +
of O +
the O +
27 O +
( O -
33 O -
% O -
) O +
probands O +
had O +
CRC O +
at O +
diagnosis O -
, O +
which O +
indicates O +
a O +
continued O +
decrease O +
in O +
CRC O +
at O +
diagnosis O +
over O +
time O -
. O +

This O +
is O +
in O +
agreement O +
with O +
our O +
other O +
findings O -
. O +

Except O +
for O +
more O +
rapid O +
detection O +
of O +
symptomatic O +
patients O +
with O +
classical O +
FAP O +
in O +
recent O +
years O -
, O +
a O +
shift O +
over O +
time O +
of O +
probands O +
being O +
diagnosed O +
with O +
FAP O +
towards O +
a O +
less O -
- O -
severe O +
phenotype O -
, O +
might O +
explain O +
the O +
decrease O +
in O +
CRC O +
morbidity O -
. O +

Conclusion O +
We O +
want O +
to O +
emphasize O +
the O +
importance O +
of O +
using O +
a O +
combination O +
of O +
techniques O +
to O +
achieve O +
the O +
highest O +
mutation O -
- O -
detection O +
frequency O +
possible O +
and O +
it O +
is O +
also O +
noteworthy O +
that O +
RNA O -
- O -
based O +
screening O +
is O +
of O +
importance O +
when O +
conducting O +
a O +
highly O +
sensitive O +
mutation O -
- O -
detection O +
screening O +
program O +
as O +
a O +
number O +
of O +
mutations O +
might O +
otherwise O +
be O +
overlooked O -
. O +

The O +
use O +
of O +
mRNA O +
analyses O +
has O +
been O +
crucial O +
in O +
order O +
to O +
detect O +
and O +
characterize O +
splice O +
variants O +
and O +
also O +
to O +
complement O +
MLPA O +
analyses O -
. O +

The O +
MLPA O +
method O +
has O +
improved O +
and O +
simplified O +
the O +
screening O +
procedure O +
significantly O -
, O +
but O +
it O +
is O +
important O +
to O +
remember O +
the O +
limits O +
of O +
the O +
method O -
, O +
which O +
in O +
our O +
study O +
is O +
exemplified O +
by O +
a O +
possible O +
translocation O +
that O +
is O +
not O +
detectable O +
by O +
MLPA O -
. O +

Furthermore O -
, O +
the O +
need O +
to O +
detect O +
elusive O +
APC B-Gene +
changes O +
such O +
as O +
mosaicism O -
, O +
which O +
are O +
not O +
easily O +
identified O +
using O +
standard O +
techniques O -
, O +
remains O -
. O +

Such O +
APC B-Gene +
mutations O +
may O +
be O +
the O +
cause O +
of O +
some O +
of O +
the O +
so O -
- O -
far O +
unresolved O +
de O +
novo O +
cases O +
of O +
attenuated O +
or O +
atypical O +
FAP O -
. O +

Clinical O +
data O +
from O +
this O +
study O +
indicate O +
that O +
the O +
risk O +
of O +
having O +
CRC O +
at O +
diagnosis O +
among O +
probands O +
with O +
mutations O +
outside O +
the O +
region O +
codon O +
1250–1464 O -
, O +
although O +
exhibiting O +
a O +
less O -
- O -
severe O +
phenotype O -
, O +
is O +
high O +
indicating O +
that O +
age O +
at O +
diagnosis O +
rather O +
than O +
severity O +
of O +
the O +
disease O +
predicts O +
CRC O +
morbidity O -
. O +

Early O +
detection O +
of O +
probands O +
contributes O +
to O +
the O +
decrease O +
in O +
overall O +
CRC O +
morbidity O +
seen O +
in O +
FAP O +
in O +
recent O +
years O -
. O +

Germline O +
MSH6 B-Gene +
mutations O +
are O +
more O +
prevalent O +
in O +
endometrial O +
cancer O +
patient O +
cohorts O +
than O +
Hereditary O +
Non O +
Polyposis O +
Colorectal O +
Cancer O +
cohorts O +
Abstract O +
Objective O +
To O +
determine O +
and O +
compare O +
the O +
prevalence O +
of O +
MSH6 B-Gene +
( O -
a O +
mismatch B-Gene +
repair I-Gene +
gene I-Gene -
) O +
mutations O +
in O +
a O +
cohort O +
of O +
families O +
with O +
Hereditary O +
Non O -
- O -
Polyposis O +
Colorectal O +
Cancer O +
( O -
HNPCC O -
) O -
, O +
and O +
in O +
an O +
unselected O +
cohort O +
of O +
endometrial O +
cancer O +
patients O +
( O -
EC O -
) O -
. O +

Design O +
Two O +
patient O +
cohorts O +
participated O +
in O +
the O +
study O -
. O +

A O +
cohort O +
of O +
HNPCC O +
families O +
who O +
were O +
known O +
to O +
the O +
Regional O +
Medical O +
Genetics O +
department O -
, O +
and O +
an O +
unselected O +
cohort O +
of O +
patients O +
with O +
a O +
history O +
of O +
EC O -
. O +

All O +
participants O +
received O +
genetic O +
counselling O +
on O +
the O +
implications O +
of O +
molecular O +
testing O -
, O +
and O +
blood O +
was O +
taken O +
for O +
DNA O +
extraction O +
with O +
consent O -
. O +

All O +
samples O +
underwent O +
sequencing O +
and O +
Multiple O +
Ligation O +
probe O +
analysis O +
( O -
MLPA O -
) O +
for O +
mutations O +
in O +
MSH6 B-Gene -
. O +

Populations O +
DNA O +
from O +
one O +
hundred O +
and O +
forty O -
- O -
three O +
probands O +
from O +
HNPCC O +
families O +
and O +
125 O +
patients O +
with O +
EC O +
were O +
included O +
in O +
the O +
study O -
. O +

Methods O +
Molecular O +
analysis O +
of O +
DNA O +
in O +
all O +
participants O +
from O +
both O +
cohorts O +
for O +
mutations O +
in O +
MSH6 B-Gene -
. O +

Outcome O +
measures O +
Prevalence O +
of O +
pathogenic O +
mutations O +
in O +
MSH6 B-Gene -
. O +

Results O +
A O +
truncating O +
mutation O +
in O +
MSH6 B-Gene +
was O +
identified O +
in O +
3.8 O -
% O +
( O -
95 O -
% O +
CI O +
1.0–9.5 O -
% O -
) O +
of O +
patients O +
in O +
the O +
endometrial O +
cancer O +
cohort O -
, O +
and O +
2.6 O -
% O +
( O -
95 O -
% O +
CI O +
0.5–7.4 O -
% O -
) O +
of O +
patients O +
in O +
the O +
HNPCC O +
cohort O -
. O +

A O +
missense O +
mutation O +
was O +
identified O +
in O +
2.9 O -
% O +
and O +
4.4 O -
% O +
of O +
the O +
same O +
cohorts O +
respectively O -
. O +

No O +
genomic O +
rearrangements O +
in O +
MSH6 B-Gene +
were O +
identified O -
. O +

Conclusion O +
MSH6 B-Gene +
mutations O +
are O +
more O +
common O +
in O +
EC O +
patients O +
than O +
HNPCC O +
families O -
. O +

Genomic O +
rearrangements O +
do O +
not O +
contribute O +
to O +
a O +
significant O +
proportion O +
of O +
mutations O +
in O +
MSH6 B-Gene -
, O +
but O +
missense O +
variants O +
are O +
relatively O +
common O +
and O +
their O +
pathogenicity O +
can O +
be O +
uncertain O -
. O +

HNPCC O +
families O +
may O +
be O +
ascertained O +
through O +
an O +
individual O +
presenting O +
with O +
EC O -
, O +
and O +
recognition O +
of O +
these O +
families O +
is O +
important O +
so O +
that O +
appropriate O +
cancer O +
surveillance O +
can O +
be O +
put O +
in O +
place O -
. O +

INTRODUCTION O +
HNPCC O +
is O +
an O +
autosomal O +
dominant O +
highly O +
penetrant O +
cancer O -
- O -
susceptibility O +
syndrome O +
caused O +
by O +
germline O +
mutations O +
in O +
one O +
of O +
the O +
DNA O +
mismatch O +
repair O +
( O -
MMR B-Gene -
) O +
genes O -
, O +
namely O +
MLH1 B-Gene -
, O +
MSH2 B-Gene +
and O +
MSH61 B-Gene -
. O +

Affected O +
individuals O +
have O +
a O +
predisposition O +
to O +
developing O +
early O +
onset O +
colorectal O +
cancer O +
( O -
CRC O -
) O +
and O +
other O +
HNPCC O +
associated O +
cancers O -
, O +
particularly O +
endometrial O +
cancer O +
( O -
EC O -
) O -
2 O -
. O +

Diagnosis O +
of O +
HNPCC O +
is O +
dependent O +
on O +
familial O +
clustering O +
of O +
CRC O -
's O -
, O +
and O +
other O +
HNPCC O +
related O +
cancers O -
, O +
early O +
onset O +
cancers O -
, O +
and O +
synchronous O +
and O +
metachronous O +
cancers O -
. O +

Associated O +
with O +
a O +
life O +
time O +
cancer O +
risk O +
of O +
up O +
to O +
80 O -
% O +
3,4 O -
, O +
early O +
diagnosis O +
enables O +
at O +
risk O +
family O +
members O +
to O +
be O +
enrolled O +
in O +
a O +
cancer O +
surveillance O +
programme O -
, O +
thus O +
reducing O +
mortality O +
and O +
morbidity O +
5–7 O -
. O +

The O +
Amsterdam O +
criteria O -
, O +
developed O +
in O +
1991 O +
by O +
the O +
International O +
Collaborative O +
Group O +
on O +
Hereditary O +
Non O -
- O -
polyposis O +
Colorectal O +
Cancer O +
( O -
ICG O -
- O -
HNPCC O -
) O -
8 O -
, O +
and O +
subsequently O +
revised O +
in O +
19999 O -
, O +
are O +
not O +
diagnostic O -
, O +
but O +
can O +
be O +
used O +
to O +
standardise O +
HNPCC O +
families O +
for O +
comparative O +
multi O -
- O -
centre O +
studies O +
( O -
see O +
Boxes O +
1 O +
and O +
2 O -
) O -
. O +

Amsterdam O +
criteria O +
I O +
There O +
should O +
be O +
at O +
least O +
three O +
relatives O +
with O +
histologically O +
verified O +
CRC O -
; O +
all O +
of O +
the O +
following O +
criteria O +
should O +
be O +
present O -
: O +
One O +
should O +
be O +
a O +
first O +
degree O +
relative O +
of O +
the O +
other O +
two;At O +
least O +
two O +
successive O +
generations O +
should O +
be O +
affected;At O +
least O +
one O +
CRC O +
should O +
be O +
diagnosed O +
before O +
age O +
50;FAP O +
should O +
be O +
excluded O +
in O +
the O +
CRC O +
case;Tumours O +
should O +
be O +
verified O +
by O +
pathological O +
examination O +
One O +
should O +
be O +
a O +
first O +
degree O +
relative O +
of O +
the O +
other O +
two O -
; O +
At O +
least O +
two O +
successive O +
generations O +
should O +
be O +
affected O -
; O +
At O +
least O +
one O +
CRC O +
should O +
be O +
diagnosed O +
before O +
age O +
50 O -
; O +
FAP O +
should O +
be O +
excluded O +
in O +
the O +
CRC O +
case O -
; O +
Tumours O +
should O +
be O +
verified O +
by O +
pathological O +
examination O +
Amsterdam O +
criteria O +

II O +
At O +
least O +
three O +
relatives O +
with O +
an O +
HNPCC O +
associated O +
cancer O +
* O +
One O +
affected O +
person O +
is O +
a O +
first O +
degree O +
relative O +
of O +
the O +
other O +
twoAt O +
least O +
two O +
successive O +
generations O +
are O +
affectedAt O +
least O +
one O +
person O +
was O +
diagnosed O +
before O +
the O +
age O +
of O +
50 O +
yearsFamilial O +
adenomatous O +
polyposis O +
has O +
been O +
excludedTumours O +
have O +
been O +
verified O +
by O +
pathological O +
examination O +
One O +
affected O +
person O +
is O +
a O +
first O +
degree O +
relative O +
of O +
the O +
other O +
two O +
At O +
least O +
two O +
successive O +
generations O +
are O +
affected O +
At O +
least O +
one O +
person O +
was O +
diagnosed O +
before O +
the O +
age O +
of O +
50 O +
years O +
Familial O +
adenomatous O +
polyposis O +
has O +
been O +
excluded O +
Tumours O +
have O +
been O +
verified O +
by O +
pathological O +
examination O +
MLH1 B-Gene +
and O +
MSH2 B-Gene +
mutations O +
account O +
for O +
the O +
majority O +
of O +
known O +
mutations O +
in O +
HNPCC O +
families O -
, O +
and O +
can O +
represent O +
between O +
25%10 O +
and O +
49 O -
% O +
of O +
Amsterdam O +
criteria O +
positive O +
families11 O -
. O +

Higher O +
mutation O +
detection O +
rates O +
of O +
86 O -
% O +
have O +
been O +
published O -
, O +
but O +
this O +
may O +
be O +
as O +
a O +
result O +
of O +
founder O +
mutations12 O -
. O +

MSH6 B-Gene +
mutations O +
were O +
first O +
reported O +
in O +
HNPCC O +
kindreds O +
in O +
199713,14 O -
, O +
and O +
are O +
less O +
prevalent O +
in O +
HNPCC O +
cohorts O +
with O +
MSH6 B-Gene +
mutations O +
estimated O +
to O +
represent O +
approximately O +
10 O -
% O +
of O +
all O +
MMR B-Gene +
mutations O +
in O +
HNPCC O +
families15,16 O -
. O +

Between O +
2–5 O -
% O +
of O +
HNPCC O +
families O +
including O +
Amsterdam O +
I O -
, O +
Amsterdam O +
II O -
, O +
or O +
' O -
HNPCC O +
like O -
' O +
will O +
have O +
a O +
germline O +
mutation O +
in O +
MSH615,17,18 B-Gene -
. O +

Mutations O +
have O +
been O +
described O +
in O +
PMS2 B-Gene +
and O +
PMS1 B-Gene +
in O +
HNPCC O +
kindreds O +
but O +
have O +
not O +
been O +
found O +
to O +
contribute O +
to O +
a O +
significant O +
proportion O +
of O +
families19,20 O -
. O +

METHODS O +
Subject O +
Recruitment O +
The O +
study O +
was O +
granted O +
ethical O +
approval O +
by O +
the O +
Office O +
for O +
Research O +
Ethics O +
Committees O +
Northern O +
Ireland O +
( O -
ORECNI O -
) O -
. O +

Two O +
patient O +
cohorts O +
were O +
recruited O -
; O +
HNPCC O +
and O +
endometrial O +
cancer O +
patient O +
cohorts O -
. O +

Sample O +
sizes O +
were O +
calculated O +
from O +
previous O +
studies O +
with O +
estimated O +
prevalence O +
figures O +
of O +
MSH6 B-Gene +
of O +
9%16 O +
and O +
8%25 O +
respectively O +
in O +
each O +
cohort O -
, O +
giving O +
a O +
target O +
size O +
of O +
197 O +
cases O +
for O +
an O +
estimate O +
of O +
prevalence O +
with O +
95 O -
% O +
confidence O +
intervals O +
no O +
wider O +
than O +
+ O -
/− O +
4 O -
% O +
for O +
the O +
HNPCC O +
cohort O +
and O +
a O +
target O +
size O +
of O +
177 O +
cases O +
for O +
an O +
estimate O +
of O +
prevalence O +
with O +
95 O -
% O +
confidence O +
intervals O +
no O +
wider O +
than O +
+ O -
/− O +
4 O -
% O +
for O +
the O +
endometrial O +
cohort O -
. O +

The O +
HNPCC O +
cohort O +
was O +
known O +
to O +
the O +
regional O +
genetics O +
department O -
, O +
and O +
had O +
received O +
genetic O +
counselling O +
in O +
the O +
past O -
, O +
with O +
blood O +
taken O +
for O +
diagnostic O +
testing O +
of O +
MLH1 B-Gene +
and O +
MSH2 B-Gene +
or O +
DNA O +
storage O -
. O +

All O +
families O +
who O +
met O +
the O +
Amsterdam O +
I O +
and O +
II O +
criteria O +
were O +
included O -
. O +

In O +
addition O -
, O +
inclusion O +
criteria O +
was O +
extended O +
to O +
families O +
with O +
a O +
clustering O +
of O +
CRC O -
, O +
or O +
other O +
HNPCC O +
related O +
cancer O -
, O +
with O +
at O +
least O +
three O +
affected O +
family O +
members O +
( O -
age O +
not O +
restricted O -
) O -
, O +
or O +
at O +
least O +
two O +
family O +
members O +
if O +
the O +
age O +
of O +
onset O +
was O +
below O +
50 O +
years O +
with O +
pedigrees O +
suggestive O +
of O +
autosomal O +
dominant O +
inheritance O -
, O +
or O +
an O +
individual O +
with O +
CRC O +
diagnosed O +
less O +
than O +
35 O +
years O +
– O +
similar O +
to O +
the O +
Bethesda O +
criteria O -
. O +

Probands O +
were O +
contacted O +
with O +
information O +
regarding O +
the O +
study O -
, O +
and O +
a O +
consent O +
form O +
with O +
a O +
stamped O +
addressed O +
envelope O +
( O -
SAE O -
) O +
to O +
return O +
if O +
they O +
wished O +
to O +
participate O -
. O +

One O +
hundred O +
and O +
forty O -
- O -
three O +
participants O +
in O +
total O +
were O +
recruited O +
to O +
this O +
cohort O +
35 O +
meeting O +
the O +
Amsterdam O +
I O -
, O +
6 O +
Amsterdam O +
II O -
, O +
and O +
102 O +
classified O +
as O +
' O -
HNPCC O +
like O -
' O -
. O +

Patients O +
with O +
a O +
history O +
of O +
EC O +
( O -
back O +
to O +
01 O -
/ O -
01 O -
/ O -
99 O -
) O +
were O +
identified O +
by O +
means O +
of O +
a O +
pathology O +
coding O +
database O +
covering O +
all O +
patients O +
from O +
the O +
Eastern O +
Health O +
Board O +
in O +
Northern O +
Ireland O +
and O +
recruited O +
consecutively O -
. O +

All O +
potential O +
participants O +
were O +
contacted O +
with O +
a O +
participant O +
information O +
sheet O -
, O +
with O +
a O +
detachable O +
reply O +
slip O -
, O +
to O +
be O +
returned O +
in O +
the O +
enclosed O +
SAE O -
, O +
for O +
those O +
keen O +
to O +
participate O -
. O +

For O +
patients O +
with O +
returned O +
reply O +
slips O -
, O +
a O +
clinic O +
appointment O +
was O +
offered O +
to O +
discuss O +
the O +
study O +
with O +
genetic O +
counselling O -
, O +
and O +
obtain O +
medical O +
details O -
, O +
family O +
history O -
, O +
informed O +
consent O +
and O +
a O +
blood O +
sample O +
for O +
DNA O +
extraction O -
. O +

One O +
hundred O +
and O +
eighty O -
- O -
eight O +
potential O +
participants O +
were O +
contacted O -
, O +
and O +
one O +
hundred O +
and O +
twenty O -
- O -
five O +
participants O +
were O +
recruited O +
to O +
this O +
cohort O -
. O +

Age O +
ranged O +
from O +
twenty O -
- O -
six O +
to O +
eighty O -
- O -
four O -
, O +
with O +
a O +
mean O +
age O +
of O +
58.9 O +
years O -
. O +

Mean O +
body O +
mass O +
index O +
( O -
BMI O -
) O +
in O +
this O +
cohort O +
was O +
30.65 O -
, O +
ranging O +
from O +
18.64–53.15 O -
. O +

MSH6 B-Gene +
Sequencing O +

Number O +
of O +
mutations O +
identified O +
in O +
each O +
cohort O +

DISCUSSION O +
Fifteen O +
variants O +
in O +
all O +
were O +
identified O +
from O +
the O +
two O +
cohorts O -
, O +
seven O +
of O +
which O +
resulted O +
in O +
premature O +
STOP O +
codon O +
( O -
truncating O +
mutations O -
) O -
, O +
and O +
were O +
therefore O +
considered O +
pathogenic O -
. O +

A O +
further O +
eight O +
missense O +
mutations O +
were O +
identified O -
, O +
of O +
which O +
the O +
functional O +
significance O +
is O +
not O +
known O +
at O +
this O +
time O -
. O +

A O +
summary O +
of O +
results O +
is O +
shown O +
in O +
table O +
I. O +
At O +
the O +
time O +
of O +
study O +
design O -
, O +
only O +
estimates O +
of O +
total O +
prevalence O +
were O +
available16,25 O +
and O +
the O +
cohort O +
sizes O +
actually O +
attained O +
in O +
the O +
study O +
were O +
smaller O +
than O +
planned O -
. O +

This O +
is O +
reflected O +
in O +
lower O +
precision O +
( O -
wider O +
confidence O +
limits O -
) O +
in O +
the O +
estimates O +
than O +
had O +
originally O +
been O +
specified O -
. O +

HNPCC O +
Cohort O +
A O +
definite O +
pathogenic O +
mutation O +
was O +
identified O +
in O +
2.6 O -
% O +
of O +
the O +
HNPCC O +
cohort O -
. O +

These O +
results O +
are O +
comparable O +
with O +
other O +
studies O +
carried O +
out O +
on O +
Amsterdam O -
, O +
Amsterdam O +
II O +
and O +
' O -
HNPCC O +
like O -
' O +
families O +
– O +
estimates O +
range O +
between O +
2 O -
% O +
and O +
5 O -
% O +
- O +
who O +
have O +
a O +
germline O +
mutation O +
in O +
MSH615,17,18 B-Gene -
. O +

Further O +
work O +
on O +
the O +
missense O +
variants O +
is O +
required O +
to O +
determine O +
their O +
pathogenicity O -
, O +
as O +
the O +
yield O +
of O +
MSH6 B-Gene +
mutations O +
in O +
the O +
HNPCC O +
cohort O +
could O +
increase O +
up O +
to O +
7 O -
% O +
if O +
these O +
are O +
found O +
to O +
be O +
significant O -
. O +

Endometrial O +
cohort O +
A O +
truncating O +
germline O +
mutation O +
was O +
identified O +
in O +
3.8 O -
% O +
of O +
the O +
endometrial O +
cohort O -
. O +

This O +
is O +
higher O +
than O +
that O +
obtained O +
for O +
the O +
HNPCC O +
cohort O +
of O +
whom O +
the O +
majority O +
were O +
' O -
HNPCC O +
like O -
' O -
, O +
thereby O +
broadening O +
the O +
criteria O +
to O +
fit O +
with O +
the O +
described O +
characteristics O +
of O +
a O +
MSH6 B-Gene +
phenotype15,21 O -
. O +

This O +
prevalence O +
figure O +
is O +
also O +
likely O +
to O +
increase O +
following O +
further O +
work O +
( O -
including O +
immunohistochemistry O -
) O -
, O +
being O +
carried O +
out O +
on O +
the O +
missense O +
variants O +
as O +
some O +
of O +
these O +
may O +
be O +
pathogenic O -
. O +

There O +
are O +
few O +
studies O +
looking O +
at O +
MSH6 B-Gene +
in O +
EC O -
. O +

Comparison O +
can O +
be O +
difficult O +
to O +
make O +
between O +
studies O +
because O +
of O +
pre O -
- O -
selection O +
of O +
some O +
study O +
groups O +
of O +
EC O +
patients O +
by O +
age O +
restriction O +
or O +
tumour O +
microsatellite O +
instability O -
. O +

Goodfellow26 O +
estimated O +
the O +
minimum O +
prevalence O +
of O +
inherited O +
MSH6 B-Gene +
mutations O +
in O +
EC O +
to O +
be O +
1.6 O -
% O -
, O +
from O +
a O +
sub O -
- O -
population O +
of O +
an O +
EC O +
cohort O -
, O +
selected O +
for O +
molecular O +
analysis O -
, O +
the O +
majority O +
of O +
which O +
showed O +
tumour O +
microsatellite O +
instability O +
( O -
MSI O -
) O -
. O +

A O +
comparable O +
figure O +
is O +
seen O +
by O +
Berends23 O +
one O +
MSH6 B-Gene +
mutation O +
identified O +
in O +
a O +
cohort O +
of O +
58 O +
EC O +
patients O +
diagnosed O +
less O +
than O +
50 O +
years O +
whose O +
families O +
fulfilled O +
the O +
Amsterdam O +
II O +
criteria O -
. O +

Higher O +
figures O +
of O +
4.7%24 O -
, O +
and O +
8.3%25 O -
, O +
have O +
been O +
observed O +
in O +
EC O +
cohorts O +
not O +
restricted O +
by O +
age O +
or O +
the O +
limitations O +
of O +
the O +
Amsterdam O +
II O +
criteria O -
, O +
but O +
where O +
the O +
majority O +
of O +
tumours O +
exhibit O +
MSI O -
, O +
although O +
the O +
significance O +
of O +
the O +
latter O +
study O +
will O +
be O +
limited O +
by O +
its O +
relatively O +
small O +
cohort O -
. O +

As O +
well O +
as O +
the O +
heterogeneous O +
populations O +
studied O -
, O +
the O +
variability O +
in O +
frequency O +
of O +
MSH6 B-Gene +
mutations O +
in O +
both O +
HNPCC O +
and O +
endometrial O +
cohorts O +
can O +
also O +
be O +
accounted O +
for O +
by O +
the O +
sensitivity O +
of O +
techniques O +
used O +
to O +
identify O +
variants O -
, O +
the O +
use O +
of O +
MSI O +
and O +
IHC O +
to O +
target O +
molecular O +
screening O +
of O +
MMR B-Gene +
genes O -
, O +
and O +
the O +
interpretation O +
of O +
missense O +
mutations O +
which O +
occur O +
relatively O +
frequently O +
in O +
MSH623 B-Gene -
. O +

Founder O +
mutations O +
in O +
certain O +
populations O +
can O +
also O +
contribute O +
to O +
higher O +
than O +
average O +
prevalence O +
rates O +
of O +
MMR B-Gene +
genes12 O -
. O +

Further O +
work O +
on O +
functional O -
, O +
population O +
and O +
family O +
studies O +
is O +
required O +
to O +
determine O +
the O +
pathogenicity O +
of O +
the O +
eight O +
missense O +
mutations O +
identified O -
. O +

Genomic O +
Rearrangements O +
Genomic O +
rearrangements O +
account O +
for O +
between O +
17%28 O +
to O +
54.8 O -
% O +
of O +
pathogenic O +
mutations O +
in O +
MLH1 B-Gene +
and O +
MSH2 B-Gene +
in O +
HNPCC O +
families29 O -
. O +

The O +
prevalence O +
of O +
genomic O +
rearrangements O +
in O +
MSH6 B-Gene +
is O +
less O +
well O +
studied O -
, O +
but O +
it O +
had O +
been O +
estimated O +
that O +
rearrangements O +
may O +
account O +
for O +
10–20 O -
% O +
of O +
mutations O +
in O +
MSH630 B-Gene -
. O +

No O +
genomic O +
rearrangements O +
were O +
identified O +
in O +
our O +
HNPCC O +
cohort O +
consistent O +
with O +
findings O +
by O +
Charbonnier31 O +
and O +
Wagner18 O -
. O +

Likewise O +
genomic O +
rearrangements O +
were O +
not O +
detected O +
in O +
any O +
of O +
our O +
EC O +
patients O +
in O +
keeping O +
with O +
findings O +
by O +
Ollikaninen32 O -
. O +

Studies O +
that O +
have O +
identified O +
MSH6 B-Gene +
genomic O +
rearrangements O +
have O +
been O +
particularly O +
large O +
HNPCC O +
cohorts33 O -
, O +
or O +
EC O +
cohorts O +
pre O -
- O -
selected O +
by O +
MSI24 O -
, O +
yielding O +
a O +
genomic O +
rearrangement O +
in O +
MSH6 B-Gene +
in O +
less O +
than O +
1 O -
% O +
of O +
the O +
chosen O +
population O -
. O +

Promoter O +
Region O +
Sequencing O +
is O +
highly O +
sensitive O +
for O +
detection O +
of O +
mutations O +
in O +
the O +
coding O +
regions O -
; O +
however O +
the O +
promoter O +
region O +
of O +
MSH6 B-Gene +
was O +
not O +
sequenced O +
in O +
this O +
study O -
. O +

Previous O +
studies O +
have O +
mainly O +
concentrated O +
on O +
coding O +
regions O -
, O +
and O +
exonic O +
/ O +
intronic O +
boundaries O -
. O +

Two O +
deletions O +
of O +
the O +
MSH6 B-Gene +
promoter O +
region O +
have O +
been O +
described O +
in O +
HNPCC O +
families22,33 O -
, O +
but O +
other O +
studies O +
looking O +
at O +
the O +
promoter O +
region O +
of O +
MSH6 B-Gene +
in O +
EC O +
cohorts27 O +
or O +
in O +
HNPCC O +
patients O +
negative O +
for O +
a O +
mutation O +
in O +
MLH1 B-Gene +
or O +
MSH217 B-Gene -
, O +
did O +
not O +
identify O +
any O +
pathogenic O +
mutations O -
. O +

Studies O +
looking O +
specifically O +
at O +
the O +
promoter O +
region O +
of O +
the O +
more O +
prevalent O +
MMR B-Gene +
genes O -
, O +
MLH1 B-Gene +
and O +
MSH2 B-Gene -
, O +
identified O +
three O +
possible O +
pathogenic O +
mutations O +
in O +
the O +
promoter O +
area O +
in O +
141 O +
HNPCC O +
patients O +
and O +
patients O +
with O +
early O +
onset O +
CRC O +
( O -
< O -
45 O +
years O -
) O -
34 O -
. O +

Given O +
that O +
MSH6 B-Gene +
mutations O +
occur O +
at O +
a O +
relatively O +
low O +
rate O +
in O +
both O +
HNPCC O +
and O +
EC O +
patients O -
, O +
we O +
can O +
assume O +
that O +
mutations O +
of O +
the O +
promoter O +
region O +
in O +
either O +
cohort O +
are O +
unlikely O +
to O +
significantly O +
alter O +
the O +
prevalence O +
figures O +
calculated O +
from O +
this O +
study O -
. O +

Redundancy O +
of O +
MSH6 B-Gene +
mutations O +
Although O +
germline O +
mutations O +
in O +
MSH6 B-Gene +
are O +
distributed O +
throughout O +
the O +
length O +
of O +
MSH6 B-Gene +
displaying O +
little O +
redundancy O -
, O +
the O +
majority O +
of O +
pathogenic O +
mutations O +
identified O +
are O +
in O +
exon O +
415 O -
, O +
with O +
fifty O -
- O -
seven O +
percent O +
of O +
truncating O +
mutations O +
identified O +
in O +
this O +
study O +
( O -
4 O -
/ O -
7 O -
) O +
occurring O +
in O +
exon O +
4 O -
, O +
the O +
largest O +
of O +
MSH6 B-Gene +
exons O -
, O +
indicating O +
that O +
analysis O +
of O +
MSH6 B-Gene +
in O +
HNPCC O +
families O +
without O +
a O +
known O +
mutation O +
should O +
commence O +
at O +
exon O +
4 O -
. O +

MSH6 B-Gene +
phenotype O +
None O +
of O +
the O +
truncating O +
mutations O +
identified O +
in O +
this O +
study O +
met O +
the O +
original O +
Amsterdam O +
criteria O -
, O +
the O +
majority O +
having O +
a O +
' O -
HNPCC O +
like O -
' O +
phenotype O -
, O +
with O +
a O +
later O +
age O +
of O +
cancer O +
onset O -
, O +
and O +
non O -
- O -
penetrance O +
in O +
family O +
members O +
( O -
Table O +
IV O -
) O -
. O +

This O +
further O +
supports O +
current O +
evidence O +
that O +
application O +
of O +
the O +
Amsterdam O +
criteria O +
to O +
HNPCC O +
families O +
to O +
select O +
for O +
molecular O +
testing O +
will O +
result O +
in O +
a O +
significant O +
proportion O +
of O +
MSH6 B-Gene +
mutations O +
being O +
missed15,22 O -
. O +

Classification O +
of O +
families O +
with O +
a O +
MSH6 B-Gene +
variant O +
identified O +
Previously O +
unidentified O +
HNPCC O +
families O +
Eighteen O +
out O +
of O +
125 O +
participants O +
( O -
14.4 O -
% O -
) O +
from O +
the O +
endometrial O +
cohort O +
had O +
a O +
significant O +
previously O +
unidentified O +
HNPCC O +
phenotype O -
. O +

Five O +
of O +
these O +
participants O +
had O +
a O +
variant O +
identified O -
, O +
three O +
truncating O +
mutations O +
and O +
two O +
missense O +
mutations O -
. O +

These O +
findings O +
are O +
in O +
keeping O +
with O +
findings O +
from O +
other O +
studies O +
where O +
previously O +
unidentified O +
HNPCC O +
families O +
have O +
been O +
ascertained O +
through O +
an O +
individual O +
with O +
EC23 O -
. O +

Increased O +
awareness O +
of O +
HNPCC O +
and O +
other O +
hereditary O +
cancer O +
syndromes O +
amongst O +
physicians O -
/ O -
surgeons O +
directly O +
involved O +
with O +
the O +
care O +
of O +
cancer O +
patients O +
such O +
as O +
gynaecologists O -
, O +
surgeons O -
, O +
oncologists O -
, O +
and O +
general O +
practitioners O +
is O +
essential O +
for O +
their O +
identification O -
. O +

Endometrial O +
Cancer O +
HNPCC O -
, O +
traditionally O +
identified O +
as O +
a O +
condition O +
with O +
a O +
genetic O +
predisposition O +
to O +
CRC O -
, O +
has O +
now O +
been O +
recognised O +
as O +
conferring O +
a O +
significant O +
risk O +
of O +
EC O +
to O +
females O -
, O +
particularly O +
those O +
with O +
a O +
mutation O +
in O +
MSH6 B-Gene -
. O +

In O +
addition O +
to O +
other O +
Mendelian O +
inherited O +
syndromes O +
with O +
a O +
predisposition O +
to O +
EC O +
such O +
as O +
Muir O +
Torré O -
, O +
Cowden O +
and O +
Turcot O +
syndrome O -
, O +
there O +
are O +
families O +
who O +
show O +
a O +
clustering O +
of O +
EC O +
alone O +
that O +
do O +
not O +
have O +
an O +
identifiable O +
molecular O +
basis O -
. O +

Un O -
- O -
identified O +
genes O +
or O +
predisposing O +
low O +
penetrant O +
polymorphisms O +
may O +
contribute O -
. O +

The O +
importance O +
of O +
environmental O +
factors O +
conferring O +
a O +
risk O +
to O +
the O +
development O +
of O +
EC O +
can O -
not O +
be O +
underestimated O -
. O +

Obesity O +
is O +
associated O +
with O +
increased O +
levels O +
of O +
endogenous O +
oestrogens O -
, O +
and O +
is O +
a O +
significant O +
risk O +
factor O +
for O +
the O +
development O +
of O +
EC O -
. O +

Mean O +
BMI O +
in O +
the O +
endometrial O +
cohort O +
was O +
30.65 O +
and O +
ranged O +
from O +
18.64–53.15 O -
, O +
with O +
only O +
28 O +
( O -
22.4 O -
% O -
) O +
of O +
participants O +
having O +
a O +
BMI O +
within O +
the O +
normal O +
range O +
( O -
< O -
25 O -
) O -
. O +

In O +
comparison O +
it O +
is O +
estimated O +
that O +
44 O -
% O +
of O +
UK O +
females O +
over O +
16 O +
years O +
have O +
a O +
BMI O +
within O +
the O +
normal O +
range O -
. O +

( O -
Figures O +
published O +
by O +
the O +
Department O +
of O +
Health O +
and O +
estimated O +
by O +
the O +
Health O +
Survey O +
for O +
England O +
2003 O -
; O +
) O -
. O +

The O +
mean O +
BMI O +
for O +
the O +
four O +
participants O +
from O +
the O +
endometrial O +
cohort O +
with O +
a O +
truncating O +
mutation O +
in O +
MSH6 B-Gene +
was O +
26.2 O -
, O +
ranging O +
from O +
22.36–31.05 O -
. O +

One O +
of O +
these O +
participants O +
had O +
a O +
BMI O +
in O +
the O +
overweight O +
range O -
, O +
and O +
one O +
had O +
a O +
BMI O +
in O +
the O +
obese O +
range O -
. O +

It O +
is O +
likely O +
that O +
obesity O +
has O +
an O +
additive O +
effect O +
to O +
the O +
underlying O +
risk O +
form O +
a O +
MMR B-Gene +
mutation O -
, O +
but O +
larger O +
studies O +
would O +
be O +
required O +
to O +
determine O +
this O -
. O +

Novel O +
Roles O +
for O +
MLH3 B-Gene +
Deficiency O +
and O +
TLE6-Like B-Gene +
Amplification O +
in O +
DNA O +
Mismatch O +
Repair O -
- O -
Deficient O +
Gastrointestinal O +
Tumorigenesis O +
and O +
Progression O +
Abstract O +
DNA O +
mismatch O +
repair O +
suppresses O +
gastrointestinal O +
tumorgenesis O -
. O +

Four O +
mammalian O +
E. O +
coli O +
MutL O +
homologues O +
heterodimerize O +
to O +
form O +
three O +
distinct O +
complexes O -
: O +
MLH1 B-Gene -
/ O -
PMS2 B-Gene -
, O +
MLH1 B-Gene -
/ O -
MLH3 B-Gene -
, O +
and O +
MLH1 B-Gene -
/ O -
PMS1 B-Gene -
. O +

To O +
understand O +
the O +
mechanistic O +
contributions O +
of O +
MLH3 B-Gene +
and O +
PMS2 B-Gene +
in O +
gastrointestinal O +
tumor O +
suppression O -
, O +
we O +
generated O +
Mlh3− B-Gene -
/ O -
−;Apc1638N O +
and O +
Mlh3− B-Gene -
/ O -
−;Pms2− O -
/ O -
−;Apc1638N O +
( O -
MPA O -
) O +
mice O -
. O +

Mlh3 B-Gene +
nullizygosity O +
significantly O +
increased O +
Apc B-Gene +
frameshift O +
mutations O +
and O +
tumor O +
multiplicity O -
. O +

Combined O +
Mlh3;Pms2 B-Gene +
nullizygosity O +
further O +
increased O +
Apc B-Gene +
base O -
- O -
substitution O +
mutations O -
. O +

The O +
spectrum O +
of O +
MPA O +
tumor O +
mutations O +
was O +
distinct O +
from O +
that O +
observed O +
in O +
Mlh1− B-Gene -
/ O -
−;Apc1638N O +
mice O -
, O +
implicating O +
the O +
first O +
potential O +
role O +
for O +
MLH1 B-Gene -
/ O -
PMS1 B-Gene +
in O +
tumor O +
suppression O -
. O +

Because O +
Mlh3;Pms2 B-Gene +
deficiency O +
also O +
increased O +
gastrointestinal O +
tumor O +
progression O -
, O +
we O +
used O +
array O -
- O -
CGH O +
to O +
identify O +
a O +
recurrent O +
tumor O +
amplicon O -
. O +

This O +
amplicon O +
contained O +
a O +
previously O +
uncharacterized O +
Transducin O +
enhancer O +
of O +
Split O +
( O -
Tle O -
) O +
family O +
gene O -
, O +
Tle6-like B-Gene -
. O +

Expression O +
of O +
Tle6-like B-Gene -
, O +
or O +
the O +
similar O +
human O +
TLE6D B-Gene +
splice O +
isoform O +
in O +
colon O +
cancer O +
cells O +
increased O +
cell O +
proliferation O -
, O +
colony O -
- O -
formation O -
, O +
cell O +
migration O -
, O +
and O +
xenograft O +
tumorgenicity O -
. O +

Tle6-like;TLE6D B-Gene +
directly O +
interact O +
with O +
the O +
gastrointestinal O +
tumor O +
suppressor O +
RUNX3 B-Gene +
and O +
antagonize O +
RUNX3 B-Gene +
target O +
transactivation O -
. O +

TLE6D B-Gene +
is O +
recurrently O +
overexpressed O +
in O +
human O +
colorectal O +
cancers O +
and O +
TLE6D B-Gene +
expression O +
correlates O +
with O +
RUNX3 B-Gene +
expression O -
. O +

Collectively O -
, O +
these O +
findings O +
provide O +
important O +
insights O +
into O +
the O +
molecular O +
mechanisms O +
of O +
individual O +
MutL O +
homologue O +
tumor O +
suppression O +
and O +
demonstrate O +
an O +
association O +
between O +
TLE B-Gene +
mediated O +
antagonism O +
of O +
RUNX3 B-Gene +
and O +
accelerated O +
human O +
colorectal O +
cancer O +
progression O -
. O +

Abstract O +
Author O +
Summary O +
Approximately O +
one O +
million O +
people O +
every O +
year O +
are O +
diagnosed O +
with O +
colorectal O +
cancer O +
worldwide O -
, O +
and O +
about O +
five O +
hundred O +
thousand O +
of O +
these O +
people O +
subsequently O +
perish O +
from O +
the O +
disease O -
. O +

Colorectal O +
cancer O +
is O +
thought O +
to O +
develop O +
through O +
a O +
series O +
of O +
early O +
and O +
later O +
stages O +
( O -
called O +
cancer O +
initiation O +
and O +
progression O -
, O +
respectively O -
) O -
. O +

Deaths O +
from O +
colorectal O +
cancer O +
are O +
particularly O +
tragic O +
because O +
the O +
disease O +
can O +
usually O +
be O +
cured O +
if O +
discovered O +
before O +
full O -
- O -
blown O +
progression O -
. O +

However O -
, O +
our O +
knowledge O +
of O +
how O +
these O +
tumors O +
progress O +
remains O +
very O +
limited O -
. O +

DNA O +
mismatch O +
repair O +
is O +
known O +
to O +
be O +
an O +
important O +
process O +
in O +
preventing O +
∼15 O -
% O +
of O +
colorectal O +
cancer O +
initiation O -
. O +

In O +
this O +
study O +
we O +
describe O +
how O +
two O +
of O +
these O +
genes O +
( O -
Mlh3 B-Gene +
and O +
Pms2 B-Gene -
) O +
that O +
have O +
partial O +
functional O +
redundancy O +
and O +
therefore O +
individually O +
are O +
rarely O +
mutated O +
are O +
also O +
important O +
in O +
preventing O +
colorectal O +
cancer O +
progression O -
. O +

Additionally O -
, O +
we O +
describe O +
a O +
new O +
gene O +
( O -
Tle6-like B-Gene -
) O +
that O -
, O +
when O +
overactive O -
, O +
makes O +
these O +
cancers O +
progress O +
more O +
rapidly O -
. O +

The O +
overall O +
goal O +
of O +
this O +
study O +
is O +
to O +
understand O +
colorectal O +
cancer O +
progression O +
better O +
so O +
that O +
we O +
can O +
come O +
up O +
with O +
new O +
ways O +
to O +
block O +
it O +
at O +
the O +
later O +
stage O -
. O +

Introduction O +
Colorectal O +
cancer O +
( O -
CRC O -
) O +
is O +
one O +
of O +
the O +
common O +
malignancies O +
in O +
industrialized O +
countries O -
. O +

Lynch O +
syndrome O -
, O +
a O +
highly O +
penetrant O +
disorder O +
that O +
confers O +
predisposition O +
to O +
cancer O +
of O +
the O +
colorectum O -
, O +
endometrium O +
and O +
other O +
extra O -
- O -
colonic O +
sites O +
[ O -
1 O -
] O -
, O +
is O +
caused O +
by O +
germline O +
mutations O +
in O +
DNA O +
Mismatch B-Gene +
Repair I-Gene +
genes I-Gene +
( O -
MMR B-Gene -
) O -
. O +

Including O +
sporadic O +
forms O -
, O +
defective O +
MMR B-Gene +
underlies O +
∼12–15 O -
% O +
of O +
CRC O +
[ O -
2 O -
] O -
. O +

MMR B-Gene +
plays O +
critical O +
roles O +
in O +
the O +
maintenance O +
of O +
genomic O +
stability O +
in O +
both O +
prokaryotes O +
and O +
eukaryotes O +
[ O -
3 O -
] O -
. O +

The O +
study O +
of O +
model O +
organisms O +
has O +
yielded O +
great O +
insights O +
into O +
the O +
mechanisms O +
through O +
which O +
MMR B-Gene +
prevents O +
cancer O +
[ O -
1 O -
] O -
, O -
[ O -
3 O -
] O -
, O -
[ O -
4 O -
] O -
, O -
[ O -
5 O -
] O -
, O -
[ O -
6 O -
] O -
, O -
[ O -
7 O -
] O -
, O -
[ O -
8 O -
] O -
. O +

Briefly O -
, O +
there O +
are O +
nine O +
mammalian O +
MMR B-Gene +
genes O +
( O -
MLH1 B-Gene -
, O +
MLH3 B-Gene -
, O +
PMS1 B-Gene -
- I-Gene -
2 I-Gene -
, O +
MSH2 B-Gene -
- I-Gene -
6 I-Gene -
) O -
. O +

The O +
mammalian O +
E O +
coli O +
MutS O +
homologues O +
( O -
MSH O -
) O +
directly O +
contact O +
DNA O -
, O +
scanning O +
along O +
the O +
genomic O +
DNA O +
for O +
mismatches O +
analogous O +
to O +
a O +
" O -
sliding O +
clamp O -
� O -
? O +
until O +
they O +
encounter O +
a O +
base O -
- O -
pair O +
containing O +
a O +
mismatch O +
[ O -
9 O -
] O -
, O -
[ O -
10 O -
] O -
. O +

MSH2-MSH6 B-Gene +
primarily O +
recognizes O +
single O -
- O -
base O +
substitutions O +
and O +
1 O +
base O -
- O -
pair O +
insertion O -
- O -
deletion O +
loop O +
( O -
IDL O -
) O +
mutations O -
, O +
while O +
MSH2-MSH3 B-Gene +
recognizes O +
1–4 O +
base O -
- O -
pair O +
insertion O -
- O -
deletion O +
mutations O +
[ O -
1 O -
] O -
, O -
[ O -
3 O -
] O -
.The O +
IDL O +
repair O +
deficiency O +
is O +
commonly O +
referred O +
to O +
as O +
Microsatellite O +
Instability O +
( O -
MSI O -
) O -
. O +

The O +
MSH O +
proteins O +
interact O +
with O +
multiple O +
proteins O +
including O +
the O +
mammalian O +
E O +
coli O +
MutL O +
homologues O +
( O -
MLH O -
) O +
and O +
yeast O +
post O -
- O -
meiotic O +
segregation O +
( O -
PMS O -
) O +
homologue O +
proteins O +
( O -
which O +
have O +
significant O +
amino O +
acid O +
identify O +
and O +
structural O +
similarity O +
to O +
the O +
MLH O +
proteins O -
) O -
, O +
as O +
well O +
as O +
RPA O -
, O +
EXO1 O -
, O +
RFC O -
, O +
HMGB1 O -
, O +
POLDC O +
and O +
other O +
proteins O +
[ O -
1 O -
] O -
, O -
[ O -
8 O -
] O -
, O -
[ O -
11 O -
] O -
, O -
[ O -
12 O -
] O -
. O +

MLH1-PMS2 B-Gene +
is O +
the O +
primary O +
MutL O +
complex O +
that O +
interacts O +
with O +
both O +
MSH2 B-Gene -
/ I-Gene -
6 I-Gene +
and O +
MSH3 B-Gene +
complexes O -
. O +

MLH1–MLH3 B-Gene +
is O +
less O +
well O +
characterized O -
, O +
but O +
is O +
believed O +
to O +
participate O +
in O +
IDL O +
repair O +
[ O -
13 O -
] O -
, O -
[ O -
14 O -
] O -
, O +
DNA O +
damage O +
response O +
[ O -
13 O -
] O -
, O +
and O +
possibly O +
single O -
- O -
base O +
point O +
mutation O +
repair O +
( O -
SBR O -
) O -
[ O -
15 O -
] O -
. O +

MLH1-PMS1 B-Gene +
exists O +
in O +
mammalian O +
cells O +
but O +
currently O +
has O +
no O +
clearly O +
defined O +
roles O +
in O +
processes O +
related O +
to O +
cancer O +
prevention O +
[ O -
16 O -
] O -
, O -
[ O -
17 O -
] O -
. O +

To O +
study O +
the O +
precise O +
mechanisms O +
through O +
which O +
MMR B-Gene +
suppresses O +
carcinogenesis O +
in O +
vivo O -
, O +
we O +
and O +
others O +
[ O -
16 O -
] O -
, O -
[ O -
18 O -
] O -
, O -
[ O -
19 O -
] O -
, O -
[ O -
20 O -
] O -
, O -
[ O -
21 O -
] O -
, O -
[ O -
22 O -
] O -
, O -
[ O -
23 O -
] O -
, O -
[ O -
24 O -
] O +
previously O +
developed O +
several O +
mouse O +
models O +
carrying O +
mutations O +
in O +
different O +
MMR B-Gene +
genes O -
. O +

Mlh1− B-Gene -
/ O -
− O +
and O +
Msh2− B-Gene -
/ O -
− O +
mice O +
develop O +
early O +
onset O +
GI O +
epithelial O +
cancers O -
, O +
lymphomas O +
and O +
other O +
types O +
of O +
cancer O -
. O +

Pms2− B-Gene -
/ O -
− O +
mice O +
develop O +
lymphomas O -
, O +
but O +
not O +
GI O +
epithelial O +
cancers O -
. O +

Mlh3− B-Gene -
/ O -
− O +
mice O +
develop O +
GI O +
and O +
extra O -
- O -
GI O +
tumors O -
, O +
have O +
decreased O +
survival O +
when O +
compared O +
with O +
Wt O +
mice O -
, O +
but O +
with O +
later O +
onset O +
than O +
Mlh1− B-Gene -
/ O -
− O +
[ O -
13 O -
] O -
. O +

Mlh3− B-Gene -
/ O -
−;Pms2− O -
/ O -
− O +
mice O +
have O +
increased O +
cancer O +
incidence O -
, O +
resistance O +
to O +
apoptosis O +
and O +
MSI O +
[ O -
13 O -
] O -
. O +

However O -
, O +
the O +
precise O +
mechanisms O +
in O +
which O +
Mlh3 B-Gene +
and O +
Pms2 B-Gene +
participate O +
to O +
suppress O +
GI O +
epithelial O +
tumorigenesis O +
and O +
progression O +
remain O +
poorly O +
characterized O -
. O +

Germ O -
- O -
line O +
mutations O +
in O +
tumor O +
suppressor O +
gene O +
APC B-Gene +
lead O +
to O +
familial O +
adenomatous O +
polyposis O +
( O -
FAP O -
) O +
[ O -
25 O -
] O -
, O -
[ O -
26 O -
] O -
. O +

Mutations O +
in O +
APC B-Gene +
are O +
found O +
in O +
the O +
majority O +
of O +
sporadic O +
CRC O +
and O +
many O +
Lynch O +
syndrome O +
tumors O +
[ O -
27 O -
] O -
, O -
[ O -
28 O -
] O -
. O +

APC B-Gene +
complexes O +
with O +
AXIN B-Gene +
and O +
CK1 B-Gene -
/ I-Gene -
2 I-Gene +
and O +
destabilizes O +
β O -
- O -
Catenin O +
by O +
enhancing O +
proteasomal O +
destruction O -
. O +

Mutated O +
APC B-Gene +
proteins O +
are O +
unable O +
to O +
down O -
- O -
regulate O +
β O -
- O -
Catenin O -
, O +
and O +
the O +
stabilized O +
β O -
- O -
Catenin O +
translocates O +
into O +
the O +
nucleus O +
where O +
it O +
acts O +
as O +
a O +
transcriptional O +
coactivator O +
of O +
the O +
DNA O +
binding O +
protein O +
TCF-4 B-Gene +
[ O -
29 O -
] O -
, O -
[ O -
30 O -
] O -
. O +

More O +
than O +
95 O -
% O +
of O +
APC B-Gene +
germ O -
- O -
line O +
mutations O +
are O +
truncating O +
or O +
nonsense O +
mutations O +
and O +
most O +
of O +
the O +
pathogenic O +
mutations O +
are O +
located O +
within O +
the O +
first O +
1500 O +
codons O -
. O +

Apc B-Gene +
mutations O +
cooperate O +
with O +
MMR B-Gene +
deficiency O +
in O +
both O +
tumorigenesis O +
and O +
tumor O +
progression O -
. O +

Apc1638N B-Gene +
mice O +
are O +
a O +
well O +
characterized O +
model O +
that O +
develops O +
GI O +
cancer O +
[ O -
31 O -
] O -
. O +

Mlh1− B-Gene -
/ O -
−;Apc1638N O +
mice O +
showed O +
significantly O +
increased O +
GI O +
tumor O +
multiplicity O +
and O +
accelerated O +
progression O +
to O +
adenocarcinoma O +
compared O +
to O +
either O +
mutation O +
separately O -
. O +

Analyses O +
of O +
GI O +
tumors O +
from O +
Mlh1− B-Gene -
/ O -
−;Apc1638N O +
and O +
Msh3− B-Gene -
/ O -
−;Msh6− O -
/ O -
−;Apc1638N O +
mice O +
revealed O +
that O +
both O +
single O -
- O -
base O +
substitutions O +
and O +
MSI O +
induced O +
frameshift O +
mutations O +
in O +
repetitive O +
sequences O +
were O +
responsible O +
for O +
most O +
mutations O +
found O +
in O +
the O +
remaining O +
wild O -
- O -
type O +
( O -
Wt O -
) O +
Apc B-Gene +
allele O +
[ O -
32 O -
] O -
, O -
[ O -
33 O -
] O -
. O +

In O +
contrast O -
, O +
tumor O -
- O -
associated O +
Apc B-Gene +
mutations O +
found O +
in O +
the O +
Wt O +
Apc B-Gene +
allele O +
in O +
Msh6− B-Gene -
/ O -
−;Apc1638N O +
tumors O +
were O +
predominantly O +
single O -
- O -
base O +
point O +
mutations O -
. O +

Results O +
Mlh3 B-Gene -
, O +
Pms2 B-Gene +
and O +
Apc B-Gene +
Mutations O +
Cooperate O +
to O +
Increase O +
Tumor O +
Incidence O -
, O +
Accelerate O +
Progression O +
and O +
Decrease O +
Overall O +
Survival O +
By O +
9.5 O +
months O +
of O +
age O -
, O +
MA O +
mice O +
develop O +
> O -
50 O -
% O +
more O +
tumors O +
than O +
Apc1638N B-Gene +
mice O +
( O -
P<0.001 O -
; O +
Mann O -
- O -
Whitney O -
) O +
( O -
Figure O +
1A O +
and O +
C O -
) O -
. O +

However O -
, O +
the O +
relative O +
ratios O +
of O +
GI O +
adenomas O +
to O +
carcinomas O +
in O +
Apc1638N B-Gene +
mice O +
( O -
65 O -
% O +
and O +
35 O -
% O +
respectively O -
) O +
were O +
very O +
similar O +
to O +
that O +
seen O +
in O +
MA O +
mice O +
( O -
70 O -
% O +
and O +
30 O -
% O +
respectively O -
) O +
and O +
overall O +
survival O +
is O +
not O +
significantly O +
affected O +
( O -
9.5 O +
vs. O +
10.5 O +
months O -
) O -
. O +

No O +
significant O +
effect O +
was O +
seen O +
on O +
extra O -
- O -
GI O +
cancer O +
incidence O +
or O +
progression O -
. O +

These O +
data O +
suggest O +
the O +
primary O +
role O +
of O +
Mlh3 B-Gene +
is O +
in O +
suppression O +
of O +
GI O +
tumor O +
initiation O +
and O +
not O +
tumor O +
progression O -
. O +

Decreased O +
survival O +
and O +
increased O +
tumor O +
multiplicity O +
and O +
progression O +
in O +
MPA O +
mice O -
. O +

( O -
A O -
) O +
Kaplan O -
- O -
Meier O +
survival O +
analysis O +
of O +
mice O +
deficient O +
in O +
Apc B-Gene +
and O +
DNA O +
Mismatch B-Gene +
Repair I-Gene +
genes I-Gene -
. O +

( O -
B O -
, O +
left O -
) O +
Three O +
small O +
intestinal O +
adenomatous O +
polyps O +
from O +
MPA O +
mouse O +
duodena O +
are O +
seen O +
in O +
cross O -
- O -
section O +
( O -
arrows O -
, O +
left O +
panel O -
) O -
. O +

( O -
B O -
, O +
right O +
panel O -
) O +
Example O +
of O +
a O +
jejeunal O +
adenocarcinoma O +
from O +
an O +
MPA O +
mouse O -
, O +
showing O +
atypical O +
glands O +
( O -
arrows O -
) O +
invading O +
deeply O +
into O +
a O +
desmoplastic O +
stroma O +
( O -
asterisks O -
) O +
containing O +
a O +
mixed O +
chronic O +
inflammatory O +
reaction O +
( O -
arrowheads O -
) O -
. O +

( O -
C O -
) O +
Tumor O +
incidence O +
and O +
multiplicity O -
. O +

a O +
Data O +
from O +
Chen O +
et O +
al O -
[ O -
13 O -
] O -
. O +

b O +
Data O +
from O +
Edelmann O +
et O +
al O +
[ O -
35 O -
] O -
, O +
for O +
comparison O -
. O +

NA O -
, O +
data O +
not O +
available O -
. O +

To O +
study O +
the O +
effects O +
of O +
combined O +
Mlh3 B-Gene +
and O +
Pms2 B-Gene +
mutations O +
in O +
vivo O -
, O +
we O +
generated O +
MPA O +
mice O -
. O +

MPA O +
mice O +
had O +
significantly O +
shorter O +
survival O +
vs. O +
Apc1638N B-Gene +
or O +
MA O +
mice O +
( O -
P<0.01 O -
, O +
Mann O -
- O -
Whitney O +
test O -
; O +
Figure O +
1A O -
, O +
C O -
) O +
and O +
developed O +
significantly O +
more O +
adenocarcinomas O +
than O +
MA O +
or O +
Apc1638N B-Gene +
mice O +
( O -
Figure O +
1B O -
, O +
C O -
) O +
( O -
P O +
= O +
0.022 O +
MPA O +
vs. O +
MA O +
and O +
p O +
= O +
0.0003 O +
MPA O +
vs. O +
Apc1638N B-Gene -
) O -
. O +

These O +
are O +
consistent O +
with O +
a O +
role O +
for O +
Mlh3;Pms2 B-Gene +
combined O +
loss O +
both O +
to O +
increase O +
GI O +
tumor O +
initiation O +
and O +
accelerates O +
progression O -
. O +

However O -
, O +
mean O +
overall O +
survival O +
of O +
MPA O +
mice O +
is O +
longer O +
than O +
that O +
previously O +
seen O +
in O +
Mlh1− B-Gene -
/ O -
−;Apc1638N O +
mice O +
[ O -
35 O -
] O -
. O +

Spectrum O +
of O +
Apc B-Gene +
Mutations O +
in O +
MA O +
and O +
MPA O +
Mice O +
Tumors O +
In O +
vitro O +
studies O +
have O +
alternatively O +
suggested O +
that O +
Mlh3 B-Gene +
participates O +
in O +
either O +
IDL O +
repair O +
[ O -
13 O -
] O +
or O +
SBR O +
[ O -
15 O -
] O -
. O +

To O +
understand O +
the O +
role O +
of O +
Mlh3 B-Gene +
in O +
these O +
processes O -
, O +
we O +
used O +
the O +
wild O +
type O +
Apc B-Gene +
allele O +
as O +
a O +
tumor O -
- O -
associated O +
in O +
vivo O +
reporter O +
gene O +
to O +
analyze O +
the O +
mutation O +
spectrum O +
from O +
MA O +
GI O +
tumors O -
. O +

A O +
total O +
of O +
49 O +
tumors O +
from O +
MA O +
mice O +
and O +
28 O +
tumors O +
from O +
Apc1638N B-Gene +
littermates O +
were O +
analyzed O +
for O +
Apc B-Gene +
truncation O +
mutations O +
by O +
IVTT O +
analysis O -
. O +

Truncated O +
Apc B-Gene +
products O +
were O +
detected O +
in O +
27 O +
of O +
49 O +
( O -
55 O -
% O -
) O +
MA O +
tumors O +
while O +
only O +
9 O +
of O +
28 O +
( O -
32 O -
% O -
) O +
were O +
found O +
in O +
Apc1638N B-Gene +
tumors O -
. O +

The O +
current O +
observed O +
incidence O +
of O +
Apc B-Gene +
somatic O +
mutations O +
of O +
Apc1638N B-Gene +
tumors O +
is O +
in O +
agreement O +
with O +
the O +
previous O +
results O +
( O -
7 O +
of O +
22 O -
, O +
32 O -
% O -
) O +
[ O -
36 O -
] O -
, O +
hence O +
for O +
better O +
understanding O +
of O +
mutational O +
differences O +
between O +
the O +
two O +
strains O -
, O +
this O +
and O +
the O +
previous O +
data O +
for O +
Apc1638N B-Gene +
tumors O +
were O +
combined O +
and O +
used O +
for O +
further O +
comparisons O -
. O +

This O +
23 O -
% O +
increase O +
in O +
somatic O +
Apc B-Gene +
mutations O +
in O +
MA O +
mice O +
was O +
significant O +
( O -
P<0.0048 O -
; O +
Fisher O +
exact O +
test O -
) O +
and O +
was O +
attributable O +
to O +
increased O +
small O +
insertion O -
/ O -
deletion O +
frameshift O +
mutations O +
( O -
62.5 O -
% O -
) O +
vs. O +
Apc1638N B-Gene +
( O -
33.3 O -
% O -
) O +
mice O +
( O -
P<0.001 O -
; O +
Fisher O +
exact O +
test O -
; O +
Figure O +
2B O +
and O +
Tables O +
1 O +
and O +
2 O -
) O -
. O +

MA O +
mice O +
had O +
one O +
recurrent O +
insertion O -
/ O -
deletion O +
mutation O +
" O -
hotspot O -
� O -
? O +
also O +
observed O +
in O +
Mlh1;Apc1638N B-Gene +
mice O +
( O -
amino O +
acid O +
1464 O -
) O +
( O -
Figure O +
2A O -
) O -
. O +

Furthermore O -
, O +
examination O +
of O +
the O +
sequences O +
surrounding O +
each O +
Apc B-Gene +
mutation O +
site O +
in O +
MA O +
tumors O +
showed O +
that O -
, O +
unlike O +
in O +
other O +
mismatch O +
repair O +
deficient O +
tumors O +
such O +
as O +
Mlh1− B-Gene -
/ O -
−;Apc1638N O +
or O +
Msh6− B-Gene -
/ O -
−;Msh3− O -
/ O -
−;Apc1638N O +
[ O -
32 O -
] O -
, O -
[ O -
33 O -
] O -
, O +
about O +
40 O -
% O +
of O +
frameshift O +
mutations O +
occurred O +
at O +
non O -
- O -
repetitive O +
sequences O +
within O +
the O +
Apc B-Gene +
coding O +
region O -
. O +

These O +
data O +
are O +
consistent O +
with O +
a O +
primary O +
in O +
vivo O +
role O +
for O +
Mlh3 B-Gene +
in O +
DNA O +
repair O +
of O +
small O +
insertion O -
/ O -
deletion O +
mutations O +
in O +
GI O +
epithelial O +
cells O -
. O +

Distribution O +
of O +
Apc B-Gene +
mutations O -
. O +

( O -
A O -
) O +
Diagram O +
of O +
Apc B-Gene +
between O +
codons O +
677 O +
and O +
1674 O +
showing O +
positions O +
and O +
characteristics O +
of O +
truncation O +
mutations O +
detected O +
in O +
MPA O +
( O -
top O -
) O -
, O +
MA O +
( O -
middle O -
) O +
and O +
Apc1638N B-Gene +
( O -
bottom O -
) O +
gastrointestinal O +
tumors O -
. O +

( O -
Open O +
triangle O +
symbol O -
, O +
deletion O -
; O +
solid O +
triangle O -
, O +
insertion O -
; O +
blue O +
bar O -
, O +
substitution O -
) O -
. O +

Each O +
symbol O +
represents O +
an O +
independent O +
mutation O -
. O +

Note O +
the O +
common O +
hotspots O +
at O +
position O +
1464 O +
in O +
both O +
strains O -
. O +

The O +
three O +
15-aa O +
( O -
A O -
– O -
C O -
) O -
, O +
four O +
20-aa O +
( O -
1–4 O -
) O +
β O -
- O -
catenin O +
binding O +
repeats O +
and O +
one O +
SAMP O +
repeat O +
in O +
this O +
segment O +
of O +
Apc B-Gene +
are O +
indicated O -
. O +

The O +
two O +
nuclear O +
export O +
signals O +
are O +
at O +
the O +
ends O +
of O +
the O +
third O +
and O +
fourth O +
20-aa O +
repeats O -
. O +

( O -
B O -
) O +
Spectrum O +
of O +
Apc B-Gene +
truncation O +
mutations O +
in O +
MMR O +
deficient O +
Apc1638N B-Gene +
tumors O -
. O +

a O +
Combined O +
with O +
previous O +
data O +
from O +
Wong O +
et O +
al O -
, O +
2002 O -
. O +

b O +
Data O +
from O +
Kuraguchi O +
et O +
al O -
, O +
2000 O -
, O +
for O +
comparison O -
. O +

Apc B-Gene +
truncation O +
mutations O +
in O +
intestinal O +
tumors O +
from O +
MutL O +
homolog O +
deficient O +
Apc1638N B-Gene +
mice O -
. O +

Combined O +
with O +
previous O +
data O +
from O +
Wong O +
et O +
al O +
2002 O +
[ O -
36 O -
] O -
. O +

Data O +
from O +
Kuraguchi O +
et O +
al O +
2000 O +
[ O -
32 O -
] O +
for O +
comparison O -
. O +

Sequences O +
of O +
Apc B-Gene +
mutations O +
in O +
MutL O +
homolog O +
deficient O +
Apc1638N B-Gene +
tumors O -
. O +

Previous O +
data O +
from O +
Wong O +
et O +
al O +
2002 O -
. O +

We O +
also O +
studied O +
the O +
tumor O -
- O -
associated O +
Apc B-Gene +
mutations O +
in O +
GI O +
tumors O +
from O +
MPA O +
mice O -
. O +

The O +
overall O +
incidence O +
of O +
Apc B-Gene +
truncation O +
mutations O +
in O +
MPA O +
tumors O +
were O +
similar O +
to O +
that O +
observed O +
in O +
MA O +
tumors O -
, O +
yet O +
the O +
nature O +
of O +
mutations O +
characterized O +
was O +
distinct O -
. O +

Compared O +
with O +
MA O +
mice O +
( O -
37.5 O -
% O -
) O -
, O +
combined O +
Mlh3;Pms2 B-Gene +
deficiency O +
caused O +
a O +
significant O +
increase O +
in O +
the O +
proportion O +
of O +
single O -
- O -
base O +
point O +
mutations O +
( O -
57.2 O -
% O -
, O +
P<0.01 O -
; O +
Figure O +
2 O +
and O +
Table O +
2 O -
) O -
. O +

Within O +
the O +
types O +
of O +
single O -
- O -
base O +
point O +
mutations O -
, O +
MPA O +
tumors O +
showed O +
higher O +
frequency O +
of O +
C∶G→T∶A O +
transition O +
mutations O +
( O -
12 O +
of O +
16 O -
, O +
75 O -
% O -
) O +
compared O +
to O +
MA O +
tumors O +
( O -
7 O +
of O +
12 O -
, O +
58.3 O -
% O -
) O -
. O +

However O -
, O +
this O +
high O +
frequency O +
was O +
not O +
as O +
prominent O +
as O +
that O +
of O +
Mlh1;Apc1638N B-Gene +
tumors O +
which O +
showed O +
the O +
majority O +
( O -
23 O +
of O +
25 O -
, O +
92 O -
% O -
) O +
of O +
base O +
substitutions O +
to O +
be O +
transition O +
mutations O -
[ O -
32 O -
] O -
. O +

The O +
C∶G→T∶A O +
transition O +
mutations O +
found O +
in O +
tumors O -
, O +
irrespective O +
of O +
genotypes O -
, O +
occurred O +
at O +
either O +
CpG O +
dinucleotides O +
or O +
CpNpG O +
sites O -
, O +
typical O +
targets O +
for O +
DNA O +
methylation O -
. O +

Among O +
these O -
, O +
Apc B-Gene +
codon O +
R854 O +
seems O +
to O +
be O +
a O +
preferential O +
target O +
for O +
base O +
substitution O +
mutation O -
, O +
which O +
was O +
not O +
only O +
demonstrated O +
to O +
be O +
a O +
mutational O +
hotspot O +
in O +
Mlh1;Apc1638N B-Gene +
mice O +
[ O -
32 O -
] O +
but O +
also O +
in O +
MPA O +
mice O -
. O +

Identification O +
of O +
Genomic O +
Copy O +
Amplification O +
in O +
MPA O +
Tumors O +
Associated O +
with O +
Tumor O +
Progression O +
Apc B-Gene +
mutation O +
is O +
thought O +
to O +
be O +
an O +
early O +
event O +
in O +
CRC O +
carcinogenesis O -
. O +

The O +
significantly O +
increased O +
number O +
of O +
adenocarcinomas O +
vs. O +
adenomas O +
seen O +
in O +
MPA O +
vs. O +
MA O +
or O +
Apc1638N B-Gene +
mice O +
suggested O +
that O +
MPA O +
tumors O +
have O +
accelerated O +
tumor O +
progression O -
. O +

While O +
there O +
is O +
extensive O +
evidence O +
that O +
increased O +
mutation O +
rates O +
and O +
decreased O +
apoptosis O +
contribute O +
to O +
MMR B-Gene +
defective O +
CRC O -
, O +
it O +
is O +
likely O +
that O +
additional O +
mechanisms O +
participate O +
in O +
tumor O +
progression O +
as O +
well O -
. O +

Because O +
chromosomal O +
and O +
segmental O +
aneuploidy O +
has O +
been O +
described O +
in O +
a O +
subset O +
of O +
MMR B-Gene +
deficient O +
adenocarcinomas O +
[ O -
37 O -
] O -
, O -
[ O -
38 O -
] O -
, O -
[ O -
39 O -
] O -
, O +
we O +
performed O +
array O +
comparative O +
genomic O +
hybridization O +
( O -
aCGH O -
) O +
analyses O +
of O +
GI O +
tumor O +
vs. O +
E18.5 O +
C57BL O -
/ O -
6 O +
embryonic O +
control O +
DNA O +
from O +
Apc B-Gene -
, O +
MA O -
, O +
and O +
MPA O +
mice O +
to O +
identify O +
specific O +
genetic O +
changes O +
that O +
accelerate O +
MPA O +
GI O +
tumor O +
progression O -
. O +

Comparison O +
of O +
aCGH O +
profiles O +
revealed O +
a O +
recurrent O +
5-Mb O +
base O +
pairs O +
amplification O +
on O +
chromosome O +
12F2 O +
( O -
66.7%∼83.3 O -
% O -
; O +
see O +
Table O +
3 O +
for O +
detail O -
; O +
Figure O +
3A O +
and O +
B O -
) O +
in O +
MPA O +
GI O +
tumors O +
not O +
seen O +
in O +
Apc1638N B-Gene +
or O +
MA O +
tumors O +
( O -
Figure O +
S1 O -
) O -
. O +

To O +
define O +
the O +
critical O +
interval O +
for O +
this O +
amplification O +
on O +
chromosome O +
12F2 O +
we O +
bred O +
a O +
new O +
cohort O +
of O +
MPA O +
mice O +
and O +
quantified O +
copy O +
number O +
variation O +
in O +
the O +
tumor O +
using O +
real O -
- O -
time O +
quantitative O +
PCR O +
( O -
qPCR O -
) O +
( O -
Figure O +
3C O +
and O +
Table O +
4 O -
) O -
. O +

Using O +
qPCR O +
with O +
primer O +
sets O +
for O +
the O +
six O +
genes O +
within O +
the O +
amplified O +
region O +
and O +
two O +
flanking O +
genes O -
, O +
we O +
identified O +
one O +
gene O +
that O +
showed O +
recurrent O +
increased O +
level O +
of O +
genomic O +
DNA O +
in O +
tumor O +
tissues O +
( O -
Figure O +
3C O -
) O -
, O +
Transducin B-Gene -
- I-Gene -
like I-Gene +
enhancer I-Gene +
protein I-Gene +
6-like I-Gene -
, O +
( O -
Tle6-like B-Gene -
) O -
. O +

TLE B-Gene +
family O +
members O +
act O +
as O +
transcriptional O +
corepressors O +
[ O -
40 O -
] O -
, O -
[ O -
41 O -
] O +
without O +
any O +
intrinsic O +
DNA O -
- O -
binding O +
activity O -
. O +

They O +
are O +
recruited O +
to O +
specific O +
gene O +
regulatory O +
sequences O +
in O +
a O +
context O -
- O -
dependent O +
manner O +
by O +
forming O +
complexes O +
with O +
different O +
DNA O -
- O -
binding O +
transcription O +
factors O -
. O +

Two O +
evolutionarily O +
conserved O +
domains O +
define O +
the O +
TLE B-Gene +
gene O +
family O -
: O +
an O +
N O -
- O -
terminal O +
glutamine O -
- O -
rich O +
( O -
Q O -
) O +
domain O +
that O +
mediates O +
TLE B-Gene +
family O +
member O +
heterodimerization O -
, O +
and O +
a O +
C O -
- O -
terminal O +
domain O +
of O +
WD B-Gene +
motif O +
repeats O +
that O +
mediates O +
direct O +
interactions O +
with O +
sequence O +
specific O +
DNA O +
binding O +
transcription O +
factors O +
( O -
Figure O +
4 O -
) O -
[ O -
40 O -
] O -
, O -
[ O -
41 O -
] O -
. O +

Previously O +
TLE B-Gene +
family O +
members O +
have O +
been O +
described O +
containing O +
only O +
the O +
Q O +
domain O -
, O +
such O +
as O +
Grg1-S B-Gene +
[ O -
42 O -
] O -
, O +
or O +
only O +
the O +
WD B-Gene +
repeat O +
motif O -
, O +
such O +
as O +
Grg6 B-Gene -
/ O -
Tle6 B-Gene -
[ O -
43 O -
] O -
. O +

Tle6-like B-Gene +
similarly O +
contains O +
only O +
the O +
C O -
- O -
terminal O +
WD B-Gene +
repeat O +
domain O +
and O +
had O +
highest O +
amino O +
acid O +
identity O +
( O -
84.4 O -
% O -
) O +
with O +
TLE6 B-Gene +
( O -
Figure O +
4A O +
and O +
Figure O +
S2 O -
) O -
. O +

Array O -
- O -
CGH O +
analysis O +
of O +
Mlh3;Pms2;Apc B-Gene +
deficient O +
GI O +
tumors O -
. O +

( O -
A O -
) O +
Display O +
of O +
CGH O +
signal O +
from O +
a O +
representative O +
tumor O +
genome O +
wide O -
. O +

Red O +
arrow O +
indicates O +
the O +
gain O +
of O +
signal O +
on O +
chromosome O +
12 O -
. O +

( O -
B O -
) O +
Higher O +
resolution O +
view O +
of O +
mouse O +
chromosome O +
12 O +
signal O -
. O +

Red O +
dot O +
line O +
indicates O +
the O +
amplification O -
. O +

( O -
C O -
) O +
Quantitative O +
PCR O +
of O +
genomic O +
DNA O +
level O +
from O +
MPA O +
tumors O -
. O +

Dotted O +
box O +
indicates O +
the O +
amplified O +
region O +
detected O +
by O +
array O -
- O -
CGH O -
. O +

( O -
D O -
) O +
Quantitative O +
PCR O +
of O +
Tle6-like B-Gene +
level O +
in O +
cDNA O +
from O +
MPA O +
tumors O -
. O +

( O -
E O -
) O +
Immunoblot O +
of O +
Tle6-like B-Gene +
in O +
MPA O +
tumors O -
. O +

N O -
, O +
normal O +
tissues O -
; O +
T O -
, O +
tumors O -
. O +

TLE B-Gene +
Family O -
. O +

Schematic O +
diagram O +
of O +
TLE B-Gene +
protein O +
family O +
members O -
. O +

( O -
A O -
) O +
Numbers O +
indicate O +
amino O +
acids O -
. O +

Q O -
, O +
glutamine O +
rich O +
domain O -
; O +
GP O -
, O +
Glycine O -
/ O -
praline O +
rich O +
domain O -
; O +
CcN O -
, O +
domain O +
containing O +
putative O +
phosphorylation O +
sites O +
and O +
putative O +
nuclear O +
localization O +
signal O -
; O +
SP O -
, O +
serine O -
/ O -
praline O +
rich O +
domain O -
; O +
WD B-Gene +
repeats O -
, O +
domain O +
containing O +
series O +
of O +
tandem O +
repeats O +
of O +
tryptophan O +
and O +
aspartic O +
acid O +
residues O -
. O +

( O -
B O -
) O +
Diagram O +
of O +
TLE6 B-Gene +
RNA O +
and O +
alternative O +
splice O +
form O +
TLE6D B-Gene +
is O +
indicated O -
. O +

TLE6A B-Gene +
is O +
the O +
full O +
length O +
mRNA O +
transcript O -
. O +

Orange O +
bars O +
indicate O +
position O +
of O +
primer O +
sets O +
for O +
qPCR O -
. O +

Arrows O +
indicate O +
exon O -
- O -
exon O +
junctions O -
. O +

Amplifications O +
of O +
Chromosome O +
12 O -
. O +

Primers O +
Used O +
in O +
Real O -
- O -
Time O +
PCR O -
. O +

RNA O +
and O +
Protein O +
Expression O +
Levels O +
of O +
Tle6-like B-Gene +
Are O +
Increased O +
in O +
MPA O +
Tumors O +
To O +
understand O +
the O +
impact O +
of O +
gene O +
amplification O +
on O +
Tle6-like B-Gene +
expression O -
, O +
we O +
isolated O +
total O +
RNA O +
from O +
tumor O +
and O +
normal O +
tissues O +
from O +
MPA O +
mice O +
and O +
used O +
qPCR O +
to O +
quantify O +
relative O +
Tle6-like B-Gene +
mRNA O +
expression O -
. O +

As O +
a O +
result O +
of O +
copy O +
number O +
amplification O -
, O +
Tle6-like B-Gene +
mRNA O +
levels O +
were O +
significantly O +
increased O +
in O +
tumors O +
compared O +
with O +
adjacent O +
normal O +
GI O +
tissue O +
( O -
Figure O +
3D O -
) O -
. O +

To O +
understand O +
whether O +
Tle6-like B-Gene +
protein O +
levels O +
are O +
subsequently O +
increased O -
, O +
we O +
generated O +
anti O -
- O -
Tle6-like B-Gene +
specific O +
antisera O -
. O +

Western O +
blot O +
analysis O +
with O +
this O +
antisera O +
demonstrated O +
that O +
Tle6-like B-Gene +
protein O +
levels O +
are O +
significantly O +
increased O +
in O +
GI O +
tumors O +
compared O +
to O +
surrounding O +
normal O +
GI O +
epithelial O +
tissue O +
from O +
MPA O +
mice O +
( O -
Figure O +
3E O -
) O -
. O +

Overall O -
, O +
these O +
data O +
suggest O +
increased O +
genomic O +
DNA O +
copy O +
number O +
of O +
Tle6-like B-Gene +
causes O +
increased O +
mRNA O +
and O +
protein O +
expression O +
of O +
Tle6-like B-Gene +
in O +
MPA O +
tumors O -
. O +

Expression O +
Level O +
of O +
TLE6 B-Gene +
Alternative I-Gene +
Spliced I-Gene +
Isoform I-Gene +
D I-Gene +
( O -
TLE6D B-Gene -
) O +
Is O +
Increased O +
in O +
Human O +
Colorectal O +
Tumors O +
Gene O +
diversity O +
can O +
be O +
generated O +
by O +
several O +
mechanisms O -
, O +
including O +
gene O +
duplication O +
and O +
paralogue O +
evolutionary O +
divergence O -
, O +
and O +
the O +
generation O +
of O +
alternative O +
mRNA O +
splice O +
isoforms O +
that O +
modify O +
coding O +
sequence O -
. O +

The O +
mouse O +
Tle6-like B-Gene -
- O -
containing O +
amplicon O +
is O +
syntenic O +
to O +
human O +
chromosome O +
14q33 O -
, O +
but O +
amplification O +
of O +
this O +
chromosomal O +
region O +
is O +
not O +
associated O +
with O +
CRC O -
. O +

Upon O +
further O +
analysis O -
, O +
we O +
discovered O +
that O +
14q33 O +
contains O +
no O +
human O +
ortholog O +
of O +
mouse O +
Tle6-like B-Gene -
, O +
or O +
any O +
other O +
TLE B-Gene +
family O +
member O -
. O +

However O -
, O +
when O +
we O +
analyzed O +
TLE6 B-Gene +
mRNAs O +
bioinformatically O -
, O +
we O +
identified O +
a O +
previously O +
identified O +
alternative O +
spliced O +
isoform O +
of O +
TLE6 B-Gene +
( O -
TLE6D B-Gene -
) O +
( O -
Genbank O +
Accession O +
# O -
BX375733 O -
) O +
that O +
contains O +
only O +
the O +
C O -
- O -
terminal O +
WD B-Gene +
repeat O +
domain O +
of O +
TLE6 B-Gene -
, O +
and O +
therefore O +
has O +
the O +
same O +
domain O +
structure O +
as O +
mouse O +
Tle6-like B-Gene +
( O -
Figure O +
4B O -
) O +
To O +
understand O +
expression O +
of O +
TLE6A B-Gene +
( O -
full O -
- O -
length O +
isoform O -
) O +
and O +
TLE6D B-Gene +
in O +
human O +
CRC O -
, O +
we O +
generated O +
three O +
sets O +
of O +
RT O -
- O -
PCR O +
primers O -
: O +
one O +
for O +
the O +
TLE6D B-Gene +
N O -
- O -
terminus O -
, O +
one O +
crossing O +
the O +
splice O +
junction O +
that O +
is O +
specific O +
for O +
TLE6D B-Gene +
and O +
one O +
that O +
detects O +
TLE6A B-Gene +
but O +
not O +
TLE6D B-Gene +
( O -
Figure O +
4B O -
) O -
. O +

We O +
then O +
calculated O +
expression O +
of O +
these O +
transcripts O +
in O +
40 O +
human O +
CRC O +
samples O +
and O +
normal O +
tissue O -
. O +

Compared O +
to O +
adjacent O +
normal O +
tissue O -
, O +
the O +
TLE6D B-Gene -
- I-Gene -
specific I-Gene +
and O +
TLE6 B-Gene +
C O -
- O -
terminus O +
qPCR O +
showed O +
significantly O +
increased O +
expression O +
in O +
a O +
subset O +
of O +
human O +
CRCs O +
( O -
Figure O +
5A O -
) O -
, O +
but O +
not O +
for O +
the O +
TLE6 B-Gene +
N O -
- O -
terminal O +
or O +
TLE6A B-Gene +
qPCR O +
( O -
data O +
not O +
shown O -
) O -
. O +

These O +
data O +
suggest O +
that O +
the O +
TLE6D B-Gene +
isoform O +
specifically O +
is O +
overexpressed O +
in O +
a O +
subset O +
of O +
human O +
CRCs O -
. O +

TLE6D B-Gene +
and O +
RUNX3 B-Gene +
mRNA O +
expression O +
levels O +
in O +
human O +
colorectal O +
cancers O -
. O +

( O -
A O -
, O -
B O -
) O +
Dotplots O +
of O +
TLE6D B-Gene +
and O +
RUNX3 B-Gene +
expression O +
levels O +
for O +
each O +
of O +
the O +
40 O +
samples O -
. O +

Expression O +
is O +
shown O +
as O +
fold O +
elevation O +
vs. O +
accompanying O +
normal O +
adjacent O +
mucosa O -
. O +

( O -
C O -
) O +
Superimposed O +
plot O +
of O +
TLE6D B-Gene +
and O +
RUNX3 B-Gene +
expression O +
levels O +
by O +
sample O +
( O -
Pearson O +
correlation O +
0.724 O -
; O +
Pvalue<0.001 O -
) O -
. O +

( O -
D O -
) O +
A O +
scatterplot O +
of O +
log O -
- O -
transformed O +
RUNX3 B-Gene +
by O +
TLE6D B-Gene +
expression O +
levels O +
along O +
with O +
the O +
least O +
squares O +
estimate O +
of O +
the O +
regression O +
of O +
RUNX3 B-Gene +
on O +
TLE6D B-Gene -
. O +

Expression O +
levels O +
were O +
log O -
- O -
transformed O +
in O +
the O +
regression O +
analysis O +
due O +
to O +
heavy O +
skewness O -
. O +

Based O +
upon O +
the O +
regression O -
, O +
it O +
was O +
estimated O +
that O +
the O +
geometric O +
mean O +
of O +
RUNX3 B-Gene +
expression O +
increased O +
0.525 O +
with O +
a O +
2-fold O +
increase O +
in O +
TLE6D B-Gene +
expression O +
( O -
95 O -
% O +
CI O -
: O +
0.165 O -
, O +
0.563 O -
; O +
p O +
Value<0.001 O -
) O -
. O +

Tle6-like B-Gene +
and O +
TLE6D B-Gene +
Enhance O +
Cell O +
Proliferation O -
, O +
Colony O +
Formation O -
, O +
and O +
Cell O +
Migration O +
Because O +
GI O +
tumors O +
from O +
MPA O +
mice O +
showed O +
increased O +
number O +
of O +
adenocarcinoma O +
than O +
Apc1638N B-Gene +
or O +
MA O +
mice O -
, O +
we O +
evaluated O +
whether O +
increased O +
levels O +
of O +
Tle6-like B-Gene +
can O +
contribute O +
to O +
mechanisms O +
that O +
underlie O +
tumor O +
progression O -
. O +

We O +
generated O +
stable O +
cell O +
293 O +
cell O +
lines O +
that O +
express O +
Tle6-like B-Gene +
or O +
TLE6D B-Gene -
. O +

For O +
both O +
Tle6-like B-Gene +
and O +
TLE6D B-Gene +
overexpressing O +
cell O +
lines O -
, O +
cell O +
proliferation O +
rates O +
were O +
significantly O +
increased O +
compared O +
with O +
vector O -
- O -
transfected O +
control O +
cells O +
( O -
Figure O +
6A O -
) O -
. O +

Similar O +
results O +
were O +
also O +
seen O +
in O +
HCT116 O +
and O +
3T3 O +
cells O +
( O -
data O +
not O +
shown O -
) O -
. O +

We O +
next O +
tested O +
the O +
effect O +
of O +
Tle6-like B-Gene -
/ O -
TLE6 B-Gene +
expression O +
on O +
the O +
ability O +
to O +
form O +
colonies O +
in O +
vitro O -
. O +

Mouse O +
embryonic O +
fibroblasts O +
transfected O +
with O +
Tle6-like B-Gene +
or O +
TLE6D B-Gene +
significantly O +
increased O +
colony O +
formation O +
( O -
four O -
- O -
fold O +
and O +
two O -
- O -
fold O -
, O +
respectively O -
) O +
compared O +
with O +
empty O +
vector O -
- O -
transfected O +
control O +
cells O +
( O -
Figure O +
6B O +
and O +
C O -
) O -
. O +

We O +
also O +
tested O +
the O +
mobility O +
of O +
the O +
cells O +
transfected O +
with O +
Tle6-like B-Gene -
/ O -
TLE6D B-Gene +
by O +
in O +
vitro O +
migration O +
assay O -
. O +

Cell O +
lines O +
stably O +
expressing O +
Tle6-like B-Gene +
or O +
TLE6D B-Gene +
were O +
able O +
to O +
migrate O +
a O +
significantly O +
longer O +
distance O +
when O +
compared O +
with O +
control O +
cell O +
lines O +
expressing O +
only O +
the O +
vector O +
( O -
Figure O +
6D O -
) O -
. O +

In O +
contrast O -
, O +
no O +
effect O +
of O +
Tle6-like B-Gene +
or O +
TLE6D B-Gene +
ectopic O +
expression O +
was O +
seen O +
on O +
induction O +
or O +
resistance O +
of O +
apoptosis O +
induced O +
by O +
serum O -
- O -
depletion O +
in O +
culture O +
medium O +
( O -
data O +
not O +
shown O -
) O -
. O +

In O +
summary O -
, O +
these O +
results O +
are O +
consistent O +
with O +
a O +
proliferation O +
and O +
migration O +
advantage O +
for O +
tumor O +
cells O +
expressing O +
Tle6sh B-Gene +
or O +
TLE6D B-Gene -
. O +

Tle6-like B-Gene +
and O +
TLE6D B-Gene +
Enhance O +
Cell O +
Proliferation O -
, O +
Colony O +
Formation O -
, O +
and O +
Cell O +
Migration O -
. O +

( O -
A O -
) O +
HCT116 O +
Cell O +
proliferation O +
MTT O +
assay O -
. O +

( O -
B O -
) O +
Representative O +
picture O +
of O +
plates O +
of O +
colony O +
formation O +
assay O +
on O +
MEFs O +
transfected O +
with O +
vector O -
, O +
TLE6D B-Gene -
, O +
and O +
Tle6-like B-Gene -
. O +

( O -
C O -
) O +
Plot O +
of O +
number O +
of O +
colonies O +
from O +
colony O +
formation O +
assay O -
. O +

( O -
D O -
) O +
In O +
Vitro O +
Cell O +
Mobility O +
Assay O -
. O +
" O +

Wound O -
� O -
? O +
was O +
generated O +
by O +
razor O +
blade O -
, O +
clearing O +
the O +
adherent O +
cells O +
on O +
the O +
right O +
side O +
of O +
the O +
slides O -
. O +

Black O +
lines O +
indicate O +
the O +
edge O +
of O +
the O +
" O -
wound O -
� O -
? O -
. O +

Representative O +
pictures O +
from O +
HCT116 O +
cells O +
transfected O +
with O +
vector O -
, O +
TLE6D B-Gene -
, O +
and O +
Tle6-like B-Gene +
are O +
shown O -
. O +

Tle6-like B-Gene +
and O +
TLE6D B-Gene +
Expression O +
Increases O +
Xenograft O +
Tumor O +
Proliferation O +
in O +
vivo O +
Because O +
Tle6-like B-Gene +
or O +
TLE6D B-Gene +
ectopic O +
expression O +
increased O +
cell O +
proliferation O +
and O +
migration O +
in O +
vitro O -
, O +
we O +
evaluated O +
their O +
impact O +
in O +
vivo O -
. O +

We O +
injected O +
HCT116 O +
cells O +
stably O +
expressing O +
Tle6-like B-Gene -
, O +
TLE6D B-Gene +
or O +
vector O +
s.c O -
. O +

into O +
nude O +
mice O +
and O +
quantified O +
tumor O +
growth O -
. O +

As O +
expected O -
, O +
HCT116 O +
cells O +
transfected O +
with O +
vector O +
formed O +
xenograft O +
tumors O -
. O +

In O +
parallel O -
, O +
HCT116 O +
cells O +
expressing O +
Tle6-like B-Gene +
and O +
TLE6D B-Gene +
formed O +
significantly O +
larger O +
tumors O +
( O -
Figure O +
7 O -
) O -
. O +

These O +
results O +
suggest O +
that O +
Tle6-like B-Gene +
and O +
TLE6D B-Gene +
expression O +
increases O +
CRC O +
cell O +
proliferation O +
and O +
growth O -
, O +
in O +
vivo O -
. O +

Tle6-like B-Gene +
and O +
TLE6D B-Gene +
Enhance O +
Gastrointestinal O +
Tumor O +
Progression O -
. O +

( O -
A O -
) O +
Left O +
panel O -
, O +
Xenograft O +
of O +
HCT116 O +
cell O +
lines O +
expression O +
Tle6-like B-Gene +
or O +
vector O +
alone O -
. O +

Right O +
Panel O -
, O +
Xenograft O +
of O +
HCT116 O +
cell O +
lines O +
expression O +
TLE6D B-Gene +
or O +
vector O +
alone O -
. O +

( O -
B O -
) O +
Representative O +
xenograft O +
tumors O +
of O +
HCT116 O +
cells O +
expressing O +
pCS2+MT O +
-Tle6-like O -
, O +
pCS2+MT O +
vector O -
, O +
pcDNA6 O -
/ O -
HisA O -
- O -
TLE6D B-Gene +
and O +
empty O +
pcDNA6 O -
/ O -
HisA O +
vector O -
. O +

( O -
C O -
) O +
Tumor O +
weight O +
in O +
HCT116 O +
xenograft O +
tumors O +
expressing O +
Tle6-like B-Gene +
or O +
empty O +
pCS2+MT O +
vector O +
and O +
TLE6D B-Gene +
and O +
empty O +
pcDNA6 O -
/ O -
HisA O +
vector O +
( O -
Error O +
bars O +
indicate O +
the O +
standard O +
deviation O +
of O +
the O +
mean O -
; O +
p O +
Value<0.005 O -
) O -
. O +

Tle6-like B-Gene +
and O +
TLE6D B-Gene +
Interact O +
with O +
the O +
RUNX3 B-Gene +
GI O +
Tumor O +
Suppressor O +
and O +
Antagonize O +
RUNX3 B-Gene +
Mediated O +
Transactivation O +
RUNX B-Gene +
genes O +
encode O +
transcription O +
factors O +
that O +
activate O +
or O +
repress O +
transcription O +
of O +
key O +
regulators O +
of O +
growth O -
, O +
survival O +
and O +
differentiation O +
pathways O +
[ O -
44 O -
] O -
, O -
[ O -
45 O -
] O -
. O +

This O +
gene O +
family O +
is O +
defined O +
by O +
the O +
Runt B-Gene +
domain O -
, O +
which O +
mediates O +
both O +
protein O -
- O -
DNA O +
and O +
protein O -
- O -
protein O +
interactions O +
with O +
transcriptional O +
co O -
- O -
regulators O -
. O +

TLE B-Gene +
proteins O +
interact O +
with O -
, O +
and O +
regulate O +
the O +
function O +
of O -
, O +
RUNX B-Gene +
proteins O +
through O +
direct O +
interactions O +
between O +
the O +
TLE B-Gene +
WD B-Gene +
domain O +
and O +
the O +
Runt B-Gene +
domain O +
and O +
the O +
interactions O +
antagonize O +
RUNX B-Gene -
- O -
mediated O +
transactivation O +
[ O -
44 O -
] O -
, O -
[ O -
45 O -
] O -
, O -
[ O -
46 O -
] O -
, O -
[ O -
47 O -
] O -
, O -
[ O -
48 O -
] O -
. O +

RUNX3 B-Gene +
has O +
been O +
shown O +
to O +
play O +
important O +
roles O +
in O +
GI O +
epithelial O +
cell O +
development O +
and O +
tumorgenesis O -
. O +

Loss O +
of O +
Runx3 B-Gene +
predisposes O +
knockout O +
mice O +
to O +
gastric O +
hyperplasia O -
, O +
indicating O +
a O +
tumor O +
suppressor O -
- O -
like O +
role O +
for O +
this O +
gene O +
[ O -
34 O -
] O -
, O -
[ O -
49 O -
] O -
, O -
[ O -
50 O -
] O -
, O -
[ O -
51 O -
] O -
, O -
[ O -
52 O -
] O -
. O +

In O +
human O +
gastric O +
cancers O -
, O +
hypermethylation O +
of O +
RUNX3 B-Gene -
, O +
hemizygous O +
deletion O +
and O +
truncating O +
point O +
mutations O +
have O +
been O +
observed O +
[ O -
34 O -
] O -
, O -
[ O -
52 O -
] O -
, O -
[ O -
53 O -
] O -
, O -
[ O -
54 O -
] O -
, O -
[ O -
55 O -
] O -
, O -
[ O -
56 O -
] O -
, O -
[ O -
57 O -
] O -
, O -
[ O -
58 O -
] O -
. O +

To O +
test O +
whether O +
Tle6-like B-Gene -
/ O -
TLE6D B-Gene +
interact O +
with O +
RUNX3 B-Gene -
, O +
we O +
first O +
evaluated O +
sub O -
- O -
cellular O +
localization O +
using O +
immunofluorescence O +
staining O +
in O +
293 O +
cells O +
co O -
- O -
transfected O +
with O +
Tle6-like B-Gene +
or O +
TLE6D B-Gene +
and O +
native O +
RUNX3 B-Gene +
( O -
Figure O +
S3 O -
) O -
. O +

Using O +
anti O -
- O -
Myc O -
, O +
anti O -
- O -
Xpress O +
and O +
anti O -
- O -
RUNX3 B-Gene +
antibodies O -
, O +
we O +
observed O +
that O +
highest O +
levels O +
of O +
Tle6-like B-Gene +
and O +
TLE6 B-Gene +
and O +
are O +
in O +
the O +
nucleus O +
overlapping O +
with O +
nuclear O +
RUNX3 B-Gene +
staining O -
. O +

Furthermore O -
, O +
in O +
293 O +
cells O -
, O +
transiently O +
transfected O +
with O +
Tle6-like B-Gene +
or O +
TLE6D B-Gene -
, O +
endogenous O +
RUNX3 B-Gene +
co O -
- O -
immunoprecipitated O +
with O +
anti O -
- O -
Myc O +
or O +
anti O -
- O -
Xpress O +
antibodies O +
( O -
Figure O +
8A O +
and O +
B O -
) O -
, O +
suggesting O +
an O +
interaction O +
between O +
Tle6-like B-Gene -
/ O -
TLE6D B-Gene +
and O +
RUNX3 B-Gene -
. O +

Similar O +
co O -
- O -
localization O +
and O +
co O -
- O -
immunoprecipitation O +
results O +
were O +
seen O +
in O +
HCT116 O +
and O +
3T3 O +
cells O +
( O -
data O +
not O +
shown O -
) O -
. O +

Finally O -
, O +
to O +
evaluate O +
the O +
functional O +
consequences O +
of O +
Tle6-like B-Gene -
/ O -
TLE6D B-Gene +
interaction O +
on O +
RUNX3 B-Gene +
transcriptional O +
regulation O +
we O +
used O +
a O +
well O +
characterized O +
RUNX3 B-Gene +
transactivation O +
on O +
promoter O +
target O -
, O +
osteocalcin O +
( O -
OC O -
) O -
, O +
fused O +
to O +
a O +
luciferase O +
reporter O +
gene O +
[ O -
47 O -
] O -
. O +

As O +
expected O -
, O +
transfected O +
RUNX3 B-Gene +
activated O +
luciferase O +
expression O +
in O +
293 O -
, O +
Hela O +
or O +
HCT116 O +
cells O +
( O -
Figure O +
8C O -
, O +
lane O +
1 O +
and O +
2 O -
) O -
. O +

Co O -
- O -
transfection O +
of O +
Tle6-like B-Gene +
or O +
TLE6D B-Gene +
decreased O +
RUNX3 B-Gene +
transcriptional O +
reporter O +
activity O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
( O -
Figure O +
8C O -
) O -
, O +
whereas O +
Tle6-like B-Gene -
/ O -
TLE6D B-Gene +
transfection O +
had O +
no O +
effect O +
on O +
promoters O +
lacking O +
RUNX3 B-Gene +
binding O +
sites O -
, O +
such O +
as O +
the O +
TOPFLASH O -
/ O -
FOPFLASH O +
system O +
( O -
data O +
not O +
shown O -
) O -
. O +

Taken O +
together O -
, O +
these O +
results O +
are O +
consistent O +
with O +
a O +
model O +
whereby O +
Tle6-like B-Gene -
/ O -
TLE6D B-Gene +
expression O +
antagonizes O +
RUNX3 B-Gene +
GI O +
tumor O +
suppressor O +
mediated O +
target O +
gene O +
transactivation O +
through O +
an O +
interaction O +
between O +
the O +
Tle6-like B-Gene -
/ O -
TLE6D B-Gene +
and O +
RUNX3 B-Gene -
, O +
providing O +
a O +
selective O +
growth O +
advantage O +
for O +
cell O +
proliferation O +
and O +
migration O -
. O +

Tle6-like B-Gene +
and O +
TLE6D B-Gene +
Antagonize O +
RUNX3 B-Gene +
Gene O +
Target O +
Transcription O -
. O +

( O -
A O +
and O +
B O -
) O +
Tle6-like B-Gene -
/ O -
TLE6D B-Gene +
interacts O +
with O +
endogenous O +
RUNX3 B-Gene +
in O +
293 O +
cells O -
. O +

Left O +
panel O +
represents O +
the O +
immunoblot O +
of O +
protein O +
extracts O +
before O +
immunoprecipitation O -
. O +

Right O +
panel O +
represents O +
the O +
immunoblot O +
after O +
the O +
immunoprecipitation O -
. O +

( O -
C O -
) O +
Luciferase O +
reporter O +
assay O -
. O +

Cells O +
were O +
transient O +
tranfected O +
with O +
indicated O +
plasmids O +
and O +
relative O +
luciferase O +
activities O +
were O +
determined O +
the O +
next O +
day O -
. O +

( O -
Error O +
bars O +
indicate O +
the O +
standard O +
deviation O +
of O +
the O +
mean O -
) O -
. O +

TLE6D B-Gene +
is O +
Highly O +
Expressed O +
in O +
Human O +
CRCs O +
with O +
High O +
RUNX3 B-Gene +
Expression O +
Levels O +
In O +
gastric O +
cancer O -
, O +
RUNX3 B-Gene +
activity O +
is O +
most O +
commonly O +
reduced O +
through O +
a O +
mechanism O +
involving O +
RUNX3 B-Gene +
promoter O +
hypermethylation O +
and O +
subsequently O +
decreased O +
mRNA O +
expression O -
. O +

However O -
, O +
its O +
expression O +
levels O +
in O +
CRC O +
have O +
not O +
been O +
well O +
characterized O -
. O +

We O +
therefore O +
used O +
qPCR O +
to O +
evaluate O +
RUNX3 B-Gene +
expression O +
in O +
40 O +
human O +
CRC O +
and O +
matched O +
normal O +
GI O +
epithelial O +
samples O -
, O +
normalized O +
to O +
GAPDH B-Gene +
expression O -
. O +

In O +
many O +
CRCs O -
, O +
RUNX3 B-Gene +
expression O +
is O +
low O -
, O +
consistent O +
with O +
a O +
role O +
in O +
GI O +
tumor O +
suppression O -
. O +

However O -
, O +
in O +
a O +
subset O +
of O +
CRCs O +
RUNX3 B-Gene +
expression O +
is O +
paradoxically O +
increased O +
( O -
Figure O +
5B O -
) O -
. O +

To O +
test O +
whether O +
elevated O +
TLE6D B-Gene +
expression O +
is O +
associated O +
with O +
RUNX3 B-Gene +
activation O -
, O +
we O +
used O +
qPCR O +
to O +
analyze O +
TLE6D B-Gene +
expression O +
levels O +
in O +
the O +
same O +
matched O +
sets O +
of O +
CRCs O +
and O +
normal O +
mucosa O -
. O +

We O +
observed O +
a O +
clear O +
correlation O +
of O +
RUNX3 B-Gene +
and O +
TLE6D B-Gene +
expression O +
levels O +
( O -
R O +
= O +
0.723 O -
; O +
Figure O +
5C O -
) O -
. O +

However O -
, O +
at O +
the O +
same O +
time O +
no O +
clear O +
correlation O +
was O +
seen O +
for O +
RUNX3 B-Gene +
and O +
TLE6D B-Gene +
expression O +
levels O +
with O +
regard O +
to O +
MSI O -
- O -
H O -
/ O -
MSS O +
status O +
or O +
for O +
expression O +
levels O +
of O +
the O +
full O +
length O +
TLE6 B-Gene +
and O +
RUNX B-Gene +
( O -
data O +
not O +
shown O -
) O -
. O +

Overall O -
, O +
in O +
combination O +
with O +
the O +
functional O +
antagonism O +
of O +
RUNX3 B-Gene +
activity O +
by O +
TLE6D B-Gene +
observed O +
in O +
colon O +
cancer O +
cells O -
, O +
the O +
correlation O +
of O +
RUNX3 B-Gene +
and O +
TLE6D B-Gene +
expression O +
in O +
human O +
CRCs O +
suggests O +
that O +
TLE6D B-Gene +
may O +
interact O +
with O +
the O +
RUNX3 B-Gene +
GI O +
epithelial O +
tumor O +
suppressor O +
and O +
inactivate O +
RUNX3 B-Gene +
in O +
a O +
subset O +
of O +
CRCs O +
independent O +
of O +
MSI O +
status O -
. O +

However O -
, O +
further O +
experiments O +
will O +
be O +
required O +
to O +
analyze O +
the O +
association O +
between O +
RUNX3 B-Gene +
and O +
TLE6D B-Gene +
expression O +
levels O +
and O +
functional O +
interactions O +
in O +
more O +
detail O -
. O +

Discussion O +
Because O +
APC B-Gene +
is O +
a O +
common O +
mutation O +
target O +
in O +
MMR B-Gene -
- O -
deficient O +
CRC O -
, O +
we O +
created O +
novel O +
mouse O +
models O +
combining O +
different O +
mutations O +
in O +
these O +
genes O +
to O +
analyze O +
their O +
roles O +
in O +
MMR B-Gene -
- O -
deficient O +
GI O +
carcinogenesis O +
and O +
progression O -
. O +

The O +
observation O +
that O +
MA O +
mice O +
have O +
increased O +
tumor O +
multiplicity O +
but O +
no O +
accelerated O +
tumor O +
progression O +
or O +
decreased O +
survival O +
vs. O +
Apc1638N B-Gene +
mice O +
suggests O +
a O +
primary O +
role O +
for O +
the O +
Mlh1–Mlh3 B-Gene +
heterodimer O +
in O +
suppression O +
of O +
GI O +
tumor O +
initiation O -
. O +

While O +
previous O +
in O +
vitro O +
studies O +
have O +
alternatively O +
suggested O +
that O +
Mlh1–Mlh3 B-Gene +
participates O +
in O +
IDL O +
repair O +
[ O -
13 O -
] O +
and O +
SBR O -
[ O -
15 O -
] O -
, O -
[ O -
59 O -
] O -
, O +
our O +
study O +
provides O +
the O +
first O +
in O +
vivo O +
evidence O +
that O +
Mlh3 B-Gene +
deficiency O +
significantly O +
increases O +
IDL O +
mutation O +
frequency O -
. O +

This O +
type O +
of O +
mutation O +
occurred O +
both O +
at O +
repetitive O +
and O +
non O -
- O -
repetitive O +
Apc B-Gene +
sequences O -
, O +
implicating O +
its O +
role O +
in O +
repair O +
of O +
both O +
types O +
of O +
IDL O +
( O -
Figure O +
2 O -
) O -
. O +

Previous O +
studies O +
of O +
Pms2− B-Gene -
/ O -
−;ApcMin O +
mice O +
have O +
shown O +
a O +
primary O +
role O +
for O +
Mlh1-Pms2 B-Gene +
in O +
GI O +
tumorgenesis O +
suppression O +
but O +
not O +
tumor O +
progression O -
[ O -
60 O -
] O -
. O +

We O +
therefore O +
combined O +
these O +
mutations O +
to O +
create O +
MPA O +
mice O -
. O +

Like O +
Mlh1− B-Gene -
/ O -
−;Apc1638N O +
mice O -
, O +
MPA O +
mice O +
have O +
significantly O +
increased O +
GI O +
tumor O +
multiplicity O -
, O +
accelerated O +
tumor O +
progression O +
and O +
decreased O +
overall O +
survival O -
[ O -
61 O -
] O +
. O +

MPA O +
tumors O +
harbor O +
proportionally O +
more O +
C∶G→T∶A O +
( O -
at O +
either O +
CpG O +
or O +
CpNpG O +
sites O -
) O +
transition O +
mutations O +
than O +
MA O +
tumors O -
, O +
showing O +
recurrence O +
in O +
certain O +
arginine O +
codons O -
, O +
one O +
of O +
which O +
was O +
at O +
Apc B-Gene +
codon O +
854 O -
, O +
a O +
SBR O +
hotspot O +
that O +
was O +
also O +
previously O +
seen O +
in O +
Mlh1− B-Gene -
/ O -
−;Apc1638N O +
mice O -
. O +

In O +
addition O +
to O +
Mlh1-Pms2 B-Gene +
and O +
Mlh1–Mlh3 B-Gene -
, O +
several O +
lines O +
of O +
evidence O +
from O +
our O +
study O +
suggest O +
a O +
potential O +
role O +
for O +
Mlh1-Pms1 B-Gene +
in O +
suppression O +
of O +
GI O +
tumorigenesis O -
. O +

First O -
, O +
MPA O +
mice O +
have O +
later O +
mean O +
GI O +
tumor O +
onset O +
compared O +
to O +
previous O +
studies O +
of O +
Mlh1− B-Gene -
/ O -
−;Apc1638N O +
mice O -
[ O -
32 O -
] O -
. O +

Second O -
, O +
the O +
multiplicity O +
of O +
GI O +
tumors O +
is O +
decreased O +
vs O +
Mlh1− B-Gene -
/ O -
−;Apc1638N O +
mice O -
. O +

Third O -
, O +
two O +
Apc B-Gene +
insertion O -
/ O -
deletion O +
mutation O +
hotspots O +
seen O +
in O +
Mlh1− B-Gene -
/ O -
−;Apc1638N O +
mice O +
have O +
not O +
been O +
detected O +
in O +
MPA O +
tumors O -
. O +

These O +
data O +
are O +
consistent O +
with O +
previous O +
studies O +
of O +
yeast O +
Mlh2p B-Gene +
( O -
orthologue O +
of O +
mammalian O +
PMS1 B-Gene -
) O +
that O +
demonstrate O +
a O +
minor O +
role O +
for O +
this O +
protein O +
in O +
IDL O +
repair O +
[ O -
62 O -
] O -
. O +

Because O +
the O +
combination O +
of O +
Mlh3 B-Gene -
, O +
Pms2 B-Gene +
and O +
Apc B-Gene +
mutations O +
accelerates O +
tumor O +
progression O -
, O +
we O +
searched O +
MPA O +
GI O +
tumor O +
specific O +
genetic O +
changes O +
associated O +
with O +
progression O +
using O +
high O -
- O -
resolution O +
aCGH O -
. O +

MPA O +
tumors O +
contained O +
a O +
recurrent O +
5-Mb O +
amplicon O +
with O +
a O +
critical O +
interval O +
containing O +
a O +
novel O -
, O +
poorly O +
characterized O +
member O +
of O +
the O +
TLE B-Gene +
family O +
of O +
transcriptional O +
co O -
- O -
repressors O -
, O +
Tle6-like B-Gene -
. O +

Unexpectedly O -
, O +
this O +
MPA O +
recurrent O +
amplification O +
hotspot O +
is O +
not O +
detected O +
by O +
aCGH O +
in O +
GI O +
tumors O +
from O +
Mlh1− B-Gene -
/ O -
−;Apc1638N O +
mice O +
( O -
data O +
not O +
shown O -
) O -
. O +

The O +
reason O +
for O +
this O +
difference O +
is O +
unclear O -
, O +
but O +
again O +
suggests O +
that O +
Mlh1-Pms1 B-Gene +
may O +
play O +
a O +
role O +
in O +
causing O +
chromosomal O +
instability O -
. O +

TLE B-Gene +
genes O +
are O +
the O +
mammalian O +
homologues O +
of O +
Drosophlia O +
groucho O +
that O +
play O +
critical O +
roles O +
in O +
a O +
wide O +
range O +
of O +
developmental O +
and O +
cellular O +
pathways O +
[ O -
40 O -
] O -
. O +

TLE B-Gene +
proteins O +
are O +
transcriptional O +
corepressors O +
for O +
specific O +
families O +
of O +
DNA O -
- O -
binding O +
transcription O +
factors O -
, O +
including O +
RUNX B-Gene +
proteins O -
[ O -
48 O -
] O -
. O +

In O +
addition O -
, O +
Tle1 B-Gene -
/ O -
Grg1 B-Gene +
has O +
been O +
shown O +
to O +
act O +
as O +
a O +
lung O -
- O -
specific O +
oncogene O +
in O +
a O +
transgenic O +
mouse O +
model O +
[ O -
63 O -
] O -
. O +

Mouse O +
Tle6 B-Gene -
/ O -
Grg6 B-Gene +
has O +
been O +
shown O +
to O +
synergize O +
with O +
the O +
E2A O -
- O -
HLF O +
oncoprotein O +
in O +
antagonism O +
of O +
Runx1 O +
transactivation O +
in O +
murine O +
pro O -
- O -
B O +
cells O -
, O +
causing O +
acute O +
leukemogenesis O +
[ O -
64 O -
] O -
. O +

Tle6 B-Gene -
/ O -
Grg6 B-Gene +
also O +
participates O +
in O +
developmental O +
mechanisms O +
of O +
neurogenesis O +
[ O -
43 O -
] O -
. O +

Here O -
, O +
we O +
provide O +
data O +
that O +
a O +
previously O +
uncharacterized O +
TLE B-Gene +
family O +
member O +
containing O +
only O +
the O +
WD B-Gene +
repeat O +
domain O -
, O +
Tle6-like B-Gene -
, O +
has O +
amplified O +
gene O +
copy O +
number O -
, O +
mRNA O +
and O +
protein O +
levels O +
in O +
GI O +
epithelial O +
tumors O +
from O +
MMR B-Gene +
deficient O -
/ O -
Apc B-Gene +
mutant O +
mice O -
, O +
and O +
is O +
associated O +
with O +
accelerated O +
tumor O +
progression O -
. O +

Consistent O +
with O +
this O +
observation O -
, O +
in O +
functional O +
studies O +
Tle6-like B-Gene -
/ O -
TLE6D B-Gene +
enhances O +
cell O +
proliferation O -
, O +
colony O -
- O -
formation O -
, O +
migration O +
and O +
xenograft O +
tumorgenicity O -
. O +

While O +
TLE B-Gene +
family O +
members O +
have O +
previously O +
been O +
shown O +
to O +
repress O +
Wnt B-Gene -
/ O -
β O -
- O -
catenin O +
signaling O +
[ O -
42 O -
] O -
, O -
[ O -
65 O -
] O -
, O -
[ O -
66 O -
] O -
, O -
[ O -
67 O -
] O -
, O +
we O +
were O +
unable O +
to O +
demonstrate O +
any O +
Tle6-like B-Gene -
/ O -
TLE6D B-Gene +
protein O -
- O -
protein O +
interactions O +
with O +
β O -
- O -
catenin O +
or O +
effect O +
of O +
Tle6-like B-Gene -
/ O -
TLE6D B-Gene +
overexpression O +
on O +
β O -
- O -
catenin O +
reporter O +
gene O +
activity O +
using O +
TOPFlash O +
in O +
transient O +
transfection O +
in O +
colon O +
cancer O +
cell O +
lines O +
( O -
data O +
not O +
shown O -
) O -
, O +
suggesting O +
that O +
Tle6-like B-Gene -
/ O -
TLE6D B-Gene +
might O +
not O +
be O +
involved O +
in O +
canonical O +
Wnt B-Gene +
pathway O -
. O +

cDNA O +
Preparation O +
and O +
Real O -
- O -
Time O +
PCR O +
For O +
RNA O +
extractions O -
, O +
Trizol O +
reagent O +
( O -
Invitrogen O -
) O +
was O +
used O +
to O +
isolate O +
total O +
RNA O -
. O +

RNA O +
were O +
further O +
digested O +
with O +
RNAse O -
- O -
free O +
DNAseI O +
( O -
Promega O -
) O +
and O +
cleaned O +
with O +
RNeasy O +
Mini O +
kit O +
( O -
Qiagen O -
) O -
. O +

High O +
Capacity O +
cDNA O +
Archive O +
kit O +
from O +
Applied O +
Biosystems O +
was O +
used O +
to O +
make O +
cDNA O +
from O +
the O +
RNA O +
samples O -
. O +

Real O -
- O -
time O +
quantitative O +
PCR O +
was O +
performed O +
with O +
either O +
SYBRGreen O +
PCR O +
master O +
mix O +
or O +
Taqman O +
PCR O +
master O +
mix O +
( O -
Applied O +
Biosystems O -
) O +
following O +
the O +
manufacture O -
's O +
protocol O +
on O +
ABI O +
7900 O +
machine O -
. O +

Primers O +
used O +
for O +
SYBR O +
Green O +
assays O +
are O +
listed O +
in O +
Table O +
1 O -
. O +

Each O +
gene O +
was O +
normalized O +
to O +
the O +
internal O +
control O +
gene O +
Gapdh O +
and O +
then O +
compared O +
to O +
a O +
known O +
single O +
copy O +
gene O +
( O -
Alkbh O -
) O -
, O +
which O +
is O +
located O +
on O +
non O -
- O -
amplified O +
region O +
on O +
chromosome O +
12 O +
D3 O +
in O +
the O +
MPA O +
tumors O -
. O +

Generation O +
of O +
Tle6-Like B-Gene +
Antibody O +
The O +
whole O +
Tle6-like B-Gene +
gene O +
( O -
encoded O +
240 O +
amino O +
acids O -
) O +
was O +
cloned O +
in O +
to O +
pET28b O +
vector O +
and O +
Tle-6like O +
protein O +
was O +
induced O +
and O +
purified O +
from O +
E. O +
coli O -
. O +

Rabbit O +
anti O -
- O -
serum O +
was O +
raised O +
against O +
Tle6-like B-Gene +
protein O -
. O +

The O +
anti O -
- O -
serum O +
was O +
further O +
purified O +
using O +
affinity O +
column O -
, O +
in O +
which O +
Tle6like B-Gene +
protein O +
was O +
covalently O +
bound O +
to O +
CNBr O -
- O -
activated O +
Sepharose O +
4B O +
( O -
Sigma O -
) O -
. O +

The O +
purified O +
antibody O +
was O +
used O +
in O +
immunoblotting O +
at O +
1∶100 O +
dilutions O -
. O +

Cell O +
Culture O +
HCT116 O -
, O +
293 O -
, O +
Hela O +
or O +
3T3 O +
cells O +
were O +
maintained O +
in O +
DMEM O +
with O +
10%FBS O +
and O +
transfected O +
using O +
Lipofectamine O +
2000 O +
( O -
Invitrogen O -
) O -
. O +

The O +
human O +
isoform O +
TLE6D B-Gene +
cDNA O +
clone O +
was O +
purchased O +
from O +
Invitrogen O +
( O -
Full O -
- O -
length O +
Human O +
Clones O +
CS0DC017YC05 O -
; O +
Accession O +
number O +
BX375733 O -
) O -
. O +

Tle6-like B-Gene +
was O +
cloned O +
from O +
cDNA O +
samples O +
from O +
MPA O +
mice O -
. O +

We O +
subcloned O +
Tle6-like B-Gene +
and O +
TLE6D B-Gene +
into O +
either O +
Xpress O -
- O -
epitope O -
- O -
tagged O +
pcDNA6 O -
/ O -
HisA O +
vector O +
( O -
Invitrogen O -
) O +
or O +
Myc B-Gene -
- O -
tagged O +
pCS2+MT O +
vector O -
. O +

Cells O +
were O +
transfected O +
with O +
following O +
plasmids O -
: O +
pcDNA6 O -
/ O -
HisA O -
, O +
pcDNA6 O -
/ O -
HisA O -
- O -
Tle6-like O -
, O +
pcDNA6 O -
/ O -
HisA O -
- O -
TLE6D O -
, O +
pCS2+MT O -
, O +
pCS2+MT O -
- O -
Tle6-like O -
, O +
pCS2+MT O -
- O -
TLE6D O -
. O +

Stable O +
cell O +
lines O +
from O +
each O +
transfectant O +
were O +
generated O +
with O +
the O +
selection O +
medium O +
containing O +
10 O +
µg O -
/ O -
ml O +
blasticidin O +
( O -
Calbiochem O -
) O +
for O +
10 O +
days O -
. O +

The O +
pooled O +
populations O +
of O +
cells O +
that O +
survived O +
were O +
used O +
in O +
the O +
experiments O +
for O +
MTT O +
assay O +
and O +
cell O +
mobility O +
assay O -
. O +

The O +
transient O -
- O -
transfected O +
cells O +
were O +
used O +
for O +
colony O +
formation O +
assay O -
, O +
immunoprecipitation O -
, O +
and O +
reporter O +
assay O -
. O +

MTT O +
Cell O +
Proliferation O +
Assay O +
and O +
Colony O +
Formation O +
Assay O +
For O +
the O +
cell O +
proliferation O +
assay O -
, O +
4000 O +
cells O +
were O +
plated O +
in O +
96-well O +
plates O +
and O +
MTT O +
assay O +
were O +
used O +
to O +
determine O +
the O +
cell O +
numbers O +
in O +
a O +
time O -
- O -
course O +
experiment O -
. O +

Briefly O -
, O +
cells O +
were O +
washed O +
with O +
PBS O +
and O +
treated O +
with O +
5 O +
µg O -
/ O -
ml O +
MTT O +
( O -
[ O -
3- O -
( O -
4,5-dimethylthiazol-2-yl O -
) O -
- O +
diphenyltetrazolium O +
bromide O -
] O -
Sigma O -
, O +
St. O +
Louis O -
, O +
MO O -
) O +
for O +
5 O +
hours O -
. O +

After O +
removal O +
of O +
MTT O -
, O +
DMSO O +
was O +
added O +
to O +
dissolve O +
the O +
dark O +
purple O +
formazam O +
crystals O +
in O +
the O +
viable O +
cells O +
and O +
absorbance O +
of O +
600 O +
nm O +
were O +
determined O +
by O +
a O +
multiwell O +
scanning O +
spectrophotometer O -
. O +

The O +
cell O +
numbers O +
were O +
calculated O +
with O +
a O +
control O +
standard O +
curve O -
. O +

For O +
colony O -
- O -
formation O +
assay O -
, O +
MEF O +
cells O +
were O +
seeded O +
in O +
6 O +
well O +
plates O +
and O +
transient O -
- O -
transfected O +
with O +
1 O +
µg O +
of O +
the O +
respective O +
plasmids O +
in O +
the O +
next O +
day O -
. O +

After O +
24 O +
h O -
, O +
cells O +
were O +
trypsinzed O -
, O +
transferred O +
to O +
10-cm O +
plates O +
and O +
allowed O +
to O +
grow O +
with O +
the O +
selection O +
medium O +
containing O +
10 O +
µg O -
/ O -
ml O +
blasticidin O +
for O +
2 O +
weeks O -
. O +

Survived O +
cells O +
were O +
fixed O +
in O +
30 O -
% O +
ethanol O +
and O +
stained O +
with O +
0.25 O -
% O +
methylene O +
blue O -
. O +

Colonies O +
containing O +
more O +
than O +
50 O +
cells O +
were O +
counted O -
. O +

Both O +
assays O +
were O +
repeated O +
three O +
times O +
in O +
three O +
independently O -
- O -
derived O +
cell O +
lines O -
. O +

In O +
Vitro O +
Cell O +
Mobility O +
Assay O +
The O +
monolayer O +
" O -
wounding O +
assay O -
� O -
? O +
was O +
used O +
to O +
demonstrate O +
the O +
in O +
vitro O +
cell O +
migration O -
. O +

Human O +
colon O +
cancer O +
HCT116 O +
cells O +
stably O +
expressing O +
corresponding O +
plasmids O +
were O +
plated O +
on O +
glass O +
microscopy O +
slides O +
and O +
cultured O +
to O +
confluence O -
. O +

A O +
" O -
wound O -
� O -
? O +
was O +
generated O +
by O +
scratching O +
the O +
slide O +
with O +
a O +
razor O +
blade O -
, O +
clearing O +
a O +
portion O +
of O +
adherent O +
cells O +
on O +
the O +
slide O -
. O +

Photo O +
documentation O +
was O +
taken O +
at O +
day O +
4 O +
and O +
the O +
migration O +
of O +
cells O +
from O +
the O +
cut O +
edge O +
of O +
the O +
monolayer O +
into O +
the O +
clear O +
portion O +
of O +
the O +
slides O +
was O +
assessed O -
. O +

Two O +
independently O -
- O -
derived O +
stable O +
cell O +
lines O +
for O +
each O +
plasmid O +
were O +
used O +
in O +
this O +
assay O -
. O +

Antibodies O -
, O +
Immunoprecipitation O -
, O +
and O +
Immunoblotting O +
Transient O -
- O -
transfected O +
293 O +
cells O +
in O +
10-cm O +
plate O +
were O +
lysed O +
with O +
1 O +
ml O +
of O +
NP-40 O +
lysis O +
buffer O +
and O +
prepared O +
as O +
described O +
before O +
[ O -
13 O -
] O -
. O +

Five O +
hundred O +
µl O +
of O +
lysates O +
were O +
pre O -
- O -
cleared O +
with O +
50 O +
µl O +
ProteinA O -
/ O -
G O +
agarose O +
beads O +
( O -
Santa O +
Cruz O -
) O +
for O +
1 O +
h. O +
After O +
spinning O +
down O +
the O +
ProteinA O -
/ O -
G O +
beads O -
, O +
the O +
collected O +
supernatants O +
were O +
incubated O +
with O +
5 O +
µg O +
anti O -
- O -
Xpress O +
or O +
anti O -
- O -
myc O +
monoclonal O +
antibody O +
( O -
Invitrogen O -
) O +
and O +
50 O +
µl O +
ProteinA O -
/ O -
G O +
beads O +
overnight O +
at O +
4 O -
° O -
C O -
. O +

The O +
next O +
day O -
, O +
the O +
beads O +
were O +
washed O +
with O +
NP-40 O +
buffer O +
5 O +
times O +
and O +
incubate O +
with O +
4 O -
× O +
protein O +
loading O +
dye O +
( O -
Invitrogen O -
) O +
10 O +
min O +
at O +
95 O -
° O -
C O +
to O +
elute O +
the O +
binding O +
proteins O -
. O +

These O +
samples O +
were O +
resolved O +
by O +
SDS O -
- O -
PAGE O +
and O +
the O +
immunoblotting O +
was O +
used O +
as O +
previously O +
described O +
to O +
detect O +
the O +
corresponding O +
proteins O -
. O +

The O +
antibodies O +
used O +
in O +
immunoblotting O +
are O -
: O +
mouse O +
monoclonal O +
anti O -
- O -
Xpress O +
and O +
anti O -
- O -
myc O +
( O -
1∶2000 O -
, O +
Invitrogen O -
) O -
, O +
rabbit O +
anti O -
- O -
RUNX3 B-Gene +
( O -
1∶1000 O -
, O +
Abcam O -
) O +
and O +
goat O +
anti O -
- O -
β O -
- O -
actin O +
( O -
1∶1000 O -
, O +
Santa O +
Cruz O +
Biotechnologe O -
) O -
. O +

Luciferase O +
Reporter O +
Assay O +
293 O -
, O +
Hela O +
or O +
3T3 O +
cells O +
were O +
transient O -
- O -
transfected O +
accordingly O +
with O +
the O +
Flag O -
- O -
RUNX3 B-Gene +
( O -
a O +
kind O +
gift O +
from O +
Dr. O +
Yoshiaki O +
Ito O -
) O +
and O +
rat O +
Osteocalcin O +
promoter O +
fused O +
to O +
luciferase O +
reporter O +
construct O +
( O -
OC O -
- O -
Luci O -
, O +
a O +
kind O +
gift O +
from O +
Dr. O +
Gary O +
Stein O -
) O -
, O +
and O +
plasmids O +
as O +
described O +
above O -
. O +

Luciferase O +
activities O +
were O +
determined O +
using O +
Dual O -
- O -
Luciferase O +
reporter O +
assay O +
systems O +
kit O +
( O -
Promega O -
) O +
on O +
the O +
luminemeter O -
. O +

Tumor O +
Growth O +
in O +
Nude O +
Mice O +
Female O +
6-week O -
- O -
old O +
nude O +
mice O +
( O -
Charles O +
River O +
Laboratories O -
, O +
Wilmington O -
, O +
MA O -
) O +
were O +
divided O +
into O +
four O +
experimental O +
groups O -
, O +
five O +
for O +
each O -
. O +

One O +
million O +
HCT116 O +
cells O +
stably O +
transfected O +
with O +
vectors O +
( O -
pCS2+MT O +
or O +
pCDNA6 O -
/ O -
HisA O -
) O -
, O +
pCS2+MT O -
- O -
Tle6sh B-Gene -
, O +
or O +
pCDNA6 O -
/ O -
HisA O -
- O -
TLE6D B-Gene +
were O +
injected O +
subcutaneously O +
in O +
the O +
flanks O +
of O +
each O +
mice O -
. O +

Mice O +
were O +
monitored O +
daily O +
for O +
palpable O +
tumors O -
. O +

Because O +
of O +
rapid O +
growth O -
, O +
tumors O +
were O +
dissected O +
out O +
3 O +
weeks O +
after O +
injection O +
and O +
were O +
analyzed O -
. O +

Convergence O +
of O +
Mutation O +
and O +
Epigenetic O +
Alterations O +
Identifies O +
Common O +
Genes O +
in O +
Cancer O +
That O +
Predict O +
for O +
Poor O +
Prognosis O +
Abstract O +
Background O +

The O +
identification O +
and O +
characterization O +
of O +
tumor O +
suppressor O +
genes O +
has O +
enhanced O +
our O +
understanding O +
of O +
the O +
biology O +
of O +
cancer O +
and O +
enabled O +
the O +
development O +
of O +
new O +
diagnostic O +
and O +
therapeutic O +
modalities O -
. O +

Whereas O +
in O +
past O +
decades O -
, O +
a O +
handful O +
of O +
tumor O +
suppressors O +
have O +
been O +
slowly O +
identified O +
using O +
techniques O +
such O +
as O +
linkage O +
analysis O -
, O +
large O -
- O -
scale O +
sequencing O +
of O +
the O +
cancer O +
genome O +
has O +
enabled O +
the O +
rapid O +
identification O +
of O +
a O +
large O +
number O +
of O +
genes O +
that O +
are O +
mutated O +
in O +
cancer O -
. O +

However O -
, O +
determining O +
which O +
of O +
these O +
many O +
genes O +
play O +
key O +
roles O +
in O +
cancer O +
development O +
has O +
proven O +
challenging O -
. O +

Specifically O -
, O +
recent O +
sequencing O +
of O +
human O +
breast O +
and O +
colon O +
cancers O +
has O +
revealed O +
a O +
large O +
number O +
of O +
somatic O +
gene O +
mutations O -
, O +
but O +
virtually O +
all O +
are O +
heterozygous O -
, O +
occur O +
at O +
low O +
frequency O -
, O +
and O +
are O +
tumor B-Gene -
- O -
type O +
specific O -
. O +

We O +
hypothesize O +
that O +
key O +
tumor O +
suppressor O +
genes O +
in O +
cancer O +
may O +
be O +
subject O +
to O +
mutation O +
or O +
hypermethylation O -
. O +

Methods O +
and O +
Findings O +
Here O -
, O +
we O +
show O +
that O +
combined O +
genetic O +
and O +
epigenetic O +
analysis O +
of O +
these O +
genes O +
reveals O +
many O +
with O +
a O +
higher O +
putative O +
tumor O +
suppressor O +
status O +
than O +
would O +
otherwise O +
be O +
appreciated O -
. O +

At O +
least O +
36 O +
of O +
the O +
189 O +
genes O +
newly O +
recognized O +
to O +
be O +
mutated O +
are O +
targets O +
of O +
promoter O +
CpG O +
island O +
hypermethylation O -
, O +
often O +
in O +
both O +
colon O +
and O +
breast O +
cancer O +
cell O +
lines O -
. O +

Analyses O +
of O +
primary O +
tumors O +
show O +
that O +
18 O +
of O +
these O +
genes O +
are O +
hypermethylated O +
strictly O +
in O +
primary O +
cancers O +
and O +
often O +
with O +
an O +
incidence O +
that O +
is O +
much O +
higher O +
than O +
for O +
the O +
mutations O +
and O +
which O +
is O +
not O +
restricted O +
to O +
a O +
single O +
tumor O -
- O -
type O -
. O +

In O +
the O +
identical O +
breast O +
cancer O +
cell O +
lines O +
in O +
which O +
the O +
mutations O +
were O +
identified O -
, O +
hypermethylation O +
is O +
usually O -
, O +
but O +
not O +
always O -
, O +
mutually O +
exclusive O +
from O +
genetic O +
changes O +
for O +
a O +
given O +
tumor O -
, O +
and O +
there O +
is O +
a O +
high O +
incidence O +
of O +
concomitant O +
loss O +
of O +
expression O -
. O +

Sixteen O +
out O +
of O +
18 O +
( O -
89 O -
% O -
) O +
of O +
these O +
genes O +
map O +
to O +
loci O +
deleted O +
in O +
human O +
cancers O -
. O +

Lastly O -
, O +
and O +
most O +
importantly O -
, O +
the O +
reduced O +
expression O +
of O +
a O +
subset O +
of O +
these O +
genes O +
strongly O +
correlates O +
with O +
poor O +
clinical O +
outcome O -
. O +

Conclusions O +
Using O +
an O +
unbiased O +
genome O -
- O -
wide O +
approach O -
, O +
our O +
analysis O +
has O +
enabled O +
the O +
discovery O +
of O +
a O +
number O +
of O +
clinically O +
significant O +
genes O +
targeted O +
by O +
multiple O +
modes O +
of O +
inactivation O +
in O +
breast O +
and O +
colon O +
cancer O -
. O +

Importantly O -
, O +
we O +
demonstrate O +
that O +
a O +
subset O +
of O +
these O +
genes O +
predict O +
strongly O +
for O +
poor O +
clinical O +
outcome O -
. O +

Our O +
data O +
define O +
a O +
set O +
of O +
genes O +
that O +
are O +
targeted O +
by O +
both O +
genetic O +
and O +
epigenetic O +
events O -
, O +
predict O +
for O +
clinical O +
prognosis O -
, O +
and O +
are O +
likely O +
fundamentally O +
important O +
for O +
cancer O +
initiation O +
or O +
progression O -
. O +

Abstract O +
Stephen O +
Baylin O +
and O +
colleagues O +
show O +
that O +
a O +
combined O +
genetic O +
and O +
epigenetic O +
analysis O +
of O +
breast O +
and O +
colon O +
cancers O +
identifies O +
a O +
number O +
of O +
clinically O +
significant O +
genes O +
targeted O +
by O +
multiple O +
modes O +
of O +
inactivation O -
. O +

Abstract O +
Editors O -
' O +
Summary O +
Background O -
. O +

Cancer O +
is O +
one O +
of O +
the O +
developed O +
world O -
's O +
biggest O +
killers O -
— O -
over O +
half O +
a O +
million O +
Americans O +
die O +
of O +
cancer O +
each O +
year O -
, O +
for O +
instance O -
. O +

As O +
a O +
result O -
, O +
there O +
is O +
great O +
interest O +
in O +
understanding O +
the O +
genetic O +
and O +
environmental O +
causes O +
of O +
cancer O +
in O +
order O +
to O +
improve O +
cancer O +
prevention O -
, O +
diagnosis O -
, O +
and O +
treatment O -
. O +

Cancer O +
begins O +
when O +
cells O +
begin O +
to O +
multiply O +
out O +
of O +
control O -
. O +

DNA O +
is O +
the O +
sequence O +
of O +
coded O +
instructions O -
— O -
genes O -
— O -
for O +
how O +
to O +
build O +
and O +
maintain O +
the O +
body O -
. O +

Certain O +
" O -
tumor O +
suppressor O -
� O -
? O +
genes O -
, O +
for O +
instance O -
, O +
help O +
to O +
prevent O +
cancer O +
by O +
preventing O +
tumors O +
from O +
developing O -
, O +
but O +
changes O +
that O +
alter O +
the O +
DNA O +
code O +
sequence O -
— O -
mutations O -
— O -
can O +
profoundly O +
affect O +
how O +
a O +
gene O +
works O -
. O +

Modern O +
techniques O +
of O +
genetic O +
analysis O +
have O +
identified O +
genes O +
such O +
as O +
tumor O +
suppressors O +
that O -
, O +
when O +
mutated O -
, O +
are O +
linked O +
to O +
the O +
development O +
of O +
certain O +
cancers O -
. O +

Why O +
Was O +
This O +
Study O +
Done O -
? O +

However O -
, O +
in O +
recent O +
years O -
, O +
it O +
has O +
become O +
increasingly O +
apparent O +
that O +
mutations O +
are O +
neither O +
necessary O +
nor O +
sufficient O +
to O +
explain O +
every O +
case O +
of O +
cancer O -
. O +

This O +
has O +
led O +
researchers O +
to O +
look O +
at O +
so O -
- O -
called O +
epigenetic O +
factors O -
, O +
which O +
also O +
alter O +
how O +
a O +
gene O +
works O +
without O +
altering O +
its O +
DNA O +
sequence O -
. O +

An O +
example O +
of O +
this O +
is O +
" O -
methylation O -
, O -
� O -
? O +
which O +
prevents O +
a O +
gene O +
from O +
being O +
expressed O -
— O -
deactivates O +
it O +

—by O +
a O +
chemical O +
tag O -
. O +

Methylation O +
of O +
genes O +
is O +
part O +
of O +
the O +
normal O +
functioning O +
of O +
DNA O -
, O +
but O +
abnormal O +
methylation O +
has O +
been O +
linked O +
with O +
cancer O -
, O +
aging O -
, O +
and O +
some O +
rare O +
birth O +
abnormalities O -
. O +

Previous O +
analysis O +
of O +
DNA O +
from O +
breast O +
and O +
colon O +
cancer O +
cells O +
had O +
revealed O +
189 O +
" O -
candidate O +
cancer O +
genes O -
� O -
?—mutated O +
genes O +
that O +
were O +
linked O +
to O +
the O +
development O +
of O +
breast O +
and O +
colon O +
cancer O -
. O +

However O -
, O +
it O +
was O +
not O +
clear O +
how O +
those O +
mutations O +
gave O +
rise O +
to O +
cancer O -
, O +
and O +
individual O +
mutations O +
were O +
present O +
in O +
only O +
5 O -
% O +
to O +
15 O -
% O +
of O +
specific O +
tumors O -
. O +

The O +
authors O +
of O +
this O +
study O +
wanted O +
to O +
know O +
whether O +
epigenetic O +
factors O +
such O +
as O +
methylation O +
contributed O +
to O +
causing O +
the O +
cancers O -
. O +

What O +
Did O +
the O +
Researchers O +
Do O +
and O +
Find O -
? O +

The O +
researchers O +
first O +
identified O +
56 O +
of O +
the O +
189 O +
candidate O +
cancer O +
genes O +
as O +
likely O +
tumor B-Gene +
suppressors I-Gene +
and O +
then O +
determined O +
that O +
36 O +
of O +
these O +
genes O +
were O +
methylated O +
and O +
deactivated O -
, O +
often O +
in O +
both O +
breast O +
and O +
colon O +
( O -
laboratory O -
- O -
grown O -
) O +
cancer O +
cells O -
. O +

In O +
nearly O +
all O +
cases O -
, O +
the O +
methylated O +
genes O +
were O +
not O +
active O +
but O +
could O +
be O +
reactivated O +
by O +
being O +
demethylated O -
. O +

They O +
further O +
showed O +
that O -
, O +
in O +
normal O +
colon O +
and O +
breast O +
tissue O +
samples O -
, O +
18 O +
of O +
the O +
36 O +
genes O +
were O +
unmethylated O +
and O +
functioned O +
normally O -
, O +
but O +
in O +
cells O +
taken O +
from O +
breast O +
and O +
colon O +
cancer O +
tumors O +
they O +
were O +
methylated O -
. O +

In O +
contrast O +
to O +
the O +
genetic O +
mutations O -
, O +
the O +
18 O +
genes O +
were O +
frequently O +
methylated O +
across O +
a O +
range O +
of O +
tumor O +
types O -
, O +
and O +
eight O +
genes O +
were O +
methylated O +
in O +
both O +
the O +
breast O +
and O +
colon O +
cancers O -
. O +

The O +
authors O +
found O +
by O +
reviewing O +
the O +
genetics O +
and O +
epigenetics O +
of O +
those O +
18 O +
genes O +
in O +
breast O +
and O +
colon O +
cancer O +
that O +
they O +
were O +
either O +
mutated O -
, O +
methylated O -
, O +
or O +
both O -
. O +

A O +
literature O +
review O +
showed O +
that O +
at O +
least O +
six O +
of O +
the O +
18 O +
genes O +
were O +
known O +
to O +
have O +
tumor B-Gene +
suppressor I-Gene +
properties O -
, O +
and O +
the O +
authors O +
determined O +
that O +
16 O +
were O +
located O +
in O +
parts O +
of O +
DNA O +
known O +
to O +
be O +
missing O +
from O +
cells O +
taken O +
from O +
a O +
range O +
of O +
cancer O +
tumors O -
. O +

Finally O -
, O +
the O +
researchers O +
analyzed O +
data O +
on O +
cancer O +
cases O +
to O +
show O +
that O +
methylation O +
of O +
these O +
18 O +
genes O +
was O +
correlated O +
with O +
reduced O +
function O +
of O +
these O +
genes O +
in O +
tumors O +
and O +
with O +
a O +
greater O +
likelihood O +
that O +
a O +
cancer O +
will O +
be O +
terminal O +
or O +
spread O +
to O +
other O +
parts O +
of O +
the O +
body O -
. O +

What O +
Do O +
These O +
Findings O +
Mean O -
? O +

The O +
researchers O +
considered O +
only O +
the O +
189 O +
candidate O +
cancer O +
genes O +
found O +
in O +
one O +
previous O +
study O +
and O +
not O +
other O +
genes O +
identified O +
elsewhere O -
. O +

They O +
also O +
did O +
not O +
consider O +
the O +
biological O +
effects O +
of O +
the O +
individual O +
mutations O +
found O +
in O +
those O +
genes O -
. O +

Despite O +
this O -
, O +
they O +
have O +
demonstrated O +
that O +
methylation O +
of O +
specific O +
genes O +
is O +
likely O +
to O +
play O +
a O +
role O +
in O +
the O +
development O +
of O +
breast O +
and/or O +
colon O +
cancer O +
cells O +
either O +
together O +
with O +
mutations O +
or O +
independently O -
, O +
most O +
likely O +
by O +
turning O +
off O +
their O +
tumor O +
suppression O +
function O -
. O +

More O +
broadly O -
, O +
however O -
, O +
the O +
study O +
adds O +
to O +
the O +
evidence O +
that O +
future O +
analysis O +
of O +
the O +
role O +
of O +
genes O +
in O +
cancer O +
should O +
include O +
epigenetic O +
as O +
well O +
as O +
genetic O +
factors O -
. O +

In O +
addition O -
, O +
the O +
authors O +
have O +
also O +
shown O +
that O +
a O +
number O +
of O +
these O +
genes O +
may O +
be O +
useful O +
for O +
predicting O +
clinical O +
outcomes O +
for O +
a O +
range O +
of O +
tumor O +
types O -
. O +

Additional O +
Information O -
. O +

Please O +
access O +
these O +
Web O +
sites O +
via O +
the O +
online O +
version O +
of O +
this O +
summary O +
at O +
http://dx.doi.org/10.1371/journal.pmed.0050114 O -
. O +

A O +
December O +
2006 O +
PLoS O +
Medicine O +
Perspective O +
article O +
reviews O +
the O +
value O +
of O +
examining O +
methylation O +
as O +
a O +
factor O +
in O +
common O +
cancers O +
and O +
its O +
use O +
for O +
early O +
detection O +
The O +
Web O +
site O +
of O +
the O +
American O +
Cancer O +
Society O +
has O +
a O +
wealth O +
of O +
information O +
and O +
resources O +
on O +
a O +
variety O +
of O +
cancers O -
, O +
including O +
breast O +
and O +
colon O +
cancer O +
Breastcancer.org O +
is O +
a O +
nonprofit O +
organization O +
providing O +
information O +
about O +
breast O +
cancer O +
on O +
the O +
Web O -
, O +
including O +
research O +
news O +
Cancer O +
Research O +
UK O +
provides O +
information O +
on O +
cancer O +
research O +

The O +
Sidney O +
Kimmel O +
Comprehensive O +
Cancer O +
Center O +
at O +
Johns O +
Hopkins O +
publishes O +
background O +
information O +
on O +
the O +
authors O -
' O +
research O +
on O +
methylation O -
, O +
setting O +
out O +
its O +
potential O +
for O +
earlier O +
diagnosis O +
and O +
better O +
treatment O +
of O +
cancer O +

Introduction O +
It O +
is O +
widely O +
accepted O +
that O +
loss O +
of O +
tumor O +
suppressor O +
function O +
leads O +
to O +
the O +
initiation O +
and O +
progression O +
of O +
human O +
cancer O +
[ O -
1,2 O -
] O -
. O +

Inactivation O +
of O +
tumor O +
suppressor O +
genes O +
can O +
result O +
from O +
both O +
genetic O +
mechanisms O +
such O +
as O +
mutation O +
or O +
epigenetic O +
mechanisms O +
such O +
as O +
DNA O +
hypermethylation O +
[ O -
3–5 O -
] O -
. O +

Identification O +
of O +
these O +
genes O +
provides O +
insight O +
into O +
the O +
biological O +
processes O +
underlying O +
oncogenesis O +
and O +
is O +
useful O +
for O +
developing O +
new O +
therapeutic O +
and O +
diagnostic O +
modalities O -
. O +

Recently O -
, O +
several O +
efforts O +
to O +
examine O +
the O +
cancer O +
genome O +
utilizing O +
large O -
- O -
scale O +
sequencing O +
have O +
revealed O +
that O +
a O +
large O +
number O +
of O +
genes O +
undergo O +
somatic O +
mutation O +
in O +
cancer O +
[ O -
6,7 O -
] O -
. O +

Sjoblom O +
et O +
al. O +
sequenced O +
13,023 O +
human O +
genes O +
in O +
breast O +
and O +
colon O +
cancer O +
and O +
identified O +
1,149 O +
that O +
harbored O +
somatic O +
mutations O -
. O +

Through O +
statistical O +
analysis O -
, O +
they O +
showed O +
that O +
the O +
majority O +
of O +
these O +
changes O +
were O +
passenger O +
mutations O +
and O +
that O +
189 O +
genes O +
were O +
likely O +
selected O +
for O +
during O +
tumorigenesis O +
( O -
candidate O +
cancer O +
genes O +
[ O -
CAN O -
] O -
) O -
. O +

Interestingly O -
, O +
for O +
virtually O +
all O +
of O +
the O +
newly O +
discovered O +
mutations O -
, O +
the O +
frequencies O +
in O +
each O +
tumor O +
type O +
were O +
low O -
— O -
in O +
the O +
range O +
of O +
5 O -
% O +
to O +
15 O -
% O -
. O +

Furthermore O -
, O +
the O +
vast O +
majority O +
of O +
these O +
mutations O +
were O +
heterozygous O +
missense O +
mutations O -
. O +

Thus O -
, O +
it O +
is O +
difficult O +
to O +
know O +
whether O +
each O +
mutation O +
conveys O +
an O +
oncogenic O +
or O +
tumor O +
suppressor O +
function O -
. O +

Moreover O -
, O +
if O +
the O +
genes O +
are O +
tumor O +
suppressors O -
, O +
the O +
heterozygous O +
nature O +
of O +
the O +
mutations O +
would O +
provide O +
loss O +
of O +
function O +
effects O +
through O +
a O +
state O +
of O +
haploinsufficiency O -
. O +

This O +
has O +
been O +
seen O +
for O +
a O +
number O +
of O +
cancer O +
genes O +
including O +
APC B-Gene +
and O +
MSH2 B-Gene +
[ O -
8,9 O -
] O -
. O +

It O +
may O +
also O +
be O +
possible O +
that O +
many O +
of O +
the O +
heterozygous O +
mutations O +
are O +
dominant O +
and O +
oncogenic O -
. O +

Similarly O -
, O +
Greenman O +
et O +
al. O +
demonstrated O +
that O +
the O +
mutational O +
spectrum O +
of O +
protein O +
kinases O +
in O +
tumors O +
is O +
highly O +
variable O +
and O +
that O +
mutations O +
in O +
a O +
large O +
number O +
of O +
cancer O +
genes O +
are O +
operative O +
in O +
human O +
tumors O +
[ O -
6 O -
] O -
. O +

Again O -
, O +
it O +
is O +
unknown O +
whether O +
most O +
of O +
the O +
mutated O +
genes O +
are O +
oncogenes O +
or O +
tumor O +
suppressors O -
. O +

Finally O -
, O +
most O +
of O +
the O +
mutations O +
identified O +
in O +
breast O +
cancers O +
were O +
not O +
present O +
in O +
colon O +
tumors O +
and O +
vice O +
versa O +
[ O -
7 O -
] O -
, O +
suggesting O +
that O +
the O +
mutational O +
spectrum O +
is O +
highly O +
tumor O -
- O -
type O +
specific O -
. O +

Epigenetic O +
silencing O +
is O +
a O +
prevalent O +
mechanism O +
by O +
which O +
abnormal O +
gene O +
inactivation O +
can O +
occur O +
in O +
cancer O -
. O +

These O +
epigenetic O +
abnormalities O +
can O +
cooperate O +
with O +
genetic O +
alterations O +
to O +
effect O +
aberrant O +
gene O +
function O +
that O +
results O +
in O +
cancer O +
[ O -
5 O -
] O -
. O +

A O +
predominant O +
mode O +
of O +
epigenetic O +
alteration O +
in O +
cancer O +
is O +
gene O +
silencing O +
via O +
CpG O +
island O +
promoter O +
hypermethylation O +
( O -
henceforth O +
called O +
hypermethylation O -
) O -
. O +

Hypermethylation O +
has O +
now O +
been O +
observed O +
to O +
result O +
in O +
abnormal O +
silencing O +
of O +
a O +
number O +
of O +
tumor O +
suppressors O +
in O +
many O +
human O +
malignancies O +
such O +
as O +
cancers O +
of O +
the O +
breast O -
, O +
prostate O -
, O +
colon O -
, O +
stomach O -
, O +
esophagous O -
, O +
blood O -
, O +
central O +
nervous O +
system O -
, O +
and O +
lung O +
[ O -
10 O -
] O -
. O +

Hypermethylation O +
acts O +
by O +
recruiting O +
methyl O -
- O -
cytosine O -
- O -
binding O +
proteins O +
and O +
histone O +
deacetylases O -
, O +
which O +
in O +
a O +
coordinated O +
fashion O +
modify O +
nucleosomes O +
to O +
form O +
transcriptionally O +
repressive O +
chromatin O +
[ O -
11,12 O -
] O -
. O +

Repressive O +
histone O +
marks O +
such O +
as O +
methylation O +
of O +
lysine-9 O +
on O +
histone O +
3 O +
( O -
H3K9 O -
) O +
may O +
initiate O +
and O +
help O +
maintain O +
this O +
state O +
of O +
repression O +
[ O -
13,14 O -
] O -
. O +

Hypermethylation O +
is O +
heritable O +
and O +
thus O +
constitutes O +
a O +
form O +
of O +
cellular O +
memory O -
. O +

As O +
such O -
, O +
abnormal O +
silencing O +
of O +
tumor O +
suppressor O +
genes O +
can O +
help O +
drive O +
clonal O +
selection O +
during O +
tumorigenesis O -
. O +

Human O +
Tumor O +
Analysis O +
Formalin O -
- O -
fixed O -
, O +
paraffin O -
- O -
embedded O +
tissues O +
from O +
primary O +
breast O +
( O -
n O +
= O +
30 O -
) O +
and O +
colorectal O +
cancers O +
( O -
n O +
= O +
20 O -
) O +
were O +
obtained O +
from O +
the O +
archive O +
of O +
the O +
Department O +
of O +
Pathology O +
of O +
the O +
Johns O +
Hopkins O +
Hospital O -
. O +

Analysis O +
of O +
breast O +
tumors O +
was O +
performed O +
on O +
12 O +
early O +
stage O +
and O +
12 O +
late O +
stage O +
primary O +
cancers O +
( O -
Dataset O +
S1 O -
) O -
. O +

Ten O +
stage O +
2 O +
and O +
ten O +
stage O +
3 O +
colon O +
cancers O +
were O +
analyzed O -
. O +

Approval O +
was O +
obtained O +
by O +
the O +
Medical O +
Ethical O +
Committee O +
of O +
Johns O +
Hopkins O +
Hospital O -
. O +

DNA O +
was O +
isolated O +
using O +
the O +
Puregene O +
DNA O +
isolation O +
kit O +
( O -
Gentra O +
Systems O -
) O -
. O +

MSP O +
analysis O +
was O +
performed O +
as O +
described O +
above O -
. O +

Results O +
Discovery O +
of O +
Common O +
Targets O +
of O +
Mutation O +
and O +
Hypermethylation O +
in O +
Breast O +
and O +
Colon O +
Cancer O +
We O +
chose O +
to O +
examine O +
breast O +
and O +
colon O +
cancers O +
because O +
of O +
their O +
substantial O +
epidemiological O +
prevalence O +
and O +
clinical O +
significance O -
, O +
and O +
because O +
extensive O +
genome O -
- O -
wide O +
mutational O +
analysis O +
has O +
been O +
conducted O +
in O +
these O +
tumor O +
types O +
[ O -
7 O -
] O -
. O +

The O +
strategy O +
we O +
utilized O +
to O +
identify O +
the O +
common O +
gene O +
targets O +
of O +
mutation O +
and O +
hypermethylation O +
is O +
depicted O +
in O +
Figure O +
1A O -
. O +

The O +
utility O +
of O +
our O +
microarray O +
screen O +
was O +
previously O +
validated O +
and O +
enables O +
the O +
identification O +
of O +
hypermethylated O +
genes O +
that O +
are O +
re O -
- O -
expressed O +
following O +
treatment O +
with O +
the O +
DNMT O +
inhibitor O +
DAC O -
, O +
but O +
not O +
following O +
treatment O +
with O +
the O +
HDAC O +
I O -
/ O -
II O +
inhibitor O +
trichostatin O +
A O +
( O -
TSA O -
) O +
alone O +
[ O -
15,24 O -
] O -
. O +

Following O +
drug O +
treatments O -
, O +
the O +
cells O +
were O +
subjected O +
to O +
microarray O +
analysis O -
, O +
and O +
we O +
then O +
searched O +
for O +
CAN B-Gene +
genes O +
that O +
fell O +
either O +
in O +
the O +
top O +
( O -
expression O +
change O +
> O -
2-fold O +
after O +
DAC O +
treatment O +
and O +
< O -
1.4-fold O +
for O +
TSA O -
) O +
or O +
next O +
tier O +
( O -
expression O +
change O +
> O -
1.4-fold O +
after O +
DAC O +
treatment O +
and O +
< O -
1.4-fold O +
following O +
TSA O -
) O -
. O +

We O +
assigned O +
them O +
status O +
as O +
candidate O +
DNA O +
hypermethylated O +
genes O +
to O +
be O +
analyzed O +
further O -
. O +

Genes O +
without O +
promoter O +
CpG O +
islands O +
were O +
excluded O +
from O +
further O +
analysis O -
. O +

This O +
approach O +
allows O +
the O +
identification O +
of O +
greater O +
than O +
70 O -
% O +
of O +
the O +
hypermethylated O +
genes O +
in O +
cell O +
lines O +
with O +
a O +
false O +
negative O +
rate O +
of O +
9 O -
% O +
[ O -
15 O -
] O -
. O +

In O +
total O -
, O +
we O +
identified O +
56 O +
( O -
out O +
of O +
189 O +
CAN B-Gene +
genes O -
) O +
that O +
met O +
our O +
microarray O +
criteria O +
for O +
candidate O +
DNA O +
hypermethylated O +
genes O -
, O +
with O +
an O +
approximately O +
equal O +
fraction O +
originating O +
from O +
breast O +
and O +
colon O +
lines O -
. O +

Strategy O +
to O +
Identify O +
Common O +
Gene O +
Targets O +
of O +
Mutation O +
and O +
Promoter O +
Hypermethylation O +
in O +
Cancer O +
( O -
A O -
) O +
Large O -
- O -
scale O +
sequencing O +
of O +
breast O +
and O +
colon O +
cancers O +
identified O +
189 O +
CAN B-Gene +
genes O +
as O +
reported O +
by O +
Sjoblom O +
et O +
al. O +
[ O -
7 O -
] O -
. O +

Candidate O +
hypermethylated O +
genes O +
were O +
identified O +
via O +
expression O +
microarray O +
analysis O +
as O +
described O +
in O +
the O +
text O -
. O +

The O +
cell O +
lines O +
used O +
in O +
the O +
analyses O +
were O +
the O +
breast O +
cancer O +
lines O +
MCF7 O -
, O +
MDA O -
- O -
MB-231 O -
, O +
MDA O -
- O -
MB-468 O -
, O +
and O +
T-47D O -
; O +
and O +
the O +
colon O +
cancer O +
lines O +
SW480 O -
, O +
RKO O -
, O +
HCT116 O -
, O +
Caco-2 O -
, O +
Colo320 O -
, O +
and O +
HT-29 O -
. O +

Filters O +
were O +
used O +
as O +
discussed O +
in O +
the O +
text O -
. O +

Genes O +
without O +
promoter O +
CpG O +
islands O +
were O +
excluded O -
. O +

( O -
B O -
) O +
Frequency O +
of O +
promoter O +
methylation O +
in O +
the O +
36 O +
CAN B-Gene +
genes O +
that O +
are O +
subject O +
to O +
hypermethylation O -
. O +

x O -
- O -
Axis O +
denotes O +
percent O +
methylation O -
. O +

Methylation O +
status O +
was O +
determined O +
in O +
the O +
six O +
colorectal O +
cancer O +
cell O +
lines O +
and O +
in O +
the O +
15 O +
breast O +
cancer O +
lines O +
described O +
in O +
the O +
text O +
( O -
four O +
lines O +
used O +
for O +
microarray O +
analysis O +
plus O +
11 O +
" O -
Discovery O +
Phase O -
� O -
? O +

breast O +
cancer O +
lines O -
) O -
. O +

We O +
next O +
analyzed O +
in O +
the O +
laboratory O -
, O +
using O +
MSP O +
[ O -
23 O -
] O +
and O +
RT O -
- O -
PCR O -
, O +
the O +
DNA O +
methylation O +
and O +
expression O +
status O +
of O +
the O +
above O +
56 O +
genes O -
, O +
including O +
the O +
response O +
of O +
the O +
latter O +
to O +
treatment O +
of O +
cells O +
with O +
DAC O -
, O +
in O +
four O +
breast O +
cancer O +
cell O +
lines O +
( O -
MCF7 O -
, O +
MDA O -
- O -
MB-231 O -
, O +
MDA O -
- O -
MB-468 O -
, O +
and O +
T-47D O -
) O +
and O +
six O +
colorectal O +
cancer O +
( O -
CRC O -
) O +
cell O +
lines O +
( O -
SW480 O -
, O +
RKO O -
, O +
HCT116 O -
, O +
Caco-2 O -
, O +
Colo320 O -
, O +
and O +
HT-29 O -
) O -
. O +

Importantly O -
, O +
we O +
also O +
focused O -
, O +
additionally O -
, O +
on O +
the O +
exact O +
11 O +
breast O +
cancer O +
lines O +
used O +
in O +
the O +
large O -
- O -
scale O +
sequence O +
analysis O +
reported O +
by O +
Sjoblom O +
et O +
al. O +
to O +
identify O +
the O +
CAN O +
genes O +
( O -
HCC38 O -
, O +
HCC1954 O -
, O +
HCC1008 O -
, O +
HCC1143 O -
, O +
HCC1187 O -
, O +
HCC1395 O -
, O +
HCC1937 O -
, O +
HCC2218 O -
, O +
HCC2157 O -
, O +
Hs578 O -
T O -
, O +
and O +
HCC1599 O -
) O -
. O +

Thirty O -
- O -
six O +
of O +
the O +
genes O +
were O +
found O +
to O +
be O +
hypermethylated O +
in O +
the O +
original O +
breast O +
and O +
colon O +
cancer O +
cell O +
lines O +
in O +
which O +
they O +
were O +
identified O +
as O +
candidates O +
and O +
in O +
the O +
11 O +
breast O +
cancer O +
lines O +
in O +
which O +
the O +
original O +
CAN O +
gene O +
mutations O +
were O +
found O +
( O -
Figure O +
1B O -
, O +
Table O +
1 O -
) O -
. O +

RT O -
- O -
PCR O +
analysis O +
demonstrated O +
markedly O +
reduced O +
or O +
no O +
expression O +
accompanying O +
this O +
hypermethylated O +
state O +
and O +
re O -
- O -
expression O +
after O +
DAC O +
treatment O +
( O -
examples O +
in O +
Figures O +
2 O +
and O +
3 O +
and O +
summarized O +
in O +
Table O +
S1 O -
) O -
. O +

Bisulfite O -
- O -
Sequencing O +
Results O +
Location O +
relative O +
to O +
the O +
transcriptional O +
start O +
site O +
is O +
shown O +
on O +
the O +
x O -
- O -
axis O +
of O +
each O +
plot O -
. O +

Empty O +
circles O +
represent O +
unmethylated O +
CpGs O -
, O +
and O +
black O +
circles O +
represent O +
methylated O +
CpGs O -
. O +

The O +
corresponding O +
results O +
obtained O +
with O +
MSP O +
are O +
noted O +
above O +
each O +
plot O -
. O +

Hypermethylation O +
of O +
Common O +
Target O +
Genes O +
is O +
More O +
Frequent O +
Than O +
Mutation O +
and O +
is O +
Not O +
Restricted O +
to O +
a O +
Single O +
Tumor O +
Type O +
We O +
determined O +
whether O +
the O +
36 O +
common O +
target O +
genes O +
were O +
hypermethylated O +
in O +
primary O +
colon O +
and O +
breast O +
tumors O -
. O +

Eighteen O +
of O +
these O +
genes O +
were O +
methylated O +
in O +
cell O +
lines O +
only O -
, O +
but O +
not O +
in O +
primary O +
breast O +
or O +
colorectal O +
tumors O -
, O +
or O +
were O +
methylated O +
in O +
normal O +
breast O +
or O +
colon O +
tissue O -
. O +

Importantly O -
, O +
the O +
other O +
18 O +
genes O +
showed O +
cancer O -
- O -
specific O +
methylation O -
— O -
being O +
hypermethylated O +
in O +
primary O +
tumors O +
but O +
not O +
in O +
normal O +
colon O +
or O +
breast O +
tissue O +
( O -
Figure O +
5 O -
, O +
Table O +
2 O -
) O -
. O +

Among O +
these O +
18 O +
genes O -
, O +
the O +
frequency O +
of O +
methylation O +
( O -
defined O +
as O +
the O +
percentage O +
of O +
tumor O +
samples O +
that O +
demonstrate O +
promoter O +
CpG O +
island O +
methylation O -
) O +
varied O +
between O +
breast O +
and O +
colon O +
cancers O -
. O +

Some O +
genes O +
were O +
methylated O +
in O +
breast O +
but O +
not O +
colon O +
cancers O -
, O +
while O +
others O +
were O +
methylated O +
in O +
tumors O +
from O +
colon O +
but O +
not O +
breast O -
. O +

Most O +
importantly O -
, O +
however O -
, O +
while O +
only O +
6 O -
% O +
of O +
all O +
CAN B-Gene +
genes O +
( O -
12 O -
/ O -
189 O -
) O +
are O +
mutated O +
in O +
both O +
colon O +
and O +
breast O +
cancers O +
[ O -
7 O -
] O -
, O +
of O +
the O +
18 O +
CAN B-Gene +
genes O +
with O +
cancer O -
- O -
specific O +
methylation O -
, O +
44 O -
% O +
were O +
hypermethylated O +
in O +
both O +
colon O +
and O +
breast O +
tumors O +
( O -
8 O -
/ O -
18 O -
) O +
( O -
Table O +
2 O -
) O -
. O +

This O +
is O +
a O +
highly O +
significant O +
difference O +
as O +
determined O +
by O +
the O +
chi O -
- O -
square O +
test O +
( O -
p O +
= O +
0.004 O -
) O -
. O +

Frequency O +
of O +
Cancer O -
- O -
Specific O +
Methylation O +
of O +
CAN B-Gene +
Genes O +
in O +
Primary O +
Breast O +
and O +
Colon O +
Tumors O +
For O +
each O +
gene O -
, O +
results O +
are O +
shown O +
in O +
the O +
following O +
order O -
: O +
normal O +
breast O -
, O +
normal O +
colon O -
, O +
breast O +
cancer O -
, O +
colon O +
cancer O -
. O +

Genetic O +
Versus O +
Epigenetic O +
Events O +
in O +
Breast O +
and O +
Colon O +
Cancer O +
The O +
above O +
results O +
suggest O +
that O +
when O +
epigenetic O +
silencing O +
is O +
taken O +
into O +
consideration O -
, O +
the O +
biological O +
alterations O +
of O +
a O +
significant O +
number O +
of O +
genes O +
in O +
breast O +
and O +
colon O +
cancers O +
may O +
share O +
more O +
similarities O +
than O +
is O +
apparent O +
from O +
mutational O +
analysis O +
alone O -
. O +

Figure O +
6 O +
shows O +
the O +
number O +
of O +
genes O +
( O -
from O +
among O +
the O +
18 O +
genes O +
showing O +
cancer O -
- O -
specific O +
methylation O -
) O +
that O +
are O +
hypermethylated O +
per O +
tumor O +
for O +
both O +
breast O +
and O +
colon O +
cancers O -
. O +

A O +
greater O +
proportion O +
of O +
the O +
genes O +
are O +
hypermethylated O +
in O +
colon O +
cancer O +
compared O +
to O +
breast O +
cancer O -
. O +

It O +
is O +
highly O +
likely O +
that O +
this O +
represents O +
an O +
intrinsic O +
difference O +
between O +
breast O +
and O +
colon O +
tumors O +
and O +
not O +
a O +
statistical O +
bias O +
because O +
approximately O +
equal O +
numbers O +
of O +
the O +
genes O +
found O +
to O +
be O +
methylated O +
were O +
methylated O +
in O +
each O +
tumor O +
type O -
. O +

Patterns O +
of O +
Mutation O +
and O +
Hypermethylation O +
in O +
Breast O +
and O +
Colon O +
Cancer O +
( O -
A O -
) O +
Frequency O +
of O +
cancer O -
- O -
specific O +
hypermethylation O +
of O +
CAN B-Gene +
genes O -
. O +

Data O +
were O +
generated O +
from O +
analysis O +
of O +
only O +
the O +
18 O +
genes O +
demonstrating O +
cancer O -
- O -
specific O +
hypermethylation O -
. O +

Results O +
for O +
breast O +
cancer O -
. O +

p O -
- O -
Value O +
was O +
calculated O +
using O +
Student O -
's O +
t O -
- O -
test O -
. O +

( O -
B O -
) O +
Results O +
for O +
colon O +
cancer O -
. O +

Concomitant O +
Analysis O +
of O +
Genetic O +
and O +
Methylation O +
Events O +
We O +
next O +
compared O +
the O +
genetic O +
and O +
epigenetic O +
status O +
of O +
the O +
18 O +
genes O +
directly O +
in O +
the O +
11 O +
" O -
Discovery O +
Phase O -
� O -
? O +

breast O +
cancer O +
lines O +
in O +
which O +
the O +
mutations O +
for O +
CAN B-Gene +
genes O +
were O +
documented O +
by O +
Sjoblom O +
et O +
al. O +
( O -
Figure O +
7 O -
) O +
[ O -
7 O -
] O -
. O +

Several O +
observations O +
are O +
apparent O -
. O +

First O -
, O +
genes O +
that O +
are O +
mutated O +
in O +
colon O +
cancer O +
but O +
not O +
in O +
breast O +
may O +
instead O +
be O +
hypermethylated O +
in O +
breast O +
cancer O +
and O +
vice O +
versa O -
. O +

Furthermore O -
, O +
while O +
the O +
breast O +
cancer O +
mutations O +
for O +
a O +
given O +
gene O +
are O +
usually O +
found O +
in O +
only O +
one O +
line O -
, O +
hypermethylation O +
of O +
most O +
of O +
the O +
genes O +
occurs O +
in O +
multiple O +
lines O +
for O +
both O +
breast O +
and O +
colon O +
cancers O +
( O -
Figure O +
7A O +
and O +
7B O -
) O -
. O +

Concomitant O +
Mapping O +
of O +
Mutation O +
and O +
Methylation O +
of O +
CAN B-Gene +
Genes O +
in O +
Human O +
Breast O +
and O +
Colon O +
Cancers O +
( O -
A O -
) O +
Results O +
for O +
breast O +
CAN B-Gene +
genes O -
. O +

Gene O +
names O +
are O +
listed O +
at O +
the O +
right O +
of O +
the O +
map O -
. O +

For O +
each O +
gene O -
, O +
the O +
methylation O +
and O +
mutational O +
status O +
is O +
shown O +
for O +
the O +
11 O +
breast O +
cell O +
lines O +
that O +
were O +
subject O +
to O +
large O -
- O -
scale O +
sequencing O +
described O +
by O +
Sjoblom O +
et O +
al. O +
[ O -
7 O -
] O +
and O +
normal O +
breast O +
tissue O -
. O +

Green O +
indicates O +
no O +
methylation O +
or O +
mutation O +
detected O -
. O +

Red O +
indicates O +
complete O +
methylation O +
or O +
homozygous O +
mutation O -
. O +

Orange O +
denotes O +
heterozygous O +
mutation O +
or O +
partial O +
methylation O -
. O +

( O -
B O -
) O +
Results O +
for O +
colon O +
CAN B-Gene +
genes O -
. O +

Data O +
are O +
presented O +
in O +
the O +
same O +
format O +
as O +
in O +
( O -
A O -
) O -
. O +

Second O -
, O +
within O +
a O +
single O +
cancer O -
, O +
mutation O +
and O +
methylation O +
of O +
a O +
specific O +
gene O +
are O +
not O +
always O +
mutually O +
exclusive O +
events O -
. O +

For O +
example O -
, O +
in O +
HCC2157 O -
, O +
the O +
APC2 B-Gene +
gene O +
undergoes O +
both O +
mutation O +
( O -
in O +
one O +
allele O -
) O +
and O +
hypermethylation O +
( O -
of O +
both O +
alleles O -
) O -
. O +

In O +
some O +
cancers O -
, O +
partial O +
methylation O +
of O +
genes O +
such O +
as O +
GPNMB B-Gene +
and O +
COL7A1 B-Gene +
occur O +
in O +
the O +
same O +
cells O +
harboring O +
heterozygous O +
mutations O -
. O +

Sequencing O +
of O +
cDNA O +
from O +
these O +
cancers O +
revealed O +
they O +
possess O +
partial O +
methylation O +
on O +
both O +
mutant O +
and O +
wild O -
- O -
type O +
alleles O +
and O +
not O +
selective O +
hypermethylation O +
of O +
the O +
wild O -
- O -
type O +
allele O +
( O -
unpublished O +
data O -
) O -
. O +

We O +
measured O +
expression O +
levels O +
of O +
APC2 B-Gene -
, O +
GPNMB B-Gene -
, O +
and O +
COL7A1 B-Gene +
using O +
real O -
- O -
time O +
PCR O +
in O +
these O +
cell O +
lines O +
with O +
partial O +
methylation O +
( O -
as O +
well O +
as O +
lines O +
with O +
unmethylated O +
and O +
fully O +
methylated O +
alleles O +
of O +
these O +
genes O -
) O +
( O -
Figure O +
S1 O -
) O -
. O +

In O +
each O +
case O -
, O +
higher O +
levels O +
of O +
methylation O +
were O +
associated O +
with O +
decreasing O +
levels O +
of O +
expression O -
. O +

It O +
is O +
possible O +
that O +
multiple O +
events O +
contribute O +
to O +
the O +
incremental O +
inactivation O +
of O +
the O +
genes O +
in O +
these O +
cancers O -
. O +

Alternatively O -
, O +
it O +
is O +
also O +
possible O +
that O +
these O +
genes O +
have O +
a O +
limited O +
role O +
in O +
cancer O +
and O +
are O +
not O +
under O +
the O +
same O +
selective O +
constraints O +
as O +
bona O +
fide O +
tumor O +
suppressors O -
. O +

In O +
previous O +
studies O -
, O +
methylation O +
has O +
been O +
observed O +
to O +
result O +
in O +
a O +
functional O +
loss O +
of O +
heterozygosity O +
( O -
LOH O -
) O +
for O +
heterozygously O +
mutated O +
genes O +
such O +
as O +
p16 B-Gene +
where O +
the O +
mutated O +
allele O +
is O +
expressed O +
[ O -
27 O -
] O -
. O +

These O +
results O +
are O +
consistent O +
with O +
the O +
finding O +
that O -
, O +
rarely O -
, O +
genetic O +
alterations O +
and O +
methylation O +
can O +
converge O +
on O +
the O +
same O +
allele O +
[ O -
27,28 O -
] O -
. O +

However O -
, O +
we O +
did O +
not O +
observe O +
this O +
to O +
be O +
the O +
case O +
with O +
the O +
majority O +
of O +
the O +
CAN B-Gene +
genes O +
currently O +
under O +
study O -
. O +

We O +
actually O +
observed O +
that O +
for O +
five O +
out O +
of O +
11 O +
breast O +
CAN B-Gene +
genes O -
, O +
mutation O +
and O +
methylation O +
converged O +
in O +
the O +
same O +
tumor O +
( O -
Figure O +
7A O -
) O -
. O +

Such O +
convergence O +
strongly O +
suggests O +
that O +
these O +
common O +
target O +
genes O +
play O +
an O +
important O +
role O +
in O +
tumor O +
suppression O -
, O +
but O +
that O +
the O +
methylation O +
may O +
complement O +
the O +
loss O +
of O +
function O +
of O +
these O +
genes O +
in O +
a O +
way O +
different O +
than O +
with O +
other O +
mutations O +
previously O +
examined O -
. O +

Functional O +
Associations O +
of O +
Common O +
Target O +
Genes O +
Functional O +
associations O +
of O +
genes O +
were O +
determined O +
using O +
Gene O +
Ontology O +
( O -
GO O -
) O +
groups O +
and O +
available O +
literature O -
. O +

Evidence O +
for O +
tumor O +
suppressor O +
function O +
was O +
scored O +
positive O +
if O +
reports O +
in O +
the O +
literature O +
show O +
that O +
the O +
gene O +
of O +
interest O +
can O +
suppress O +
growth O +
of O +
cancer O +
cells O +
in O +
vitro O -
, O +
in O +
vivo O -
, O +
or O +
in O +
murine O +
genetic O +
models O -
, O +
or O +
modulate O +
known O +
tumor O +
suppressor O +
function O -
. O +

loc O -
. O -
, O +
location O -
. O +

Known O +
cancer O +
susceptibility O +
location O +
was O +
scored O +
positive O +
if O +
evidence O +
exists O +
in O +
the O +
literature O +
for O +
LOH O +
or O +
homozygous O +
deletion O +
in O +
primary O +
human O +
tumors O +
at O +
the O +
region O +
shown O +
using O +
either O +
standard O +
genetic O +
mapping O +
or O +
comparative O +
genomic O +
hybridization O +
( O -
CGH O -
) O +
analysis O +
( O -
shaded O -
) O -
. O +

Decreased O +
Expression O +
of O +
Common O +
Target O +
Genes O +
Predict O +
for O +
Poor O +
Clinical O +
Prognosis O +
One O +
of O +
the O +
main O +
hopes O +
of O +
comprehensively O +
cataloging O +
cancer O +
mutations O +
is O +
that O +
doing O +
so O +
may O +
provide O +
novel O +
biomarkers O +
and O +
knowledge O +
of O +
genes O +
involved O +
in O +
key O +
pathways O +
in O +
oncogenesis O -
. O +

To O +
this O +
end O -
, O +
we O +
first O +
determined O +
whether O +
cancer O -
- O -
specific O +
methylation O +
of O +
the O +
common O +
target O +
genes O +
would O +
correlate O +
in O +
any O +
way O +
with O +
tumor O +
stage O +
or O +
grade O -
. O +

We O +
determined O +
this O -
, O +
first O -
, O +
by O +
directly O +
analyzing O +
the O +
methylation O +
state O +
of O +
breast O +
cancers O +
of O +
varying O +
stages O +
( O -
1–4 O -
) O +
and O +
grades O +
( O -
1–3 O -
) O -
. O +

We O +
found O +
that O +
SYNE1 B-Gene +
and O +
COL7A1 B-Gene +
are O +
preferentially O +
methylated O +
in O +
advanced O +
tumors O +
and O +
PTPRD B-Gene -
, O +
SYNE1 B-Gene -
, O +
and O +
EVL B-Gene +
are O +
preferentially O +
hypermethylated O +
in O +
high O -
- O -
grade O +
tumors O +
( O -
Figure O +
9 O -
) O -
. O +

For O +
example O -
, O +
in O +
stage O +
1 O +
and O +
2 O +
tumors O -
, O +
SYNE1 B-Gene +
is O +
silenced O +
8 O -
% O +
( O -
1 O -
/ O -
12 O -
) O +
of O +
the O +
time O +
whereas O +
in O +
stage O +
3 O +
and O +
4 O +
tumors O -
, O +
the O +
frequency O +
of O +
silencing O +
is O +
50 O -
% O +
( O -
6 O -
/ O -
12 O -
) O -
. O +

This O +
is O +
consistent O +
with O +
a O +
role O +
during O +
tumor O +
progression O +
or O +
during O +
initiation O +
of O +
tumors O +
predestined O +
to O +
evolve O +
aggressive O +
clinical O +
behavior O -
. O +

Hypermethylation O +
of O +
Selected O +
" O -
Common O +
Target O -
� O -
? O +

Genes O +
Predict O +
for O +
Poor O +
Clinical O +
Prognosis O +
Hypermethylation O +
of O +
selected O +
common O +
target O +
genes O +
by O +
grade O +
and O +
stage O +
in O +
primary O +
breast O +
tumors O -
. O +

The O +
first O +
graph O +
shows O +
the O +
frequency O +
of O +
methylation O +
of O +
at O +
least O +
one O +
of O +
the O +
three O +
genes O +
listed O +
in O +
low- O +
versus O +
high O -
- O -
grade O +
breast O +
tumors O -
. O +

The O +
second O +
( O -
SYNE1 B-Gene -
) O +
and O +
third O +
( O -
COL7A1 B-Gene -
) O +
graphs O +
show O +
the O +
frequency O +
of O +
methylation O +
of O +
the O +
indicated O +
genes O +
in O +
different O +
stages O +
of O +
breast O +
cancer O -
. O +

p O -
- O -
Values O +
are O +
adjusted O +
using O +
the O +
Holm O +
method O -
. O +

Given O +
our O +
results O +
above O -
, O +
and O +
considering O +
that O +
tumor O +
stage O +
and O +
grade O +
are O +
strong O +
prognostic O +
determinants O +
of O +
disease O -
- O -
free O +
survival O +
and O +
propensity O +
for O +
metastases O +
in O +
breast O +
and O +
colon O +
cancer O -
, O +
we O +
next O +
sought O +
to O +
validate O +
whether O +
expression O +
of O +
the O +
genes O +
we O +
identified O +
to O +
be O +
targets O +
of O +
hypermethylation O +
and O +
mutation O +
affected O +
clinical O +
endpoints O +
using O +
data O +
from O +
external O +
cohorts O -
. O +

Gene O +
expression O +
signatures O +
from O +
tumors O +
have O +
proven O +
very O +
useful O +
for O +
predicting O +
clinical O +
outcome O +
[ O -
35,36 O -
] O -
. O +

To O +
begin O +
to O +
address O +
this O +
question O -
, O +
we O +
analyzed O +
an O +
extensive O +
microarray O +
database O -
, O +
utilizing O +
large O +
numbers O +
of O +
expression O +
profiles O +
on O +
very O +
well O +
documented O +
clinical O +
samples O +
from O +
published O +
expression O +
microarray O +
studies O +
( O -
Table O +
S2 O -
) O -
. O +

The O +
microarray O +
meta O -
- O -
analysis O +
algorithms O +
and O +
statistical O +
analysis O +
used O +
were O +
as O +
previously O +
described O +
[ O -
20 O -
] O -
. O +

These O +
databases O +
have O +
been O +
instrumental O +
in O +
a O +
number O +
of O +
cancer O +
gene O +
discovery O +
efforts O +
[ O -
37–39 O -
] O -
. O +

We O +
first O +
verified O +
whether O +
we O +
could O +
see O +
in O +
the O +
databases O +
the O +
key O +
predicted O +
relationship O +
between O +
DNA O +
methylation O +
and O +
repressed O +
gene O +
expression O -
. O +

Unlike O +
for O +
gene O +
mutations O -
, O +
which O +
alone O +
could O +
indicate O +
either O +
oncogenic O +
or O +
tumor O +
suppressor O +
changes O -
, O +
the O +
occurrence O +
of O +
hypermethylation O +
suggests O +
the O +
latter O +
in O +
genes O +
targeted O +
by O +
both O +
mechanisms O -
. O +

We O -
, O +
thus O -
, O +
asked O +
whether O +
genes O +
undergoing O +
a O +
significant O +
incidence O +
of O +
cancer O -
- O -
specific O +
methylation O +
correlated O +
with O +
decreased O +
expression O +
in O +
tumor O +
versus O +
normal O +
tissue O -
. O +

Genes O +
undergoing O +
cancer O -
- O -
specific O +
methylation O +
with O +
low O +
frequencies O +
of O +
methylation O +
would O +
not O +
be O +
predicted O +
to O +
have O +
obvious O +
gene O +
expression O +
correlations O +
in O +
the O +
large O +
database O +
sets O -
. O +

We O +
analyzed O +
the O +
following O +
genes O -
: O +
COL7A1 B-Gene -
, O +
PTPRD B-Gene -
, O +
GPNMB B-Gene -
, O +
APC2 B-Gene -
, O +
ICAM5 B-Gene -
, O +
EVL B-Gene -
, O +
SYNE1 B-Gene -
, O +
and O +
MMP2 B-Gene -
. O +

All O +
of O +
these O +
genes O +
were O +
predicted O +
by O +
our O +
analysis O +
of O +
microarray O +
data O +
to O +
have O +
decreased O +
overall O +
expression O +
in O +
breast O +
and/or O +
colon O +
cancer O +
compared O +
to O +
normal O +
tissue O +
( O -
p O -
- O -
values O +
0.047–2.9e−7 O -
) O +
in O +
the O +
studies O +
listed O +
in O +
Table O +
S2 O -
. O +

These O +
in O +
silico O +
results O +
are O +
consistent O +
with O +
the O +
observations O +
we O +
made O +
with O +
direct O +
laboratory O +
analyses O -
. O +

We O +
next O +
examined O +
whether O +
decreased O +
expression O +
of O +
the O +
genes O +
undergoing O +
cancer O -
- O -
specific O +
silencing O +
correlated O +
with O +
the O +
key O +
clinical O +
characteristics O +
noted O +
in O +
Figure O +
10 O -
. O +

The O +
finding O +
of O +
decreased O +
expression O +
levels O +
of O +
seven O +
genes O +
is O +
associated O +
with O +
unfavorable O +
clinical O +
characteristics O +
in O +
either O +
breast O -
, O +
colon O +
cancer O -
, O +
or O +
both O -
. O +

Importantly O -
, O +
these O +
genes O +
included O +
the O +
four O +
genes O -
, O +
SYNE B-Gene +
1 I-Gene -
, O +
COL7A1 B-Gene -
, O +
PTPRD B-Gene -
, O +
and O +
EVL B-Gene -
, O +
for O +
which O -
, O +
in O +
the O +
studies O +
described O +
in O +
Figure O +
9 O -
, O +
we O +
found O +
relationships O +
between O +
stage O +
and O +
grade O +
in O +
the O +
studies O +
from O +
our O +
own O +
tumor O +
samples O +
at O +
Johns O +
Hopkins O +
Hospital O -
. O +

Figures O +
11–13 O +
show O +
plots O +
of O +
normalized O +
expression O +
values O +
for O +
selected O +
genes O +
across O +
multiple O +
tumors O +
with O +
the O +
indicated O +
characteristics O -
. O +

Importantly O -
, O +
decreased O +
expression O +
of O +
five O +
of O +
the O +
six O +
genes O +
predicted O +
for O +
decreased O +
disease O -
- O -
free O +
or O +
overall O +
survival O +
in O +
these O +
cancers O +
as O +
well O +
as O +
other O +
poor O +
prognosis O +
features O +
such O +
as O +
high O +
grade O +
( O -
Figure O +
10 O -
) O -
. O +

These O +
relationships O +
are O +
highlighted O +
by O +
the O +
fact O +
that O -
, O +
when O +
we O +
also O +
analyzed O +
a O +
number O +
of O +
CAN O +
genes O +
that O +
we O +
directly O +
determined O +
to O +
not O +
have O +
altered O +
methylation O +
expression O +
levels O +
in O +
breast O +
or O +
colon O +
cancers O +
( O -
including O +
GGA1 B-Gene -
, O +
PTPN14 B-Gene -
, O +
ABCB8 B-Gene -
, O +
OTOF B-Gene -
, O +
SIX4 B-Gene -
, O +
SLCO1B3 B-Gene -
, O +
and O +
HIST1H1B B-Gene -
) O -
, O +
the O +
clinical O +
endpoints O +
we O +
mentioned O +
above O +
were O +
not O +
associated O +
with O +
decreased O +
expression O +
of O +
any O +
of O +
these O +
genes O -
. O +

Decreased O +
Expression O +
of O +
Hypermethylated O +
" O -
Common O +
Target O -
� O -
? O +

Genes O +
Predict O +
for O +
Poor O +
Clinical O +
Prognosis O +
Summary O +
of O +
results O +
from O +
analysis O +
of O +
expression O +
microarray O +
data O -
. O +

p O -
- O -
Values O +
from O +
representative O +
analyses O +
for O +
specific O +
genes O +
are O +
shown O -
. O +

Blue O +
indicates O +
that O +
a O +
decrease O +
in O +
expression O +
of O +
the O +
indicated O +
gene O +
is O +
significantly O +
associated O +
with O +
the O +
following O -
: O +
overall O +
survival O +
or O +
disease O -
- O -
specific O +
survival O +
less O +
than O +
5 O +
y O -
, O +
metastasis O +
versus O +
primary O +
tumor O -
, O +
and/or O +
increased O +
grade O +
or O +
invasiveness O -
. O +

The O +
p O -
- O -
value O +
was O +
calculated O +
using O +
the O +
Student O -
's O +
t O -
- O -
test O +
with O +
adjustment O +
for O +
multiple O +
testing O +
as O +
described O +
previously O +
[ O -
21 O -
] O -
. O +

Decreased O +
Expression O +
of O +
Selected O +
" O -
Common O +
Target O -
� O -
? O +

Genes O +
Predict O +
for O +
Poor O +
Clinical O +
Prognosis O +
Box O -
- O -
plots O +
showing O +
decreased O +
expression O +
of O +
candidate O +
genes O +
correlate O +
with O +
unfavorable O +
clinical O +
features O -
. O +

The O +
y O -
- O -
axis O +
represents O +
normalized O +
expression O -
. O +

Shaded O +
boxes O +
represent O +
the O +
interquartile O +
range O +
( O -
25th–75th O +
percentile O -
) O -
. O +

Whiskers O +
represent O +
the O +
10th–90th O +
percentile O -
. O +

The O +
bars O +
denote O +
the O +
median O -
. O +

Related O +
to O +
the O +
above O +
correlation O +
with O +
survival O -
, O +
decreased O +
expression O +
of O +
five O +
of O +
the O +
genes O +
was O +
seen O +
in O +
metastases O +
when O +
compared O +
to O +
primary O +
tumors O -
, O +
such O +
as O +
GPNMB B-Gene -
, O +
LGR6 B-Gene -
, O +
EVL B-Gene -
, O +
and O -
, O +
especially O -
, O +
PTPRD B-Gene -
. O +

Intriguingly O -
, O +
GPNMB B-Gene +
encodes O +
the O +
glycoprotein O +
nonmetastatic O +
melanoma O +
protein O +
B O -
, O +
which O +
has O +
been O +
shown O +
to O +
be O +
differentially O +
expressed O +
between O +
highly O +
and O +
lowly O +
metastatic O +
melanoma O +
cell O +
lines O +
and O +
xenografts O -
. O +

In O +
these O +
contexts O -
, O +
markedly O +
lower O +
expression O +
levels O +
characterize O +
metastatic O +
cells O +
and O +
overexpression O +
of O +
the O +
GPNMB B-Gene +
protein O +
lowers O +
metastatic O +
potential O +
[ O -
40 O -
] O -
. O +

Finally O -
, O +
four O +
genes O +
are O +
underexpressed O +
with O +
increasing O +
tumor O +
grade O +
( O -
COL7A1 B-Gene -
, O +
SYNE1 B-Gene -
, O +
PTRD B-Gene -
, O +
and O +
EVL B-Gene -
) O -
. O +

Since O +
grade O +
is O +
a O +
strong O +
predictor O +
of O +
local O +
recurrence O +
and O +
metastasis O -
, O +
silencing O +
of O +
these O +
genes O +
may O +
be O +
clinically O +
relevant O +
determinants O +
of O +
prognosis O +
( O -
reviewed O +
in O +
[ O -
41 O -
] O -
) O -
. O +

It O +
is O +
important O +
to O +
note O +
that O +
our O +
direct O +
analysis O +
of O +
tumor O +
samples O +
( O -
Figure O +
9 O -
) O +
is O +
consistent O +
with O +
our O +
analysis O +
of O +
microarray O +
gene O +
expression O +
data O +
( O -
Figures O +
10–13 O -
) O +
from O +
these O +
other O +
cohorts O -
. O +

Figures O +
12 O +
and O +
13 O +
show O +
the O +
normalized O +
expression O +
levels O +
of O +
two O +
of O +
these O +
genes O -
, O +
SYNE1 B-Gene +
and O +
EVL B-Gene -
. O +

For O +
each O +
gene O -
, O +
expression O +
is O +
decreased O +
with O +
increasing O +
grade O +
in O +
nearly O +
all O +
available O +
datasets O +
in O +
the O +
literature O -
. O +

This O +
decreased O +
expression O +
parallels O +
the O +
greater O +
frequency O +
of O +
methylation O +
of O +
these O +
genes O +
in O +
tumors O +
with O +
increasing O +
grade O -
. O +

EVL B-Gene +
is O +
intriguing O +
as O +
it O +
is O +
hypermethylated O +
and O +
silenced O +
with O +
increasing O +
tumor O +
grade O +
and O +
aggressiveness O +
in O +
primary O +
breast O +
tumors O -
. O +

However O -
, O +
we O +
only O +
observed O +
it O +
to O +
be O +
silenced O +
in O +
colon O +
cell O +
lines O +
but O +
not O +
in O +
the O +
breast O +
cell O +
lines O +
that O +
we O +
examined O -
. O +

It O +
is O +
possible O +
that O +
EVL B-Gene +
methylation O +
occurs O +
in O +
other O +
breast O +
lines O +
we O +
have O +
not O +
examined O +
here O +
and O +
marks O +
a O +
small O +
subset O +
of O +
aggressive O +
tumors O -
. O +

All O +
datasets O +
used O +
in O +
the O +
above O +
microarray O +
meta O -
- O -
analyses O +
as O +
well O +
as O +
details O +
on O +
the O +
previously O +
published O +
samples O +
used O +
are O +
publicly O +
available O +
at O +
www.oncomine.org O -
. O +

SYNE1 B-Gene +
Expression O +
Is O +
Decreased O +
with O +
Increasing O +
Tumor O +
Grade O +
in O +
Breast O +
Carcinoma O +
Representative O +
data O +
are O +
shown O +
across O +
multiple O +
independently O +
published O +
microarray O +
studies O +
as O +
indicated O -
. O +

p O -
- O -
Values O +
for O +
correlation O +
are O +
shown O +
below O -
. O +

References O +
refer O +
to O +
those O +
listed O +
in O +
Table O +
S2 O -
. O +

EVL B-Gene +
Expression O +
Is O +
Decreased O +
with O +
Increasing O +
Tumor O +
Grade O +
in O +
Breast O +
Carcinoma O +
Representative O +
data O +
are O +
shown O +
across O +
multiple O +
independently O +
published O +
microarray O +
studies O +
as O +
indicated O -
. O +

p O -
- O -
Values O +
for O +
correlation O +
are O +
shown O +
below O -
. O +

References O +
refer O +
to O +
those O +
listed O +
in O +
Table O +
S2 O -
. O +

Second O -
, O +
our O +
results O +
suggest O +
that O +
tumors O +
may O +
be O +
less O +
biologically O +
heterogeneous O +
with O +
respect O +
to O +
denoting O +
key O +
tumor O +
suppressor O +
pathway O +
disruptions O +
when O +
consideration O +
is O +
given O +
to O +
both O +
genetic O +
and O +
epigenetic O +
changes O -
. O +

To O +
our O +
knowledge O -
, O +
this O +
study O +
represents O +
the O +
most O +
comprehensive O +
analysis O +
of O +
genes O +
targeted O +
by O +
both O +
mutation O +
and O +
hypermethylation O -
. O +

Prior O +
to O +
the O +
present O +
study O -
, O +
only O +
a O +
small O +
number O +
of O +
genes O +
had O +
been O +
found O +
to O +
be O +
frequently O +
affected O +
by O +
both O +
mutations O +
and O +
promoter O +
hypermethylation O -
. O +

Most O +
of O +
these O +
genes O +
were O +
the O +
initial O +
classic O +
tumor B-Gene +
suppressor I-Gene +
genes O +
where O +
the O +
epigenetic O +
event O +
was O +
first O +
defined O +
as O +
meaningfully O +
functional O -
. O +

These O +
genes O +
are O +
closely O +
linked O +
to O +
cancer O +
initiation O +
and O +
include O +
those O +
for O +
which O +
germ O -
- O -
line O +
mutations O +
occur O -
, O +
such O +
as O +
VHL B-Gene -
, O +
BRCA1 B-Gene -
, O +
and O +
STK11 B-Gene +
in O +
familial O +
forms O +
of O +
renal O -
, O +
breast O -
, O +
and O +
colon O +
cancer O -
, O +
respectively O +
[ O -
10,52,53 O -
] O -
. O +

These O +
tumor O +
suppressors O +
are O +
frequently O +
hypermethylated O +
in O +
sporadic O +
forms O +
of O +
the O +
corresponding O +
tumor O +
types O +
[ O -
54–56 O -
] O -
. O +

Furthermore O -
, O +
methylation O -
- O -
associated O +
silencing O +
can O +
act O +
as O +
a O +
" O -
second O +
genetic O +
hit O -
� O -
? O +
in O +
these O +
genes O +
in O +
tumors O +
from O +
individuals O +
harboring O +
germline O +
mutations O -
, O +
resulting O +
in O +
functional O +
LOH O +
[ O -
57 O -
] O -
. O +

Our O +
current O +
findings O +
now O +
indicate O +
that O -
, O +
particularly O +
for O +
tumor B-Gene +
suppressor I-Gene +
genes O +
with O +
a O +
low O +
incidence O +
of O +
mutations O -
, O +
it O +
may O +
be O +
the O +
rule O +
rather O +
than O +
the O +
exception O +
that O +
epigenetic O +
inactivation O +
is O +
a O +
more O +
frequent O +
event O +
than O +
genetic O +
disruption O -
. O +

Tumor O +
suppressors O +
that O +
are O +
important O +
for O +
tumorigenesis O +
may O -
, O +
then O -
, O +
often O +
be O +
targeted O +
by O +
multiple O +
methods O +
of O +
functional O +
inactivation O -
. O +

A O +
third O +
important O +
conclusion O +
is O +
that O +
there O +
may O +
be O +
more O +
similarity O +
among O +
individual O +
breast O +
and O +
colon O +
tumors O +
than O +
is O +
apparent O +
from O +
analysis O +
of O +
the O +
mutational O +
spectrum O +
only O -
, O +
and O -
, O +
therefore O -
, O +
any O +
comparison O +
of O +
biological O +
changes O +
between O +
tumors O +
may O +
need O +
to O +
account O +
for O +
epigenetic O +
effects O +
in O +
addition O +
to O +
genetic O +
ones O -
. O +

Clearly O -
, O +
the O +
same O +
tumor O +
suppressor O +
genes O +
in O +
different O +
cancers O +
may O +
undergo O +
different O +
modes O +
of O +
inactivation O -
. O +

This O +
scenario O +
is O +
analogous O +
to O +
the O +
situation O +
that O +
is O +
observed O +
for O +
oncogenes O +
such O +
as O +
MYC B-Gene -
. O +

In O +
hematopoietic O +
malignancies O -
, O +
aberrant O +
activation O +
of O +
MYC B-Gene +
results O +
frequently O +
from O +
translocations O +
whereas O +
the O +
gene O +
is O +
more O +
often O +
subject O +
to O +
amplifications O +
and O +
mutations O +
in O +
solid O +
tumors O +
[ O -
58,59 O -
] O -
. O +

The O +
processes O +
underlying O +
these O +
differences O +
are O +
fundamentally O +
important O +
for O +
understanding O +
cancer O +
and O +
are O +
worthy O +
of O +
future O +
study O -
. O +

Finally O -
, O +
it O +
is O +
important O +
to O +
reiterate O +
that O +
our O +
findings O +
have O +
allowed O +
us O +
to O +
begin O +
querying O +
the O +
clinical O +
significance O +
of O +
genes O +
targeted O +
by O +
mutation O +
and O +
hypermethylation O -
. O +

By O +
correlating O +
our O +
data O +
to O +
expression O +
changes O +
in O +
cancer O +
microarray O +
databases O +
and O +
relating O +
these O +
to O +
important O +
clinical O +
parameters O -
, O +
we O +
have O +
identified O +
genes O +
that O +
may O +
track O +
with O +
disease O +
prognosis O -
. O +

Indeed O -
, O +
previously O -
, O +
the O +
discovery O +
of O +
hypermethylated O +
genes O +
such O +
as O +
MGMT B-Gene +
have O +
proven O +
very O +
useful O +
for O +
predicting O +
clinical O +
prognosis O +
and O +
response O +
to O +
therapy O +
in O +
diseases O +
such O +
as O +
malignant O +
glioma O +
[ O -
60 O -
] O -
, O +
gastric O +
cancer O +
[ O -
61 O -
] O -
, O +
and O +
lung O +
cancer O +
[ O -
62,63 O -
] O -
. O +

A O +
recent O +
study O +
showed O +
that O +
a O +
polycomb O +
repression O +
signature O +
in O +
metastatic O +
prostate O +
cancer O +
predicts O +
for O +
cancer O +
outcome O +
[ O -
64 O -
] O -
. O +

Our O +
study O +
suggests O +
that O +
matching O +
large O -
- O -
scale O +
mutational O +
and O +
epigenetic O +
analysis O +
will O +
be O +
useful O +
for O +
advancing O +
our O +
knowledge O +
of O +
the O +
biology O +
of O +
human O +
cancers O -
. O +

These O +
results O +
may O +
be O +
useful O +
for O +
the O +
development O +
of O +
new O -
, O +
more O +
effective O +
biomarkers O +
and O +
therapeutics O -
. O +

Background O +
Parathyroid O +
disease O +
with O +
hypersecretion O +
of O +
parathyroid O +
hormone O +
and O +
generally O +
also O +
hypercalcemia O +
occurs O +
in O +
primary O +
hyperparathyroidism O +
( O -
pHPT O -
) O -
, O +
due O +
to O +
growth O +
regulatory O +
disturbance O +
in O +
one O +
or O +
several O +
parathyroid O +
glands O -
. O +

Activation O +
of O +
CCND1 B-Gene +
oncogene O +
expression O +
or O +
inactivation O +
of O +
the O +
MEN1 B-Gene +
tumor O +
suppressor O +
gene O +
contributes O +
to O +
deregulated O +
growth O +
control O +
in O +
a O +
fraction O +
of O +
sporadic O +
parathyroid O +
adenomas O +
[ O -
1 O -
- O -
4 O -
] O -
. O +

Activation O +
of O +
the O +
Wnt O -
/ O -
β O -
- O -
catenin O +
signaling O +
pathway O +
by O +
aberrant O +
accumulation O +
of O +
stabilized O +
β O -
- O -
catenin O +
is O +
involved O +
in O +
the O +
development O +
of O +
many O +
neoplasms O -
. O +

β O -
- O -
catenin O +
accumulation O +
is O +
typically O +
caused O +
by O +
mutations O +
in O +
components O +
of O +
the O +
signaling O +
pathway O -
, O +
such O +
as O +
APC B-Gene -
, O +
Axin B-Gene -
, O +
β B-Gene -
- I-Gene -
Trcp I-Gene -
, O +
and O +
WTX B-Gene -
, O +
or O +
results O +
from O +
secondary O +
events O -
. O +

In O +
addition O -
, O +
protein O +
stabilizing O +
mutations O +
in O +
the O +
glycogen O +
synthase O +
kinase O +
3β O +
phosphorylation O +
sites O +
of O +
β O -
- O -
catenin O +
( O -
Ser-33 O -
, O +
Ser-37 O -
, O +
Thr-41 O -
, O +
Ser-45 O -
) O +
occur O +
with O +
varying O +
frequency O +
in O +
several O +
neoplasms O +
[ O -
5 O -
- O -
9 O -
] O -
. O +

We O +
recently O +
reported O +
activation O +
of O +
the O +
Wnt O -
/ O -
β O -
- O -
catenin O +
signaling O +
pathway O +
by O +
aberrant O +
accumulation O +
of O +
β O -
- O -
catenin O +
in O +
parathyroid O +
adenomas O +
from O +
patients O +
with O +
pHPT O +
[ O -
10 O -
] O -
. O +

The O +
accumulation O +
of O +
β O -
- O -
catenin O +
was O +
caused O +
by O +
expression O +
of O +
an O +
aberrantly O +
spliced O +
internally O +
truncated O +
Wnt B-Gene +
receptor O +
LRP5 B-Gene +
or O +
by O +
a O +
stabilizing O +
mutation O +
( O -
S37A O -
) O +
in O +
CTNNB1 B-Gene +
exon O +
3 O +
[ O -
10,11 O -
] O -
. O +

Stabilizing O +
mutations O +
of O +
CTNNB1 B-Gene +
have O +
not O +
been O +
detected O +
in O +
parathyroid O +
adenomas O +
of O +
patients O +
from O +
Japan O +
and O +
the O +
United O +
States O +
[ O -
12,13 O -
] O -
. O +

Here O +
we O +
have O +
determined O +
the O +
frequency O +
and O +
zygosity O +
of O +
mutations O +
in O +
exon O +
3 O +
of O +
CTNNB1 B-Gene -
, O +
and O +
β O -
- O -
catenin O +
expression O +
status O +
in O +
a O +
large O +
series O +
of O +
parathyroid O +
adenomas O +
of O +
Swedish O +
patients O -
. O +

Methods O +
Tissue O +
Specimens O +
Sporadic O +
parathyroid O +
adenomas O +
( O -
n O +
= O +
104 O -
) O +
were O +
acquired O +
from O +
104 O +
Swedish O +
patients O +
with O +
pHPT O +
diagnosed O +
and O +
operated O +
on O +
in O +
the O +
clinical O +
routine O +
at O +
the O +
Uppsala O +
University O +
Hospital O -
. O +

Normal O +
parathyroid O +
tissue O +
was O +
obtained O +
as O +
normal O +
gland O +
biopsies O +
in O +
patients O +
subjected O +
to O +
parathyroidectomy O -
. O +

Tissues O +
were O +
intraoperatively O +
snap O +
frozen O -
. O +

Informed O +
consent O +
and O +
approval O +
of O +
institutional O +
ethical O +
committee O +
were O +
obtained O -
. O +

DNA O +
Sequencing O +
DNA O +
from O +
parathyroid O +
tumors O +
was O +
prepared O +
by O +
standard O +
procedures O +
including O +
proteinase O +
K O +
treatment O +
and O +
phenol O +
extraction O -
. O +

Blood O +
DNA O +
was O +
prepared O +
using O +
the O +
Wizard O +
Genomic O +
DNA O +
Purification O +
Kit O +
( O -
Promega O +
Corp. O -
, O +
Madison O -
, O +
WI O -
) O -
. O +

DNA O +
was O +
PCR O +
amplified O +
with O +
primers O +
for O +
exon O +
3 O +
of O +
CTNNB1 B-Gene -
. O +

PCR O +
forward O +
primer O -
: O +
5'-TGA O +
TGG O +
AGT O +
TGG O +
ACA O +
TGG O +
CC O -
; O +
reverse O -
: O +
5'-CTC O +
ATA O +
CAG O +
GAC O +
TTG O +
GGA O +
GG O -
. O +

The O +
complementary O +
strand O +
was O +
also O +
sequenced O +
for O +
fragments O +
with O +
mutation O -
. O +

The O +
PCR O +
fragments O +
were O +
sequenced O +
directly O +
on O +
the O +
3130xl O +
Genetic O +
Analyzer O +
using O +
the O +
ABI O +
Prism O +
Dye O +
Terminator O +
Cycle O +
Sequencing O +
Ready O +
Reaction O +
kit O +
( O -
Applied O +
Biosystems O -
, O +
Foster O +
City O -
, O +
CA O -
) O -
. O +

Restriction O +
Enzyme O +
Digestion O +
CTNNB1 B-Gene +
exon O +
3 O +
PCR O +
fragments O +
were O +
purified O +
using O +
the O +
GFX O +
PCR O +
DNA O +
and O +
Gel O +
Band O +
Purification O +
Kit O +
( O -
GE O +
Healthcare O +
Europe O +
GmbH O -
, O +
Uppsala O -
, O +
Sweden O -
) O +
and O +
cleaved O +
with O +
Xma O +
I O +
or O +
Nla O +
III O +
according O +
to O +
instructions O +
by O +
the O +
manufacturer O +
( O -
New O +
England O +
Biolabs O -
, O +
Inc. O -
, O +
Beverly O -
, O +
MA O -
) O -
. O +

Products O +
were O +
analyzed O +
by O +
agarose O +
gel O +
electrophoresis O -
. O +

CTNNB1 B-Gene +
Gene O +
Copy O +
Number O +
Tumor O +
( O -
S37A O -
) O +
and O +
blood O +
DNA O +
from O +
4 O +
patients O +
were O +
extracted O +
as O +
described O +
above O -
. O +

DNA O +
was O +
marked O +
with O +
fluorescence O +
dye O +
and O +
hybridized O +
to O +
the O +
Affymetrix O +
GeneChip O +
Mapping O +
500 O +
K O +
Set O +
Arrays O +
250K_Nsp_SNP O +
and O +
250K_Sty_SNP O +
according O +
to O +
the O +
manufacturer O -
's O +
instructions O -
, O +
and O +
analysed O +
by O +
GeneChip O +
Genotyping O +
Analysis O +
Software O +
( O -
GTYPE O -
) O +
using O +
Chromosome O +
Copy O +
Number O +
Analysis O +
Tool O +
( O -
CNAT O -
) O +
( O -
Affymetrix O -
, O +
Inc. O +
Santa O +
Clara O -
, O +
California O -
, O +
USA O -
) O -
. O +

Informative O +
SNPs O +
used O +
in O +
the O +
gene O +
copy O +
number O +
determination O +
are O +
shown O +
in O +
Table O +
1 O -
. O +

The O +
experiment O +
was O +
performed O +
at O +
the O +
Bioinformatics O +
and O +
Expression O +
Analysis O +
core O +
facility O +
at O +
NOVUM O -
, O +
Karolinska O +
Institute O -
, O +
Huddinge O -
, O +
Sweden O -
. O +

SNP O +
genotyping O +
Constitutional O +
DNA O +
and O +
parathyroid O +
adenoma O +
DNA O +
with O +
CTNNB1 B-Gene +
mutation O +
S37A O +
from O +
4 O +
pHPT O +
patients O +
were O +
genotyped O +
with O +
the O +
GeneChip O +
500 O +
K O +
Mapping O +
Array O +
Set O -
. O +

The O +
CTNNB1 B-Gene +
gene O +
is O +
located O +
between O +
positions O +
41216016 O +
and O +
41256928 O +
. O +

ECN O -
, O +
equal O +
copy O +
number O -
. O +

NI O -
, O +
non O -
- O -
informative O -
. O +

Immunohistochemistry O +
and O +
Western O +
Blotting O +
Frozen O +
tissue O +
sections O +
were O +
stained O +
as O +
described O +
[ O -
10 O -
] O +
using O +
an O +
anti O -
- O -
β O -
- O -
catenin O +
goat O +
polyclonal O +
antibody O +
with O +
an O +
epitope O +
mapping O +
at O +
the O +
C O -
- O -
terminus O +
( O -
Santa O +
Cruz O +
Biotechnology O -
, O +
INC O -
. O -
, O +
Santa O +
Cruz O -
, O +
CA O -
; O +
catalog O +
no. O +
sc-1496 O -
) O -
. O +

Protein O +
extracts O +
for O +
Western O +
blotting O +
were O +
prepared O +
[ O -
10 O -
] O +
in O +
Cytobuster O +
Protein O +
Extract O +
Reagent O +
( O -
Novagen O +
Inc. O -
, O +
Madison O -
, O +
Wisconsin O -
, O +
USA O -
) O +
supplemented O +
with O +
Complete O +
protease O +
inhibitor O +
cocktail O +
( O -
Roche O +
Diagnostics O +
GmbH O -
, O +
Penzberg O -
, O +
Germany O -
) O -
. O +

The O +
anti O -
- O -
active O +
( O -
nonphosphorylated O -
) O +
β O -
- O -
catenin O +
[ O -
14 O -
] O +
mouse O +
monoclonal O +
antibody O +
( O -
Upstate O -
, O +
Lake O +
Placid O -
, O +
USA O -
, O +
# O +
05 O -
- O -
665 O -
) O -
, O +
the O +
anti O -
- O -
β O -
- O -
catenin O +
goat O +
polyclonal O +
antibody O +
( O -
above O -
) O -
, O +
and O +
anti O -
- O -
actin O +
goat O +
polyclonal O +
antibody O +
( O -
Santa O +
Cruz O +
Biotechnology O +
INC O -
. O -
) O +
were O +
used O -
. O +

After O +
incubation O +
with O +
the O +
appropriate O +
secondary O +
antibodies O -
, O +
bands O +
were O +
visualized O +
using O +
the O +
enhanced O +
chemiluminescence O +
system O +
( O -
GE O +
Healthcare O +
Europe O +
GmbH O -
, O +
Uppsala O -
, O +
Sweden O -
) O -
. O +

Membranes O +
were O +
scanned O +
by O +
the O +
ChemiDoc O +
XRS O +
and O +
the O +
band O +
intensities O +
were O +
determined O +
using O +
Quantity O +
One O +
Software O +
( O -
Bio O -
- O -
Rad O +
Laboratories O -
, O +
Inc. O -
, O +
Hercules O -
, O +
California O -
, O +
USA O -
) O -
. O +

Results O +
Homozygous O +
CTNNB1 B-Gene +
Stabilizing O +
Mutation O +
S37A O +
DNA O +
sequencing O +
analysis O +
detected O +
the O +
CTNNB1 B-Gene +
stabilizing O +
mutation O +
S37A O +
( O -
TCT O +
> O +
GCT O -
) O +
in O +
6 O +
out O +
of O +
the O +
104 O +
( O -
5.8 O -
% O -
) O +
analyzed O +
parathyroid O +
adenomas O +
( O -
Figure O +
1 O -
) O -
. O +

Constitutional O +
DNA O +
( O -
blood O -
) O +
from O +
4 O +
out O +
of O +
the O +
6 O +
patients O +
were O +
available O -
, O +
and O +
encoded O +
the O +
wild O -
- O -
type O +
CTNNB1 B-Gene +
sequence O -
. O +

The O +
mutations O +
were O +
apparently O +
homozygous O +
by O +
DNA O +
sequencing O +
( O -
Figure O +
1 O -
) O -
, O +
as O +
we O +
reported O +
previously O +
for O +
3 O +
out O +
of O +
20 O +
adenomas O +
[ O -
10 O -
] O -
. O +

Taking O +
our O +
previous O +
study O +
into O +
account O +
[ O -
10 O -
] O -
, O +
a O +
total O +
of O +
9 O +
out O +
of O +
124 O +
( O -
7.3 O -
% O -
) O +
randomly O +
selected O +
parathyroid O +
adenomas O +
displayed O +
the O +
CTNNB1 B-Gene +
stabilizing O +
mutation O +
S37A O -
. O +

Representative O +
results O +
of O +
direct O +
DNA O +
sequencing O +
of O +
CTNNB1 B-Gene +
exon O +
3 O -
. O +

Constitutional O +
DNA O +
from O +
blood O +
( O -
left O +
panel O -
) O +
and O +
parathyroid O +
adenoma O +
( O -
right O +
panel O -
) O +
of O +
the O +
same O +
pHPT O +
patient O -
. O +

Homozygosity O +
for O +
the O +
mutation O +
was O +
further O +
substantiated O +
by O +
analytical O +
restriction O +
enzyme O +
digestions O -
. O +

As O +
expected O -
, O +
all O +
9 O +
fragments O +
harbouring O +
S37A O +
were O +
completely O +
cleaved O +
by O +
Nla O +
III O +
and O +
not O +
by O +
Xma O +
I O +
( O -
Figure O +
2A O -
) O -
. O +

Vice O +
versa O +
was O +
observed O +
for O +
fragments O +
with O +
the O +
wild O -
- O -
type O +
codon O +
S37 O -
. O +

PCR O +
amplified O +
fragments O +
were O +
used O +
for O +
the O +
DNA O +
sequencing O +
and O +
restriction O +
analyses O -
, O +
and O +
PCR O +
reactions O +
could O +
in O +
theory O +
favour O +
the O +
mutant O +
allele O -
( O -
s O -
) O -
. O +

Unbiased O +
PCR O +
reactions O +
were O +
however O +
confirmed O +
by O +
performing O +
PCR O +
amplification O +
in O +
a O +
1:1 O +
mixture O +
of O +
constitutional O +
DNA O +
and O +
S37A O +
mutant O +
tumor O +
DNA O -
, O +
and O +
by O +
subsequent O +
analytical O +
restriction O +
enzyme O +
digestion O +
( O -
Figure O +
2B O -
) O -
. O +

Analytical O +
restriction O +
enzyme O +
cleavage O +
analysis O -
. O +

( O -
A O -
) O -
, O +
CTNNB1 B-Gene +
exon O +
3 O +
PCR O +
fragments O +
( O -
176 O +
bp O -
) O +
were O +
digested O +
with O +
Xmn O +
I O +
or O +
Nla O +
III O +
that O +
cuts O +
only O +
wild O -
- O -
type O +
or O +
only O +
S37A O +
mutant O +
sequences O -
, O +
respectively O -
. O +

Three O +
out O +
of O +
the O +
nine O +
parathyroid O +
adenomas O +
with O +
S37A O +
mutation O +
were O +
identified O +
in O +
our O +
previous O +
study O +
[ O -
10 O -
] O -
. O +

Nla O +
III O +
cuts O +
also O +
outside O +
of O +
codon O +
37 O -
, O +
close O +
to O +
the O +
fragment O +
end O +
( O -
23 O +
bp O -
) O -
. O +

U O -
; O +
uncleaved O +
CTNNB1 B-Gene +
exon O +
3 O +
PCR O +
fragment O -
. O +

( O -
B O -
) O -
, O +
CTNNB1 B-Gene +
exon O +
3 O +
was O +
PCR O +
amplified O +
from O +
a O +
1:1 O +
mixture O +
of O +
constitutional O +
DNA O +
and O +
tumor O +
DNA O +
with O +
the O +
S37A O +
mutation O -
. O +

The O +
fragment O +
was O +
analyzed O +
by O +
restriction O +
enzyme O +
digestions O +
as O +
in O +
( O -
A O -
) O -
. O +

In O +
order O +
to O +
resolve O +
the O +
issue O +
of O +
zygosity O +
for O +
the O +
S37A O +
mutation O -
, O +
4 O +
tumor O +
DNAs O +
with O +
the O +
corresponding O +
constitutional O +
DNAs O +
were O +
genotyped O +
with O +
the O +
GeneChip O +
500 O +
K O +
Mapping O +
Array O +
Set O +
( O -
Affymetrix O -
) O -
. O +

Gene O +
copy O +
number O +
analysis O +
was O +
done O +
by O +
comparison O +
of O +
informative O +
single O -
- O -
nucleotide O +
polymorphisms O +
( O -
SNPs O -
) O -
. O +

Five O +
informative O +
SNPs O +
in O +
CTNNB1 B-Gene +
and O +
2 O +
SNPs O +
downstream O +
of O +
the O +
gene O +
showed O +
equal O +
copy O +
number O +
for O +
the O +
4 O +
paired O +
DNA O +
samples O +
( O -
Table O +
1 O -
) O -
. O +

Thus O -
, O +
taking O +
also O +
the O +
DNA O +
sequencing O +
results O +
into O +
account O +
the O +
S37A O +
mutation O +
was O +
homozygous O +
in O +
these O +
4 O +
tumours O -
, O +
rather O +
than O +
hemizygous O +
with O +
one O +
mutant O +
and O +
one O +
deleted O +
CTNNB1 B-Gene +
allele O -
. O +

β O -
- O -
catenin O +
Protein O +
Expression O +
Previously O -
, O +
we O +
reported O +
aberrant O +
accumulation O +
of O +
β O -
- O -
catenin O +
in O +
all O +
( O -
n O +
= O +
37 O -
) O +
analyzed O +
parathyroid O +
adenomas O +
[ O -
10 O -
] O -
. O +

Of O +
the O +
tumors O +
analyzed O +
here O +
by O +
DNA O +
sequencing O -
, O +
81 O +
frozen O +
parathyroid O +
adenomas O -
, O +
including O +
6 O +
with O +
the O +
S37A O +
mutation O -
, O +
were O +
of O +
sufficient O +
good O +
quality O +
for O +
immunohistochemical O +
analysis O +
with O +
a O +
β O -
- O -
catenin O +
goat O +
polyclonal O +
peptide O +
antiserum O +
[ O -
10 O -
] O -
. O +

The O +
three O +
pHPT O +
tumors O +
with O +
S37A O +
mutation O +
described O +
previously O +
[ O -
10 O -
] O +
were O +
also O +
included O -
. O +

In O +
addition O +
to O +
membraneous O +
staining O -
, O +
all O +
84 O +
tumors O +
displayed O +
distinct O +
cytoplasmic O -
/ O -
nuclear O +
immunoreactivity O +
( O -
Figure O +
3 O -
) O -
. O +

Western O +
blotting O +
analysis O +
was O +
performed O +
to O +
compare O +
the O +
expression O +
level O +
of O +
β O -
- O -
catenin O +
as O +
well O +
as O +
of O +
nonphosphorylated O +
active O +
β O -
- O -
catenin O +
( O -
ratio O +
of O +
β O -
- O -
catenin O +
to O +
actin O -
) O +
in O +
tumors O +
with O +
( O -
n O +
= O +
8) O +
and O +
without O +
( O -
n O +
= O +
6 O -
) O +
the O +
stabilizing O +
mutation O +
S37A O +
( O -
Figure O +
4 O -
) O -
. O +

The O +
six O +
tumors O +
without O +
β O -
- O -
catenin O +
stabilizing O +
mutation O +
all O +
expressed O +
the O +
internally O +
truncated O +
LRP5 B-Gene +
receptor O +
[ O -
11 O -
] O -
, O +
and O +
as O +
expected O +
[ O -
10,11 O -
] O +
all O +
fourteen O +
tumors O +
showed O +
accumulation O +
of O +
nonphosphorylated O +
active O +
β O -
- O -
catenin O +
in O +
comparison O +
to O +
normal O +
parathyroid O +
tissue O +
( O -
not O +
shown O -
) O -
. O +

A O +
small O +
but O +
significantly O +
higher O +
expression O +
level O +
was O +
observed O +
of O +
both O +
β O -
- O -
catenin O +
and O +
nonphosphorylated O +
active O +
β O -
- O -
catenin O +
in O +
tumors O +
with O +
stabilizing O +
mutation O +
S37A O +
in O +
comparison O +
to O +
those O +
with O +
wild O +
type O +
β O -
- O -
catenin O -
. O +

The O +
ratio O +
of O +
nonphosphorylated O +
active O +
β O -
- O -
catenin O +
to O +
β O -
- O -
catenin O +
was O +
also O +
slightly O +
higher O +
in O +
tumors O +
with O +
β O -
- O -
catenin O +
stabilizing O +
mutation O +
( O -
Figure O +
4 O -
) O -
. O +

No O +
particular O +
clinical O +
characteristics O -
, O +
including O +
age O -
, O +
sex O -
, O +
serum O +
calcium O +
level O -
, O +
serum O +
PTH O +
level O +
or O +
gland O +
weight O +
related O +
to O +
presence O +
of O +
the O +
S37A O +
mutation O -
. O +

Immunohistochemical O +
analysis O +
of O +
β O -
- O -
catenin O -
. O +

Immunostaining O +
of O +
84 O +
parathyroid O +
adenomas O +
with O +
an O +
anti O -
- O -
β O -
- O -
catenin O +
goat O +
polyclonal O +
antibody O -
. O +

The O +
first O +
9 O +
tumor O +
specimens O -
, O +
of O +
which O +
3 O +
were O +
described O +
previously O +
[ O -
10 O -
] O -
, O +
displayed O +
CTNNB1 B-Gene +
homozygous O +
stabilizing O +
mutation O +
S37A O -
. O +

No O +
staining O +
was O +
seen O +
in O +
the O +
absence O +
of O +
primary O +
antibodies O +
( O -
last O +
4 O +
specimens O -
) O -
. O +

Western O +
blotting O +
analysis O +
of O +
total O +
and O +
non O -
- O -
phosphorylated O +
active O +
β O -
- O -
catenin O -
. O +

Eight O +
pHPT O +
tumors O +
with O +
CTNNB1 B-Gene +
mutation O +
S37A O +
and O +
six O +
pHPT O +
tumors O +
without O +
mutation O +
were O +
analyzed O -
. O +

The O +
group O +
of O +
six O +
tumors O +
expressed O +
the O +
internally O +
truncated O +
LRP5 B-Gene +
receptor O +
[ O -
11 O -
] O -
. O +

All O +
analyzed O +
tumors O +
showed O +
accumulation O +
of O +
active O +
β O -
- O -
catenin O +
in O +
comparison O +
to O +
normal O +
parathyroid O +
tissue O +
( O -
not O +
shown O -
) O -
. O +

An O +
anti O -
- O -
active O +
( O -
nonphosphorylated O -
) O +
β O -
- O -
catenin O +
monoclonal O +
antibody O +
[ O -
14 O -
] O +
and O +
a O +
goat O +
polyclonal O +
antibody O +
with O +
an O +
epitope O +
mapping O +
at O +
the O +
C O -
- O -
terminus O +
of O +
β O -
- O -
catenin O +
were O +
used O -
. O +

Quantisation O +
of O +
the O +
obtained O +
signals O +
are O +
shown O +
below O -
. O +

* O -
, O +
p O +
< O +
0.05 O -
. O +

Discussion O +
We O +
have O +
found O +
that O +
a O +
total O +
of O +
9 O +
out O +
of O +
124 O +
( O -
7.3 O -
% O -
) O +
randomly O +
selected O +
parathyroid O +
adenomas O +
displayed O +
the O +
CTNNB1 B-Gene +
stabilizing O +
homozygous O +
mutation O +
S37A O -
. O +

None O +
of O +
these O +
9 O +
tumors O +
expressed O +
the O +
internally O +
truncated O +
LRP5 B-Gene +
receptor O +
[ O -
11 O -
] O +
( O -
data O +
not O +
shown O -
) O -
, O +
further O +
emphasizing O +
the O +
previous O +
observation O +
that O +
these O +
events O +
are O +
mutually O +
exclusive O +
[ O -
11 O -
] O -
. O +

The O +
mutated O +
LRP5 B-Gene +
receptor O -
, O +
with O +
the O +
central O +
region O +
deleted O -
, O +
is O +
expressed O +
in O +
the O +
majority O +
of O +
pHPT O +
tumors O +
and O +
is O +
required O +
for O +
accumulation O +
of O +
β O -
- O -
catenin O +
and O +
parathyroid O +
tumor O +
cell O +
growth O +
[ O -
11 O -
] O -
. O +

The O +
S37A O +
CTNNB1 B-Gene +
mutation O +
commonly O +
occurs O +
also O +
in O +
gastrointestinal O +
carcinoid O +
tumors O +
where O +
26 O +
out O +
of O +
29 O +
tumors O +
with O +
mutations O +
harboured O +
S37A O +
[ O -
15 O -
] O -
. O +

The O +
mutant O +
protein O +
shows O +
resistance O +
to O +
ubiquination O +
and O +
proteosomal O +
degradation O -
, O +
with O +
a O +
longer O +
half O -
- O -
life O +
than O +
wild O -
- O -
type O +
β O -
- O -
catenin O -
. O +

S37A O +
β O -
- O -
catenin O +
also O +
shows O +
an O +
enhanced O +
affinity O +
for O +
LEF1 B-Gene +
and O +
TCF4 B-Gene -
, O +
its O +
DNA O -
- O -
binding O +
partners O +
in O +
transcriptional O +
regulation O +
[ O -
16 O -
- O -
18 O -
] O -
. O +

Homozygous O +
mutation O +
as O +
detected O +
by O +
direct O +
DNA O +
sequencing O +
of O +
CTNNB1 B-Gene +
seems O +
to O +
be O +
uncommon O +
in O +
other O +
neoplasms O -
, O +
but O +
have O +
been O +
described O +
in O +
a O +
rectal O +
carcinoid O +
tumor O +
and O +
in O +
colorectal O +
cancer O +
[ O -
15,19 O -
] O -
. O +

To O +
be O +
conclusive O +
regarding O +
zygosity O -
, O +
direct O +
DNA O +
sequencing O +
clearly O +
requires O +
low O +
or O +
no O +
contamination O +
of O +
normal O +
cell O +
populations O +
in O +
the O +
tumor O +
sample O -
. O +

In O +
colorectal O +
cancer O +
cells O +
with O +
inactivating O +
APC B-Gene +
hemizygous O +
mutation O +
or O +
activating O +
CTNNB1 B-Gene +
heterozygous O +
mutation O -
, O +
the O +
total O +
β O -
- O -
catenin O +
signaling O +
activity O +
seemed O +
dependent O +
also O +
on O +
silencing O +
of O +
SFRP B-Gene +
genes O +
by O +
promoter O +
hypermethylation O +
with O +
consistent O +
constitutive O +
WNT O +
signaling O +
[ O -
20 O -
] O -
. O +

Whether O +
combined O +
activity O +
of O +
two O +
mutant O +
S37A O +
CTNNB1 B-Gene +
alleles O +
suffices O +
for O +
benign O +
parathyroid O +
tumor O +
growth O +
or O +
whether O +
constitutive O +
WNT O +
signaling O +
is O +
required O +
in O +
addition O -
, O +
remain O +
to O +
be O +
investigated O -
. O +

DNA O +
sequence O +
analysis O +
of O +
24 O +
parathyroid O +
adenomas O +
from O +
Japanese O +
patients O +
revealed O +
no O +
CTNNB1 B-Gene +
mutations O -
, O +
and O +
immunohistochemistry O +
showed O +
weak O +
cytoplasmic O +
β O -
- O -
catenin O +
staining O +
in O +
2 O +
tumors O +
[ O -
12 O -
] O -
. O +

In O +
another O +
study O +
from O +
Japan O +
( O -
n O +
= O +
9 O -
) O -
, O +
cytoplasmic O +
and/or O +
membranous O +
β O -
- O -
catenin O +
staining O +
was O +
seen O +
in O +
8 O +
adenomas O +
and O +
nuclear O +
staining O +
in O +
one O +
adenoma O -
. O +

DNA O +
sequencing O +
analysis O +
was O +
not O +
done O +
in O +
these O +
specimens O +
[ O -
21 O -
] O -
. O +

Furthermore O -
, O +
a O +
recent O +
study O +
did O +
not O +
detect O +
CTNNB1 B-Gene +
exon O +
3 O +
mutations O +
in O +
97 O +
sporadic O +
parathyroid O +
adenomas O +
from O +
patients O +
who O +
had O +
undergone O +
parathyroidectomy O +
in O +
the O +
United O +
States O -
. O +

Unfortunately O -
, O +
β O -
- O -
catenin O +
protein O +
expression O +
was O +
not O +
evaluated O +
in O +
this O +
report O +
[ O -
13 O -
] O -
. O +

Since O +
we O +
observed O +
a O +
CTNNB1 B-Gene +
mutation O +
frequency O +
of O +
7.3 O -
% O +
in O +
adenomas O +
from O +
Swedish O +
patients O -
, O +
this O +
may O +
suggest O +
possible O +
contribution O +
of O +
geographical O +
origin O +
( O -
dietary O +
or O +
environmental O +
differences O -
, O +
or O +
different O +
genetic O +
backgrounds O -
) O +
to O +
mechanisms O +
of O +
parathyroid O +
disease O -
. O +

The O +
CTNNB1 B-Gene +
mutation O +
frequency O +
vary O +
considerably O +
also O +
in O +
colorectal O +
cancer O +
( O -
1–60 O -
% O -
) O +
and O +
melanomas O +
( O -
0.02–27 O -
% O -
) O -
, O +
apparently O +
not O +
related O +
to O +
geographical O +
origin O +
[ O -
8,17,22 O -
- O -
30 O -
] O -
. O +

The O +
observations O +
may O +
be O +
attributed O +
to O +
the O +
stochastic O +
distribution O +
of O +
probability O +
in O +
analyzed O +
material O +
or O +
to O +
other O +
causalities O -
, O +
like O +
that O +
the O +
tumor O +
sample O +
purity O +
and O +
pathology O +
must O +
be O +
guaranteed O -
. O +

Conclusion O +
By O +
analyzing O +
a O +
large O +
series O +
of O +
tumors O +
from O +
Swedish O +
patients O -
, O +
this O +
study O +
further O +
emphasizes O +
β O -
- O -
catenin O +
accumulation O +
as O +
the O +
most O +
common O +
aberration O +
in O +
parathyroid O +
tumors O +
of O +
primary O +
origin O -
. O +

CTNNB1-stabilizing B-Gene +
mutations O +
were O +
found O +
in O +
5.8 O -
% O +
of O +
the O +
tumors O -
, O +
or O +
in O +
7.3 O -
% O +
when O +
taking O +
our O +
previous O +
study O +
[ O -
10 O -
] O +
into O +
account O -
. O +

The O +
WNT O -
/ O -
β O -
- O -
catenin O +
signaling O +
pathway O -
, O +
with O +
β O -
- O -
catenin O +
and O +
the O +
internally O +
truncated O +
LRP5 B-Gene +
receptor O +
[ O -
11 O -
] O +
in O +
particular O -
, O +
present O +
therapeutic O +
targets O +
for O +
hyperparathyroidism O -
. O +

The O +
association O +
between O +
genetic O +
variants O +
in O +
and O +
and O +
the O +
development O +
of O +
sporadic O +
colorectal O +
cancer O +
in O +
the O +
Danish O +
population O +
Abstract O +
Background O +
Mutations O +
in O +
the O +
mismatch B-Gene +
repair I-Gene +
genes I-Gene +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
predispose O +
to O +
hereditary O +
non O -
- O -
polyposis O +
colorectal O +
cancer O +
( O -
HNPCC O -
) O -
. O +

Genetic O +
screening O +
of O +
more O +
than O +
350 O +
Danish O +
patients O +
with O +
colorectal O +
cancer O +
( O -
CRC O -
) O +
has O +
led O +
to O +
the O +
identification O +
of O +
several O +
new O +
genetic O +
variants O +
( O -
e.g. O +
missense O -
, O +
silent O +
and O +
non O -
- O -
coding O -
) O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
the O +
frequency O +
of O +
these O +
variants O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
in O +
Danish O +
patients O +
with O +
sporadic O +
colorectal O +
cancer O +
and O +
in O +
the O +
healthy O +
background O +
population O -
. O +

The O +
purpose O +
was O +
to O +
reveal O +
if O +
any O +
of O +
the O +
common O +
variants O +
lead O +
to O +
increased O +
susceptibility O +
to O +
colorectal O +
cancer O -
. O +

Methods O +
Associations O +
between O +
genetic O +
variants O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
and O +
sporadic O +
colorectal O +
cancer O +
were O +
evaluated O +
using O +
a O +
case O -
- O -
cohort O +
design O -
. O +

The O +
genotyping O +
was O +
performed O +
on O +
DNA O +
isolated O +
from O +
blood O +
from O +
the O +
380 O +
cases O +
with O +
sporadic O +
colorectal O +
cancer O +
and O +
a O +
sub O -
- O -
cohort O +
of O +
770 O +
individuals O -
. O +

The O +
DNA O +
samples O +
were O +
analyzed O +
using O +
Single O +
Base O +
Extension O +
( O -
SBE O -
) O +
Tag O -
- O -
arrays O -
. O +

A O +
Bonferroni O +
corrected O +
Fisher O +
exact O +
test O +
was O +
used O +
to O +
test O +
for O +
association O +
between O +
the O +
genotypes O +
of O +
each O +
variant O +
and O +
colorectal O +
cancer O -
. O +

Linkage O +
disequilibrium O +
( O -
LD O -
) O +
was O +
investigated O +
using O +
HaploView O +
( O -
v3.31 O -
) O -
. O +

Results O +
Heterozygous O +
and O +
homozygous O +
changes O +
were O +
detected O +
in O +
13 O +
of O +
35 O +
analyzed O +
variants O -
. O +

Two O +
variants O +
showed O +
a O +
borderline O +
association O +
with O +
colorectal O +
cancer O -
, O +
whereas O +
the O +
remaining O +
variants O +
demonstrated O +
no O +
association O -
. O +

Furthermore O -
, O +
the O +
genomic O +
regions O +
covering O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
displayed O +
high O +
linkage O +
disequilibrium O +
in O +
the O +
Danish O +
population O -
. O +

Twenty O -
- O -
two O +
variants O +
were O +
neither O +
detected O +
in O +
the O +
cases O +
with O +
sporadic O +
colorectal O +
cancer O +
nor O +
in O +
the O +
sub O -
- O -
cohort O -
. O +

Some O +
of O +
these O +
rare O +
variants O +
have O +
been O +
classified O +
either O +
as O +
pathogenic O +
mutations O +
or O +
as O +
neutral O +
variants O +
in O +
other O +
populations O +
and O +
some O +
are O +
unclassified O +
Danish O +
variants O -
. O +

Conclusion O +
None O +
of O +
the O +
variants O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
analyzed O +
in O +
the O +
present O +
study O +
were O +
highly O +
associated O +
with O +
colorectal O +
cancer O +
in O +
the O +
Danish O +
population O -
. O +

High O +
linkage O +
disequilibrium O +
in O +
the O +
genomic O +
regions O +
covering O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene -
, O +
indicate O +
that O +
common O +
genetic O +
variants O +
in O +
the O +
two O +
genes O +
in O +
general O +
are O +
not O +
involved O +
in O +
the O +
development O +
of O +
sporadic O +
colorectal O +
cancer O -
. O +

Nevertheless O -
, O +
some O +
of O +
the O +
rare O +
unclassified O +
variants O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
might O +
be O +
involved O +
in O +
the O +
development O +
of O +
colorectal O +
cancer O +
in O +
the O +
families O +
where O +
they O +
were O +
originally O +
identified O -
. O +

Background O +
Colorectal O +
cancer O +
( O -
CRC O -
) O +
is O +
a O +
common O +
malignant O +
disease O +
in O +
the O +
western O +
world O -
. O +

The O +
lifetime O +
risk O +
is O +
about O +
5 O -
% O +
and O +
rising O +
[ O -
1 O -
] O -
. O +

In O +
2003 O -
, O +
approximately O +
3,600 O +
new O +
cases O +
where O +
registered O +
by O +
the O +
Danish O +
Cancer O +
Registry O +
equivalent O +
to O +
10 O -
% O +
of O +
the O +
total O +
number O +
of O +
malignant O +
cancer O +
cases O +
in O +
Denmark O -
, O +
making O +
CRC O +
the O +
third O +
most O +
common O +
cancer O +
in O +
the O +
country O +
[ O -
2 O -
] O -
. O +

A O +
twin O +
study O +
has O +
demonstrated O +
that O +
up O +
to O +
35 O -
% O +
of O +
the O +
CRCs O +
can O +
be O +
explained O +
by O +
inherited O +
susceptibility O +
[ O -
3 O -
] O -
. O +

However O -
, O +
only O +
approximately O +
5 O -
% O +
of O +
the O +
CRCs O +
are O +
explained O +
by O +
well O +
defined O +
hereditary O +
syndromes O +
displaying O +
a O +
Mendelian O +
inheritance O +
pattern O -
. O +

The O +
most O +
common O +
form O +
of O +
hereditary O +
CRC O +
is O +
hereditary O +
non O -
- O -
polyposis O +
colorectal O +
cancer O +
( O -
HNPCC O -
) O +
[ O -
4,5 O -
] O -
. O +

Diagnosis O +
of O +
HNPCC O +
is O +
based O +
on O +
kindred O +
analysis O +
using O +
the O +
Amsterdam O +
II O +
criteria O +
[ O -
6 O -
] O -
. O +

In O +
the O +
major O +
part O +
of O +
the O +
HNPCC O +
families O +
the O +
disease O +
is O +
caused O +
by O +
loss O +
of O +
function O +
pathogenic O +
mutations O +
such O +
as O +
nonsense O -
, O +
frameshift O +
and O +
non O -
- O -
coding O +
mutations O +
affecting O +
splice O +
sites O +
identified O +
mainly O +
in O +
three O +
genes O +
i.e. O +
hMLH1 B-Gene -
, O +
hMSH2 B-Gene +
and O +
hMSH6 B-Gene +
[ O -
7 O -
] O -
. O +

A O +
part O +
from O +
the O +
clearly O +
pathogenic O +
mutations O +
genetic O +
screening O +
has O +
also O +
revealed O +
numerous O +
missense O -
, O +
silent O +
and O +
non O -
- O -
coding O +
variants O +
of O +
unknown O +
significance O +
in O +
hMLH1 B-Gene -
, O +
hMSH2 B-Gene +
and O +
hMSH6 B-Gene -
. O +

Ideally O -
, O +
segregation O +
studies O +
should O +
be O +
conducted O +
to O +
reveal O +
the O +
pathogenicity O +
of O +
a O +
given O +
variant O -
. O +

However O -
, O +
such O +
analyses O +
are O +
often O +
not O +
feasible O +
due O +
to O +
limited O +
family O +
sizes O +
and O +
unavailability O +
of O +
clinical O +
specimens O -
. O +

Consequently O -
, O +
different O +
evaluation O +
methods O +
have O +
been O +
used O -
, O +
especially O +
for O +
the O +
missense O +
variants O -
, O +
to O +
be O +
able O +
to O +
distinguish O +
neutral O +
variants O +
from O +
disease O -
- O -
causing O +
mutations O -
. O +

Functional O +
analyses O +
of O +
individual O +
missense O +
variants O +
have O +
been O +
carried O +
out O +
using O +
different O +
in O +
vitro O +
assays O +
e.g. O +
[ O -
8 O -
- O -
13 O -
] O -
. O +

The O +
functional O +
studies O +
have O +
revealed O +
both O +
loss O +
of O +
function O +
mutations O +
that O +
are O +
most O +
likely O +
pathogenic O +
[ O -
8 O -
- O -
13 O -
] O +
and O +
variants O +
with O +
reduced O +
activity O +
[ O -
8 O -
- O -
11 O -
] O -
. O +

Apart O +
from O +
non O -
- O -
coding O +
mutations O +
affecting O +
the O +
classical O +
splice O +
sites O +
at O +
intron O -
/ O -
exon O +
junctions O -
, O +
missense O +
changes O +
as O +
well O +
as O +
silent O +
changes O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
have O +
also O +
been O +
shown O +
to O +
alter O +
pre O -
- O -
mRNA O +
splicing O +
and O +
thereby O +
causing O +
exon O +
skipping O +
[ O -
14,15 O -
] O -
. O +

Functional O +
analyses O +
are O +
laborious O +
and O +
therefore O +
in O +
silico O +
methods O +
available O +
on O +
the O +
internet O +
( O -
e.g. O +
SIFT O -
, O +
PolyPhen O +
and O +
PMUT O -
) O +
have O +
be O +
used O +
to O +
identify O +
variants O +
that O +
should O +
be O +
selected O +
for O +
further O +
functional O +
analysis O +
[ O -
16 O -
] O -
. O +

In O +
silico O +
predictions O +
and O +
in O +
vitro O +
functional O +
analyses O +
provide O +
an O +
idea O +
of O +
which O +
variants O +
are O +
pathogenic O -
. O +

However O -
, O +
population O +
studies O +
are O +
needed O +
to O +
reveal O +
the O +
in O +
vivo O +
pathogenicity O +
of O +
the O +
individual O +
variants O -
. O +

At O +
present O -
, O +
very O +
few O +
population O +
studies O +
have O +
dealt O +
with O +
the O +
association O +
of O +
common O +
variants O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
with O +
susceptibility O +
to O +
sporadic O +
CRC O +
[ O -
17 O -
- O -
19 O -
] O -
. O +

Methods O +
Subjects O -
/ O -
cohort O +
The O +
subjects O +
were O +
selected O +
from O +
the O +
Danish O +
Diet O -
, O +
Cancer O +
and O +
Health O +
( O -
DCH O -
) O +
study O -
, O +
which O +
is O +
an O +
ongoing O +
prospective O +
follow O -
- O -
up O +
study O +
[ O -
20 O -
] O -
. O +

In O +
all O +
57,053 O +
men O +
and O +
women O +
born O +
in O +
Denmark O -
, O +
living O +
in O +
the O +
greater O +
Copenhagen O +
or O +
Aarhus O +
areas O -
, O +
aged O +
50–64 O -
, O +
and O +
with O +
no O +
previous O +
cancer O +
diagnosis O +
at O +
the O +
time O +
of O +
enrolment O -
, O +
were O +
included O +
in O +
the O +
study O -
. O +

The O +
participants O +
were O +
recruited O +
during O +
the O +
years O +
1993–1997 O -
. O +

At O +
the O +
time O +
of O +
enrolment O -
, O +
biological O +
material O +
from O +
blood O -
, O +
urine O -
, O +
nails O +
and O +
fat O +
tissue O +
was O +
sampled O +
and O +
stored O +
in O +
liquid O +
nitrogen O +
at O +
-150 O -
° O -
C O -
. O +

Among O +
the O +
cohort O +
members O +
380 O +
cases O +
with O +
CRC O +
diagnosed O +
between O +
1994 O +
and O +
2004 O +
were O +
identified O +
in O +
the O +
files O +
of O +
the O +
Danish O +
Cancer O +
Registry O -
. O +

A O +
sub O -
- O -
cohort O +
of O +
770 O +
controls O +
( O -
including O +
10 O +
cases O -
) O +
was O +
selected O +
randomly O +
from O +
the O +
cohort O -
. O +

The O +
characteristics O +
of O +
the O +
cohort O +
are O +
shown O +
in O +
Table O +
1 O -
. O +

General O +
protocols O +
concerning O +
the O +
Diet O -
, O +
Cancer O +
and O +
Health O +
study O +
have O +
been O +
evaluated O +
and O +
approved O +
by O +
the O +
Regional O +
Scientific O +
Committees O +
on O +
Human O +
Studies O +
in O +
Copenhagen O +
and O +
Aarhus O +
( O -
journal O +
number O -
: O +
H O -
- O -
KF-01 O -
- O -
345 O -
/ O -
93 O -
) O +
and O +
the O +
Danish O +
Data O +
Protection O +
Agency O -
. O +

A O +
protocol O +
regarding O +
the O +
present O +
study O +
has O +
been O +
submitted O +
and O +
approved O +
by O +
the O +
mentioned O +
committees O +
as O +
a O +
supplement O +
to O +
the O +
initial O +
protocols O -
. O +

Characteristics O +
of O +
the O +
cohort O +
* O -
Age O +
at O +
inclusion O +
into O +
the O +
cohort O +
given O +
as O +
mean O +
( O -
sd O -
) O +
in O +
years O +
Another O +
cohort O +
named O +
familiar O +
CRC O +
consisting O +
of O +
285 O +
CRC O +
cases O +
was O +
also O +
included O +
in O +
the O +
study O -
. O +

The O +
majority O +
of O +
the O +
variants O +
were O +
initially O +
identified O +
in O +
this O +
cohort O -
. O +

Some O +
variants O +
were O +
found O +
only O +
in O +
one O +
family O +
whereas O +
others O +
were O +
identified O +
in O +
several O +
families O +
in O +
the O +
cohort O -
. O +

The O +
cohort O +
consists O +
of O +
individuals O +
from O +
HNPCC O +
families O +
( O -
based O +
on O +
the O +
Amsterdam O +
II O +
criteria O -
) O +
or O +
individuals O +
from O +
families O +
not O +
fulfilling O +
the O +
Amsterdam O +
II O +
criteria O -
, O +
but O +
with O +
a O +
clear O +
familial O +
accumulation O +
of O +
CRC O -
. O +

The O +
presence O +
of O +
other O +
clearly O +
pathogenic O +
mutations O +
in O +
the O +
hMLH1 B-Gene -
, O +
hMSH2 B-Gene +
and O +
hMSH6 B-Gene +
has O +
been O +
excluded O +
by O +
sequencing O -
. O +

All O +
individuals O +
in O +
the O +
cohort O +
of O +
familiar O +
CRC O +
have O +
been O +
consulted O +
by O +
a O +
clinical O +
geneticist O +
and O +
informed O +
consent O +
was O +
obtained O +
from O +
all O +
individuals O +
in O +
the O +
cohort O -
. O +

Detailed O +
information O +
on O +
each O +
individual O +
family O +
in O +
this O +
cohort O +
is O +
not O +
available O -
. O +

DNA O +
samples O +
DNA O +
was O +
extracted O +
from O +
frozen O +
leukocytes O +
as O +
described O +
previously O +
[ O -
21 O -
] O -
. O +

Variants O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
Initially O -
, O +
47 O +
variants O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
were O +
included O +
in O +
the O +
study O -
. O +

Forty O -
- O -
one O +
of O +
the O +
variants O +
have O +
previously O +
been O +
identified O +
either O +
in O +
Danish O +
HNPCC O +
patients O +
( O -
i.e. O +
fulfilling O +
the O +
Amsterdam O +
II O +
criteria O -
) O +
or O +
in O +
patients O +
not O +
fulfilling O +
the O +
Amsterdam O +
II O +
criteria O +
but O +
with O +
a O +
familial O +
accumulation O +
of O +
CRC O -
. O +

Six O +
variants O +
have O +
been O +
identified O +
in O +
other O +
Caucasian O +
populations O -
. O +

Of O +
the O +
initial O +
47 O +
selected O +
variants O -
, O +
12 O +
variants O +
were O +
excluded O +
either O +
due O +
to O +
troubles O +
regarding O +
the O +
primer O +
design O +
or O +
lack O +
of O +
amplification O +
product O +
in O +
the O +
multiplex O +
PCR O -
. O +

The O +
remaining O +
35 O +
analyzed O +
variants O +
are O +
listed O +
in O +
Table O +
2 O -
. O +

Results O +
Performance O +
of O +
the O +
Single O +
Base O +
Extension O -
- O -
tag O +
arrays O +
Single O +
base O +
extension O +
( O -
SBE O -
) O -
-tag O +
arrays O +
is O +
a O +
well O +
described O +
method O +
for O +
analysing O +
single O +
nucleotide O +
polymorphisms O +
[ O -
23 O -
] O -
. O +

Initially O -
, O +
47 O +
variants O +
were O +
included O +
in O +
the O +
study O -
. O +

However O -
, O +
12 O +
variants O +
either O +
failed O +
the O +
initial O +
primer O +
design O +
or O +
they O +
did O +
not O +
perform O +
well O +
in O +
the O +
multiplex O +
PCR O +
reaction O -
. O +

The O +
accuracy O +
of O +
the O +
SBE O -
- O -
tag O +
array O +
in O +
the O +
genotyping O +
of O +
the O +
remaining O +
35 O +
variants O +
was O +
tested O +
using O +
samples O +
with O +
known O +
genotypes O -
. O +

All O +
tested O +
samples O +
were O +
correctly O +
genotyped O +
( O -
data O +
not O +
shown O -
) O -
. O +

A O +
total O +
of O +
31 O +
of O +
35 O +
variants O +
performed O +
very O +
well O +
in O +
the O +
assay O -
, O +
i.e. O +
more O +
than O +
70 O -
% O +
of O +
the O +
samples O +
had O +
positive O +
call O +
( O -
data O +
not O +
shown O -
) O -
. O +

Frequency O +
of O +
variants O +
in O +
the O +
three O +
analysed O +
cohorts O +
We O +
have O +
identified O +
the O +
frequency O +
of O +
35 O +
variants O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
in O +
a O +
well O +
defined O +
cohort O +
of O +
770 O +
individuals O +
representative O +
of O +
the O +
Danish O +
population O -
. O +

In O +
addition O -
, O +
the O +
frequency O +
of O +
the O +
variants O +
was O +
also O +
identified O +
in O +
380 O +
cases O +
with O +
sporadic O +
CRC O +
and O +
in O +
285 O +
individuals O +
with O +
familiar O +
CRC O -
. O +

The O +
analyzed O +
variants O +
were O +
initially O +
identified O +
in O +
the O +
familiar O +
CRC O +
cohort O +
and O +
the O +
cohort O +
was O +
included O +
in O +
the O +
study O +
to O +
elucidate O +
whether O +
a O +
common O +
variant O +
could O +
explain O +
the O +
elevated O +
cancer O +
susceptibility O +
in O +
these O +
families O -
. O +

The O +
characteristics O +
of O +
the O +
cohort O +
of O +
sporadic O +
CRC O +
cases O +
and O +
the O +
sub O -
- O -
cohort O +
are O +
shown O +
in O +
Table O +
1 O -
. O +

Thirteen O +
out O +
of O +
35 O +
variants O +
were O +
polymorphic O +
in O +
the O +
cohort O +
of O +
sporadic O +
CRC O +
cases O +
and/or O +
in O +
the O +
sub O -
- O -
cohorts O +
( O -
Tables O +
2 O +
and O +
3 O -
) O -
. O +

Ten O +
of O +
these O +
variants O +
were O +
detected O +
with O +
a O +
frequency O +
≥1 O -
% O +
in O +
the O +
sub O -
- O -
cohort O +
and O +
are O +
therefore O +
relatively O +
common O +
in O +
the O +
Danish O +
population O -
. O +

The O +
remaining O +
three O +
variants O +
were O +
present O +
with O +
a O +
frequency O +
< O -
1 O -
% O +
( O -
Table O +
3 O -
) O -
. O +

None O +
of O +
the O +
analysed O +
variants O +
deviated O +
significantly O +
from O +
the O +
Hardy O -
- O -
Weinberg O +
equilibrium O -
. O +

Out O +
of O +
the O +
13 O +
identified O +
variants O +
9 O +
were O +
non O -
- O -
coding O +
or O +
silent O +
variants O +
and O +
3 O +
were O +
non O -
- O -
conserved O +
missense O +
changes O +
and O +
one O +
was O +
a O +
conserved O +
missense O +
change O +
( O -
Table O +
2 O -
) O -
. O +

The O +
frequency O +
of O +
11 O -
/ O -
13 O +
variants O +
did O +
not O +
differ O +
significantly O +
between O +
any O +
of O +
the O +
three O +
analyzed O +
cohorts O +
neither O +
individually O +
( O -
Table O +
4 O -
) O +
nor O +
as O +
pairs O +
( O -
data O +
not O +
shown O -
) O -
. O +

The O +
frequency O +
of O +
one O +
variant O -
; O +
hMSH2 B-Gene +
c.-118 O +
T O -
> O -
C O +
differed O +
significantly O +
between O +
the O +
sporadic O +
CRC O +
cases O +
and O +
the O +
sub O -
- O -
cohort O +
with O +
a O +
borderline O +
significant O +
p O -
- O -
value O +
of O +
0.0037 O +
( O -
significance O +
level O -
: O +
0.05 O -
/ O -
13 O +
= O +
0.0038 O -
) O -
. O +

One O +
previous O +
study O +
has O +
demonstrated O +
a O +
slight O +
difference O +
between O +
the O +
frequencies O +
of O +
this O +
variant O +
in O +
HNPCC O +
cases O +
and O +
controls O +
( O -
p O -
- O -
value O +
of O +
0.034 O -
) O +
[ O -
32 O -
] O -
, O +
whereas O +
another O +
study O +
detected O +
no O +
difference O +
[ O -
33 O -
] O -
. O +

In O +
addition O -
, O +
it O +
has O +
also O +
been O +
shown O +
that O +
the O +
variant O +
does O +
not O +
change O +
the O +
promoter O +
activity O +
of O +
the O +
hMSH2 B-Gene +
promoter O +
in O +
vitro O +
and O +
it O +
is O +
therefore O +
most O +
likely O +
not O +
involved O +
in O +
increased O +
susceptibility O +
to O +
CRC O +
[ O -
32 O -
] O -
. O +

The O +
frequency O +
of O +
the O +
variant O +
hMLH1 B-Gene +
c.1668 O -
- O -
19 O +
A O -
> O -
G O +
differed O +
between O +
the O +
familiar O +
CRC O +
cases O +
and O +
the O +
sub O -
- O -
cohort O +
with O +
a O +
borderline O +
significant O +
p O -
- O -
value O +
of O +
0.0044 O +
( O -
significance O +
level O -
: O +
0.05 O -
/ O -
15 O +
= O +
0.0033 O -
) O -
. O +

This O +
variant O +
is O +
an O +
intronic O +
variant O +
which O +
has O +
never O +
been O +
characterized O +
neither O +
in O +
vivo O +
nor O +
in O +
vitro O -
. O +

In O +
silico O +
analyses O +
using O +
SNAP O +
( O -
a O +
SNP O +
Annotations O +
Platform O -
) O +
[ O -
30 O -
] O +
demonstrated O +
that O +
the O +
presence O +
of O +
this O +
variant O +
results O +
in O +
the O +
elimination O +
of O +
an O +
Exon O +
Splicing O +
Enhancer O +
( O -
ESE O -
) O +
( O -
SRp40 O -
) O +
and O +
the O +
introduction O +
of O +
a O +
new O +
ESE O +
( O -
SRp55 O -
) O +
( O -
data O +
not O +
shown O -
) O -
. O +

However O -
, O +
in O +
vitro O +
analysis O +
must O +
be O +
performed O +
to O +
reveal O +
if O +
these O +
changes O +
result O +
in O +
an O +
aberrant O +
splice O +
pattern O -
. O +

Genotype O +
frequencies O +
of O +
the O +
variants O +
in O +
the O +
analyzed O +
cohorts O +
* O +
identified O +
in O +
CRC O +
families O +
from O +
other O +
populations O +
than O +
the O +
Danish O +
§ O +
na O -
: O +
not O +
analyzed O +
Variants O +
that O +
where O +
polymorphic O +
in O +
sporadic O +
CRC O +
cohort O +
or O +
in O +
the O +
sub O -
- O -
cohort O +
are O +
in O +
bold O +
The O +
p O -
- O -
values O +
of O +
marginal O +
Fisher O -
's O +
exact O +
tests O +
between O +
groups O +

The O +
Bonferroni O +
corrected O +
p O -
- O -
value O +
of O +
sporadic O +
versus O +
sub O -
- O -
cohort O +
is O +
0.05 O -
/ O -
13 O +
= O +
0.0038 O +

The O +
Bonferroni O +
corrected O +
p O -
- O -
value O +
of O +
familiar O -
- O -
versus O +
sub O -
- O -
cohort O +
is O +
0.05 O -
/ O -
15 O +
= O +
0.0033 O +
Polymorphic O +
variants O +
with O +
borderline O +
significant O +
p O -
- O -
values O +
are O +
in O +
bold O +
Twenty O -
- O -
two O +
of O +
the O +
variants O +
analysed O +
in O +
the O +
present O +
study O +
were O +
neither O +
detected O +
in O +
the O +
sporadic O +
cases O +
nor O +
in O +
the O +
sub O -
- O -
cohort O +
( O -
Tables O +
2 O +
and O +
3 O -
) O -
. O +

Among O +
those O +
were O +
the O +
six O +
variants O +
originally O +
identified O +
in O +
other O +
Caucasian O +
populations O +
i.e. O +
hMLH1 B-Gene +
c.1558 O -
+ O -
11 O +
G O -
> O -
A O +
and O +
MSH2 B-Gene +
c.287 O +
G O -
> O -
A O -
, O +
c.329 O +
A O -
> O -
G O -
, O +
c.380 O +
A O -
> O -
G O -
, O +
c.2006 O -
- O -
6 O +
T O -
> O -
C O -
/ O -
G O +
and O +
c.2139 O +
G O -
> O -
T O +
( O -
see O +
Table O +
2 O +
for O +
references O -
) O -
. O +

The O +
remaining O +
16 O +
variants O -
, O +
which O +
have O +
all O +
been O +
identified O +
in O +
Danish O +
individuals O +
with O +
a O +
familiar O +
accumulation O +
of O +
CRC O -
, O +
are O +
therefore O +
very O +
rare O +
variants O +
in O +
the O +
Danish O +
population O -
. O +

Some O +
of O +
these O +
rare O +
variants O +
have O +
been O +
classified O +
either O +
as O +
neutral O +
variants O +
( O -
e.g. O +
hMLH1 B-Gene +
c.2152 O +
C O -
> O -
T O +
and O +
hMSH2 B-Gene +
c.2500G O -
> O -
A O -
) O +
or O +
pathogenic O +
mutations O +
( O -
e.g. O +
hMLH1 B-Gene +
c.350 O +
C O -
> O -
T O -
, O +
and O +
hMSH2 B-Gene +
c131 O +
C O -
> O -
T O -
) O +
in O +
Danish O +
HNPCC O +
families O +
and/or O +
HNPCC O +
families O +
from O +
other O +
populations O +
( O -
see O +
Table O +
2 O +
for O +
references O -
) O -
. O +

To O +
our O +
knowledge O -
, O +
some O +
of O +
the O +
rare O +
variants O +
have O +
never O +
been O +
described O +
previously O +
neither O +
in O +
the O +
Danish O +
population O +
nor O +
in O +
other O +
populations O +
( O -
Table O +
2 O -
) O -
. O +

These O +
variants O +
are O +
most O +
likely O +
private O +
variants O +
found O +
only O +
in O +
the O +
families O +
where O +
they O +
were O +
originally O +
identified O -
. O +

Four O +
of O +
the O +
rare O +
unclassified O +
variants O +
are O +
missense O +
variants O +
changing O +
either O +
non O -
- O -
conserved O +
amino O +
acids O +
i.e. O +
hMLH1 B-Gene +
c.1379 O +
A O -
> O -
C O +
and O +
c.1689 O +
A O -
> O -
G O +
or O +
conserved O +
amino O +
acids O +
i.e. O +
hMSH2 B-Gene +
c.2062 O +
A O -
> O -
G O +
and O +
c.2542 O +
G O -
> O -
T. O +
Linkage O +
disequilibrium O +
Linkage O +
disequilibrium O +
( O -
LD O -
) O +
analyses O +
of O +
the O +
genomic O +
regions O +
covering O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
demonstrated O +
high O +
LD O +
in O +
the O +
genomic O +
regions O +
covering O +
the O +
two O +
genes O -
. O +

LD O +
plots O +
of O +
the O +
sub O -
- O -
cohort O +
in O +
the O +
genomic O +
regions O +
covering O +
the O +
two O +
genes O +
are O +
shown O +
in O +
Figures O +
1A O +
and O +
1B O -
. O +

The O +
nine O +
polymorphic O +
variants O +
in O +
hMLH1 B-Gene +
in O +
the O +
sub O -
- O -
cohort O +
are O +
scattered O +
along O +
the O +
whole O +
genomic O +
region O +
of O +
the O +
gene O -
. O +

Only O +
three O +
polymorphic O +
variants O +
were O +
identified O +
in O +
hMSH2 B-Gene -
. O +

Two O +
of O +
these O +
variants O +
demonstrated O +
high O +
LD O -
. O +

They O +
are O +
positioned O +
widely O +
apart O +
and O +
thus O +
cover O +
a O +
large O +
area O +
of O +
the O +
genomic O +
region O +
of O +
hMSH2 B-Gene -
. O +

The O +
low O +
LD O +
of O +
the O +
third O +
polymorphic O +
variant O +
in O +
hMSH2 B-Gene +
might O +
be O +
due O +
to O +
the O +
low O +
minor O +
allele O +
frequency O +
of O +
the O +
variant O -
. O +

The O +
high O +
LD O +
in O +
the O +
genomic O +
regions O +
covering O +
the O +
two O +
genes O +
indicates O +
that O +
common O +
genetic O +
variants O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
in O +
general O +
are O +
not O +
involved O +
in O +
the O +
development O +
of O +
sporadic O +
CRC O +
in O +
the O +
Danish O +
population O -
. O +

LD O +
plots O +
of O +
the O +
sub O -
- O -
cohort O +
in O +
the O +
genomic O +
regions O +
covering O +
hMLH1 B-Gene +
( O -
A O -
) O +
and O +
hMSH2 B-Gene +
( O -
B O -
) O -
. O +

Each O +
square O +
indicates O +
the O +
level O +
of O +
LD O +
between O +
two O +
variants O -
. O +

The O +
colours O +
are O +
defined O +
as O -
: O +
red O +
( O -
high O +
LD O -
) O -
, O +
LOD O +
≥ O +
2 O +
and O +
D O -
' O +
= O +
1 O -
; O +
blue O -
, O +
LOD<2 O +
and O +
D O -
' O +
= O +
1 O -
; O +
white O -
, O +
LOD<2 O +
and O +
D'<1 O -
. O +

The O +
top O +
of O +
the O +
figure O +
shows O +
the O +
genomic O +
position O +
and O +
the O +
known O +
genes O +
in O +
the O +
region O -
. O +

In O +
silico O +
characterization O +
of O +
the O +
variants O +
In O +
silico O +
functional O +
characterization O +
of O +
the O +
included O +
missense O +
variants O +
was O +
performed O +
using O +
SIFT O +
[ O -
27 O -
] O -
, O +
PolyPhen O +
[ O -
28 O -
] O +
and O +
PMUT O +
[ O -
29 O -
] O -
. O +

Nine O +
of O +
the O +
missense O +
mutations O +
had O +
previously O +
been O +
characterized O +
at O +
the O +
functional O +
level O +
using O +
different O +
in O +
vitro O +
assays O +
( O -
references O +
in O +
Table O +
5 O -
) O -
. O +

To O +
test O +
the O +
accuracy O +
of O +
the O +
in O +
silico O +
functional O +
predictions O +
we O +
compared O +
the O +
results O +
of O +
the O +
in O +
silico O +
analyses O +
with O +
the O +
results O +
of O +
the O +
in O +
vitro O +
functional O +
analyses O +
( O -
Table O +
5 O -
) O -
. O +

Concordance O +
between O +
predictions O +
of O +
all O +
the O +
in O +
silico O +
algorithms O +
and O +
the O +
results O +
of O +
the O +
in O +
vitro O +
functional O +
analyses O +
were O +
found O +
for O +
3 O -
/ O -
9 O +
missense O +
variants O +
i.e. O +
MLH1 B-Gene +
p. O +

Val219Ile O -
, O +
p. O +

Ser406Asn O +
and O +
p. O +

Pro648Ser O -
. O +

None O +
of O +
the O +
in O +
silico O +
algorithms O +
were O +
more O +
accurate O +
in O +
their O +
predictions O +
than O +
the O +
others O +
when O +
compared O +
to O +
the O +
results O +
of O +
the O +
in O +
vitro O +
functional O +
analysis O -
. O +

The O +
predictions O +
of O +
the O +
SIFT O +
and O +
PolyPhen O +
algorithms O +
were O +
frequently O +
similar O +
and O +
often O +
differed O +
from O +
the O +
prediction O +
made O +
by O +
PMUT O -
. O +

The O +
above O +
results O +
demonstrate O +
the O +
importance O +
of O +
the O +
use O +
of O +
in O +
vitro O +
functional O +
analysis O +
for O +
the O +
characterization O +
of O +
missense O +
variants O +
identified O +
in O +
individuals O +
with O +
hereditary O +
CRC O +
such O +
as O +
HNPCC O -
. O +

In O +
silico O +
functional O +
characterization O +
of O +
the O +
missense O +
variants O +
NA O -
, O +
not O +
available O +
Danish O +
variants O +
that O +
have O +
not O +
been O +
described O +
previously O +
are O +
in O +
bold O +
There O +
was O +
no O +
overall O +
concordance O +
between O +
the O +
in O +
silico O +
functional O +
predictions O +
of O +
the O +
four O +
unclassified O +
Danish O +
variants O +
i.e. O +
MLH1 B-Gene +
p. O +

Glu460Ala O -
, O +
and O +
p. O +

Ile563Met O +
and O +
MSH2 B-Gene +
p. O +

Met688Val O +
and O +
p. O +

Ala848Ser O +
( O -
Table O +
5 O -
. O -
) O -
. O +

The O +
MLH1 B-Gene +
p. O +

Glu460Ala O +
variant O +
changes O +
a O +
non O -
- O -
conserved O +
amino O +
acid O +
situated O +
in O +
the O +
central O +
region O +
of O +
MLH1 B-Gene +
( O -
Table O +
5 O -
) O -
. O +

No O +
defined O +
functional O +
domain O +
has O +
been O +
assigned O +
to O +
this O +
region O +
of O +
the O +
protein O +
[ O -
34 O -
] O -
. O +

The O +
MLH1 B-Gene +
p. O +

Ile563Met O +
variant O +
changes O +
a O +
non O -
- O -
conserved O +
amino O +
acid O +
situated O +
in O +
the O +
PMS2 B-Gene +
interaction O +
domain O +
of O +
MLH1 B-Gene +
( O -
Table O +
5 O -
) O +
[ O -
34 O -
] O -
. O +

The O +
two O +
variants O +
in O +
MSH2 B-Gene +
i.e. O +
p. O +

Met688Val O +
and O +
p. O +

Ala848Ser O +
result O +
in O +
the O +
elimination O +
of O +
conserved O +
amino O +
acids O +
in O +
the O +
Walker O +
A O +
motif O -
, O +
required O +
for O +
ATP O +
binding O +
and O +
the O +
MutL O +
homologue O +
interaction O +
domain O -
, O +
respectively O +
( O -
Table O +
5 O +
and O +
Figure O +
2 O -
) O +
[ O -
35 O -
] O -
. O +

All O +
the O +
above O +
characteristics O +
of O +
the O +
missense O +
variants O +
indicate O +
that O +
at O +
least O +
the O +
two O +
missense O +
variants O +
in O +
MSH2 B-Gene +
might O +
be O +
disease O +
causing O +
mutations O -
. O +

However O -
, O +
further O +
functional O +
analyses O +
are O +
needed O +
before O +
any O +
final O +
conclusions O +
can O +
be O +
drawn O -
. O +

Phylogeny O +
of O +
the O +
MSH2 B-Gene +
Met688Val O +
and O +
Ala848Ser O +
variants O -
. O +

Multiple O +
sequence O +
alignment O +
of O +
the O +
hMSH2 B-Gene +
polypeptide O +
sequence O +
and O +
orthologues O +
from O +
other O +
species O +
were O +
generated O +
using O +
the O +
ClustalW O +
algorithm O +
[ O -
31 O -
] O -
. O +

The O +
following O +
polypeptide O +
sequences O +
were O +
used O +
in O +
the O +
alignment O -
: O +
P43246 O +
( O -
Human O -
; O +
Homo O +
sapiens O -
) O -
, O +
CAA57049 O +
( O -
Mouse O -
; O +
Mus O +
musculus O -
) O -
, O +
S53609 O +
( O -
Frog O -
; O +
Xenopus O +
laevis O -
) O -
, O +
XP O +
426110 O +
( O -
Chicken O -
; O +
Gallus O +
gallus O -
) O +
and O +
CAB42554 O +
( O -
Maize O -
; O +
Zea O +
mays O -
) O -
. O +

The O +
putative O +
role O +
of O +
all O +
35 O +
variants O +
in O +
pre O -
- O -
mRNA O +
splicing O +
was O +
analyzed O +
using O +
SNAP O +
[ O -
30 O -
] O -
. O +

These O +
analyses O +
showed O +
that O +
several O +
of O +
the O +
variants O +
potentially O +
either O +
abolish O +
or O +
introduce O +
Exon O +
Splicing O +
Enhancers O +
( O -
ESEs O -
) O -
( O -
data O +
not O +
shown O -
) O -
. O +

Discussion O +
Identification O +
of O +
missense O -
, O +
silent O +
and O +
non O -
- O -
coding O +
variants O +
in O +
genes O +
involved O +
in O +
hereditary O +
diseases O +
always O +
raises O +
the O +
intriguing O +
question O +
whether O +
these O +
variants O +
are O +
the O +
disease O +
causing O +
mutations O +
in O +
the O +
family O -
/ O -
families O +
where O +
they O +
are O +
identified O -
. O +

Alternatively O -
, O +
they O +
may O +
be O +
common O +
variants O +
causing O +
a O +
slight O +
increase O +
in O +
sporadic O +
disease O +
susceptibility O +
in O +
the O +
general O +
population O +
or O +
simple O +
neutral O +
variants O +
that O +
are O +
not O +
involved O +
in O +
disease O +
development O -
. O +

Missense O -
, O +
silent O +
and O +
non O -
- O -
coding O +
variants O +
are O +
identified O +
frequently O +
in O +
MMR B-Gene +
genes O +
( O -
e.g. O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene -
) O +
in O +
families O +
fulfilling O +
the O +
Amsterdam O +
II O +
criteria O -
. O +

Functional O +
analyses O +
have O +
shown O +
that O +
some O +
of O +
the O +
missense O +
variants O +
identified O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
result O +
in O +
reduced O +
MMR B-Gene +
activity O +
and O +
it O +
has O +
therefore O +
been O +
suggested O +
that O +
the O +
decreased O +
efficiency O +
of O +
DNA O +
MMR B-Gene +
could O +
lead O +
to O +
increased O +
cancer O +
susceptibility O +
[ O -
8 O -
- O -
11 O -
] O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
have O +
used O +
a O +
case O -
- O -
cohort O +
design O +
to O +
elucidate O +
the O +
possible O +
association O +
between O +
35 O +
variants O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene -
, O +
either O +
individually O +
or O +
as O +
pairs O -
, O +
and O +
the O +
risk O +
of O +
sporadic O +
CRC O +
in O +
the O +
Danish O +
population O -
. O +

The O +
Danish O +
Diet O -
, O +
Cancer O +
and O +
Health O +
( O -
DCH O -
) O +
cohort O +
is O +
large O -
, O +
population O +
based O +
and O +
genetically O +
homogeneous O +
[ O -
20 O -
] O -
. O +

The O +
sub O -
- O -
cohort O +
used O +
in O +
the O +
comparisons O +
was O +
selected O +
randomly O +
from O +
the O +
same O +
cohort O +
that O +
gave O +
rise O +
to O +
the O +
cases O +
with O +
sporadic O +
CRC O -
; O +
selection O +
bias O +
is O +
thus O +
unlikely O -
. O +

The O +
cases O +
and O +
the O +
individuals O +
in O +
the O +
sub O -
- O -
cohort O +
have O +
been O +
in O +
the O +
study O +
equally O +
long O +
time O +
and O +
have O +
approximately O +
the O +
same O +
mean O +
age O +
( O -
Table O +
1 O -
) O -
. O +

We O +
estimated O +
that O +
our O +
study O +
would O +
be O +
able O +
to O +
detect O +
a O +
disease O +
susceptibility O +
locus O +
with O +
an O +
odds O +
ratio O +
( O -
OR O -
) O +
of O +
2.5 O +
with O +
a O +
power O +
of O +
0.82 O -
, O +
if O +
the O +
frequency O +
of O +
the O +
disease O +
causing O +
genotype O +
is O +
0.05 O -
, O +
and O +
a O +
power O +
of O +
0.77 O +
if O +
the O +
OR O +
is O +
2.0 O +
and O +
the O +
disease O +
causing O +
genotype O +
has O +
a O +
frequency O +
of O +
0.1 O -
. O +

Consequently O -
, O +
common O +
disease O +
causing O +
alleles O +
of O +
moderate O +
effect O +
would O +
most O +
likely O +
not O +
be O +
missed O +
in O +
the O +
present O +
study O -
. O +

To O +
our O +
knowledge O -
, O +
the O +
frequencies O +
of O +
a O +
large O +
number O +
of O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
variants O +
and O +
their O +
association O +
with O +
sporadic O +
CRC O +
have O +
never O +
been O +
analyzed O +
in O +
a O +
large O +
well O +
defined O +
Caucasian O +
population O -
. O +

A O +
previously O +
published O +
case O -
- O -
control O +
study O +
have O +
demonstrated O +
no O +
association O +
between O +
MMR B-Gene +
gene O +
variants O +
and O +
the O +
susceptibility O +
to O +
sporadic O +
ovarian O +
cancer O +
[ O -
36 O -
] O -
. O +

In O +
addition O -
, O +
previous O +
association O +
studies O +
performed O +
in O +
Chinese O +
and O +
Korean O +
populations O +
did O +
not O +
find O +
any O +
association O +
between O +
variants O +
in O +
MMR B-Gene +
genes O +
and O +
sporadic O +
CRC O +
[ O -
17,18 O -
] O -
. O +

The O +
MLH1 B-Gene +
c.415 O +
G O -
> O -
C O +
( O -
p. O +

Asp132His O -
) O +
variant O +
has O +
been O +
shown O +
to O +
be O +
associated O +
with O +
susceptibility O +
to O +
sporadic O +
CRC O +
in O +
an O +
Israeli O +
population O -
, O +
although O +
the O +
CRCs O +
associated O +
with O +
the O +
variant O +
usually O +
are O +
not O +
MSI O +
[ O -
19 O -
] O -
. O +

However O -
, O +
the O +
p. O +

Asp132His O +
variant O +
was O +
present O +
but O +
not O +
associated O +
with O +
sporadic O +
CRC O +
in O +
a O +
Chinese O +
population O +
[ O -
17 O -
] O -
. O +

Furthermore O -
, O +
the O +
variant O +
was O +
not O +
detected O +
in O +
a O +
population O +
of O +
more O +
1,100 O +
Americans O +
with O +
HNPCC O -
- O -
related O +
cancers O +
[ O -
37 O -
] O -
. O +

The O +
p. O +

Asp132His O +
variant O +
was O +
not O +
polymorphic O +
in O +
the O +
Danish O +
cohort O +
of O +
familiar O +
CRC O +
analyzed O +
in O +
the O +
present O +
study O +
( O -
data O +
not O +
shown O -
) O -
. O +

The O +
frequency O +
of O +
the O +
variant O +
was O +
not O +
analyzed O +
in O +
the O +
cohort O +
of O +
cases O +
with O +
sporadic O +
CRC O +
nor O +
in O +
the O +
sub O -
- O -
cohort O -
. O +

However O -
, O +
due O +
to O +
high O +
LD O +
in O +
the O +
genomic O +
region O +
of O +
hMLH1 B-Gene +
this O +
variant O -
, O +
if O +
present O +
in O +
the O +
Danish O +
population O -
, O +
is O +
most O +
likely O +
not O +
associated O +
with O +
sporadic O +
CRC O -
. O +

Conclusion O +
More O +
than O +
half O +
of O +
the O +
analysed O +
variants O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
were O +
not O +
polymorphic O +
in O +
the O +
analysed O +
cohort O -
. O +

The O +
position O +
of O +
some O +
of O +
these O +
rare O +
variants O +
in O +
conserved O +
regions O +
of O +
hMSH2 B-Gene +
might O +
indicate O +
an O +
association O +
to O +
the O +
development O +
of O +
colorectal O +
cancer O +
in O +
the O +
families O +
where O +
they O +
were O +
identified O +
originally O -
. O +

This O +
hypothesis O +
needs O +
to O +
be O +
investigated O +
further O -
, O +
using O +
segregation O +
and O +
functional O +
analysis O -
. O +

None O +
of O +
the O +
polymorphic O +
variants O +
were O +
highly O +
associated O +
with O +
CRC O +
in O +
the O +
Danish O +
population O -
. O +

In O +
addition O -
, O +
we O +
demonstrated O +
high O +
LD O +
in O +
the O +
genomic O +
regions O +
covering O +
the O +
two O +
genes O -
. O +

Consequently O -
, O +
we O +
conclude O +
that O +
common O +
genetic O +
variants O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
in O +
general O +
are O +
not O +
involved O +
in O +
the O +
development O +
of O +
sporadic O +
CRC O +
in O +
the O +
Danish O +
population O -
. O +

Background O +
The O +
sib O +
pair O +
design O +
has O +
been O +
widely O +
used O +
in O +
human O +
studies O +
for O +
mapping O +
genes O +
that O +
affect O +
both O +
quantitative O +
and O +
dichotomous O +
traits O -
. O +

The O +
objective O +
of O +
sibling O +
studies O +
is O +
to O +
determine O +
whether O +
the O +
siblings O +
( O -
or O +
other O +
close O +
relatives O -
) O +
tend O +
to O +
express O +
the O +
same O +
disease O +
phenotype O +
( O -
or O +
similar O +
values O +
of O +
a O +
quantitative O +
trait O -
) O +
when O +
they O +
share O +
a O +
commonly O +
inherited O +
genomic O +
segment O +
measured O +
by O +
genetic O +
markers O -
. O +

Because O +
two O +
loci O +
located O +
close O +
together O +
on O +
the O +
same O +
chromosome O +
tend O +
to O +
be O +
inherited O +
together O -
, O +
sibs O +
who O +
have O +
inherited O +
an O +
allele O +
predisposing O +
them O +
to O +
disease O +
will O +
also O +
inherit O +
a O +
variety O +
of O +
other O +
genetic O +
characteristics O +
located O +
in O +
the O +
same O +
genomic O +
segment O +
as O +
the O +
gene O +
responsible O +
for O +
disease O +
susceptibility O -
. O +

By O +
examining O -
, O +
in O +
a O +
set O +
of O +
pairs O +
of O +
affected O +
sibs O -
, O +
the O +
degree O +
of O +
sharing O +
of O +
genetic O +
marker O +
alleles O +
located O +
throughout O +
the O +
genome O -
, O +
researchers O +
can O +
identify O +
regions O +
that O +
are O +
shared O +
more O +
often O +
than O +
would O +
be O +
expected O +
by O +
chance O -
. O +

This O +
excess O +
allele O +
sharing O +
constitutes O +
the O +
statistical O +
evidence O +
for O +
linkage O +
between O +
the O +
shared O +
markers O +
and O +
putative O +
disease O +
susceptibility O +
loci O -
. O +

The O +
popularity O +
of O +
the O +
sib O -
- O -
pair O +
and O +
related O +
small O -
- O -
family O +
study O +
designs O +
reflects O +
several O +
attractive O +
characteristics O -
. O +

For O +
highly O +
penetrant O +
alleles O -
, O +
extended O +
families O +
can O +
often O +
be O +
recruited O +
and O +
so O +
provide O +
a O +
powerful O +
source O +
of O +
information O +
for O +
disease O +
localization O +
and O +
fine O +
mapping O -
. O +

However O -
, O +
for O +
complex O +
diseases O +
that O +
result O +
from O +
interactions O +
among O +
loci O +
or O +
that O +
result O +
from O +
both O +
genetic O +
and O +
environmental O +
effects O -
, O +
large O +
pedigrees O +
that O +
include O +
multiple O +
affected O +
individuals O +
may O +
be O +
rare O +
and O +
may O +
not O +
reflect O +
a O +
single O +
etiologically O -
- O -
related O +
genetic O +
factor O -
. O +

Since O +
the O +
pioneering O +
work O +
of O +
Haseman O +
and O +
Elston O +
[ O -
1 O -
] O +
on O +
quantitative O +
trait O +
mapping O -
, O +
many O +
alternative O +
approaches O +
and O +
extensions O +
to O +
the O +
design O +
have O +
been O +
developed O +
to O +
handle O +
multilocus O +
data O +
[ O -
2 O -
] O -
, O +
extended O +
relative O +
pairs O +
[ O -
3 O -
- O -
6 O -
] O -
, O +
consideration O +
of O +
environmental O +
risk O +
factors O +
[ O -
7 O -
- O -
9 O -
] O -
, O +
and O +
other O +
situations O +
encountered O +
in O +
studies O +
of O +
complex O +
diseases O -
. O +

In O +
concept O -
, O +
for O +
the O +
study O +
of O +
complex O +
diseases O -
, O +
the O +
design O +
and O +
execution O +
of O +
a O +
sib O -
- O -
pair O +
study O +
is O +
simple O -
. O +

Straightforward O +
power O +
calculations O +
( O -
e.g. O +
[ O -
10 O -
] O -
) O +
suggest O +
that O +
adequate O +
power O +
to O +
detect O +
linkage O +
might O +
be O +
obtained O +
with O +
relatively O +
modest O +
sample O +
sizes O +
even O +
for O +
complex O -
, O +
low O -
- O -
penetrance O +
susceptibility O +
syndromes O -
. O +

Readily O +
available O +
software O +
packages O +
[ O -
11 O -
] O +
obtain O +
exact O +
IBD O +
sharing O +
distributions O +
and O +
compute O +
linkage O +
tests O +
using O +
exact O +
methods O +
without O +
requiring O +
explicit O +
specification O +
of O +
an O +
inheritance O +
model O -
, O +
penetrance O +
function O -
, O +
or O +
disease O +
allele O +
frequencies O -
. O +

Numerous O +
authors O +
have O +
observed O +
that O +
nonparametric O +
or O +
model O -
- O -
free O +
linkage O +
statistics O -
, O +
in O +
spite O +
of O +
their O +
name O -
, O +
make O +
hidden O +
assumptions O +
about O +
mode O +
of O +
inheritance O +
and O +
penetrance O +
( O -
e.g. O -
, O +
[ O -
12 O -
- O -
14 O -
] O -
) O +
which O +
determine O +
the O +
situations O +
in O +
which O +
they O +
become O +
most O +
powerful O -
. O +

Nevertheless O -
, O +
these O +
methods O +
have O +
been O +
highly O +
popular O +
because O +
of O +
the O +
ease O +
in O +
implementing O +
them O +
and O +
in O +
interpreting O +
the O +
results O -
, O +
as O +
well O +
as O +
the O +
perception O +
that O +
they O +
remain O +
powerful O +
across O +
a O +
broad O +
spectrum O +
of O +
underlying O +
genetic O +
mechanisms O -
. O +

The O +
modern O +
approaches O +
to O +
identifying O +
new O +
genes O +
associated O +
with O +
disease O +
allow O +
very O +
fine O +
analysis O +
of O +
associaton O +
and O +
can O +
be O +
performed O +
in O +
population O +
based O +
case O -
- O -
control O +
studies O -
. O +

However O -
, O +
the O +
sibpair O +
design O +
is O +
still O +
valuable O +
because O +
it O +
requires O +
few O +
assumptions O +
other O +
than O +
acceptably O +
high O +
penetrance O +
to O +
identify O +
genetic O +
loci O -
. O +

There O +
remains O +
skepticism O +
about O +
relying O +
solely O +
on O +
genome O -
- O -
wide O -
- O -
association O +
studies O +
[ O -
15 O -
] O -
, O +
and O +
sib O -
- O -
pair O +
studies O +
continue O +
to O +
be O +
utilized O +
and O +
published O +
in O +
the O +
literature O +
[ O -
16 O -
- O -
18 O -
] O -
. O +

While O +
association O +
based O +
studies O +
have O +
provided O +
many O +
novel O +
insights O +
into O +
the O +
genetic O +
architecture O +
of O +
complex O +
diseases O -
, O +
they O +
require O +
that O +
linkage O +
disequilibrium O +
is O +
present O +
between O +
genetic O +
markers O +
and O +
disease O +
causing O +
variants O -
. O +

Such O +
a O +
requirement O +
might O +
not O +
be O +
met O +
for O +
diseases O +
that O +
are O +
due O +
to O +
susceptibility O +
loci O +
undergoing O +
recurrent O +
mutations O +
[ O -
19 O -
] O +
or O +
for O +
genomic O +
regions O +
that O +
show O +
copy O +
number O +
variation O +
and O +
so O +
do O +
not O +
yield O +
reliable O +
SNP O +
data O +
without O +
the O +
implementation O +
of O +
specialized O +
procedures O +
because O +
of O +
deviations O +
from O +
Hardy O -
- O -
Weinberg O +
disequilibrium O +
[ O -
20 O -
] O -
. O +

Sibships O +
and O +
small O +
families O +
are O +
relatively O +
easy O +
to O +
identify O +
and O +
recruit O +
( O -
compared O +
with O +
designs O +
that O +
make O +
use O +
of O +
large O +
multiplex O +
families O -
) O -
. O +

Moreover O -
, O +
a O +
number O +
of O +
familial O +
disease O +
registries O +
and O +
high O -
- O -
risk O +
clinics O +
have O +
been O +
established O +
and O +
have O +
enrolled O +
substantial O +
numbers O +
of O +
sib O +
pairs O +
and O +
other O +
groupings O +
of O +
affected O +
relatives O -
, O +
so O +
that O +
in O +
many O +
cases O +
recruitment O +
has O +
already O +
occurred O -
. O +

In O +
practice O -
, O +
however O -
, O +
the O +
design O +
of O +
an O +
effective O +
small O -
- O -
family O +
linkage O +
study O +
requires O +
more O +
care O +
than O +
is O +
immediately O +
apparent O -
, O +
particularly O +
for O +
complex O +
diseases O +
such O +
as O +
cancer O -
, O +
in O +
which O +
late O +
onset O -
, O +
incomplete O +
penetrance O -
, O +
large O +
numbers O +
of O +
phenocopies O -
, O +
gene O -
- O -
environment O +
interaction O -
, O +
and O +
locus O +
heterogeneity O +
must O +
be O +
anticipated O -
. O +

The O +
purpose O +
of O +
this O +
paper O +
is O +
to O +
evaluate O +
the O +
impact O +
of O +
choices O +
of O +
family O +
sampling O +
strategies O +
in O +
selecting O +
the O +
design O +
of O +
a O +
study O +
aimed O +
at O +
identifying O +
novel O +
genetic O +
factors O +
that O +
predispose O +
individuals O +
to O +
colon O +
cancer O -
. O +

The O +
study O +
is O +
a O +
collaborative O +
effort O +
by O +
two O +
National O +
Cancer O +
Institute O -
- O -
sponsored O +
consortia O +
investigating O +
the O +
genetics O +
of O +
cancer O -
: O +
the O +
Cancer O +
Genetics O +
Network O +
( O -
CGN O -
) O +
and O +
Cooperative O +
Family O +
Registry O +
for O +
Colon O +
Cancer O +
Studies O +
( O -
CFRCCS O -
) O -
. O +

All O +
population O +
based O +
studies O +
of O +
colon O +
cancer O +
have O +
documented O +
its O +
strong O +
familiality O +
[ O -
21 O -
- O -
24 O -
] O -
. O +

Historical O +
cohort O +
studies O +
show O +
an O +
approximately O +
2.5 O +
fold O +
increased O +
risk O +
for O +
colorectal O +
cancer O +
in O +
the O +
first O +
degree O +
relatives O +
of O +
colorectal O +
cancer O +
cases O +
compared O +
to O +
first O +
degree O +
relatives O +
of O +
unaffected O +
controls O +
[ O -
25 O -
- O -
28 O -
] O -
. O +

Nongenetic O +
factors O +
specifically O +
implicated O +
as O +
protecting O +
individuals O +
from O +
risk O +
for O +
colon O +
cancer O +
include O +
use O +
of O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drugs O -
, O +
a O +
diet O +
rich O +
in O +
leafy O +
vegetables O -
, O +
and O +
exercise O +
[ O -
29 O -
- O -
34 O -
] O -
. O +

Although O +
these O +
environmental O +
risk O +
factors O +
have O +
been O +
identified O +
as O +
substantially O +
affecting O +
the O +
risk O +
for O +
colon O +
cancer O +
they O +
display O +
only O +
a O +
weak O +
correlation O +
in O +
family O +
members O -
, O +
which O +
is O +
insufficient O +
to O +
explain O +
the O +
high O +
familial O +
risk O +
[ O -
35 O -
] O -
. O +

Moreover O -
, O +
Khoury O -
, O +
et O +
al. O +
[ O -
36 O -
] O +
point O +
out O +
that O +
both O +
the O +
correlations O +
of O +
exposure O +
among O +
siblings O +
and O +
relative O +
risks O +
due O +
to O +
shared O +
exposures O +
need O +
to O +
be O +
very O +
large O +
in O +
order O +
to O +
produce O +
observable O +
increases O +
in O +
relative O +
risk O +
to O +
siblings O +
of O +
cases O -
. O +

It O +
seems O +
unlikely O +
that O +
such O +
a O +
combination O +
of O +
highly O +
correlated O +
exposures O +
and O +
large O +
relative O +
risk O +
exists O +
for O +
colorectal O +
cancer O -
. O +

The O +
basic O +
assumption O +
for O +
our O +
studies O +
was O +
thus O +
a O +
two O -
- O -
locus O +
non O -
- O -
interacting O +
model O -
, O +
with O +
a O +
rare O +
high O -
- O -
penetrance O +
gene O +
( O -
e.g. O +
hMSH2 B-Gene -
/ O -
hMLH1 B-Gene +
for O +
HNPCC O +
in O +
the O +
case O +
of O +
colon O +
cancer O -
) O -
, O +
unlinked O +
to O +
the O +
search O +
region O +
for O +
new O +
loci O +
and O +
a O +
more O +
common O +
but O +
less O +
penetrant O +
gene O +
being O +
sought O +
by O +
the O +
linkage O +
analysis O -
. O +

We O +
also O +
evaluated O +
the O +
effect O +
of O +
experimental O +
elimination O +
of O +
a O +
previously O -
- O -
known O +
predisposition O +
syndrome O +
such O +
as O +
HNPCC O -
. O +

We O +
investigated O +
both O +
the O +
power O +
and O +
the O +
relative O +
efficiency O +
of O +
different O +
designs O +
under O +
a O +
range O +
of O +
assumptions O +
about O +
the O +
contribution O +
of O +
an O +
additional O +
unlinked O +
locus O -
. O +

The O +
single O +
unlinked O +
locus O +
with O +
varying O +
allele O +
frequency O +
and O +
penetrance O +
that O +
we O +
simulated O +
could O +
also O +
approximate O +
the O +
effects O +
of O +
a O +
few O +
unlinked O +
noninteracting O +
alleles O -
. O +

Although O +
our O +
efforts O +
focused O +
on O +
a O +
study O +
of O +
colorectal O +
cancer O -
, O +
the O +
general O +
issues O +
identified O +
above O +
are O +
similar O +
to O +
considerations O +
encountered O +
in O +
the O +
design O +
of O +
genetic O +
studies O +
of O +
other O +
common O +
conditions O +
such O +
as O +
other O +
cancers O -
, O +
diabetes O -
, O +
hypertension O +
and O +
many O +
other O +
chronic O +
diseases O +
that O +
arise O +
from O +
both O +
environmental O +
and O +
genetic O +
causes O -
. O +

Allele O +
Frequency O +
and O +
Penetrance O +
Most O +
of O +
the O +
models O +
we O +
studied O +
include O +
a O +
two O -
- O -
locus O +
noninteracting O +
model O +
for O +
which O +
neither O +
locus O +
had O +
been O +
molecularly O +
determined O +
and O +
only O +
one O +
was O +
linked O +
to O +
the O +
markers O +
under O +
consideration O -
. O +

The O +
unlinked O +
locus O +
varied O +
in O +
allele O +
frequency O +
and O +
penetrance O -
. O +

In O +
some O +
simulations O +
the O +
unlinked O +
locus O +
had O +
no O +
effect O +
on O +
disease O -
, O +
but O +
in O +
others O +
the O +
penetrance O +
and/or O +
allele O +
frequency O +
were O +
assumed O +
to O +
be O +
greater O +
than O +
that O +
of O +
the O +
linked O +
locus O -
. O +

The O +
two O +
loci O +
contributed O +
multiplicatively O +
in O +
a O +
logistic O +
model O +
for O +
penetrance O +
of O +
the O +
form O +
logit O +
Pr O -
( O -
Y O +
= O +
1|G1 O -
, O +
G2 O -
) O +
= O +
α O +
+ O +
β1Dom O -
( O -
G1 O -
) O +
+ O +
β2Dom O -
( O -
G2 O -
) O +
where O +
Dom O -
( O -
G O -
) O +
indicates O +
a O +
dominant O +
coding O +
of O +
the O +
genotype O -
, O +
i.e. O +
presence O +
of O +
one O +
or O +
two O +
copies O +
of O +
the O +
deleterious O +
allele O +
identically O +
increases O +
the O +
risk O +
of O +
the O +
disease O -
. O +

We O +
also O +
simulated O +
some O +
situations O +
in O +
which O +
only O +
one O +
autosomal O +
dominant O +
predisposition O +
syndrome O +
was O +
present O +
in O +
the O +
population O -
. O +

In O +
the O +
U.S. O +
population O -
, O +
lifetime O +
risks O +
for O +
colorectal O +
cancer O +
are O +
approximately O +
2.5–5 O +
percent O +
[ O -
45 O -
] O -
. O +

In O +
the O +
context O +
of O +
a O +
high O -
- O -
risk O +
cancer O +
clinic O -
, O +
however O -
, O +
patients O +
are O +
frequently O +
seen O +
at O +
younger O +
ages O -
, O +
and O +
hence O +
the O +
background O +
risk O +
of O +
colorectal O +
cancer O +
among O +
sibships O +
ascertained O +
through O +
high O -
- O -
risk O +
clinics O +
is O +
considerably O +
less O +
than O +
5 O -
% O -
. O +

We O +
set O +
the O +
natural O +
log O +
of O +
the O +
background O +
rate O +
of O +
colorectal O +
cancer O +
in O +
our O +
simulations O +
to O +
α O +
= O +
-4 O -
, O +
so O +
that O +
the O +
overall O +
population O +
prevalence O +
of O +
disease O +
was O +
approximately O +
2 O -
% O -
. O +

Objective O +
estimates O +
of O +
allele O +
frequencies O +
and O +
relative O +
risks O +
for O +
unknown O +
mutations O +
are O +
not O +
available O -
, O +
so O +
we O +
chose O +
values O +
that O +
were O +
consistent O +
both O +
with O +
frequencies O +
of O +
known O +
mutations O +
[ O -
46,47 O -
] O +
and O +
with O +
population O +
attributable O +
risk O +
estimates O +
for O +
familial O +
colorectal O +
cancer O +
[ O -
24,48 O -
] O -
. O +

As O +
an O +
example O -
, O +
with O +
an O +
allele O +
frequency O +
of O +
q1 O +
= O +
0.003 O +
and O +
a O +
log O +
relative O +
risk O +
of O +
β1 O +
= O +
3 O +
( O -
relative O +
risk O +
= O +
20.1 O -
) O -
, O +
q2 O +
= O +
0.001 O +
and O +
β2 O +
= O +
4.6 O +
( O -
relative O +
risk O +
= O +
99.5 O -
) O -
, O +
the O +
resulting O +
penetrances O +
are O +
0.018 O +
for O +
carriers O +
of O +
neither O +
mutation O -
, O +
0.268 O +
for O +
carriers O +
of O +
a O +
mutation O +
in O +
the O +
linked O +
gene O -
, O +
0.646 O +
for O +
carriers O +
of O +
a O +
mutation O +
in O +
the O +
unlinked O +
gene O -
, O +
and O +
0.973 O +
for O +
carriers O +
of O +
both O +
mutations O -
. O +

The O +
linked O +
locus O +
accounts O +
for O +
approximately O +
7.2 O -
% O +
of O +
colorectal O +
cancers O +
and O +
the O +
unlinked O +
locus O +
accounts O +
for O +
approximately O +
6.0 O -
% O +
of O +
colorectal O +
cancers O -
. O +

Table O +
1 O +
lists O +
the O +
parameters O +
that O +
we O +
used O +
in O +
combinatios O +
for O +
the O +
simulations O -
, O +
along O +
with O +
the O +
values O +
we O +
assigned O +
in O +
various O +
simulations O -
. O +

Parameters O +
employed O +
in O +
simulations O +
Parameters O +
and O +
parameter O +
values O +
employed O +
in O +
the O +
simulations O +
Sampling O +
Plans O +
The O +
primary O +
concern O +
in O +
the O +
design O +
of O +
CFRCCS O -
- O -
CGN O +
colon O +
cancer O +
study O +
is O +
to O +
maximize O +
the O +
relative O +
efficiency O +
per O +
genotype O -
, O +
i.e. O -
, O +
to O +
find O +
the O +
combination O +
of O +
family O +
structures O +
and O +
numbers O +
of O +
families O +
that O +
will O +
produce O +
the O +
greatest O +
power O +
for O +
a O +
given O +
number O +
of O +
genotypings O -
. O +

While O +
the O +
number O +
of O +
ASPs O +
available O +
for O +
study O +
will O +
affect O +
the O +
power O +
of O +
the O +
study O -
, O +
at O +
the O +
time O +
when O +
we O +
were O +
designing O +
the O +
study O -
, O +
approximately O +
425 O +
ASPs O +
( O -
plus O +
about O +
400 O +
other O +
relative O +
pairs O -
) O +
were O +
already O +
available O +
from O +
the O +
combined O +
CFRCCS O +
resources O -
, O +
and O +
samples O +
were O +
already O +
available O +
from O +
many O +
of O +
the O +
potential O +
subjects O -
. O +

An O +
additional O +
500 O -
+ O +
sib O +
pairs O +
were O +
anticipated O +
from O +
the O +
CGN O +
sites O -
. O +

Thus O -
, O +
the O +
primary O +
constraint O +
was O +
the O +
total O +
cost O +
of O +
genotyping O +
in O +
a O +
full O +
genome O +
scan O -
, O +
not O +
the O +
number O +
of O +
families O -
. O +

We O +
therefore O +
chose O +
to O +
concentrate O +
on O +
four O +
main O +
questions O +
of O +
efficiency O -
: O +
1 O -
) O +
whether O +
( O -
and O +
how O +
many O -
) O +
unaffected O +
sibs O +
should O +
be O +
genotyped O -
, O +
2 O -
) O +
how O +
critical O +
the O +
absence O +
of O +
parental O +
genotypes O +
is O +
to O +
the O +
efficiency O +
of O +
the O +
analysis O -
; O +
3 O -
) O +
the O +
relative O +
loss O +
in O +
efficiency O +
of O +
genotyping O +
spouses O +
and O +
offspring O +
of O +
a O +
deceased O +
affected O +
sib O -
, O +
and O +
4 O -
) O +
how O +
different O +
strategies O +
for O +
addressing O +
genetic O +
heterogeneity O +
might O +
affect O +
these O +
efficiency O +
comparisons O -
. O +

Although O +
our O +
primary O +
interest O +
was O +
in O +
the O +
relative O +
efficiency O +
per O +
genotype O -
, O +
we O +
also O +
wished O +
to O +
observe O +
the O +
effects O +
on O +
overall O +
power O +
and O +
sample O +
size O +
requirements O -
. O +

We O +
were O +
particularly O +
interested O +
in O +
the O +
question O +
of O +
whether O +
the O +
total O +
number O +
of O +
families O +
that O +
might O +
be O +
available O +
for O +
study O +
in O +
this O +
large O +
collaborative O +
project O +
would O +
be O +
adequate O +
for O +
the O +
detection O +
of O +
linkage O +
given O +
a O +
set O +
of O +
realistic O +
assumptions O +
concerning O +
the O +
genetics O +
of O +
colorectal O +
cancer O +
susceptibility O -
. O +

Linkage O +
Tests O +
for O +
Concordant O +
and O +
Discordant O +
Sib O +
Pairs O +
Model O -
- O -
free O +
linkage O +
analysis O +
is O +
usually O +
based O +
on O +
a O +
comparison O +
of O +
the O +
observed O +
number O +
of O +
alleles O +
at O +
a O +
marker O +
locus O +
shared O +
identical O +
by O +
descent O +
( O -
IBD O -
, O +
i.e. O -
, O +
derived O +
from O +
a O +
common O +
ancestor O -
) O +
between O +
pairs O +
of O +
relatives O +
with O +
given O +
phenotypes O +
with O +
that O +
expected O +
simply O +
on O +
the O +
basis O +
of O +
their O +
relationships O -
. O +

However O -
, O +
IBD O +
status O +
can O +
only O +
be O +
determined O +
unambiguously O +
when O +
both O +
parents O +
are O +
different O +
heterozygotes O -
. O +

Since O +
late O -
- O -
onset O +
diseases O +
such O +
as O +
colon O +
cancer O +
severely O +
restrict O +
the O +
availability O +
of O +
parental O +
genotypes O -
, O +
the O +
first O +
step O +
is O +
to O +
estimate O +
the O +
IBD O +
probabilities O +
from O +
the O +
marker O +
data O +
on O +
all O +
available O +
pedigree O +
members O -
, O +
using O +
statistical O +
approaches O +
such O +
as O +
those O +
as O +
implemented O +
in O +
such O +
software O +
as O +
GENEHUNTER O +
[ O -
49 O -
] O -
, O +
GENIBD O +
[ O -
50 O -
] O -
, O +
Simwalk O +
2 O +
[ O -
51 O -
] O -
, O +
or O +
Merlin O +
[ O -
52 O -
] O -
. O +

The O +
family O +
structure O +
to O +
be O +
analyzed O +
can O +
include O +
parents O -
, O +
affected O +
and O +
unaffected O +
sibs O -
, O +
as O +
well O +
as O +
the O +
spouse O +
and O +
offspring O +
of O +
an O +
unavailable O +
affected O +
sib O +
if O +
they O +
were O +
sampled O -
. O +

For O +
the O +
simulation O +
studies O +
reported O +
here O -
, O +
we O +
compared O +
the O +
power O +
and O +
efficiency O +
of O +
two O +
tests O -
: O +
the O +
classic O +
" O -
means O +
test O -
" O +
for O +
linkage O +
[ O -
53 O -
] O -
, O +
which O +
compares O +
the O +
observed O +
proportion O +
of O +
alleles O +
shared O +
IBD O +
against O +
the O +
expected O +
proportion O +
of O +
0.5 O -
; O +
and O +
a O +
modified O +
means O +
test O +
which O +
compares O +
the O +
observed O +
proportion O +
of O +
alleles O +
shared O +
IBD O +
among O +
ASPs O +
with O +
the O +
observed O +
proportion O +
shared O +
IBD O +
among O +
discordant O +
sib O +
pairs O -
. O +

The O +
latter O +
test O +
has O +
been O +
suggested O +
to O +
control O +
for O +
potential O +
bias O +
( O -
as O +
discussed O +
below O -
) O +
as O +
well O +
as O +
to O +
improve O +
power O -
. O +

For O +
this O +
analysis O -
, O +
we O +
followed O +
the O +
general O +
approach O +
described O +
by O +
Guo O +
and O +
Elston O +
[ O -
54 O -
] O +
but O +
with O +
modifications O -
. O +

Since O +
combinations O +
of O +
pairs O +
of O +
IBD O +
values O +
within O +
a O +
family O +
are O +
not O +
independent O +
[ O -
55 O -
] O -
, O +
we O +
constructed O +
the O +
test O +
using O +
the O +
mean O +
IBD O +
sharing O +
among O +
pairs O +
of O +
each O +
type O +
( O -
concordant O +
affected O +
and O +
discordant O -
) O +
within O +
each O +
family O -
. O +

We O +
allowed O +
for O +
the O +
correlation O +
in O +
mean O +
IBD O +
values O +
for O +
the O +
concordant O +
affected O +
and O +
discordant O +
sib O +
pairs O +
by O +
constructing O +
a O +
paired O +
t O -
- O -
test O +
that O +
allowed O +
for O +
the O +
correlation O +
in O +
mean O +
IBD O +
values O +
between O +
the O +
sets O +
of O +
concordant O +
and O +
discordant O +
pairs O -
. O +

Specifically O -
, O +
letting O +
pfjki O +
denote O +
the O +
estimated O +
probability O +
that O +
sib O +
pair O +
( O -
j O -
, O +
k O -
) O +
in O +
family O +
f O +
= O +
1 O -
, O -
. O +
. O +

.,F O +
shares O +
i O +
= O +
0,1,2 O +
alleles O +
IBD O -
, O +
we O +
first O +
computed O +
the O +
mean O +
pcf O +
of O +
( O -
pfjk1 O -
/ O -
2 O +
+ O +
pfjk2 O -
) O +
in O +
all O +
affected O +
pairs O +
in O +
family O +
f O +
and O +
the O +
corresponding O +
mean O +
pdf O +
in O +
discordant O +
pairs O +
in O +
the O +
same O +
family O -
. O +

We O +
then O +
computed O +
the O +
means O +
pc O +
and O +
pd O +
and O +
standard O +
deviations O +
sc O +
and O +
sd O +
of O +
these O +
quantities O +
across O +
families O -
, O +
and O +
conducted O +
a O +
standard O +
one O -
- O -
sample O +
t O -
- O -
test O +
comparing O +
pc O +
to O +
1 O -
/ O -
2 O +
and O +
a O +
two O -
- O -
sample O +
t O -
- O -
test O +
comparing O +
pc O +
to O +
pd O -
, O +
where O +
F O +
is O +
the O +
total O +
number O +
of O +
families O +
in O +
the O +
sample O -
: O +
Zc O +
= O +
√F O +
( O -
Pc O +
- O +
1 O -
/ O -
2 O -
) O -
/ O -
Sc O +
Zd O +
= O +
√F O +
( O -
Pc O +
- O +
Pd O -
) O -
/ O -
√ O -
( O -
Sc2 O +
+ O +
Sd2 O -
) O +
both O +
of O +
which O +
are O +
tested O +
against O +
a O +
standard O +
Normal O +
distribution O -
. O +

Note O +
Zd O +
does O +
not O +
take O +
account O +
of O +
the O +
correlation O +
in O +
IBD O +
status O +
between O +
the O +
two O +
types O +
of O +
pairs O +
within O +
a O +
sibship O -
, O +
so O +
we O +
used O +
a O +
paired O +
t O -
- O -
test O +
to O +
allow O +
for O +
this O -
, O +
i.e. O -
, O +
Zp O +
= O +
√F O +
( O -
Pcf O +
- O +
Pdf O -
) O -
/ O -
Sw O +
where O +
sw O +
denotes O +
the O +
empirical O +
standard O +
deviation O +
of O +
pcf O +
- O +
pdf O +
across O +
families O -
. O +

Simulation O +
Methods O +
For O +
a O +
given O +
family O +
structure O +
and O +
choice O +
of O +
parameters O +
( O -
described O +
below O -
) O -
, O +
we O +
simulated O +
phenotype O +
and O +
marker O +
data O +
as O +
follows O -
. O +

First O -
, O +
we O +
generated O +
genotypes O +
G O +
at O +
the O +
two O +
disease O +
loci O +
by O +
sampling O +
from O +
their O +
respective O +
population O +
distributions O +
( O -
commonly O +
called O +
gene O +
dropping O -
) O -
. O +

We O +
then O +
retained O +
the O +
simulated O +
genotype O +
vector O +
with O +
probability O +
Pr O -
( O -
Y|G O -
) O -
, O +
where O +
Y O +
= O +
( O -
1, O -
... O -
,1,0, O -
... O -
,0 O -
) O +
denotes O +
the O +
phenotype O +
vector O +
of O +
the O +
sibship O +
under O +
the O +
design O +
being O +
considered O +
( O -
with O +
D O +
affected O +
( O -
Yi O +
= O +
1 O -
) O +
and O +
U O +
unaffected O +
( O -
Yi O +
= O +
0 O -
) O +
members O -
) O -
. O +

This O +
process O +
was O +
continued O +
until O +
the O +
total O +
sample O +
size O +
of O +
F O +
families O +
was O +
ascertained O -
. O +

For O +
each O +
family O +
structure O -
, O +
marker O +
data O +
were O +
then O +
simulated O +
conditional O +
on O +
the O +
genotypes O +
at O +
the O +
linked O +
locus O -
. O +

We O +
assumed O +
each O +
marker O +
locus O +
had O +
four O +
alleles O +
and O +
that O +
it O +
was O +
linked O +
to O +
the O +
disease O +
locus O +
with O +
two O +
different O +
recombination O +
values O +
of O +
5 O +
and O +
10 O +
centiMorgans O +
between O +
the O +
disease O +
and O +
marker O +
loci O -
. O +

Regardless O +
of O +
the O +
number O +
of O +
markers O -
, O +
marker O +
alleles O +
were O +
simulated O +
by O +
dropping O -
, O +
for O +
each O +
parent O -
, O +
the O +
parental O +
allele O +
corresponding O +
to O +
the O +
chromosome O +
of O +
origin O +
of O +
the O +
allele O +
inherited O +
at O +
marker O +
l O +
- O +
1 O +
with O +
probability O +
1 O +
- O +
θl O -
, O +
or O +
the O +
opposite O +
chromosome O +
with O +
probability O +
θl O -
, O +
for O +
marker O +
loci O +
l O +
= O +
1 O +
... O +
L O -
, O +
l O +
= O +
0 O +
at O +
the O +
disease O +
locus O -
, O +
where O +
θl O +
is O +
the O +
probability O +
of O +
recombination O +
between O +
loci O +
l O +
- O +
1 O +
and O +
l. O +
All O +
marker O +
alleles O +
were O +
independent O +
of O +
the O +
second O +
( O -
unlinked O -
) O +
disease O +
locus O -
, O +
if O +
one O +
was O +
employed O +
in O +
a O +
given O +
simulation O -
. O +

We O +
computed O +
IBD O +
probabilities O +
for O +
each O +
marker O +
locus O +
by O +
enumerating O +
all O +
possible O +
alleles O +
for O +
each O +
untyped O +
founder O +
and O +
all O +
possible O +
segregation O +
indicators O +
for O +
all O +
nonfounders O +
that O +
are O +
consistent O +
with O +
the O +
observed O +
marker O +
data O -
. O +

We O +
then O +
accumulated O +
the O +
probabilities O +
pfjki O +
of O +
each O +
of O +
these O +
configurations O +
into O +
an O +
array O +
[ O -
56 O -
] O -
. O +

These O +
probabilities O +
depend O +
upon O +
the O +
population O +
marker O +
allele O +
frequencies O -
, O +
which O +
we O +
estimated O +
in O +
each O +
replicate O +
by O +
a O +
simple O +
counting O +
procedure O +
from O +
all O +
the O +
subjects O +
available O +
for O +
study O +
[ O -
57 O -
] O -
. O +

We O +
did O +
not O +
adjust O +
for O +
correlations O +
among O +
family O +
members O +
as O +
the O +
estimates O +
of O +
allele O +
frequencies O +
so O +
obtained O +
are O +
consistent O +
[ O -
57 O -
] O +
and O +
are O +
accurate O +
for O +
the O +
large O +
number O +
of O +
families O +
we O +
are O +
here O +
evaluating O +
in O +
each O +
simulation O -
. O +

In O +
order O +
to O +
compare O +
the O +
test O +
size O +
of O +
each O +
linkage O +
test O +
we O +
employed O -
, O +
we O +
carried O +
out O +
10,000 O +
replicate O +
simulations O +
of O +
F O +
= O +
100 O +
families O +
under O +
the O +
null O +
hypothesis O +
of O +
no O +
linkage O +
between O +
the O +
marker O +
and O +
either O +
disease O +
locus O -
. O +

For O +
these O +
analyses O -
, O +
we O +
simulated O +
families O +
of O +
two O +
affected O +
sibs O -
, O +
both O +
genotyped O -
, O +
and O +
two O +
unaffected O +
sibs O -
, O +
both O +
genotyped O -
. O +

We O +
also O +
considered O +
the O +
behavior O +
of O +
multipoint O +
variants O +
of O +
the O +
Zc O +
and O +
Zp O +
statistics O +
under O +
the O +
null O -
. O +

To O +
calculate O +
these O -
, O +
we O +
initially O +
simulated O +
six O +
markers O +
with O +
four O +
alleles O +
each O +
spaced O +
at O +
10 O +
cM O +
intervals O -
, O +
and O +
obtained O +
multipoint O +
estimates O +
of O +
pairwise O +
IBD O +
sharing O +
at O +
20 O +
cM O +
from O +
the O +
origin O +
using O +
the O +
program O +
Merlin O +
[ O -
58 O -
] O -
, O +
then O +
calculated O +
Zmc O +
and O +
Zmp O +
using O +
the O +
formulas O +
given O +
above O -
. O +

The O +
disease O +
genes O +
were O +
unlinked O +
to O +
the O +
six O +
markers O -
. O +

We O +
then O +
repeated O +
the O +
simulations O +
after O +
reducing O +
the O +
marker O +
distance O +
by O +
half O -
. O +

We O +
did O +
not O +
go O +
below O +
5 O +
cM. O +
For O +
each O +
non O -
- O -
null O +
simulation O -
, O +
we O +
generated O +
20 O +
replicate O +
simulations O +
of O +
F O +
= O +
500 O +
families O +
each O -
. O +

As O +
a O +
measure O +
of O +
cost O +
efficiency O +
per O +
genotype O -
, O +
we O +
divided O +
the O +
average O +
Zc2 O +
( O -
or O +
Zp2 O -
) O +
scores O +
across O +
the O +
20 O +
replicates O +
by O +
the O +
number O +
of O +
genotypes O +
required O -
, O +
and O +
reported O +
the O +
ratio O +
( O -
times O +
100 O -
) O +
of O +
this O +
value O +
to O +
that O +
based O +
on O +
Zc2 O +
for O +
families O +
consisting O +
only O +
of O +
two O +
sampled O +
affected O +
sibs O -
. O +

We O +
call O +
this O +
the O +
asymptotic O +
relative O +
efficiency O +
( O -
ARE O -
) O -
. O +

We O +
chose O +
to O +
generate O +
20 O +
replicate O +
observations O +
for O +
any O +
given O +
combination O +
of O +
parameter O +
values O +
because O +
we O +
wished O +
to O +
simulate O +
a O +
wide O +
variety O +
of O +
non O -
- O -
null O +
conditions O -
, O +
while O +
producing O +
an O +
adequate O +
number O +
of O +
replicate O +
observations O +
to O +
obtain O +
reliable O +
estimates O +
of O +
noncentrality O +
parameters O -
. O +

Results O +
Test O +
Size O +
In O +
Tables O +
2 O +
and O +
3 O +
we O +
compare O +
the O +
performance O +
of O +
each O +
linkage O +
statistic O +
under O +
the O +
null O +
hypothesis O +
of O +
no O +
linkage O +
to O +
its O +
asymptotic O +
expectation O -
. O +

The O +
values O +
in O +
Tables O +
2 O +
and O +
3 O +
were O +
obtained O +
for O +
10,000 O +
replicate O +
observations O +
of O +
a O +
design O +
with O +
two O +
affected O +
sibs O +
( O -
both O +
sampled O -
) O -
, O +
and O +
two O +
unaffected O +
sibs O +
( O -
both O +
sampled O -
) O -
, O +
with O +
no O +
parents O +
or O +
offspring O +
sampled O -
. O +

The O +
observed O +
mean O +
and O +
standard O +
deviation O +
of O +
each O +
statistic O +
is O +
reported O -
, O +
along O +
with O +
the O +
probability O +
of O +
Type O +
I O +
error O +
for O +
assumed O +
one O -
- O -
tailed O +
test O +
sizes O +
ranging O +
from O +
0.1 O +
to O +
0.0005 O -
. O +

Overall O -
, O +
the O +
concordant O +
test O -
, O +
Zc O -
, O +
and O +
the O +
paired O +
test O -
, O +
Zp O -
, O +
most O +
closely O +
matched O +
the O +
nominal O +
test O +
size O -
. O +

Both O +
the O +
mean O +
and O +
standard O +
deviation O +
of O +
Zc O +
were O +
close O +
to O +
theoretical O +
expectations O -
. O +

The O +
standard O +
deviation O +
of O +
Zp O +
was O +
only O +
slightly O +
larger O -
, O +
and O +
the O +
mean O +
was O +
slightly O +
less O +
than O +
zero O +
( O -
0.05 O +
> O +
p O +
> O +
0.01 O -
) O -
. O +

The O +
standard O +
deviation O +
of O +
Zd O +
was O +
about O +
9 O -
% O +
larger O +
than O +
expected O -
, O +
so O +
the O +
significance O +
of O +
tests O +
based O +
on O +
this O +
statistic O +
will O +
be O +
overstated O +
unless O +
adjustments O +
are O +
made O -
. O +

We O +
therefore O +
omit O +
Zd O +
from O +
further O +
consideration O -
. O +

Simulation O +
results O +
Observed O +
versus O +
expected O +
distributions O +
of O +
linkage O +
test O +
statistics O -
, O +
based O +
on O +
10,000 O +
simulations O +
of O +
100 O +
families O +
with O +
the O +
following O +
configuration O -
: O +
2 O +
affected O +
sibs O -
, O +
both O +
sampled O -
, O +
and O +
2 O +
unaffected O +
sibs O -
, O +
both O +
sampled O -
, O +
disease O +
locus O +
unlinked O +
to O +
markers O +
( O -
null O +
model O -
) O -
. O +

amean O +
concordant O +
test O -
; O +
bmean O +
discordant O +
( O -
unpaired O -
) O +
test O -
; O +
cmean O +
paired O +
test O -
; O +
dmean O +
multipoint O +
concordant O +
test O +
( O -
10 O +
cM O +
spacing O +
between O +
markers O -
) O -
; O +
emean O +
multipoint O +
paired O +
test O -
; O +
fp O -
- O -
value O +
of O +
test O +
that O +
mean O +
does O +
not O +
equal O +
0 O -
; O +
Simulation O +
results O +
under O +
varied O +
conditions O +
of O +
heterogeneity O +
Observed O +
versus O +
expected O +
distributions O +
of O +
linkage O +
test O +
statistics O +
under O +
varying O +
conditions O +
of O +
disease O +
allele O +
and/or O +
population O +
heterogeneity O +
in O +
marker O +
allele O +
frequencies O -
, O +
based O +
on O +
10,000 O +
simulations O +
of O +
100 O +
families O +
with O +
the O +
following O +
configuration O -
: O +
2 O +
affected O +
sibs O -
, O +
both O +
sampled O -
, O +
and O +
2 O +
unaffected O +
sibs O -
, O +
both O +
sampled O -
, O +
disease O +
locus O +
unlinked O +
to O +
markers O +
( O -
null O +
model O -
) O -
. O +

emean O +
multipoint O +
paired O +
test O -
; O +
fp O -
- O -
value O +
of O +
test O +
that O +
mean O +
does O +
not O +
equal O +
0 O -
; O +
gtwo O +
populations O +
modeled O +
in O +
an O +
80% O -
/ O -
20 O -
% O +
mixture O -
: O +
1 O -
) O +
marker O +
allele O +
frequencies O +
for O +
all O +
markers O +
[ O -
0.25,0.25,0.25,0.25 O -
] O -
, O +
unlinked O +
disease O +
allele O +
0.0035 O -
; O +
2 O -
) O +
marker O +
alleles O +
[ O -
0.25,0.25,0.25,0.25 O -
] O -
, O +
unlinked O +
disease O +
allele O +
0.001 O -
; O +
htwo O +
populations O +
modeled O +
in O +
an O +
80% O -
/ O -
20 O -
% O +
mixture O -
: O +
1 O -
) O +
marker O +
allele O +
frequencies O +
for O +
all O +
markers O +
[ O -
0.25,0.25,0.25,0.25 O -
] O -
, O +
unlinked O +
disease O +
allele O +
0.003 O -
; O +
2 O -
) O +
marker O +
alleles O +
[ O -
0.4,0.3,0.2,0.1 O -
] O -
, O +
unlinked O +
disease O +
allele O +
0.003 O -
; O +
itwo O +
populations O +
modeled O +
in O +
an O +
80% O -
/ O -
20 O -
% O +
mixture O -
: O +
1 O -
) O +
marker O +
allele O +
frequencies O +
for O +
all O +
markers O +
[ O -
0.25,0.25,0.25,0.25 O -
] O -
, O +
unlinked O +
disease O +
allele O +
0.0035 O -
; O +
2 O -
) O +
marker O +
alleles O +
[ O -
0.4,0.3,0.2,0.1 O -
] O -
, O +
unlinked O +
disease O +
allele O +
0.001 O -
. O +

The O +
mean O +
multipoint O +
estimate O +
of O +
allele O +
sharing O +
was O +
significantly O +
below O +
0.5 O +
for O +
concordant O +
pairs O +
in O +
these O +
null O +
simulations O -
, O +
leading O +
to O +
a O +
conservative O +
bias O +
in O +
Zmc O -
. O +

Zmp O +
is O +
also O +
conservatively O +
biased O -
, O +
but O +
much O +
less O +
so O -
, O +
because O +
the O +
statistic O +
compares O +
estimated O +
sharing O +
between O +
concordant O +
pairs O +
with O +
estimated O +
sharing O +
between O +
discordant O +
pairs O -
, O +
which O +
is O +
also O +
estimated O +
to O +
be O +
significantly O +
less O +
than O +
0.5 O +
by O +
the O +
multipoint O +
algorithm O -
. O +

Schork O +
and O +
Greenwood O -
, O +
Cordell O -
, O +
and O +
others O +
[ O -
62,63 O -
] O +
recently O +
demonstrated O +
the O +
bias O +
toward O +
the O +
null O +
that O +
occurs O +
when O +
using O +
an O +
NPL O +
statistic O +
with O +
an O +
incompletely O +
informative O +
marker O +
unless O +
an O +
adjustment O +
is O +
made O +
for O +
incomplete O +
marker O +
informativity O -
. O +

Since O +
marker O +
informativity O +
decreases O +
with O +
increasing O +
marker O +
intervals O -
, O +
the O +
increasing O +
conservativism O +
of O +
the O +
Zmc O +
with O +
increasing O +
marker O +
intervals O +
is O +
not O +
surprising O -
. O +

Unaffected O +
siblings O +
can O +
be O +
used O +
for O +
studies O +
that O +
take O +
advantage O +
of O +
linkage O +
disequilibrium O +
to O +
identify O +
associations O -
. O +

Colorectal O +
cancer O +
and O +
other O +
late O +
onset O +
diseases O +
with O +
incompletely O +
penetrant O +
susceptibility O +
alleles O +
complicate O +
the O +
identification O +
of O +
unaffected O +
individuals O +
for O +
association O +
studies O -
, O +
because O +
the O +
probability O +
that O +
a O +
person O +
who O +
does O +
not O +
currently O +
exhibit O +
the O +
disease O +
will O +
become O +
affected O +
sometime O +
in O +
the O +
future O +
can O +
be O +
relatively O +
large O -
. O +

In O +
association O +
studies O +
using O +
families O -
, O +
the O +
oldest O +
unaffected O +
sibling O +
is O +
the O +
most O +
informative O +
because O +
s O -
/ O -
he O +
is O +
more O +
likely O +
to O +
have O +
attained O +
the O +
age O +
at O +
which O +
all O +
the O +
cases O +
in O +
the O +
family O +
were O +
diagnosed O +
( O -
although O +
Kraft O +
and O +
Thomas O +
[ O -
68,69 O -
] O +
have O +
shown O +
how O +
younger O +
siblings O +
can O +
also O +
be O +
used O -
) O -
. O +

The O +
inclusion O +
of O +
unaffected O +
sibs O +
is O +
also O +
advantageous O +
with O +
respect O +
to O +
the O +
common O +
practice O +
of O +
genotyping O +
in O +
batches O -
, O +
particularly O +
by O +
nuclear O +
family O -
. O +

A O +
correlation O +
may O +
be O +
induced O +
artificially O +
if O +
the O +
genotyping O +
errors O +
are O +
resolved O +
within O +
families O +
by O +
requiring O +
Mendelian O +
segregation O +
of O +
alleles O -
, O +
which O +
can O +
lead O +
to O +
false O +
positive O +
evidence O +
for O +
linkage O -
, O +
unless O +
the O +
unaffected O +
relatives O +
are O +
used O +
for O +
comparison O -
. O +

Such O +
excess O +
evidence O +
for O +
linkage O +
tends O +
to O +
accrue O +
from O +
the O +
families O +
with O +
available O +
parents O +
because O +
these O +
pedigrees O +
are O +
the O +
mostly O +
likely O +
to O +
yield O +
non O -
- O -
Mendelian O +
segregation O +
due O +
to O +
genotyping O +
errors O -
, O +
which O +
have O +
to O +
be O +
resolved O +
in O +
turn O +
[ O -
70,71 O -
] O -
. O +

Good O +
laboratory O +
practice O +
requires O +
that O +
at O +
least O +
some O +
samples O +
receive O +
duplicate O +
genotyping O +
so O +
that O +
it O +
would O +
be O +
possible O +
to O +
identify O +
problematic O +
markers O +
showing O +
excess O +
genotyping O +
error O +
rates O -
. O +

Meiotic O +
drive O +
exists O +
in O +
some O +
mammals O +
and O +
if O +
present O +
in O +
humans O +
could O +
conceivably O +
increase O +
the O +
expected O +
IBD O +
sharing O +
at O +
a O +
locus O +
above O +
0.5 O -
. O +

If O +
meiotic O +
drive O +
is O +
present O +
in O +
humans O +
then O +
multiple O +
studies O +
of O +
many O +
different O +
diseases O +
should O +
show O +
this O +
effect O +
[ O -
72 O -
] O -
. O +

One O +
sampling O +
option O +
that O +
we O +
have O +
shown O +
can O +
be O +
viable O +
includes O +
sibships O +
in O +
which O +
an O +
affected O +
member O +
is O +
dead O +
but O +
the O +
spouse O +
and O +
offspring O +
of O +
the O +
deceased O +
are O +
available O -
, O +
thus O +
effectively O +
increasing O +
the O +
number O +
of O +
pairs O +
and O +
yielded O +
a O +
total O +
information O +
content O +
per O +
family O +
approaching O +
other O +
designs O +
based O +
on O +
affected O +
sibs O -
. O +

In O +
the O +
context O +
of O +
a O +
high O -
- O -
risk O +
clinic O -
, O +
pursuing O +
the O +
family O +
of O +
a O +
dead O +
sib O +
can O +
be O +
quite O +
labor O +
intensive O +
compared O +
with O +
the O +
cost O +
of O +
recruiting O +
more O +
sibships O -
. O +

However O -
, O +
in O +
an O +
established O +
registry O -
, O +
the O +
opposite O +
may O +
be O +
true O -
, O +
so O +
that O +
extending O +
the O +
relatives O +
to O +
be O +
sampled O +
becomes O +
a O +
more O +
cost O -
- O -
effective O +
strategy O -
. O +

Such O +
a O +
scheme O +
could O +
be O +
worthy O +
of O +
further O +
consideration O +
in O +
situations O +
where O +
the O +
prospects O +
of O +
recruiting O +
additional O +
sibships O +
are O +
limited O -
. O +

Using O +
spouses O +
and O +
offspring O +
as O +
proxies O +
for O +
missing O +
or O +
deceased O +
sibs O +
is O +
obviously O +
less O +
efficient O +
than O +
had O +
the O +
affected O +
sibs O +
themselves O +
been O +
available O -
, O +
but O +
still O +
can O +
provide O +
adequate O +
linkage O +
information O +
and O +
may O +
be O +
required O +
if O +
the O +
disease O +
is O +
often O +
lethal O +
so O +
that O +
samples O +
from O +
affected O +
sibs O +
are O +
hard O +
to O +
obtain O -
. O +

Even O +
when O +
affected O +
siblings O +
are O +
unavailable O +
for O +
study O -
, O +
it O +
is O +
still O +
possible O +
to O +
genotype O +
blocks O +
that O +
may O +
be O +
available O +
from O +
residual O +
tissues O -
, O +
such O +
as O +
lymph O +
nodes O -
, O +
that O +
were O +
obtained O +
for O +
the O +
purposes O +
of O +
staging O -
. O +

However O -
, O +
genetic O +
analysis O +
of O +
blocks O +
is O +
more O +
difficult O +
than O +
from O +
blood O +
samples O +
because O +
the O +
DNA O +
is O +
partially O +
degraded O -
, O +
which O +
may O +
preclude O +
multiplex O +
genotyping O -
. O +

Therefore O -
, O +
genotyping O +
the O +
relatives O +
of O +
the O +
affected O +
but O +
unavailable O +
cosib O +
may O +
be O +
more O +
efficient O +
than O +
genotyping O +
residual O +
tissues O -
. O +

Available O +
parents O +
contributed O +
somewhat O +
to O +
the O +
efficiency O +
obtained O +
in O +
our O +
simulated O +
linkage O +
studies O -
. O +

There O +
are O +
other O +
benefits O +
of O +
including O +
parents O +
when O +
they O +
are O +
available O -
, O +
including O +
greatly O +
reduced O +
sensitivity O +
to O +
allele O +
frequency O +
misspecification O -
, O +
substantial O +
improvements O +
to O +
haplotype O +
estimation O -
, O +
and O +
identifying O +
nonpaternities O +
or O +
other O +
errors O +
in O +
family O +
structure O +
or O +
in O +
genotyping O -
. O +

There O +
are O +
some O +
practical O +
advantages O +
to O +
including O +
both O +
parents O +
of O +
each O +
sibship O -
, O +
whenever O +
possible O -
. O +

However O -
, O +
parents O +
are O +
likely O +
to O +
be O +
available O +
only O +
for O +
a O +
small O +
minority O +
of O +
the O +
families O +
because O +
most O +
inherited O +
cancers O +
have O +
a O +
relatively O +
late O +
onset O -
, O +
albeit O +
typically O +
earlier O +
than O +
for O +
sporadic O +
cases O -
. O +

For O +
example O -
, O +
data O +
from O +
the O +
high O -
- O -
risk O +
families O +
of O +
the O +
CFRCCS O +
and O +
the O +
population O -
- O -
based O +
Diet O -
, O +
Activity O +
and O +
Reproduction O +
in O +
Colon O +
Cancer O +
( O -
DARCC O -
) O +
study O +
[ O -
26 O -
] O +
show O +
that O +
about O +
3–4 O -
% O +
of O +
the O +
living O +
ASPs O +
have O +
two O +
parents O +
alive O +
while O +
about O +
12 O -
% O +
( O -
DARCC O -
) O +
to O +
22 O -
% O +
( O -
CFRCCS O -
) O +
have O +
only O +
one O -
. O +

The O +
sib O +
pair O +
protocol O +
of O +
the O +
Eastern O +
Cooperative O +
Oncology O +
Group O +
( O -
ECOG O -
) O +
for O +
mapping O +
the O +
interactive O +
susceptibility O +
loci O +
of O +
four O +
major O +
malignancies O +
includes O +
the O +
accrual O +
of O +
parents O +
only O +
when O +
both O +
are O +
available O -
. O +

However O -
, O +
their O +
rationale O +
is O +
quite O +
different O +
from O +
that O +
of O +
allele O -
- O -
sharing O +
methodology O +
because O +
the O +
parental O +
data O +
are O +
collected O +
for O +
a O +
separate O +
parallel O +
analysis O +
using O +
the O +
transmission O +
disequilibrium O +
test O +
( O -
TDT O -
) O +
[ O -
73 O -
] O -
. O +

The O +
family O +
structures O +
that O +
could O +
be O +
studied O +
are O +
not O +
necessarily O +
restricted O +
to O +
the O +
sibs O +
of O +
a O +
proband O +
ascertained O +
through O +
a O +
registry O +
or O +
clinic O -
. O +

Consideration O +
should O +
also O +
be O +
given O +
to O +
collecting O +
the O +
extended O +
family O +
members O +
of O +
the O +
affected O +
sibs O -
. O +

Familial O +
cancer O +
registries O +
such O +
as O +
the O +
CFRCCS O +
and O +
CGN O +
routinely O +
collect O +
family O +
history O +
from O +
all O +
their O +
participants O -
. O +

Recent O +
reports O +
indicate O +
that O +
study O +
subjects O +
are O +
capable O +
of O +
accurately O +
reporting O +
cancer O +
status O +
among O +
their O +
close O +
relatives O -
, O +
with O +
accuracy O +
varying O +
by O +
cancer O +
site O +
and O +
degree O +
of O +
relationship O +
[ O -
74 O -
] O -
. O +

Pedigrees O +
that O +
extend O +
to O +
affected O +
aunts O +
and O +
uncles O +
or O +
grandparents O +
of O +
the O +
affected O +
sibs O +
could O +
be O +
used O +
in O +
a O +
confirmatory O +
analysis O +
for O +
the O +
source O +
of O +
the O +
segregating O +
disease O +
allele O +
by O +
the O +
method O +
of O +
Olson O +
and O +
Elston O +
[ O -
75 O -
] O -
, O +
without O +
obtaining O +
their O +
blood O +
specimens O -
, O +
by O +
correlating O +
the O +
parent O +
of O +
origin O +
of O +
shared O +
alleles O +
with O +
the O +
side O +
of O +
the O +
family O +
of O +
the O +
affected O +
aunt O +
or O +
uncle O -
. O +

For O +
rare O +
autosomal O +
dominant O +
traits O -
, O +
Risch O +
[ O -
76 O -
] O +
showed O +
that O +
cousin O +
pairs O +
actually O +
provide O +
more O +
information O +
for O +
detecting O +
tight O +
linkage O +
than O +
sib O +
pairs O -
. O +

Narod O +
and O +
Amos O +
( O -
[ O -
77 O -
] O -
) O +
also O +
showed O +
through O +
simulation O +
the O +
efficacy O +
of O +
incorporating O +
cousins O +
in O +
a O +
linkage O +
study O +
of O +
breast O +
cancer O -
, O +
which O +
like O +
colorectal O +
cancer O +
shows O +
genetic O +
heterogeneity O -
, O +
a O +
likely O +
high O +
proportion O +
of O +
phenocopies O -
, O +
and O +
environmental O +
and O +
life O -
- O -
style O +
related O +
risk O +
factors O -
. O +

However O -
, O +
Risch O +
also O +
found O +
that O +
for O +
recessive O +
conditions O +
or O +
when O +
the O +
disease O +
and O +
marker O +
loci O +
were O +
not O +
tightly O +
linked O -
, O +
a O +
sib O +
pair O +
design O +
was O +
more O +
effective O +
than O +
other O +
designs O -
. O +

Since O +
the O +
mode O +
of O +
inheritance O +
for O +
as O +
yet O +
unidentified O +
genetic O +
factors O +
remains O +
unknown O -
, O +
the O +
sibship O +
design O +
remains O +
preferable O +
to O +
other O +
family O +
units O +
since O +
it O +
provides O +
power O +
under O +
all O +
genetic O +
models O -
. O +

We O +
estimated O +
the O +
numbers O +
of O +
families O +
required O +
to O +
study O +
colorectal O +
cancer O +
and O +
similar O +
diseases O +
with O +
reasonable O +
power O -
, O +
if O +
our O +
assumptions O +
about O +
disease O +
allele O +
frequencies O -
, O +
mode O +
of O +
inheritance O -
, O +
and O +
heterogeneity O +
are O +
not O +
too O +
far O +
from O +
the O +
truth O -
. O +

Our O +
simulation O +
studies O +
show O +
that O +
at O +
least O +
500–1000 O +
families O +
are O +
required O +
to O +
provide O +
reasonable O +
assurance O +
of O +
adequate O +
power O +
across O +
a O +
range O +
of O +
genetic O +
models O +
that O +
are O +
consistent O +
with O +
the O +
observed O +
familiality O +
and O +
population O +
prevalence O +
of O +
colorectal O +
cancer O -
. O +

Colon O +
cancer O +
risk O +
is O +
strongly O +
associated O +
with O +
certain O +
environmental O +
factors O -
, O +
some O +
of O +
which O +
might O +
interact O +
with O +
the O +
gene O -
( O -
s O -
) O +
being O +
sought O -
. O +

Although O +
1000 O +
pairs O +
will O +
most O +
likely O +
provide O +
adequate O +
power O +
to O +
identify O +
genetic O +
risk O +
factors O -
, O +
the O +
further O +
delineation O +
of O +
gene O -
- O -
environment O +
interactions O +
may O +
yet O +
require O +
larger O +
sample O +
sizes O +
[ O -
78 O -
] O -
. O +

Our O +
simulation O +
study O +
focused O +
upon O +
efficiency O +
of O +
various O +
genotyping O +
approaches O -
, O +
where O +
we O +
assumed O +
that O +
samples O +
from O +
individuals O +
are O +
already O +
available O -
. O +

If O +
samples O +
are O +
not O +
available O -
, O +
then O +
additional O +
design O +
constraints O +
may O +
become O +
important O -
. O +

For O +
instance O -
, O +
the O +
collection O +
of O +
sib O +
pairs O +
affected O +
by O +
disease O +
can O +
be O +
a O +
slow O +
process O +
and O +
trade O -
- O -
offs O +
between O +
efficiency O +
in O +
genotyping O +
versus O +
power O +
from O +
available O +
samples O +
may O +
need O +
to O +
be O +
evaluated O -
. O +

Because O +
the O +
costs O +
of O +
drawing O +
blood O +
and O +
extracting O +
DNA O +
are O +
far O +
smaller O +
than O +
those O +
of O +
genotyping O +
the O +
400–1000 O +
markers O +
needed O +
for O +
a O +
genome O +
scan O -
, O +
and O +
because O +
the O +
unaffected O +
and O +
affected O +
siblings O +
can O +
contribute O +
different O +
information O -
, O +
we O +
suggest O +
collecting O +
all O +
available O +
members O +
of O +
each O +
sibship O -
, O +
but O +
only O +
genotyping O +
affected O +
sibs O -
, O +
parents O -
, O +
and O +
any O +
spouse O -
/ O -
offspring O +
proxies O +
for O +
an O +
initial O +
genome O +
scan O -
. O +

DNA O +
from O +
the O +
unaffected O +
sibs O +
may O +
still O +
be O +
useful O +
for O +
fine O +
mapping O +
and O +
association O +
studies O +
and O +
for O +
estimating O +
the O +
penetrance O -
. O +

The O +
CFRCCS O +
and O +
DARCC O +
databases O +
indicate O +
that O +
about O +
90 O -
% O +
of O +
the O +
living O +
ASPs O +
have O +
at O +
least O +
one O +
unaffected O +
sib O +
alive O -
, O +
with O +
a O +
mean O +
of O +
about O +
2.5 O -
. O +

Since O +
the O +
optimal O +
number O +
of O +
unaffected O +
sibs O +
to O +
sample O +
per O +
sibship O +
if O +
more O +
than O +
one O +
were O +
available O +
has O +
not O +
been O +
resolved O -
, O +
an O +
ad O -
- O -
hoc O +
plan O +
may O +
be O +
to O +
obtain O +
the O +
blood O +
specimens O +
from O +
all O +
those O +
who O +
consent O -
. O +

If O +
the O +
genotyping O +
resources O +
were O +
constrained O +
( O -
e.g. O +
to O +
at O +
most O +
two O +
unaffecteds O +
per O +
sibship O -
) O -
, O +
an O +
efficient O +
protocol O +
is O +
to O +
start O +
with O +
the O +
oldest O +
first O -
- O -
degree O +
relative O +
and O +
to O +
proceed O +
downwards O -
, O +
i.e. O +
include O +
both O +
parents O +
if O +
available O -
, O +
otherwise O +
one O +
parent O +
and O +
the O +
oldest O +
unaffected O +
sib O -
, O +
etc O -
. O +

Population O +
heterogeneity O +
and O +
allele O +
frequencies O +
have O +
an O +
important O +
impact O +
on O +
the O +
study O +
design O -
. O +

In O +
the O +
absence O +
of O +
parents O -
, O +
the O +
marker O +
allele O +
frequencies O +
in O +
the O +
study O +
population O +
have O +
to O +
be O +
estimated O +
as O +
the O +
basis O +
for O +
estimating O +
the O +
IBD O +
probabilities O -
, O +
which O +
requires O +
an O +
assumption O +
of O +
homogeneity O +
of O +
marker O +
allele O +
frequencies O -
. O +

Population O +
heterogeneity O +
arises O +
when O +
the O +
allele O +
frequencies O +
vary O +
across O +
subgroups O -
, O +
because O +
of O +
demographic O -
, O +
geographical O -
, O +
or O +
other O +
factors O -
. O +

Table O +
3 O +
shows O +
that O +
an O +
incorrect O +
assumption O +
of O +
population O +
homogeneity O +
so O +
the O +
assumption O +
of O +
a O +
common O +
allele O +
frequency O +
across O +
the O +
entire O +
collection O +
of O +
families O +
can O +
bias O +
affecteds O -
- O -
only O +
linkage O +
results O -
, O +
depending O +
on O +
the O +
degree O +
of O +
admixture O +
and O +
the O +
degree O +
to O +
which O +
the O +
allele O +
frequencies O +
vary O +
among O +
the O +
subpopulations O -
. O +

We O +
observed O +
moderate O +
to O +
substantial O +
losses O +
of O +
power O +
to O +
detect O +
linkage O +
in O +
the O +
limited O +
number O +
of O +
simulations O +
we O +
performed O +
with O +
population O +
heterogeneity O +
of O +
this O +
sort O +
( O -
see O +
Table O +
6 O -
) O -
. O +

The O +
use O +
of O +
unaffected O +
sibs O +
provides O +
one O +
means O +
of O +
overcoming O +
the O +
problem O +
of O +
heterogeneity O +
in O +
marker O +
allele O +
frequencies O -
, O +
since O +
both O +
concordant O +
and O +
discordant O +
pairs O +
tend O +
to O +
be O +
biased O +
in O +
a O +
similar O +
manner O +
by O +
any O +
misspecification O +
of O +
allele O +
frequencies O -
. O +

To O +
fully O +
exploit O +
this O +
advantage O -
, O +
however O -
, O +
a O +
matched O +
comparison O +
is O +
needed O +
so O +
that O +
the O +
analysis O +
focuses O +
on O +
the O +
within O -
- O -
family O +
differences O +
in O +
IBD O +
probabilities O +
between O +
the O +
two O +
types O +
of O +
pairs O -
. O +

This O +
would O +
overcome O +
any O +
problems O +
of O +
imbalance O +
in O +
the O +
ethnic O +
distribution O +
of O +
concordant O +
and O +
discordant O +
pairs O -
. O +

While O +
this O +
can O +
be O +
accomplished O +
by O +
means O +
of O +
a O +
simple O +
paired O +
t O -
- O -
test O -
, O +
like O +
Zp O -
, O +
a O +
more O +
sophisticated O +
GEE-2 O +
approach O +
is O +
possible O -
, O +
modeling O +
the O +
entire O +
vector O +
of O +
phenotypes O +
in O +
each O +
family O +
in O +
relation O +
to O +
its O +
IBD O +
matrix O +
[ O -
79 O -
] O -
. O +

This O +
would O +
have O +
the O +
advantage O +
of O +
combining O +
information O +
from O +
both O +
types O +
of O +
comparison O +
in O +
a O +
matched O +
fashion O -
, O +
so O +
that O +
all O +
families O -
, O +
including O +
those O +
with O +
no O +
unaffected O +
sibs O -
, O +
would O +
contribute O -
. O +

The O +
simulations O +
summarized O +
in O +
Table O +
6 O +
do O +
not O +
show O +
any O +
power O +
advantage O +
for O +
either O +
Zp O +
or O +
multipoint O +
approaches O +
under O +
the O +
simulated O +
conditions O +
of O +
population O +
admixture O -
, O +
although O +
the O +
anti O -
- O -
conservative O +
bias O +
in O +
Zc O +
under O +
heterogeneity O +
of O +
marker O +
allele O +
frequencies O +
may O +
partially O +
obscure O +
a O +
real O +
power O +
difference O +
between O +
the O +
concordant O +
and O +
discordant O +
tests O -
. O +

Population O +
admixture O +
presents O +
a O +
particularly O +
insidious O +
threat O +
to O +
the O +
validity O +
of O +
tests O +
for O +
linkage O +
if O +
parents O +
or O +
unaffected O +
siblings O +
are O +
not O +
available O -
. O +

However O -
, O +
it O +
might O +
be O +
possible O +
to O +
detect O +
population O +
substructure O +
by O +
checking O +
for O +
the O +
departure O +
from O +
disequilibrium O +
that O +
it O +
engenders O -
. O +

We O +
did O +
not O +
directly O +
study O +
the O +
asymptotic O +
relative O +
efficiency O +
of O +
10 O +
cm O +
versus O +
5 O +
cm O +
linkage O +
scans O -
. O +

At O +
the O +
time O +
we O +
designed O +
our O +
study O -
, O +
the O +
usual O +
practice O +
in O +
genotyping O +
facilities O +
is O +
to O +
first O +
apply O +
a O +
10 O +
cm O +
map O +
and O +
then O +
to O +
follow O +
up O +
with O +
denser O +
mapping O +
in O +
linked O +
regions O -
. O +

We O +
generally O +
anticipated O +
that O +
an O +
initial O +
5 O +
cM O +
mapping O +
strategy O +
is O +
not O +
cost O +
effective O +
and O +
that O +
some O +
version O +
of O +
grid O +
tightening O +
would O +
ordinarly O +
be O +
employed O +
[ O -
67 O -
] O -
. O +

Currently O +
with O +
the O +
availability O +
of O +
more O +
modern O +
technology O -
, O +
a O +
10 O +
cM O +
scan O +
is O +
now O +
considered O +
rather O +
sparse O -
, O +
and O +
the O +
5 O +
cM O +
scan O +
is O +
considered O +
a O +
better O +
standard O -
, O +
with O +
fine O +
mapping O +
at O +
1 O +
cM O +
( O -
although O +
you O +
still O +
see O +
published O +
studies O +
that O +
use O +
10 O +
cM O +
scans O -
; O +
see O +
[ O -
16 O -
- O -
18 O -
] O -
) O -
. O +

Many O +
studies O +
now O +
use O +
SNP O +
platforms O -
, O +
although O +
it O +
is O +
not O +
clear O +
whether O +
these O +
are O +
optimal O +
for O +
sibpair O +
studies O -
. O +

When O +
dense O +
sets O +
of O +
SNPs O +
are O +
analyzed O -
, O +
there O +
is O +
much O +
more O +
potential O +
for O +
biases O +
to O +
appear O +
if O +
parental O +
data O +
are O +
unavailable O +
and O +
linkage O +
disequilibrium O +
among O +
the O +
markers O +
is O +
not O +
adequately O +
modeled O +
[ O -
80 O -
] O -
. O +

Such O +
biases O +
are O +
reduced O +
when O +
an O +
additional O +
unaffected O +
sibling O +
or O +
a O +
parent O +
is O +
included O +
in O +
the O +
analysis O -
. O +

Other O +
than O +
the O +
need O +
to O +
address O +
the O +
potential O +
for O +
bias O -
, O +
the O +
high O +
marker O +
informativity O +
of O +
microsatellites O +
compared O +
with O +
SNPs O +
would O +
suggest O +
that O +
results O +
from O +
our O +
simulation O +
studies O +
should O +
shed O +
light O +
on O +
optimal O +
designs O +
for O +
studies O +
of O +
small O +
families O -
, O +
whether O +
microsatellites O +
or O +
SNPs O +
are O +
used O +
for O +
analysis O -
. O +

We O +
have O +
also O +
observed O +
that O -
, O +
if O +
genetic O +
testing O +
is O +
available O +
for O +
previously O -
- O -
identified O +
syndromes O -
, O +
and O +
if O +
those O +
syndromes O +
are O +
thought O +
to O +
account O +
for O +
a O +
larger O +
portion O +
of O +
the O +
disease O +
burden O +
than O +
the O +
syndrome O +
of O +
interest O -
, O +
prior O +
exclusion O +
of O +
families O +
linked O +
to O +
the O +
known O +
syndrome O +
can O +
meaningfully O +
increase O +
the O +
power O +
of O +
the O +
study O -
. O +

Finally O +
we O +
note O +
that O +
the O +
colon O +
sibpair O +
study O -
, O +
for O +
which O +
this O +
paper O +
was O +
written O -
, O +
was O +
completed O +
after O +
accruing O +
less O +
than O +
100 O +
families O -
. O +

In O +
fact O -
, O +
most O +
of O +
the O +
colon O +
sibpair O +
studies O +
that O +
have O +
been O +
published O +
include O +
fewer O +
than O +
100 O +
families O -
, O +
because O +
recruitment O +
is O +
a O +
major O +
challenge O -
. O +

Although O +
the O +
results O +
discussed O +
here O +
suggest O +
numbers O +
that O +
may O +
be O +
challenging O +
to O +
accrue O -
, O +
the O +
published O +
literature O +
has O +
reported O +
positive O +
studies O -
, O +
suggesting O +
that O +
the O +
assumptions O +
used O +
in O +
our O +
calculations O +
may O +
have O +
been O +
too O +
conservative O -
. O +

In O +
addition O -
, O +
linkage O +
studies O +
are O +
meant O +
to O +
be O +
performed O +
in O +
an O +
iterative O +
fashion O +
so O +
that O +
the O +
results O +
from O +
ongoing O +
studies O +
can O +
be O +
combined O -
. O +

Since O +
our O +
conclusions O +
and O +
recommendations O +
arising O +
from O +
the O +
simulations O +
describe O +
relative O +
advantage O +
of O +
various O +
designs O -
, O +
our O +
results O +
are O +
of O +
value O +
in O +
future O +
study O +
design O -
. O +

In O +
this O +
study O -
, O +
familial O +
colorectal O +
cancer O +
was O +
defined O +
broadly O +
to O +
include O +
colorectal O +
cancer O +
patients O +
who O +
have O +
at O +
least O +
one O +
first O -
- O -
degree O +
relative O +
with O +
colorectal O +
cancer O -
. O +

Although O +
these O +
cancers O +
may O +
have O +
a O +
familial O +
tendency O +
clinically O -
, O +
their O +
heredity O +
has O +
not O +
been O +
determined O +
yet O -
. O +

Molecular O +
profiles O -
, O +
including O +
promoter O +
methylation O -
, O +
have O +
not O +
been O +
thoroughly O +
examined O +
in O +
these O +
types O +
of O +
tumors O -
. O +

To O +
broaden O +
our O +
understanding O +
of O +
carcinogenesis O +
in O +
these O +
colorectal O +
cancers O -
, O +
and O +
to O +
determine O +
the O +
effect O +
of O +
methylation O +
in O +
familial O +
colon O +
tumors O +
not O +
fulfilling O +
the O +
Amsterdam O +
criteria O -
, O +
we O +
assayed O +
the O +
methylation O +
status O +
of O +
the O +
promoter O +
region O +
of O +
several O +
tumor O -
- O -
related O +
genes O -
. O +

MATERIALS O +
AND O +
METHODS O +
Characteristics O +
of O +
patients O +
and O +
specimens O +
We O +
enrolled O +
25 O +
colorectal O +
cancer O +
patients O +
with O +
a O +
family O +
history O +
of O +
colorectal O +
cancer O -
, O +
defined O +
as O +
at O +
least O +
one O +
first O -
- O -
degree O +
relative O +
with O +
colorectal O +
cancer O -
, O +
but O +
who O +
did O +
not O +
meet O +
the O +
strict O +
Amsterdam O +
criteria O +
I O +
and O +
II O +
for O +
HNPCC O -
. O +

None O +
of O +
these O +
patients O +
was O +
known O +
to O +
have O +
germline O +
mutations O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene -
, O +
indicative O +
of O +
HNPCC O +
in O +
the O +
previous O +
study O +
( O -
16 O -
) O -
. O +

Family O +
history O +
was O +
obtained O +
from O +
answers O +
to O +
a O +
questionnaire O +
and O +
from O +
an O +
interview O +
with O +
a O +
physician O +
at O +
the O +
colorectal O +
cancer O +
clinic O +
of O +
Asan O +
Medical O +
Center O -
. O +

Patients O +
with O +
a O +
vague O +
family O +
history O +
and O +
those O +
with O +
polyposis O +
were O +
excluded O -
. O +

As O +
a O +
control O +
group O -
, O +
we O +
enrolled O +
30 O +
patients O +
with O +
sporadic O +
colorectal O +
cancers O +
and O +
no O +
family O +
history O +
of O +
colon O +
tumors O -
, O +
including O +
adenomas O +
and O +
HNPCC O -
- O -
related O +
tumors O +
in O +
first- O +
and O +
second O -
- O -
degree O +
relatives O -
. O +

This O +
study O +
was O +
approved O +
by O +
the O +
institutional O +
review O +
board O +
of O +
the O +
hospital O -
, O +
and O +
written O +
informed O +
consent O +
was O +
obtained O +
from O +
all O +
the O +
participants O +
prior O +
to O +
the O +
study O +
entry O -
. O +

The O +
colorectal O +
cancers O +
with O +
family O +
history O +
tended O +
to O +
be O +
located O +
in O +
colon O +
rather O +
than O +
in O +
rectum O -
, O +
and O +
there O +
was O +
no O +
difference O +
in O +
other O +
clinicopathologic O +
variables O +
between O +
two O +
groups O +
( O -
Table O +
1 O -
) O -
. O +

All O +
55 O +
tumors O +
were O +
confirmed O +
as O +
adenocarcinomas O +
upon O +
histologic O +
examination O -
. O +

After O +
resection O -
, O +
tumor O +
and O +
non O -
- O -
neoplastic O +
colonic O +
mucosa O +
( O -
mucosa O -
) O +
were O +
obtained O +
and O +
stored O +
at O +
-80 O -
℃ O +
until O +
DNA O +
extraction O -
. O +

Sodium O +
bisulphite O +
modification O +
and O +
methylation O -
- O -
specific O +
PCR O +
( O -
MSP O -
) O +
MSP O +
distinguishes O +
unmethylated O +
from O +
methylated O +
alleles O +
based O +
on O +
sequence O +
alterations O +
produced O +
by O +
treatment O +
of O +
DNA O +
with O +
bisulphite O -
, O +
which O +
converts O +
unmethylated O -
, O +
but O +
not O +
methylated O -
, O +
cytosine O +
to O +
uracil O -
, O +
followed O +
by O +
polymerase O +
chain O +
reaction O +
( O -
PCR O -
) O +
using O +
primers O +
specific O +
to O +
methylated O +
or O +
unmethylated O +
DNA O +
( O -
17 O -
) O -
. O +

The O +
methylation O +
status O +
of O +
6 O +
genes O +
was O +
analysed O +
by O +
MSP O -
: O +
COX2 B-Gene -
, O +
MGMT B-Gene -
, O +
hMLH1 B-Gene -
, O +
TIMP3 B-Gene -
, O +
p16 B-Gene -
, O +
and O +
MINT2 B-Gene -
. O +

One O +
microgram O +
of O +
genomic O +
DNA O +
was O +
denatured O +
with O +
NaOH O +
and O +
modified O +
with O +
sodium O +
bisulphite O -
. O +

The O +
DNA O +
samples O +
were O +
purified O +
using O +
Wizard O +
DNA O +
purification O +
resin O +
( O -
Promega O -
, O +
Madison O -
, O +
WI O -
, O +
U.S.A. O -
) O +
and O +
resuspended O +
in O +
ddH2O O -
. O +

PCR O +
was O +
performed O +
using O +
a O +
mixture O +
containing O +
10 O -
× O -
PCR O +
buffer O +
( O -
16.6 O +
mM O +
ammonium O +
sulphate O -
, O +
67 O +
mM O +
Tris O +
( O -
pH O +
8.8 O -
) O -
, O +
6.7 O +
mM O +
MgCl2 O -
, O +
and O +
10 O +
mM O +
2-mercaptoethanol O -
) O -
, O +
1.25 O +
mM O +
of O +
each O +
dNTP O -
, O +
300 O +
ng O +
of O +
each O +
primer O -
, O +
and O +
bisulphite O -
- O -
modified O +
DNA O +
( O -
50 O +
ng O -
) O +
in O +
a O +
final O +
volume O +
of O +
50 O +
µL. O +
Following O +
a O +
hot O +
start O +
at O +
95 O -
℃ O +
for O +
5 O +
min O -
, O +
1.25 O +
units O +
of O +
Taq O +
polymerase O +
( O -
Promega O -
) O +
were O +
added O -
, O +
and O +
amplification O +
was O +
carried O +
out O +
in O +
a O +
Hybaid O +
OmniGene O +
temperature O +
cycler O +
( O -
Hybaid O -
, O +
Middlesex O -
, O +
United O +
Kingdom O -
) O +
using O +
previously O +
reported O +
primer O +
sequences O +
and O +
PCR O +
conditions O +
( O -
18 O -
) O -
. O +

Control O +
PCR O +
reactions O +
lacking O +
genomic O +
DNA O +
were O +
performed O +
for O +
each O +
set O +
of O +
reactions O -
. O +

Ten O +
microliters O +
of O +
each O +
PCR O +
reaction O +
product O +
were O +
electrophoresed O +
on O +
nondenaturing O +
6 O -
% O +
polyacrylamide O +
gels O -
, O +
which O +
were O +
stained O +
with O +
ethidium O +
bromide O +
and O +
visualized O +
under O +
UV O +
illumination O +
( O -
Fig. O +
1 O -
) O -
. O +

Bisulphite O +
genomic O +
sequencing O +
of O +
representative O +
MSP O +
samples O +
for O +
each O +
gene O +
was O +
performed O -
, O +
validating O +
the O +
adequacy O +
of O +
the O +
bisulphite O +
modification O +
and O +
indicating O +
that O +
all O +
of O +
the O +
cytosines O +
at O +
non O -
- O -
CpG O +
sites O +
were O +
converted O +
to O +
thymines O -
. O +

All O +
of O +
the O +
sequenced O +
MSP O +
products O +
showed O +
extensive O +
methylation O +
of O +
CpG O +
sites O +
within O +
the O +
primer O +
sequences O -
. O +

Correlation O +
of O +
clinicopathologic O +
characteristics O +
and O +
MSP O +
results O +
To O +
clarify O +
the O +
clinical O +
significance O +
of O +
the O +
methylation O +
status O +
of O +
individual O +
genes O +
or O +
the O +
extent O +
of O +
methylation O +
of O +
multiple O +
CpG O +
islands O -
, O +
we O +
compared O +
molecular O +
and O +
clinicopathologic O +
features O +
of O +
colorectal O +
cancer O +
patients O +
( O -
Table O +
2 O -
) O -
. O +

We O +
did O +
not O +
detect O +
any O +
differences O +
in O +
clinicopathologic O +
features O +
between O +
the O +
MP O +
and O +
MR O +
groups O +
or O +
between O +
groups O +
of O +
patients O +
with O +
or O +
without O +
a O +
family O +
history O +
of O +
colorectal O +
cancer O -
. O +

In O +
the O +
group O +
of O +
sporadic O +
colorectal O +
cancers O -
, O +
however O -
, O +
we O +
found O +
that O +
the O +
methylation O +
index O +
was O +
higher O +
in O +
older O +
patients O +
( O -
p<0.001 O -
) O +
and O +
in O +
those O +
with O +
right O +
colon O +
tumors O +
( O -
p=0.041 O -
) O -
. O +

Comparisons O +
of O +
methylation O +
in O +
patients O +
with O +
and O +
without O +
a O +
family O +
history O +
of O +
colorectal O +
cancer O +
The O +
overall O +
frequency O +
of O +
methylation O +
in O +
tumors O +
did O +
not O +
differ O +
between O +
patients O +
with O +
and O +
without O +
a O +
family O +
history O +
of O +
colorectal O +
cancer O +
( O -
p=0.524 O +
for O +
methylation O +
index O -
; O +
p=0.774 O +
for O +
MP O +
vs. O +
MR O -
) O -
. O +

When O +
we O +
analysed O +
methylation O +
of O +
individual O +
genes O -
, O +
however O -
, O +
we O +
found O +
that O +
MGMT B-Gene +
was O +
more O +
frequently O +
methylated O +
in O +
colorectal O +
cancers O +
of O +
patients O +
with O +
a O +
family O +
history O +
( O -
p=0.016 O -
) O -
, O +
whereas O +
p16 B-Gene +
was O +
more O +
frequently O +
methylated O +
in O +
sporadic O +
colorectal O +
cancers O +
( O -
p=0.046 O -
) O +
( O -
Fig. O +
4 O -
) O -
. O +

We O +
found O +
that O +
the O +
normal O +
mucosa O +
in O +
patients O +
with O +
family O +
history O +
showed O +
more O +
frequent O +
methylation O +
than O +
did O +
normal O +
mucosa O +
of O +
sporadic O +
cancer O +
patients O +
( O -
p=0.016 O +
for O +
methylation O +
index O -
; O +
p=0.037 O +
for O +
MP O +
vs. O +
MR O -
) O -
, O +
but O +
there O +
was O +
no O +
difference O +
in O +
methylation O +
of O +
any O +
of O +
the O +
individual O +
genes O -
. O +

MSI O +
Of O +
the O +
25 O +
colorectal O +
cancers O +
with O +
family O +
history O -
, O +
four O +
( O -
16.0 O +
% O -
) O +
were O +
MSI O -
- O -
H O +
and O +
five O +
( O -
20.0 O -
% O -
) O +
were O +
MSI O -
- O -
L. O +
In O +
contrast O -
, O +
of O +
the O +
30 O +
colorectal O +
cancer O +
without O +
family O +
history O -
, O +
two O +
( O -
6.7 O +
% O -
) O +
were O +
MSI O -
- O -
H O +
and O +
28 O +
( O -
93.3 O -
% O -
) O +
were O +
MSS O +
( O -
MSI O -
- O -
H O +
vs. O +
MSIL O +
vs. O +
MSS O -
, O +
p=0.014 O -
) O -
. O +

When O +
we O +
divided O +
the O +
microsatellite O +
status O +
into O +
two O +
groups O +
( O -
MSI O -
- O -
H O +
vs. O +
MSI O -
- O -
L O +
plus O +
MSS O -
) O -
, O +
we O +
observed O +
no O +
difference O +
between O +
colorectal O +
cancers O +
with O +
and O +
without O +
family O +
history O -
. O +

We O +
found O +
that O +
the O +
hMLH1 B-Gene +
gene O +
was O +
methylated O +
in O +
three O +
of O +
the O +
MSI O -
- O -
H O +
tumors O +
( O -
50.0 O -
% O -
) O -
, O +
three O +
of O +
the O +
MSI O -
- O -
L O +
tumors O +
( O -
60.0 O -
% O -
) O -
, O +
and O +
one O +
of O +
the O +
MSS O +
tumors O +
( O -
2.3 O -
% O -
) O -
. O +

When O +
we O +
analysed O +
the O +
correlations O +
between O +
MSI O +
and O +
clinicopathologic O +
characteristics O -
, O +
we O +
found O +
that O +
the O +
tumors O +
with O +
MSI O +
showed O +
right O +
side O +
predominance O +
( O -
MSI O -
- O -
H O +
vs. O +
MSI O -
- O -
L O +
plus O +
MSS O -
; O +
p=0.022 O -
) O +
and O +
were O +
more O +
frequently O +
methylated O +
at O +
hMLH1 B-Gene +
( O -
p=0.022 O -
) O +
and O +
TIMP3 B-Gene +
( O -
p=0.029 O -
) O -
. O +

DISCUSSION O +
Aberrant O +
methylation O +
in O +
promoter O +
CpG O +
islands O +
of O +
tumor O +
suppressor O +
genes O +
is O +
associated O +
with O +
transcriptional O +
silencing O +
of O +
these O +
genes O +
and O +
is O +
thought O +
to O +
be O +
an O +
alternative O +
mechanism O +
in O +
carcinogenesis O +
( O -
5 O -
, O +
6 O -
) O -
. O +

Colorectal O +
cancers O +
with O +
CpG O +
island O +
methylation O +
are O +
thought O +
to O +
have O +
a O +
distinct O +
clinicopathologic O +
phenotype O +
and O +
genetic O +
profiles O -
, O +
including O +
MSI O +
and O +
frequent O +
mutations O +
of O +
the O +
K B-Gene -
- I-Gene -
ras I-Gene +
gene O -
, O +
but O +
they O +
lack O +
p53 B-Gene +
mutations O +
( O -
19 O -
, O +
20 O -
) O -
. O +

There O +
is O +
as O +
yet O +
no O +
consensus O +
about O +
the O +
definition O +
of O +
CIMP O +
and O +
the O +
panel O +
of O +
CpG O +
sites O +
that O +
should O +
be O +
analysed O +
to O +
classify O +
tumors O +
as O +
CIMP O -
. O +

This O +
is O +
not O +
trivial O -
, O +
given O +
that O +
each O +
study O +
uses O +
different O +
methods O +
to O +
assay O +
DNA O +
methylation O -
, O +
assays O +
different O +
genes O -
, O +
has O +
different O +
definitions O +
of O +
CIMP O -
, O +
and O +
examines O +
a O +
different O +
minimal O +
number O +
of O +
genes O -
. O +

Genes O +
related O +
to O +
carcinogenesis O +
may O +
be O +
tissue O -
- O -
dependent O -
, O +
and O +
the O +
definition O +
of O +
CIMP O +
for O +
colorectal O +
cancer O +
might O +
not O +
be O +
applicable O +
to O +
other O +
cancers O -
. O +

CIMP O +
has O +
been O +
generally O +
defined O +
as O +
methylation O +
of O +
at O +
least O +
two O +
MINTs B-Gene +
or O +
target O +
genes O +
such O +
as O +
p16 B-Gene -
, O +
p14 B-Gene -
, O +
or O +
hMLH1 B-Gene -
, O +
when O +
a O +
small O +
panel O +
of O +
such O +
markers O +
is O +
examined O +
( O -
7 O -
, O +
21 O -
, O +
22 O -
) O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
have O +
assayed O +
six O +
markers O -
: O +
MINT2 B-Gene -
, O +
p16 B-Gene -
, O +
TIMP3 B-Gene -
, O +
hMLH1 B-Gene -
, O +
MGMT B-Gene -
, O +
and O +
COX2 B-Gene -
. O +

All O +
of O +
these O +
have O +
been O +
found O +
to O +
be O +
methylated O +
mainly O +
in O +
cancers O +
and O +
are O +
frequently O +
methylated O +
in O +
gastrointestinal O +
tumors O +
( O -
23 O -
, O +
24 O -
) O -
. O +

Moreover O -
, O +
these O +
genes O +
have O +
been O +
reported O +
to O +
be O +
closely O +
related O +
to O +
colorectal O +
carcinogenesis O -
; O +
specifically O -
, O +
cell O -
- O -
cycle O +
regulation O +
( O -
COX2 B-Gene +
and O +
p16 B-Gene -
) O -
, O +
DNA O +
repair O +
or O +
protection O +
( O -
MGMT B-Gene -
, O +
and O +
hMLH1 B-Gene -
) O -
, O +
and O +
metastasis O +
and O +
invasion O +
( O -
TIMP3 B-Gene -
) O -
. O +

In O +
our O +
opinion O -
, O +
this O +
selection O +
satisfies O +
the O +
minimum O +
conditions O +
for O +
studying O +
methylation O +
in O +
colorectal O +
cancer O +
( O -
19 O -
) O -
. O +

We O +
categorized O +
colorectal O +
tumors O +
as O +
MP O +
or O +
MR O +
to O +
avoid O +
confusion O +
with O +
other O +
definitions O +
of O +
CIMP O +
( O -
7 O -
, O +
20 O -
, O +
25 O -
) O -
, O +
and O +
calculated O +
and O +
compared O +
methylation O +
indices O +
to O +
reduce O +
the O +
bias O +
from O +
our O +
selection O +
of O +
genes O -
. O +

In O +
this O +
study O -
, O +
we O +
have O +
focused O +
on O +
a O +
subgroup O +
of O +
familial O +
colorectal O +
cancers O -
; O +
i.e. O -
, O +
tumors O +
from O +
patients O +
with O +
first O -
- O -
degree O +
relatives O +
with O +
colorectal O +
cancers O +
and O +
no O +
germline O +
mutations O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
( O -
16 O -
) O -
. O +

This O +
group O +
of O +
cancers O +
may O +
be O +
a O +
mixture O +
of O +
heterogeneous O +
tumors O +
with O +
different O +
molecular O +
profiles O -
. O +

Several O +
mechanisms O +
of O +
genetic O +
predisposition O +
to O +
colorectal O +
cancer O +
with O +
a O +
familial O +
tendency O +
have O +
been O +
suggested O -
. O +

These O +
include O +
defects O +
in O +
MMR B-Gene +
genes O +
other O +
than O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene -
, O +
low O +
penetrance O +
of O +
polymorphisms O -
, O +
simple O +
phenocopy O -
, O +
or O +
technically O +
undetectable O +
alterations O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
( O -
16 O -
, O +
26 O -
, O +
27 O -
) O -
. O +

Therefore O -
, O +
in O +
interpreting O +
the O +
results O +
of O +
this O +
study O -
, O +
our O +
definition O +
of O +
familial O +
cancers O +
should O +
be O +
considered O -
. O +

That O +
is O -
, O +
we O +
enrolled O +
and O +
classified O +
patients O +
as O +
having O +
familial O +
colorectal O +
cancer O -
, O +
who O +
have O +
been O +
known O +
not O +
to O +
have O +
a O +
mutation O +
in O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene -
, O +
and O +
have O +
at O +
least O +
one O +
first O -
- O -
degree O +
relative O +
without O +
considering O +
familial O +
history O +
of O +
cancers O +
in O +
other O +
organs O +
and O +
in O +
second O -
- O -
degree O +
relatives O -
. O +

Therefore O -
, O +
our O +
results O +
may O +
not O +
be O +
representative O +
of O +
the O +
methylation O +
status O +
in O +
hereditary O +
cancers O +
not O +
fulfilling O +
the O +
Amsterdam O +
criteria O +
of O +
HNPCC O -
. O +

The O +
present O +
study O +
was O +
also O +
limited O +
by O +
the O +
small O +
number O +
of O +
samples O +
studied O -
. O +

A O +
' O -
field O +
defect O -
' O +
is O +
an O +
area O +
of O +
abnormal O +
tissue O +
that O +
predisposes O +
to O +
the O +
development O +
of O +
cancer O -
. O +

The O +
molecular O +
basis O +
is O +
relatively O +
simple O +
to O +
understand O +
when O +
it O +
occurs O +
in O +
patients O +
who O +
have O +
a O +
genetic O +
predisposition O +
for O +
cancer O +
development O +
or O +
massive O +
exposure O +
to O +
a O +
carcinogen O -
. O +

Within O +
this O +
defective O +
field O -
, O +
a O +
second O +
change O +
may O +
confer O +
a O +
growth O +
advantage O +
on O +
a O +
given O +
cell O +
relative O +
to O +
other O +
cells O -
. O +

In O +
colorectal O +
cancer O +
patients O +
with O +
germline O +
genetic O +
defects O -
, O +
all O +
cells O +
in O +
the O +
colonic O +
mucosa O +
have O +
the O +
same O +
genetic O +
alteration O -
, O +
leading O +
to O +
the O +
frequent O +
development O +
of O +
tumors O +
in O +
these O +
individuals O -
. O +

In O +
some O +
of O +
these O +
patients O -
, O +
however O -
, O +
the O +
selective O +
advantage O +
of O +
genetic O +
alterations O +
is O +
not O +
great O +
( O -
36 O -
) O -
. O +

Methylation O +
has O +
been O +
proposed O +
as O +
a O +
candidate O +
mediator O +
of O +
this O +
field O +
defect O +
and O +
methylation O +
status O +
of O +
normal O +
mucosa O +
was O +
explored O +
to O +
verify O +
the O +
role O +
of O +
methylation O +
as O +
an O +
earliest O +
event O +
in O +
carcinogenetic O +
pathway O +
( O -
37 O -
, O +
38 O -
) O -
. O +

A O +
recent O +
study O +
reported O +
that O +
some O +
colorectal O +
cancers O +
arise O +
from O +
a O +
field O +
defect O +
defined O +
by O +
epigenetic O +
inactivation O +
of O +
some O +
genes O +
such O +
as O +
MGMT B-Gene +
( O -
38 O -
) O -
. O +

Detection O +
of O +
this O +
abnormality O +
may O +
useful O +
in O +
predict O +
the O +
colorectal O +
cancer O +
risk O -
. O +

Germline O +
defects O +
that O +
alter O +
methylation O +
machinery O +
may O +
increase O +
methylation O +
frequency O +
in O +
normal O +
colonic O +
mucosa O +
of O +
individuals O +
with O +
a O +
family O +
history O +
of O +
colorectal O +
cancer O -
, O +
and O +
this O +
may O +
be O +
associated O +
with O +
the O +
frequent O +
and O +
multiple O +
incidences O +
of O +
colorectal O +
tumors O +
in O +
these O +
patients O -
. O +

We O +
found O +
that O +
methylation O +
status O +
of O +
mucosa O +
differed O +
between O +
in O +
the O +
patients O +
of O +
sporadic O +
and O +
familial O +
colorectal O +
cancers O -
, O +
although O +
we O +
did O +
not O +
detect O +
differences O +
in O +
individual O +
genes O -
. O +

This O +
finding O +
might O +
be O +
a O +
small O +
clue O +
that O +
field O +
defect O +
related O +
to O +
methylation O +
has O +
variable O +
effects O +
regarding O +
selective O +
power O +
and O +
involved O +
genes O +
for O +
field O +
defect O +
is O +
also O +
diverse O +
according O +
to O +
the O +
specific O +
carcinogenetic O +
pathway O -
. O +

A O +
methylation O +
field O +
effect O +
in O +
the O +
entire O +
whole O +
colonic O +
mucosa O +
may O +
be O +
associated O +
with O +
the O +
process O +
of O +
carcinogenesis O +
in O +
familial O +
colorectal O +
cancer O -
, O +
at O +
least O +
in O +
those O +
tumors O +
with O +
high O +
methylation O +
rates O +
in O +
normal O +
mucosa O -
. O +

Conclusively O -
, O +
alterations O +
in O +
the O +
methylation O +
machinery O +
may O +
also O +
be O +
associated O +
with O +
both O +
sporadic O +
and O +
familial O +
colorectal O +
carcinogenesis O -
, O +
although O +
there O +
are O +
qualitative O +
and O +
quantitative O +
differences O +
in O +
methylation O +
between O +
sporadic O +
and O +
familial O +
tumors O -
. O +

Our O +
findings O -
, O +
however O -
, O +
do O +
not O +
support O +
the O +
concept O +
that O +
a O +
germline O +
defect O +
in O +
the O +
methylation O +
machinery O +
is O +
responsible O +
for O +
the O +
development O +
of O +
most O +
tumors O +
with O +
multiple O +
epimutation O -
. O +

This O +
epigenetic O +
mechanism O +
can O +
silence O +
different O +
genes O +
affected O +
by O +
other O +
genetic O +
backgrounds O -
, O +
leading O +
to O +
divergent O +
pathways O +
of O +
development O +
in O +
hereditary O +
and O +
sporadic O +
colorectal O +
cancers O -
. O +

Introduction O +
Colorectal O +
cancer O +
( O -
CRC O -
) O +
is O +
the O +
second O +
leading O +
cause O +
of O +
cancer O -
- O -
related O +
deaths O +
in O +
the O +
United O +
States O -
, O +
despite O +
recent O +
improvements O +
in O +
the O +
diagnosis O +
and O +
treatment O +
of O +
the O +
disease O +
[ O -
1 O -
] O -
. O +

The O +
incidence O +
and O +
mortality O +
rate O +
of O +
CRC O +
are O +
higher O +
in O +
African O +
Americans O +
than O +
in O +
the O +
general O +
population O +
[ O -
1,2 O -
] O -
. O +

Many O +
epidemiological O +
and O +
genetic O +
investigations O +
have O +
focused O +
on O +
African O +
Americans O +
[ O -
2 O -
- O -
4 O -
] O +
with O +
the O +
goal O +
of O +
deciphering O +
the O +
reasons O +
for O +
such O +
disparities O -
. O +

While O +
socio O -
- O -
economic O +
factors O +
are O +
likely O +
involved O +
( O -
e.g. O -
, O +
African O +
Americans O +
tend O +
to O +
reach O +
more O +
advanced O +
stages O +
of O +
disease O +
before O +
diagnosis O -
) O -
, O +
biological O +
factors O +
also O +
contribute O +
to O +
the O +
disparity O +
[ O -
5 O -
] O -
. O +

Dietary O +
and O +
environmental O +
factors O +
certainly O +
play O +
an O +
important O +
role O -
, O +
as O +
Japanese O +
immigrants O +
to O +
the O +
US O +
show O +
higher O +
colon O +
cancer O +
rates O +
than O +
do O +
Japanese O +
people O +
living O +
in O +
Japan O -
. O +

The O +
latter O +
also O +
started O +
showing O +
higher O +
rates O +
of O +
colon O +
cancer O +
along O +
with O +
the O +
westernization O +
of O +
their O +
diets O +
[ O -
6,7 O -
] O -
. O +

The O +
recent O +
approval O +
by O +
the O +
FDA O +
of O +
Bidil O -
, O +
a O +
drug O +
for O +
heart O +
failure O +
in O +
African O +
Americans O -
, O +
illustrates O +
ethnical O -
/ O -
racial O +
genetic O +
specificities O +
that O +
lead O +
to O +
different O +
interactions O +
with O +
a O +
given O +
drug O +
or O +
molecule O +
[ O -
8 O -
] O -
. O +

Only O +
limited O +
genetic O +
and O +
epigenetic O +
studies O +
exist O +
from O +
Africa O +
and O +
other O +
continents O -
, O +
including O +
Asia O -
, O +
that O +
have O +
populations O +
known O +
to O +
be O +
of O +
African O +
descent O -
. O +

In O +
Oman O -
, O +
some O +
tribes O +
have O +
Bedouin O +
roots O +
and O +
others O +
have O +
Asian O +
and/or O +
African O +
origins O +
[ O -
9 O -
] O -
. O +

In O +
general O -
, O +
the O +
Omani O +
population O +
has O +
Asian O +
and O +
African O +
ethnicities O +
[ O -
10 O -
] O -
. O +

Other O +
ethnic O +
groups O +
in O +
Asia O +
are O +
not O +
considered O +
to O +
be O +
of O +
African O +
descent O -
, O +
such O +
as O +
Caucasian O +
people O +
in O +
Iran O -
. O +

In O +
this O +
study O -
, O +
we O +
used O +
samples O +
from O +
patients O +
treated O +
for O +
CRC O +
in O +
Oman O -
, O +
Iran O +
and O +
the O +
US O +
( O -
African O +
Americans O -
) O +
for O +
genetic O +
and O +
epigenetic O +
investigation O -
. O +

We O +
chose O +
these O +
three O +
populations O +
based O +
on O +
their O +
similarities O +
and O +
differences O +
in O +
African O +
ethnicity O +
[ O -
10 O -
- O -
14 O -
] O -
. O +

Colon O +
cancer O +
develops O +
through O +
different O +
pathways O -
, O +
all O +
involving O +
changes O +
at O +
the O +
chromosomal O +
or O +
genetic O +
levels O -
. O +

Other O +
modifications O +
occur O +
epigenetically O +
and O +
affect O +
the O +
level O +
of O +
expression O +
of O +
certain O +
targeted O +
genes O +
that O +
are O +
essential O +
for O +
the O +
normal O +
control O +
of O +
cell O +
division O +
within O +
the O +
colon O +
mucosa O +
[ O -
15 O -
] O -
. O +

It O +
is O +
now O +
widely O +
accepted O +
that O +
sporadic O +
colorectal O +
cancers O +
frequently O +
arise O +
from O +
pre O -
- O -
neoplastic O +
lesions O +
through O +
the O +
activation O +
of O +
oncogenes O +
( O -
K B-Gene -
- I-Gene -
ras I-Gene -
, O +
BRAF B-Gene -
) O +
and O +
the O +
inactivation O +
of O +
tumor O +
suppressor O +
genes O +
( O -
APC B-Gene -
, O +
p53 B-Gene -
, O +
DCC B-Gene -
) O +
and O +
mismatch O +
repair O +
( O -
MMR B-Gene -
) O +
genes O +
( O -
MLH1 B-Gene +
and O +
MSH2 B-Gene -
) O +
[ O -
16,17 O -
] O -
. O +

Also O -
, O +
activating O +
mutations O +
in O +
BRAF B-Gene -
, O +
one O +
of O +
the O +
RAF B-Gene +
genes O +
which O +
encode O +
kinases O +
that O +
are O +
regulated O +
by O +
Ras B-Gene +
and O +
mediate O +
cellular O +
responses O +
to O +
growth O +
signals O -
, O +
have O +
been O +
found O +
to O +
be O +
associated O +
with O +
MSI O -
- O -
H O +
cancers O +
[ O -
18 O -
] O -
. O +

The O +
DNA O +
MMR B-Gene +
process O +
can O +
be O +
impeded O +
by O +
genes O +
that O +
are O +
either O +
mutated O +
[ O -
19 O -
] O +
or O +
silenced O +
[ O -
4 O -
] O -
, O +
leading O +
to O +
the O +
expression O +
of O +
non O -
- O -
functional O +
proteins O +
or O +
to O +
a O +
lack O +
of O +
expression O -
, O +
respectively O -
. O +

MMR B-Gene +
pathway O +
is O +
primarily O +
responsible O +
for O +
colon O +
cancer O +
development O +
in O +
families O +
with O +
Hereditary O +
Non O +
Polyposis O +
Colon O +
Cancer O +
( O -
HNPCC O -
) O -
, O +
which O +
represents O +
about O +
5 O -
% O +
of O +
the O +
generally O +
inventoried O +
colon O +
cancer O +
cases O +
[ O -
20 O -
] O -
. O +

Histopathological O +
analysis O +
Independent O +
pathologists O +
who O +
were O +
unaware O +
of O +
the O +
MSI O +
status O +
of O +
any O +
of O +
the O +
samples O +
evaluated O +
specific O +
histopathological O +
characteristics O -
. O +

Grading O +
of O +
tumors O +
was O +
achieved O +
by O +
staining O +
with O +
Hematoxylin O -
- O -
Eosin O +
( O -
H&E O -
) O -
. O +

Tumors O +
were O +
classified O +
as O +
proximal O +
( O -
proximal O +
to O +
the O +
splenic O +
flexure O -
) O +
or O +
distal O -
. O +

The O +
TNM O +
system O +
of O +
the O +
International O +
Union O +
against O +
cancer O +
was O +
used O +
for O +
tumor O +
staging O -
. O +

Mucin O +
production O +
was O +
evaluated O +
using O +
the O +
modified O +
criteria O +
of O +
Wiggers O +
et O +
al O -
, O +
[ O -
22 O -
] O +
and O +
reported O +
as O +
absent O +
( O -
no O +
extracellular O +
mucin O +
production O -
) O -
, O +
focal O +
( O -
when O +
extracellular O +
mucin O +
production O +
was O +
present O +
in O +
< O +
50 O -
% O +
of O +
the O +
cells O -
) O +
or O +
predominant O +
( O -
when O +
the O +
area O +
of O +
extra O +
cellular O +
mucin O +
production O +
was O +
present O +
in O +
≥ O +
50 O -
% O +
of O +
the O +
cells O -
) O -
. O +

Immunohistochemistry O +
Tissue O +
obtained O +
from O +
paraffin O -
- O -
embedded O +
blocks O +
was O +
used O +
for O +
the O +
immunohistochemistry O +
experiments O -
. O +

Sections O +
( O -
5 O +
μm O -
) O +
were O +
mounted O +
on O +
charged O +
glass O +
slides O -
, O +
deparaffinized O +
with O +
xylene O +
for O +
2 O +
× O +
10 O +
min O +
and O +
rehydrated O +
using O +
a O +
graded O +
ethanol O +
series O -
. O +

Antigen O +
retrieval O +
was O +
performed O +
by O +
placing O +
the O +
samples O +
in O +
a O +
microwave O +
oven O +
for O +
12 O +
min O -
, O +
with O +
occasional O +
interruption O +
to O +
avoid O +
tissue O +
degradation O +
by O +
excessive O +
heat O -
. O +

The O +
slides O +
were O +
then O +
treated O +
with O +
hydrogen O +
peroxide O -
, O +
followed O +
by O +
incubation O +
with O +
the O +
primary O +
and O +
secondary O +
antibodies O -
, O +
a O +
streptavidin O -
- O -
biotin O +
complex O -
, O +
an O +
amplification O +
reagent O -
, O +
streptavidin O -
- O -
peroxidase O +
and O +
substrate O -
- O -
chromogen O +
solution O +
using O +
the O +
Envision O +
system O +
according O +
to O +
the O +
manufacturers O -
' O +
protocol O +
( O -
DAKO O -
) O -
. O +

The O +
samples O +
were O +
then O +
counterstained O +
with O +
hematoxylin O -
, O +
rinsed O +
with O +
ethanol O -
, O +
dried O +
and O +
visualized O +
by O +
a O +
light O +
microscopy O -
. O +

Tissue O +
samples O +
to O +
which O +
no O +
primary O +
antibody O +
had O +
been O +
added O +
were O +
used O +
as O +
negative O +
controls O -
. O +

All O +
immunohistochemistry O +
reagents O +
were O +
purchased O +
from O +
DAKO O +
( O -
Carpinteria O -
, O +
CA O -
) O +
and O +
the O +
antibodies O +
( O -
hMLH1 B-Gene +
clone O +
G168 O -
- O -
15 O -
, O +
1 O -
/ O -
100 O +
dilution O +
and O +
hMSH2 B-Gene +
clone O +
556349 O -
, O +
1 O -
/ O -
500 O +
dilution O -
) O +
were O +
purchased O +
from O +
PharMigen O +
( O -
San O +
Diego O -
, O +
CA O -
) O -
. O +

The O +
slides O +
were O +
read O +
by O +
pathologists O +
unaware O +
of O +
the O +
MSI O +
status O -
. O +

Absence O +
of O +
MLH1 B-Gene +
and O +
MSH2 B-Gene +
nuclear O +
expression O +
was O +
defined O +
as O +
negative O +
staining O -
. O +

BRAF B-Gene +
mutation O +
analysis O +
Samples O +
were O +
analyzed O +
for O +
the O +
presence O +
of O +
a O +
point O +
mutation O +
that O +
frequently O +
takes O +
place O +
in O +
the O +
oncogene O +
BRAF B-Gene -
, O +
leading O +
to O +
the O +
change O +
of O +
valine O +
into O +
glutamic O +
acid O +
at O +
position O +
600 O +
of O +
the O +
BRAF B-Gene +
protein O -
. O +

DNA O +
from O +
the O +
analyzed O +
samples O +
was O +
used O +
as O +
a O +
template O +
in O +
PCR O +
reactions O +
using O +
two O +
BRAF B-Gene +
primers O +
encompassing O +
BRAF B-Gene +
exon O +
15 O +
where O +
the O +
above O +
substitution O +
is O +
known O +
to O +
take O +
place O -
. O +

Amplified O +
fragments O +
were O +
analyzed O +
by O +
sequencing O +
in O +
a O +
3130 O +
ABI O +
GeneScan O +
to O +
confirm O +
the O +
presence O +
of O +
the O +
mutation O -
. O +

Statistical O +
analysis O +
The O +
MSI O +
phenotypes O +
were O +
divided O +
into O +
two O +
groups O -
: O +
non O -
- O -
MSI O +
( O -
MSS+MSI O -
- O -
L O -
) O +
and O +
MSI O -
- O -
H O +
( O -
two O +
or O +
more O +
markers O +
unstable O -
) O -
. O +

Age O +
of O +
patients O +
was O +
a O +
continuous O +
variable O -
, O +
while O +
the O +
stage O +
of O +
the O +
cancer O -
, O +
gender O -
, O +
location O -
, O +
mucin O +
production O -
, O +
differentiation O -
, O +
and O +
hMLH1 B-Gene +
and O +
hMSH2 B-Gene +
methylation O +
were O +
categorical O +
variables O -
. O +

For O +
statistical O +
analysis O -
, O +
mucin O +
production O +
was O +
categorized O +
as O +
0 O +
( O -
no O +
production O -
) O -
, O +
< O +
50 O -
% O +
or O +
≥ O +
50 O -
% O -
. O +

The O +
distributions O +
of O +
categorical O +
variables O +
were O +
shown O +
by O +
frequency O +
table O -
, O +
and O +
for O +
age O +
by O +
computing O +
mean O +
( O -
SD O -
) O -
. O +

We O +
tested O +
the O +
distribution O +
of O +
categorical O +
variables O +
between O +
MSI O -
- O -
H O +
and O +
non O +
MSI O -
- O -
H O +
groups O +
by O +
asymptotic O +
Chi O -
- O -
Square O +
or O +
the O +
Fisher's O -
- O -
Exact O +
test O -
, O +
as O +
appropriate O +
and O +
computing O +
of O +
OR O +
( O -
95 O -
% O +
CI O -
) O -
. O +

The O +
age O +
difference O +
between O +
two O +
groups O +
was O +
tested O +
by O +
student O +
t O +
test O -
. O +

The O +
univariate O +
analysis O +
was O +
done O +
for O +
both O +
races O +
separately O -
. O +

We O +
selected O +
race O -
, O +
age O +
( O -
as O +
a O +
continuous O +
variable O -
) O -
, O +
differentiation O -
, O +
tumor O +
site O +
( O -
right O +
vs. O +
left O -
) O -
, O +
stage O +
[ O -
1 O -
- O -
4 O -
] O -
, O +
BRAF B-Gene +
mutation O -
, O +
hMHL1 B-Gene +
and O +
hMSH2 B-Gene +
expression O +
( O -
positive O +
vs. O +
negative O -
) O -
, O +
and O +
P16 B-Gene +
and O +
hMHL1 B-Gene +
methylation O +
to O +
enter O +
to O +
a O +
Backward O +
logistic O +
regression O +
model O -
, O +
with O +
MSI O +
as O +
a O +
dependent O +
variable O -
. O +

Univariate O +
analysis O +
showed O +
evidences O +
of O +
interaction O +
between O +
race O +
and O +
some O +
markers O -
, O +
so O +
we O +
developed O +
a O +
model O -
, O +
with O +
interaction O +
terms O -
. O +

Then O +
a O +
final O +
model O +
was O +
developed O +
with O +
the O +
variables O +
with O +
significant O +
effect O +
( O -
p O +
< O +
0.05 O -
) O +
on O +
the O +
risk O +
of O +
MSI O -
- O -
H O +
including O +
interaction O +
term O -
. O +

All O +
analysis O +
was O +
performed O +
by O +
the O +
SPSS O +
program O +
15.0 O +
( O -
Chicago O -
, O +
IL O -
) O -
. O +

Results O +
Distinct O +
clinicopathological O +
features O +
according O +
to O +
MSI O +
status O +
and O +
tumor O +
Site O +
The O +
clinical O +
and O +
pathological O +
characteristics O +
of O +
the O +
patients O +
are O +
presented O +
in O +
Table O +
1 O -
, O +
2 O -
, O +
3 O -
. O +

For O +
MSI O +
experiments O -
, O +
we O +
analyzed O +
samples O +
from O +
95 O +
African O +
American O +
patients O -
, O +
( O -
56 O +
females O -
, O +
39 O +
males O -
) O -
. O +

The O +
mean O +
( O -
SD O -
) O +
age O +
of O +
the O +
African O +
American O +
patients O +
( O -
at O +
the O +
time O +
of O +
tissue O +
collection O -
) O +
was O +
65.7 O +
[ O -
15 O -
] O +
years O -
. O +

Of O +
the O +
95 O +
analyzed O +
African O +
American O +
samples O -
, O +
29 O +
( O -
30.5 O -
% O -
) O +
were O +
MSI O -
- O -
H O -
, O +
and O +
66 O +
( O -
69.5 O -
% O -
) O +
were O +
non O -
- O -
MSI O -
- O -
H O +
( O -
Table O +
1 O -
) O -
. O +

Four O +
MSI O -
- O -
H O +
patients O +
had O +
a O +
strong O +
family O +
history O +
of O +
colon O +
cancer O -
, O +
and O +
met O +
the O +
Amsterdam O +
criteria O +
for O +
HNPCC O -
. O +

Thirteen O +
other O +
patients O +
met O +
the O +
Bethesda O +
criteria O +
[ O -
23 O -
] O -
, O +
based O +
on O +
the O +
age O +
at O +
diagnosis O +
of O +
CRC O -
; O +
however O -
, O +
tissue O +
samples O +
from O +
thirteen O +
of O +
these O +
patients O +
were O +
non O -
- O -
MSI O -
- O -
H. O +
Sixty O -
- O -
one O +
tissue O +
samples O +
from O +
the O +
Omani O +
patients O +
were O +
analyzed O +
( O -
24 O +
females O -
, O +
37 O +
males O -
; O +
mean O +
age O +
( O -
SD O -
) O +
was O +
52.7 O +
( O -
13.6 O -
) O -
. O +

MSI O +
analysis O +
showed O +
that O +
53 O +
( O -
86.9 O -
% O -
) O +
of O +
Omani O +
samples O +
were O +
non O -
- O -
MSI O -
- O -
H O -
, O +
and O +
8 O +
( O -
13.1 O -
% O -
) O +
were O +
MSI O -
- O -
H O +
( O -
Table O +
2 O -
) O -
. O +

From O +
this O +
group O -
, O +
five O +
patients O +
that O +
were O +
MSI O -
- O -
H O +
had O +
a O +
strong O +
family O +
history O +
of O +
colon O +
cancer O +
meeting O +
the O +
Amsterdam O +
criteria O +
for O +
HNPCC O -
. O +

Nineteen O +
other O +
patients O +
met O +
the O +
Bethesda O +
criteria O +
[ O -
23 O -
] O -
, O +
based O +
on O +
the O +
age O +
at O +
diagnosis O +
of O +
CRC O -
; O +
however O -
, O +
tissue O +
samples O +
from O +
fourteen O +
of O +
these O +
patients O +
were O +
non O -
- O -
MSI O -
- O -
H. O +
Fifty O -
- O -
three O +
tissue O +
samples O +
from O +
Iranian O +
patients O +
were O +
analyzed O +
( O -
64 O -
% O +
female O -
; O +
mean O +
age O +
( O -
SD O -
) O +
in O +
Iranian O +
patients O +
was O +
59.8 O +
( O -
12.7 O -
; O +
Table O +
3 O -
) O -
. O +

Fourteen O +
( O -
26 O -
% O -
) O +
of O +
the O +
Iranian O +
samples O +
were O +
MSI O -
- O -
H O +
tumors O -
. O +

The O +
HNPCC O +
and O +
Familial O +
Adenoma O +
Polyposis O +
were O +
not O +
seen O +
in O +
Iranian O +
patients O +
in O +
this O +
study O -
. O +

In O +
the O +
Omani O +
and O +
Iranian O +
populations O -
, O +
there O +
were O +
more O +
MSI O -
- O -
H O +
tumors O +
in O +
males O +
than O +
females O +
( O -
75 O -
% O +
vs O +
25 O -
% O +
in O +
Omani O -
; O +
57 O -
% O +
vs. O +
43 O -
% O +
in O +
Iranian O -
) O -
; O +
in O +
the O +
African O +
American O +
group O -
, O +
there O +
were O +
more O +
MSI O -
- O -
H O +
tumors O +
in O +
females O +
( O -
66 O -
% O +
vs O +
34 O -
% O -
) O -
. O +

However O -
, O +
these O +
gender O +
differences O +
were O +
insignificant O +
trends O -
. O +

Clinicopathological O +
and O +
genetic O +
characteristics O +
of O +
AA O +
CRC O +
cases O +
Clinicopathological O +
and O +
genetic O +
characteristics O +
of O +
Iranian O +
CRC O +
cases O -
. O +

Clinicopathological O +
and O +
genetic O +
characteristics O +
of O +
Omani O +
CRC O +
cases O -
. O +

Parentheses O +
indicate O +
percentages O -
: O +
All O +
values O +
are O +
based O +
on O +
column O +
except O +
a O +
based O +
on O +
row O -
. O +

MSP O +
= O +
methylation O -
- O -
specific O +
PCR O -
; O +
IHC O +
= O +
immunohistochemistry O +
A O +
total O +
of O +
57 O +
( O -
60 O -
% O -
) O +
primary O +
African O +
American O +
tumors O +
were O +
located O +
in O +
the O +
proximal O +
colon O +
and O +
40 O -
% O +
[ O -
38 O -
] O +
were O +
distal O -
. O +

Within O +
the O +
MSI O -
- O -
H O +
group O -
, O +
19 O +
( O -
66 O -
% O -
) O +
were O +
proximal O +
and O +
10 O +
( O -
34 O -
% O -
) O +
were O +
distal O +
( O -
Table O +
1 O -
) O -
. O +

The O +
non O -
- O -
MSI O -
- O -
H O +
group O +
showed O +
a O +
distribution O +
with O +
38 O +
( O -
57 O -
% O -
) O +
proximal O +
tumors O +
and O +
28 O +
( O -
43 O -
% O -
) O +
distal O +
tumors O -
. O +

Mucin O +
production O +
was O +
noted O +
in O +
27 O +
tumors O +
including O +
12 O +
MSI O -
- O -
H O +
and O +
15 O +
non O -
- O -
MSI O -
- O -
H O +
tumors O -
. O +

Fifty O -
- O -
one O +
of O +
the O +
Omani O +
tumors O +
were O +
located O +
in O +
the O +
distal O +
colon O +
( O -
84 O -
% O -
) O -
. O +

The O +
prevalence O +
of O +
distal O +
lesions O +
in O +
the O +
MSI O -
- O -
H O +
group O +
was O +
87 O -
% O -
. O +

Of O +
the O +
61 O +
Omani O +
samples O -
, O +
47 O +
( O -
77 O -
% O -
) O +
showed O +
no O +
mucin O +
production O -
, O +
14 O +
( O -
23 O -
% O -
) O +
had O +
focal O +
mucin O +
production O +
( O -
Table O +
2 O -
) O -
. O +

The O +
percentage O +
of O +
lesions O +
that O +
produced O +
mucin O +
was O +
20 O -
% O +
and O +
37 O -
% O +
for O +
MSI O -
- O -
H O +
and O +
Non O -
- O -
MSI O -
- O -
H O -
, O +
respectively O -
. O +

Frequency O +
of O +
proximal O +
tumors O +
in O +
Iranian O +
patients O +
was O +
13 O +
( O -
24 O -
% O -
) O +
and O +
the O +
prevalence O +
of O +
proximal O +
lesions O +
in O +
the O +
MSI O -
- O -
H O +
group O +
was O +
79 O -
% O +
[ O -
11 O -
] O -
. O +

In O +
univariate O +
analysis O -
, O +
a O +
proximal O +
location O +
increases O +
the O +
rate O +
of O +
MSI O -
- O -
H O +
in O +
Iranian O +
patients O +
significantly O +
( O -
OR O +
= O +
66.67 O -
( O -
10–500 O -
) O -
) O +
( O -
p O +
= O +
0.001 O -
; O +
Table O +
3 O -
) O -
) O -
. O +

These O +
results O +
are O +
in O +
concordance O +
with O +
the O +
MSP O +
analysis O +
showing O +
that O +
a O +
majority O +
of O +
samples O +
displayed O +
methylation O +
at O +
the O +
hMLH1 B-Gene +
promoter O -
. O +

The O +
methylation O +
of O +
hMLH1 B-Gene +
is O +
most O +
likely O +
from O +
a O +
specific O +
genome O +
methylation O +
process O +
in O +
progression O +
of O +
colon O +
cancer O -
. O +

The O +
African O +
American O +
group O +
was O +
older O +
than O +
both O +
the O +
Omani O +
and O +
Iranian O +
group O -
. O +

It O +
has O +
been O +
demonstrated O +
that O +
older O +
people O -
, O +
particularly O +
those O +
in O +
the O +
7th–9th O +
decade O +
of O +
life O -
, O +
have O +
a O +
much O +
higher O +
chance O +
of O +
hypermethylation O +
of O +
hMLH1 B-Gene +
and O +
MSI O -
. O +

This O +
is O +
consistent O +
with O +
hMLH1 B-Gene +
methylation O +
in O +
the O +
African O +
American O +
cancers O +
both O +
in O +
MSI O -
- O -
H O +
and O +
non O -
- O -
MSI O +
cases O -
. O +

However O -
, O +
in O +
Iranians O -
, O +
a O +
higher O +
profile O +
of O +
epigenetic O +
silencing O +
of O +
hMLH1 B-Gene +
may O +
explain O +
the O +
MSI O -
- O -
H O +
tumors O +
but O +
not O +
in O +
non O -
- O -
MSI O -
. O +

In O +
addition O -
, O +
the O +
distal O +
location O +
of O +
Omani O +
tumors O +
may O +
also O +
play O +
an O +
important O +
role O +
in O +
the O +
presentation O +
of O +
the O +
disease O +
compared O +
to O +
the O +
African O +
American O +
who O +
has O +
generally O +
proximal O +
CRC O -
. O +

Our O +
results O +
demonstrate O +
that O +
methylation O +
of O +
hMLH1 B-Gene +
is O +
the O +
major O +
cause O +
of O +
MSI O +
in O +
sporadic O +
CRC O +
consistent O +
with O +
our O +
previous O +
findings O +
[ O -
3,4 O -
] O -
. O +

The O +
fact O +
that O +
the O +
hMLH1 B-Gene +
gene O +
is O +
methylated O +
indicates O +
that O +
it O +
may O +
be O +
inactivated O +
by O +
an O +
epigenetic O +
mechanism O -
. O +

The O +
association O +
of O +
higher O +
levels O +
of O +
CpG O +
island O +
methylation O +
with O +
more O +
advanced O +
histological O +
changes O +
suggests O +
that O +
CpG O +
methylation O +
plays O +
a O +
role O +
in O +
CRC O +
[ O -
30 O -
] O -
. O +

However O -
, O +
the O +
pathophysiology O +
of O +
hyper O -
- O -
methylation O +
( O -
the O +
why O -
, O +
when O +
and O +
where O -
) O +
has O +
yet O +
to O +
be O +
elucidated O -
. O +

Cancers O +
can O +
be O +
classified O +
according O +
to O +
their O +
degree O +
of O +
methylation O -
. O +

Those O +
with O +
high O +
degrees O +
of O +
methylation O +
( O -
the O +
CpG O +
island O +
methylator O +
phenotype O -
, O +
or O +
CIMP O -
) O +
represent O +
a O +
clinically O +
and O +
etiologically O +
distinct O +
group O +
that O +
is O +
characterized O +
by O +
' O -
epigenetic O +
instability O -
' O -
. O +

The O +
MSI O -
- O -
H O +
and O +
CIMP O +
phenotype O +
may O +
explain O +
the O +
criteria O +
in O +
proximal O +
tumors O +
in O +
African O +
American O +
and O +
Iranian O +
but O +
not O +
the O +
distal O +
ones O +
in O +
Omani O +
tumors O -
; O +
however O -
, O +
the O +
CpG O +
island O +
methylation O +
status O +
of O +
a O +
broader O +
panel O +
of O +
genes O +
needs O +
to O +
be O +
investigated O +
to O +
determine O +
whether O +
this O +
is O +
the O +
case O -
. O +

Some O +
samples O +
for O +
MLH1 B-Gene +
methylation O +
failed O +
to O +
display O +
MLH1 B-Gene +
protein O +
by O +
immunohistochemistry O +
and O +
were O +
non O -
- O -
MSI O +
( O -
MSS O +
and O +
MSI O -
- O -
L O -
) O -
. O +

Possible O +
explanations O +
might O +
be O +
that O +
the O +
targeted O +
CpG O +
island O +
for O +
methylation O +
in O +
this O +
study O +
is O +
located O +
upstream O +
of O +
the O +
gene O -
, O +
and O +
has O +
a O +
minor O +
effect O +
on O +
the O +
transcription O +
of O +
MLH1 B-Gene +
protein O +
[ O -
35 O -
] O +
or O +
that O +
the O +
detected O +
methylation O +
is O +
only O +
in O +
a O +
small O +
cell O +
population O +
that O +
does O +
not O +
reflect O +
the O +
overall O +
tumor O +
phenotype O -
. O +

Full O +
methylation O +
of O +
the O +
hMLH1 B-Gene +
promoter O +
region O +
and O +
subsequent O +
gene O +
inactivation O +
may O +
play O +
a O +
crucial O +
role O +
in O +
carcinogenesis O +
of O +
MSI O -
- O -
H O +
CRCs O -
. O +

Therefore O -
, O +
in O +
our O +
on O -
- O -
going O +
investigation O -
, O +
we O +
are O +
studying O +
the O +
methylation O +
status O +
of O +
the O +
lesions O +
by O +
examining O +
all O +
CpG O +
sites O +
[ O -
36 O -
] O +
especially O +
within O +
non O -
- O -
MSI O +
tumors O +
where O +
data O +
reveals O +
lack O +
of O +
protein O +
expression O -
. O +

Some O +
non O -
- O -
MSI O +
tumors O +
were O +
methylated O +
at O +
the O +
MLH1 B-Gene +
site O +
and O +
this O +
may O +
be O +
due O +
to O +
the O +
partial O +
or O +
hemi O -
- O -
methylation O +
at O +
an O +
altered O +
MLH1 B-Gene +
site O -
. O +

This O +
is O +
consistent O +
with O +
the O +
lack O +
of O +
correlation O +
of O +
between O +
the O +
methylation O +
status O +
and O +
level O +
of O +
expression O +
of O +
MLH1 B-Gene -
[ O -
37 O -
] O -
. O +

Indeed O -
, O +
more O +
markers O +
need O +
to O +
be O +
considered O +
to O +
measure O +
methylation O +
in O +
order O +
to O +
establish O +
a O +
methylation O +
phenotype O +
that O +
correlates O +
the O +
protein O +
expression O +
status O +
and O +
allows O +
for O +
the O +
understanding O +
of O +
preferential O +
carcinogenic O +
pathways O -
. O +

Positive O +
staining O +
was O +
confirmed O +
in O +
adjacent O +
normal O +
tissue O +
within O +
the O +
same O +
slide O +
validating O +
of O +
the O +
staining O +
for O +
specimens O +
that O +
were O +
found O +
to O +
be O +
negative O +
for O +
either O +
MLH1 B-Gene +
or O +
MSH2 B-Gene -
. O +

In O +
addition O -
, O +
preferential O +
microsatellite O +
loci O +
containing O +
large O +
repeat O +
units O -
, O +
but O +
not O +
loci O +
containing O +
mono- O +
or O +
dinucleotide O +
repeats O +
units O -
, O +
may O +
contribute O +
to O +
the O +
non O -
- O -
MSI O +
tumors O -
, O +
particularly O +
MSI O -
- O -
L O +
CRC O +
tumors O -
. O +

Many O +
explanations O +
could O +
account O +
for O +
the O +
differences O +
between O +
African O +
Americans O +
and O +
the O +
other O +
populations O -
. O +

The O +
difference O +
in O +
MSI O +
frequency O +
might O +
be O +
due O +
to O +
genetic O +
specificities O +
or O +
to O +
behavioral O -
/ O -
dietary O +
causes O +
[ O -
38 O -
] O -
. O +

Dietary O +
factors O +
such O +
as O +
folate O -
, O +
vitamins O -
, O +
and O +
methionine O +
may O +
be O +
associated O +
with O +
colon O +
cancer O +
because O +
of O +
involvement O +
in O +
DNA O +
methylation O +
and O +
hence O +
on O +
the O +
CpG O +
island O -
, O +
MSI O +
and O +
BRAF B-Gene -
. O +

A O +
recent O +
study O +
questioned O +
the O +
unique O +
role O +
for O +
dietary O +
folate O -
, O +
alcohol O -
, O +
vitamins O +
B6 O +
and O +
B12 O +
and O +
methionine O +
in O +
the O +
CIMP O +
phenotype O +
[ O -
39 O -
] O -
. O +

In O +
addition O -
, O +
use O +
of O +
alcohol O +
and O +
obesity O +
were O +
associated O +
with O +
an O +
increased O +
risk O +
of O +
tumors O +
that O +
were O +
MSI O -
- O -
H O +
and O +
CIMP O -
- O -
low O +
( O -
less O +
than O +
two O +
markers O +
methylated O -
) O +
[ O -
39 O -
] O -
. O +

The O +
number O +
of O +
lymph O +
nodes O -
, O +
distance O +
organ O +
metastases O +
and O +
additional O +
impairment O +
of O +
the O +
MMR B-Gene +
system O +
may O +
associate O +
with O +
the O +
more O +
aggressive O +
behavior O +
of O +
CRC O +
in O +
African O +
Americans O -
. O +

Studies O +
have O +
investigated O +
the O +
traditional O +
( O -
nonserrated O -
) O +
adenoma O -
- O -
carcinoma O +
sequence O +
and O +
the O +
serrated O +
polyp O +
neoplasia O +
for O +
BRAF B-Gene +
and O +
MSI O -
. O +

MSI O -
- O -
H O +
was O +
identified O +
only O +
in O +
the O +
adenocarcinoma O +
component O +
of O +
serrated O +
carcinomas O +
[ O -
40,41 O -
] O -
. O +

BRAF B-Gene +
mutation O +
has O +
been O +
shown O +
to O +
be O +
a O +
specific O +
marker O +
for O +
a O +
serrated O +
polyp O +
pathway O +
that O +
has O +
its O +
origin O +
in O +
a O +
hyperplastic O +
polyp O +
and O +
a O +
potential O +
end O +
point O +
as O +
MSI O +
carcinoma O -
. O +

A O +
recent O +
study O +
indicated O +
that O +
MSI O -
- O -
H O +
in O +
the O +
sporadic O +
colorectal O +
cancers O +
may O +
be O +
part O +
of O +
a O +
clinically O +
distinct O +
subgroup O +
with O +
a O +
high O +
incidence O +
of O +
BRAF B-Gene +
mutation O +
developed O +
from O +
serrated O +
polyps O +
[ O -
26 O -
] O -
. O +

In O +
this O +
study O +
we O +
categorized O +
the O +
histological O +
status O +
of O +
the O +
end O +
point O +
such O +
as O +
carcinomas O +
with O +
residual O +
adenoma O -
, O +
the O +
serrated O +
polyp O +
neoplasia O +
pathway O +
and O +
the O +
traditional O +
( O -
nonserrated O -
) O +
adenoma O -
- O -
carcinoma O +
sequence O -
. O +

However O -
, O +
we O +
did O +
not O +
find O +
any O +
evidence O +
of O +
serrated O +
or O +
serrated O +
hyperplastic O +
tissue O +
in O +
the O +
MSI O -
- O -
H O +
tumors O -
. O +

Therefore O -
, O +
our O +
BRAF B-Gene +
and O +
MSI O -
- O -
H O +
analyses O +
indicate O +
that O +
tumors O +
may O +
not O +
belong O +
to O +
the O +
serrated O +
pathway O -
, O +
which O +
needs O +
additional O +
investigation O -
. O +

Most O +
hyperplastic O +
polyps O +
occur O +
in O +
the O +
rectum O +
and O +
sigmoid O +
colon O -
, O +
but O +
most O +
serrated O +
( O -
hyperplastic O -
) O +
polyps O +
occur O +
in O +
the O +
right O +
colon O +
and O +
are O +
associated O +
with O +
proximal O +
cancers O +
[ O -
40,41 O -
] O -
. O +

All O +
but O +
one O +
( O -
13 O -
% O -
) O +
Omani O -
, O +
79 O -
% O +
Iranian O -
, O +
66 O -
% O +
of O +
African O +
American O +
MSI O -
- O -
H O +
tumors O +
were O +
proximal O +
with O +
no O +
evidence O +
of O +
serrated O +
hyperplastic O +
polyps O -
. O +

Tumors O +
in O +
these O +
populations O +
were O +
moderately O +
differentiated O +
with O +
mixed O +
adenomas O -
. O +

Therefore O -
, O +
at O +
this O +
time O +
it O +
is O +
not O +
clear O +
whether O +
or O +
not O +
mixed O +
adenoma O +
types O +
have O +
any O +
role O +
in O +
the O +
MSI O -
- O -
H O +
in O +
African O +
Americans O -
. O +

The O +
population O +
of O +
the O +
Sultanate O +
of O +
Oman O +
is O +
especially O +
interesting O +
because O +
it O +
represents O +
a O +
combination O +
of O +
African O +
and O +
Asian O +
heritage O +
in O +
a O +
small O +
country O +
with O +
the O +
distribution O +
of O +
CRC O +
disease O +
in O +
young O +
people O -
, O +
which O +
may O +
be O +
due O +
to O +
the O +
age O +
structure O +
of O +
the O +
population O +
in O +
Oman O -
. O +

The O +
effect O +
of O +
environmental O +
factors O +
such O +
as O +
diet O -
, O +
physical O +
activity O -
, O +
access O +
to O +
health O +
care O -
, O +
frequent O +
tribal O +
marriage O +
and O +
lifestyle O +
can O +
not O +
be O +
ruled O +
out O +
for O +
the O +
occurrence O +
of O +
the O +
CRC O +
in O +
young O +
age O +
[ O -
9,10,42,43 O -
] O -
. O +

The O +
Iranian O +
population O +
is O +
a O +
large O +
collection O +
of O +
ethnic O +
groups O +
and O +
their O +
descent O +
were O +
from O +
ancient O +
Iranian O +
peoples O -
[ O -
44 O -
] O -
. O +

Modern O +
Persians O +
themselves O +
are O +
also O +
a O +
heterogeneous O +
group O +
of O +
peoples O +
descended O +
from O +
various O +
Caucasian O +
peoples O +
[ O -
14,45 O -
] O -
. O +

The O +
younger O +
age O +
distribution O +
of O +
Iranian O +
CRC O +
disease O +
also O +
may O +
be O +
due O +
to O +
the O +
age O +
structure O +
of O +
the O +
population O -
. O +

However O -
, O +
the O +
effect O +
of O +
environmental O +
factors O +
such O +
as O +
diet O +
and O +
lifestyle O +
can O +
not O +
be O +
ruled O +
out O -
. O +

Our O +
data O +
on O +
CRC O +
lead O +
us O +
to O +
speculate O +
the O +
complex O +
interactions O +
of O +
genotype O -
, O +
environmental O +
factors O +
( O -
such O +
as O +
diet O -
) O -
, O +
and O +
other O +
lifestyle O +
factors O +
in O +
the O +
pattern O +
of O +
bowel O +
cancer O -
. O +

Further O +
epidemiology O +
data O +
to O +
compare O +
the O +
age O -
- O -
specific O +
incident O +
rates O +
for O +
Oman O -
, O +
Iran O +
and O +
African O +
American O +
is O +
needed O +
to O +
confirm O +
this O +
finding O -
. O +

The O +
proximal O +
location O +
of O +
tumors O +
in O +
African O +
Americans O +
is O +
consistent O +
with O +
the O +
tumors O +
in O +
Western O +
and O +
Asian O +
studies O +
[ O -
31 O -
- O -
33,46,47 O -
] O +
which O +
may O +
reflect O +
the O +
impact O +
of O +
western O +
diets O +
on O +
the O +
African O +
Americans O -
. O +

However O -
, O +
the O +
high O +
MSI O +
level O +
for O +
African O +
Americans O +
for O +
this O +
limited O +
sample O +
size O +
may O +
in O +
part O +
be O +
due O +
to O +
the O +
increased O +
age O +
of O +
these O +
patients O +
along O +
with O +
finding O +
the O +
majority O +
of O +
the O +
tumors O +
on O +
the O +
right O +
side O +
of O +
the O +
colon O -
. O +

The O +
Iranian O +
tumors O +
closely O +
mimic O +
what O +
we O +
see O +
in O +
Caucasians O +
in O +
the O +
U.S. O -
, O +
most O +
tumors O +
are O +
left O +
sided O -
, O +
most O +
of O +
the O +
MSI O -
- O -
H O +
tumors O +
are O +
right O +
sided O +
and O +
the O +
MSI O -
- O -
H O +
tumors O +
are O +
associated O +
with O +
higher O +
tumor O +
differentiation O -
. O +

The O +
distal O +
location O +
of O +
the O +
Omani O +
tumors O +
and O +
the O +
low O +
MSI O +
level O +
is O +
an O +
important O +
observation O +
compared O +
to O +
the O +
moderate O +
and O +
high O +
proximal O +
MSI O +
level O +
in O +
Iranian O +
and O +
African O +
American O +
tumors O -
, O +
respectively O -
. O +

The O +
alteration O +
of O +
K B-Gene -
- I-Gene -
RAS I-Gene +
may O +
also O +
contribute O +
to O +
the O +
methylator O +
phenotype O +
in O +
CRC O -
, O +
especially O +
in O +
the O +
Iranian O +
tumors O -
, O +
which O +
we O +
plan O +
to O +
study O +
in O +
the O +
future O +
[ O -
30 O -
] O -
. O +

The O +
rate O +
of O +
mutation O +
and O +
its O +
level O +
in O +
MMR B-Gene +
deficiency O +
may O +
contribute O +
and O +
determine O +
the O +
frameshift O +
rate O +
for O +
the O +
loss O +
of O +
these O +
proteins O +
in O +
CRC O -
, O +
hence O +
different O +
behavior O +
from O +
these O +
tumors O -
. O +

All O +
of O +
these O +
factors O +
may O +
contribute O +
to O +
the O +
risk O +
of O +
colon O +
cancer O +
and O +
presentation O +
of O +
the O +
disease O +
in O +
African O +
American O -
, O +
Omani O +
and O +
Iranian O +
patients O -
. O +

We O +
can O -
not O +
rule O +
out O +
a O +
genetic O +
predisposition O +
in O +
these O +
patients O +
since O +
we O +
did O +
not O +
have O +
access O +
to O +
detailed O +
family O +
history O +
and O -
, O +
therefore O -
, O +
some O +
of O +
the O +
subjects O +
may O +
have O +
had O +
genetic O +
and O +
epigenetic O +
predispositions O -
. O +

In O +
this O +
study O +
we O +
did O +
not O +
use O +
other O +
groups O +
such O +
as O +
white O +
Americans O -
, O +
other O +
Africans O +
and O +
Asian O +
in O +
our O +
controls O +
for O +
any O +
direct O +
or O +
indirect O +
comparison O +
analysis O -
. O +

We O +
plan O +
to O +
have O +
a O +
more O +
detailed O +
study O +
regarding O +
the O +
diversity O +
of O +
these O +
populations O +
since O +
the O +
scope O +
of O +
this O +
study O +
focused O +
on O +
the O +
clinicopathological O +
features O -
. O +

In O +
conclusion O -
, O +
this O +
first O +
comparative O +
clinicopathological O +
investigation O +
in O +
three O +
different O +
populations O +
suggests O +
that O +
the O +
MSI O -
- O -
H O +
CRC O +
phenotype O +
in O +
African O +
American O -
, O +
Iranian O +
and O +
Omani O +
patients O +
is O +
significantly O +
associated O +
with O +
BRAF B-Gene +
mutation O +
and O +
hMLH1 B-Gene +
expression O -
. O +

CRCs O +
in O +
African O +
Americans O +
tend O +
to O +
be O +
higher O +
in O +
microsatellite O +
instability O +
( O -
32 O -
% O -
) O +
and O +
more O +
often O +
located O +
in O +
the O +
proximal O +
colon O -
, O +
compared O +
to O +
Iranian O +
and O +
Omani O +
CRC O +
tumors O -
. O +

The O +
high O +
level O +
of O +
MSI O -
- O -
H O +
in O +
African O +
Americans O +
may O +
have O +
significant O +
implications O +
in O +
treatment O +
plans O -
, O +
because O +
MSI O -
- O -
H O +
lesions O +
are O +
often O +
right O -
- O -
sided O +
and O +
may O +
show O +
a O +
different O +
response O +
to O +
chemotherapeutic O +
agents O +
such O +
as O +
5-fluorourcil O +
[ O -
48 O -
] O -
. O +

Results O +
The O +
median O +
age O +
at O +
diagnosis O +
of O +
the O +
primary O +
CRC O +
was O +
46.8 O +
years O +
in O +
the O +
HNPCC O +
group O +
versus O +
61 O +
years O +
in O +
sporadic O +
CRC O +
group O -
. O +

In O +
the O +
HNPCC O +
group O +
34 O +
patients O +
( O -
85 O -
% O -
) O +
had O +
colon O +
tumours O +
and O +
6 O +
( O -
15 O -
% O -
) O +
had O +
rectal O +
cancer O -
. O +

In O +
sporadic O +
colorectal O +
cancer O +
group O +
326 O +
( O -
57 O -
% O -
) O +
had O +
colon O +
tumors O +
and O +
247 O +
( O -
43 O -
% O -
) O +
had O +
rectal O +
cancer O +
( O -
p O +
= O +
0.0001 O -
) O +
( O -
Table O +
1 O -
) O -
. O +

Distribution O +
of O +
colorectal O +
cancer O +
by O +
site O +
* O -
P O +
= O +
0.0001 O +
In O +
the O +
sporadic O +
cancer O +
group O +
353 O +
( O -
61.6 O -
% O -
) O +
had O +
an O +
early O -
- O -
stage O +
cancer O +
( O -
94 O +
Dukes O -
' O +
A O +
and O +
259 O +
Dukes O -
' O +
B O -
) O +
and O +
220 O +
( O -
38.4 O -
% O -
) O +
had O +
an O +
advanced O +
carcinoma O +
( O -
123 O +
Dukes O -
' O +
C O +
and O +
97 O +
Dukes O -
' O +
D O -
) O -
. O +

In O +
the O +
HNPCC O +
group O +
28 O +
( O -
70 O -
% O -
) O +
had O +
an O +
early O +
stage O +
cancer O +
( O -
9 O +
Dukes O -
' O +
A O +
and O +
19 O +
Dukes O -
' O +
B O -
) O +
and O +
12 O +
( O -
30 O -
% O -
) O +
had O +
an O +
advanced O +
carcinoma O +
( O -
10 O +
Dukes O -
' O +
C O +
and O +
2 O +
Dukes O -
' O +
D O -
) O -
. O +

The O +
difference O +
was O +
not O +
statistically O +
significant O +
( O -
p O +
= O +
0.29 O -
) O +
( O -
Table O +
2 O -
) O -
. O +

Distribution O +
of O +
colorectal O +
cancer O +
by O +
Dukes O -
' O +
stage O +
The O +
presence O +
of O +
synchronous O +
or O +
metachronous O +
tumours O +
was O +
also O +
investigated O +
for O +
this O +
population O -
. O +

In O +
particular O -
, O +
we O +
did O +
not O +
have O +
more O +
than O +
one O +
cancer O +
at O +
the O +
first O +
diagnosis O +
in O +
either O +
the O +
HNPCC O +
group O +
or O +
sporadic O +
CRC O +
group O -
. O +

Metachronous O +
tumours O +
were O +
observed O +
in O +
4 O -
/ O -
40 O +
( O -
10 O -
% O -
) O +
of O +
HNPCC O +
tumors O +
and O +
in O +
10 O -
/ O -
573 O +
( O -
1.7 O -
% O -
) O +
of O +
sporadic O +
colorectal O +
cancer O +
( O -
p O +
= O +
0.001 O -
) O -
. O +

The O +
median O +
observation O +
time O +
of O +
two O +
groups O +
is O +
respectively O +
56 O +
months O +
for O +
sporadic O +
CRC O +
and O +
54 O +
months O +
for O +
HNPCC O -
. O +

The O +
5-years O +
cumulative O +
disease O -
- O -
overall O +
survival O +
after O +
the O +
primary O +
CRC O +
was O +
94,2 O -
% O +
in O +
the O +
HNPCC O +
patients O +
and O +
75.3 O -
% O +
in O +
the O +
sporadic O +
CRC O +
ones O +
( O -
Figure O +
1 O -
) O +
( O -
p O +
< O +
0.0001 O -
) O -
. O +

After O +
stratification O +
for O +
Dukes O -
' O +
classification O -
, O +
survival O +
of O +
Dukes O -
' O +
A O +
and O +
B O +
cancers O +
( O -
considered O +
as O +
localized O +
carcinoma O -
) O +
was O +
84.3 O -
% O +
in O +
the O +
sporadic O +
cancer O +
patients O +
and O +
96.3 O -
% O +
in O +
the O +
HNPCC O +
patients O -
. O +

Five O +
year O +
survival O +
for O +
Dukes'C O +
was O +
63.5 O -
% O +
and O +
92.8 O -
% O +
in O +
the O +
sporadic O +
CRC O +
and O +
HNPCC O +
respectively O -
. O +

Survival O +
for O +
Dukes O -
' O +
D O +
was O +
26.6 O -
% O +
in O +
the O +
sporadic O +
CRC O +
but O +
in O +
the O +
HNPCC O +
group O +
we O +
could O +
not O +
estimate O +
survival O +
curves O +
by O +
Kaplan O +
Meier O +
method O +
due O +
to O +
the O +
small O +
number O +
of O +
available O +
patients O -
. O +

After O +
stratification O +
for O +
Dukes O -
' O +
stage O +
survival O +
remained O +
statistically O +
significant O -
, O +
better O +
for O +
HNPCC O +
versus O +
sporadic O +
colorectal O +
cancer O +
( O -
p O +
< O +
0.0001 O -
) O -
. O +

Overall O +
5-year O +
survival O +
of O +
sporadic O +
colorectal O +
cancer O +
( O -
sCRC O -
) O +
and O +
Hereditary O +
Nonpolyposis O +
Colorectal O +
Cancer O +
( O -
HNPCC O -
) O -
. O +

Considering O +
the O +
different O +
localization O +
of O +
tumor O -
, O +
we O +
stratified O +
patients O +
by O +
rectal O +
and O +
colon O +
cancer O -
. O +

The O +
cumulative O +
survival O +
after O +
5 O +
years O +
of O +
patients O +
with O +
rectal O +
cancer O -
, O +
was O +
69.7 O -
% O +
in O +
the O +
sporadic O +
CRC O +
and O +
83.3 O -
% O +
in O +
the O +
HNPCC O +
patients O -
. O +

In O +
colon O +
cancer O +
we O +
had O +
a O +
cumulative O +
survival O +
of O +
79.3 O -
% O +
and O +
96.3 O -
% O +
in O +
sporadic O +
CRC O +
and O +
HNPCC O +
respectively O -
. O +

The O +
log O -
- O -
rank O +
test O +
stratified O +
by O +
localization O +
was O +
significant O +
( O -
p O +
< O +
0.0001 O -
) O -
. O +

When O +
we O +
stratified O +
these O +
two O +
groups O +
of O +
patients O +
by O +
age O +
we O +
did O +
not O +
find O +
any O +
difference O +
in O +
survival O -
. O +

Discussion O +
Different O +
survival O +
rates O +
of O +
patients O +
with O +
colorectal O +
cancer O +
have O +
been O +
investigated O +
in O +
several O +
studies O +
[ O -
20 O -
- O -
22,28 O -
- O -
31 O -
] O -
. O +

The O +
results O +
are O +
sometimes O +
conflicting O +
because O +
of O +
the O +
different O +
pathogenetic O +
mechanism O +
of O +
tumorigenesis O +
between O +
sporadic O +
and O +
familiar O +
types O +
of O +
colorectal O +
syndrome O +
( O -
HNPCC O +
in O +
particular O -
) O -
. O +

These O +
differences O +
are O +
probably O +
due O +
to O +
different O +
clinical O +
pathological O +
characteristics O +
of O +
neoplasia O +
and O +
genetic O +
alterations O -
. O +

Two O +
major O +
mechanisms O +
of O +
genomic O +
instability O +
have O +
been O +
identified O +
in O +
sporadic O +
colorectal O +
cancer O +
progression O -
. O +

The O +
first O -
, O +
known O +
as O +
chromosomal O +
instability O +
( O -
CIN O -
) O -
, O +
results O +
from O +
a O +
series O +
of O +
genetic O +
changes O +
that O +
involve O +
the O +
activation O +
of O +
oncogenes O -
, O +
such O +
as O +
Ki B-Gene -
- I-Gene -
ras I-Gene -
, O +
and O +
inactivation O +
of O +
tumor O -
- O -
suppressor O +
genes O -
, O +
such O +
as O +
TP53 B-Gene +
and O +
APC B-Gene +
[ O -
32 O -
- O -
34 O -
] O -
. O +

The O +
second O -
, O +
known O +
as O +
microsatellite O +
instability O +
( O -
MSI O -
) O -
, O +
was O +
described O +
in O +
association O +
with O +
hereditary O +
nonpolyposis O +
colorectal O +
cancer O +
[ O -
35 O -
- O -
37 O -
] O -
. O +

The O +
aim O +
of O +
our O +
retrospective O +
cohort O +
study O +
was O +
to O +
compare O +
the O +
survival O +
between O +
patients O +
with O +
sporadic O +
and O +
hereditary O +
colorectal O +
cancer O +
after O +
surgical O +
resection O -
. O +

A O +
Finnish O +
study O +
[ O -
30 O -
] O +
and O +
a O +
recent O +
Lithuanian O +
study O +
[ O -
22 O -
] O +
reported O +
an O +
improved O +
prognosis O +
for O +
HNPCC O +
patients O +
compared O +
to O +
sporadic O +
colorectal O +
cancer O +
patients O -
, O +
but O +
an O +
Italian O +
study O +
could O +
not O +
confirm O +
this O +
result O +
[ O -
28 O -
] O -
. O +

The O +
localization O +
of O +
tumor O +
is O +
an O +
important O +
prognostic O +
factor O +
for O +
survival O -
. O +

In O +
our O +
study O +
right O +
localization O +
( O -
from O +
cecum O +
to O +
splenic O +
flexure O -
) O +
is O +
significantly O +
more O +
represented O +
in O +
the O +
HNPCC O +
group O +
with O +
respect O +
to O +
the O +
sporadic O +
colorectal O +
cancer O +
group O +
( O -
p O +
< O +
0.0001 O -
) O -
. O +

This O +
different O +
anatomical O +
distribution O +
between O +
HNPCC O +
and O +
sporadic O +
CRC O -
, O +
confirmed O +
in O +
literature O +
[ O -
34,35 O -
] O -
, O +
is O +
one O +
of O +
the O +
Amsterdam O +
criteria O +
for O +
the O +
diagnosis O +
of O +
HNPCC O +
and O +
determines O +
a O +
better O +
prognosis O -
, O +
being O +
less O +
aggressive O -
. O +

We O +
have O +
considered O +
survival O -
, O +
stratified O +
by O +
site O -
, O +
in O +
the O +
two O +
groups O +
and O +
we O +
demonstrated O +
that O +
survival O +
for O +
rectal O +
cancer O +
does O +
not O +
differ O +
statistically O -
, O +
so O +
the O +
presence O +
of O +
rectal O +
cancer O +
with O +
a O +
known O +
worse O +
prognosis O +
and O +
high O +
rate O +
of O +
recurrence O +
does O +
not O +
influence O +
survival O +
of O +
sCRC O +
or O +
HNPCC O +
( O -
p O +
= O +
0.45 O -
) O -
. O +

The O +
statistically O +
significant O +
difference O +
of O +
survival O +
was O +
for O +
colon O +
cancer O +
( O -
right O +
location O -
) O -
, O +
independent O +
of O +
stage O +
at O +
diagnosis O -
, O +
between O +
sporadic O +
and O +
HNPCC O +
cancer O +
( O -
p O +
< O +
0.0001 O -
) O -
. O +

Furthermore O -
, O +
in O +
order O +
to O +
have O +
a O +
better O +
definition O +
of O +
population O +
in O +
the O +
study O -
, O +
we O +
considered O +
several O +
clinical O +
features O +
such O +
as O +
the O +
presence O +
of O +
synchronous O +
or O +
metachronous O +
tumors O -
. O +

None O +
of O +
these O +
features O +
were O +
represented O +
sufficiently O +
enough O +
in O +
either O +
of O +
the O +
groups O +
as O +
to O +
influence O +
survival O +
rates O -
. O +

The O +
5 O +
years O +
cumulative O +
survival O +
in O +
HNPCC O +
and O +
in O +
sporadic O +
colorectal O +
cancer O +
was O +
94.2 O -
% O +
versus O +
75.3 O -
% O +
respectively O -
. O +

This O +
difference O +
was O +
statistically O +
significant O +
( O -
p O +
< O +
0.0001 O -
) O -
. O +

These O +
results O +
do O +
not O +
confirm O +
the O +
observations O +
previously O +
reported O +
by O +
Bertario O +
et O +
al O +
[ O -
31 O -
] O +
where O +
5 O +
years O +
cumulative O +
survival O +
in O +
HNPCC O -
, O +
FAP O +
and O +
sporadic O +
colorectal O +
cancer O +
groups O +
was O +
not O +
statistically O +
different O -
. O +

Otherwise O -
, O +
our O +
results O +
conflicts O +
with O +
those O +
of O +
Barnetson O +
et O +
al O +
[ O -
21 O -
] O -
, O +
in O +
which O +
survival O +
was O +
not O +
significantly O +
different O +
among O +
carriers O +
and O +
non O -
- O -
carriers O +
of O +
MMR B-Gene +
mutations O +
in O +
a O +
series O +
of O +
early O +
colorectal O +
cancer O +
patients O -
. O +

However O -
, O +
after O +
stratification O +
for O +
Dukes O -
' O +
stage O +
survival O +
remained O +
statistically O +
significant O -
, O +
better O +
for O +
HNPCC O +
versus O +
sporadic O +
colorectal O +
cancer O +
( O -
p O +
< O +
0.0001 O -
) O -
. O +

In O +
our O +
study O +
the O +
stage O +
distribution O +
was O +
not O +
significantly O +
different O +
between O +
the O +
two O +
groups O +
( O -
sCRC O +
versus O +
HNPCC O -
) O -
, O +
61.6 O -
% O +
vs. O +
70 O -
% O +
and O +
38.4 O -
% O +
vs. O +
30 O -
% O +
respectively O +
( O -
p O +
= O +
0.29 O -
) O -
, O +
demonstrating O +
that O +
it O +
did O +
not O +
influence O +
the O +
overall O +
survival O +
between O +
the O +
two O +
groups O -
. O +

Myrhoj O +
et O +
al O +
[ O -
29 O -
] O +
reported O +
an O +
improved O +
prognosis O +
of O +
cancer O +
in O +
patients O +
with O +
HNPCC O +
versus O +
sporadic O +
CRC O -
, O +
but O +
in O +
the O +
HNPCC O +
series O +
included O +
a O +
high O +
proportion O +
of O +
localized O +
tumors O +
and O +
this O +
indicated O +
that O +
the O +
good O +
prognosis O +
was O +
based O +
on O +
a O +
more O +
favourable O +
stage O +
at O +
diagnosis O -
. O +

Several O +
studies O +
described O +
a O +
trend O +
toward O +
prolonged O +
survival O +
and O +
better O +
prognosis O +
in O +
patients O +
with O +
mutations O +
or O +
MSI O +
in O +
HNPCC O -
, O +
revealing O +
the O +
presence O +
of O +
distinct O +
biological O +
features O +
of O +
colon O +
cancer O +
in O +
families O +
with O +
or O +
without O +
mutations O +
[ O -
25 O -
] O -
, O +
though O -
, O +
as O +
above O +
mentioned O -
, O +
it O +
was O +
not O +
observed O +
by O +
other O +
authors O +
[ O -
21 O -
] O -
. O +

In O +
our O +
study O +
15 O +
HNPCC O +
patients O +
had O +
positive O +
MSI O +
mutational O +
analysis O -
; O +
overall O +
survival O +
of O +
this O +
series O +
of O +
patients O +
was O +
100 O -
% O -
. O +

Introduction O +
The O +
DNA O +
MMR B-Gene +
system O +
consists O +
of O +
proteins O +
that O +
act O +
in O +
concert O +
to O +
recognize O +
and O +
coordinate O +
repair O +
of O +
nucleotide O +
base O +
mismatches O +
and O +
slippage O +
mistakes O +
at O +
microsatellite O +
sequences O +
on O +
newly O +
synthesized O +
DNA O +
[ O -
1 O -
] O -
. O +

In O +
humans O -
, O +
MMR B-Gene +
activity O +
requires O +
the O +
proper O +
functioning O +
of O +
hMutSα O +
and O +
hMutSβ O +
to O +
recognize O +
defects O -
, O +
and O +
hMutLα O +
to O +
coordinate O +
repair O -
. O +

hMutSα O +
( O -
heterodimer O +
of O +
hMSH2 B-Gene +
and O +
hMSH6 B-Gene -
) O +
recognizes O +
single O +
nucleotide O +
interstrand O +
mispairs O +
and O +
insertion O -
/ O -
deletion O +
loops O +
( O -
IDLs O -
) O +
containing O +
1 O +
or O +
2 O +
looped O +
nucleotides O -
, O +
whereas O +
hMutSβ O +
( O -
heterodimer O +
of O +
hMSH2 B-Gene +
and O +
hMSH3 B-Gene -
) O +
recognizes O +
IDLs O +
containing O +
2 O +
or O +
more O +
looped O +
nucleotides O +
that O +
occur O +
at O +
microsatellite O +
sequences O +
[ O -
2 O -
] O -
. O +

The O +
hMutS O +
complexes O +
interact O +
with O +
the O +
hMutLα O +
protein O +
complex O +
( O -
heterodimer O +
of O +
hMLH1 B-Gene +
and O +
hPMS2 B-Gene -
) O +
to O +
coordinate O +
excision O +
and O +
repair O +
of O +
the O +
mispair O +
or O +
IDL O +
[ O -
3 O -
] O -
– O -
[ O -
5 O -
] O -
. O +

Loss O +
of O +
any O +
of O +
the O +
components O +
of O +
the O +
MMR B-Gene +
system O +
inactivates O +
or O +
attenuates O +
DNA O +
repair O -
, O +
and O +
is O +
the O +
cause O +
of O +
microsatellite O +
instability O +
( O -
MSI O -
) O +
[ O -
6 O -
] O -
, O +
[ O -
7 O -
] O -
. O +

Patients O +
with O +
germline O +
mutations O +
of O +
hMSH2 B-Gene -
, O +
hMLH1 B-Gene -
, O +
hMSH6 B-Gene -
, O +
or O +
hPMS2 B-Gene +
have O +
Lynch O +
syndrome O +
( O -
formerly O +
known O +
as O +
hereditary O +
nonpolyposis O +
colon O +
cancer O +
or O +
HNPCC O -
) O -
, O +
the O +
most O +
common O +
familial O +
form O +
of O +
colorectal O +
cancer O +
[ O -
8 O -
] O -
– O -
[ O -
11 O -
] O -
. O +

Epigenetic O +
inactivation O +
of O +
hMLH1 B-Gene +
through O +
promoter O +
hypermethylation O +
occurs O +
in O +
15–20 O -
% O +
of O +
sporadic O +
colorectal O +
cancers O +
[ O -
12 O -
] O -
, O +
[ O -
13 O -
] O -
. O +

In O +
either O +
instance O -
, O +
the O +
resulting O +
colorectal O +
cancers O +
display O +
the O +
phenotype O +
of O +
MSI O +
observed O +
as O +
novel O +
length O +
mutations O +
at O +
microsatellites O +
[ O -
7 O -
] O -
. O +

Microsatellites O +
are O +
nucleotide O +
repeat O +
sequences O +
that O +
are O +
ubiquitous O +
throughout O +
the O +
genome O +
[ O -
14 O -
] O -
. O +

Rarely O +
but O +
significantly O -
, O +
microsatellites O +
are O +
present O +
in O +
the O +
coding O +
regions O +
( O -
exons O -
) O +
of O +
critical O +
growth O +
regulatory O +
genes O +
and O +
are O +
targeted O +
for O +
frameshift O +
mutation O +
when O +
DNA O +
MMR B-Gene +
is O +
defective O +
[ O -
15 O -
] O -
. O +

These O +
frameshift O +
mutations O -
, O +
which O +
occur O +
due O +
to O +
non O -
- O -
repair O +
of O +
exonic O +
IDL O -
, O +
are O +
thought O +
to O +
drive O +
the O +
pathogenesis O +
of O +
colorectal O +
cancers O +
and O +
other O +
MSI O +
tumors O -
. O +

The O +
type O +
II O +
receptor O +
for O +
transforming O +
growth O +
factor O +
β O +
( O -
TGFBR2 B-Gene -
) O +
has O +
an O +
A10 O +
microsatellite O +
within O +
exon O +
3 O -
. O +

Frameshift O +
mutation O +
of O +
this O +
polyadenine O +
sequence O +
truncates O +
TGFBR2 B-Gene -
, O +
making O +
it O +
nonfunctional O +
for O +
TGFβ B-Gene +
signaling O +
[ O -
16 O -
] O -
. O +

In O +
70–90 O -
% O +
of O +
colorectal O +
cancers O +
with O +
MSI O -
, O +
TGFBR2 B-Gene +
is O +
frameshift O +
mutated O +
at O +
both O +
alleles O +
[ O -
17 O -
] O -
. O +

This O +
mutation O +
allows O +
the O +
tumor O +
to O +
escape O +
the O +
growth O +
suppressive O +
effects O +
of O +
TGFβ B-Gene -
– O -
SMAD B-Gene +
signaling O -
. O +

TGFBR2 B-Gene +
mutation O +
appears O +
to O +
be O +
a O +
late O +
event O +
in O +
MSI O +
adenomas O +
and O +
tightly O +
correlated O +
with O +
progression O +
of O +
these O +
adenomas O +
to O +
malignant O +
carcinomas O +
[ O -
18 O -
] O -
. O +

The O +
activin O +
type O +
II O +
receptor O -
, O +
ACVR2 B-Gene -
, O +
contains O +
polyadenine O +
tracts O +
at O +
both O +
exons O +
3 O +
and O +
10 O +
but O +
only O +
its O +
exon O +
10 O +
A8 O +
tract O +
is O +
mutated O +
in O +
∼85 O -
% O +
of O +
colorectal O +
cancers O +
with O +
MSI O +
[ O -
19 O -
] O -
, O +
[ O -
20 O -
] O -
. O +

The O +
biallelic O +
frameshift O +
mutation O +
causes O +
ACVR2 B-Gene +
protein O +
loss O -
, O +
and O +
is O +
associated O +
with O +
histologically O +
poor O +
grade O +
tumors O +
and O +
significantly O +
larger O +
volume O +
tumors O +
[ O -
20 O -
] O -
, O +
[ O -
21 O -
] O -
. O +

Restoration O +
of O +
ACVR2 B-Gene +
in O +
colon O +
cancer O +
cells O +
causes O +
growth O +
suppression O +
[ O -
22 O -
] O -
. O +

Results O +
Successful O +
cloning O +
and O +
stable O +
transfection O +
of O +
pIREShyg2-TGFBR2-EGFP O +
and O +
pIREShyg2 O +
ACVR2-EGFP B-Gene +
plasmids O +
The O +
plasmid O +
pIREShyg2-EGFP O +
allows O +
the O +
expression O +
of O +
EGFP O +
under O +
the O +
control O +
of O +
a O +
constitutive O +
cytomegalovirus O +
promoter O -
, O +
which O +
is O +
active O +
throughout O +
the O +
cell O +
cycle O +
[ O -
25 O -
] O -
. O +

We O +
inserted O +
portions O +
of O +
exon O +
3 O +
of O +
TGFBR2 B-Gene +
or O +
exon O +
10 O +
of O +
ACVR2 B-Gene +
as O +
outlined O +
in O +
Fig. O +
1 O +
after O +
the O +
translation O +
initiation O +
codon O +
of O +
the O +
EGFP O +
gene O -
, O +
either O +
in O -
- O -
frame O +
of O +
an O +
EGFP O +
( O -
IF O -
) O +
or O +
+ O -
1 O +
bp O +
out O +
of O +
frame O +
of O +
the O +
EGFP O +
( O -
OF O -
) O +
in O +
pIREShyg2-EGFP O -
. O +

For O +
experimental O +
plasmids O -
, O +
TGFBR2 B-Gene +
or O +
ACVR2 B-Gene +
sequences O +
were O +
cloned O +
+ O -
1 O +
bp O +
OF O +
in O +
pIREShyg2-EGFP O +
and O +
thus O +
a O +
−1 O +
bp O +
frameshift O +
mutation O +
at O +
the O +
coding O +
microsatellite O +
would O +
shift O +
the O +
EGFP O +
gene O +
into O +
the O +
proper O +
reading O +
frame O +
to O +
allow O +
EGFP O +
expression O -
. O +

Mutation O +
resistant O +
( O -
MR O -
) O +
counterpart O +
plasmids O +
were O +
constructed O +
by O +
interrupting O +
the O +
coding O +
microsatellites O +
( O -
A10 O +
to O +
A2CA2GA2CA O +
in O +
TGFBR2 B-Gene +
and O +
A8 O +
to O +
A3GA4 O +
in O +
ACVR2 B-Gene -
) O +
and O +
would O +
be O +
resistant O +
to O +
frameshift O +
mutation O -
. O +

The O +
MR O +
TGFBR2 B-Gene +
and O +
MR O +
ACVR2 B-Gene +
plasmids O +
were O +
placed O +
OF O +
( O -
+ O -
1 O +
bp O -
) O +
and O +
IF O +
to O +
be O +
used O +
as O +
negative O +
and O +
positive O +
controls O +
for O +
EGFP O +
expression O -
, O +
respectively O -
. O +

Transient O +
transfections O +
of O +
these O +
plasmids O +
into O +
the O +
hMLH1− B-Gene -
/ O -
− O +
background O +
were O +
performed O +
to O +
verify O +
their O +
EGFP O +
expression O +
in O +
cells O +
and O +
detected O +
by O +
a O +
fluorescence O +
microscope O +
before O +
stable O +
cell O +
lines O +
with O +
different O +
MMR B-Gene +
deficiency O +
were O +
established O -
. O +

Positive O +
controls O +
expressed O +
EGFP O +
whereas O +
negative O +
controls O +
did O +
not O +
express O +
EGFP O +
in O +
the O +
cells O -
. O +

pIREShyg2-TGFBR2-EGFP O +
and O +
pIREShyg2-ACVR2-EGFP O +
plasmids O -
. O +

Portions O +
of O +
exon O +
3 O +
of O +
TGFBR2 B-Gene +
and O +
exon O +
10 O +
of O +
ACVR2 B-Gene +
sequences O +
containing O +
coding O +
microsatellites O +
were O +
inserted O +
immediately O +
after O +
the O +
start O +
codon O +
of O +
the O +
EGFP O +
gene O -
, O +
being O +
in O +
frame O +
with O +
EGFP O +
( O -
IF O -
) O +
or O +
+ O -
1 O +
bp O +
out O +
of O +
reading O +
frame O +
with O +
the O +
EGFP O +
( O -
OF O -
) O +
in O +
pIREShyg2-EGFP O -
. O +

Mutation O +
resistant O +
( O -
MR O -
) O +
plasmids O +
were O +
constructed O +
by O +
interrupting O +
the O +
coding O +
microsatellite O +
sequences O +
( O -
A10 O +
to O +
A2CA2GA2CA O +
in O +
TGFBR2 B-Gene +
and O +
A8 O +
to O +
A3GA4 O +
in O +
ACVR2 B-Gene -
) O -
, O +
preventing O +
frameshift O +
mutation O -
. O +

Deletion O +
of O +
1 O +
bp O +
in O +
OF O +
plasmids O -
, O +
experimental O +
plasmids O -
, O +
restores O +
the O +
proper O +
reading O +
frame O +
and O +
allows O +
EGFP O +
expression O -
. O +

MR O +
IF O +
and O +
MR O +
OF O +
plasmids O +
were O +
used O +
for O +
positive O +
and O +
negative O +
control O +
for O +
EGFP O +
expression O -
, O +
respectively O -
. O +

Subsequently O -
, O +
twenty O -
- O -
four O +
stable O +
cell O +
lines O +
with O +
differing O +
MMR B-Gene +
genetic O +
backgrounds O +
( O -
Table O +
S1 O -
) O +
were O +
established O +
with O +
hygromycin O +
B O +
selection O +
after O +
transfection O -
, O +
as O +
outlined O +
in O +
Table O +
S2 O -
. O +

After O +
selection O -
, O +
colonies O +
from O +
each O +
cell O +
line O +
were O +
initially O +
pooled O +
and O +
cultured O +
for O +
mutation O +
analysis O -
. O +

After O +
5 O +
weeks O -
, O +
the O +
proportion O +
of O +
fluorescent O +
cells O +
within O +
each O +
cell O +
line O +
was O +
measured O +
by O +
flow O +
cytometry O -
. O +

All O +
eight O +
cell O +
lines O +
containing O +
MR O +
TGFBR2 B-Gene +
IF O +
or O +
MR O +
ACVR2 B-Gene +
IF O +
sequence O +
showed O +
fluorescence O +
between O +
88 O -
% O +
and O +
100 O -
% O +
( O -
median O +
99.1 O -
% O -
) O -
, O +
indicating O +
robust O +
selection O +
efficiency O +
of O +
the O +
MR O +
IF O +
stable O +
cell O +
lines O +
( O -
Fig. O +
2 O -
) O -
. O +

In O +
hMLH1− B-Gene -
/ O -
− O +
and O +
hMSH6− B-Gene -
/ O -
− O +
cells O +
containing O +
TGFBR2 B-Gene +
OF O +
or O +
ACVR2 B-Gene +
OF O +
sequences O -
, O +
newly O +
fluorescent O +
cells O +
were O +
observed O +
ranging O +
between O +
0.14 O -
% O +
and O +
1.22 O -
% O +
( O -
median O +
0.32 O -
% O -
) O +
net O +
fluorescence O +
over O +
counterpart O +
cell O +
lines O +
containing O +
MR O +
TGFBR2 B-Gene +
OF O +
or O +
MR O +
ACVR2 B-Gene +
OF O +
sequences O -
. O +

The O +
hMLH1− B-Gene -
/ O -
− O +
cells O +
with O +
TGFBR2 B-Gene +
OF O +
sequence O +
showed O +
the O +
highest O +
net O +
fluorescence O +
( O -
1.22 O -
% O -
) O +
among O +
cell O +
lines O +
with O +
TGFBR2 B-Gene +
OF O +
or O +
ACVR2 B-Gene +
OF O +
sequences O +
( O -
Fig. O +
2 O -
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
hMSH3− B-Gene -
/ O -
− O +
and O +
MMR B-Gene +
proficient O +
stable O +
cell O +
lines O +
did O +
not O +
show O +
any O +
net O +
fluorescence O -
. O +

The O +
−1 O +
bp O +
mutation O +
frequency O +
at O +
each O +
time O +
point O +
was O +
expressed O +
as O +
a O +
fold O +
change O +
using O +
the O +
following O +
formula O -
: O +
( O -
EGFP O +
positive O +
cells O -
/ O -
total O +
live O +
cells O +
from O +
TGFBR2 B-Gene +
OF O +
or O +
ACVR2 B-Gene +
OF O +
cells O -
) O -
/ O -
( O -
EGFP O +
positive O +
cells O -
/ O -
total O +
live O +
cells O +
from O +
MR O +
TGFBR2 B-Gene +
OF O +
or O +
MR O +
ACVR2 B-Gene +
OF O +
cells O -
) O +
( O -
Fig. O +
4 O -
) O -
. O +

The O +
M2 O +
population O +
accumulated O +
over O +
time O +
( O -
most O +
dramatically O +
with O +
TGFBR2 B-Gene +
and O +
ACVR2 B-Gene +
sequences O +
in O +
hMLH1− B-Gene -
/ O -
− O +
background O -
) O +
whereas O +
the O +
M1 O +
population O +
showed O +
little O +
change O +
( O -
Fig. O +
4 O -
) O -
, O +
indicating O +
that O +
M1 O +
and O +
M2 O +
are O +
distinct O +
populations O -
. O +

The O +
M1 O +
and O +
M2 O +
populations O +
were O +
plotted O +
separately O +
for O +
analysis O +
of O +
mutation O +
frequency O -
. O +

Mutation O +
frequencies O +
of O +
TGFBR2 B-Gene +
exon O +
3 O +
and O +
ACVR2 B-Gene +
exon O +
10 O +
are O +
dependent O +
on O +
the O +
MMR B-Gene +
background O -
. O +

Nonfluorescent O +
cells O +
were O +
analyzed O +
for O +
EGFP O +
expression O +
by O +
flow O +
cytometry O +
at O +
7 O -
, O +
14 O -
, O +
21 O -
, O +
28 O -
, O +
and/or O +
35 O +
days O +
after O +
being O +
sorted O +
and O +
cultured O -
, O +
and O +
EGFP O +
analysis O +
was O +
performed O +
as O +
described O +
in O +
Fig. O +
3 O -
. O +

Mutation O +
frequency O +
at O +
each O +
time O +
point O +
was O +
expressed O +
as O +
a O +
fold O +
change O +
using O +
the O +
following O +
formula O -
: O +
( O -
EGFP O +
positive O +
cells O -
/ O -
total O +
live O +
cells O +
from O +
TGFBR2 B-Gene +
OF O +
or O +
ACVR2 B-Gene +
OF O +
cells O -
) O -
/ O -
( O -
EGFP O +
positive O +
cells O -
/ O -
total O +
live O +
cells O +
from O +
MR O +
TGFBR2 B-Gene +
OF O +
or O +
MR O +
ACVR2 B-Gene +
OF O +
cells O -
) O -
. O +

Overall O -
, O +
the O +
M1 O +
population O +
showed O +
little O +
change O +
in O +
mutation O +
frequency O +
whereas O +
mutation O +
frequency O +
of O +
the O +
M2 O +
population O +
accumulated O +
over O +
time O -
, O +
indicating O +
that O +
M1 O +
and O +
M2 O +
populations O +
are O +
distinct O +
populations O -
. O +

In O +
the O +
M2 O +
population O -
, O +
note O +
that O +
the O +
hMLH1 B-Gene +
deficiency O +
conferred O +
higher O +
mutation O +
frequencies O +
in O +
both O +
ACVR2 B-Gene +
and O +
TGFBR2 B-Gene +
sequences O +
compared O +
to O +
hMSH6 B-Gene +
and O +
hMSH3 B-Gene +
deficiencies O +
and O +
that O +
TGFBR2 B-Gene +
sequence O +
showed O +
a O +
higher O +
mutation O +
frequency O +
than O +
ACVR2 B-Gene +
sequence O +
in O +
identical O +
MMR B-Gene +
deficiencies O -
. O +

Cell O +
lines O +
showing O +
lower O +
mutation O +
frequencies O +
( O -
less O +
than O +
25-fold O +
change O -
) O +
were O +
separately O +
plotted O +
in O +
the O +
right O +
panel O +
using O +
a O +
smaller O +
y O -
- O -
axis O +
scale O -
. O +

Data O +
are O +
means O +
from O +
three O +
independent O +
experiments O +
at O +
each O +
time O +
point O -
. O +

In O +
the O +
M1 O +
population O -
, O +
mutation O +
frequency O +
of O +
the O +
TGFBR2 B-Gene +
sequence O +
in O +
hMLH1− B-Gene -
/ O -
− O +
cells O +
was O +
higher O +
than O +
other O +
cell O +
lines O +
and O +
increased O +
over O +
time O +
( O -
highest O +
at O +
day O +
35 O -
, O +
21-fold O +
change O -
) O -
, O +
although O +
the O +
increase O +
over O +
time O +
was O +
small O +
when O +
compared O +
to O +
the O +
increase O +
in O +
the O +
M2 O +
population O +
( O -
Fig. O +
4A O -
) O -
. O +

There O +
was O +
no O +
consistent O +
increase O +
in O +
the O +
M1 O +
population O +
in O +
other O +
cell O +
lines O +
over O +
time O +
except O +
hMSH3− B-Gene -
/ O -
− O +
TGFBR2 B-Gene +
cells O +
that O +
showed O +
a O +
slow O +
increase O +
in O +
mutation O +
frequency O +
up O +
to O +
day O +
35 O +
( O -
5-fold O +
change O -
) O -
. O +

In O +
the O +
M2 O +
population O -
, O +
the O +
TGFBR2 B-Gene +
sequence O +
in O +
the O +
hMLH1− B-Gene -
/ O -
− O +
background O +
demonstrated O +
the O +
highest O +
mutation O +
frequency O +
( O -
highest O +
at O +
day O +
21 O -
, O +
240-fold O +
change O -
) O +
over O +
time O +
compared O +
to O +
other O +
different O +
MMR B-Gene +
deficient O +
backgrounds O +
as O +
predicted O +
in O +
EGFP O +
histograms O +
( O -
Fig. O +
3E O -
) O -
. O +

Mutation O +
frequency O +
of O +
the O +
TGFBR2 B-Gene +
sequence O +
in O +
the O +
hMSH6− B-Gene -
/ O -
− O +
background O +
also O +
increased O +
over O +
time O +
and O +
showed O +
the O +
highest O +
mutation O +
frequency O +
on O +
day O +
35 O +
( O -
14-fold O +
change O -
) O -
, O +
although O +
this O +
frequency O +
is O +
much O +
lower O +
than O +
TGFBR2 B-Gene +
sequence O +
in O +
hMLH1− B-Gene -
/ O -
− O +
cells O +
( O -
Fig. O +
4B O -
) O -
. O +

At O +
day O +
35 O -
, O +
frameshift O +
mutation O +
of O +
ACVR2 B-Gene +
sequence O +
in O +
the O +
hMLH1− B-Gene -
/ O -
− O +
background O +
was O +
79-fold O +
higher O +
than O +
the O +
negative O +
control O +
whereas O +
ACVR2 B-Gene +
sequence O +
in O +
the O +
hMSH6− B-Gene -
/ O -
− O +
background O +
showed O +
a O +
4-fold O +
change O +
in O +
mutation O +
frequency O -
. O +

In O +
all O +
hMSH3− B-Gene -
/ O -
− O +
stable O +
cell O +
lines O -
, O +
M2 O +
cells O +
were O +
rare O +
events O +
( O -
average O +
0.009 O -
% O -
) O +
at O +
all O +
time O +
points O +
and O +
there O +
was O +
no O +
significant O +
difference O +
in O +
numbers O +
of O +
the O +
M2 O +
population O +
between O +
MR O +
TGFBR2 B-Gene +
or O +
MR O +
ACVR2 B-Gene +
OF O +
and O +
TGFBR2 B-Gene +
or O +
ACVR2 B-Gene +
OF O +
cells O -
, O +
respectively O -
, O +
as O +
shown O +
in O +
Fig. O +
3E O -
. O +

Thus O -
, O +
fold O +
changes O +
in O +
the O +
M2 O +
population O +
were O +
1 O +
at O +
all O +
time O +
points O +
for O +
both O +
TGFBR2 B-Gene +
and O +
ACVR2 B-Gene +
sequences O +
in O +
hMSH3− B-Gene -
/ O -
− O +
cell O +
lines O +
( O -
Fig. O +
4B O -
) O -
. O +

The O +
M1 O +
population O +
represents O +
pass O -
- O -
through O +
heteroduplexes O -
, O +
while O +
the O +
M2 O +
population O +
represents O +
fully O +
mutant O +
sequences O +
To O +
confirm O +
that O +
fluorescence O +
from O +
the O +
M1 O +
and O +
M2 O +
populations O +
was O +
driven O +
by O +
−1 O +
bp O +
frameshift O +
mutation O +
at O +
the O +
coding O +
microsatellites O +
of O +
TGFBR2 B-Gene +
OF O +
and O +
ACVR2 B-Gene +
OF O -
, O +
at O +
day O +
21 O +
after O +
being O +
plated O +
as O +
nonfluorescent O +
cells O -
, O +
cells O +
from O +
the O +
M1 O +
and/or O +
M2 O +
populations O +
of O +
hMLH1− B-Gene -
/ O -
− O +
TGFBR2 B-Gene +
OF O +
or O +
ACVR2 B-Gene +
OF O +
cells O -
, O +
hMSH6− B-Gene -
/ O -
− O +
TGFBR2 B-Gene +
OF O +
or O +
ACVR2 B-Gene +
OF O +
cells O -
, O +
and O +
hMSH3− B-Gene -
/ O -
− O +
TGFBR2 B-Gene +
OF O +
or O +
ACVR2 B-Gene +
OF O +
cells O +
were O +
sorted O +
and O +
expanded O +
for O +
sequencing O +
analysis O -
. O +

DNA O +
from O +
each O +
cell O +
line O +
was O +
amplified O +
by O +
PCR O -
, O +
sub O -
- O -
cloned O +
into O +
a O +
TA O +
cloning O +
vector O +
and O +
single O +
cell O +
clones O +
were O +
individually O +
sequenced O +
to O +
assess O +
for O +
frameshift O +
mutation O +
at O +
the O +
coding O +
microsatellites O +
of O +
TGFBR2 B-Gene +
exon O +
3 O +
and O +
ACVR2 B-Gene +
exon O +
10 O -
. O +

As O +
expected O -
, O +
nearly O +
all O +
DNA O +
clones O +
( O -
86–100 O -
% O -
) O +
from O +
the O +
M2 O +
population O +
of O +
all O +
cell O +
lines O +
with O +
hMLH1− B-Gene -
/ O -
− O +
and O +
hMSH6− B-Gene -
/ O -
− O +
revealed O +
−1 O +
bp O +
frameshift O +
mutation O +
( O -
A9 O +
at O +
TGFBR2 B-Gene +
and O +
A7 O +
at O +
ACVR2 B-Gene -
) O -
, O +
indicating O +
fully O +
mutant O +
sequences O +
inducing O +
EGFP O +
expression O +
( O -
Fig. O +
5A O -
) O -
. O +

Rare O +
A8 O +
sequences O +
were O +
observed O +
in O +
M2 O +
clones O +
from O +
hMSH6− B-Gene -
/ O -
− O +
TGFBR2 B-Gene +
OF O +
cells O -
. O +

In O +
particular O -
, O +
all O +
clones O +
from O +
the O +
M2 O +
population O +
of O +
hMLH1− B-Gene -
/ O -
− O +
TGFBR2 B-Gene +
OF O +
cells O +
revealed O +
frame O +
shift O +
mutations O +
( O -
A9 O -
) O +
with O +
no O +
wild O +
type O +
A10 O +
sequence O +
( O -
Fig. O +
5A O -
) O -
. O +

This O +
observation O +
correlates O +
with O +
the O +
highest O +
mutation O +
frequency O +
of O +
hMLH1− B-Gene -
/ O -
− O +
TGFBR2 B-Gene +
cells O +
over O +
time O +
( O -
Fig. O +
4B O -
) O -
. O +

In O +
comparison O -
, O +
clones O +
from O +
the O +
M1 O +
population O +
of O +
hMLH1− B-Gene -
/ O -
− O +
TGFBR2 B-Gene +
OF O +
and O +
hMLH1− B-Gene -
/ O -
− O +
ACVR2 B-Gene +
OF O +
revealed O +
84 O +
and O +
69 O -
% O +
of O +
mutant O +
( O -
A9 O +
and O +
A7 O -
) O +
microsatellites O -
, O +
respectively O -
, O +
and O +
clones O +
from O +
the O +
M1 O +
population O +
of O +
hMSH6− B-Gene -
/ O -
− O +
TGFBR2 B-Gene +
OF O +
and O +
hMSH6− B-Gene -
/ O -
− O +
ACVR2 B-Gene +
OF O +
cells O +
expressed O +
50 O +
and O +
53 O -
% O +
of O +
mutant O +
( O -
A9 O +
and O +
A7 O -
) O +
microsatellites O -
, O +
respectively O +
( O -
Fig. O +
5A O -
) O -
. O +

A O +
rare O +
A11 O +
sequence O +
was O +
also O +
observed O +
in O +
M1 O +
clones O +
from O +
hMSH6− B-Gene -
/ O -
− O +
TGFBR2 B-Gene +
OF O +
cells O -
. O +

In O +
the O +
M1 O +
population O -
, O +
clones O +
of O +
hMLH1− B-Gene -
/ O -
− O +
TGFBR2 B-Gene +
OF O +
cells O +
showed O +
a O +
−1 O +
bp O +
frameshift O +
mutation O +
in O +
84 O -
% O -
, O +
corresponding O +
to O +
the O +
highest O +
increase O +
in O +
mutation O +
frequency O +
in O +
the O +
M1 O +
population O +
of O +
all O +
cell O +
lines O +
over O +
time O +
( O -
Fig. O +
4A O -
) O -
. O +

Only O +
five O +
percent O +
( O -
1 O -
/ O -
20 O -
) O +
of O +
M1 O +
clones O +
from O +
hMSH3− B-Gene -
/ O -
− O +
TGFBR2 B-Gene +
OF O +
cells O +
revealed O +
a O +
mutated O +
microsatellite O +
sequence O +
( O -
A9 O -
) O +
( O -
Fig. O +
5A O -
) O -
. O +

The O +
M1 O +
population O +
from O +
hMSH3− B-Gene -
/ O -
− O +
ACVR2 B-Gene +
OF O +
cells O +
did O +
not O +
show O +
any O +
frameshift O +
mutation O +
( O -
data O +
not O +
shown O -
) O +
and O +
thus O +
sub O -
- O -
cloning O +
was O +
not O +
done O +
for O +
sequencing O +
analysis O -
. O +

As O +
expected O -
, O +
all O +
MR O +
stable O +
cell O +
lines O +
did O +
not O +
show O +
frameshift O +
mutations O +
at O +
microsatellites O +
with O +
MMR B-Gene -
- O -
deficiency O -
. O +

In O +
addition O -
, O +
all O +
MMR B-Gene +
proficient O +
HT29 O +
stable O +
cell O +
lines O +
did O +
not O +
show O +
any O +
frameshift O +
mutations O +
at O +
microsatellites O +
of O +
TGFBR2 B-Gene +
and O +
ACVR2 B-Gene -
. O +

Calculated O +
mutation O +
rates O +
at O +
coding O +
microsatellites O +
of O +
TGFBR2 B-Gene +
exon3 O +
and O +
ACVR2 B-Gene +
exon O +
10 O +
in O +
cells O +
with O +
MMR B-Gene +
deficiency O -
. O +

Data O +
from O +
the O +
M2 O +
cell O +
population O +
from O +
each O +
time O +
point O +
between O +
day O +
14 O +
and O +
day O +
35 O +
were O +
used O +
for O +
mutation O +
rate O +
analysis O -
. O +

Single O +
mutation O +
rates O +
were O +
calculated O +
by O +
combining O +
and O +
averaging O +
time O -
- O -
specific O +
mutation O +
rates O -
. O +

Rates O +
are O +
expressed O +
as O +
mutations O +
at O +
microsatellite O +
sequence O +
per O +
cell O +
per O +
generation O -
. O +

Data O +
shown O +
are O +
mean±SEM O -
. O +

* O -
P<0.01 O +
comparing O +
hMLH1− B-Gene -
/ O -
− O +
TGFBR2 B-Gene +
with O +
each O +
of O +
hMLH1− B-Gene -
/ O -
− O +
ACVR2 B-Gene -
, O +
hMSH6− B-Gene -
/ O -
− O +
TGFBR2 B-Gene -
, O +
and O +
hMSH6− B-Gene -
/ O -
− O +
ACVR2 B-Gene -
. O +

† O +
P<0.01 O +
comparing O +
hMLH1− B-Gene -
/ O -
− O +
ACVR2 B-Gene +
with O +
each O +
of O +
hMSH6− B-Gene -
/ O -
− O +
TGFBR2 B-Gene -
, O +
and O +
hMSH6− B-Gene -
/ O -
− O +
ACVR2 B-Gene -
. O +

Discussion O +
In O +
this O +
study O -
, O +
we O +
developed O +
an O +
experimental O +
model O +
in O +
which O +
the O +
actual O +
human O +
coding O +
sequences O +
of O +
TGFBR2 B-Gene +
exon O +
3 O +
and O +
ACVR2 B-Gene +
exon O +
10 O +
were O +
evaluated O +
in O +
real O +
time O +
for O +
−1 O +
bp O +
frameshift O +
mutations O +
in O +
human O +
cells O +
with O +
differing O +
MMR B-Gene +
genetic O +
backgrounds O +
( O -
hMLH1− B-Gene -
/ O -
− O -
, O +
hMSH6− B-Gene -
/ O -
− O -
, O +
hMSH3− B-Gene -
/ O -
− O -
, O +
and O +
MMR B-Gene -
- O -
proficient O -
) O -
. O +

Our O +
aim O +
was O +
to O +
test O +
the O +
hypothesis O +
that O +
the O +
frequency O +
and O +
rate O +
of O +
targeted O +
genes O +
for O +
frameshift O +
mutation O +
in O +
human O +
MSI O +
tumors O +
are O +
dependent O +
on O +
the O +
MMR B-Gene +
genetic O +
background O -
. O +

−1 O +
bp O +
frameshift O +
mutations O +
in O +
exon O +
3 O +
of O +
TGFBR2 B-Gene +
and O +
exon O +
10 O +
of O +
ACVR2 B-Gene +
are O +
common O +
in O +
MSI O +
tumors O -
, O +
and O +
are O +
thought O +
to O +
help O +
drive O +
the O +
pathogenesis O +
of O +
colorectal O +
cancers O +
manifesting O +
MSI O -
. O +

Although O +
the O +
general O +
frequencies O +
of O +
TGFBR2 B-Gene +
and O +
ACVR2 B-Gene +
mutations O +
are O +
culled O +
from O +
general O +
colorectal O +
cancer O +
cohorts O -
, O +
there O +
is O +
no O +
experimental O +
data O +
on O +
mutation O +
rates O +
of O +
these O +
targeted O +
genes O +
and O +
how O +
MMR B-Gene +
deficiency O +
can O +
influence O +
those O +
rates O -
. O +

In O +
this O +
study O -
, O +
we O +
made O +
several O +
unique O +
observations O -
: O +
( O -
1 O -
) O +
the O +
−1 O +
bp O +
frameshift O +
mutations O +
at O +
coding O +
microsatellites O +
within O +
human O +
TGFBR2 B-Gene +
exon O +
3 O +
and O +
ACVR2 B-Gene +
exon O +
10 O +
sequences O +
were O +
observed O +
in O +
real O +
time O +
in O +
different O +
human O +
MMR B-Gene +
deficient O +
backgrounds O -
; O +
( O -
2 O -
) O +
both O +
coding O +
microsatellites O +
of O +
TGFBR2 B-Gene +
and O +
ACVR2 B-Gene +
mutate O +
through O +
heteroduplex O +
formation O +
( O -
M1 O -
) O +
before O +
full O +
mutation O +
( O -
M2 O -
) O -
; O +
( O -
3 O -
) O +
MMR B-Gene -
- O -
deficient O +
backgrounds O +
determine O +
the O +
mutation O +
frequency O +
and O +
rate O +
of O +
the O +
coding O +
microsatellites O +
of O +
TGFBR2 B-Gene +
and O +
ACVR2 B-Gene -
, O +
for O +
which O +
hMLH1 B-Gene -
> O -
hMSH6 B-Gene -
> O -
hMSH3 B-Gene +
deficiency O -
; O +
( O -
4 O -
) O +
hMSH3− B-Gene -
/ O -
− O +
background O +
does O +
not O +
generate O +
any O +
significant O +
frameshift O +
mutation O +
in O +
the O +
tested O +
sequences O -
; O +
and O +
( O -
5 O -
) O +
the O +
coding O +
A10 O +
microsatellite O +
of O +
TGFBR2 B-Gene +
mutates O +
at O +
a O +
higher O +
rate O +
than O +
the O +
A8 O +
coding O +
microsatellite O +
of O +
ACVR2 B-Gene +
in O +
hMLH1− B-Gene -
/ O -
− O +
and O +
hMSH6− B-Gene -
/ O -
− O +
backgrounds O -
. O +

Our O +
experimental O +
model O +
revealed O +
two O +
distinct O +
fluorescent O +
populations O +
of O +
mutant O +
cells O -
, O +
M1 O +
expressing O +
dim O +
EGFP O +
and O +
M2 O +
expressing O +
bright O +
EGFP O +
( O -
Fig. O +
3 O -
) O -
. O +

The O +
M2 O +
population O +
accumulated O +
over O +
time O +
whereas O +
the O +
M1 O +
population O +
showed O +
little O +
change O +
( O -
Fig. O +
4 O -
) O -
. O +

These O +
observations O +
were O +
similar O +
to O +
a O +
study O +
that O +
observed O +
frameshift O +
mutation O +
at O +
a O +
noncoding O +
( O -
CA O -
) O -
13 O +
microsatellite O +
in O +
an O +
hMLH1− B-Gene -
/ O -
− O +
background O +
[ O -
25 O -
] O -
. O +

We O +
confirmed O +
that O +
EGFP O +
expression O +
from O +
M1 O +
and O +
M2 O +
populations O +
was O +
driven O +
as O +
a O +
result O +
of O +
a O +
−1 O +
bp O +
frameshift O +
mutation O +
of O +
TGFBR2 B-Gene +
OF O +
and O +
ACVR2 B-Gene +
OF O +
cells O +
by O +
TA O +
subcloning O +
and O +
DNA O +
sequencing O +
analysis O +
( O -
Fig. O +
5 O -
) O -
. O +

In O +
particular O -
, O +
the O +
M2 O +
clones O +
from O +
hMLH1− B-Gene -
/ O -
− O +
TGFBR2 B-Gene +
OF O +
cells O +
revealed O +
that O +
all O +
clones O +
underwent O +
−1 O +
bp O +
frameshift O +
mutation O -
, O +
indicating O +
that O +
the O +
M2 O +
clones O +
are O +
fully O +
mutant O +
cells O +
containing O +
a O +
frameshifted O +
A9 O -
/ O -
T9 O +
microsatellite O -
. O +

The O +
M2 O +
clones O +
from O +
hMSH6− B-Gene -
/ O -
− O +
TGFBR2 B-Gene +
OF O -
, O +
hMLH1− B-Gene -
/ O -
− O +
ACVR2 B-Gene +
OF O -
, O +
and O +
hMSH6− B-Gene -
/ O -
− O +
ACVR2 B-Gene +
OF O +
cells O +
showed O +
∼10–15 O -
% O +
WT O +
microsatellite O +
sequences O +
that O +
are O +
derived O +
from O +
the O +
M1 O +
cell O +
population O -
. O +

Clones O +
from O +
M1 O +
populations O +
in O +
hMLH1− B-Gene -
/ O -
− O +
and O +
hMSH6− B-Gene -
/ O -
− O +
backgrounds O +
revealed O +
the O +
coexistence O +
of O +
mutated O +
( O -
65±14 O -
% O -
, O +
A9 O +
for O +
TGFBR2 B-Gene +
and O +
A7 O +
for O +
ACVR2 B-Gene -
) O +
and O +
WT O +
( O -
35±14 O -
% O -
, O +
A10 O +
and O +
A8 O -
) O +
microsatellite O +
sequences O -
, O +
indicating O +
the O +
existence O +
of O +
intermediate O +
mutant O +
cells O +
containing O +
A8 O -
/ O -
T7 O +
or O +
A10 O -
/ O -
T9 O +
heteroduplexes O +
within O +
the O +
M1 O +
population O +
transferring O +
into O +
full O +
mutant O +
cells O +
as O +
previously O +
observed O +
[ O -
25 O -
] O -
. O +

Relative O +
to O +
the O +
M2 O +
population O -
, O +
the O +
M1 O +
population O +
increased O +
initially O +
but O +
reached O +
a O +
steady O +
state O +
as O +
a O +
constant O +
supply O +
of O +
actively O +
mutating O +
cells O +
transitioned O +
into O +
the O +
M2 O +
population O -
. O +

Although O +
∼5 O -
% O +
of O +
cells O +
in O +
hMSH3− B-Gene -
/ O -
− O +
TGFBR2 B-Gene +
revealed O +
mutated O +
microsatellite O +
sequence O +
( O -
A9 O -
) O +
in O +
the O +
M1 O +
population O -
, O +
none O +
transitioned O +
into O +
the O +
M2 O +
population O -
. O +

This O +
is O +
likely O +
due O +
to O +
repair O +
by O +
hMutSα O +
at O +
the O +
IDL O -
, O +
for O +
which O +
hMutSβ O +
is O +
not O +
needed O +
for O +
repair O -
. O +

Materials O +
and O +
Methods O +
Cloning O +
of O +
pIREShyg2-TGFBR2-EGFP O +
and O +
pIREShyg2-ACVR2-EGFP O +
plasmids O +
Plasmid O +
pIREShyg2-EGFP O +
was O +
a O +
kind O +
gift O +
from O +
C. O +
Richard O +
Boland O -
, O +
MD O +
( O -
Baylor O +
Univ O -
. O +

Med O +
Center O -
, O +
Dallas O -
, O +
TX O -
) O -
. O +

Details O +
of O +
cloning O +
of O +
pIREShyg2-EGFP O +
were O +
previously O +
described O +
[ O -
24 O -
] O -
. O +

Portions O +
of O +
exon O +
3 O +
of O +
TGFBR2 B-Gene +
and O +
exon O +
10 O +
of O +
AVCR2 B-Gene +
( O -
shown O +
in O +
Fig. O +
1 O -
) O +
were O +
amplified O +
by O +
PCR O +
from O +
the O +
MMR B-Gene +
proficient O +
human O +
colon O +
carcinoma O +
cell O +
line O +
FET O +
( O -
kind O +
gift O +
of O +
Michael O +
Brattain O -
, O +
Ph.D. O +
Roswell O +
Park O +
Cancer O +
Inst O -
; O +
Buffalo O -
, O +
NY O -
) O -
. O +

New O +
PmeI O +
and O +
AscI O +
sites O +
were O +
created O +
in O +
the O +
5′ O +
and O +
3′ O +
ends O +
of O +
those O +
TGFBR2 B-Gene +
and O +
ACVR2 B-Gene +
sequences O +
by O +
PCR O -
, O +
respectively O +
( O -
primers O -
: O +
5′-GCGTCGTTTAAACCTGCTTCTCCAAAGTGCATTATG-3′ O +
and O +
5′-AAGGCGCGCCAAGAAAGTCTCACCAGGCTT-3′ O +
for O +
TGFBR2 B-Gene +
and O +
5′- O +
AGCTTTGTTTAAACGACCTGTAGATGAATACATGT-3′ O +
and O +
5′-AAGGCGCGCCAAACAGGCCT O +
CTTTTTTTTATG-3′ O +
for O +
ACVR2 B-Gene -
) O -
. O +

The O +
PCR O +
products O +
and O +
pIREShyg2-EGFP O +
were O +
digested O +
with O +
PmeI O +
and O +
AscI O +
( O -
New O +
England O +
Biolabs O -
, O +
Ipswich O -
, O +
MA O -
) O +
and O +
the O +
digested O +
PCR O +
products O +
were O +
cloned O +
into O +
PmeI O -
– O -
AscI O +
sites O +
of O +
pIREShyg2-EGFP O +
to O +
generate O +
pIREShyg2-TGFBR2-EGFP O +
and O +
pIREShyg2-ACVR2-EGFP O +
plasmids O +
( O -
Fig. O +
1 O -
) O -
. O +

Experimental O +
plasmids O +
were O +
constructed O +
in O +
which O +
the O +
TGFBR2 B-Gene +
and O +
ACVR2 B-Gene +
sequences O +
were O +
cloned O +
+ O -
1 O +
bp O +
OF O +
in O +
pIREShyg2-EGFP O +
immediately O +
after O +
the O +
translation O +
initiation O +
codon O +
of O +
the O +
EGFP O +
gene O -
, O +
and O +
thus O +
frameshift O +
mutation O +
of O +
−1 O +
bp O +
would O +
allow O +
expression O +
of O +
EGFP O +
( O -
Fig. O +
1 O -
) O -
. O +

As O +
negative O +
control O +
plasmids O +
for O +
EGFP O +
expression O -
, O +
mutation O +
resistant O +
( O -
MR O -
) O +
counterpart O +
plasmids O +
( O -
+ O -
1 O +
bp O +
OF O +
plasmids O -
) O +
were O +
constructed O +
by O +
changing O +
1 O +
or O +
3 O +
nucleotide O +
sequences O +
( O -
A10 O +
to O +
A2CA2GA2CA O +
in O +
TGFBR2 B-Gene +
and O +
A8 O +
to O +
A3GA4 O +
in O +
ACVR2 B-Gene -
) O +
within O +
microsatellites O +
using O +
a O +
Quickchange O +
II O +
site O -
- O -
directed O +
mutagenesis O +
kit O +
( O -
Stratagene O -
, O +
La O +
Jolla O -
, O +
CA O -
) O -
, O +
preventing O +
any O +
frameshift O +
mutation O +
( O -
Fig. O +
1 O -
) O -
. O +

MR O +
IF O +
plasmids O +
containing O +
portions O +
of O +
TGFBR2 B-Gene +
or O +
ACVR2 B-Gene +
were O +
constructed O +
as O +
positive O +
controls O +
for O +
EGFP O +
expression O +
( O -
Fig. O +
1 O -
) O -
. O +

The O +
ligation O +
products O +
were O +
transformed O +
into O +
DH5α O +
cells O -
. O +

Positive O +
colonies O +
were O +
screened O -
, O +
and O +
the O +
correct O +
sequences O +
of O +
TGFBR2 B-Gene +
and O +
ACVR2 B-Gene +
were O +
confirmed O +
by O +
sequencing O +
in O +
an O +
ABI O +
3700 O +
analyzer O -
. O +

Cell O +
lines O -
, O +
transfection O -
, O +
and O +
selection O +
The O +
human O +
colon O +
cancer O +
cell O +
lines O -
, O +
HT29 O +
( O -
MMR B-Gene +
proficient O -
) O -
, O +
HCT116 O +
( O -
hMLH1− B-Gene -
/ O -
− O +
and O +
hMSH3− B-Gene -
/ O -
− O -
) O -
, O +
and O +
DLD-1 O +
( O -
hMSH6− B-Gene -
/ O -
− O -
) O +
were O +
obtained O +
from O +
American O +
Type O +
Culture O +
Collection O +
( O -
Rockville O -
, O +
MD O -
) O +
and O +
maintained O +
in O +
either O +
Dulbeeco O -
's O +
modified O +
Eagle O -
's O +
medium O +
( O -
DMEM O -
, O +
Invtrogen O +
Corp O -
, O +
Carlsbad O -
, O +
CA O -
, O +
for O +
HT29 O +
cells O -
) O +
or O +
Iscove O -
's O +
modified O +
Dulbeeco O -
's O +
medium O +
( O -
IMDM O -
, O +
Invitrogen O +
Corp O -
, O +
for O +
HCT116 O +
and O +
DLD-1 O +
cells O -
) O +
with O +
10 O -
% O +
fetal O +
bovine O +
serum O +
( O -
FBS O -
) O +
and O +
penicillin O +
( O -
100 O +
U O -
/ O -
ml O -
) O -
/ O -
streptomycin O +
( O -
100 O +
µg O -
/ O -
ml O -
) O +
( O -
P O -
/ O -
S O -
, O +
Invitrogen O +
Corp O -
) O +
as O +
supplements O -
. O +

The O +
HCT116 O +
cell O +
line O +
containing O +
transferred O +
chromosome O +
3 O +
( O -
HCT116+chr3 O -
, O +
hMLH1 B-Gene +
restored O +
but O +
hMSH3− B-Gene -
/ O -
− O -
) O +
was O +
developed O +
as O +
previously O +
described O +
[ O -
6 O -
] O +
and O +
maintained O +
in O +
IMDM O +
containing O +
10 O -
% O +
FBS O -
, O +
P O -
/ O -
S O -
, O +
and O +
400 O +
µg O -
/ O -
ml O +
of O +
G418 O +
sulfate O +
( O -
CellGro O -
, O +
Manassas O -
, O +
VA O -
) O -
. O +

Cells O +
were O +
transfected O +
with O +
various O +
pIREShyg2-TGFBR2-EGFP O +
and O +
pIREShyg2-ACVR2-EGFP O +
plasmids O +
by O +
using O +
Nucleofector O +
kit O +
V O +
and O +
L O +
( O -
Amaxa O -
, O +
Cologne O -
, O +
Germany O -
) O -
, O +
following O +
the O +
manufacturer O -
's O +
instructions O -
. O +

Selection O +
with O +
hygromycin O +
B O +
( O -
Invitrogen O +
Corp O -
) O +
was O +
started O +
at O +
24 O +
hr O +
after O +
nucleofection O +
to O +
generate O +
stable O +
cell O +
lines O -
. O +

After O +
selection O -
, O +
colonies O +
from O +
each O +
cell O +
line O +
were O +
initially O +
pooled O +
and O +
cultured O +
for O +
mutation O +
analysis O -
. O +

All O +
stable O +
cell O +
lines O +
were O +
confirmed O +
by O +
sequencing O -
. O +

Analysis O +
of O +
mutant O +
cells O +
by O +
flow O +
cytometry O +
Five O +
thousand O +
nonfluorescent O +
cells O +
expressing O +
MR O +
TGFBR2 B-Gene +
OF O -
, O +
TGFBR2 B-Gene +
OF O -
, O +
MR O +
ACVR2 B-Gene +
OF O -
, O +
or O +
ACVR2 B-Gene +
OF O +
were O +
sorted O +
into O +
24-well O +
plates O +
on O +
a O +
FACS O +
ARIA O +
by O +
using O +
Diva O +
software O +
( O -
Becton O +
Dickinson O +
Immunocytometry O +
Systems O +
( O -
BDIS O -
) O -
, O +
San O +
Jose O -
, O +
CA O -
) O -
. O +

During O +
a O +
7 O +
to O +
35 O +
day O +
analysis O +
period O -
, O +
cultures O +
were O +
expanded O +
as O +
required O +
to O +
keep O +
cells O +
in O +
exponential O +
growth O -
. O +

Cells O +
were O +
trypsinized O -
, O +
washed O +
in O +
PBS O -
, O +
and O +
resuspended O +
in O +
a O +
total O +
volume O +
of O +
200 O +
µl O +
of O +
PBS O -
/ O -
0.5 O +
µg O -
/ O -
ml O +
of O +
propidium O +
iodide O +
( O -
PI O -
) O +
and O +
3 O -
% O +
BSA O -
. O +

Cell O +
suspensions O +
were O +
analyzed O +
on O +
a O +
FACSCalibur O +
with O +
CELLQUEST O +
acquisition O +
and O +
analysis O +
software O +
( O -
BDIS O -
, O +
CA O -
) O -
. O +

At O +
specified O +
time O +
points O -
, O +
three O +
cultures O +
were O +
analyzed O +
in O +
parallel O -
. O +

To O +
identify O +
EGFP O -
- O -
positive O +
cells O -
, O +
region O +
1 O +
( O -
R1 O -
) O +
was O +
set O +
in O +
the O +
forward O -
/ O -
side O +
scatter O +
and O +
region O +
3 O +
( O -
R3 O -
) O +
was O +
set O +
in O +
the O +
forward O -
/ O -
PI O +
scatter O -
, O +
and O +
then O +
R1 O +
and O +
R3 O +
were O +
gated O +
by O +
live O +
cells O -
. O +

Region O +
2 O +
( O -
R2 O -
) O +
was O +
set O +
in O +
the O +
fluorescence O +
1 O +
( O -
FL1 O -
, O +
green O -
) O -
/ O -
fluorescence O +
2 O +
( O -
FL2 O -
, O +
red O -
) O +
scatter O -
. O +

Cells O +
from O +
the O +
gated O +
R1 O -
, O +
R3 O -
, O +
and O +
R2 O +
were O +
plotted O +
further O +
on O +
a O +
fluorescence O +
intensity O +
histogram O -
, O +
and O +
three O +
populations O +
were O +
separated O -
. O +

The O +
population O +
displaying O +
no O +
fluorescence O +
was O +
named O +
M0 O -
, O +
the O +
population O +
with O +
low O +
fluorescence O +
intensity O -
, O +
M1 O -
, O +
and O +
the O +
one O +
with O +
high O +
fluorescence O +
intensity O -
, O +
M2 O -
. O +

The O +
counts O +
of O +
M1 O +
and O +
M2 O +
cells O +
were O +
expressed O +
as O +
percentages O +
of O +
R3 O +
( O -
total O +
live O +
cell O +
number O -
) O -
. O +

PCR O +
and O +
DNA O +
sequencing O +
Total O +
cellular O +
DNA O +
from O +
stable O +
cell O +
lines O +
and O +
M1 O +
and O +
M2 O +
cell O +
populations O +
were O +
PCR O -
- O -
amplified O +
by O +
specific O +
primers O +
( O -
5′-GCGTCGTTTAAACCTGCTTCTCCAAAGTGCATTATG-3′ O +
and O +
5′-TGCCGTCGTCCTTGAAGAAGA-3′ O +
for O +
exon O +
3 O +
of O +
TGFBR2 B-Gene +
and O +
5′- O +
GATCCGCCACCATGTTTAAACGAC-3′ O +
and O +
5′-GCTGTTGTAGTTGTACTCCAGCTTG-3′ O +
for O +
exon O +
10 O +
of O +
ACVR2 B-Gene -
) O +
in O +
a O +
reaction O +
containing O +
the O +
primers O -
, O +
buffer O -
, O +
DNA O +
template O -
, O +
deoxynucleotides O -
, O +
and O +
Pfu O +
Ultra O +
high O +
fidelity O +
DNA O +
polymerase O +
( O -
Stratagene O -
) O -
. O +

The O +
PCR O +
products O +
were O +
used O +
for O +
DNA O +
sequencing O +
to O +
identify O +
stable O +
cell O +
lines O +
and O +
frameshift O +
mutations O +
at O +
coding O +
microsatellites O -
. O +

In O +
addition O -
, O +
we O +
subcloned O +
PCR O -
- O -
amplified O +
TGFBR2 B-Gene +
and O +
ACVR2 B-Gene +
DNA O +
fragments O +
from O +
M1 O +
and O +
M2 O +
cell O +
populations O +
utilizing O +
a O +
TA O +
cloning O +
vector O +
( O -
Invitrogen O +
Corp O -
) O +
as O +
per O +
the O +
manufacturer O -
's O +
protocol O -
. O +

DNA O +
clones O +
were O +
then O +
individually O +
sequenced O +
to O +
determine O +
the O +
prevalence O +
of O +
mutated O +
and O +
WT O +
TGFBR2 B-Gene +
and O +
ACVR2 B-Gene +
sequences O -
. O +

Determination O +
of O +
−1 O +
bp O +
frameshift O +
mutation O +
rates O +
of O +
TGFBR2 B-Gene +
exon O +
3 O +
and O +
ACVR2 B-Gene +
exon O +
10 O +
in O +
human O +
cells O +
The O +
mutation O +
rate O +
was O +
defined O +
as O +
the O +
probability O +
of O +
a O +
cell O +
undergoing O +
a O +
mutation O +
in O +
its O +
lifetime O +
and O +
expressed O +
per O +
cell O +
per O +
generation O -
. O +

We O +
used O +
a O +
" O -
method O +
of O +
the O +
mean O -
� O -
? O +
developed O +
by O +
Luria O +
and O +
Delbruck O +
[ O -
28 O -
] O +
to O +
estimate O +
mutation O +
rate O -
. O +

The O +
" O -
method O +
of O +
the O +
mean O -
� O -
? O +
is O +
moment O -
- O -
based O -
, O +
whereby O +
the O +
mutation O +
rate O +
is O +
estimated O +
as O +
a O +
function O +
of O +
the O +
sample O +
mean O +
of O +
the O +
number O +
of O +
mutants O -
. O +

The O +
formula O +
used O +
in O +
the O +
computation O +
is O +
r̂ O +
= O +
μN O +
ln O -
( O -
μNC O -
) O -
, O +
where O +
r̂ O +
is O +
the O +
mean O +
number O +
of O +
mutants O +
in O +
a O +
culture O -
, O +
C O +
is O +
the O +
number O +
of O +
parallel O +
cultures O -
, O +
μ O +
is O +
the O +
mutation O +
rate O -
, O +
and O +
N O +
is O +
the O +
number O +
of O +
cells O +
at O +
risk O +
of O +
undergoing O +
a O +
mutation O -
, O +
which O +
Luria O -
– O -
Delbruck O +
assumed O +
to O +
be O +
equal O +
to O +
the O +
final O +
number O +
of O +
cells O +
in O +
a O +
culture O -
. O +

Three O +
parallel O +
cultures O +
were O +
used O -
, O +
and O +
r̂ O +
was O +
estimated O +
as O +
the O +
mean O +
of O +
the O +
number O +
of O +
mutants O +
across O +
the O +
three O +
cultures O -
. O +

The O +
total O +
number O +
of O +
cells O +
N O +
was O +
based O +
on O +
averaging O +
across O +
cultures O -
. O +

The O +
formula O +
listed O +
above O +
was O +
used O +
to O +
calculate O +
mutation O +
rates O +
of O +
the O +
M2 O +
cell O +
population O +
( O -
full O +
mutants O -
) O +
using O +
data O +
from O +
flow O +
cytometry O +
analysis O +
at O +
each O +
time O +
point O +
between O +
day O +
14 O +
and O +
day O +
35 O -
. O +

Single O +
mutation O +
rates O +
were O +
then O +
calculated O +
by O +
combining O +
and O +
averaging O +
time O -
- O -
specific O +
mutation O +
rates O +
to O +
minimize O +
the O +
variance O +
of O +
the O +
estimate O +
as O +
previously O +
described O +
[ O -
25 O -
] O -
. O +

Data O +
were O +
expressed O +
as O +
mean±the O +
standard O +
errors O +
of O +
mean O +
( O -
SEM O -
) O -
. O +

Early O -
- O -
onset O +
breast O +
cancer O +
in O +
a O +
Lebanese O +
family O +
with O +
Lynch O +
syndrome O +
due O +
to O +
MSH2 B-Gene +
gene O +
mutation O +
Abstract O +
Background O +
There O +
are O +
still O +
controversies O +
about O +
the O +
integration O +
of O +
breast O +
cancer O +
as O +
a O +
part O +
of O +
the O +
disease O +
spectrum O +
in O +
Lynch O +
syndrome O -
. O +

Methods O +
A O +
regular O +
follow O -
- O -
up O +
of O +
a O +
Lebanese O +
pedigree O +
with O +
Lynch O +
syndrome O +
due O +
to O +
a O +
point O +
mutation O +
of O +
MSH2 B-Gene +
gene O +
at O +
the O +
splice O +
donor O +
site O +
of O +
intron O +
3 O +
started O +
in O +
1996 O -
. O +

Results O +
A O +
26-year O -
- O -
old O +
pregnant O +
woman O -
, O +
mutation O +
carrier O -
, O +
developed O +
an O +
aggressive O +
breast O +
cancer O -
, O +
refractory O +
to O +
standard O +
chemotherapy O +
regimens O -
. O +

The O +
microsatellite O +
analysis O +
of O +
the O +
tumor O +
showed O +
an O +
unstable O +
pattern O +
for O +
markers O +
BAT25 O +
and O +
BAT26 O -
. O +

The O +
immunohistochemical O +
staining O +
was O +
negative O +
for O +
MSH2 B-Gene +
and O +
MSH6 B-Gene +
and O +
normal O +
for O +
MLH1 B-Gene +
and O +
PMS6 B-Gene +
enzymes O -
. O +

Conclusion O +
The O +
segregation O +
of O +
the O +
mutation O +
with O +
the O +
disease O +
phenotype O +
and O +
these O +
results O +
suggest O +
that O +
MSH2 B-Gene +
inactivation O +
may O +
be O +
involved O +
in O +
the O +
accelerated O +
breast O +
carcinogenesis O +
and O +
might O +
be O +
considered O +
in O +
the O +
cancer O +
screening O +
program O -
. O +

Background O +
The O +
identification O +
of O +
the O +
germline O +
mutation O +
in O +
a O +
Lynch O +
syndrome O +
family O +
allows O +
mutation O +
carriers O +
to O +
be O +
included O +
in O +
lifesaving O +
cancer O +
surveillance O +
programs O +
[ O -
1 O -
] O -
. O +

The O +
occurrence O +
of O +
cancer O +
of O +
a O +
type O +
that O +
is O +
atypical O +
for O +
the O +
hereditary O +
cancer O +
syndrome O +
in O +
a O +
family O +
makes O +
the O +
interpretation O +
of O +
the O +
pedigree O +
difficult O -
. O +

It O +
is O +
not O +
uncommon O +
to O +
see O +
Lynch O +
syndrome O +
pedigrees O +
with O +
breast O +
cancer O +
( O -
BC O -
) O -
. O +

However O -
, O +
there O +
is O +
no O +
agreement O +
as O +
to O +
whether O +
breast O +
cancer O +
is O +
part O +
of O +
the O +
disease O +
spectrum O +
[ O -
2 O -
- O -
4 O -
] O -
. O +

Most O +
genetic O +
and O +
immunohistochemical O +
studies O +
on O +
familial O +
and O +
sporadic O +
breast O +
cancers O +
did O +
not O +
evoke O +
any O +
strong O +
relationship O +
with O +
the O +
mismatch B-Gene +
repair I-Gene +
( O -
MMR B-Gene -
) O +
gene O +
defect O -
. O +

Muller O +
et O +
al O +
[ O -
3 O -
] O +
found O +
that O +
synchronous O +
and O +
metachronous O +
breast O +
cancers O +
from O +
Lynch O +
syndrome O +
families O +
usually O +
arise O +
sporadically O +
because O +
they O +
display O +
a O +
stable O +
micro O +
satellite O +
pattern O +
and O +
normal O +
MMR B-Gene +
protein O +
expression O -
. O +

Wong O +
et O +
al O +
[ O -
5 O -
] O +
in O +
an O +
extensive O +
screening O +
study O +
of O +
59 O +
multiple O -
- O -
case O +
BC O +
families O -
; O +
did O +
not O +
identify O +
any O +
genetic O +
abnormality O +
that O +
might O +
implicate O +
MSH2 B-Gene +
as O +
a O +
BC O +
susceptibility O +
gene O -
. O +

Khilko O +
et O +
al O +
[ O -
6 O -
] O +
in O +
an O +
immunohistochemical O +
staining O +
of O +
211 O +
BC O +
specimens O +
did O +
not O +
show O +
any O +
loss O +
of O +
MMR B-Gene +
protein O +
expression O -
. O +

Here O -
, O +
we O +
report O +
a O +
Lebanese O +
Lynch O +
syndrome O +
family O +
( O -
figure O +
1 O -
) O +
with O +
a O +
case O +
of O +
early O -
- O -
onset O +
breast O +
cancer O -
, O +
in O +
which O +
the O +
microsatellite O +
instability O +
( O -
MSI O -
) O +
and O +
the O +
immunohistochemical O +
( O -
IHC O -
) O +
studies O +
suggest O +
strongly O +
a O +
relationship O +
with O +
the O +
MSH2 B-Gene +
gene O +
defect O -
. O +

Analysis O +
of O +
the O +
Lebanese O +
pedigree O +
with O +
Lynch O +
syndrome O +
due O +
to O +
MSH2 B-Gene +
gene O +
mutation O -
. O +

Methods O +
Seventeen O +
carriers O +
of O +
MSH2 B-Gene +
gene O +
point O +
mutation O -
, O +
IVS3 O -
+ O -
1G O -
> O -
A O -
, O +
were O +
included O +
in O +
a O +
regular O +
surveillance O +
program O -
. O +

An O +
eight O -
- O -
year O +
follow O -
- O -
up O +
result O +
of O +
this O +
family O +
was O +
published O +
in O +
a O +
previous O +
report O +
[ O -
7 O -
] O -
. O +

The O +
MSI O +
analysis O +
was O +
performed O +
after O +
PCR O +
amplification O +
of O +
tumor O +
and O +
normal O +
surrounding O +
borders O +
DNA O +
at O +
eight O +
loci O +
containing O +
mononucleotide O +
and O +
dinucleotide O +
repeated O +
sequences O +
using O +
fluorescent O +
specific O +
primers O +
for O +
each O +
locus O -
: O +
BAT-25 O -
, O +
BAT-26 O -
, O +
D2S123 O -
, O +
D17S250 O -
, O +
RIITGFβ O -
, O +
NR21 O -
, O +
NR22 O -
, O +
and O +
NR24 O -
. O +

The O +
PCR O +
products O +
were O +
electrophoresed O +
for O +
three O +
hours O +
in O +
an O +
Applied O +
Biosystems O +
( O -
ABI O -
) O +
Prism O +
sequencer O -
. O +

Data O +
were O +
collected O +
using O +
the O +
GeneScan O +
program O +
for O +
fragment O +
analysis O +
and O +
alterations O +
in O +
the O +
micro O +
satellites O +
were O +
detected O +
by O +
comparing O +
normal O +
tissue O +
and O +
tumor O +
tissue O +
DNA O +
strands O +
in O +
neighboring O +
lanes O -
. O +

The O +
IHC O +
staining O +
was O +
also O +
performed O +
in O +
paraffin O +
embedded O +
tumor O +
and O +
normal O +
tissues O +
for O +
MSH2 B-Gene -
, O +
MLH1 B-Gene -
, O +
MSH6 B-Gene -
, O +
PMS2 B-Gene -
, O +
CK7 B-Gene +
and O +
CK20 B-Gene -
. O +

Testing O +
for O +
germline O +
BRCA1 B-Gene -
, O +
BRCA2 B-Gene +
and O +
TP53 B-Gene +
mutations O +
was O +
not O +
available O +
in O +
our O +
clinic O -
. O +

Results O +
and O +
discussion O +
Although O +
no O +
new O +
colorectal O +
or O +
gynecological O +
tumor O +
was O +
screen O -
- O -
detected O +
since O +
the O +
previous O +
update O +
on O +
this O +
pedigree O +
[ O -
7 O -
] O +
an O +
unforeseen O +
breast O +
cancer O +
in O +
a O +
26 O +
years O +
old O +
pregnant O +
female O +
( O -
III O +
34 O -
) O +
has O +
occurred O -
. O +

No O +
family O +
history O +
of O +
breast O +
cancer O +
was O +
noted O +
in O +
any O +
branch O +
of O +
the O +
family O -
. O +

No O +
breast O +
or O +
ovarian O +
cancer O +
was O +
known O +
in O +
any O +
paternal O +
family O +
member O +
of O +
this O +
patient O -
. O +

Screening O +
for O +
breast O +
cancer O +
was O +
not O +
part O +
of O +
our O +
surveillance O +
program O -
, O +
since O +
there O +
was O +
no O +
reason O +
to O +
suspect O +
such O +
a O +
tumor O +
as O +
early O +
as O +
26 O +
years O +
and O +
during O +
pregnancy O -
. O +

This O +
patient O +
who O +
carries O +
the O +
MSH2 B-Gene +
germline O +
mutation O +
developed O +
an O +
infiltrating O +
ductal O +
carcinoma O +
of O +
the O +
left O +
breast O +
with O +
distant O +
metastases O +
at O +
the O +
first O +
presentation O -
. O +

The O +
tumor O +
was O +
of O +
high O +
histological O +
grade O +
with O +
negative O +
estrogen O +
receptors O +
and O +
positive O +
c O -
- O -
erb O +
B2 O +
oncoprotein O +
expression O -
. O +

This O +
metastatic O +
breast O +
cancer O +
did O +
not O +
respond O +
to O +
standard O +
chemotherapy O +
regimens O +
including O +
Trastuzumab O -
, O +
Taxanes O +
and O +
Doxorubicin O -
. O +

MSI O +
was O +
present O +
in O +
4 O +
out O +
of O +
8 O +
loci O +
in O +
the O +
tumor O +
specimen O -
. O +

The O +
IHC O +
analysis O +
revealed O +
a O +
negative O +
expression O +
for O +
CK20 B-Gene -
, O +
MSH2 B-Gene +
and O +
MSH6 B-Gene +
and O +
a O +
positive O +
expression O +
for O +
CK7 B-Gene +
and O +
MLH1 B-Gene +
proteins O -
, O +
which O +
confirm O +
the O +
mammary O +
origin O +
of O +
the O +
tumor O +
and O +
the O +
role O +
of O +
the O +
defective O +
MSH2 B-Gene +
gene O +
in O +
the O +
pathogenesis O +
( O -
Tables O +
1 O +
and O +
2 O -
) O -
. O +

Microsatellite O +
Instability O +
( O -
MSI O -
) O +
test O +
results O -
. O +

Immunohistochemical O +
( O -
IHC O -
) O +
test O +
results O -
. O +

MMR B-Gene +
gene O +
mutation O +
carriers O +
are O +
at O +
high O +
risk O +
of O +
developing O +
Lynch O +
syndrome O -
- O -
related O +
cancers O -
. O +

Some O +
of O +
them O +
develop O +
sporadic O +
cancers O +
due O +
to O +
exposure O +
to O +
non O -
- O -
genetic O +
risk O +
factors O -
, O +
polymorphisms O +
in O +
other O +
genes O +
and O +
chance O -
. O +

These O +
sporadic O +
tumors O +
may O +
include O +
breast O +
cancer O +
and O +
usually O +
exhibit O +
stable O +
microsatellite O +
patterns O +
and O +
normal O +
MMR B-Gene +
protein O +
expressions O -
. O +

The O +
absence O +
of O +
an O +
MSI O -
- O -
high O +
pattern O +
in O +
a O +
breast O +
cancer O +
specimen O +
from O +
MSH2 B-Gene +
mutation O +
carrier O +
indicates O +
that O +
the O +
development O +
of O +
such O +
a O +
tumor O +
is O +
unrelated O +
to O +
MMR B-Gene +
gene O +
impairment O -
, O +
despite O +
the O +
presence O +
of O +
the O +
constitutional O +
mutation O -
. O +

In O +
contrast O -
, O +
a O +
microsatellite O +
instable O +
early O +
onset O +
breast O +
cancer O +
that O +
did O +
not O +
express O +
the O +
MSH2 B-Gene +
protein O +
in O +
IHC O +
and O +
occurs O +
in O +
a O +
proven O +
MMR B-Gene +
gene O +
mutation O +
carrier O +
is O +
highly O +
suggestive O +
of O +
its O +
belonging O +
to O +
the O +
tumor O +
spectrum O +
of O +
the O +
disease O +
[ O -
8,9 O -
] O -
. O +

Still O -
, O +
there O +
is O +
currently O +
no O +
evidence O +
to O +
suggest O +
that O -
, O +
in O +
general O -
, O +
female O +
Lynch O +
syndrome O +
mutation O +
carriers O +
are O +
at O +
a O +
strongly O +
increased O +
risk O +
to O +
develop O +
breast O +
cancer O -
. O +

In O +
some O +
cases O -
, O +
as O +
we O +
and O +
others O +
have O +
shown O -
, O +
deficient O +
DNA O +
mismatch O +
repair O +
can O +
contribute O +
to O +
breast O +
cancer O +
development O +
in O +
Lynch O +
syndrome O +
families O -
. O +

These O +
findings O +
do O +
not O +
necessarily O +
imply O +
that O +
the O +
underlying O +
germline O +
MMR B-Gene +
mutation O +
was O +
also O +
the O +
strongest O +
and O +
most O +
important O +
risk O +
factor O +
in O +
those O +
breast O +
cancer O +
cases O -
. O +

Other O +
genetic O +
and O +
non O -
- O -
genetic O +
risk O +
factors O +
may O +
have O +
contributed O +
and O +
therefore O +
all O +
close O +
relatives O +
of O +
breast O +
cancer O +
patients O +
in O +
Lynch O +
syndrome O +
families O -
, O +
including O +
the O +
relatives O +
that O +
do O +
not O +
carry O +
the O +
MMR B-Gene +
mutation O -
, O +
might O +
have O +
an O +
increased O +
breast O +
cancer O +
risk O -
. O +

Testing O +
for O +
other O +
germline O +
mutation O -
, O +
e.g. O +
of O +
BRCA1 B-Gene -
, O +
BRCA2 B-Gene +
and O +
possibly O +
TP53 B-Gene -
, O +
should O +
be O +
considered O -
, O +
especially O +
in O +
early O -
- O -
onset O +
cases O +
and O +
unfortunately O -
, O +
we O +
can O -
not O +
exclude O +
the O +
presence O +
of O +
such O +
mutation O +
in O +
our O +
patient O -
. O +

It O +
is O +
not O +
yet O +
possible O +
to O +
accurately O +
predict O +
breast O +
cancer O +
risk O +
for O +
MMR B-Gene +
mutation O +
carriers O +
in O +
families O +
with O +
one O +
or O +
more O +
cases O +
of O +
breast O +
cancer O -
. O +

In O +
lynch O +
syndrome O +
families O -
; O +
one O +
might O +
consider O +
breast O +
cancer O +
surveillance O +
for O +
close O +
female O +
relatives O +
of O +
breast O +
cancer O +
cases O -
, O +
especially O +
of O +
those O +
cases O +
with O +
early O -
- O -
onset O +
breast O +
cancer O -
. O +

Such O +
surveillance O +
might O +
follow O +
the O +
guidelines O +
for O +
families O +
with O +
breast O +
cancer O +
and O +
absence O +
of O +
detectable O +
germline O +
mutations O +
in O +
known O +
hereditary O +
breast O +
cancer O -
- O -
associated O +
genes O -
. O +

Although O +
the O +
efficacy O +
of O +
the O +
surveillance O +
program O +
in O +
reducing O +
colorectal O +
cancer O +
mortality O +
in O +
Lynch O +
syndrome O +
has O +
been O +
proven O -
, O +
the O +
benefit O +
of O +
breast O +
cancer O +
screening O +
in O +
selected O +
Lynch O +
syndrome O +
families O +
remains O +
to O +
be O +
seen O -
. O +

In O +
our O +
opinion O -
, O +
cancers O +
occurring O +
in O +
Lynch O +
syndrome O +
families O +
which O +
are O +
not O +
typical O +
for O +
that O +
syndrome O +
should O +
undergo O +
MSI O +
analysis O +
and O +
immunostaining O +
for O +
the O +
MMR B-Gene +
gene O +
protein O +
expression O +
in O +
order O +
to O +
better O +
assess O +
the O +
phenotype O -
- O -
genotype O +
relationship O +
and O +
ultimately O +
change O +
the O +
surveillance O +
guidelines O +
accordingly O -
. O +

Evidence O +
for O +
classification O +
of O +
c.1852_1853AA O -
> O -
GC O +
in O +
MLH1 B-Gene +
as O +
a O +
neutral O +
variant O +
for O +
Lynch O +
syndrome O +
Abstract O +
Background O +
Lynch O +
syndrome O +
( O -
LS O -
) O +
is O +
an O +
autosomal O +
dominant O +
inherited O +
cancer O +
syndrome O +
characterized O +
by O +
early O +
onset O +
cancers O +
of O +
the O +
colorectum O -
, O +
endometrium O +
and O +
other O +
tumours O -
. O +

A O +
significant O +
proportion O +
of O +
DNA O +
variants O +
in O +
LS O +
patients O +
are O +
unclassified O -
. O +

Reports O +
on O +
the O +
pathogenicity O +
of O +
the O +
c.1852_1853AA O -
> O -
GC O +
( O -
p. O +

Lys618Ala O -
) O +
variant O +
of O +
the O +
MLH1 B-Gene +
gene O +
are O +
conflicting O -
. O +

In O +
this O +
study O -
, O +
we O +
provide O +
new O +
evidence O +
indicating O +
that O +
this O +
variant O +
has O +
no O +
significant O +
implications O +
for O +
LS O -
. O +

Methods O +
The O +
following O +
approach O +
was O +
used O +
to O +
assess O +
the O +
clinical O +
significance O +
of O +
the O +
p. O +

Lys618Ala O +
variant O -
: O +
frequency O +
in O +
a O +
control O +
population O -
, O +
case O -
- O -
control O +
comparison O -
, O +
co O -
- O -
occurrence O +
of O +
the O +
p. O +

Lys618Ala O +
variant O +
with O +
a O +
pathogenic O +
mutation O -
, O +
co O -
- O -
segregation O +
with O +
the O +
disease O +
and O +
microsatellite O +
instability O +
in O +
tumours O +
from O +
carriers O +
of O +
the O +
variant O -
. O +

We O +
genotyped O +
p. O +

Lys618Ala O +
in O +
1034 O +
individuals O +
( O -
373 O +
sporadic O +
colorectal O +
cancer O +
[ O -
CRC O -
] O +
patients O -
, O +
250 O +
index O +
subjects O +
from O +
families O +
suspected O +
of O +
having O +
LS O +
[ O -
revised O +
Bethesda O +
guidelines O -
] O +
and O +
411 O +
controls O -
) O -
. O +

Three O +
well O -
- O -
characterized O +
LS O +
families O +
that O +
fulfilled O +
the O +
Amsterdam O +
II O +
Criteria O +
and O +
consisted O +
of O +
members O +
with O +
the O +
p. O +

Lys618Ala O +
variant O +
were O +
included O +
to O +
assess O +
co O -
- O -
occurrence O +
and O +
co O -
- O -
segregation O -
. O +

A O +
subset O +
of O +
colorectal O +
tumour O +
DNA O +
samples O +
from O +
17 O +
patients O +
carrying O +
the O +
p. O +

Lys618Ala O +
variant O +
was O +
screened O +
for O +
microsatellite O +
instability O +
using O +
five O +
mononucleotide O +
markers O -
. O +

Results O +
Twenty O -
- O -
seven O +
individuals O +
were O +
heterozygous O +
for O +
the O +
p. O +

Lys618Ala O +
variant O -
; O +
nine O +
had O +
sporadic O +
CRC O +
( O -
2.41 O -
% O -
) O -
, O +
seven O +
were O +
suspected O +
of O +
having O +
hereditary O +
CRC O +
( O -
2.8 O -
% O -
) O +
and O +
11 O +
were O +
controls O +
( O -
2.68 O -
% O -
) O -
. O +

There O +
were O +
no O +
significant O +
associations O +
in O +
the O +
case O -
- O -
control O +
and O +
case O -
- O -
case O +
studies O -
. O +

The O +
p. O +

Lys618Ala O +
variant O +
was O +
co O -
- O -
existent O +
with O +
pathogenic O +
mutations O +
in O +
two O +
unrelated O +
LS O +
families O -
. O +

In O +
one O +
family O -
, O +
the O +
allele O +
distribution O +
of O +
the O +
pathogenic O +
and O +
unclassified O +
variant O +
was O +
in O +
trans O -
, O +
in O +
the O +
other O +
family O +
the O +
pathogenic O +
variant O +
was O +
detected O +
in O +
the O +
MSH6 B-Gene +
gene O +
and O +
only O +
the O +
deleterious O +
variant O +
co O -
- O -
segregated O +
with O +
the O +
disease O +
in O +
both O +
families O -
. O +

Only O +
two O +
positive O +
cases O +
of O +
microsatellite O +
instability O +
( O -
2 O -
/ O -
17 O -
, O +
11.8 O -
% O -
) O +
were O +
detected O +
in O +
tumours O +
from O +
p. O +

Lys618Ala O +
carriers O -
, O +
indicating O +
that O +
this O +
variant O +
does O +
not O +
play O +
a O +
role O +
in O +
functional O +
inactivation O +
of O +
MLH1 B-Gene +
in O +
CRC O +
patients O -
. O +

Conclusions O +
The O +
p. O +

Lys618Ala O +
variant O +
should O +
be O +
considered O +
a O +
neutral O +
variant O +
for O +
LS O -
. O +

These O +
findings O +
have O +
implications O +
for O +
the O +
clinical O +
management O +
of O +
CRC O +
probands O +
and O +
their O +
relatives O -
. O +

Background O +
Genetic O +
testing O +
is O +
conducted O +
for O +
diverse O +
purposes O -
, O +
including O +
confirmation O +
of O +
diagnosis O -
, O +
risk O +
prediction O -
, O +
carrier O +
testing O +
and O +
reproductive O +
decision O -
- O -
making O -
. O +

The O +
identification O +
of O +
germ O -
- O -
line O +
mutations O +
in O +
patients O +
with O +
inherited O +
cancer O +
syndromes O +
enables O +
them O +
to O +
be O +
included O +
in O +
cancer O +
surveillance O +
programmes O -
. O +

Such O +
programmes O +
are O +
effective O +
in O +
reducing O +
cancer O +
mortality O +
in O +
the O +
families O +
concerned O -
. O +

Moreover O -
, O +
family O +
members O +
who O +
do O +
not O +
carry O +
the O +
mutation O +
can O +
be O +
treated O +
safely O +
as O +
low O -
- O -
risk O +
individuals O -
, O +
avoiding O +
unnecessary O +
screening O +
and O +
preventing O +
anxiety O +
in O +
the O +
individuals O +
concerned O -
. O +

Unfortunately O -
, O +
the O +
number O +
of O +
suspected O +
familial O +
cancer O +
cases O +
in O +
which O +
a O +
causative O +
mutation O +
is O +
identified O +
is O +
far O +
from O +
ideal O -
. O +

All O +
members O +
from O +
a O +
family O +
with O +
a O +
strong O +
history O +
of O +
cancer O +
and O +
no O +
causative O +
mutation O +
detected O +
are O +
included O +
in O +
a O +
surveillance O +
program O -
. O +

Identification O +
of O +
mutations O +
depends O +
on O +
the O +
specific O +
syndrome O +
and O +
the O +
criteria O +
applied O +
to O +
select O +
patients O +
for O +
genetic O +
analyses O -
. O +

The O +
results O +
of O +
sequence O -
- O -
based O +
genetic O +
tests O +
may O +
be O +
reported O +
to O +
physicians O +
as O -
: O +
1 O -
) O +
positive O -
, O +
in O +
which O +
a O +
mutation O +
that O +
clearly O +
disrupts O +
gene O +
function O +
is O +
detected O +
and O +
is O +
highly O +
likely O +
to O +
have O +
clinical O +
consequences O -
; O +
2 O -
) O +
a O +
genetic O +
variant O +
is O +
detected O +
but O +
it O +
is O +
not O +
known O +
whether O +
the O +
variant O +
has O +
any O +
effect O +
on O +
gene O +
function O +
that O +
might O +
confer O +
an O +
increased O +
cancer O +
risk O +
( O -
these O +
variants O +
are O +
known O +
as O +
variants O +
of O +
uncertain O -
/ O -
unclassified O +
significance O +
or O +
unclassified O +
variants O +
[ O -
UVs O -
] O -
) O -
; O +
and O +
3 O -
) O +
negative O -
, O +
in O +
which O +
deleterious O +
variant O +
or O +
UV O +
is O +
detected O +
[ O -
1 O -
] O -
. O +

The O +
majority O +
of O +
UVs O +
are O +
missense O +
mutations O +
or O +
small O +
in O -
- O -
frame O +
deletions O -
. O +

The O +
human O +
gene O +
pool O +
harbours O +
a O +
vast O +
number O +
of O +
rare O +
missense O +
substitutions O -
, O +
70 O -
% O +
of O +
which O +
are O +
at O +
least O +
mildly O +
deleterious O +
[ O -
2 O -
] O -
. O +

Integration O +
of O +
various O +
lines O +
of O +
evidence O +
may O +
help O +
to O +
classify O +
UVs O -
. O +

Information O +
on O -
: O +
1 O -
) O +
frequencies O +
in O +
cases O +
and O +
controls O -
, O +
2 O -
) O +
co O -
- O -
occurrence O +
( O -
in O +
trans O -
) O +
with O +
deleterious O +
mutations O -
, O +
3 O -
) O +
co O -
- O -
segregation O +
with O +
disease O +
in O +
pedigrees O -
, O +
4 O -
) O +
pathological O +
factors O -
, O +
5 O -
) O +
amino O +
acid O +
polarity O +
or O +
size O -
, O +
6 O -
) O +
evolutionary O +
conservation O +
of O +
the O +
residue O -
, O +
7 O -
) O +
splice O +
predictions O +
and O +
8) O +
in O +
vitro O +
and/or O +
in O +
vivo O +
functional O +
assays O +
may O +
enable O +
UVs O +
to O +
be O +
classified O +
as O +
pathogenic O +
or O +
non O -
- O -
pathogenic O +
[ O -
3 O -
] O -
. O +

Lynch O +
syndrome O +
( O -
MIM O -
# O +
120435 O -
) O +
( O -
LS O -
) O +
is O +
an O +
autosomal O +
dominant O +
inherited O +
cancer O +
syndrome O +
characterized O +
by O +
early O +
onset O +
colorectal O +
cancer O +
( O -
CRC O -
) O -
, O +
cancer O +
of O +
the O +
endometrium O +
and O +
tumours O +
of O +
the O +
stomach O -
, O +
pancreas O -
, O +
small O +
intestine O -
, O +
ovary O -
, O +
bladder O +
and O +
bile O +
duct O +
[ O -
4 O -
] O -
. O +

LS O -
- O -
associated O +
tumours O +
are O +
characterized O +
by O +
DNA O +
mismatch O +
repair O +
( O -
MMR B-Gene -
) O +
deficiency O -
, O +
which O +
may O +
be O +
evidenced O +
by O +
microsatellite O +
instability O +
( O -
MSI O -
) O +
or O +
loss O +
of O +
expression O +
of O +
MMR B-Gene +
proteins O +
using O +
immunohistochemistry O +
[ O -
5 O -
] O -
. O +

The O +
proportion O +
of O +
genetic O +
UVs O +
in O +
LS O +
varies O +
from O +
1 O -
/ O -
5 O +
to O +
1 O -
/ O -
3 O +
of O +
all O +
unique O +
variants O +
detected O +
[ O -
6 O -
] O -
. O +

The O +
MLH1 B-Gene +
p. O +

Lys618Ala O +
( O -
c.1852_1853AA O -
> O -
GC O -
) O +
variant O +
was O +
initially O +
considered O +
a O +
deleterious O +
variant O +
based O +
on O +
its O +
recurrent O +
presence O +
in O +
LS O +
families O -
, O +
in O +
silico O +
predictions O +
and O +
in O +
vitro O +
experiments O +
on O +
its O +
functional O +
effect O -
. O +

However O -
, O +
recent O +
data O +
on O +
its O +
co O -
- O -
segregation O +
with O +
LS O +
have O +
cast O +
doubt O +
on O +
its O +
clinical O +
significance O +
[ O -
6 O -
] O -
. O +

In O +
this O +
study O -
, O +
we O +
provide O +
evidence O +
supporting O +
the O +
contention O +
that O +
this O +
variant O +
has O +
no O +
significant O +
implications O +
in O +
LS O -
. O +

The O +
following O +
approach O +
was O +
used O +
to O +
assess O +
the O +
clinical O +
significance O +
of O +
the O +
p. O +

Lys618Ala O +
variant O -
: O +
frequency O +
in O +
a O +
control O +
population O -
, O +
case O -
- O -
control O +
and O +
case O -
- O -
case O +
comparisons O -
, O +
co O -
- O -
occurrence O +
with O +
a O +
pathogenic O +
mutation O -
, O +
co O -
- O -
segregation O +
with O +
the O +
disease O +
and O +
MSI O +
in O +
tumours O +
from O +
carrier O +
individuals O -
. O +

Methods O +
Controls O +
and O +
sporadic O +
and O +
familial O +
CRC O +
cases O +
We O +
genotyped O +
the O +
p. O +

Lys618Ala O +
variant O +
in O +
MLH1 B-Gene +
in O +
1034 O +
individuals O +
( O -
373 O +
sporadic O +
CRC O +
patients O -
, O +
250 O +
index O +
subjects O +
from O +
families O +
suspected O +
of O +
having O +
LS O +
[ O -
revised O +
Bethesda O +
Guidelines O -
] O +
and O +
411 O +
controls O -
) O -
. O +

The O +
controls O +
were O +
selected O +
from O +
the O +
same O +
hospitals O -
, O +
had O +
no O +
personal O +
histories O +
of O +
cancer O +
and O +
had O +
diagnoses O +
unrelated O +
to O +
the O +
variables O +
of O +
interest O -
. O +

They O +
were O +
matched O +
for O +
age O -
, O +
gender O +
and O +
race O -
/ O -
ethnicity O +
with O +
the O +
sporadic O +
CRC O +
patients O -
. O +

No O +
familial O +
history O +
of O +
cancer O +
was O +
available O +
from O +
the O +
control O +
group O -
. O +

Patients O +
diagnosed O +
at O +
an O +
age O +
over O +
50 O +
years O +
and O +
not O +
referred O +
to O +
Genetic O +
Counselling O +
Units O +
were O +
considered O +
as O +
sporadic O +
CRC O -
. O +

Samples O +
from O +
sporadic O +
CRC O +
patients O +
were O +
obtained O +
from O +
the O +
Elche O +
University O +
Hospital O +
BioBank O +
and O +
the O +
Castellon O +
Provincial O +
Hospital O +
BioBank O -
. O +

Written O +
consent O +
to O +
be O +
included O +
in O +
the O +
respective O +
biobanks O +
was O +
obtained O +
from O +
each O +
patient O -
. O +

CRC O +
patients O -
, O +
as O +
index O +
subjects O +
from O +
families O +
with O +
suspicion O +
of O +
LS O +
that O +
attended O +
Genetic O +
Counselling O +
at O +
the O +
Cancer O +
Units O +
of O +
the O +
Elche O +
and O +
La O +
Fe O +
Hospitals O -
, O +
were O +
recruited O -
. O +

The O +
study O +
was O +
approved O +
by O +
the O +
Ethics O +
Committee O +
of O +
the O +
Elche O +
University O +
Hospital O -
. O +

The O +
median O +
age O +
of O +
patients O +
in O +
the O +
sporadic O +
CRC O +
group O +
was O +
70 O +
years O +
( O -
range O -
, O +
52 O -
- O -
93 O +
years O -
) O -
, O +
47 O +
years O +
( O -
range O -
, O +
21 O -
- O -
87 O +
years O -
) O +
for O +
the O +
familial O +
group O +
and O +
71 O +
years O +
( O -
range O -
, O +
25 O -
- O -
96 O +
years O -
) O +
for O +
the O +
controls O -
. O +

The O +
sex O +
distribution O +
was O +
58 O -
% O +
men O +
and O +
42 O -
% O +
women O +
for O +
the O +
sporadic O +
CRC O +
group O +
and O +
53.3 O -
% O +
men O +
and O +
46.7 O -
% O +
women O +
for O +
the O +
controls O -
. O +

Families O +
carrying O +
the O +
p. O +

Lys618Ala O +
variant O +
Three O +
characterized O +
LS O +
families O +
that O +
fulfilled O +
the O +
Amsterdam O +
II O +
Criteria O +
and O +
that O +
consisted O +
of O +
members O +
with O +
the O +
p. O +

Lys618Ala O +
variant O +
were O +
included O +
to O +
assess O +
co O -
- O -
occurrence O +
and O +
co O -
- O -
segregation O -
. O +

Two O +
families O +
attended O +
the O +
Genetic O +
Counselling O +
in O +
Cancer O +
Units O +
of O +
the O +
Elche O +
and O +
La O +
Fe O +
Hospitals O +
and O +
one O +
family O +
was O +
a O +
member O +
of O +
the O +
EPICOLON O +
cohort O +
[ O -
7 O -
] O -
. O +

Concomitant O +
deleterious O +
variants O +
were O +
detected O +
in O +
two O +
of O +
the O +
families O -
: O +
one O +
in O +
the O +
MLH1 B-Gene +
gene O +
( O -
c.676C O -
> O -
T O -
; O +
p. O +

Arg226X O -
) O +
and O +
the O +
other O +
in O +
the O +
MSH6 B-Gene +
gene O +
( O -
c.3013C O -
> O -
T O -
; O +
p. O +

Arg1005X O -
) O -
. O +

Seventeen O +
affected O +
and O +
unaffected O +
family O +
members O +
from O +
these O +
two O +
families O +
were O +
tested O +
for O +
the O +
pathogenic O +
and O +
p. O +

Lys618Ala O +
variants O -
. O +

Genotyping O +
of O +
the O +
MLH1 B-Gene +
p. O +

Lys618Ala O +
variant O +
DNA O +
from O +
blood O +
cells O +
( O -
familial O +
cancer O +
cases O +
and O +
controls O -
) O +
or O +
colorectal O +
mucosa O +
of O +
normal O +
appearance O +
( O -
sporadic O +
cases O -
) O +
was O +
used O +
for O +
the O +
c.1852_1853AA O -
> O -
GC O +
variant O +
genotyping O -
. O +

This O +
was O +
assessed O +
using O +
the O +
iPLEX O +
Gold O +
method O +
( O -
Sequenom O -
, O +
CA O -
, O +
USA O -
) O -
, O +
in O +
which O +
single O -
- O -
base O +
extension O +
and O +
MALDI O -
- O -
TOF O +
technology O +
are O +
employed O +
for O +
allelic O +
discrimination O -
. O +

These O +
experiments O +
were O +
carried O +
out O +
at O +
the O +
Centro O +
Español O +
de O +
Genotipado O +
( O -
CEGEN O -
) O +
genotyping O +
platform O +
facilities O -
. O +

Quality O +
control O +
for O +
genotyping O +
was O +
conducted O +
by O +
direct O +
sequencing O +
of O +
familial O +
cancer O +
subjects O +
who O +
underwent O +
genetic O +
analysis O +
for O +
MLH1 B-Gene +
( O -
49 O -
/ O -
1034 O -
, O +
4.7 O -
% O -
) O -
. O +

Microsatellite O +
instability O +
and O +
MLH1 B-Gene +
immunohistochemical O +
expression O +
A O +
subset O +
of O +
colorectal O +
tumour O +
DNA O +
samples O +
from O +
17 O +
patients O +
carrying O +
the O +
p. O +

Lys618Ala O +
variant O +
( O -
eight O +
from O +
the O +
familial O +
group O +
and O +
nine O +
from O +
the O +
sporadic O +
CRC O +
group O -
) O +
was O +
screened O +
for O +
MSI O +
status O +
using O +
five O +
mononucleotide O +
markers O +
( O -
BAT26 O -
, O +
BAT25 O -
, O +
NR21 O -
, O +
NR24 O +
and O +
NR27 O -
) O +
and O +
multiplex O +
PCR O +
as O +
previously O +
described O +
by O +
Buhard O +
et O +
al O +
[ O -
8 O -
] O -
. O +

Tumours O +
from O +
p. O +

Lys618Ala O +
carrier O +
cases O +
in O +
the O +
familial O +
group O +
( O -
seven O +
index O +
subjects O +
and O +
one O +
relative O -
) O +
were O +
also O +
analysed O +
for O +
MLH1 B-Gene +
protein O +
expression O +
using O +
immunohistochemistry O +
and O +
anti O -
- O -
MLH1 B-Gene +
antibodies O +
( O -
PharMingen O -
, O +
CA O -
, O +
USA O -
) O +
as O +
described O +
elsewhere O +
[ O -
7 O -
] O -
. O +

Tumour O +
cells O +
were O +
judged O +
negative O +
for O +
protein O +
expression O +
only O +
if O +
they O +
lacked O +
staining O +
in O +
a O +
sample O +
in O +
which O +
normal O +
colonocytes O +
and O +
stroma O +
cells O +
were O +
stained O -
. O +

If O +
no O +
immunostaining O +
of O +
normal O +
tissue O +
could O +
be O +
demonstrated O -
, O +
the O +
results O +
were O +
considered O +
unreliable O -
. O +

MLH1 B-Gene +
promoter O +
hypermethylation O +
by O +
Methylation O +
Sensitive O +
Multiplex O +
Ligation O -
- O -
dependent O +
Probe O +
Amplification O +
( O -
MS O -
- O -
MLPA O -
) O -
, O +
and O +
BRAF B-Gene +
p. O +

Val600Glu O +
mutation O +
by O +
direct O +
sequencing O +
from O +
tumor O +
DNA O +
was O +
also O +
assess O +
when O +
MLH1 B-Gene +
loss O +
of O +
expression O +
was O +
detected O -
. O +

Statistical O +
analysis O +
Hardy O -
- O -
Weinberg O +
equilibrium O +
was O +
calculated O +
for O +
the O +
control O -
, O +
sporadic O +
CRC O +
and O +
familial O +
CRC O +
groups O -
. O +

Allelic O +
and O +
genotype O +
frequencies O +
were O +
calculated O -
. O +

In O +
the O +
case O -
- O -
control O +
study O +
of O +
sporadic O +
CRC O -
, O +
we O +
estimated O +
the O +
odds O +
ratio O +
( O -
OR O -
) O +
and O +
95 O -
% O +
confidence O +
interval O +
( O -
95 O -
% O +
CI O -
) O +
for O +
the O +
p. O +

Lys618Ala O +
variant O +
using O +
unconditional O +
logistic O +
regression O +
adjusted O +
for O +
age O +
and O +
sex O -
. O +

We O +
analysed O +
for O +
potential O +
effect O +
modification O +
by O +
age O +
using O +
an O +
analysis O +
stratified O +
according O +
to O +
median O +
age O +
at O +
diagnosis O +
for O +
the O +
sporadic O +
CRC O +
cases O +
( O -
≤70 O +
years O +
or O +
> O -
70 O +
years O -
) O -
. O +

A O +
χ2 O +
test O +
was O +
used O +
to O +
evaluate O +
differences O +
in O +
p. O +

Lys618Ala O +
carrier O +
frequencies O +
between O +
the O +
tumour O +
and O +
control O +
groups O -
. O +

A O +
probability O +
level O +
of O +
< O -
0.05 O +
was O +
considered O +
significant O -
. O +

Results O +

No O +
discordances O +
were O +
detected O +
in O +
the O +
genotyping O +
quality O +
control O -
. O +

The O +
genotype O +
distributions O +
in O +
the O +
control O -
, O +
sporadic O +
and O +
familial O +
CRC O +
populations O +
did O +
not O +
deviate O +
significantly O +
from O +
that O +
expected O +
for O +
a O +
population O +
in O +
Hardy O -
- O -
Weinberg O +
equilibrium O +
( O -
Table O +
1 O -
) O -
. O +

Allelic O +
and O +
genotypic O +
frequencies O +
and O +
Hardy O -
- O -
Weinberg O +
equilibrium O +
* O -
Individuals O +
from O +
apparently O +
unrelated O +
families O +
Twenty O -
- O -
seven O +
individuals O +
were O +
heterozygous O +
for O +
the O +
p. O +

Lys618Ala O +
variant O +
( O -
Figure O +
1 O -
) O -
; O +
11 O +
were O +
controls O +
( O -
11 O -
/ O -
411 O -
, O +
2.68 O -
% O -
) O -
, O +
nine O +
were O +
CRC O +
patients O +
from O +
the O +
sporadic O +
group O +
( O -
9 O -
/ O -
373 O -
, O +
2.41 O -
% O -
) O +
and O +
seven O +
were O +
CRC O +
patients O +
from O +
the O +
familial O +
group O +
( O -
7 O -
/ O -
250 O -
, O +
2.8 O -
% O -
) O -
. O +

None O +
of O +
the O +
individuals O +
was O +
homozygous O +
for O +
the O +
minor O +
allele O -
. O +

Results O +
of O +
genotyping O +
for O +
the O +
p. O +

Lys618Ala O +
variant O +
using O +
the O +
iPLEX O +
Sequenom O +
( O -
A O -
) O +
and O +
sequencing O +
( O -
B O -
) O +
methods O -
. O +

There O +
were O +
no O +
significant O +
associations O +
in O +
the O +
case O -
- O -
control O +
and O +
case O -
- O -
case O +
studies O +
( O -
80 O -
% O +
detection O +
power O -
, O +
OR O +
= O +
3.0 O -
; O +
two O -
- O -
sided O +
test O -
, O +
alpha O +
level O +
= O +
5 O -
% O -
) O +
( O -
Table O +
2 O -
) O +
and O +
no O +
statistically O +
significant O +
associations O +
when O +
the O +
OR O +
was O +
adjusted O +
for O +
age O +
and O +
sex O -
. O +

Results O +
of O +
case O -
- O -
control O +
and O +
case O -
- O -
case O +
analyses O -
. O +

Odds O +
ratios O +
( O -
ORs O -
) O +
and O +
95 O -
% O +
confidence O +
intervals O +
( O -
95 O -
% O +
CIs O -
) O +
for O +
the O +
p. O +

Lys618Ala O +
variant O +
In O +
one O +
of O +
the O +
families O +
with O +
LS O -
, O +
the O +
index O +
subject O +
was O +
heterozygous O +
for O +
a O +
pathogenic O +
MLH1 B-Gene +
variant O +
( O -
c.767C O -
> O -
T O -
; O +
p. O +

Arg226X O -
) O +
and O +
the O +
p. O +

Lys618Ala O +
variant O -
. O +

Two O +
of O +
his O +
offspring O -
, O +
who O +
were O +
diagnosed O +
with O +
CRC O +
at O +
the O +
ages O +
of O +
36 O +
and O +
39 O +
years O -
, O +
carried O +
the O +
deleterious O +
variant O +
but O +
not O +
the O +
p. O +

Lys618Ala O +
variant O -
. O +

An O +
unaffected O +
daughter O +
( O -
III-12 O -
) O +
carried O +
the O +
p. O +

Lys618Ala O +
variant O +
but O +
not O +
the O +
deleterious O +
variant O -
. O +

Two O +
nephews O +
( O -
III-3 O -
; O +
III-4 O -
) O +
were O +
also O +
diagnosed O +
with O +
CRC O +
at O +
the O +
ages O +
of O +
30 O +
and O +
42 O +
years O +
and O +
they O +
carried O +
only O +
the O +
deleterious O +
variant O -
. O +

Two O +
other O +
healthy O +
nephews O +
( O -
III-6 O -
; O +
III-7 O -
) O +
had O +
the O +
wild O +
types O +
of O +
the O +
two O +
variants O +
( O -
Family O +
# O -
1 O -
, O +
Figure O +
2 O -
) O -
. O +

Pedigree O +
for O +
Family O +
# O -
1 O +
( O -
CRC O -
: O +
Colorectal O +
cancer O -
; O +

GC O -
: O +
Gastric O +
cancer O -
; O +
DC O -
: O +
Duodenal O +
cancer O -
) O -
. O +

In O +
the O +
second O +
LS O +
family O -
, O +
the O +
index O +
subject O -
, O +
one O +
sister O +
and O +
one O +
brother O +
with O +
CRC O +
( O -
II-5 O -
; O +
II-6 O -
; O +
II-7 O -
, O +
respectively O -
) O +
had O +
a O +
deleterious O +
variant O +
in O +
MSH6 B-Gene +
( O -
c.3013C O -
> O -
T O -
; O +
p. O +

Arg1005X O -
) O +
but O +
did O +
not O +
have O +
the O +
p. O +

Lys618Ala O +
variant O -
. O +

This O +
variant O +
was O +
present O +
in O +
only O +
three O +
of O +
four O +
unaffected O +
nephews O +
( O -
III-2 O -
; O +
III-3 O -
; O +
III-4 O -
) O +
and O +
was O +
inherited O +
from O +
the O +
parental O +
branch O -
, O +
in O +
which O +
there O +
was O +
no O +
familial O +
history O +
of O +
cancer O -
. O +

Individuals O +
III-3 O +
and O +
III-4 O +
inherited O +
also O +
the O +
deleterious O +
variant O -
. O +

No O +
genetic O +
testing O +
was O +
available O +
from O +
the O +
father O +
or O +
paternal O +
relatives O +
( O -
Family O +
# O -
2 O -
, O +
Figure O +
3 O -
) O -
. O +

Pedigree O +
for O +
Family O +
# O -
2 O +
( O -
CRC O -
: O +
Colorectal O +
cancer O -
; O +
EC O -
: O +
Endometrial O +
cancer O -
) O -
. O +

The O +
p. O +

Lys618Ala O +
variant O +
was O +
present O +
in O +
the O +
third O +
family O +
that O +
fulfilled O +
the O +
Amsterdam O +
II O +
Criteria O -
. O +

A O +
first O -
- O -
grade O +
familiar O +
non O -
- O -
carrier O +
of O +
this O +
variant O +
was O +
diagnosed O +
with O +
a O +
colonic O +
polyp O +
with O +
a O +
high O +
grade O +
of O +
dysplasia O +
at O +
the O +
age O +
of O +
39 O +
years O +
and O +
with O +
four O +
colonic O +
polyps O +
at O +
the O +
age O +
of O +
42 O +
years O +
( O -
Family O +
# O -
3 O -
, O +
Figure O +
4 O -
) O -
. O +

Discussion O +
The O +
accelerated O +
development O +
of O +
genetic O +
counselling O +
in O +
cancer O +
during O +
the O +
past O +
few O +
years O +
is O +
due O +
to O +
the O +
feedback O +
and O +
interactive O +
information O +
sharing O +
on O +
genetic O +
studies O -
, O +
clinical O +
management O +
and O +
psychological O +
issues O +
in O +
families O +
with O +
a O +
high O +
risk O +
of O +
cancer O -
. O +

Identification O +
of O +
deleterious O +
variants O +
in O +
such O +
families O +
is O +
essential O +
for O +
accurate O +
assessment O +
of O +
individual O +
risk O +
and O -
, O +
if O +
required O -
, O +
subsequent O +
inclusion O +
into O +
a O +
personalized O +
surveillance O +
programme O -
. O +

Unfortunately O -
, O +
genetic O +
testing O +
for O +
hereditary O +
cancer O +
frequently O +
fails O +
to O +
identify O +
unambiguous O +
deleterious O +
variants O -
. O +

Erroneous O +
classification O +
of O +
a O +
genetic O +
variant O +
may O +
have O +
a O +
great O +
effect O +
on O +
at O -
- O -
risk O +
familial O +
who O +
undergo O +
genetic O +
testing O +
for O +
risk O +
prediction O +
because O +
it O +
results O +
in O +
incorrect O +
clinical O +
recommendations O -
. O +

LS O +
is O +
the O +
most O +
common O +
hereditary O +
CRC O -
- O -
predisposing O +
syndrome O +
and O +
accounts O +
for O +
3 O -
% O +
of O +
unselected O +
CRC O +
cases O -
. O +

A O +
significant O +
proportion O +
of O +
DNA O +
variations O +
found O +
in O +
patients O +
suspected O +
of O +
having O +
LS O +
are O +
UVs O +
( O -
32 O -
% O -
, O +
18 O -
% O +
and O +
38 O -
% O +
for O +
MLH1 B-Gene -
, O +
MSH2 B-Gene +
and O +
MSH6 B-Gene -
, O +
respectively O -
) O +
[ O -
6 O -
] O -
. O +

The O +
pathogenicity O +
of O +
the O +
MLH1 B-Gene +
p. O +

Lys618Ala O +
variant O +
remains O +
controversial O +
because O +
of O +
conflicting O +
data O +
[ O -
InSiGHT O -
, O +
http://www.insight-group.org O -
] O +
( O -
Figure O +
5 O -
) O -
. O +

Classification O +
of O +
the O +
MLH1 B-Gene +
p. O +

Lys618Ala O +
variant O +
according O +
to O +
the O +
InSiGHT O +
database O +
( O -
accessed O +
on O +
07 O -
/ O -
2010 O -
) O -
. O +

The O +
p. O +

Lys618Ala O +
substitution O +
replaces O +
a O +
charged O +
amino O +
acid O +
with O +
a O +
neutral O +
one O -
, O +
and O +
occurs O +
alongside O +
four O +
charged O +
amino O +
acids O +
that O +
are O +
well O +
conserved O +
in O +
mammals O -
. O +

In O +
silico O +
predictions O +
of O +
the O +
pathogenicity O +
of O +
this O +
variant O +
using O +
the O +
PolyPhen O +
http://genetics.bwh.harvard.edu/pph/ O +
and O +
SIFT O +
http://sift.jcvi.org/ O +
computational O +
program O +
were O +
discordant O -
; O +
the O +
SIFT O +
analysis O +
classified O +
it O +
as O +
a O +
tolerant O +
variant O +
and O +
the O +
PolyPhen O +
analysis O +
classed O +
it O +
as O +
possibly O +
damaging O +
[ O -
9 O -
] O -
. O +

It O +
has O +
been O +
shown O +
that O +
this O +
variant O +
may O +
reduce O +
the O +
binding O +
ability O +
of O +
MLH1 B-Gene +
to O +
PMS2 B-Gene +
in O +
HCT116 O +
cells O +
co O -
- O -
transfected O +
with O +
mutated O +
MLH1 B-Gene +
and O +
wild O -
- O -
type O +
PMS2 B-Gene +
[ O -
10 O -
] O -
. O +

In O +
contrast O -
, O +
it O +
had O +
no O +
effect O +
on O +
the O +
ability O +
of O +
MLH1 B-Gene +
to O +
bind O +
PMS2 B-Gene +
in O +
a O +
co O -
- O -
immunoprecipitation O +
assay O +
[ O -
9 O -
] O -
. O +

Functional O +
analysis O +
using O +
the O +
pCAS O +
ex O +
vivo O +
splicing O +
assay O +
and O +
RNA O +
analysis O +
also O +
demonstrated O +
no O +
effect O +
[ O -
11 O -
] O -
. O +

Moreover O -
, O +
a O +
significant O +
decrease O +
in O +
MLH1 B-Gene +
protein O +
stability O +
has O +
been O +
found O +
for O +
the O +
p. O +

Lys618Ala O +
variant O +
[ O -
9 O -
] O -
. O +

The O +
results O +
of O +
in O +
silico O +
prediction O +
and O +
functional O +
assays O +
alone O +
are O +
insufficient O +
to O +
determine O +
whether O +
this O +
variant O +
is O +
deleterious O +
or O +
a O +
rare O +
functional O +
polymorphism O -
. O +

For O +
this O +
purpose O -
, O +
it O +
is O +
necessary O +
to O +
integrate O +
indirect O +
evidence O +
with O +
direct O +
genetic O +
evidence O +
involving O +
clinical O +
observations O +
of O +
disease O +
occurrence O -
. O +

The O +
frequency O +
of O +
variants O +
in O +
unaffected O +
controls O +
is O +
used O +
often O +
to O +
distinguish O +
between O +
neutral O +
and O +
potentially O +
deleterious O +
variants O -
. O +

If O +
the O +
frequency O +
of O +
a O +
variant O +
among O +
a O +
few O +
hundred O +
controls O +
is O +
≥1 O -
% O -
, O +
it O +
is O +
highly O +
unlikely O +
to O +
be O +
a O +
high O -
- O -
risk O +
variant O -
. O +

In O +
such O +
cases O -
, O +
it O +
is O +
still O +
possible O +
that O +
the O +
variant O +
will O +
be O +
associated O +
with O +
a O +
modest O +
risk O +
of O +
the O +
disease O +
[ O -
3 O -
] O -
. O +

Case O -
- O -
control O +
studies O +
enable O +
quantification O +
of O +
the O +
disease O +
risk O +
associated O +
with O +
the O +
variant O -
. O +

The O +
main O +
disadvantage O +
of O +
such O +
analyses O +
is O +
that O +
a O +
large O +
sample O +
size O +
is O +
required O +
to O +
obtain O +
sufficient O +
power O +
to O +
detect O +
the O +
lower O +
risk O +
level O -
. O +

The O +
sample O +
size O +
required O +
is O +
related O +
inversely O +
to O +
the O +
frequency O +
of O +
the O +
variant O +
in O +
the O +
population O -
. O +

The O +
sample O +
size O +
used O +
in O +
the O +
present O +
study O +
resulted O +
in O +
80 O -
% O +
power O +
to O +
detect O +
an O +
OR O +
of O +
3.0 O +
( O -
two O -
- O -
sided O +
test O -
; O +
alpha O +
level O -
, O +
5 O -
% O -
) O -
. O +

The O +
frequency O +
of O +
the O +
p. O +

Lys618Ala O +
variant O +
in O +
our O +
control O +
series O +
was O +
2.7 O -
% O +
and O +
no O +
significant O +
differences O +
were O +
observed O +
in O +
the O +
sporadic O +
and O +
familial O +
groups O -
, O +
indicating O +
that O +
a O +
high O +
penetrance O +
effect O +
for O +
colorectal O +
carcinogenesis O +
can O +
be O +
excluded O -
. O +

Similar O +
results O +
were O +
reported O +
in O +
case O -
- O -
control O +
studies O +
on O +
Scottish O +
and O +
Danish O +
populations O +
[ O -
12,13 O -
] O -
. O +

